0001493152-23-009276.txt : 20230328 0001493152-23-009276.hdr.sgml : 20230328 20230328160538 ACCESSION NUMBER: 0001493152-23-009276 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 85 CONFORMED PERIOD OF REPORT: 20221231 FILED AS OF DATE: 20230328 DATE AS OF CHANGE: 20230328 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ScoutCam Inc. CENTRAL INDEX KEY: 0001577445 STANDARD INDUSTRIAL CLASSIFICATION: OPTICAL INSTRUMENTS & LENSES [3827] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 333-188920 FILM NUMBER: 23769512 BUSINESS ADDRESS: STREET 1: 14201 N. HAYDEN ROAD, SUITE A-1 CITY: SCOTTSDALE STATE: AZ ZIP: 85260 BUSINESS PHONE: 480-659-6404 MAIL ADDRESS: STREET 1: 14201 N. HAYDEN ROAD, SUITE A-1 CITY: SCOTTSDALE STATE: AZ ZIP: 85260 FORMER COMPANY: FORMER CONFORMED NAME: Intellisense Solutions Inc. DATE OF NAME CHANGE: 20130521 10-K 1 form10-k.htm
0001577445 false FY 24762 P3Y P3Y 0001577445 2022-01-01 2022-12-31 0001577445 2022-06-30 0001577445 2023-03-28 0001577445 2022-12-31 0001577445 2021-12-31 0001577445 2021-01-01 2021-12-31 0001577445 us-gaap:CommonStockMember 2021-12-31 0001577445 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001577445 us-gaap:RetainedEarningsMember 2021-12-31 0001577445 us-gaap:CommonStockMember 2020-12-31 0001577445 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001577445 us-gaap:RetainedEarningsMember 2020-12-31 0001577445 2020-12-31 0001577445 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001577445 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001577445 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001577445 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001577445 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001577445 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001577445 us-gaap:CommonStockMember 2022-12-31 0001577445 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001577445 us-gaap:RetainedEarningsMember 2022-12-31 0001577445 2021-08-08 2021-08-09 0001577445 us-gaap:MachineryAndEquipmentMember srt:MinimumMember 2022-01-01 2022-12-31 0001577445 us-gaap:MachineryAndEquipmentMember srt:MaximumMember 2022-01-01 2022-12-31 0001577445 us-gaap:OfficeEquipmentMember 2022-01-01 2022-12-31 0001577445 us-gaap:ComputerEquipmentMember 2022-01-01 2022-12-31 0001577445 us-gaap:LeaseholdImprovementsMember 2022-01-01 2022-12-31 0001577445 us-gaap:MachineryAndEquipmentMember 2022-12-31 0001577445 us-gaap:MachineryAndEquipmentMember 2021-12-31 0001577445 SCTC:LeaseholdImprovementsOfficeFurnitureAndEquipmentMember 2022-12-31 0001577445 SCTC:LeaseholdImprovementsOfficeFurnitureAndEquipmentMember 2021-12-31 0001577445 us-gaap:ComputerEquipmentMember 2022-12-31 0001577445 us-gaap:ComputerEquipmentMember 2021-12-31 0001577445 us-gaap:ForeignCountryMember 2022-01-01 2022-12-31 0001577445 us-gaap:DomesticCountryMember 2022-01-01 2022-12-31 0001577445 us-gaap:IsraelTaxAuthorityMember us-gaap:TaxYear2021Member 2021-12-30 2021-12-31 0001577445 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-12-31 0001577445 us-gaap:IsraelTaxAuthorityMember SCTC:AgreementMember 2022-07-01 2022-07-31 0001577445 us-gaap:IsraelTaxAuthorityMember 2022-07-01 2022-07-31 0001577445 SCTC:DirectorsMember 2022-12-31 0001577445 SCTC:DirectorsMember 2021-12-31 0001577445 SCTC:SmartecRAndDLtdMember 2022-12-31 0001577445 SCTC:SmartecRAndDLtdMember 2021-12-31 0001577445 SCTC:MedigusLtdMember 2022-12-31 0001577445 SCTC:MedigusLtdMember 2021-12-31 0001577445 us-gaap:PrivatePlacementMember 2020-05-17 2020-05-18 0001577445 us-gaap:PrivatePlacementMember 2020-05-18 0001577445 SCTC:BoardOfDirectorsMember 2021-01-20 0001577445 us-gaap:PrivatePlacementMember 2019-12-01 2019-12-31 0001577445 us-gaap:PrivatePlacementMember 2019-12-31 0001577445 SCTC:WarrantAMember 2022-12-31 0001577445 SCTC:WarrantBMember 2022-12-31 0001577445 SCTC:WarrantBMember 2021-12-31 0001577445 SCTC:ConsultantMember 2022-01-01 2022-12-31 0001577445 SCTC:ConsultantMember 2021-01-01 2021-12-31 0001577445 SCTC:WarrantAMember 2020-01-01 2020-12-31 0001577445 SCTC:WarrantAMember 2020-12-31 0001577445 SCTC:WarrantBMember 2021-04-01 2021-06-30 0001577445 SCTC:WarrantBMember 2021-06-30 0001577445 SCTC:WarrantAMember 2021-04-01 2021-06-30 0001577445 us-gaap:PrivatePlacementMember 2020-03-02 2020-03-03 0001577445 us-gaap:PrivatePlacementMember 2020-03-03 0001577445 SCTC:WarrantAMember 2020-03-03 0001577445 SCTC:WarrantBMember 2020-03-03 0001577445 us-gaap:WarrantMember 2020-03-02 2020-03-03 0001577445 SCTC:WarrantAMember 2021-01-01 2021-12-31 0001577445 SCTC:WarrantBMember 2021-01-01 2021-12-31 0001577445 us-gaap:WarrantMember 2020-05-17 2020-05-18 0001577445 SCTC:WarrantAMember 2020-05-18 0001577445 SCTC:WarrantBMember 2020-05-18 0001577445 SCTC:WarrantAMember 2021-02-01 2021-02-28 0001577445 SCTC:WarrantAMember 2021-11-01 2021-11-30 0001577445 SCTC:LetterAgreementMember SCTC:MedigusLtdMember 2020-06-23 0001577445 SCTC:LetterAgreementMember SCTC:MedigusLtdMember us-gaap:CommonStockMember 2020-06-21 2020-06-23 0001577445 SCTC:LetterAgreementMember SCTC:MedigusLtdMember SCTC:WarrantAMember 2020-06-23 0001577445 SCTC:LetterAgreementMember SCTC:MedigusLtdMember SCTC:WarrantBMember 2020-06-23 0001577445 SCTC:WarrantAMember 2020-06-23 0001577445 SCTC:WarrantBMember 2020-06-23 0001577445 SCTC:WarrantAMember 2021-06-01 2021-06-30 0001577445 SCTC:WarrantBMember 2021-12-22 2021-12-23 0001577445 SCTC:InvestmentCMember 2021-03-28 2021-03-29 0001577445 SCTC:InvestorsCMember 2021-03-28 2021-03-29 0001577445 SCTC:InvestorsCMember 2021-03-29 0001577445 SCTC:TwoThousandAndTwentyShareIncentivePlanMember SCTC:EmployeesConsultantsDirectorsAndOtherServiceProvidersMember 2020-02-01 2020-02-29 0001577445 SCTC:TwoThousandAndTwentyShareIncentivePlanMember SCTC:BoardOfDirectorsMember 2020-03-14 2020-03-15 0001577445 SCTC:TwoThousandAndTwentyShareIncentivePlanMember SCTC:EmployeesConsultantsDirectorsAndOtherServiceProvidersMember 2020-06-22 2020-06-22 0001577445 SCTC:TwoThousandAndTwentyShareIncentivePlanMember SCTC:EmployeesConsultantsDirectorsAndOtherServiceProvidersMember 2021-04-01 2021-06-30 0001577445 SCTC:TwoThousandAndTwentyShareIncentivePlanMember 2021-01-01 2021-12-31 0001577445 SCTC:TwoThousandAndTwentyShareIncentivePlanMember 2022-01-01 2022-12-31 0001577445 SCTC:TwoThousandAndTwentyShareIncentivePlanMember srt:MinimumMember 2022-01-01 2022-12-31 0001577445 SCTC:TwoThousandAndTwentyShareIncentivePlanMember srt:MaximumMember 2022-01-01 2022-12-31 0001577445 us-gaap:StockOptionMember 2022-01-01 2022-12-31 0001577445 us-gaap:StockOptionMember 2022-12-31 0001577445 us-gaap:EmployeeStockOptionMember SCTC:ProfGoldwasserMember 2022-12-31 0001577445 us-gaap:EmployeeStockOptionMember SCTC:ProfGoldwasserMember 2021-12-31 0001577445 us-gaap:EmployeeStockOptionMember SCTC:ProfGoldwasserMember 2022-01-01 2022-12-31 0001577445 us-gaap:EmployeeStockOptionMember SCTC:ProfGoldwasserMember 2021-01-01 2021-12-31 0001577445 us-gaap:EmployeeStockOptionMember 2021-12-31 0001577445 us-gaap:EmployeeStockOptionMember srt:BoardOfDirectorsChairmanMember 2022-01-01 2022-12-31 0001577445 us-gaap:EmployeeStockOptionMember srt:BoardOfDirectorsChairmanMember 2021-01-01 2021-12-31 0001577445 srt:OfficerMember 2022-01-01 2022-12-31 0001577445 SCTC:EmployeeAndDirectorsMember 2022-01-01 2022-12-31 0001577445 SCTC:EmployeeAndDirectorsMember 2021-01-01 2021-12-31 0001577445 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-12-31 0001577445 us-gaap:RestrictedStockUnitsRSUMember 2022-12-31 0001577445 us-gaap:RestrictedStockMember 2022-01-01 2022-12-31 0001577445 SCTC:WarrantMarchTwoThousandTwentyOneMember 2022-01-01 2022-12-31 0001577445 SCTC:WarrantMarchTwoThousandTwentyOneMember 2022-12-31 0001577445 us-gaap:WarrantMember 2022-12-31 0001577445 2020-01-01 2020-12-31 0001577445 us-gaap:RestrictedStockUnitsRSUMember 2021-12-31 0001577445 srt:MinimumMember 2022-12-31 0001577445 srt:MaximumMember 2022-12-31 0001577445 srt:MinimumMember 2021-12-31 0001577445 srt:MaximumMember 2021-12-31 0001577445 srt:MinimumMember 2022-01-01 2022-12-31 0001577445 srt:MaximumMember 2022-01-01 2022-12-31 0001577445 srt:MinimumMember 2021-01-01 2021-12-31 0001577445 srt:MaximumMember 2021-01-01 2021-12-31 0001577445 us-gaap:ServiceMember 2022-01-01 2022-12-31 0001577445 us-gaap:ServiceMember 2021-01-01 2021-12-31 0001577445 us-gaap:ProductMember 2022-01-01 2022-12-31 0001577445 us-gaap:ProductMember 2021-01-01 2021-12-31 0001577445 SCTC:CustomerAMember 2022-04-01 2022-06-30 0001577445 us-gaap:ServiceMember 2022-01-01 2022-12-31 0001577445 SCTC:RelatedDevelopmentCostsMember 2022-01-01 2022-12-31 0001577445 us-gaap:ProductMember 2022-01-01 2022-12-31 0001577445 country:US 2022-01-01 2022-12-31 0001577445 country:US 2021-01-01 2021-12-31 0001577445 country:GB 2022-01-01 2022-12-31 0001577445 country:GB 2021-01-01 2021-12-31 0001577445 country:IL 2022-01-01 2022-12-31 0001577445 country:IL 2021-01-01 2021-12-31 0001577445 SCTC:OtherMember 2022-01-01 2022-12-31 0001577445 SCTC:OtherMember 2021-01-01 2021-12-31 0001577445 SCTC:CustomerAMember 2022-01-01 2022-12-31 0001577445 SCTC:CustomerAMember 2021-01-01 2021-12-31 0001577445 SCTC:CustomerBMember 2022-01-01 2022-12-31 0001577445 SCTC:CustomerBMember 2021-01-01 2021-12-31 0001577445 SCTC:CustomerCMember 2022-01-01 2022-12-31 0001577445 SCTC:CustomerCMember 2021-01-01 2021-12-31 0001577445 SCTC:LeaseAgreementMember 2020-01-01 2020-12-31 0001577445 SCTC:LeaseAgreementMember 2022-01-01 2022-01-02 0001577445 SCTC:LeaseAgreementMember 2022-01-01 2022-12-31 0001577445 SCTC:StockPurchaseAgreementsMember us-gaap:SubsequentEventMember 2023-03-15 2023-03-16 0001577445 SCTC:StockPurchaseAgreementsMember us-gaap:SubsequentEventMember 2023-03-16 0001577445 SCTC:StockPurchaseAgreementsMember us-gaap:SubsequentEventMember us-gaap:CommonStockMember 2023-03-16 0001577445 SCTC:StockPurchaseAgreementsMember us-gaap:SubsequentEventMember us-gaap:WarrantMember 2023-03-16 0001577445 SCTC:StockPurchaseAgreementsMember us-gaap:SubsequentEventMember us-gaap:WarrantMember 2023-03-15 2023-03-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure iso4217:ILS

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-K

 

(Mark One)

 

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the Fiscal Year Ended: December 31, 2022

 

or

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Commission file number 333-188920

 

SCOUTCAM INC.

(Exact name of registrant as specified in its charter)

 

Nevada   47-4257143
State or other jurisdiction of
incorporation or organization		  

(I.R.S. Employer

Identification No.)

 

Suite 7A and 3B, Industrial Park, P.O. Box 3030

Omer, Israel 8496500

(Address of principal executive offices) (Zip Code)

 

Tel: +972 73 370-4691

 

Registrant’s telephone number, including area code

 

Securities registered pursuant to Section 12(b) of the Act: None

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
N/A   N/A   N/A

 

Securities registered pursuant to Section 12(g) of the Act: None

 

N/A

(Title of class)

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer ☒ Smaller reporting company ☒
    Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

 

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the fi ling reflect the correction of an error to previously issued financial statements. ☐

 

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒

 

The aggregate market value of the voting and non-voting stock held by non-affiliates of the registrant as of June 30, 2022, based on the price at which the common equity was last sold on the OTCQB Market on such date, was $19.22 million. For purposes of this computation only, all officers, directors and 10% or greater stockholders of the registrant are deemed to be affiliates.

 

As of March 28, 2023, there were 10,432,518 shares of the registrant’s common stock outstanding.

 

DOCUMENTS INCORPORATED BY REFERENCE

 

None.

 

 

 

 

 

 

TABLE OF CONTENTS

 

Forward-Looking Statements 3
     
Part I    
     
Item 1. Business 4
item 1a. risk factors 11
Item 1b. unresolved staff comments 27
Item 2. properties 27
item 3. legal proceedings 27
item 4. mine safety disclosures. 27
     
PART II    
     
item 5. market for registrant’s common equity, related stockholder matters and issuer purchases 28
Item 6. [RESERVED] 30
item 7. management’s discussion and analysis of financial condition and results of operations 30
item 7a. quantitative and qualitative disclosures about market risk 39
item 8. financial statements and supplementary data 39
item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 39
item 9a. controls and Procedures 39
Item 9b. Other information 40
Item 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS 40
     
PART III    
     
Item 10. Directors, Executive Officers and corporate governance 41
item 11. Executive Compensation 46
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder matters 49
Item 13. Certain relationships and related transactions, and director independence 51
Item 14. Principal accounting fees and services 53
     
PART IV    
     
Item 15. exhibits AND financial statement schedules 54
     
ITEM 16. FORM 10-K SUMMARY 55
     

SIGNATURES

 56

 

2

 

 

Forward-Looking Statements

 

This Annual Report on Form 10-K includes a number of forward-looking statements that reflect management’s current views with respect to future events and financial performance. Forward-looking statements are projections in respect of future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology. Those statements include statements regarding the intent, belief or current expectations of our Company and members of our management team as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements.

 

These statements are only predictions and involve known and unknown risks, uncertainties and other factors including, but not limited to:

 

  ● our financial performance, including our history of operating losses;
     
  ● our ability to obtain additional funding to continue our operations;
     
  ● our ability to successfully develop and commercialize our products;
     
  ● changes in the regulatory environments of the United States and other countries in which we intend to operate;
     
  ● our ability to attract and retain key management and marketing personnel;
     
  ● competition from new market entrants; and
     
  ● our ability to identify and pursue development of additional products.

 

Readers are urged to carefully review and consider the various disclosures made by us in this Annual Report and in our other reports filed with the Securities and Exchange Commission. We undertake no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes in future operating results over time except as required by law. We believe that our assumptions are based upon reasonable data derived from and known about our business and operations. No assurances are made that actual results of operations or the results of our future activities will not differ materially from our assumptions.

 

As used in this Annual Report and unless otherwise indicated, the terms “ScoutCam,” “we,” “us,” “our,” or “our Company” refer to ScoutCam Inc. Unless otherwise specified, all dollar amounts are expressed in United States dollars.

 

3

 

 

Part I

 

Item 1. Business

 

Overview

 

Our Mission

 

We are a pioneer in the development, production, and marketing of innovative Predictive Maintenance (PdM) and Condition Based Monitoring (CBM) technologies, providing visual sensing and AI-based video analytics solutions for critical systems in the aviation, maritime, industrial non-destructing-testing industries, transportation, and energy industries. Some of our products utilize our unique micro visualization technology in medical devices for complex and minimally invasive medical procedures. Our technology includes proven video technologies and products amalgamated into a first-of-its-kind, FDA-cleared minimally invasive surgical device. At the present time, we derive a substantial portion of our revenue from applications of our micro visualization technology within the medical field.

 

Our Business Model

 

Our unique video-based sensors, embedded software, and AI algorithms are being deployed in hard-to-reach locations and harsh environments across a variety of PdM and CBM use cases. Our solution allows maintenance and operations teams visibility into areas which are inaccessible under normal circumstances, or where the operating ambience otherwise is not suitable for continuous real-time monitoring, and has various applications which have relevancy in a wide range of industry segments that utilize complicated mechanics requiring ongoing monitoring and predictive maintenance applications. Our current business model is a business-to-business (B2B) approach in which we seek to identify target businesses interested in integrating our micro visualization technology or commissioning individual projects using our technology. We have several successful proof of concepts in airborne platforms of various OEM’s in aerospace and have completed a successful demonstration project for a top global elevator systems manufacturer. As provided above, we are developing additional applications for our visual solutions portfolio (composed of image acquisition, data collection, and storage and image processing), including PdM and CBM (we refer to these applications and sectors as Industry 4.0, or I4.0), which generate a number of potential benefits for our customers.

 

The following graphic demonstrates ScoutCam’s value proposition, starting with increased safety and reduced down time due to our ability to visually analyze any failure occurrence in real time, and including more sophisticated benefits like big data analytics that provide predictive insights regarding to an entire system life cycle, spare parts management and smart prediction regrading system performance.

 

 

4

 

 

Who we are: History and Background

 

We were incorporated as a corporation under the laws of the State of Nevada on March 22, 2013, under the name Intellisense Solutions Inc. We were initially engaged in the business of developing web portals to allow companies and individuals to engage in the purchase and sale of vegetarian food products over the Internet. However, we were unable to execute our original business plan, develop significant operations or achieve commercial sales.

 

We received initial funding in March 2014 in the aggregate amount of $19,980 through the sale of common stock to two of our former officers and directors, who purchased in the aggregate 1,998,000 shares of our common stock at $0.01 per share.

 

On January 10, 2019, we formed Canna Patch Ltd., or Canna Patch, an Israeli corporation, of which 90% was initially owned by our Company, and the remaining 10% owned by Rafael Ezra, Canna Patch’s Chief Technology Officer. Canna Patch did not have any operations and on December 4, 2019, we sold 100% of our holdings in Canna Patch.

 

On September 16, 2019, Intellisense and Medigus Ltd., an Israeli company traded on the Nasdaq Capital Market, entered into an Exchange Agreement (as defined herein).

 

On December 30, 2019, we acquired ScoutCam Ltd. As a result of our acquisition of ScoutCam Ltd., we now own all of ScoutCam Ltd.’s issued and outstanding share capital and have integrated and adopted ScoutCam Ltd.’s business into our Company as our primary business activity.

 

ScoutCam Ltd. was formed in the State of Israel on January 3, 2019, as a wholly-owned subsidiary of Medigus and commenced operations on March 1, 2019. ScoutCam Ltd. was incorporated as part of a reorganization of Medigus, which was designed to distinguish ScoutCam Ltd.’s miniaturized imaging business, or the micro ScoutCam™ portfolio, from Medigus’ other operations and to enable Medigus to form a separate business unit with dedicated resources focused on the promotion of such technology. On December 1, 2019, Medigus and ScoutCam Ltd. consummated a certain Amended and Restated Asset Transfer Agreement, which transferred and assigned certain assets and intellectual property rights related to its miniaturized imaging business. On May 18, 2020, in connection with the Arkin Transaction (as defined below), the Company and Medigus entered into a certain Side Letter Agreement (the “Letter Agreement”), whereby the parties agreed to amend certain terms of the Amended and Restated Asset Transfer Agreement and the License Agreement.

 

On April 20, 2020, ScoutCam Ltd. entered into an Amended and Restated Intercompany Services Agreement with Medigus (the “Intercompany Services Agreement”), which effectively amended and restated an intercompany services agreement dated May 30, 2019.

 

For additional information about the Exchange Agreement, the Amended and Restated Asset Transfer Agreement, the Letter Agreement and the Intercompany Services Agreement, refer to – “CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE” below.

 

Sales and Marketing

 

ScoutCam’s vision is to become a leading provider of video analytics based, PdM solutions for the aerospace, other industry and medical critical system markets.

 

We engage companies seeking to add video visualization to their existing or new product(s) or considering the development of new products that include micro video visualization. Our approach to the medical market is ordinarily conducted in two phases. During the first phase, we conduct the research and development that is required in order to specify, design, develop, and produce the designated visualization apparatus, for an agreed-upon compensation amount (e.g., a non-recurrent engineering fee). During the second phase, we manufacture the apparatus and offer it to the customer for an agreed-upon transfer price.

 

In the I4.0 domain, which target PdM and CBM applications, we engage with companies that wish to increase the monitoring capabilities of different elements of a device using our visual monitoring solutions (these include build of image acquisition, data collection and storage, and image processing capabilities based on AI, ML, cloud, and additional algorithm concepts). Based on our product portfolio with customized solutions as needed, this will allow our customers to receive real time alerts on anomalies and failures of monitored components, analyze and track trends and development of the anomaly, and predict any impending failure of the component as a result of such anomaly over time and usage. As a result, we expect customers to benefit from a reduction in downtime, lower maintenance expenses, and increased safety of their monitored equipment, using the prediction capabilities of the platform to efficiently plan maintenance work on future faulty components. Another outcome we expect is more cost effective management of resources, since components will only need to be replaced as a result of their actual condition rather than a strict maintenance schedule.

 

5

 

 

The use of an image based platform in the fields of PdM and CBM provides richer and more informative data and insights than traditional sensing methods. Together with the AI and ML models customized for the relevant use cases, we expect this will provide customers with a clearer view of the status of their equipment, increasing revenues by saving on direct expenses, and increasing the uptime of their equipment.

 

On February 6, 2023, we announced the completion of a major development stage in equipping Elbit Systems Ltd.’s leading defense UAS aerial platforms with our real time video monitoring system. Through the program, our unique video-based sensors, embedded software, machine vision and algorithms support a variety of predictive maintenance and condition-based monitoring use cases for unmanned aerial vehicles in harsh environments and hard-to-reach locations, as it features a modular open system architecture, enabling seamless integration with advanced unmanned aerial platforms.

 

In order to engage new customers, we employ various marketing strategies. We employ several professional experienced managers in relevant fields of expertise, in addition to a team of consultants who analyze global trends and designated geographical territories to assist us in targeting potential customers.

 

Our marketing efforts include, but are not limited to, the following:

 

  ● engaging third party companies and local consultants as territorial representatives in key markets and leading companies in relevant industries;
     
  ● initiating business engagements based on leads received through our marketing efforts, through active interaction with key industry influencers, providing financed proof of concept in order to generate tailored product orders, or via other methods or means;
     
  ● conducting proof of concept demonstrations in order to evaluate the feasibility of integration for monitoring their systems and to demonstrate the significant value proposition of our technology to customers;
     
  ● networking through personal contacts in the aerospace, critical industry, transportation, maritime, medical, and defense industries; and
     
  ● participating in major aerospace, maritime, and vision technology exhibitions as well as industry 4.0 specific events.

 

In addition to our business development efforts that are mainly based on currently existing or future customer needs, we aim to identify new market opportunities. These efforts include systematic analysis of various industrial and medical fields and procedures to identify where visualization solutions, including image analysis, might add value. When a potential opportunity is identified, we seek to protect our rights by establishing relevant intellectual property safeguards, developing prototypes for the required application. In the medical domain, we currently sell our system to a fortune 500 corporation; in this respect, we seek to partner with additional relevant companies to progress our technology into prototypes which, in turn, will be developed into market-ready products.

 

In January 2022, we entered into a patent cross-licensing arrangement with Japan-based Sumita Optical Glass, Inc. (Sumita), a specialty optical fiber technology company, pursuant to which we granted a non-exclusive license to Sumita to our patents related to “Small Diameter Video Camera Heads and Medical Devices and Visualization Probes containing them” in return for payment of royalties and a grant-back license to ScoutCam of Sumita’s patent and patent applications related to fiber optics illumination. For additional information on our patent portfolio, refer to – “PROPRIETARY RIGHTS AND TECHNOLOGY” below.

 

6

 

 

Our Customers

 

Currently, we have one major customer, a leading Fortune 500 multinational healthcare corporation, that is expected to generate most of our forecasted revenue in the near term. In June 2022, we announced that we completed the verification and validation stage of our miniature camera solution with this client and, on January 26, 2023, we announced that we had received an order from this client for $1.45 million.

 

In addition, we derive a substantial portion of our revenue from applications of our micro visualization technology within the medical field.

 

In addition, we announced the completion of a major development stage to equip Elbit Systems Ltd.’s leading defense UAS aerial platforms with our real time video monitoring system.

 

Competition

 

There are currently several companies that develop and provide monitoring solutions for PdM and CBM. These monitoring solutions can be the sensor itself, data collection and storage, AI processing, or a combination of these capabilities. The CBM and PdM solutions are usually based on traditional sensing solutions such as vibration, temperature, and acoustic sensors. Based on our research and discussions with customers, we believe these traditional sensing methods are limited in their ability to provide an in depth view of the condition of the monitored components and usually alert on the occurrence of an anomaly when component failure has already occurred, which is too late in some cases. From the AI perspective, there are several vendors providing off-the-shelf AI capabilities which then require customization per market, use case, and/or data source. We believe that our more holistic approach and reliance on image-based solutions creates richer and more informative data, leveraged by AI and ML algorithms, enabling our customers to deploy predictive maintenance programs.

 

Proprietary Rights and Technology

 

Our solution for the market is based on our core intellectual property which we seek to review and patent on a regular basis, where applicable. We are heavily invested in creating patents for our core technology.

 

Our patent portfolio currently contains patent families which we consider material to our business and operating success. Our intellectual property rights include patents and patent applications that were transferred to us by Medigus as part of the Addendum No. 1 to Amended and Restated Asset Transfer Agreement (the “Addendum”), the License Agreement and the Letter Agreement, and additional patent assets developed by ScoutCam. For additional information about the License Agreement refer to – “CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE” below. Under the Addendum, and subject to certain limitations as further set forth therein, Medigus transferred to us the following material patent families in exchange for a license in connection with the marketing and sale of the Medigus Ultrasonic Surgical Endostapler:

 

● Patent family related to Integrated Endoscope Irrigation: this patent family relates to our ability to develop visualization components and endoscopes, which include irrigation with a smaller outer diameter by saving the space of the tube that is required to lead the fluids in a conventional manner. This patent has been granted in Canada, Europe (validated in Germany, Spain, France, Great Britain and Italy), Israel, Japan (original and divisional), and the United States (two patents), and has two pending continuations in the United States. The expiration dates for the two patents in the United States are November 28, 2033 and February 28, 2033;

 

● Patent family related to Small Diameter Video Camera Heads and Medical Devices and Visualization Probes containing them: this patent family relates to our ability to develop cameras, visualization components, and medical devices with a small diameter, thus enabling the insertion of the camera into smaller cavities or leaving more space in the device for the use and application of other functions, such as a working channel. This patent has been granted in Japan, Korea, Israel, the United States (2 patents, original and continuation in part), and Europe (3 patents, original and 2 divisionals, currently under appeal after opposition proceedings, validated in Germany, France, Great Britain, and Italy). The expiration dates for these patents are March 16, 2031 (for the patents in the United States), and September 16, 2030 (for patents in each of the other aforementioned jurisdictions).

 

7

 

 

As a result of oppositional proceedings initiated by a third party in 2018, the Opposition Division of the EU Patent Office decided in 2019 to revoke two of the three European patents (EP 2.478.693 and EP 2.621.159) and in 2021 to maintain the third patent (EP 2.621.158). Following appeals by Company and the third party of the 2019 and 2021 decisions, respectively, the Opposition Division of the EU Patent Office is expected to hear and decide these matters in early 2024;

 

As a result of a supplemental examination filed by the Company regarding one of the U.S. Patents (10,188,275), the U.S. Patent Office decided to open reexamination proceedings for 23 of the 24 granted claims. The U.S. Patent Office is expected to conduct the reexamination proceedings during the course of 2024; and

 

In addition, our intellectual property rights further include the following material patent applications filed by ScoutCam:

 

● Patent family related to Miniature Precision Medical Device: these pending patent applications relate to our ability to develop a miniature precision medical device comprising an endoscope with at least one camera, where at least one sensor of one camera is distally located at a tip of a shaft of the endoscope. Surrounding or next to the sensor, such shaft has sufficient space to accommodate at least one accessory such as, for example, illumination source, irrigation tool, or suctioning tool. This patent family has pending patent application in the United States and its expected expiry dates, if issued, will be in 2039-2040.

 

● Patent family related to Medical Ophthalmic Device: this patent family is related to a tool comprising a hand piece having a flattened cannulated tip that is adapted to receive flow from a pumping unit, in order to generate a jet of fluid suitable for procedures such as “hydro-dissecting” cells in the eye. According to a representation of the invention, the tool comprises a visualization probe with at least one camera, wherein the sensor of the camera is distally located at the tip of the tool to be inserted into the eye for imaging from within the eye. This patent family is pending in China, Europe, Japan, Korea, and the United States. The patent application’s expected expiry dates, if issued, will be in 2039-2040.

 

● Patent family related to Systems and Methods for Monitoring Potential Failure in a Machine or a Component Thereof. This patent family relates to system and methods for monitoring potential failure in a machine or a component thereof using at least one optical sensor. Such sensors can be used in conjunction with diagnostic software/hardware tools to display and analyze changes in critical images that could not have been displayed or analyzed using existing systems. This patent family includes a pending Patent Cooperation Treaty patent application and national phase applications filed in Israel and the U.S. If ultimately issued by the United States Patent and Trademark Office, such patent would be expected to expire in early 2042. Additional national phase patent application can be filed in other jurisdictions by the end of July 2023.

 

We have also applied for provisional applications relating to our predictive maintenance innovative technology and developments. All of these applications are expected to have a lifetime of 20 years from filing.

 

Despite our efforts to protect our intellectual property, unauthorized parties may still copy or otherwise obtain and use our technology. For additional information, refer to – “WE MAY NOT BE SUCCESSFUL IN ENFORCING OUR INTELLECTUAL PROPERTY RIGHTS AGAINST THIRD PARTIES” below.

 

Employment

 

We currently have approximately 45 full-time (or near full-time) employees. This number is expected to grow. We may recruit additional employees to the R&D team.

 

Research and Development

 

Our R&D organization is responsible for the design, development, testing, and delivery of new technologies, features, products, and integrations of our component parts. Research and development employees are located primarily in our principal corporate office on Omer, Israel. We currently have approximately 21 employees in our research and development organization. We intend to continue to invest in our research and development capabilities.

 

8

 

 

Our R&D efforts are focused on the following areas: (i) maturing our multi camera solution based on advanced visualization sensor technologies focusing on sensing, computing, and prediction, cooperating with customers for mutual development projects that demonstrate our technology by reaching customer KPIs and (ii) our industrial cloud-based product, which leverages our already in place cloud environment to develop mutual proof of concept and minimal valuable product for our customers that enable cloud base solutions for customer KPIs.

 

Regulation

 

Our approach to regulation is generally determined based on a given project. In our engagements with customers operating in the biomedical sector, we comply with the medical device standards in that corresponding territory, such as the FDA or International Organization for Standardization (ISO), among others. Compliance with these regulations is achieved through our QA department and the support we receive from highly experienced quality assurance and regulatory affairs consultants. In addition, we are being audited annually by MEDCERT GmbH, a German Notified Body.

 

For instance, ISO 13485:2016 is a regulatory benchmark that we comply with while working on our medical device projects. ISO 13845:2016 is similar to ISO 9001 in terms of its quality management system (QMS) requirements, however, ISO 13485:2016 is generally considered more rigorous and comprehensive.

 

Given that we do not manufacture or distribute end-user products to the medical sector, and instead service businesses pursuant to a B2B model, we are subject to fewer regulatory standards commonly associated with medical device manufacturers or distributors. We develop and manufacture components for other companies, and therefore our involvement in the regulatory submission demands comparatively less responsibility. This notwithstanding, we communicate with business customers in order to identify certain regulatory dimensions inherent to a project, to which we should pay additional attention. For example, when a component of ours is integrated into a business’s end-user product, such as for the purpose of touching human tissue, we develop and manufacture our parts and components while taking into account certain applicable regulatory standards. These standards might include, inter alia, relevant FDA regulations (e.g. CFR 21 part 820, the medical device reporting requirements (MDR), among others) as well as ISO regulations (e.g. ISO 14644-1, specifically in connection with cleanrooms and associated controlled environments, among other items, or ISO 10993, in connection with the biological evaluation of medical devices). Furthermore, we prioritize our team’s compliance with the Restriction of Hazardous Substances Directives (RoHS) and REACH (EC 1907/2006).

 

Similarly, if a component part of ours is incorporated into an electronic device for the purpose of being used inside a human body, we comply with certain FDA requirements as well as IEC 60601 for safety and electrostatic discharge, including the heating of parts at more than 42 degrees Celsius and a variety of additional technical standards designed for the safety and essential performance of electronic medical equipment. Moreover, we perform risk management assessments in accordance with EN ISO 14971:2019 and ISO/TR 24971:2020.

 

In certain instances, our customers prefer that we conduct the testing of its products in internationally certified labs in order to further guarantee that our component parts satisfy applicable regulatory standards. In this scenario, we perform the required tests as a service to the customer and provide the customer with the official test results, specifically in accordance with ISO/IEC 17025:2017, which the customer can later use in order to apply for the required marketing clearance of its end-user product.

 

Since we are seeking to sell our products to customers in the aviation sector, we have completed the process of implementing the AS9100D Standard to comply with aerospace industry requirements.

 

As a U.S. company with foreign offices, we are subject to a variety of foreign laws governing our foreign operations, as well as U.S. laws that restrict trade and certain practices, such as the Foreign Corrupt Practices Act.

 

9

 

 

Israeli Government Programs

 

As a result of certain agreements between Medigus and ScoutCam Ltd. (for additional information about these agreements refer to – “CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE” below) the Israel Innovation Authority, or the IIA, approved a transfer of IIA know-how developed by Medigus in the framework of the Bio Medical Photonic Consortium, or the Medigus Consortium, to ScoutCam Ltd.

 

Accordingly, all rights and obligations with regard to the IIA under the Encouragement of Research, Development and Technological Innovation in the Industry Law, 5744-1984, or the Innovation Law, in connection with such know-how now apply to ScoutCam Ltd.

 

The following are details regarding the rights and obligations within the framework of ScoutCam Ltd.’s activity in the Medigus Consortium, which continue to apply to ScoutCam Ltd. notwithstanding the termination of the Medigus Consortium:

 

  (i) The property rights to information which has been developed belongs to the Medigus Consortium member that developed it. However, the developing entity is obligated to provide the other members in the Medigus Consortium a license for the use of the new information, without consideration, provided that the other members do not transfer such information to any entity which is not a member of the Medigus Consortium. The provision of a license or of the right to use the new information to a third party is subject to approval by the administration of the MAGNET Program at the IIA;
  (ii) The Medigus Consortium member is entitled to register a patent for the new information which has been developed by it within the framework of its activity in the Medigus Consortium. The foregoing registration does not require approval from the administration of the MAGNET Program at the IIA; and
  (iii) The know-how and technology developed under the program is subject to the restrictions set forth under the Innovation Law, including restrictions on the transfer of such know-how and any manufacturing rights with respect thereto, without first obtaining the approval of the IIA. Such approval may entail additional payments to the IIA, as determined under the Innovation Law and regulations.

 

Obligations relevant to us under the Innovation Law include the following:

 

  ●

Local Manufacturing Obligation. The terms of the grants under the Innovation Law require that we manufacture the products developed with these grants in Israel. Under the regulations promulgated under the Innovation Law, the products may be manufactured outside Israel by us or by another entity only if prior approval is received from the IIA (such approval is not required for the transfer of less than 10% of the manufacturing capacity in the aggregate, in which case a notice should be provided to the IIA). In general, due to manufacturing outside Israel, with respect to royalties bearing grants we would be required to pay royalties at an increased rate, usually 1% in addition to the standard rate and increased royalties cap (between 120% and 300% of the grants, depending on the manufacturing volume that is performed outside Israel).

     
  ●

Know-How Transfer Limitation. The Innovation Law restricts the ability to transfer, in any manner, know-how funded directly or indirectly by the IIA (sale of products is not prohibited), unless the IIA approves doing so and subject to the terms of the Innovation Law and of the IIA’s approval.

 

Among other things, transfer of IIA funded know-how outside of Israel requires prior approval of IIA and in certain circumstances is subject to certain payments to the IIA, calculated according to a formula provided under the Innovation Law. If we wish to transfer IIA funded know-how outside of Israel, the terms for approval will be determined according to the character of the transaction and the consideration paid to us for such transfer. The IIA approval to transfer know-how created, in whole or in part, in connection with a IIA-funded project to third party outside Israel where the transferring company remains an operating Israeli entity is subject to payment of a redemption fee to the IIA calculated according to a formula provided under the Innovation Law that is based, in general, on the ratio between the aggregate IIA grants to the company’s aggregate investments in the project that was funded by these IIA grants, multiplied by the transaction consideration, considering statutory depreciation and less royalties already paid to the IIA. The transfer of such know-how to a party outside Israel where the transferring company ceases to exist as an Israeli entity is subject to a redemption fee formula that is based, in general, on the ratio between aggregate IIA grants received by the company and the company’s aggregate research and development expenses, multiplied by the transaction consideration considering statutory depreciation and less royalties already paid to the IIA.

 

10

 

 

    The regulations promulgated under the Innovation Law establish a maximum payment of the redemption fee paid to the IIA under the above mentioned formulas and differentiates between two situations: (i) in the event that the company transfers its IIA funded know-how, in whole or in part, or is sold as part of an M&A transaction, and subsequently ceases to conduct business in Israel, the maximum redemption fee under the above mentioned formulas will be no more than six times the amount received (plus annual interest) for the applicable know-how being transferred, or the entire amount received from the IIA, as applicable; (ii) in the event that following the transactions described above (e.g. asset sale of IIA funded know-how or transfer as part of an M&A transaction) the company continues to conduct its research and development activity in Israel (for at least three years following such transfer and maintain staff of at least 75% of the number of research and development employees it had for the six months before the know-how was transferred and keeps the same scope of employment for such research and development staff), then the company is eligible for a reduced cap of the redemption fee of no more than three times the amounts received (plus annual interest) for the applicable know-how being transferred. In addition, special rules and payment formulas apply for certain kinds of transfers of know-how outside of Israel, such as R&D licenses. Transfer of IIA-funded know-how outside of Israel not according to the R&D Law may give rise to financial exposure as well as criminal liability.
     
  ● Approval of the transfer of IIA funded technology to another Israeli company may be granted only if the recipient assumes and abides by the provisions of the Innovation Law and related regulations, including the restrictions on the transfer of know-how and manufacturing rights outside of Israel (in addition, there will be an obligation to pay royalties to the IIA from the income of such sale transaction as part of the royalty payment obligation).
     
  ● Approval to manufacture products outside of Israel or consent to the transfer of technology, if requested, might not be granted. Furthermore, the IIA may impose certain conditions on any arrangement under which it permits ScoutCam Ltd. to transfer technology or development out of Israel.

 

item 1a. risk factors

 

Risk Factor Summary

 

Below is a summary of the principal factors that make an investment in the Company speculative or risky. This summary does not address all of the risks that we face. Additional discussion of the risks summarized in this risk factor summary, and other risks that we face, can be found below, after this summary, and should be carefully considered.

 

Risks Related to Our Business, Operations and Financial Condition

 

  ● We have had a limited operating history and may not be able to successfully operate our business or execute our business plan.
  ● If we are unable to establish sales, marketing and distribution capabilities or enter into successful relationships with business targets and third parties to perform these services, we may not be successful in commercializing our products and technology.
  ● We may require substantial additional funding, which may not be available to us on acceptable terms, or at all.
  ● Our failure to effectively manage growth could impair our business.
  ● Our commercial success depends upon the degree of market acceptance by prospective markets and industries.
  ● Weakened global economic conditions may harm our industry, business and results of operations.
  ● The continuing effects of the COVID-19 pandemic are highly unpredictable and could be significant, and the duration and extent to which this will impact our future results of operations and overall financial performance remains uncertain.

 

11

 

 

Risk Related to Third Parties

 

  ● Our reliance on third-party suppliers for most of the components of our products, including miniature video sensors could harm our ability to meet demand for our products in a timely and cost-effective manner.
  ● We may not be able to manage our strategic partners.
  ● We may not have sufficient manufacturing capabilities to satisfy any growing demand for our products. We may be unable to control the availability or cost of producing such products.

 

Risks Related to Competition

 

  ● We expect to face some competition possibly from our customer. If we cannot successfully compete there might be adverse effect on the company.
  ● Failure to comply with anti-bribery, anti-corruption and anti-money laundering laws could subject us to penalties and other adverse consequences.

 

Risks Related to Intellectual Property

 

 

●

 

We may not be able to obtain all possible patents or other intellectual property rights necessary to protect our proprietary technology and business.

  ● We may not be successful in enforcing our intellectual property rights against third parties.
  ● We may be subject to infringement claims and other litigation, which could adversely affect our business.
  ● Governmental regulation of non-practicing patent holders may adversely affect our business.

 

General Risk Factors Related to Our Business

 

  ● Our business and operations would suffer in the event of computer system failures, cyber-attacks, or deficiencies in our cyber-security.
  ● We may be subject to product liability claims, product actions, including product recalls, and other field or regulatory actions that could be expensive, divert management’s attention, and harm our business.
  ● Testing of our technologies potential applications for our products will be required and there is no assurance of regulatory approval.
  ● We rely on highly skilled personnel, and, if we are unable to attract, retain, or motivate qualified personnel, we may not be able to operate our business effectively.

 

Risks Related to this Offering and Our Common Stock

 

  ● Although we have filed an application to list our securities on Nasdaq, there can be no assurance that our securities will be so listed or, if listed, that we will be able to comply with the continued listing standards.
  ● Trading on the OTC Markets is volatile, sporadic and often thin, which could depress the market price of our common stock and make it difficult for our stockholders to resell their common stock.
  ● Nevada law and provisions in our amended and restated articles of incorporation and amended and restated bylaws could make a merger, tender offer or proxy contest difficult, thereby depressing the market price of our common stock.
  ● The market price of our common stock may be highly volatile and such volatility could cause you to lose some or all of your investment.
  ● Because our common stock may be deemed a “penny stock,” it may be more difficult for investors to sell shares of our common stock, and the market price of our common stock may be adversely affected.
  ● Compliance with the reporting requirements of federal securities laws can be expensive.
  ● Our investors’ ownership in the Company may be diluted in the future.
  ● Directors, executive officers, principal stockholders, and affiliated entities own a significant percentage of our capital stock, and they may make decisions that our stockholders do not consider to be in their best interests.
  ● We do not anticipate paying any cash dividends in the foreseeable future.

 

12

 

 

Risks Related to our Operations in Israel

 

  ● We are subject to the risks of political, economic, health, and military instability in countries outside the United States in which we operate.
  ● Political, economic and military instability in Israel may impede our ability to operate and harm our financial results.
  ● It may be difficult for investors in the United States to enforce any judgments obtained against us or some of our directors or officers.
  ● Exchange rate fluctuations between foreign currencies and the U.S. Dollar may negatively affect our earnings.
  ● Certain technology developed and used by us received Israeli government grants for certain research and development activities. The terms of those grants require us to satisfy specified conditions in addition to repayment of the grants upon certain events.
  ● We may become subject to claims for remuneration or royalties for assigned service invention rights by our employees, which could result in litigation and adversely affect our business.

 

Certain factors may have a material adverse effect on our business, financial condition, and results of operations. You should carefully consider the following risks, together with all of the other information contained in this Annual Report on Form 10-K, including the sections titled “Forward-Looking Statements” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our financial statements and the related notes included elsewhere in this Annual Report on Form 10-K. Any of the following risks could materially and adversely affect our business, strategies, prospects, financial condition, results of operations, and cash flows. In such case, the market price of our common stock could decline. Our business, prospects, financial condition, or results of operations could also be harmed by risks and uncertainties not currently known to us or that we currently do not believe are material.

 

Risks Related to Our Business, Operations and Financial Condition

 

We have had a limited operating history and may not be able to successfully operate our business or execute our business plan.

 

Given our limited operating history, it is hard to evaluate our proposed business and prospects. Our proposed business operations will be subject to numerous risks, uncertainties, expenses and difficulties associated with early-stage enterprises. Such risks include, but are not limited to, the following:

 

  ● the absence of a lengthy operating history;
     
  ● potential for ongoing operating losses;
     
  ● operating in multiple currencies;
     
  ● our ability to anticipate and adapt to a developing market(s);
     
  ● acceptance of our products by the medical and industrial (I4.0) markets and consumers;
     
  ● introducing innovation to conservative industries;
     
  ● development risks and implementation of new software and algorithm for AI and cloud utilization;
     
  ● insufficient capital to fully realize our operating plan;
     
  ● a competitive environment;
     
  ● the ability to identify, attract, and retain qualified personnel; and
     
  ● operating in an environment that is highly regulated by a number of agencies.

 

Because we are subject to these risks, evaluating our business may be difficult, our business strategy may be unsuccessful and we may be unable to address such risks in a cost-effective manner, if at all. We have not earned a profit in any full fiscal year since our inception, and we cannot be certain as to when or if we will achieve or maintain profitability. If we are unable to successfully address these risks our business could be harmed.

 

13

 

 

If we are unable to establish sales, marketing and distribution capabilities or enter into successful relationships with business targets and third parties to perform these services, we may not be successful in commercializing our products and technology.

 

Given that we are currently as a B2B company, our business is reliant on our ability to successfully attract potential business targets. Furthermore, we have a limited sales and marketing infrastructure and have limited experience in the sale, marketing, or distribution of our technologies beyond the B2B model. To achieve commercial success for our technologies or any future developed product, we will need to establish a sales and marketing infrastructure or to out-license such future products.

 

In the future, we may consider building a focused sales and marketing infrastructure to market any developed products and potentially other products in the United States or elsewhere in the world. There are risks involved with establishing our own sales, marketing, and distribution capabilities. For example, recruiting and training a sales force could be expensive and time consuming and could delay any product launch. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.

 

Factors that may inhibit our efforts to commercialize any future products on our own include:

 

  ● we have not recruited adequate numbers of effective sales and marketing personnel;
     
  ● the challenge of sales personnel to obtain access to potential customers;
     
  ● the lack of complementary products to be offered by sales personnel or lack of product-market fit, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and
     
  ● unforeseen costs and expenses associated with creating an independent sales and marketing organization.

 

If we are unable to establish our own sales, marketing, and distribution capabilities or enter into successful arrangements with third parties to perform these services, we will not be successful in commercializing our technologies or any future products we may develop and our revenues and profitability may be materially adversely affected.

 

We may require substantial additional funding, which may not be available to us on acceptable terms, or at all.

 

Our cash and short-term deposit balance as of December 31, 2022 was $13.1 million. We may require additional funding to fund and grow our operations and to develop certain products. There can be no assurance that financing will be available in amounts or on terms acceptable to us, if at all. In the event we required additional capital, the inability to obtain such capital will restrict our ability to grow and may reduce our ability to continue to conduct business operations. If we require and are unable to obtain additional financing, we will likely be required to curtail our development plans. In that event, current stockholders would likely experience a loss of most or all of their investment. Additional funding that we do obtain may be dilutive to the interests of existing stockholders.

 

Our failure to effectively manage growth could impair our business.

 

Our business strategy contemplates a period of rapid growth which may put a strain on our administrative and operational resources, and our funding requirements. Our ability to effectively manage growth will require us to successfully expand the capabilities of our operational and management systems, and to attract, train, manage, and retain qualified personnel. There can be no assurance that we will be able to do so, particularly if losses continue and we are unable to obtain sufficient financing. If we are unable to appropriately manage growth, our business, prospects, financial condition, and results of operations could be adversely affected.

 

14

 

 

Our commercial success depends upon the degree of market acceptance by such prospective markets and industries as defense and aviation, as well as by the medical community.

 

Our current business model is that of a B2B approach in which we seek to identify target businesses interested in integrating our technology or commissioning individual projects using our technology. Any product that we commission or that is brought to the market may or may not gain market acceptance by prospective customers. The commercial success of our technologies, commissioned products, and any future product that we may develop depends in part on the medical community as well as other industries for various use cases, depending on the acceptance by such industries of our commissioned products as a useful and cost-effective solution compared to current technologies. During 2022, we commenced proactive market penetration into industries other than the biomedical sector, such as the defense and aviation industries. If our technology or any future product that we may develop does not achieve an adequate level of acceptance, or does not garner significant commercial appeal, we may not generate significant revenue and may not become profitable. The degree of market acceptance will depend on a number of factors, including:

 

  ● the cost, safety, efficacy/performance, perceived value and convenience of our technology and any commissioned product and any future product that we may develop in relation to alternative products;

 

  ● the ability of third parties to enter into relationships with us;
     
  ● the effectiveness of our sales and marketing efforts;
     
  ● the strength of marketing and distribution support for, and timing of market introduction of, competing technology and products; and
     
  ● publicity concerning our technology or commissioned products or competing technology and products.

 

Our efforts to penetrate industries and educate the marketplace on the benefits of our technology, and reasons to seek the commissioning of products based on our technology, may require significant resources and may never be successful. Such efforts to educate the marketplace may require more resources than are required by conventional technologies.

 

Weakened global economic conditions may harm our industry, business and results of operations.

 

Our overall performance depends in part on worldwide economic conditions. Global financial developments and downturns seemingly unrelated to us or may harm us. The United States and other key international economies have been affected from time to time by falling demand for a variety of goods and services, restricted credit, reduced liquidity, reduced corporate profitability, volatility in credit, equity and foreign exchange markets, bankruptcies, inflation and overall uncertainty with respect to the economy, including with respect to tariff and trade issues. Weak economic conditions or the perception thereof, or significant uncertainty regarding the stability of financial markets related to stock market volatility, inflation, recession, changes in tariffs, trade agreements, or governmental fiscal, monetary and tax policies, among others, could adversely impact our business, financial condition and operating results.

 

More recently, inflation rates in the U.S. have been higher than in previous years, which may result in decreased demand for our products and services, increases in our operating costs including our labor costs, constrained credit and liquidity, reduced government spending and volatility in financial markets. The Federal Reserve has raised, and may again raise, interest rates in response to concerns over inflation risk. Increases in interest rates on credit and debt that would increase the cost of any borrowing that we may make from time to time and could impact our ability to access the capital markets. Increases in interest rates, especially if coupled with reduced government spending and volatility in financial markets, may have the effect of further increasing economic uncertainty and heightening these risks. In an inflationary environment, we may be unable to raise the sales prices of our products at or above the rate at which our costs increase, which could reduce our profit margins and have a material adverse effect on our financial results and net income. We also may experience lower than expected sales and potential adverse impacts on our competitive position if there is a decrease in consumer spending or a negative reaction to our pricing. A reduction in our revenue would be detrimental to our profitability and financial condition and could also have an adverse impact on our future growth.

 

15

 

 

The continuing effects of the COVID-19 pandemic are highly unpredictable and could be significant, and the duration and extent to which this will impact our future results of operations and overall financial performance remains uncertain.

 

The extent to which the COVID-19 pandemic ultimately impacts our business will depend on future developments, which are highly uncertain and cannot be predicted, such as the duration of future outbreaks, including current and subsequent variants of COVID-19, travel restrictions and social distancing in Israel, the United States and other countries, business closures or business disruptions, and the effectiveness of actions taken in Israel, the United States and other countries to contain and treat the disease and to address its impact, including on financial markets or otherwise. These measures have impacted, and may further impact, our suppliers and other business partners from conducting business activities as usual (including, without limitation, the availability and pricing of materials, manufacturing and delivery efforts, clinical trials and other aspects that may affect our business) for an unknown period of time. In addition, we, our suppliers and other business partners may experience significant impairments of business activities due to operational shutdowns or suspensions that may be requested or mandated by national or local governmental authorities or self-imposed by us, our suppliers or other business partners.

 

Risk Related to Third Parties

 

Our reliance on third-party suppliers for most of the components of our products could harm our ability to meet demand for our products in a timely and cost-effective manner.

 

We rely on our third-party suppliers to obtain an adequate supply of quality components on a timely basis with favorable terms to manufacture our commissioned products. Some of those components that we sell are provided to us by a limited number of suppliers. We will be subject to disruptions in our operations if our sole or limited supply contract manufacturers decrease or stop production of components or do not produce components and products of sufficient quantity or quality. Alternative sources for our components will not always be available.

 

Though we attempt to ensure the availability of more than one supplier for each important component in any product that we commission, the number of suppliers engaged in the provision of miniature video sensors which are suitable for our CMOS technology mainly in the medical domain is very limited, and therefore in some cases we engage with a single supplier, which may result in our dependency on such supplier. This is the case regarding sensors for the CMOS type technology that are produced by a single supplier in the United States. As we do not have a direct general contract in place with this supplier, there is no contractual commitment on the part of such supplier for any set quantity of such sensors. The loss of our sole supplier in providing us with miniature sensors for our CMOS technology products mainly in the medical domain, and our inability or delay in finding a suitable replacement supplier, could negatively affect our business, financial condition, results of operations, and reputation.

 

We are also subject to other risks inherent in the manufacturing of our products and their supply chain, including industrial accidents, natural disasters (including as a result of climate change), environmental events, strikes, and other labor disputes, capacity constraints, disruptions in material or packaging supplies, as well as global shortages, disruptions in supply chain or information technology, loss or impairment of key manufacturing sites or suppliers, product quality control, safety, increase in commodity prices and energy costs, licensing requirements and other regulatory issues, as well as other external factors over which we have no control. If such an event were to occur, it could have an adverse effect on our business, financial condition, and results of operations.

 

In addition, if we cannot supply commissioned products or future potentially developed products due to a lack of components or are unable to utilize other components in a timely manner, our business will be significantly harmed. If inventory shortages occur, they could be expected to have a material and adverse effect on our future revenues and ability to effectively project future sales and operating results.

 

16

 

 

We may not be able to manage our strategic partners effectively.

 

We have entered into, and we may continue to enter into, strategic alliances with third parties to gain access to new and innovative technologies and markets. These parties are often large, established companies. Negotiating and performing under these arrangements involves significant time and expense, and we may not have sufficient resources to devote to our strategic alliances, particularly those with companies that have significantly greater financial and other resources than we do. The anticipated benefits of these arrangements may never materialize and performing under these arrangements may adversely affect our results of operations.

 

Failure to manage our current partners effectively or enter into new strategic alliances may affect our success in executing our business plan and may adversely affect our business, financial condition, and results of operation. We may not realize the anticipated benefits of any or all partnerships or may not realize them in the time frame expected.

 

We may not have sufficient manufacturing capabilities to satisfy any growing demand for our commissioned products. We may be unable to control the availability or cost of producing such products.

 

Our current manufacturing capabilities may not reach the required production levels necessary in order to meet growing demands for any products we may commission or future products we may develop. There can be no assurance that our commissioned products can be manufactured at our desired commercial quantities, in compliance with our requirements, and at an acceptable cost. Any such failure could delay or prevent us from shipping said products and marketing our technologies in accordance with our target growth strategies.

 

Risks Related to Competition

 

We expect to face competition. If we cannot successfully compete with new or existing technologies or future developed products, our marketing and sales will suffer and we may never be profitable.

 

We expect to compete against existing technologies and proven products in different industries. In addition, some of these competitors, either alone or together with their collaborative partners, operate larger research and development programs than we do, and may have substantially greater financial resources than we do, as well as significantly greater experience in obtaining regulatory approvals applicable to the commercialization of relevant competitive technologies and future products.

 

Failure to comply with anti-bribery, anti-corruption and anti-money laundering laws could subject us to penalties and other adverse consequences.

 

We are subject to the U.S. Foreign Corrupt Practices Act, or the FCPA, Chapter 9 (sub-chapter 5) of the Israeli Penal Law, 5737-1977, and the Israeli Prohibition on Money Laundering Law, 5760-2000, collectively, the Israeli Anti-Corruption Laws, and the UK Bribery Act 2010, or UK Bribery Act, and other anticorruption, anti-bribery and anti-money laundering laws in the jurisdictions in which we do business, both domestic and abroad. These laws generally prohibit us and our employees from improperly influencing government officials or commercial parties in order to obtain or retain business, direct business to any person or gain any advantage. The FCPA, the Israeli Anti-Corruption Laws, the UK Bribery Act, and other applicable anti-bribery and anti-corruption laws also may hold us liable for acts of corruption and bribery committed by our third-party business partners, representatives and agents. In addition, we leverage third parties to sell our products and conduct our business abroad. We and our third-party business partners, representatives and agents may have direct or indirect interactions with officials and employees of government agencies or state-owned or affiliated entities and we may be held liable for the corrupt or other illegal activities of these third-party business partners and intermediaries, our employees, representatives, contractors, channel partners and agents, even if we do not explicitly authorize such activities. These laws also require that we keep accurate books and records and maintain internal controls and compliance procedures designed to prevent any such actions. While we have policies and procedures to address compliance with such laws, we cannot assure you that our employees and agents will not take actions in violation of our policies or applicable law, for which we may be ultimately held responsible and our exposure for violating these laws increases as our international presence is established and as we increase sales and operations in foreign jurisdictions. Any violation of the FCPA, the Israeli Anti-Corruption Laws, the UK Bribery Act, or other applicable anti-bribery, anti-corruption laws and anti-money laundering laws could result in whistleblower complaints, adverse media coverage, investigations, imposition of significant legal fees, loss of export privileges, severe criminal or civil sanctions or suspension or debarment from U.S. government contracts, substantial diversion of management’s attention, a decline in the market price of our common stock or overall adverse consequences to our reputation and business, all of which may have an adverse effect on our results of operations and financial condition.

 

17

 

 

Risks Related to Intellectual Property

 

We may not be able to obtain patents or other intellectual property rights necessary to protect our proprietary technology and business.

 

We may seek to patent concepts, components, processes, designs and methods, and other inventions and technologies that we consider to have commercial value or that will likely give us a technological advantage. Despite devoting resources to the research and development of proprietary technology, we may not be able to develop technology that is patentable or protectable. Patents may not be issued in connection with pending patent applications, and claims allowed may not be sufficient to allow them to use the inventions that they create exclusively. Furthermore, any patents issued could be challenged, re-examined, held invalid or unenforceable, or circumvented and may not provide sufficient protection or a competitive advantage. In addition, despite efforts to protect and maintain patents, competitors and other third parties may be able to design around their patents or develop products similar to our work products that are not within the scope of their patents. Finally, patents provide certain statutory protection only for a limited period of time that varies depending on the jurisdiction and type of patent.

 

Prosecution and protection of the rights sought in patent applications and patents can be costly, lengthy, and uncertain, often involve complex legal and factual issues, and consume significant time and resources. In addition, the breadth of claims allowed in our patents, their enforceability, and our ability to protect and maintain them cannot be predicted with any certainty. The laws of certain countries may not protect intellectual property rights to the same extent as the laws of the United States. Even if our patents are held to be valid and enforceable in a certain jurisdiction, any legal proceedings that we may initiate against third parties to enforce such patents will likely be expensive, take significant time, and divert management’s attention from other business matters. We cannot assure that any of our issued patents or pending patent applications provide any protectable, maintainable, or enforceable rights or competitive advantages to us.

 

In addition to patents, we plan to rely on a combination of copyrights, trademarks, trade secrets, and other related laws and confidentiality procedures and contractual provisions to protect, maintain, and enforce our proprietary technology and intellectual property rights in the United States and other countries. However, our ability to protect our brands by registering certain trademarks may be limited. In addition, while we will generally enter into confidentiality and nondisclosure agreements with our employees, consultants, contract manufacturers, distributors and resellers, and with others to attempt to limit access to and distribution of our proprietary and confidential information, it is possible that:

 

● misappropriation of our proprietary and confidential information, including technology, will nevertheless occur;
   
● our confidentiality agreements will not be honored or may be rendered unenforceable;

 

● third parties will independently develop equivalent, superior, or competitive technology or products;
   
● disputes will arise with our current or future strategic licensees, customers, or others concerning the ownership, validity, enforceability, use, patentability, or registrability of intellectual property; or
   
● unauthorized disclosure of our know-how, trade secrets, or other proprietary or confidential information will occur.

 

We may not be successful in enforcing our intellectual property rights against third parties.

 

Unlicensed copying and use of our intellectual property or infringement of our intellectual property rights may result in the loss of revenue to us and cause us other harm. We seek diligently to enforce our intellectual property rights. Although we devote significant resources to developing and protecting our technologies, and evaluating potential competitors of our technologies for infringement of our intellectual property rights, these infringements may nonetheless go undetected or may arise in the future. In the ordinary course of business, we encounter companies that we suspect are infringing on our intellectual property rights. When we encounter a company that we suspect is infringing our intellectual property rights, we may try to analyze their products and/or try to negotiate a license arrangement with such party. If we try and are unable to negotiate a license or secure the agreement of such alleged infringing party to cease its activities, we must make decisions as to how best to enforce our intellectual property rights.

 

18

 

 

The process of negotiating a license with a third party can be lengthy, and may take months or even years in some circumstances. Even if we are successful in securing a license agreement, there can be no assurance that our technologies will be used in a product that is ultimately brought to market, achieves commercial acceptance or results in significant royalties to us. We generally incur expense prior to entering into our license agreements, generating a license fee, and establishing a royalty stream from each customer. We may incur costs in any particular period before any associated revenue stream begins, if at all. Further, it is possible that third parties who we believe are infringing our intellectual property rights are unwilling to license our intellectual property from us on terms we can accept, or at all.

 

If we cannot persuade a third party who we believe is infringing our technology to enter into a license with us, we may be required to consider other alternatives to enforce our rights, including commencing litigation. The decision to commence litigation over infringement of a patent is complex and may lead to several risks to us, including the following, among others:

 

  ● the time, significant expense and distraction to management of managing such litigation;
     
  ● the uncertainty of litigation and its potential outcomes;
     
  ● the possibility that in the course of such litigation, the defendant may challenge the validity of our patents, which could result in a re-examination or post grant review of our patents and the possibility that our patents may be limited in scope or invalidated altogether;
     
  ● the potential that the defendant may successfully persuade a court that their technology or products do not infringe our intellectual property rights;
     
  ● the impact of such litigation on other licensing relationships we have or seek to establish, including the timing of renewing or entering into such relationships, as applicable, as well as the terms of such relationships; and
     
  ● adverse publicity to us or harm to relationships we have with customers or others.

 

Also, enforcement of patent protection throughout the world is generally established on a country-by-country basis and we may not have as much success enforcing our patents in foreign jurisdictions as in the United States. Further, in some instances, certain foreign governmental entities that might infringe our intellectual property rights may enjoy sovereign immunity from such claims. Consequently, effective protection of our intellectual property rights may be unavailable or limited.

 

Defendants in any litigation we consider commencing may have substantially greater financial and management resources necessary to manage litigation than we have. Further, such potential defendants may also have their own substantial patent portfolio. Patent litigation can endure for years and result in millions of dollars of expenses. If our counterparties in such litigation have substantially greater resources than we have, we may not be able to withstand the time, expense, or distraction of the litigation, even though we may have a better litigation position than such counterparties. In such instances we may not recover the expenses of litigation, and we may be required to enter into settlement agreements that would be adverse to us or our intellectual property portfolio.

 

The foregoing and other factors may cause us not to file or continue litigation against alleged infringers of our intellectual property rights, or may cause us not to file for, or pursue, patent protection for our inventive technology, in certain jurisdictions. Our failure to seek to enforce our intellectual property rights may weaken our ability to enforce our intellectual property in the future or make our efforts to license our intellectual property rights more difficult.

 

If we fail to protect our intellectual property rights adequately, if there are adverse changes in applicable laws, or if we become involved in litigation relating to our intellectual property rights or the intellectual property rights of others, our business could be seriously harmed. In such cases, the value ascribed to our intellectual property could diminish, we may incur significant legal expenses that could harm our results of operations, and our patents or other intellectual property rights may be limited or invalidated. Any of the foregoing could have a negative effect on the value of our common stock.

 

19

 

 

We may be subject to infringement claims and other litigation, which could adversely affect our business.

 

As more companies engage in business activities relating to predictive maintenance solutions, and develop corresponding intellectual property rights, it is increasingly likely that claims may arise which assert that some of our products or services infringe upon other parties’ intellectual property rights. These claims could subject us to costly litigation and divert management resources. These claims may require us to pay significant damages, cease production of infringing products, terminate our use of infringing technology, or develop non-infringing technologies. In these circumstances, continued use of our technology may require that we acquire licenses to the intellectual property that is the subject of the alleged infringement, and we might not be able to obtain these licenses on commercially reasonable terms or at all. Our use of protected technology may result in liability that could threaten our continued operation.

 

Some of the contracts with our customers include indemnity and similar provisions regarding our non-infringement of third-party intellectual property rights. As deployment of our technology increases, and more companies enter our markets, the likelihood of a third party lawsuit resulting from these provisions increases. If an infringement arose in a context governed by such a contract, we may have to refund to our customer amounts already paid to us or pay significant damages, or we may be sued by the party whose intellectual property has allegedly been infringed upon.

 

Governmental regulation of non-practicing patent holders may adversely affect our business.

 

Governmental policymakers and commercial participants have proposed reforming U.S. patent laws and regulations in a manner that may limit a patent-holder’s ability to enforce its patents against others to the extent that the holder is not practicing the subject matter of the patent at issue. The U.S. International Trade Commission has also recently taken certain actions that have been viewed as unfavorable to patentees seeking recourse in this forum. While we cannot predict what form any new patent reform laws or regulations may ultimately take, or what impact they may have on our business, any laws or regulations that restrict our ability to enforce our patent rights against third parties could have a material adverse effect on our business.

 

General Risk Factors Related to Our Business

 

Our business and operations would suffer in the event of computer system failures, cyber-attacks, or deficiencies in our cyber-security.

 

Security incidents involving our information technology systems and those of third parties on which we rely have occurred in the past, such as phishing attacks, although none of these incidents have been material to our business. Such security incidents may occur in the future. Despite the implementation of security measures, our internal computer systems, and those of third parties on which we rely, are vulnerable to damage from computer viruses, malware, natural disasters, terrorism, war, telecommunication and electrical failures, cyber-attacks or cyber-intrusions over the Internet, attachments to emails, persons inside our organization, or persons with access to systems inside our organization. The risk of a security breach or disruption, particularly through cyber-attacks or cyber intrusion, including by computer hackers, foreign governments, and cyber terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our product development programs. To the extent that any disruption or security breach was to result in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur material legal claims and liability, and damage to our reputation, and the further development of our product candidates could be delayed. We face an increasingly difficult challenge to attract and retain highly qualified security personnel to assist us in combatting these security threats.

 

We may be subject to product liability claims, product actions, including product recalls, and other field or regulatory actions that could be expensive, divert management’s attention, and harm our business.

 

Our business exposes us to potential liability risks, product actions, and other field or regulatory actions that are inherent in the manufacturing, marketing and sale of medical device, or any other products that we may have commissioned for a target business. We may be held liable if such products cause injury or death or are found otherwise unsuitable or defective during usage. Our products incorporate mechanical and electrical parts, complex computer software, and other sophisticated components, any of which can contain errors or failures. Complex computer software is particularly vulnerable to errors and failures, especially when first introduced. In addition, new products or enhancements to our existing products may contain undetected errors or performance problems that, despite testing, are discovered only after installation.

 

If any of our commissioned products are defective, whether due to design or manufacturing defects, improper use of the product, or other reasons, we may voluntarily or involuntarily undertake an action to remove, repair, or replace the product at our expense. In some circumstances we will be required to notify regulatory authorities of an action pursuant to a product failure.

 

20

 

 

Testing of our technologies potential applications for our products will be required and there is no assurance of regulatory approval.

 

The effect of government regulation and the need for compliance may delay marketing of our technologies and future potentially developed products for a considerable period of time, impose costly procedures upon our activities, and provide an advantage to larger companies that compete with us. There can be no assurance that we will be able to achieve regulatory compliance for any of our products. Any such delay in achieving such regulatory compliance would materially and adversely affect the marketing of any contemplated products and the ability to earn product revenue. Further, regulation of manufacturing facilities by state, local, and other authorities is subject to change. Any additional regulation could result in limitations or restrictions on our ability to utilize any of our technologies, thereby adversely affecting our operations. Various federal and foreign statutes and regulations also govern or influence the manufacturing, safety, labeling, storage, record keeping, and marketing of our products. The process of compliance with relevant U.S. and foreign statutes and regulations are time-consuming and require the expenditure of substantial resources. In addition, these requirements and processes vary widely from country to country.

 

We rely on highly skilled personnel as a result of the high-tech applications we utilize, and if we are unable to attract, retain, or motivate qualified personnel, we may not be able to operate our business effectively.

 

Our success depends in large part on continued employment of senior management and key personnel who can effectively operate our business, as well as our ability to attract and retain skilled employees. Competition for highly skilled management, technical, research and development, and other employees is intense and we may not be able to attract or retain highly qualified personnel in the future. Our long-term incentive programs may not be attractive enough or perform sufficiently to attract or retain qualified personnel.

 

If a significant portion of our employees leaves us, we might fail to effectively manage a transition to new personnel, or if we fail to attract and retain qualified and experienced professionals on acceptable terms, our business, financial condition, and results of operations could be adversely affected.

 

Further, the volatility of our stock price may make our equity compensation less attractive to current and potential employees.

 

Our success also depends on our having highly trained financial, technical, R&D, sales, and marketing personnel. We will need to continue to hire additional personnel as our business grows. A shortage in the number of people with these skills or our failure to attract them to our company could impede our ability to increase revenues from our existing technology and services, ensure full compliance with international and federal regulations, or launch new product offerings and would have an adverse effect on our business and financial results.

 

We may be unable to keep pace with changes in technology as our business and market strategy evolves.

 

We will need to respond to technological advances in a cost-effective and timely manner in order to remain competitive. The need to respond to technological changes may require us to make substantial, unanticipated expenditures. There can be no assurance that we will be able to respond successfully to technological change.

 

21

 

 

Risks Related to this Offering and Our Common Stock

 

Although we have filed an application to list our securities on Nasdaq, there can be no assurance that our securities will be so listed or, if listed, that we will be able to comply with the continued listing standards.

 

In June 2021 we filed a comprehensive listing application package with The Nasdaq Stock Market, or Nasdaq, to request an uplisting of the Company’s common stock. Nasdaq has not approved our application, and there can be no assurance that Nasdaq will approve us for listing on The Nasdaq Capital Market and, even if our securities are listed, we cannot assure you that we will be able to maintain such listing. In addition, if after listing, Nasdaq delists our securities from trading on its exchange for failure to meet the continued listing standards, we and our shareholders could face significant material adverse consequences including a limited availability of market quotations for our common stock, confirmation that our stock is “penny stock” and subject to increased regulations, and a decreased ability to issue additional securities or obtain additional financing in the future.

 

Trading on the OTC Markets is volatile, sporadic and often thin, which could depress the market price of our common stock and make it difficult for our stockholders to resell their common stock.

 

Our common stock is currently quoted on the OTCQB tier of the OTC Markets. Trading in securities quoted on the OTC Markets is often thin and characterized by wide fluctuations in trading prices due to many factors, some of which may have little to do with our operations or business prospects. This volatility could depress the market price of our common stock for reasons unrelated to operating performance. Moreover, the OTC Markets is not a stock exchange, and trading of securities on the OTC Markets is often more sporadic than the trading of securities listed on a stock exchange like NASDAQ or the NYSE. Our common stock has a history of thin trading. During the 52-week period ended December 31, 2022, trades were only reported on 37 trading days. These factors may result in investors having difficulty reselling any shares of our common stock.

 

Anti-takeover provisions contained in our articles and bylaws, as well as provisions of Nevada law, could impair a takeover attempt.

Our amended and restated articles of incorporation and bylaws currently contain provisions that, together with Nevada law, could have the effect of rendering more difficult or discouraging an acquisition deemed undesirable by our board of directors. Our corporate governance documents presently include provisions such as providing for a “staggered” board of directors in which only one-third (1/3) of the directors can be elected in any year, and limiting the liability of, and providing indemnifications to, our directors and officers. These provisions, alone or together, could delay hostile takeovers and changes in control of our company or changes in our management.

 

As a Nevada corporation, we may also become subject to the provisions of Nevada Revised Statutes Sections 78.378 through 78.3793, which prohibit an acquirer, under certain circumstances, from voting shares of a corporation’s stock after crossing specific threshold ownership percentages, unless the acquirer obtains the approval of the stockholders of the issuer corporation. The first such threshold is the acquisition of at least one-fifth, but less than one-third of the outstanding voting power of the issuer. We may become subject to the above referenced Statutes if we have 200 or more stockholders of record, at least 100 of whom are residents of the State of Nevada and do business in the State of Nevada directly or through an affiliated corporation.

 

Any provision of our amended and restated articles of incorporation, our bylaws or Nevada law that has the effect of delaying or deterring a change in control of our company could limit the opportunity for our stockholders to receive a premium for their shares of our common stock and could also affect the price that some investors are willing to pay for our common stock.

 

The market price of our common stock may be highly volatile and such volatility could cause you to lose some or all of your investment.

 

The market price of our common stock may fluctuate significantly in response to numerous factors, some of which are beyond our control, such as:

 

● the announcement of new products or product enhancements by us or our competitors;
   
● developments concerning intellectual property rights;

 

22

 

 

● changes in legal, regulatory, and enforcement frameworks impacting our technology or the application of our technology;
   
● variations in our and our competitors’ results of operations;
   
● fluctuations in earnings estimates or recommendations by securities analysts, if our common stock is covered by analysts;
   
● the results of product liability or intellectual property lawsuits;
   
●

future issuances of common stock or other securities;

 

● the addition or departure of key personnel;

 

● announcements by us or our competitors of acquisitions, investments or strategic alliances;
   
● current or anticipated impact of military conflict, including the conflict between Russia and Ukraine, terrorism or other geopolitical events;
   
● sanctions imposed by the United States and other countries in response to such conflicts, including the one in Ukraine, may also adversely impact the financial markets and the global economy, and any economic countermeasures by affected countries and others could exacerbate market and economic instability; and
   
● general market conditions and other events or factors, many of which are beyond our control.
   

In addition, the stock market has experienced significant volatility, particularly with respect to pharmaceutical, biotechnology and other life sciences company stocks. The volatility of pharmaceutical, biotechnology and other life sciences company stocks often does not relate to the operating performance of the companies represented by the stock. In the past, securities class action litigation has often been initiated against companies following periods of volatility in their stock price. This type of litigation could result in substantial costs and divert our management’s attention and resources, and could also require us to make substantial payments to satisfy judgments or to settle litigation.

 

Because our common stock may be deemed a “penny stock,” it may be more difficult for investors to sell shares of our common stock, and the market price of our common stock may be adversely affected.

 

Our common stock may be a “penny stock” if, among other things, the stock price is below $5.00 per share, it is not listed on a national securities exchange, or it has not met certain net tangible asset or average revenue requirements. Broker-dealers who sell penny stocks must provide purchasers of these stocks with a standardized risk-disclosure document prepared by the SEC. This risk-disclosure document provides information about penny stocks and the nature and level of risks involved in investing in the penny-stock market. A broker must also give a purchaser, orally or in writing, bid and offer quotations and information regarding broker and salesperson compensation, make a written determination that the penny stock is a suitable investment for the purchaser and obtain the purchaser’s written agreement to the purchase. Broker-dealers must also provide customers that hold penny stock in their accounts with such broker-dealer a monthly statement containing price and market information relating to the penny stock. If a penny stock is sold to an investor in violation of the penny stock rules, the investor may be able to cancel its purchase and get their money back.

 

If applicable, the penny stock rules may make it difficult for stockholders to sell their shares of our common stock. Because of the rules and restrictions applicable to a penny stock, there is less trading in penny stocks and the market price of our common stock may be adversely affected. Also, many brokers choose not to participate in penny stock transactions. Accordingly, stockholders may not always be able to resell their shares of our common stock publicly at times and prices that they feel are appropriate.

 

23

 

 

Compliance with the reporting requirements of federal securities laws can be expensive.

 

We are a public reporting company in the United States, and accordingly, subject to the information and reporting requirements of the Securities Exchange Act of 1934 and other federal securities laws. The costs of preparing and filing annual and quarterly reports and other information with the SEC and furnishing audited reports to stockholders are substantial. Failure to comply with the applicable securities laws could result in private or governmental legal action against us or our officers and directors, which could have a detrimental impact on our business and financials, the value of our stock, and the ability of stockholders to resell their stock.

 

Our investors’ ownership in the Company may be diluted in the future.

 

In the future, we may issue additional authorized but previously unissued equity securities, resulting in the dilution of ownership interests of our present stockholders. We have in the past and may continue to issue a substantial number of shares of common stock or other securities convertible into or exercisable for common stock in connection with capital raising activity, hiring or retaining employees, future acquisitions, raising additional capital in the future to fund our operations, and other business purposes. We expect to authorize in the future a substantial number of shares of our common stock for issuance under a stock option or similar plan, and may issue equity awards to management, employees and other eligible persons. Additional shares of common stock issued by us in the future will dilute an investor’s investment in the Company. In addition, we may seek stockholder approval to increase the amount of the Company’s authorized stock, which would create the potential for further dilution of current investors.

 

Directors, executive officers, principal stockholders, and affiliated entities own a significant percentage of our capital stock, and they may make decisions that our stockholders do not consider to be in their best interests.

 

As of March 28, 2023, our directors, executive officers, principal stockholders, and affiliated entities may be deemed to beneficially own, in the aggregate, approximately 84.40% of our outstanding voting securities. As a result, if some or all of such parties acted together, they would have the ability to exert substantial influence over the election of our board of directors and the outcome of issues requiring approval by our stockholders. This concentration of ownership may also have the effect of delaying or preventing a change in control of the Company that may be favored by other stockholders. This could prevent transactions in which stockholders might otherwise recover a premium for their shares over current market prices. This concentration of ownership and influence in management and board decision-making could also harm the price of our capital stock by, among other things, discouraging a potential acquirer from seeking to acquire shares of our capital stock (whether by making a tender offer or otherwise) or otherwise attempting to obtain control of our Company.

 

We do not anticipate paying any cash dividends in the foreseeable future.

 

We have never declared or paid cash dividends, and we do not anticipate paying cash dividends in the foreseeable future. Therefore, you should not rely on an investment in our common stock as a source for any future dividend income. Our board of directors has complete discretion as to whether to distribute dividends. Even if our board of directors decides to declare and pay dividends, the timing, amount, and form of future dividends, if any, will depend on our future results of operations and cash flow, our capital requirements and surplus, the amount of distributions, if any, received by us from our subsidiary, our financial condition, contractual restrictions, and other factors deemed relevant by our board of directors.

 

Risks Related to our Operations in Israel

 

We are subject to the risks of political, economic, health, and military instability in countries outside the United States in which we operate.

 

Some of our products are produced in Israel, India, China, and other countries which are particularly subject to risks of political, economic, health, and military instability. This instability could result in wars, riots, nationalization of industry, currency fluctuations, and labor unrest or unavailability. These conditions could have an adverse impact on our ability to manufacture, ship, and operate in these regions and, depending on the extent and severity of these conditions, could result in a reduction in customer orders and sales to certain regions and end-markets and materially and adversely affect our overall financial condition and operating results. We have principal manufacturing facilities and operations located in Israel. Accordingly, our business will be directly influenced by the political, economic and military conditions affecting Israel at any given time.

 

24

 

 

Political, economic and military instability in Israel may impede our ability to operate and harm our financial results.

 

Our offices and management team are located in Israel. Accordingly, political, economic, and military conditions in Israel and the surrounding region may directly affect our business and operations. Since the establishment of the State of Israel in 1948, a number of armed conflicts have occurred between Israel and its neighboring countries. We have never experienced any material interruption in our operations attributable to these factors, in spite of several Middle East crises, including wars. A change in the security and political situation in Israel and in the economy could have a material adverse effect on our business, operating results, and financial condition.

 

In recent years, Israel has been subject to certain political instability and increased number of elections were held. Actual or perceived political instability in Israel or any negative changes in the political environment, may individually or in the aggregate adversely affect the Israeli economy and, in turn, our business, financial condition, results of operations and growth prospects. Israel is still engaged in sporadic armed conflicts with Hamas, an Islamist terrorist group that controls the Gaza Strip, with Hezbollah, an Islamist terrorist group that controls large portions of southern Lebanon, and with Iranian-backed military forces in Syria. In addition, Iran has threatened to attack Israel and may be developing nuclear weapons. Some of these hostilities were accompanied by missiles being fired from the Gaza Strip against civilian targets in various parts of Israel, including areas in which our employees and some of our consultants are located, and negatively affected business conditions in Israel. Any hostilities involving Israel or the interruption or curtailment of trade between Israel and its trading partners could adversely affect our operations and results of operations.

 

Our commercial insurance does not cover losses that may occur as a result of events associated with war and terrorism. Although the Israeli government currently covers the reinstatement value of direct damages that are caused by terrorist attacks or acts of war, we cannot assure you that this government coverage will be maintained or that it will sufficiently cover our potential damages. Any losses or damages incurred by us could have a material adverse effect on our business. Any armed conflicts or political instability in the region would likely negatively affect business conditions and could harm our results of operations.

 

Further, in the past, the State of Israel and Israeli companies have been subjected to economic boycotts. Several countries still restrict business with the State of Israel and with Israeli companies. These restrictive laws and policies may have an adverse impact on our operating results, financial condition, or the expansion of our business. A campaign of boycotts, divestment, and sanctions has been undertaken against Israel, which could also adversely impact our business.

 

In addition, many Israeli citizens are obligated to perform several days, and in some cases more, of annual military reserve duty each year until they reach the age of 40 (or older, for reservists who are military officers or who have certain occupations) and, in the event of a military conflict, may be called to active duty. In response to increases in terrorist activity, there have been periods of significant call-ups of military reservists. It is possible that there will be military reserve duty call-ups in the future. Our operations could be disrupted by such call-ups, which may include the call-up of members of our management. Such disruption could materially adversely affect our business, prospects, financial condition, and results of operations.

 

In the beginning of 2023, the newly formed government commenced a legislative process to effect changes in the Israeli legal system. Certain financial, legal, and commercial organizations and entities have claimed that such changes will weaken the Israeli legal system and, as a result, could lead to negative impact on the economic and financial conditions of the State of Israel. At this stage, where the proposed legislation has not become effective, and its scope is not fully determined, we cannot assess the possible impacts of these changes and their likelihood. Changes in the Israeli economy could make it more difficult for us to operate our business and could have a material adverse effect on our business, reputation, financial condition, results of operation, and cash flow.

 

25

 

 

It may be difficult for investors in the United States to enforce any judgments obtained against us or some of our directors or officers.

 

It may be difficult to acquire jurisdiction and enforce liabilities against any of our officers and directors who are based in Israel. It may not be possible for United States investors to enforce their legal rights, to effect service of process upon our directors or officers or to enforce judgments of United States courts predicated upon civil liabilities and criminal penalties of our directors and officers under federal securities laws. Moreover, we have been advised that Israel does not have treaties providing for the reciprocal recognition and enforcement of judgments of courts with the United States. Further, it is unclear if extradition treaties now in effect between the United States and Israel would permit effective enforcement of criminal penalties of the federal securities laws. Even if an Israeli court agrees to hear a claim, it may determine that the Israeli law, and not U.S. law, is applicable to the claim. Further, if U.S. law is found to be applicable, certain content of applicable U.S. law must be proved as a fact, which can be a time-consuming and costly process, and certain matters of procedure would still be governed by the Israeli law. Consequently, you may be effectively prevented from pursuing remedies under U.S. federal and state securities laws against us or any of our non-U.S. directors or officers.

 

Exchange rate fluctuations between foreign currencies and the U.S. Dollar may negatively affect our earnings.

 

Our reporting and functional currency is the U.S. dollar. Our revenues are currently primarily payable in U.S. dollars and we expect our future revenues to be denominated primarily in U.S. dollars. However, some of our expenses are in New Israeli Shekels (NIS) and as a result, we are exposed to the currency fluctuation risks relating to the recording of our expenses in U.S. dollars. We may, in the future, decide to enter into currency hedging transactions. These measures, however, may not adequately protect us from material adverse effects.

 

Exchange rate movements have impacted and may continue to impact our consolidated revenues and operating results. It is particularly difficult to forecast exchange rate movements and unanticipated currency fluctuations have affected and could continue to affect our financial results and cause our results to differ from investor expectations or our own guidance in any future periods. Volatility in exchange rates and global financial markets is expected to continue due to political and economic uncertainty globally

 

Certain technology developed and used by us received Israeli government grants for certain research and development activities. The terms of those grants require us to satisfy specified conditions in addition to repayment of the grants upon certain events.

 

The research and development efforts that contributed to certain technology used by us was financed in part through grants from the IIA to Medigus, which was subsequently transferred to ScoutCam Ltd. (for more information about such agreements, refer to – “CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE” below”). The terms of such grants require ScoutCam Ltd. to comply with the requirements of the Innovation Law. When a company develops know-how, technology or products using IIA grants, the terms of these grants and the Innovation Law restrict the transfer outside of Israel of such know-how, and the manufacturing or manufacturing rights of such products, technologies or know-how, without the prior approval of the IIA. Therefore, if aspects of our technologies are deemed to have been developed with IIA funding, the discretionary approval of an IIA committee would be required for any transfer to third parties outside of Israel of know-how or manufacturing or manufacturing rights related to those aspects of such technologies. We may not receive those approvals. Furthermore, the IIA may impose certain conditions on any arrangement under which it permits us to transfer technology or development out of Israel.

 

The transfer of IIA-supported technology or know-how or manufacturing or manufacturing rights related to aspects of such technologies outside of Israel may involve the payment of significant penalties and other amounts, depending upon the value of the transferred technology or know-how, the amount of IIA support, the time of completion of the IIA-supported research project and other factors. These restrictions and requirements for payment may impair our ability to sell our technology assets outside of Israel or to outsource or transfer development or manufacturing activities with respect to any product or technology outside of Israel. Furthermore, the consideration available to our shareholders in a transaction involving the transfer outside of Israel of technology or know-how developed with IIA funding (such as a merger or similar transaction) may be reduced by any amounts that we are required to pay to the IIA.

 

26

 

 

We may become subject to claims for remuneration or royalties for assigned service invention rights by our employees, which could result in litigation and adversely affect our business.

 

A significant portion of our intellectual property has been developed by our employees in the course of their employment for us. Under the Israeli Patent Law, 5727-1967, or the Patent Law, inventions conceived by an employee in the course and as a result of or arising from his or her employment with a company are regarded as “service inventions,” which belong to the employer, absent a specific agreement between the employee and employer giving the employee service invention rights. The Patent Law also provides that if there is no such agreement between an employer and an employee, the Israeli Compensation and Royalties Committee, or the Committee, a body constituted under the Patent Law, will determine whether the employee is entitled to remuneration for his inventions. Recent case law clarifies that the right to receive consideration for “service inventions” can be waived by the employee and that in certain circumstances, such waiver does not necessarily have to be explicit. The Committee will examine, on a case-by-case basis, the general contractual framework between the parties, using interpretation rules of the general Israeli contract laws. Further, the Committee has not yet determined one specific formula for calculating this remuneration (but rather uses the criteria specified in the Patent Law). Although we generally enter into assignment-of-invention agreements with our employees pursuant to which such individuals assign to us all rights to any inventions created in the scope of their employment or engagement with us, we may face claims demanding remuneration in consideration for assigned inventions. As a consequence of such claims, we could be required to pay additional remuneration or royalties to our current and/or former employees, or be forced to litigate such claims, which could negatively affect our business.

 

Item 1b. unresolved staff comments

 

Not applicable.

 

Item 2. properties

 

We do not own property and currently lease our principal corporate office and corporate headquarters, which is also our registered office, and is located at Industrial Park, P.O. Box 3030, Omer, Israel 8496500. Our Omer facility, part of which we sublease to a third party, include approximately 1,356 square meters of office and laboratory space. In addition, we lease offices in Raman Gan, Israel and Haifa, Israel.

 

We believe our leased office is sufficient to meet our current needs.

 

item 3. legal proceedings

 

Three of our European patents in our patent family related to Small Diameter Video Camera Heads and Medical Devices and Visualization Probes are currently in oppositional proceedings before the Opposition Division of the EP Patent Office. One U.S. patent of the same family is currently under reexamination proceedings before the U.S. Patent and Trademark Office. For additional information about these proceedings refer to – “PROPRIETARY RIGHTS AND TECHNOLOGY” above. Other than the above, we are not aware of any pending legal proceedings to which we are a party, or to which any director, officer or affiliate of our Company, or any owner of record or beneficially of more than 5% of any class of our voting securities, is a party adverse to us or has a material interest adverse to us.

 

item 4. mine safety disclosures.

 

Not applicable.

 

27

 

 

part II

 

item 5. market for registrant’s common equity, related stockholder matters and issuer purchases

 

Market Information

 

Our common stock is quoted on the OTCQB under the symbol “SCTC”. Trading in stocks quoted on the OTCQB is often thin and is characterized by wide fluctuations in trading prices due to many factors that may be unrelated to a company’s operations or business prospects. We cannot assure you that there will be a market in the future for our common stock.

 

OTCQB securities are not listed or traded on the floor of an organized national or regional stock exchange. Instead, OTCQB securities transactions are conducted through a telephone and computer network connecting dealers in stocks. OTCQB issuers are traditionally smaller companies that do not meet the financial and other listing requirements of a regional or national stock exchange.

 

Holders

 

As of December 31, 2022, there were 35 stockholders of record of our common stock and 7,121,737 shares of our common stock outstanding. The number of stockholders of record does not include beneficial owners of our common stock, whose shares are held in “street name” in the names of various brokers, dealers, clearing agencies, banks, and other fiduciaries.

 

Dividends

 

We have never declared or paid any cash dividends on our common stock. We currently intend to retain future earnings, if any, to increase our working capital and do not anticipate paying any cash dividends in the foreseeable future.

 

Equity Compensation Plan Information

 

2020 Share Incentive Plan

 

We have adopted the 2020 Share Incentive Plan, or the 2020 Plan, under which we may grant equity-based incentive awards to attract, motivate, and retain the talent for which we compete.

 

Authorized Shares. The maximum number of ordinary shares available for issuance under the 2020 Plan is equal to the sum of 1,824,717 shares, or such number as our board of directors may determine from time to time.

 

Administration. Our board of directors, or a duly authorized committee of our board of directors, will administer the 2020 Plan. Under the 2020 Plan, the administrator has the authority, subject to applicable law, to interpret the terms of the 2020 Plan and any award agreements or awards granted thereunder, designate recipients of awards, determine and amend the terms of awards, including the exercise price of an option award, the fair market value of an ordinary share, the time and vesting schedule applicable to an award or the method of payment for an award, accelerate or amend the vesting schedule applicable to an award, prescribe the forms of agreement for use under the 2020 Plan, and take all other actions and make all other determinations necessary for the administration of the 2020 Plan.

 

The administrator also has the authority to amend and rescind rules and regulations relating to the 2020 Plan or terminate the 2020 Plan at any time before the date of expiration of its ten year term.

 

Eligibility. The 2020 Plan provides for granting awards under various tax regimes, including, without limitation, in compliance with Section 102 of the Israeli Income Tax Ordinance (New Version), 5721-1961 (the “Ordinance”), and Section 3(i) of the Ordinance and for awards granted to our United States employees or service providers, including those who are deemed to be residents of the United States for tax purposes, Section 422 of the Internal Revenue Code (the “Code”) and Section 409A of the Code.

 

Section 102 of the Ordinance allows employees, directors, and officers who are not controlling shareholders and are considered Israeli residents to receive favorable tax treatment for compensation in the form of shares or options. Our non-employee service providers and controlling shareholders may only be granted options under section 3(i) of the Ordinance, which does not provide for similar tax benefits.

 

Grant. All awards granted pursuant to the 2020 Plan will be evidenced by an award agreement, in a form approved, from time to time, by the administrator in its sole discretion. The award agreement will set forth the terms and conditions of the award, including the type of award, number of shares subject to such award, vesting schedule and conditions (including performance goals or measures), and the exercise price, if applicable. Certain awards under the 2020 Plan may constitute or provide for a deferral of compensation, subject to Section 409A of the Code, which may impose additional requirements on the terms and conditions of such awards.

 

28

 

 

Each award will expire seven years from the date of the grant thereof, unless such shorter term of expiration is otherwise designated by the administrator.

 

Awards. The 2020 Plan provides for the grant of stock options (including incentive stock options and nonqualified stock options), shares of common stock, restricted shares, restricted share units, and other share-based awards.

 

Options granted under the 2020 Plan to our employees who are U.S. residents may qualify as “incentive stock options” within the meaning of Section 422 of the Code, or may be non-qualified stock options. The exercise price of a stock option may not be less than 100% of the fair market value of the underlying share on the date of grant (or 110% in the case of ISOs granted to certain significant stockholders).

 

Exercise. An award under the 2020 Plan may be exercised by providing the company with a written or electronic notice of exercise and full payment of the exercise price for such shares underlying the award, if applicable, in such form and method as may be determined by the administrator and permitted by applicable law. An award may not be exercised for a fraction of a share. With regard to tax withholding, exercise price, and purchase price obligations arising in connection with awards under the 2020 Plan, the administrator may, in its discretion, accept cash, provide for net withholding of shares in a cashless exercise mechanism, or direct a securities broker to sell shares and deliver all or a part of the proceeds to the Company or the trustee.

 

Transferability. Other than by will, the laws of descent and distribution, or as otherwise provided under the 2020 Plan, neither the options nor any right in connection with such options are assignable or transferable.

 

Termination of Employment. For grantees who terminated their employment with the Company or any of its affiliates prior to July 5, 2022, all vested and exercisable awards held by such grantees as of the date of termination may be exercised within three months, unless otherwise determined by the administrator. For grantees who terminated their employment with the Company or any of its affiliates after July 5, 2022, all vested and exercisable awards held by such grantees as of the date of termination may be exercised within three years, unless otherwise determined by the administrator. After such three month or three year period, as applicable, all such unexercised awards will terminate, and the shares covered by such awards shall again be available for issuance under the 2020 Plan.

 

In the event of termination of a grantee’s employment or service with the company or any of its affiliates due to such grantee’s death, permanent disability, or retirement, all vested and exercisable awards held by such grantee as of the date of termination may be exercised by the grantee or the grantee’s legal guardian, estate, or by a person who acquired the right to exercise the award by bequest or inheritance, as applicable, within twelve months after such date of termination, unless otherwise provided by the administrator. Any awards which are unvested as of the date of such termination or which are vested but not then exercised within the twelve month period following such date, will terminate and the shares covered by such awards shall again be available for issuance under the 2020 Plan.

 

Notwithstanding any of the foregoing, if a grantee’s employment or services with the company or any of its affiliates is terminated for “cause” (as defined in the 2020 Plan), all outstanding awards held by such grantee (whether vested or unvested) will terminate on the date of such termination and the shares covered by such awards shall again be available for issuance under the 2020 Plan.

 

29

 

 

Transactions. In the event of a share split, reverse share split, share dividend, recapitalization, combination, or reclassification of our shares, or any other increase or decrease in the number of issued shares effected without receipt of consideration by the company (but not including the conversion of any convertible securities of the company), the administrator in its sole discretion shall make an appropriate adjustment in the number of shares related to each outstanding award and to the number of shares reserved for issuance under the 2020 Plan, to the class and kind of shares subject to the 2020 Plan, as well as the exercise price per share of each outstanding award, as applicable, the terms and conditions concerning vesting and exercisability, and the term and duration of outstanding awards, or any other terms that the administrator adjusts in its discretion, or the type or class of security, asset, or right underlying the award (which need not be only that of the Company, and may be that of the surviving corporation or any affiliate thereof or such other entity party to any of the above transactions); provided that any fractional shares resulting from such adjustment shall be rounded down to the nearest whole share unless otherwise determined by the administrator. In the event of a distribution of a cash dividend to all shareholders, the administrator may determine, without the consent of any holder of an award, that the exercise price of an outstanding and unexercised award shall be reduced by an amount equal to the per share gross dividend amount distributed by the Company, subject to applicable law.

 

In the event of a merger or consolidation of our company, or a sale of all, or substantially all, of the Company’s shares or assets, or other transaction having a similar effect on the Company, or change in the composition of the board of directors, or liquidation or dissolution, or such other transaction or circumstances that the board of directors determines to be a relevant transaction, then without the consent of the grantee, the administrator may but is not required to (i) cause any outstanding award to be assumed or substituted by such successor corporation, or (ii) regardless of whether or not the successor corporation assumes or substitutes the award (a) provide the grantee with the option to exercise the award as to all or part of the shares, and may provide for an acceleration of vesting of unvested awards, or (b) cancel the award and pay in cash, shares of the company, the acquirer, or other corporation which is a party to such transaction, or other property as determined by the administrator as fair in the circumstances. Notwithstanding the foregoing, the administrator may upon such event amend, modify, or terminate the terms of any award as it shall deem, in good faith, appropriate.

 

Recent Sales of Unregistered Securities

 

On March 27, 2023, the Company issued 3,294,117 units to certain investors in consideration of $14 million. Each such unit consisted of (i) one share of the Company’s common stock and (ii) one warrant to purchase one share of common stock with an exercise price of $5.50 per share. Each warrant is exercisable for three years from the date of issuance. The shares of common stock and warrants were issued in a private placement pursuant to Regulation S of the Securities Act of 1933, as amended.

 

Issuer Purchases of Equity Securities

 

During the period from January 1, 2022, to December 31, 2022, we did not purchase any of our equity securities.

 

Item 6. [Reserved]

 

30

 

 

item 7. management’s discussion and analysis of financial condition and results of operations

 

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and the related notes appearing elsewhere in this Annual Report on Form 10-K. In addition to historical information, the following discussion contains forward-looking statements that involve risks, uncertainties and assumptions. See “Forward-looking Statements” for a discussion of the uncertainties and assumptions associated with these statements. Our actual results may differ materially from those discussed below. Factors that could cause or contribute to such differences include, but are not limited to, those identified below, and those discussed in the section titled “Risk Factors” included elsewhere in this Annual Report on Form 10-K.

 

Overview

 

We were incorporated under the laws of the State of Nevada on March 22, 2013, under the name Intellisense Solutions Inc. We were initially engaged in the business of developing web portals to allow companies and individuals to engage in the purchase and sale of vegetarian food products over the Internet. However, were not able to execute our original business plan, develop significant operations, or achieve commercial sales.

 

On December 30, 2019, we acquired all of the issued and outstanding share capital of ScoutCam Ltd. Following this transaction, we integrated and fully adopted ScoutCam Ltd.’s business into our Company as our primary business activity. On December 31, 2019, we changed our name to ScoutCam Inc.

 

Through ScoutCam Ltd., we are a pioneer in the development, production, and marketing of innovative Predictive Maintenance (PdM) and Condition Based Monitoring (CBM) technologies, providing visual sensing and AI-based video analytics solutions for critical systems in the aviation, maritime, industrial non-destructing-testing industries, transportation, and energy industries. Some of our products utilize our unique micro visualization technology in medical devices for complex and minimally invasive medical procedures. Our technology includes proven video technologies and products amalgamated into a first-of-its-kind, FDA-cleared minimally invasive surgical device. At the present time, we derive a substantial portion of our revenue from applications of our micro visualization technology within the medical field.

 

Our unique video-based sensors, embedded software, and AI algorithms are being deployed in hard-to-reach locations and harsh environments across a variety of PdM and CBM use cases. Our solution allows maintenance and operations teams visibility into areas which are inaccessible under normal circumstances, or where the operating ambience otherwise is not suitable for continuous real-time monitoring, and has various applications which have relevancy in a wide range of industry segments that utilize complicated mechanics requiring ongoing monitoring and predictive maintenance applications. Our current business model is a business-to-business (B2B) approach in which we seek to identify target businesses interested in integrating our micro visualization technology or commissioning individual projects using our technology.

 

Critical Accounting Policies and Estimates

 

Our management’s discussion and analysis of our financial condition and results of operations is based on our financial statements, which we have prepared in accordance with generally accepted accounting principles in the United States, or U.S. GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expenses during the reporting periods. We evaluate these estimates and judgments on an ongoing basis. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Our actual results may differ from these estimates under different assumptions or conditions.

 

While our significant accounting policies are more fully described in Note 2 to our financial statements appearing elsewhere in this Form 10-K, we believe that the following accounting policies are the most critical for fully understanding and evaluating our financial condition and results of operations.

 

Development Services Revenue and Contract Liabilities

 

We determine at contract inception whether development services are distinct from the performance obligation to manufacture the product under development. Revenues from development services that we determine as distinct from our performance obligation to manufacture the product under development are recognized over the period of the applicable service contract. Revenues from development services that we determine as not distinct from our performance obligation to manufacture the product under development are deferred until commencement of manufacturing and are recognized over the manufacturing term. As a result, during the year 2021, we have deferred all service revenues billed by us and the respective service costs.

 

31

 

 

Stock-Based Compensation

 

We apply the fair value recognition provisions of ASC 718, Compensation—Stock Compensation, or ASC 718, for stock-based awards granted to employees, directors, and other providers for their services. Determining the amount of stock-based compensation to be recorded requires us to develop estimates of the fair value of stock options as of their grant date. We estimate the fair value of each stock option grant using the Black-Scholes option-pricing model. Calculating the fair value of stock-based awards requires that we make subjective assumptions.

 

Pursuant to ASC 718, we measure stock-based awards granted to employees, members of the board of directors and other providers at fair value on the date of grant and recognize the corresponding stock-based compensation expense of those awards on a straight-line basis over the requisite service period.

 

The Black-Scholes option-pricing model requires a number of assumptions, of which the most significant are the stock price volatility and the expected option term. Our expected dividend rate is zero since we do not currently pay cash dividends and do not anticipate doing so in the foreseeable future. Each of the above factors requires us to use judgment and make estimates in determining the percentages and time periods used for the calculation. If we were to use different percentages or time periods, the fair value of option awards could be materially different. We recognize stock-based compensation cost for option awards on an accelerated basis over the employee’s requisite service period, net of estimated forfeitures.

 

Volatility is derived from the historical volatility of publicly traded set of peer companies. The risk-free interest rates used in the Black-Scholes calculations are based on the prevailing U.S. Treasury yield as determined by the U.S. Federal Reserve. We have not paid dividends and does not anticipate paying dividends in the foreseeable future. Accordingly, no dividend yield was assumed for purposes of estimating the fair value of our stock-based compensation. The weighted average expected life of options was estimated individually in respect of each grant. 

 

Comparison of the Year Ended December 31, 2022 and the Year Ended December 31, 2021

 

Overview

 

The Company’s primary business activities during 2022 were:

 

 ●During the second quarter of 2022, the Company completed the development of a product relating to a customer-specific project for a Fortune 500 multinational healthcare corporation, and moved from the development phase of the project to its production phase. As a result, during the year ended December 31, 2022, the Company recognized development services revenues and related development costs that had been previously deferred. The amounts were recognized based on the expected manufacturing term of the product, which the Company estimates at seven years.

 

●enlarging focus on R&D activities in the domain of I4.0 (including PdM and CBM in sectors such as aerospace, maritime energy and other heavy machinery, engines and complicated mechanics which have a need for monitoring and predictive maintenance applications). The main effect of this activity was an increase in the number of employees to enable the Company to manage the anticipated increased workload and solution development.

 

The following table summarizes our results of operations for the years ended December 31, 2022 and 2021, together with the changes in those items in dollars and as a percentage:

 

   2022   2021   % Change 
Revenues   665,000    387,000    72%
Cost of Revenues   1,631,000    1,108,000    47%
Gross Loss   (966,000)   (721,000)   34%
Research and development expenses   4,197,000    2,002,000    110%
Sales and marketing expense   699,000    908,000    (23)%
General and administrative expenses   3,577,000    5,481,000    (35)%
Operating Loss   (9,439,000)   (9,112,000)   4%

 

Revenues

 

As a result of the nature of our target market and the current stage of our development, a substantial portion of our revenue comes from a limited number of customers.

 

32

 

 

For the year ended December 31, 2022, we generated revenues of $665,000, an increase of $278,000, or 72%, from 2021 revenues. The increase in revenues was primarily due to the completion of development of the product relating to our miniature camera solution with a Fortune 500 company and moving to production stage. Total revenues recorded from our miniature camera solution with the Fortune 500 company during 2022, amounted to approximately $538,000. We did not record any revenue from our miniature camera solution with the Fortune 500 company during 2021.

 

This increase in revenues was partly offset by the following:

 

- Total revenues recorded from A.M. Surgical during 2021 amounted to approximately $199,000. We did not record any revenue from A.M. Surgical during 2022.

 

- A decrease of $61,000 due to an overall decrease in sales of the Company’s component products to occasional customers.

 

Remaining performance obligations (“RPO”) represents contracted revenue that have not yet been recognized, which include deferred revenue and amounts that will be invoiced and recognized as revenue in future periods. As of December 31, 2022, the total RPO amounted to $3.6 million, which we expect to recognize over the expected manufacturing term of the product under development.

 

Cost of Revenues

 

Cost of revenues for the year ended December 31, 2022, were $1,631,000, an increase of $523,000, or 47%, compared to cost of revenues of $1,108,000 for the year ended December 31, 2021. The increase was primarily due to:

 

- An increase in payroll expenses due to additional employee recruitments (such as in the areas of procurement, production planning and control, engineering, and quality inspectors) to support the transition to serial production for the Fortune 500 customer.

 

- In the second quarter of 2022, the Company completed the development service stage of its miniature camera solution and moved to the production stage. As a result, the Company recognized expenses of $180,000 during the year ended December 31, 2022, based on the expected manufacturing term of the product.

 

Gross Loss

 

Gross loss for the year ended December 31, 2022, was $966,000, an increase of $245,000, or 34%, compared to a gross loss of $721,000 for the year ended December 31, 2021. The increase was primarily due to increase in cost of revenues partially offset by an increase in revenue as described above.

 

Research and Development Expenses

 

Research and development efforts are focused on new product development and on developing additional functionality for our new and existing products. These expenses primarily consist of employee-related expenses, including salaries, benefits, and stock-based compensation expense for personnel engaged in research and development functions, consulting, and professional fees related to research and development activities, prototype materials, facility costs, and other allocated expenses, which include expenses for rent and maintenance of our facility, utilities, depreciation, and other supplies. We expense research and development costs as incurred.

 

33

 

 

Research and development expenses for the year ended December 31, 2022, were $4,197,000, an increase of $2,195,000, or 110%, compared to $2,002,000 for the year ended December 31, 2021. The increase was primarily due to an increase in payroll expenses (including stock-based compensation) due to additional employee recruitments, materials and subcontractors, rent and maintenance expenses due to enlarging focus on R&D activities in the domain of I4.0.

 

We expect that our research and development expenses will increase as we continue to develop our products and service and recruit additional research and development employees to the I4.0 domain.

 

Sales and Marketing Expenses

 

Sales and marketing expenses primarily consist of personnel costs, consulting services, promotional materials, demonstration equipment, and certain allocated facilities infrastructure costs.

 

Sales and marketing expenses for the year ended December 31, 2022, were $699,000, a decrease of $209,000, or 23%, compared to $908,000 for the year ended December 31, 2021. The decrease was primarily due to reductions in sales and marketing costs in the medical field.

 

We expect that our selling and marketing expenses will increase as we increase our selling and marketing efforts in the I4.0 domain.

 

General and Administrative Expenses

 

General and administrative expenses primarily consist of salaries and other related costs, including stock-based compensation, for personnel in executive, finance, and administrative functions. General and administrative expenses also include direct and allocated facility-related costs as well as professional fees for legal, patent, consulting, investor, public relations, accounting, auditing, tax services, and insurance costs.

 

General and administrative expenses for the year ended December 31, 2022, were $3,577,000, a decrease of $1,904,000, or 35%, compared to $5,481,000 for the year ended December 31, 2021.

 

The decrease was primarily due to:

 

- A decrease in IP expenses of $506,000.

 

- A decrease in stock-based compensation of $580,000.

 

- A decrease in professional services of $334,000, mainly due to expenses of $206,000 in expenses incurred in 2021 related to our efforts to uplist to Nasdaq.

 

- Cancellation of a provision of $129,000 related to additional taxes due following entrance into an agreement with the Israeli Tax Authority. In September 2021, the Company accrued an amount of approximately NIS 740,000 ($229,000) for additional taxes due following a VAT audit by the Israeli Tax Authority for the years 2019-2021. In July 2022, the Company reached an agreement with the Israeli Tax Authority, according to which the amount due in additional taxes was reduced to approximately NIS 340,000 ($100,000).

 

Operating loss

 

We incurred an operating loss of $9,439,000 for the year ended December 31, 2022, an increase of $327,000, or 4%, compared to operating loss of $9,112,000 for the year ended December 31, 2021. The increase in operating loss was primarily due to increases in gross loss and expenses related to research and development, partially offset by decrease in general and administrative expenses and sales and marketing expenses.

 

34

 

 

Comparison of the Year Ended December 31, 2021 and the Year Ended December 31, 2020

 

Overview

 

The Company’s primary business activities during 2021 were:

 

  ● completion of R&D and transition to the serial production in connection with a customer-specific project for a Fortune 500 multinational healthcare corporation; and
     
  ● enlarging its focus on R&D activities in the domain of I4.0 (including PdM and CBM in sectors such as the aviation, energy and automotive). The main effect of this activity was an increase in the number of employees to enable the Company to manage the anticipated increased workload and solution development.

 

Other major activities were the following:

 

  - Expanding marketing activities, including the recruitment of VP Business Development for Industry 4.0, and launching a multi-platform digital marketing campaign;
  - Extensive activity in connection with the Company’s IP, including submissions of new patent applications as well as maintenance, defense, and commercialization efforts of existing patents;
  - Increased operation expenses in order to improve the current Company’s R&D capabilities;
  - Increase in research and development activities, including the development of new products and the improvement of existing technology, and the examination of additional applications for our visualization solutions, including in the domains of PdM and CBM, as well as additional industries outside of the medical, defense, and aerospace fields, including sectors such as automotive, industrial non-destructing-testing industries, automotive and energy; and
  - Investment in capital expenses to provide the necessary facilities, IT, and lab tools for our newly recruited employees and to upgrade the Company’s production and quality control capabilities.

 

The following table summarizes our results of operations for the years ended December 31, 2021 and 2020, together with the changes in those items in dollars and as a percentage:

 

   2021   2020   % Change 
Revenues   387,000    491,000    (21)%
Cost of Revenues   1,108,000    994,000    11%
Gross Loss   (721,000)   (503,000)   43%
Research and development expenses   2,002,000    725,000    176%
Sales and marketing expense   908,000    443,000    105%
General and administrative expenses   5,481,000    3,035,000    81%
Operating Loss   (9,112,000)   (4,706,000)   94%

 

Revenues

 

For the year ended December 31, 2021, we generated revenues of $387,000, a decrease of $104,000, or 21%, from 2020 revenues. The decrease in revenues was primarily due to sales of products to A.M. Surgical. Total sales to A.M. Surgical during year ended December 31, 2021 amounted to approximately $199,000, a decrease from approximately $383,000 in 2020. This decrease was partially offset by increase in the sales of our products to other customers.

 

Remaining performance obligations (“RPO”) represents contracted revenue that has not yet been recognized, which includes deferred revenue and amounts that will be invoiced and recognized as revenue in future periods. As of December 31, 2021, the total RPO amounted to $3.2 million, which we expect to recognize over the expected manufacturing term of the product under development.

 

Cost of Revenues

 

Cost of revenues for the year ended December 31, 2021 were $1,108,000, an increase of $114,000, or 11%, compared to cost of revenues of $994,000 for the year ended December 31, 2020. The increase was primarily due to an increase in payroll expenses (including stock-based compensation) as a result of hiring additional employees as part of the transition to the production stage with respect to the contract with a Fortune 500 multinational healthcare corporation, partially offset by decrease in materials as a result of a decrease in revenues.

 

35

 

 

Gross Loss

 

Gross loss for the year ended December 31, 2021 was $721,000, an increase of $218,000, or 43%, compared to a gross loss of $503,000 for the year ended December 31, 2020. The increase was primarily due to a decrease in revenues and an increase in cost of revenues as described above.

 

Research and Development Expenses

 

Research and development expenses for the year ended December 31, 2021 were $2,002,000, an increase of $1,277,000, or 176%, compared to $725,000 for the year ended December 31, 2020. The increase was primarily due to an increase in payroll expenses (including stock-based compensation) due to additional employee recruitments, materials and subcontractors, and because we have recently begun examining additional applications for our micro ScoutCam™ portfolio outside of the medical, defense and aerospace fields, including in sectors such as automotive, industrial non-destructing-testing industries, automotive, and energy.

 

In addition, there was an increase in R&D payroll expenses in 2021 due to the fact that during 2020 a substantial part of the payroll expenses was capitalized to contract fulfillment asset and was not recognized as expenses in profit and loss.

 

We expect that our research and development expenses will increase as we continue to develop our products and service and recruit additional research and development employees to the I4.0 domain.

 

Sales and Marketing Expenses

 

Sales and marketing expenses for the year ended December 31, 2021 were $908,000, an increase of $465,000, or 105%, compared to $443,000 for the year ended December 31, 2020.

 

The increase was primarily due to expanding marketing activity, including the recruitment of a VP Business Development in Industry 4.0, hiring consultants and launching a multi-platform digital marketing campaign.

 

We expect that our selling and marketing expenses will increase as we continue to increase our selling and marketing efforts.

 

General and Administrative Expenses

 

General and administrative expenses for the year ended December 31, 2021 were $5,481,000, an increase of $2,446,000, or 81%, compared to $3,035,000 for the year ended December 31, 2020.

 

The increase was primarily due to:

 

  ● an increase of $675,000 in IP expenses due to maintenance, defense, and commercialization efforts of existing patents;
  ● the provision of $229,000 due to a VAT audit by the Israeli Tax Authority;
  ● an increase of $528,000 in stock-based compensation due to new option grants;
  ● expenses of approx. $206,000 related to our efforts to uplist to Nasdaq;
  ● an increase in in payroll expenses due to the hiring of additional employees, including a new CEO and controller, and a shift in the position of the CFO from part-time to full-time; and
  ● an increase in professional services expenses due to the hiring of a financial consultant, HR consultant, the appointment of new directors and additional hires.

 

36

 

 

Operating loss

 

We incurred an operating loss of $9,112,000 for the year ended December 31, 2021, an increase of $4,406,000, or 94%, compared to operating loss of $4,706,000 for the year ended December 31, 2020. The increase in operating loss was primarily due to increases in expenses related to general and administrative, research and development, and sales and marketing, as described above.

 

Liquidity and Capital Resources

 

As of December 31, 2022, we had cash and cash equivalents of $10.1 million and short-term deposits of $3 million compared to cash and cash equivalents of $8.6 million and short-term deposits of $11 million as of December 31, 2021. In addition, as of December 31, 2022, we incurred an accumulated deficit of $24.8 million compared to $15.3 million as of December 31, 2021.

 

Our primary sources of liquidity to date have been from fund raising and warrant exercises.

 

Additional Cash Requirements

 

We plan to continue to invest for long-term growth, and therefore we expect that our expenses will increase. We currently believe that our existing cash and cash equivalents and short-term deposits will allow our to fund ours operating plan through at least the next 12 months. We expect our expenses will increase in connection with our ongoing activities, particularly as we continue the research and development and the scale up process of our I4.0 solutions. We expect to incur significant commercialization expenses related to product sales, marketing, manufacturing, and distribution. Furthermore, we will continue to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. We may raise these funds through equity financing, debt financing, or other sources, which may result in further dilution in the equity ownership of our common stock. There is no assurance that we will be able to maintain operations at a level sufficient for investors to obtain a return on their investment in our common stock, or that we will be able to raise sufficient capital required to implement our business plan on acceptable terms, if at all. Even if we are successful in raising sufficient capital to implement our business plan, we will, most likely, continue to be unprofitable for the foreseeable future. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce, or eliminate our research and development programs or future commercialization efforts.

 

Cash Flows

 

Our primary uses of cash from operating activities have been for headcount-related expenditures, research and development costs, manufacturing costs, marketing and promotional expenses, professional services cost, and costs related to our facilities. Our cash flows from operating activities will continue to be affected due to the expected increase of spending on our business and our working capital requirements.

 

Comparison of the Year Ended December 31, 2022 and the Year Ended December 31, 2021

 

The following table sets forth the significant sources and uses of cash for the years ended December 31, 2022 and December 31, 2021 (in dollars):

 

   2022   2021 
Cash used in Operating Activities   (6,095,000)   (5,886,000)
Cash provided by (used in) Investing Activities   7,882,000    (11,595,000)
Cash provided by Financing Activities   -    22,559,000 

 

Operating Activities

 

During the year ended December 31, 2022, cash used in operating activities was $6.1 million, consisting of net loss of $9.5 million, partially offset by a non-cash benefit of $2.1 million and a favorable net change in operating assets and liabilities of $1.3 million. Our non-cash benefit consisted primarily of non-cash charges of $1.6 million for stock-based compensation. The net change in our operating assets and liabilities primarily reflects cash inflows from changes in contract liability of $1.2 million.

 

37

 

 

During the year ended December 31, 2021, cash used in operating activities was $5.9 million, consisting of net loss of $9 million, partially offset by a non-cash benefit of $2 million and a favorable net change in operating assets and liabilities of $1.1 million. Our non-cash benefit consisted primarily of non-cash charges of $2 million for stock-based compensation. The net change in our operating assets and liabilities primarily reflects cash inflows from changes in contract liability of $1.6 million partially offset by cash outflows from changes in contract fulfillment assets of $0.5 million.

 

Investing Activities

 

During the year ended December 31, 2022, cash provided by investing activities was $7.9 million, consisting mainly of withdrawal, net of short-term deposits.

 

During the year ended December 31, 2021, cash used in investing activities was $11.6 million, consisting of investment in short-term deposits of $11 million and purchases of property and equipment of $0.6 million.

 

Financing Activities

 

During the year ended December 31, 2021, cash provided by financing activities was $22.6 million, consisting primarily of $19.1 million from cash proceeds from issuance of shares and warrants in a private placement and $3.5 million proceeds from exercise of outstanding warrants.

 

Comparison of the Year Ended December 31, 2021 and the Year Ended December 31, 2020

 

The following table sets forth the significant sources and uses of cash for the years ended December 31, 2021 and December 31, 2020 (in dollars):

 

   2021   2020 
Cash used in Operating Activities   (5,886,000)   (4,187,000)
Cash used in Investing Activities   (11,595,000)   (276,000)
Cash provided by Financing Activities   22,559,000    4,506,000 

 

Operating Activities

 

Our primary uses of cash from operating activities have been for headcount-related expenditures, research and development costs, manufacturing costs, marketing and promotional expenses, professional services cost and costs related to our facilities. Our cash flows from operating activities will continue to be affected due to the expected increase of spending on our business and our working capital requirements.

 

During the year ended December 31, 2021, cash used in operating activities was $5.9 million, consisting of net loss of $9 million, partially offset by a non-cash benefit of $2 million and an favorable net change in operating assets and liabilities of $1.1 million. Our non-cash benefit consisted primarily of non-cash charges of $2 million for stock-based compensation. The net change in our operating assets and liabilities primarily reflects cash inflows from changes in contract liability of $1.6 million partially offset by cash outflows from changes in contract fulfillment assets of $0.5 million.

 

During the year ended December 31, 2020, cash used in operating activities was $4.2 million, consisting of net loss of $4.7 million, non-cash charges of $1.1 million and a unfavorable net change in operating assets and liabilities of $0.6 million. Our non-cash charges consisted primarily of stock-based compensation expense of $1.1 million. The net change in our operating assets and liabilities primarily reflects cash outflows from the changes in contract fulfillment assets of $1.1 million, accrued expenses and other of $0.4 million and other assets of $0.3 million, partially offset by cash inflows from changes in inventory of $0.7 million and change in contract liability of $0.3 million.

 

38

 

 

Investing Activities

 

During the year ended December 31, 2021, cash used in investing activities was $11.6 million, consisting of investment in short-term deposits of $11 million and purchases of property and equipment of $0.6 million.

 

During the year ended December 31, 200, cash used in investing activities was $0.3 million, consisting of purchases of property and equipment.

 

Financing Activities

 

During the year ended December 31, 2021, cash provided by financing activities was $22.6 million, consisting primarily of $19.1 million from cash proceeds from issuance of shares and warrants in a private placement and $3.5 million proceeds from exercise of outstanding warrants.

 

During the year ended December 31, 2020, cash provided by financing activities was $4.5 million, consisting primarily of $2.9 million from cash proceeds from issuance of shares and warrants and $1.8 million proceeds from exercise of warrants.

 

item 7a. quantitative and qualitative disclosures about market risk

 

As a smaller reporting company, we are not required to provide the information required by this Item.

 

item 8. financial statements and supplementary data

 

The information called for by Item 8 is included following the “Index to Financial Statements” on page F-1 of this Annual Report.

 

item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

 

Not applicable.

 

item 9a. controls and Procedures

 

Disclosure Controls and Procedures

 

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure.

 

Management’s Report on Internal Control over Financial Reporting

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Our internal control over financial reporting has been designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles in the United States of America.

 

Our internal control over financial reporting includes policies and procedures that pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect transactions and dispositions of our assets; provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles in the United States of America, and that receipts and expenditures are being made only in accordance with authorization of our management and directors; and provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our financial statements.

 

39

 

 

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

 

Management assessed the effectiveness of our internal control over financial reporting on December 31, 2022. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission 2013 framework, in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”). Based on that assessment under those criteria, management has determined that, as of December 31, 2022, our internal control over financial reporting was effective.

 

Attestation Independent Report of the Registered Public Accounting Firm

 

This annual report on Form 10-K does not include an attestation report of the Company’s independent registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by the Company’s registered public accounting firm pursuant to rules of the SEC that permit the Company to provide only management’s report in this annual report on Form 10-K.

 

Changes in Internal Control over Financial Reporting

 

There were no changes in internal control over financial reporting during the year ended December 31, 2022 that have materially affected or are reasonably likely to materially affect the Company’s internal control over financial reporting.

 

Item 9b. Other information

 

None.

 

ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS

 

Not Applicable

 

40

 

 

part iii

 

Item 10. Directors, Executive Officers and corporate governance

 

Directors, Executive Officers, Promoters and Control Persons

 

The following table sets forth the names and ages of our directors and executive officers:

 

Name   Age   Position
Prof. Benad Goldwasser†   72   Chairman of the Board
Shmuel Donnerstein†   56   Director
Ronen Rosenbloom   51   Director
Lior Amit†   56   Director
Moshe (Mori) Arkin   70   Director
Inbal Kreiss†   56   Director
Zeev Vurembrand†   71   Director
Yehu Ofer*   57   Chief Executive Officer
Tanya Yosef*   40   Chief Financial Officer
Amir Govrin*   56   Chief Technology Officer
Katrin Dlugach*   40   VP of Research and Development
Jacob Avinu*   40   Senior VP of Product Portfolio
Arik Priel*   48   Chief SW Architect

 

* Executive Officer
† Independent Director

 

Directors

 

Prof. Benad Goldwasser has served as chairman of our board of directors since December 26, 2019, and has served as chairman of ScoutCam Ltd.’s board of directors since its inception. Prof. Goldwasser is a serial entrepreneur and retired urology medical doctor. In 2016, Prof. Goldwasser launched a venture capital fund partnered with SAIL, a Shanghai Government investment company. Prof. Goldwasser has served as a member of the board of directors of Innoventric Ltd. since 2017 and Inspira Technologies Ltd. since January 2021. From 2013-2016 Prof. Goldwasser served as an external director of BioCanCell Ltd. (TASE: BICL). Prof. Goldwasser was the co-founder of Vidamed Inc., Medinol Ltd., Rita Medical Inc., Optonol Ltd. and GI View Ltd. Prof. Goldwasser served as managing director of Biomedical Investments Ltd., an Israeli Venture Capital firm. During his medical career, he served as Chairman of Urology at the Chaim Sheba Medical Center and Professor of Surgery at Tel-Aviv University. Prof. Goldwasser holds an MD and MBA from Tel-Aviv University.

 

Shmuel Donnerstein has served on our board of directors since December 26, 2019. Mr. Donnerstein has been an entrepreneur for over 40 years and is an industry veteran. Mr. Donnerstein’s experience includes establishing businesses in multiple industries in Europe and Israel. Most notably, in 2008 he established Rav Bariach 08 Industries Ltd (TASE: BRIH) after buying the assets of its predecessor in receivership and led its turnaround to become a leading security door manufacturer worldwide. Mr. Donnerstein currently serves as the Executive Chairman and majority shareholder of Rav Bariach. In addition, Mr. Donnerstein is the Chairman of Rail Vision Ltd and, in 2014, received the Israeli Industry Award from Israel’s Minister of Economy and Industry for his lifelong contribution to the Israeli Industrial sector.

 

Ronen Rosenbloom has served as a member of our board since December 26, 2019. Mr. Rosenbloom is an independent lawyer working out of a self-owned law firm specializing in white collar offences. Mr. Rosenbloom serves as chairman of the Israeli Money Laundering Prohibition committee and the Prohibition of Money Laundering Committee of the Tel Aviv District, both of the Israel Bar Association. Mr. Rosenbloom serves on the board of directors of Medigus Ltd. and Save Foods, Inc. Mr. Rosenbloom previously served as a police prosecutor in the Tel Aviv District. He has served as a member of the board of directors of Medigus Ltd. since August 2018. Mr. Rosenbloom holds an LLB from the Ono Academic College, an Israeli branch of University of Manchester.

 

41

 

 

Lior Amit has served on our board of directors since December 26, 2019. Since 2014, Mr. Amit has served as a financial consultant to multiple companies on matters related to, inter alia, mergers and acquisitions. Mr. Amit currently serves as a member of the board of directors for multiple Israeli public and private companies, including in the role of an external or independent director. He has served as a member of the board of directors of Inspira Technologies Ltd. since June 2021. Mr. Amit holds both a BA in economics and accounting and an MBA from Tel-Aviv University. Mr. Amit is a certified public accountant in Israel.

 

Moshe (Mori) Arkin has served on our board of directors since February 15, 2021. Mr. Arkin is a leading life science and pharmaceutical entrepreneur and serves as the chairman of Arkin Holdings, which he founded in 2009. Mr. Arkin has served as chairman of the board of directors of Sol Gel Technologies Ltd. (NASDAQ: SLGL) since 2014 and sits on the board of directors of several private pharmaceutical and medical device companies, including Digma Medical, a company developing systems to treat insulin resistance present in type 2 diabetes and other metabolic syndrome diseases, and Valcare Medical, a company developing heart valve devices. From 2005 to 2008, Mr. Arkin served as the head of generics at Perrigo Company, and from 2005 until 2011, as a member of its board of directors. Prior to joining Sol Gel Technologies Ltd., Mr. Arkin served as a director of cCAM Biotherapeutics Ltd., a company focused on the discovery and development of novel immunotherapies to treat cancer from 2012 until its acquisition in 2015 by Merck & Co., Inc. Mr. Arkin served as chairman of Agis Industries Ltd. from 1972 until its acquisition by Perrigo Company in 2005. Mr. Arkin holds a B.A. in psychology from the Tel Aviv University, Israel.

 

Inbal Kreiss has served on our board of directors since April 9, 2021. Ms. Kreiss is currently the Head of Innovation at the Systems, Missiles and Space Division of the Israeli Aerospace Industries Ltd. (IAI) and Chairwoman of RAKIA, Israel’s 2nd Scientific and Technological Mission to the International Space Station. Since 2013, Ms. Kreiss has served as Deputy Director of the Space Division at IAI, leading the development, construction, launch and operation of observation and communication satellites for both Israeli and foreign users. Prior to that, Ms. Kreiss held various leadership positions within IAI, including chief engineer of Israel’s Arrow 2 anti-ballistic missile defense system from 2000 to 2006, and project manager of the Arrow 3 exo-atmospheric interceptor from 2007 to 2013. Ms. Kreiss serves on the board of directors or Rail Vision Ltd. Ms. Kreiss holds a B.Sc in chemical engineering from the Technion, Israeli Institute of Technology, an Executive Masters in Business Administration from Tel Aviv University, and completed a visiting research fellowship at the Aeronautics & Astronautics Department of the Massachusetts Institute of Technology (MIT).

 

Zeev Vurembrand has served on our board of directors since May 13, 2021. Mr. Vurembrand is currently the Chief Executive Officer and Owner of Vurembrand Management & Innovation Ltd. and a member of the board of Bezeq the Israeli Telecommunication Corp. Ltd. (TASE: BEZQ) since 2017. Mr. Vurembrand has also served as chairman of the board of Lageen Ltd. since 2019. From 2013 until 2019, Mr. Vurembrand was the Chief Executive Officer of Kupat Holim Meuhedet, Israel’s third largest health care organization. From 2008 until 2013, he was the Chief Executive Officer of Alon Holding Blue Square – Israel Ltd., and prior to that, from 2007 until 2008, he was the Chief Executive Officer of Phoenix Investments and Finance Ltd. Earlier in his career, from 2002 until 2007, Mr. Vurembrand was the Chief Executive Officer of Clalit Health Services Group, Israel’s largest health care organization. Mr. Vurembrand has served on numerous boards of directors, including Africa Israel Resedence LTD. (TASE: AFRE) from 2014 until 2016, Discount Bank (TASE:DSCT) 2006 until 2007, U-Bank from 2005 until 2006, Blue Square Israel (TASE: BSI) from 2001 until 2006, and Dikla Medical Insurance Ltd. from 1995 until 2002. Mr. Vurembrand has also served on the board of trustees of Bar Ilan University since 2019. Mr. Vurembrand holds a B.Sc in industrial engineering and management from the Technion, Israeli Institute of Technology.

 

Executive Officers

 

Yehu Ofer has served as Chief Executive Officer of the Company since October 18, 2022. Mr. Ofer served as a colonel (now retired) in the IAF, commanding two operational squadrons before commanding “Wing 15”, the optic and electronic intelligence wing of the IAF. In his last position, Mr. Ofer served as Israel Defense Attaché to Italy, Greece, Serbia, and Croatia, where he oversaw the largest ever government-to-government transaction between Israel and Italy. Upon his retirement from the Israel Defense Forces in 2013, Mr. Ofer joined Elbit Systems Ltd. in its electro-optics unit as a technology development and program manager in airborne optic and laser solutions. Mr. Ofer also managed Elbit System’s aerospace division as VP of large-scale development programs and VP of the Brazil business unit. In his last position at Elbit Systems, Mr. Ofer served as VP of Global Business Development, Marketing and Sales, a position he held since 2020. Mr. Ofer holds an MBA from the University of Haifa, a Bachelor of Economics and Logistics (cum laude) from Bar Ilan University in Tel Aviv, and a degree from the National Security College in Tel Aviv.

 

42

 

 

Tanya Yosef has served as our Chief Financial Officer since December 27, 2019. Ms. Yosef is a certified public accountant with many years of experience, and held various positions with Medigus Ltd. (Nasdaq: MDGS) since December of 2009, including most recently as chief financial officer and prior thereto as financial controller. During 2008-2009 Ms. Yosef worked in the audit department at Kesselman & Kesselman, a member firm of PricewaterhouseCoopers International Limited. Ms. Yosef holds a BA in Economics and Accounting from the Ben-Gurion University, Israel.

 

Amir Govrin has served as our Chief Technology Officer since May 1, 2019. Prior to his position with ScoutCam, Mr. Govrin held various positions at Medigus Ltd. (Nasdaq: MDGS) beginning in 2003, including VP R&D, R&D manager and GERD project manager. Prior to his tenure at Medigus, Mr. Govrin was project manager at Aran R&D from 1997 until 2003, and an R&D engineer at Netafim Ltd. from 1992 until 1997. Mr. Govrin holds a B.Sc in mechanical engineering from Tel Aviv University, Israel.

 

Katrin Dlugach has served as our VP of Research and Development since July 1, 2019. Prior to her position with ScoutCam, Ms. Dlugach was a system engineer and project manager at Nanofabrica Ltd. from August 2018 to June 2019. Before that, Ms. Dlugach served in a number of roles, including chief of development and chief executive officer, at Nitinotes Ltd. from 2014 until 2018. Earlier in her career, Ms. Dlugach held a variety of R&D positions at Medigus Ltd. (Nasdaq: MDGS). Ms. Dlugach holds a B.Sc., M.Sc. and MBA from Ben-Gurion University, Israel.

 

Jacob Avinu has served as our Senior VP of Product Portfolio since November 15, 2022. Mr. Avinu has more than 15 years of experience in development, operations, and leadership in a variety of industries, including aviation and aerospace. He joined ScoutCam from Elbit Systems, where since 2018 he led the advanced capabilities R&D group in helmet-mounted displays and sensors, a key segment within the company’s aerospace division. Before joining Elbit Systems, Mr. Avinu served for six years in the Israeli Air Force as a computer vision system engineer and commander of the electronic systems development group. Mr. Avinu holds a Master of Science degree from Ben-Gurion University of the Negev in Beer-Sheva, Israel with a focus on electro-optical engineering, and a Bachelor of Science in electrical engineering from Ort Braude College of Engineering in Karmiel Israel. Mr. Avinu also studied practical engineering and electronics at the Israeli Air Force Academy.

 

Arik Priel has served as our Chief SW Architect since November 1, 2021. Mr. Priel has over 20 years of experience in leading multidisciplinary R&D and engineering teams in defining and navigating product development from concept to deployment, with a focus on cloud-based architectures and AI-based technologies. Prior to joining ScoutCam, Mr. Priel held several senior technology positions, most recently as CTO of Octopol from June 2019 to August 2021, where he combined state-of-the-art AI models together with cutting-edge software technology. Prior to Octopol, Mr. Priel served as Director of Technology at Green & Gold Analytics from March 2017 to June 2019, where he established partnerships with Microsoft and Amazon Web Services. Mr. Priel also previously served as VP R&D and established the Israeli Innovation Center of Landesk (currently named Ivanti). Mr. Priel earned both his BSc in Computer Science and Economics and MBA from Bar-Ilan University.

 

Staggered Board

 

Our board of directors is divided into three classes. Ronen Rosenbloom and Zeev Vurembrand are our Class I directors, with their terms of office to expire at our 2025 annual meeting of stockholders. Lior Amit, Shmuel Donnerstein and Inbal Kreiss are our Class II directors, with their terms of office to expire at our 2023 annual meeting of stockholders. Professor Benad Goldwasser and Moshe (Mori) Arkin are our Class III directors, with their terms of office to expire at our 2024 annual meeting of stockholders. At each annual meeting of stockholders, directors elected to succeed those directors whose terms expire shall be elected for a term of office to expire at the third succeeding annual meeting of stockholders after their election, with each director to hold office until his or her successor shall have been duly elected and qualified.

 

43

 

 

Our board of directors may consider a broad range of factors relating to the qualifications and background of nominees to serve as director, which may include various diversity factors. We have no formal policy regarding board diversity.

 

Our officers hold office until the earlier of their death, resignation or removal by our board of directors or until their successors have been selected. They serve at the pleasure of our board of directors.

 

Family Relationships

 

There are no family relationships between or among any of our directors or executive officers.

 

Involvement in Certain Legal Proceedings

 

To our knowledge, our directors and executive officers have not been involved in any of the following events during the past ten years:

 

  a) any bankruptcy petition filed by or against such person or any business of which such person was a general partner or executive officer either at the time of the bankruptcy or within two years prior to that time;
     
  b) any conviction in a criminal proceeding or being subject to a pending criminal proceeding (excluding traffic violations and other minor offenses);
     
  c) being subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining him from or otherwise limiting his involvement in any type of business, securities or banking activities or to be associated with any person practicing in banking or securities activities;
     
  d) being found by a court of competent jurisdiction in a civil action, the SEC or the Commodity Futures Trading Commission to have violated a federal or state securities or commodities law, and the judgment has not been reversed, suspended, or vacated;
     
  e) being subject of, or a party to, any federal or state judicial or administrative order, judgment decree, or finding, not subsequently reversed, suspended or vacated, relating to an alleged violation of any federal or state securities or commodities law or regulation, any law or regulation respecting financial institutions or insurance companies, or any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or
     
  f) being subject of or party to any sanction or order, not subsequently reversed, suspended, or vacated, of any self-regulatory organization, any registered entity or any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons associated with a member.

 

Compliance with Section 16(a) of the Exchange Act

 

Our common stock is not registered pursuant to Section 12 of the Exchange Act. Accordingly, our directors, officers and principal stockholders are not subject to the beneficial ownership reporting requirements of Section 16(a) of the Exchange Act.

 

Code of Ethics

 

We have adopted a code of business conduct and ethics that applies to all of our directors, officers, and employees (including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions). We have made the code of business conduct and ethics available on our website at www.scoutcam.com. We will disclose promptly by posting such disclosure on our website any amendment to or waiver from the code of business conduct and ethics for our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions, as required by law or SEC regulations. Information contained on, or that can be accessed through, our website does not constitute a part of this Annual Report.

 

44

 

 

Board Committees

 

We are not currently subject to listing requirements of any national securities exchange, which generally require the creation of an audit committee, compensation committee or process, and nominations committee or process, and that each of these committees or processes be comprised of independent directors and tasked with performing certain responsibilities for the board of directors. Notwithstanding the foregoing, we have voluntarily created an audit committee and compensation committee with responsibilities consistent with those required under SEC and Nasdaq rules.

 

Audit Committee. The members of the audit committee are Ms. Kreiss, Mr. Amit, and Mr. Vurembrand, with Mr. Vurembrand as its designated chairperson. The audit committee is governed by a written charter approved by the board of directors and available on our website at www.scoutcam.com. The board of directors has determined that all current audit committee members are financially literate under the Nasdaq listing requirements and that Mr. Vurembrand qualifies as an “audit committee financial expert” as defined by the SEC rules adopted pursuant to the Exchange Act. The Nasdaq listing requirements require that audit committees have at least three directors and that all directors be independent, as defined in the Nasdaq listing requirements and Rule 10A-3 under the Exchange Act. The Board has determined that Ms. Kreiss, Mr. Amit, and Mr. Vurembrand meet the independence criteria established in the Nasdaq listing requirements and the Exchange Act.

 

The audit committee assists the board of directors in its oversight of financial reporting practices and the quality and integrity of the financial reports of ScoutCam including compliance with legal and regulatory requirements, the independent auditors’ qualifications and independence, and the performance of ScoutCam’s internal control function. The audit committee is responsible for the appointment of ScoutCam’s independent auditors. The audit committee oversees our internal controls and risk assessment and management policies and meets with our independent auditor and management regarding our internal controls and other matters. The audit committee is responsible for periodically reviewing ScoutCam’s code of business conduct and ethics and has established procedures for the receipt, retention, and treatment of complaints received by ScoutCam regarding accounting controls or auditing matters and the confidential, anonymous submission by ScoutCam employees of concerns regarding questionable accounting or auditing matters. The audit committee is also responsible for approving or ratifying related person transactions pursuant to ScoutCam’s related person transaction approval policy contained in the audit committee charter.

 

Compensation Committee. The members of the compensation committee are Ms. Kreiss, Mr. Amit, and Mr. Vurembrand, with Ms. Kreiss as its designated chairperson., all of whom meet the independence criteria established by the Nasdaq listing requirements. The compensation committee is governed by a written charter approved by the board of directors and available on our website at www.scoutcam.com. The compensation committee is charged with the responsibility for setting executive compensation, reviewing certain compensation programs, administering our equity incentive plans, reviewing and discussing with management the compensation discussion and analysis required in proxy statements (if and when applicable), preparing a report on executive compensation required by SEC rules to be included in proxy statements (if and when applicable), and making other recommendations to the board of directors.

 

45

 

 

item 11. Executive Compensation

 

Summary Compensation Table

 

The following sets forth information about the compensation paid to or accrued by the company’s principal executive officer and its two other most highly compensated persons serving as executive officers as of December 31, 2022. These executives are referred to as the “named executive officers.”

 

Name and Principal Position  Year   Base Salary (5)   Bonus (6)   Stock Awards (7)   Option Awards (7) (8)   All Other Compensation   Total 
   $ in thousands 
Yovav Sameah,   2022   $265   $-   $432   $-   $35   $732 
Former Chief Executive Officer (1)   2021   $232   $50   $-   $1,284   $24   $1,590 
                                   
Yehu Ofer,                                  
Chief Executive Officer (2)   2022   $68   $21   $-   $774   $8   $871 
                                   
Jacob Avinu,                                  
Senior VP Product (3)   2022   $38   $14   $-   $258   $1   $311 
                                   
Amir Govrin   2022   $194   $-   $108   $-   $23   $325 
Chief Technology Officer (4)   2021   $184   $-   $-   $187   $22   $393 

 

  (1) Consists of Mr. Sameah’s s compensation earned in his capacity as the Chief Executive Officer of wholly-owned subsidiary, ScoutCam Ltd. Mr. Sameah did not earn any compensation in his capacity as the Chief Executive Officer of ScoutCam Inc. Mr. Sameah’s employment terminated on October 18, 2022.
     
  (2)

Consists of Mr. Ofer’s compensation earned in his capacity as the Chief Executive Officer of our wholly-owned subsidiary, ScoutCam Ltd. Mr. Ofer did not earn any compensation in his capacity as the Chief Executive Officer of ScoutCam Inc. Mr. Ofer’s employment commenced on October 18, 2022.

 

In connection with the appointment of Mr. Ofer as the Company’s Chief Executive Officer, the Company entered into an employment agreement with Mr. Ofer that provides for the terms and conditions of his employment as the Company’s Chief Executive Officer. The agreement provides for a monthly base salary of NIS 70,000, subject to adjustments for inflation as announced from time to time in accordance with Israeli law. The agreement also provides that Mr. Ofer is entitled to receive an equity grant of options to purchase a total of 300,000 shares of the Company’s common stock, par value $0.001 per share, at an exercise price of $4.50 per share, which shall vest and become exercisable as follows: 33.33% of the shares covered by Mr. Ofer’s options on the first anniversary of his service as CEO, and 8.33% of the shares covered by Mr. Ofer’s options at the end of each subsequent three-month period thereafter over the course of the subsequent two years. Furthermore, Mr. Ofer’s options will immediately vest upon the occurrence of the following (i) the sale of all or substantially all of the assets of the Company, (ii) the sale of more than 50% of the common stock of the Company in a non-public sale, (iii) the dissolution or liquidation of the Company or (iv) any merger, share exchange, consolidation or other reorganization or business combination if immediately after such transaction either (A) the persons who were directors of the Company immediately prior to such transaction do not constitute at least a majority of the directors of the surviving entity or (B) the persons who hold a majority of the voting capital stock of the surviving entity are not the persons who held a majority of the voting capital stock of the Company immediately prior to such transaction. Additionally, the Company agreed to pay Mr. Ofer both (i) a signing bonus in the aggregate amount of NIS 70,000 and (ii) an annual bonus pursuant to certain pre-determined measurable objectives agreed to with Mr. Ofer and approved by the board of directors by January 31 with respect to each calendar year, with the Company agreeing to recommend to the board of directors a grant of restricted stock in lieu of Mr. Ofer’s bonus through such time the Company is profitable and subject to meeting applicable objectives. In accordance with the terms of Mr. Ofer’s employment agreement, he will also receive additional benefits customary for an executive officer of his experience and for companies of similar stature and standing to that of the Company.

 

46

 

 

  (3)

Consists of Mr. Avinu’s compensation earned in his capacity as the Senior VP Product of our wholly-owned subsidiary, ScoutCam Ltd. Mr. Avinu’s employment commenced on November 15, 2022.

 

In connection with the appointment of Mr. Avinu as the Company’s Senior VP Product, the Company entered into an employment agreement with Mr. Avinu that provides for the terms and conditions of his employment as the Company’s Senior VP Product. The agreement provides for a monthly salary of NIS 60,000. The agreement also provides that Mr. Avinu is entitled to receive an equity grant of options to purchase a total of 100,000 shares of the Company’s common stock, par value $0.001 per share, at an exercise price of $4.50 per share, which shall vest and become exercisable as follows: 33.33% of the shares covered by Mr. Avinu’s options on the first anniversary of his service as SVP Product, and 8.33% of the shares covered by Mr. Avinu’s options at the end of each subsequent three-month period thereafter over the course of the subsequent two years. Additionally, the agreement provides to Mr. Avinu: (i) a signing bonus in the aggregate amount of NIS 50,000 (ii) a performance bonus in the aggregate amount of NIS 120,000 pursuant to certain objectives and (iii) the Company will consider, at to its sole discretion, after the first and second years following his employment, granting Mr. Avinu additional options / RSUs pursuant to certain objectives, subject to the approval of such grant by the CEO and board of directors of the Company. In accordance with the terms of Mr. Avinu’s employment agreement, he will also receive additional benefits customary for an executive officer of his experience and for companies of similar stature and standing to that of the Company.

     
  (4)

Consists of Mr. Govrin’s compensation earned in his capacity as the Chief Technology Officer of our wholly-owned subsidiary, ScoutCam Ltd. Mr. Govrin did not earn any compensation in his capacity as the Chief Technology Officer of ScoutCam Inc.

 

In connection with the appointment of Mr. Govrin as the Company’s Senior VP Product in May 2019, the Company entered into an employment agreement with Mr. Govrin that provides for a monthly base salary of NIS 37,000. In accordance with the terms of Mr. Govrin’s employment agreement, he will also receive additional benefits customary for an executive officer of his experience and for companies of similar stature and standing to that of the Company. Effective April 1, 2022, Mr. Govrin received an increase in his monthly base salary to NIS 41,000.

     
  (5) Base salaries are intended to provide a level of compensation sufficient to attract and retain an effective management team, when considered in combination with the other components of our executive compensation program. The relative levels of base salary for our named executive officers are designed to reflect each named executive officer’s scope of responsibility and accountability. Base salary amounts include management insurance (which includes pension, disability insurance and severance pay) and  payments towards such employee’s education fund, and Israeli social security. Each named executive officer also receives gross-up payments for the taxes on these benefits. The amounts included here are the U.S. dollar equivalent from NIS. The conversion rate used was the average of the 2021 and 2022 rates between the U.S. dollar and NIS, as published by the Bank of Israel.
     
  (6) Represents a signing bonus.
     
  (7) The amount shown in the “Option Awards” and “Stock Awards” columns represents the aggregate grant date fair value of awards computed in accordance with ASC 718, not the actual amounts paid to or realized by the Named Executive Officer during 2022 and 2021. The ASC 718 fair value amount as of the grant date for stock options generally is spread over the number of months of service required for the grant to vest..
     
  (8) The fair value of each stock option award is estimated as of the date of grant using the Black-Scholes valuation model. Additional information regarding the assumptions used to estimate the fair value of all stock option awards is included in Note 9b-c to Consolidated Financial Statements.

 

Employment Agreements

 

We, and through our Israeli subsidiary, have entered into written employment agreements with each of our executive officers. All of these agreements contain customary provisions regarding noncompetition, confidentiality of information, and assignment of inventions. However, the enforceability of the noncompetition provisions may be limited under applicable law. In addition, we have entered into agreements with each executive officer and director pursuant to which we have agreed to indemnify each of them to the fullest extent permitted by law to the extent that these liabilities are not covered by directors and officers insurance.

 

47

 

 

Equity-based compensation

 

Outstanding Equity Awards

 

The following table provides information regarding equity awards for each of our named executive officers, as that term is defined in Item 402(m)(2) of Regulation S-K as of our fiscal year end of December 31, 2022.

 

Options Award  Restricted Stock Awards 
Name and Position  No. of Securities Underlying Unexercised Options (#) Exercisable   No. of Securities Underlying Unexercised Options (#) Unexercisable   Option
Exercise Price ($)		   Vesting
Schedule		   Option
Expiration Date		  Number of Units of Stock That Have Not Vested
(#)		   Market Value of Units of Stock That Have Not Vested
($)(1)		 
Yovav Sameah,   100,487    -    3.60    (3)  October 18, 2025   -    - 
Former Chief Executive Officer                                 
                                  
Yehu Ofer,                          -    - 
Chief Executive Officer   -    300,000    4.50    (3)  November 14, 2029          
                                  
Jacob Avinu,                          -    - 
Senior VP Product Portfolio   -    100,000    4.50    (3)  November 14, 2029          
                                  
Amir Govrin   55,516    3,702    2.61    (2)  February 12, 2027   15,000    75,000 
Chief Technology Officer   13,055    13,057    4.50    (3)  May 13, 2028          

 

  (1)Based on the fair market value of our Common Stock on December 31, 2022 ($5.00 per share).
    
  (2)25% of the options granted will vest on the first anniversary date of the option grant, and 6.25% of the options will vest at the end of each subsequent three-month period thereafter over the course of the following three (3) years. Pursuant to an acceleration mechanism, any outstanding and unvested options shall immediately accelerate and vest upon the occurrence of certain events, including, inter alia, a merger or sale of all assets of the Company.
    
  (3)33.33% of the options granted will vest on the first anniversary date of the option grant, and 8.33% of the options will vest at the end of each subsequent three-month period thereafter over the course of the following two (2) years. Pursuant to an acceleration mechanism, any outstanding and unvested options shall immediately accelerate and vest upon the occurrence of certain events, including, inter alia, a merger or sale of all assets of the Company.

 

Retirement or Similar Benefit Plans

 

We do not have any arrangements or plans that provide for the payment of retirement or similar benefits to our directors or executive officers.

 

Resignation, Retirement, Other Termination, or Change in Control Arrangements

 

We have no contract, agreement, plan or arrangement, whether written or unwritten, that provides for payments to our directors or executive officers at, following, or in connection with the resignation, retirement or other termination of our directors or executive officers, or a change in control of our Company or a change in our directors’ or executive officers’ responsibilities following a change in control.

 

48

 

 

Director Compensation

 

The following table sets out the compensation paid to directors for services rendered during the year ended December 31, 2022.

 

Name  Fees Earned or
Paid in Cash		   Stock Awards (*)   Option Awards (*)   All Other
Compensation		   Total 
   $ in thousands 
Prof. Benad Goldwasser  $120   $-   $189   $-   $309 
Shmuel Donnerstein  $16   $-   $-   $-   $16 
Ronen Rosenbloom  $16   $-   $-   $-   $16 
Lior Amit  $26   $-   $-   $-   $26 
Moshe (Mori) Arkin  $16   $-   $-   $-   $16 
Inbal Kreiss  $26   $-   $-   $-   $26 
Zeev Vurembrand  $26   $-   $-   $-   $26 

 

(*) The amount shown in the “Stock Awards” and “Option Awards” columns represents the aggregate grant date fair value of awards computed in accordance with ASC 718, not the actual amounts paid to or realized by the directors during fiscal 2021. The fair value of each stock option award is estimated as of the date of grant using the Black-Scholes valuation model. Additional information regarding the assumptions used to estimate the fair value of all stock option awards is included in Note 9b-c Consolidated Financial Statements.

 

On March 15, 2020, our board of directors approved a quarterly fee of $4,000 payable to each of our currently serving directors, excluding Professor Benad Goldwasser. On each of April, 9, 2021 and August 12, 2021, our board of directors approved the same terms for directors appointed subsequent to March 15, 2020. On May 15, 2022, the board of directors approved a quarterly fee in the amount of $2,000 payable to a director for each committee on which such director serves, if any, with such fee in addition to any other fees to which such director is entitled as a member of the board of directors or any other committee.

 

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder matters

 

Security Ownership of Certain Beneficial Owners and Management

 

The table below provides information regarding the beneficial ownership of our common stock as of March 28, 2023, of (i) each of our current directors, (ii) each of the Named Executive Officers, (iii) all of our current directors and officers as a group, and (iv) each person or entity known to us who owns more than 5% of our common stock.

 

The percentage of common stock beneficially owned is based on 10,432,518 shares of common stock outstanding as of March 28, 2023. The number and percentage of shares beneficially owned by a person or entity also include shares of common stock issuable upon exercise of warrants that are currently exercisable or will become exercisable within 60 days of March 28, 2023. However, these shares are not deemed to be outstanding for the purpose of computing the percentage of shares beneficially owned of any other person or entity.

 

49

 

 

Unless otherwise indicated below, the address for each beneficial owner listed in the table below is c/o ScoutCam Inc., Suite 7A and 3B, Industrial Park, P.O. Box 3030, Omer, Israel 8496500.

 

Name and Address of Beneficial Owner   Amount and Nature
of Beneficial
Ownership(1)		     Percent of Class  
Prof. Benad Goldwasser(2)     430,633       3.98 %
Shmuel Donnerstein(3)     120,654       1.15 %
Ronen Rosenbloom(4)     19,728       *  
Lior Amit(5)     33,082       *  
Inbal Kreiss(6)     10,683       *  
Moshe (Mori) Arkin(7)     5,854,754       44.96 %
Zeev Vurembrand(8)     9,347       *  
Yehu Ofer     -       -  
Tanya Yosef(9)     41,460       *  
Amir Govrin(10)     82,874       *  
Katrin Dlugach(11)     51,414       *  
Jacob Avinu     -       -  
Arik Priel(12)     19,999       *  
Directors and officers as a group (13 individuals)     6,674,628       48.61 %
Medigus Ltd.     1,924,575       18.45 %
The More Group (13)     1,000,355       9.16 %
The Phoenix Holdings (14)     3,240,378       26.89 %
The Meitav Dash Group (15)     910,136       8.36 %

  

* Less than 1%.

 

(1) Beneficial ownership is determined in accordance with the rules of the SEC and generally includes voting or investment power with respect to securities. Each of the beneficial owners named in the table have, to our knowledge, direct ownership of and sole voting and investment power with respect to the shares of common stock beneficially owned by them.
   
(2) Includes options to purchase 386,692 shares of common stock which are currently exercisable or will become exercisable within 60 days of March 28, 2023.
   
(3) Includes options to purchase 51,717 shares of common stock which are currently exercisable or will become exercisable within 60 days of March 28, 2023.
   
(4) Includes options to purchase 19,728 shares of common stock which are currently exercisable or will become exercisable within 60 days of March 28, 2023.

 

(5) Includes options to purchase 33,082 shares of common stock which are currently exercisable or will become exercisable within 60 days of March 28, 2023.
   
(6) Includes options to purchase 10,683 shares of common stock which are currently exercisable or will become exercisable within 60 days of March 28, 2023.
   
(7) Securities included herein are held directly by Mr. Moshe Arkin, Mr. Arkin through his individual retirement account, or by M. Arkin (1999) Ltd, a company wholly-owned by Mr. Arkin. These securities include warrants to purchase 2,575,164 shares of common stock and options to purchase 15,721 shares of common stock which are currently exercisable or will become exercisable within 60 days of March 28, 2023.
   
(8) Includes options to purchase 9,347 shares of common stock which are currently exercisable or will become exercisable within 60 days of March 28, 2023.

 

50

 

 

(9) Includes options to purchase 41,460 shares of common stock which are currently exercisable or will become exercisable within 60 days of March 28, 2023.
   
(10) Includes options to purchase 82,874 shares of common stock which are currently exercisable or will become exercisable within 60 days of March 28, 2023.
   
(11) Includes options to purchase 51,414 shares of common stock which are currently exercisable or will become exercisable within 60 days of March 28, 2023.
   
(12) Includes options to purchase 19,999 shares of common stock which are currently exercisable or will become exercisable within 60 days of March 28, 2023.
   
(13) Based on information provided to or available to the Company, consists of warrants to purchase 485,343 shares of common stock. The business address of the More Group is BSR Tower 1, 2 Ben Gurion Street, Ramat Gan, Israel.
   
(14) Based on information provided to or available to the Company and on the Schedule 13G/A filed by The Phoenix Holdings with the SEC on February 14, 2023, which provides that the securities are beneficially owned by various direct or indirect, majority or wholly-owned subsidiaries of the Phoenix Holdings Ltd. (the “Subsidiaries”). The Subsidiaries manage their own funds and/or the funds of others, including for holders of exchange-traded notes or various insurance policies, members of pension or provident funds, unit holders of mutual funds, and portfolio management clients. Each of the Subsidiaries operates under independent management and makes its own independent voting and investment decisions. These securities include 1,620,189 warrants to purchase shares of common stock, which are currently exercisable or will become exercisable within 60 days of March 28, 2023. The business address of the Phoenix Holdings Ltd. is Derech Hashalom 53, Givataim 53454, Israel.
   
(15) Based on information provided to or available to the Company, consists of warrants to purchase 455,068 shares of common stock.

  

Item 13. Certain relationships and related transactions, and director independence

 

Related Party Transactions

 

On April 20, 2020, Medigus and ScoutCam Ltd. entered into an Intercompany Services Agreement, which amended and restated the intercompany services agreement executed between the parties on May 30, 2019. The agreement has an initial term of one year, and renews automatically for additional one-year periods, unless either party provides 60 (sixty) days written notice of non-renewal. Either Medigus or ScoutCam Ltd. may terminate the agreement for convenience upon providing 60 days prior written notice. The services to be provided by ScoutCam Ltd. include the provision of office space, utilities, car services, insurance, and chief financial officer services. In consideration for the foregoing services, ScoutCam Ltd. is entitled to arm’s length service fees based on the most recent transfer pricing analysis as performed by an external expert, which may be adjusted from time to time. On March 22, 2022, ScoutCam Ltd. provided prior written notice to Medigus of termination of the Intercompany Services Agreement effective May 21, 2022.

 

On May 18, 2020, we entered into and consummated a securities purchase agreement with M. Arkin (1999) Ltd. (“Arkin Ltd.”), a company wholly-owned by Moshe Arkin, a major shareholder of our Company and member of our board of directors, in connection with the sale and issuance of 229,569 units (“Arkin Units”), at a purchase price of $8.712 per Arkin Unit, and for an aggregate purchase price of $2,000,000 (the “Arkin Transaction”). Each Arkin Unit consists of: (i) two shares of common stock and (ii) (a) one warrant to purchase one share of common stock with an exercise price of $5.355 (“Warrant A”) and (b) two warrants, each to purchase one share of common stock with an exercise price of $8.037 (“Warrant B”, and together with Warrant A, the “Arkin Warrants”). The shares of common stock and Arkin Warrants were issued to Arkin Ltd. pursuant to Regulation S of the Securities Act of 1933, as amended.

 

51

 

 

Also on May 18, 2020, and in connection with the Arkin Transaction, we, Medigus and Arkin Ltd. entered into a Voting Agreement, pursuant to which Arkin Ltd. and Medigus each agreed to vote their respective shares of common stock in favor of the election of the opposite party’s designated representative(s), as applicable, to our board of directors. Each of Arkin Ltd.’s and Medigus’ rights under the Voting Agreement are contingent upon, inter alia, such party maintaining certain beneficial ownership thresholds in our company.

 

Also on May 18, 2020, in connection with the Arkin Transaction, we, Medigus and Arkin, entered into the Letter Agreement, whereby, provided that we obtain certain regulatory approvals described therein, we and Medigus agreed to amend certain terms of the Amended and Restated Asset Transfer Agreement and the License Agreement, thereby transferring outright certain patent assets from Medigus to us; provided, however, that in the event that we neglect the foregoing patent assets, we must transfer back ownership of the patent assets to Medigus for no additional consideration and absent any additional contingencies. On July 27, 2020, Medigus and ScoutCam Ltd. entered into each of the Addendum No. 1 to the Amended and Restated Asset Transfer Agreement, or the Addendum, and the Patent License Agreement Termination, in order to reflect and effect the amendments agreed upon in the Letter Agreement.

 

Beginning on January 1, 2021 and as of the date hereof, our board of directors authorized the allotment of options to purchase 128,334 shares of common stock to Prof. Benad Goldwasser and an aggregate of 901,842 options and RSUs to purchase shares of common stock to additional directors and certain officers of our company.

 

On March 29, 2021, we issued to certain investors, including M. Arkin (1999) Ltd., 2,469,156 units in exchange for an aggregate purchase price of $20 million. Each such unit consists of (i) one share of common stock and (ii) one warrant to purchase one share of common stock with an exercise price of $10.35 per share. Each such warrant is exercisable until the close of business on March 31, 2026. Pursuant to the terms of the foregoing warrants, following April 1, 2024, if the closing price of our the common stock equal or exceeds 135% of the aforementioned exercise price (subject to appropriate adjustments for stock splits, stock dividends, stock combinations and other similar transactions after the issue date of the warrants) for any thirty (30) consecutive trading days, we may force the exercise of the warrants, in whole or in part, by delivering to these investors a notice of forced exercise. The shares of common stock and the warrants were issued to such investors pursuant to Regulation S of the Securities Act of 1933, as amended. The securities issued in connection with the foregoing investment were registered by us for resale under a registration statement on Form S-1 declared effective on May 10, 2021.

 

On March 16, 2023, we entered into and consummated securities purchase agreements with (i) Moshe Arkin through his individual retirement account and (ii) The Phoenix Insurance Company Ltd. (“Phoenix Insurance”) and Shotfut Menayot Israel – Phoenix Amitim (“Phoenix Amitim”), in connection with the sale and issuance of an aggregate of 3,294,117 units, at a purchase price of $4.25 per unit, and for an aggregate purchase price of $14,000,000. Each unit consists of: (i) one share of common stock and (ii) one warrant to purchase one share of common stock with an exercise price of $5.50. As with Mr. Arkin, Phoenix Insurance and Phoenix Amitim are existing shareholders of the Company. The shares of common stock and warrants were issued pursuant to Regulation S of the Securities Act of 1933, as amended.

 

Policies and Procedures for Related Party Transactions

 

The audit committee is responsible for approving or ratifying related person transactions pursuant to ScoutCam’s related person transaction approval policy contained in the audit committee charter. In reviewing and approving any such related person transactions, the audit committee shall consider all relevant facts and circumstances, including whether the transaction is on terms comparable to those that could be obtained in an arm’s length transaction and the extent of the related person’s interest in the transaction. The audit committee shall have the authority to establish guidelines for related person transactions and intercompany arrangements where it deems it to be appropriate.

 

Director Independence

 

Our board of directors has determined that Professor Benad Goldwasser, Mr. Shmuel Donnerstein, Ms. Inbal Kreiss, Mr. Lior Amit and Mr. Zeev Vurembrand do not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director and that each of these directors is “independent”. We are not currently subject to listing requirements of any national securities exchange, which generally stipulate certain requirements that a majority of a company’s board of directors be classified as “independent”. As a result, we are not at this time required to have our board of directors comprised of a majority of “independent directors”. Notwithstanding the foregoing, we have voluntarily adopted the definition of “independent” as defined under Nasdaq Rule 5605(a)(2), and believe Professor Goldwasser, Mr. Donnerstein, Ms. Kreiss, Mr. Amit and Mr. Vurembrand qualify accordingly.

 

52

 

 

Item 14. Principal accounting fees and services

 

Audit and Accounting Fees

 

The following table sets forth the fees billed to our Company for professional services rendered by Brightman Almagor Zohar & Co., a firm in the Deloitte global network, and Kesselman & Kesselman, a member of PricwaterhouseCoopers International Limited, for the fiscal years ended December 31, 2021 and December 31, 2022:

 

Services  Year Ended
December 31, 2022		   Year Ended
December 31, 2021		 
   $ in thousands 
Audit fees(1)  $85(3)  $240(4)
Tax fees(2)   21    16 
Total fees  $106   $256 

 

  (1) Audit fees consist of audit and review services, consents and review of documents filed with the SEC.
     
  (2) Tax fees consist of services related to representing the Company before the Israel Tax Authority in a VAT assessment.
     
  (3) Audit Fees in 2022 were for services rendered by Brightman Almagor Zohar & Co., a firm in the Deloitte global network.
     
  (4) Audit Fees in 2021 consist of $123,000 in connection with the services rendered by Brightman Almagor Zohar & Co., a firm in the Deloitte global network, and $117,000in connection with the services rendered by Kesselman & Kesselman, a member of PricwaterhouseCoopers International Limited.

 

Audit Committee Administration of Engagement

 

The audit committee maintains a pre-approval policy that provides guidelines for the audit, audit-related, tax, and other permissible non-audit services that may be provided by the independent registered public accounting firm (the independent auditors) in order to ensure that the provision of such services does not impair the auditor’s independence. Under this policy, the audit committee annually pre-approves the audit fee and terms of the engagement, as set forth in the engagement letter, along with a specified list of audit-related and tax services. If any service to be provided by the independent auditors has not received pre-approval during this annual process, it will require specific pre-approval by the audit committee.

 

53

 

 

Part IV

 

Item 15. exhibits AND financial statement schedules

 

Exhibit No.  

Exhibit Description

3.1.1   Amended and Restated Articles of Incorporation (incorporated by reference to Exhibit 3.1.4 to our Quarterly Report on Form 10-Q filed with the SEC on August 12, 2021)
3.2.1*   Amended and Restated Bylaws
4.1*   Description of the Registrant’s Securities
10.1   Amended and Restated Asset Transfer Agreement, by and between ScoutCam Ltd. and Medigus Ltd., dated December 1, 2019 (incorporated by reference to Exhibit 10.7 to our Current Report on Form 8-K filed with the SEC on December 31, 2019)
10.2+   Consulting Agreement by and between ScoutCam Ltd. and Prof. Benad Goldwasser, dated July 31, 2019 (incorporated by reference to Exhibit 10.8 to our Current Report on Form 8-K filed with the SEC on December 31, 2019)
10.3*   2020 Share Incentive Plan
10.4*   Form of Notice of Option Grant and Option Agreement
10.5*   Form of Notice of RSU Grant and RSU Agreement
10.6+   Employment Agreement, by and between ScoutCam Ltd. and Amir Govrin, dated May 1, 2019 (incorporated by reference to Exhibit 10.20 to our Form S-1 filed with the SEC on May 12, 2020)
10.7+   Employment Agreement, by and between ScoutCam Ltd. and Tanya Yosef, dated January 14, 2021 (incorporated by reference to Exhibit 10.21 to our Annual Report on Form 10-K filed with the SEC on March 31, 2021)
10.8+   Employment Agreement, by and between ScoutCam Ltd. and Katrin Dlugach, dated July 1, 2019 (incorporated by reference to Exhibit 10.22 to our Annual Report on Form 10-K filed with the SEC on March 31, 2021)
10.9   Voting Agreement, dated May 18, 2020, by and among ScoutCam Inc. Medigus Ltd. and M. Arkin (1999) Ltd. (incorporated by reference to Exhibit 10.3 to our Current Report on Form 8-K filed with the SEC on May 19, 2020)
10.10**   Addendum No. 1 to the Amended and Restated Asset Transfer Agreement, dated July 27, 2020, by and between ScoutCam Ltd. and Medigus Ltd. (incorporated by reference to Exhibit 10.30 to our Registration Statement on Form S-1/A filed with the SEC on October 19, 2021)
10.11   Purchase Order Form, between ScoutCam Inc. and the Investors in the March 2021 Private Placement (incorporated by reference to Exhibit 10.34 to our Registration Statement on Form S-1 filed with the SEC on May 4, 2021)
10.12   Form of Warrant (incorporated by reference to Exhibit 10.1 of our Current Report on Form 8-K filed with the SEC on March 24, 2021)
10.13+   Employment Agreement, dated October 26 , 2021, by and between ScoutCam Ltd. and Arik Priel (incorporated by reference to Exhibit 10.23 to our Annual Report on Form 10-K filed with the SEC on March 30, 2022)
10.14+   Employment Agreement, dated July 13, 2022, by and between ScoutCam Ltd. and Yehu Ofer (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed with the SEC on October 18, 2022)
10.15+*   Employment Agreement dated September 20, 2022, by and between ScoutCam Ltd. and Jacob Avinu.
10.24   Form of Warrant to Purchase Shares of Common Stock (incorporated by reference to Exhibit 4.1 to our Current Report on Form 8-K filed with the SEC on March 17, 2023)
10.25   Stock Purchase Agreement, dated March 16, 2023 by and between ScoutCam Inc. and the Investors defined therein . (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed with the SEC on March 17, 2023)

 

54

 

 

10.26   Stock Purchase Agreement, dated March 16, 2023 by and between ScoutCam Inc. and the Investors defined therein. (incorporated by reference to Exhibit 10.2 to our Current Report on Form 8-K filed with the SEC on March 17, 2023)
10.27   Registration Rights Agreement, dated March 16, 2023, among ScoutCam Inc. and the Investor defined therein (incorporated by reference to Exhibit 10.3 to our Current Report on Form 8-K filed with the SEC on March 17, 2023)
10.28   Registration Rights Agreement, dated March 16, 2023, among ScoutCam Inc. and the Investor defined therein (incorporated by reference to Exhibit 10.4 to our Current Report on Form 8-K filed with the SEC on March 17, 2023)
21.1   Subsidiaries of the Registrant (incorporated by reference to Exhibit 21.1 to our Current Report on Form 8-K filed with the SEC on December 31, 2019)
31.1*   Section 302 Certification under the Sarbanes-Oxley Act of 2002 of the Principal Executive Officer and Principal Financial Officer
32.1*   Section 906 Certification under the Sarbanes-Oxley Act of 2002 of the Principal Executive Officer and Principal Financial Officer
     
101.INS   Inline XBRL Instance Document
101.SCH   Inline XBRL Taxonomy Extension Schema Document
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document
104   Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)

 

* Filed herewith
** Certain confidential information contained in this exhibit, marked by brackets, was omitted because it is both (i) not material and (ii) would likely cause competitive harm to the Company if publicly disclosed. “[***]” indicates where the information has been omitted from this exhibit
+ Management contract or compensatory plan or arrangement

 

(b) Financial Statement Schedules. Schedules have been omitted because the information required to be set out therein is not applicable or is shown in the financial statements or notes thereto.

 

Item 16. Form 10-K summary

 

Not applicable.

 

55

 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  SCOUTCAM INC.
     
  By: /s/ Yehu Ofer
  Name: Yehu Ofer
  Title: Chief Executive Officer
  Date: March 28, 2023

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 

Signature   Title   Date
         
/s/ Yehu Ofer   Chief Executive Officer   March 28, 2023
Yehu Ofer   (Principal Executive Officer)    
         
/s/ Tanya Yosef   Chief Financial Officer   March 28, 2023
Tanya Yosef   (Principal Financial Officer and Principal Accounting Officer)    
         
/s/ Benad Goldwasser   Chairman of the Board   March 28, 2023
Benad Goldwasser        
         
/s/ Shmuel Donnerstein   Director   March 28, 2023
Shmuel Donnerstein        
         
/s/ Ronen Rosenbloom   Director   March 28, 2023
Ronen Rosenbloom        
         
/s/ Lior Amit   Director   March 28, 2023
Lior Amit        
         
/s/ Mori Arkin   Director   March 28, 2023
Mori Arkin        
         
/s/ Inbal Kreiss    Director   March 28, 2023
Inbal Kreiss        
         
/s/ Zeev Vurembrand   Director   March 28, 2023
Zeev Vurembrand        

 

56

 

 

SCOUTCAM INC.

 

TABLE OF CONTENTS

 

  Page
Consolidated Financial Statements – in US Dollars (USD) in thousands  
Report of Independent Registered Public Accounting Firm (PCAOB ID 1197) F-2
Consolidated Balance Sheets F-3
Consolidated Statements of Operations F-4
Consolidated Statements of Changes in Shareholders’ Equity F-5
Consolidated Statements of Cash Flows F-6
Notes to the Consolidated Financial Statements F-8

 

F-1

 

 

 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To the shareholders and the Board of Directors of Scoutcam Inc.

 

Opinion on the Financial Statements

 

We have audited the accompanying consolidated balance sheets of Scoutcam Inc. and its Subsidiary (the “Company”) as of December 31, 2022 and 2021, the related consolidated statements of operations, changes in shareholders’ equity and cash flows for each of the two years in the period ended December 31, 2022, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2022, in conformity with accounting principles generally accepted in the United States of America.

 

Basis for Opinion

 

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

Critical Audit Matter

 

The critical audit matter communicated below is a matter arising from the current-period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (1) relates to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

 

Stock-Based Compensation to Employees, Directors and Service Providers – Stock Options — Refer to Notes 2i and 9b to the consolidated financial statements

 

Critical Audit Matter Description

 

The Company issues various types of equity awards, including stock options. During the year ended December 31, 2022, the Company recorded stock options related compensation expense of $1.49 million. The Company estimated the fair value of these stock options granted using the Black-Scholes option pricing model. The Black-Scholes option-pricing model required management to make a number of assumptions, of which the most significant are the stock price volatility and the expected option term.

 

Auditing the Company’s accounting of stock-based options required auditor judgment due to the subjectivity of assumptions used to estimate the fair value of stock-based options granted.

 

How the Critical Audit Matter Was Addressed in the Audit

 

Our audit procedures related to the stock-based compensation included the following, among others:

 

●We assessed the accuracy and completeness of the awards granted during the year by reading the relevant Board of Directors minutes and grant documents.

 

●We evaluated the appropriateness of the valuation method used for the stock option grants and whether the method used for determining fair value was applied consistently with the valuation of similar grants in prior periods.

 

●We evaluated the significant assumptions used by management to calculate the fair value of stock options granted. Such evaluation included independent calculation of the expected volatility.

 

●We developed an independent estimate of the fair value for all the grants during the year and compared our estimate of fair value to the fair value used by management.

 

/s/ Brightman Almagor Zohar & Co.

Certified Public Accountants

A Firm in the Deloitte Global Network

 

Tel Aviv, Israel

March 28, 2023

 

We have served as the Company’s auditor since 2020.

 

F-2

 

 

SCOUTCAM INC.

 

CONSOLIDATED BALANCE SHEETS

 

       2022   2021 
       December 31, 
       2022   2021 
       USD in thousands 
             
Assets   Note           
                
CURRENT ASSETS:               
Cash and cash equivalents        10,099    8,581 
Short terms deposits   3    3,047    11,013 
Accounts receivable        60    8 
Inventory   4    630    167 
Other current assets        281    443 
Total current assets        14,117    20,212 
                
NON-CURRENT ASSETS:               
Contract fulfillment assets   10    1,495    1,675 
Property and equipment, net   5    648    781 
Operating lease right-of-use assets   11    307    482 
Severance pay asset        328    396 
Total non-current assets        2,778    3,334 
                
TOTAL ASSETS        16,895    23,546 
                
Liabilities and shareholders’ equity               
                
CURRENT LIABILITIES:               
Accounts payable        297    103 
Contract liabilities - short term   10    1,426    346 
Operating lease liabilities - short term   11    199    256 
Accrued compensation expenses        365    355 
Related parties   8    58    39 
Other accrued expenses   6    214    210 
Total current liabilities        2,559    1,309 
                
NON-CURRENT LIABILITIES:               
Contract liabilities - long term   10    2,218    2,074 
Operating lease liabilities - long term   11    64    203 
Liability for severance pay        268    344 
Total non-current liabilities        2,550    2,621 
                
TOTAL LIABILITIES        5,109    3,930 
                
SHAREHOLDERS’ EQUITY:   9           
Common stock, $0.001 par value; 300,000,000 shares authorized as of December 31, 2022 and December 31, 2021, 7,121,737 shares issued and outstanding as of December 31, 2022 and December 31, 2021        7    7 
Additional paid-in capital        36,541    34,903 
Accumulated deficit        (24,762)   (15,294)
TOTAL SHAREHOLDERS’ EQUITY        11,786    19,616 
                
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY        16,895    23,546 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-3

 

 

SCOUTCAM INC.

 

CONSOLIDATED STATEMENTS OF OPERATIONS

 

   Note   2022   2021 
       Year ended December 31, 
   Note   2022   2021 
       USD in thousands
(except per share data)		 
             
REVENUES   10    665    387 
COST OF REVENUES        1,631    1,108 
GROSS LOSS        (966)   (721)
RESEARCH AND DEVELOPMENT EXPENSES   12    4,197    2,002 
SALES AND MARKETING EXPENSES       699    908 
GENERAL AND ADMINISTRATIVE EXPENSES   13    3,577    5,481 
OPERATING LOSS        (9,439)   (9,112)
OTHER INCOME        30    8 
FINANCING INCOME (EXPENSES), NET        (59)   117 
LOSS BEFORE TAXES ON INCOME        (9,468)   (8,987)
TAXES ON INCOME        -    - 
NET LOSS        (9,468)   (8,987)
Net loss per share (basic and diluted, in USD)        (1.33)   (1.44)
Weighted average common shares (basic and diluted, in thousands)        7,122    6,240 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-4

 

 

SCOUTCAM INC.

 

CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY

 

                     
   Common stock   Additional paid-in capital   Accumulated deficit   Total
Shareholders’ equity		 
   Number in
thousands		   Amount   USD in thousands 
                     
Balance at January 1, 2022   7,122   $    7   $34,903   $(15,294)  $          19,616 
Stock based compensation (see note 9)   -    -    1,638    -    1,638 
Net loss   -    -    -    (9,468)   (9,468)
Balance at December 31, 2022   7,122   $7   $36,541   $(24,762)  $11,786 

 

   Common stock   Additional paid-in capital   Accumulated deficit   Total
Shareholders’ equity		 
   Number in
thousands		   Amount   USD in thousands 
                     
Balance at January 1, 2021   4,084   $    4   $10,267   $(6,307)  $            3,964 
Issuance of shares and warrants (see note 9)   2,469    2    19,116    -    19,118 
Exercise of warrants (see note 9)   568    1    3,490    -    3,491 
Stock based compensation (see note 9)   -    -    2,030    -    2,030 
Round up of shares due to reverse stock split (see note 9)   1    -*    -*    -    -*  
Net loss   -    -    -    (8,987)   (8,987)
Balance at December 31, 2021   7,122   $7   $34,903   $(15,294)  $19,616 

 

* Represents an amount less than $1 thousand

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-5

 

 

SCOUTCAM INC.

 

CONSOLIDATED STATEMENTS OF CASH FLOWS

 

   2022   2021 
   Year ended December 31, 
   2022   2021 
   USD in thousands 
CASH FLOWS FROM OPERATING ACTIVITIES:          
Net loss   (9,468)   (8,987)
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation   251    114 
Stock based compensation   1,638    2,030 
Profit (loss) from exchange differences on cash and cash equivalents   269    (130)
Profit from exchange differences from operating lease liabilities   (49)   - 
Severance pay asset and liability   (8)   (25)
Interest income in respect of deposits   (34)   (13)
           
CHANGES IN OPERATING ASSET AND LIABILITY:          
Decrease (increase) in accounts receivable   (52)   9 
Decrease (increase) in inventory   (463)   77 
Increase (decrease) in operating lease liability   (233)   20 
Decrease (increase) in ROU asset   261    (43)
Decrease (increase) in other current assets   162    (126)
Increase in account payables   194    24 
Increase (decrease) in contract fulfillment assets   180    (545)
Increase in contract liabilities   1,224    1,572 
Increase (decrease) in accrued compensation expenses   10    (14)
Increase in related parties   19    86 
Increase in other accrued expenses   4    65 
Net cash flows used in operating activities   (6,095)   (5,886)
           
CASH FLOWS FROM INVESTING ACTIVITIES:          
Purchase of property and equipment   (118)   (595)
Withdrawal of short terms deposits   14,500    - 
Investment in short terms deposits   (6,500)   (11,000)
Net cash flows provided by (used in) investing activities   7,882    (11,595)
           
CASH FLOWS FROM FINANCING ACTIVITIES:          
Proceeds from issuance of shares and warrants   -    19,118 
Proceeds from exercise of warrants   -    3,491 
Issuance expenses   -    (50)
Net cash flows provided by financing activities   -    22,559 
           
INCREASE IN CASH AND CASH EQUIVALENTS   1,787    5,078 
BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR   8,581    3,373 
PROFITS FROM EXCHANGE DIFFERENCES ON CASH AND CASH EQUIVALENTS   (269)   130 
BALANCE OF CASH AND CASH EQUIVALENTS AT END OF YEAR   10,099    8,581 

 

F-6

 

 

Non cash activities -

 

   Year ended December 31, 
   2022   2021 
   USD in thousands 
 Non cash activities        
Right-of-use assets obtained in exchange for operating lease liabilities   155    524 
Increase in property and equipment through a decrease in advances to suppliers   -    31 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-7

 

 

SCOUTCAM INC.

 

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 1 – GENERAL:

 

  a. ScoutCam Inc. (the “Company”), formerly known as Intellisense Solutions Inc., (“Intellisense”), was incorporated under the laws of the State of Nevada on March 22, 2013. Prior to the closing of the Exchange Agreement (as defined below), the Company was a non-operating “shell company”.
     
    The Company’s wholly-owned subsidiary, ScoutCam Ltd. (“ScoutCam”), was formed in the State of Israel on January 3, 2019, as a wholly-owned subsidiary of Medigus Ltd. (“Medigus”), an Israeli company traded on the Nasdaq Capital Market, and commenced operations on March 1, 2019.
     
    In December 2019, Medigus and ScoutCam consummated an asset transfer agreement, under which Medigus transferred and assigned certain assets and intellectual property rights related to its miniaturized imaging business to ScoutCam.
     
    On December 30, 2019, Intellisense and Medigus consummated a securities exchange agreement (the “Exchange Agreement”), pursuant to which Medigus delivered 100% of its holdings in ScoutCam to Intellisense in exchange for shares of Intellisense’s common stock representing 60% of the issued and outstanding share capital of Intellisense immediately upon the consummation of the Exchange Agreement.
     
    As of December 31, 2022, Medigus beneficially owned 27.02% of the Company’s outstanding common stock.
     
    The Company, through ScoutCam, is engaged in the development, production and marketing of innovative Predictive Maintenance (PdM) and Condition Based Monitoring (CBM) technologies, providing visual sensing and AI-based video analytics solutions for critical systems in the aviation, maritime, industrial non-destructing-testing industries, transportation, and energy industries. Some of the Company’s products utilize our micro visualization technology in medical devices for complex and minimally invasive medical procedures. Company’s technology includes proven video technologies and products amalgamated into a first-of-its-kind, FDA-cleared minimally invasive surgical device. The Company’s video-based sensors, embedded software and AI algorithms are being deployed in hard-to-reach locations and harsh environments across a variety of PdM and CBM use cases. The Company’s solution allows maintenance and operations teams visibility into areas which are inaccessible under normal circumstances, or where the operating ambience otherwise is not suitable for continuous real-time monitoring’ and has various applications which have relevancy in wide range of industry segments, that utilize complicated mechanics requiring ongoing monitoring and predictive maintenance applications.

 

F-8

 

 

SCOUTCAM INC.

 

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 1 – GENERAL (continued):

 

  b.

On August 9, 2021, the Company amended its Articles of Incorporation to effect a nine-to-one reverse stock split of its outstanding Common Stock.

     
    As a result of the reverse stock split, every nine shares of the Company’s outstanding Common Stock were combined and reclassified into one share of the Company’s Common Stock. No fractional shares were issued in connection with or following the reverse split. The amount of authorized capital of the Company’s Common Stock and par value of such shares remained unchanged.
     
    All share, stock option and per share information in these consolidated financial statements have been adjusted to reflect the reverse stock split on a retroactive basis.
     

 

.

 c.

Since incorporation of ScoutCam and through December 31, 2022, the Company accumulated a deficit of approximately $25 million and its activities have been funded mainly by its shareholders. The Company’s management believes the Company’ cash and cash resources as of December 31, 2022 as well as its proceeds from issuance of common stock and warrants in the private offering as detailed in Note 14, will allow the Company to fund its operating plan through at least the next 12 months. However, the Company expects to continue to incur significant research and development and other costs related to its ongoing operations and in order to continue its future operations, the Company will need to obtain additional funding until becoming profitable.

 

F-9

 

 

SCOUTCAM INC.

 

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES:

 

  a. Basis of preparation:

 

The consolidated financial statements have been prepared in accordance with United States Generally Accepted Accounting Principles in the United States (“U.S. GAAP”) applied on a consistent basis.

 

  b. Use of estimates

 

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. The Company evaluates its assumptions on an ongoing basis, including those related to contingencies and inventory impairment, as well as estimates used in applying its revenue recognition policy. Actual results may differ from these estimates.

 

  c. Functional currency

 

A majority of ScoutCam’s revenues are generated in U.S. dollars. The substantial majority of ScoutCam costs are incurred in U.S. dollars and New Israeli Shekels (“NIS”). ScoutCam management believes that the U.S. dollar is the currency of the primary economic environment in which ScoutCam operates. Thus, the functional currency of ScoutCam is the U.S. dollar.

 

Transactions and balances originally denominated in U.S. dollars are presented at their original amounts. Balances in non-U.S. dollar currencies are translated into U.S. dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For non-U.S. dollar transactions and other items in the statements of operations (indicated below), the following exchange rates are used: (i) for transactions exchange rates at transaction dates and (ii) for other items (derived from non-monetary balance sheet items such as depreciation and amortization) historical exchange rates. Currency transaction gains and losses are presented in financial income or expenses, as appropriate.

 

  d. Cash and Cash Equivalents

 

The Company considers as cash equivalents all short-term, highly liquid investments, which include short-term bank deposits with original maturities of three months or less from the date of purchase that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash.

 

  e. Short-term bank deposits

 

Bank deposits with maturities of more than three months but less than one year are included in short-term bank deposits. Such short-term bank deposits are stated at cost which approximates fair market value.

 

F-10

 

 

SCOUTCAM INC.

 

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (continued):

 

  f. Accounts receivable

 

Accounts receivable are presented in the Company’s consolidated balance sheets net of allowance for doubtful accounts. The Company estimates the collectability of its accounts receivable balances and adjusts its allowance for doubtful accounts accordingly.

 

When revenue recognition criteria are not met for a sale transaction that has been billed, the Company does not recognize deferred revenues or the related account receivable.

 

As of December 31, 2022 and 2021, no allowance for doubtful accounts was recorded.

 

  g. Property and equipment

 

Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation is calculated on a straight-line basis over the estimated useful lives.

 

The annual depreciation rates are as follows:

 

   % 
Machinery and laboratory equipment   10%-15%
Office furniture and equipment   10%
Computers and computer software   33%
Leasehold improvements   Over the shorter of the lease term (including options if any) or useful life 

 

  h. Severance pay

 

Israeli labor law generally requires payment of severance pay upon dismissal of an employee or upon termination of employment in certain other circumstances. Pursuant to Section 14 of the Severance Compensation Act, 1963 (“Section 14”), all of the ScoutCam’s employees in Israel are entitled to a monthly contribution, at a rate of 8.33% of their monthly salary, made in their name with insurance companies. Contributions under Section 14 relieve ScoutCam from any future severance payment obligation with respect to those employees. The aforementioned contributions are not recorded as an asset on the Company’s balance sheet and there is no liability recorded, as the Company does not have a future obligation to make any additional payments.

 

The asset and the liability for severance pay presented in the balance sheets reflects employees that began employment prior to automatic application of Section 14.

 

The severance pay liability of ScoutCam to its employees that began employment prior to automatic application of Section 14 is based upon the number of years of service and the latest monthly salary of such employees and is partly covered by regular deposits with recognized pension funds and deposits with severance pay funds. Under labor laws, these deposits are in the employees’ names and, subject to certain limitations, are the property of the employees. ScoutCam records the obligation as if it were payable at each balance sheet date on an undiscounted basis.

 

F-11

 

 

SCOUTCAM INC.

 

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (continued):

 

  i. Stock-Based Compensation

 

The Company measures and recognizes compensation expense for its equity classified stock-based awards granted under its plan based on estimated fair values on the grant dates. The Company calculates the estimated fair value of option awards on the grant date using the Black-Scholes option-pricing model. The Black-Scholes option-pricing model requires a number of assumptions, of which the most significant are the stock price volatility and the expected option term. The Company’s expected dividend rate is zero since the Company does not currently pay cash dividends on its stocks and does not anticipate doing so in the foreseeable future. Each of the above factors requires the Company to use judgment and make estimates in determining the percentages and time periods used for the calculation. If the Company were to use different percentages or time periods, the estimated fair value of option awards could be materially different. The Company recognizes stock-based compensation cost for option awards on an accelerated basis over the employee’s requisite service period, net of estimated forfeitures.

 

  j. Inventories

 

Inventories include raw materials, inventory in process and finished products and are valued at the lower of cost or net realizable value.

 

Inventories are stated at a lower of cost, determined by the first-in, first-out method, or market based on net realizable value. Costs of purchased raw materials and inventory in process include costs of design, raw materials, direct labor, other direct costs and fixed production overheads.

 

The inventories are adjusted for estimated excess and obsolescence and written down to net realizable value based upon estimates of future demand, technology developments and market conditions.

 

  k. Revenue recognition

 

  a) Revenue measurement

 

The Company’s revenues are measured according to the ASC 606, “Revenue from Contracts with Customers” (“ASC 606”). Under ASC 606, revenues are measured according to the amount of consideration that the Company expects to be entitled to receive in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties. Revenues are presented net of VAT.

 

  b) Revenue recognition

 

The Company recognizes revenue when a customer obtains control over promised goods or services. For each performance obligation, the Company determines at contract inception whether it satisfies the performance obligation over time or satisfies the performance obligation at a point in time.

 

Performance obligations are satisfied over time if one of the following criteria is met:

 

F-12

 

 

SCOUTCAM INC.

 

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (continued):

 

(a) the customer simultaneously receives and consumes the benefits provided by the Company’s performance; (b) the Company’s performance creates or enhances an asset that the customer controls as the asset is created or enhanced; or (c) the Company’s performance does not create an asset with an alternative use for the Company and the Company has an enforceable right to payment for performance completed to date.

 

If a performance obligation is not satisfied over time, a Company satisfies the performance obligation at a point in time.

 

The transaction price is allocated to each distinct performance obligations on a relative standalone selling price (“SSP”) basis and revenue is recognized for each performance obligation when control has passed. In most cases, the Company is able to establish SSP based on the observable prices of services sold separately in comparable circumstances to similar customers and for products based on the Company’s best estimates of the price at which the Company would have sold the product regularly on a stand-alone basis. The Company reassesses the SSP on a periodic basis or when facts and circumstances change.

 

Product Revenue

 

Revenues from product sales are recognized at a point in time when the customer obtains control of the Company’s product, typically upon shipment to the customer. Indirect taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from revenues.

 

Service Revenue

 

The Company also generates revenues from development services. Revenue from development services is recognized over the period of the applicable service contract. To the extent development services are not distinct from the performance obligation relating to the subsequent mass production phase of the prototype under development, revenue from these services is deferred until commencement of the production phase of the project and are then recognized over the expected term production.

 

F-13

 

 

SCOUTCAM INC.

 

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (continued):

 

  l. Cost of revenues

 

Cost of revenue consists of products purchased from sub-contractors, raw materials for in-house assembly line, shipping and handling costs to customers, salary, employee-related expenses, depreciation and overhead expenses.

 

Cost of revenues are expensed commensurate with the recognition of the respective revenues. Costs deferred in respect of deferral of revenues are recorded as contract fulfilment assets on the Company’s balance sheet and are written down to the extent the contract is expected to incur losses.

 

  m. Research and development costs

 

Research and development costs are expensed as incurred and includes salaries and employee-related expenses, overhead expenses, material, and third-party contractors’ charges.

 

  n. Income taxes

 

Income taxes are accounted for using the asset and liability approach under ASC-740, “Income Taxes”. The asset and liability approach requires the recognition of taxes payable or refundable for the current year and deferred tax liabilities and assets for the future tax consequences of events that have been recognized in the Company’s financial statements or tax returns.

 

The measurement of current and deferred tax liabilities and assets is based on provisions of the relevant tax law. The measurement of deferred tax assets is reduced, if necessary, by the amount of any tax benefits that, based on available evidence, are not expected to be realized.

 

Uncertain tax positions are accounted for in accordance with the provisions of ASC 740-10, under which a company may recognize the tax benefit from an uncertain tax position claimed or expected to be claimed on a tax return only if it is more likely than not that the tax position will be sustained on examination by the taxation authorities, based on the technical merits of the position, at the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement. Interest and penalties, if any, related to unrecognized tax benefits are recognized in tax expense. The Company and ScoutCam provide a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value.

 

  o. Legal contingencies

 

From time to time, the Company and its subsidiary become involved in legal proceedings or are subject to claims arising in their ordinary course of business. Such matters are generally subject to many uncertainties and outcomes are not predictable with assurance. The Company accrues for contingencies when the loss is probable and can reasonably estimate the amount of any such loss.

 

F-14

 

 

SCOUTCAM INC.

 

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 2 — SIGNIFICANT ACCOUNTING POLICIES (continued):

 

  p. Basic and diluted net loss per common stock:

 

Basic net loss per common stock is computed by dividing net loss, as adjusted, to include the weighted average number of shares of common stock outstanding during the year.

 

Diluted net loss per common stock is computed by dividing net loss, as adjusted, by the weighted average number of shares of common stock outstanding during the year, plus the number of shares of common stock that would have been outstanding if all potentially dilutive shares of common stock had been issued, using the treasury stock method, in accordance with ASC 260-10 “Earnings per Share”.

 

All outstanding stock options and warrants have been excluded from the calculation of the diluted loss per share for the years ended December 31, 2022 and December 31, 2021, since all such securities have an anti-dilutive effect.

 

  q. Leases

 

In accordance with ASC 842, the Company determines whether an arrangement is or contains a lease based on the facts and circumstances present at inception of an arrangement. An arrangement is or contains a lease if the arrangement conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

 

Arrangements that are determined to be leases at inception are recognized in long-term right-of-use assets (“ROU”) assets and short and long-term lease liabilities in the consolidated balance sheet at lease commencement. Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future fixed lease payments over the lease term at commencement date. As most of the Company’s leases do not provide an implicit rate, the Company applies its incremental borrowing rate based on the economic environment at commencement date in determining the present value of future payments. Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for operating leases or payments are recognized on a straight-line basis over the lease term.

 

The Company has elected not to recognize on the balance sheet leases with terms of 12 months or less.

 

F-15

 

 

SCOUTCAM INC.

 

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 3 - SHORT-TERM DEPOSITS

 

Short term investments as of December 31, 2022 include bank deposit bearing annual interest rates of 4%, with maturities of up to 12 months.

 

NOTE 4 - INVENTORY:

 

   2022   2021 
   December 31, 
   2022   2021 
   USD in thousands 
Raw materials and supplies   438    99 
Work in progress   148    2 
Finished goods   44    66 
 Inventory Net   630    167 

 

During the years 2022 and 2021, no impairment occurred.

 

NOTE 5 - PROPERTY AND EQUIPMENT, NET:

 

Property, plant and equipment, net consisted of the following:

 

   2022   2021 
   December 31, 
   2022   2021 
   USD in thousands 
Cost:          
Machinery and laboratory equipment   619    578 
Leasehold improvements, office furniture and equipment   351    316 
Computers and computer software   182    140 
Total property and equipment, gross   1,152    1,034 
Less: accumulated deprecation   (504)   (253)
Total property and equipment, net   648    781 

 

Depreciation expenses were $251 thousand and $114 thousand for the years ended December 31, 2022 and 2021, respectively.

 

F-16

 

 

SCOUTCAM INC.

 

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 6 – OTHER ACCRUED EXPENSES:

 

   2022   2021 
   December 31, 
   2022   2021 
   USD in thousands 
Internal Revenue Services   -    40 
Accrued expenses   214    170 
Total other accrued expenses    214    210 

 

NOTE 7 - INCOME TAXES:

 

  a. Basis of taxation

 

1.Tax rates applicable to the income of the Israeli subsidiary:

 

ScoutCam is taxed according to Israeli tax laws.

 

The Israeli corporate tax rate from the year 2018 and onwards is 23%.

 

  2.Tax rates applicable to the income of the U.S. company:

 

    The Company is taxed according to U.S. tax laws.
     
    The U.S. corporate tax rate from the year 2018 and onwards is 21%.

 

  b.

Deferred income taxes:

     
    Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s deferred tax assets are as follows:

   2022   2021 
   December 31, 
   2022   2021 
   USD in thousands 
Operating loss carryforward   26,295    15,582 
           
Net deferred tax asset before valuation allowance   

6,069

    

3,595

 
Valuation allowance   (6,069)   (3,595)
Net deferred tax   -    - 

 

    As of December 31, 2022, the Company has provided a full valuation allowance of $6,069 thousand in respect of deferred tax assets resulting from tax loss carryforward and other temporary differences. Management currently believes that because the Company has a history of losses, it is more likely than not that the deferred tax regarding the loss carryforward and other temporary differences will not be realized in the foreseeable future.
     
  c. Available carryforward tax losses:
     
    As of December 31, 2022, the Company has an accumulated tax loss carryforward of approximately $26,295 thousand. Carryforward tax losses in Israel are of unlimited duration. Under the Tax Cut and Jobs Act of 2017, or the Tax Act (subject to modifications under the Coronavirus Aid, Relief, and Economic Security Act), federal net operating losses (NOL) incurred in taxable years ending after December 31, 2017 and in future years may be carried forward indefinitely, but the deductibility of such federal net operating losses is limited. It is uncertain if and to what extent various states will conform to the newly enacted federal tax law.
     

 

 

 

 

In addition, under Section 382 of the Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, if a corporation undergoes an “ownership change,” which is generally defined as a greater than 50 percentage point change, by value, in its equity ownership over a three-year period, the corporation’s ability to use its pre-change NOL carryforwards and other pre-change tax attributes to offset its post-change income or taxes may be limited. Such limitations may result in the expiration of net operating losses before utilization.

     
  d. The main reconciling item between the statutory tax rate of the Company and the effective tax rate is the recognition of valuation allowance in respect of deferred taxes relating to accumulated net operating losses carried forward due to the uncertainty of the realization of such deferred taxes.

 

  e.

As of December 31, 2021, ScoutCam owed NIS 740 thousand, (approximately $229 thousand) in additional taxes to the Israel Tax Authority following a VAT audit in Israel for 2019-2021.

     
    On November 18, 2021, ScoutCam filed an appeal to the Israeli Tax Authority on the finding of the VAT audit.
     
    Due to the uncertainty regarding the outcome of the appeal, the financial statements as of December 31, 2021 included a provision related to the additional taxes of $229 thousand, which was included in general and administrative expenses in the statement of operation report.
     
    In July 2022, ScoutCam reached an agreement with the Israeli Tax Authority, according to which the amount due in additional taxes was reduced to NIS 340 thousand (approximately $100 thousand).

 

F-17

 

 

SCOUTCAM INC.

 

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 8 – RELATED PARTIES:

 

  a. Related Parties Balances:

 

   December 31, 
   2022   2021 
   USD in thousands 
Directors (directors’ accrued compensation)   48    - 
Smartec R&D Ltd. (see note 8c)   10    - 
Medigus   -    39 
    58    39 

 

  b. On May 18, 2020, the Company allocated in a private issuance to M. Arkin (1999) Ltd. (“Arkin”) a total of 229,569 units (as described in note 9c) at a purchase price of $8.712 per unit (“Arkin Transaction”).
     
    In connection with the Arkin Transaction, the Company, Medigus and Arkin entered into a voting agreement, pursuant to which Arkin and Medigus each agreed to vote their respective shares of common stock in favor of the election of the opposite party’s designated representative(s), as applicable, to the Board (“Voting Agreement”). Each of Arkin’s and Medigus’ rights under the Voting Agreement are contingent upon, inter alia, such party maintaining a certain beneficial ownership threshold in the Company’ as follows:
     
    (a) One person designated by Arkin is to be elected, for as long as Arkin, continues to beneficially own at least eight percent of the issued and outstanding capital stock of the Company.
     
    (b) Three persons designated by Medigus are to be elected, for as long as Medigus, continues to beneficially own at least thirty five percent of the issued and outstanding capital stock of the Company.
     
    (c) Two persons designated by Medigus are to be elected for as long as Medigus, continues to beneficially own less than thirty five percent and more than twenty percent of the issued and outstanding capital stock of the Company.
     
   

(d) One person designated by Medigus is to be elected for as long as Medigus, continues to beneficially own less than twenty percent and more than eight percent of the issued and outstanding capital stock of the Company.

     
  c. During 2021 and 2022 the Company received development services from Smartec R&D Ltd., a company owned by the Company’s CTO.
     
    Total compensation for the fiscal years ended December 31, 2021 and December 31, 2022 was $82 thousands and $117 thousands, respectively.
     
  d. During 2021 the Company received financial consultant services from Anona De Finance Ltd., a company owned by one of the Company’s directors.
     
    Total expenses for the fiscal years ended December 31, 2021 was approximately $37 thousands.

 

F-18

 

 

SCOUTCAM INC.

 

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 9 - EQUITY:

 

Increase of the authorized share capital

 

On January 20, 2021, the Company’s Board of Directors approved an increase of the authorized share capital of the Company by an additional 225,000,000 shares of common stock par value $0.001 per share, such that the authorized share capital of the Company following such increase shall be consisting of 300,000,000 shares of common stock.

 

a.Private placement:

 

  1. In December 2019, the Company allocated in a private placement, a total of 379,269 units at a purchase price of $8.712 per unit. Each unit was comprised of two shares of common stock par value $0.001 per share, one Warrant A (as described below) and two Warrants B (as described below). The immediate proceeds (gross) from the issuance of the units amounted to approximately $3.3 million.

 

Each Warrant A was exercisable into one share of common stock of the Company at an exercise price of $5.355 per share during the 12 month period following the allocation. Each Warrant B is exercisable into one share of common stock of the Company at an exercise price of $8.037 per share during the 18 month period following the allocation.

 

In addition, Shrem Zilberman Group Ltd. (the “Consultant”) will be entitled to receive the amount representing 3% of any exercise price of each Warrant A or Warrant B that may be exercised in the future. In the event the total proceeds received as a result of exercise of warrants will be less than $2 million at the time of their expiration, the Consultant will be required to invest $250,000 in the Company in return for shares of common stock of Company. As of December 31, 2021, holders of the foregoing warrants have exercised in excess of $2 million and, accordingly, the Consultant is not required to invest $250,000 in the Company.

 

During 2020, 332,551 Warrants A were exercised, and 46,718 unexercised Warrants A expired on December 30, 2020.

 

The Consultant received $53 thousand following the exercise of 332,551 Warrants A.

 

During the second quarter of 2021, 185,271 Warrants B were exercised, and 573,256 unexercised Warrants B expired on June 30, 2021.

 

The Consultant received $45 thousand following the exercise of 185,271 Warrants B.

 

  2. On March 3, 2020, the Company issued in a private placement a total of 108,880 units at a purchase price of $8.712 per unit.

 

Each unit was comprised of two shares of common stock par value $0.001 per share, one Warrant A (as described below) and two Warrants B (as described below).

 

Each Warrant A was exercisable into one share of common stock of the Company at an exercise price of $5.355 per share during the 12 month period following the allocation.

 

Each Warrant B is exercisable into one share of common stock of the Company at an exercise price of $8.037 per share during the 18 month period following the allocation.

 

The gross proceeds from the issuance of all securities offered amounted to approximately $948 thousands. After deducting issuance costs, the Company received proceeds of approximately $909 thousand.

 

F-19

 

 

SCOUTCAM INC.

 

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 9 – EQUITY (continued):

 

During 2021, 108,880 Warrants A were exercised.

 

217,760 unexercised Warrants B expired on September 3, 2021.

 

  3. On May 18, 2020, the Company allocated in a private placement to Arkin a total of 229,569 units at a purchase price of $8.712 per unit.

 

Each unit was comprised of two shares of common stock par value $0.001 per share, one Warrant A (as described below) and two Warrants B (as described below).

 

Each Warrant A was exercisable into one share of common stock of the Company at an exercise price of $5.355 per share during the 18 month period following the allocation.

 

Each Warrant B is exercisable into one share of common stock of the Company at an exercise price of $8.037 per share during the 24 month period following the allocation.

 

The gross proceeds from the issuance of all securities offered amounted to approximately $2 million. After deducting issuance costs, the Company received proceeds of approximately $1.9 million.

 

During February 2021, 37,349 Warrants A were exercised.

 

During November 2021, 192,220 Warrants A were exercised.

 

  4.

On June 23, 2020, (the “Conversion Date”), the Company entered into a side letter agreement with Medigus whereby the parties agreed to convert, at a conversion price of $4.356 per share, an outstanding line of credit previously extended by Medigus to ScoutCam, which as of the Conversion Date had $381,136 outstanding, into (a) 87,497 shares of the Company’s common stock, (b) to 43,749 Warrant A (as described below), and (c) 87,497 Warrant B (as described below). As the conversion price represented the same unit price as in the March 2020 and May 2020 private placements, no finance expenses have been recorded in statement of operations as a result of the conversion.

 

Each Warrant A is exercisable into one share of common stock of the Company at an exercise price of $5.355 per share during the 12 months period following the allocation.

 

Each Warrant B is exercisable into one share of common stock of the Company at an exercise price of $8.037 per share during the 18 months period following the allocation.

 

During June 2021, 43,749 Warrants A were exercised.

 

On December 23, 2021, 87,497 unexercised Warrants B expired.

 

  5. On March 29, 2021, the Company issued to certain investors, including Arkin, a major stockholder of the Company, of which Mori Arkin, a director of the company, is the owner, 2,469,156 units in exchange for an aggregate purchase price of $20 million. Each such unit consists of (i) one share of common stock and (ii) one warrant to purchase one share of common stock with an exercise price of $10.35 per share. Each such warrant is exercisable until the close of business on March 31, 2026. Pursuant to the terms of the foregoing warrants, following April 1, 2024, if the closing price of Company common stock equal or exceeds 135% of the aforementioned exercise price (subject to appropriate adjustments for stock splits, stock dividends, stock combinations and other similar transactions after the issue date of the warrants) for any thirty (30) consecutive trading days, the Company may force the exercise of the warrants, in whole or in part, by delivering to these investors a notice of forced exercise.

 

F-20

 

 

SCOUTCAM INC.

 

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 9 – EQUITY (continued):

 

As of December 31, 2022, the Company had the following outstanding warrants to purchase common stock:

 

Warrant  Issuance Date  Expiration Date  Exercise Price
Per Share ($)		   Number of Shares
of common stock
Underlying
Warrants		 
               
March 2021 Warrant  March 29, 2021  March 31, 2026   10.350    2,469,156 
               2,469,156 

 

b.Stock-based compensation to employees, directors and service providers:

 

In February 2020, the Company’s Board of Directors approved the 2020 Share Incentive Plan (the “Plan”).

 

The Plan initially included a pool of 580,890 shares of common stock for grant to Company employees, consultants, directors and other service providers. On March 15, 2020, the Company’s Board of Directors approved an increase to the Company’s option pool pursuant to the Plan by an additional 64,099 shares of common stock. On June 22, 2020, the Company’s Board of Directors approved an increase to the Company’s option pool pursuant to the Plan by an additional 401,950 shares of common stock. During the second quarter of 2021, the Company’s Board of Directors approved an increase to the Company’s option pool pursuant to the Plan by an additional 777,778 shares of common stock.

 

The Plan is designed to enable the Company to grant options to purchase shares of common stock and RSUs under various and different tax regimes including, without limitation: (i) pursuant and subject to Section 102 of the Israeli Tax Ordinance or any provision which may amend or replace it and any regulations, rules, orders or procedures promulgated thereunder and to designate them as either grants made through a trustee or not through a trustee; and (ii) pursuant and subject to Section 3 (i) of the Israeli Tax Ordinance.

 

During 2021, the Company granted 648,712 options pursuant to the Plan.

 

During 2022, the Company granted 479,000 options pursuant to the Plan.

 

Options granted generally have a contractual term of seven years and vest over a period of three to four years.

 

F-21

 

 

SCOUTCAM INC.

 

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 9 – EQUITY (continued):

 

Stock Option Activity

 

The following summarizes stock option activity:

 

   Amount of options   Weighted average exercise price   Weighted Average Remaining Contractual Term (years)   Aggregate Intrinsic Value (in thousands) 
       $       $ in thousands 
Outstanding - December 31, 2020   737,049    2.61    6.23    2,446 
Granted   648,712    4.09    -    - 
Forfeited   (132,207)   3.34    -    - 
Outstanding - December 31, 2021   1,253,554    3.31    5.65    5,884 
                     
Granted   479,000    4.50    -    - 
Forfeited   (172,514)   3.57    -    - 
Outstanding - December 31, 2022   1,560,040    3.64    5.17    2,116 
                     
Options Exercisable - December 31, 2022   838,994    3.10    4.24    1,595 

 

As of December 31, 2022, the aggregate intrinsic value of options granted is calculated as the difference between the exercise price and the closing price on the same date.

 

The Company estimates the fair value of stock option awards on the grant date using the Black-Scholes option pricing model. The weighted-average grant date fair value per option granted during the year ended December 31, 2022 was $2.76. The fair value of each award is estimated using Black-Scholes option-pricing model based on the following assumptions:

 

  

Year ended

December 31, 2022

  

Year ended

December 31, 2021

 
Underlying value of shares ($)   5.00-7.20    7.65-10.35 
Exercise price ($)   4.5    2.61-7.2 
Expected volatility (%)   40%    46%-49% 
Term of the options (years)   7    7 
Risk-free interest rate (%)   1.98%-3.95%    0.78%-1.51% 

 

Volatility is derived from the historical volatility of publicly traded set of peer companies. The risk-free interest rates used in the Black-Scholes calculations are based on the prevailing U.S. Treasury yield as determined by the U.S. Federal Reserve. The Company has not paid dividends and does not anticipate paying dividends in the foreseeable future. Accordingly, no dividend yield was assumed for purposes of estimating the fair value of the Company’s stock-based compensation. The weighted average expected life of options was estimated individually in respect of each grant.

 

The unrecognized compensation expense calculated under the fair-value method for stock options expected to vest as of December 31, 2022 is approximately $1.45 million and is expected to be recognized over a weighted-average period of 1.41 years.

 

During 2022 and 2021 the Company’s Board of Directors authorized the grant of options to purchase 45,000 shares of common stock of the Company and 83,334 shares of common stock of the Company, respectively, to Prof. Goldwasser, the Chairman of the Board. Total expenses recorded regarding this grant, for the year ended December 31, 2022, and December 31, 2021, are $367 thousand and $255 thousand, respectively.

 

During 2021 the Company’s Board of Directors authorized the grant of options to purchase 75,855 shares of common stock of the Company to directors of the Company. Total expenses recorded regarding this grant, for the year ended December 31, 2022, and December 31, 2021, are $213 thousand and $221 thousand, respectively.

 

During 2022 and 2021 the Company’s Board of Directors authorized the grant of options to purchase 400,000 shares of common stock of the Company and 335,987 shares of common stock of the Company, respectively, to certain officers of the Company. Total expenses recorded regarding this grant, for the year ended December 31, 2022, and December 31, 2021, are $523 thousand and $871 thousand, respectively.

 

Compensation expense recorded by the Company in respect of its stock-based employees, directors and service providers compensation awards in accordance with ASC 718-10 for the year ended December 31, 2022 and 2021 amounted to $1,487 thousands and $2,030 thousands, respectively.

 

F-22

 

 

c.Restricted stock unit (“RSU”) to employees and service providers:

 

During the year ended December 31, 2022, the Company granted 110,000 RSUs pursuant to the Plan.

 

Each RSU will vest based on continued service which is generally over three years. The grant date fair value of the award will be recognized as stock-based compensation expense over the requisite service period. The fair value of restricted stock units was estimated on the date of grant based on the fair value of the Company’s common stock.

 

The cost of the benefit embodied in the RSU granted during 2022, based on their fair value as at the grant date, is estimated to be approximately $748 thousand. These amounts will be recognized in the statements of operations over the vesting period.

 

The following table summarizes RSU activity for December 31, 2022:

 

   Amount of RSU  

Weighted

Average Grant

Date Fair

Value

per Share

   Weighted Average Remaining Contractual Term (years) 
       $     
Outstanding - December 31, 2021   -    -    - 
Granted   110,000    6.8    - 
Forfeited   (60,000)   7.2    - 
Unvested and Outstanding - December 31, 2022   50,000    6.32    6.44 

 

The unrecognized compensation expense calculated under the fair-value method for RSU expected to vest as of December 31, 2022 is approximately $164 thousand and is expected to be recognized over a weighted-average period of 1.15 years.

 

During 2022 the Company’s Board of Directors authorized the grant of options to purchase 90,000 shares of common stock of the Company to certain officers of the Company. Total expenses recorded regarding this grant, for the year ended December 31, 2022, are $127 thousand.

 

F-23

 

 

SCOUTCAM INC.

 

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 10 – REVENUES AND ENTITY WIDE DISCLOSURES:

 

ASC 280, “Segment Reporting,” establishes standards for reporting information about operating segments. The Company manages its business based on one operating segment, as described in Note 1.

 

a.Disaggregation of revenue

 SCHEDULE OF DISAGGREGATION OF REVENUE

   Year ended on
December 31,		 
   2022   2021 
   USD in thousands 
Development Services (customer A) (*)   317    - 
Products   348    387 
    665    387 

 

  (*) During the second quarter of 2022, the Company completed the development of the product relating to a customer-specific project for a Fortune 500 multinational healthcare corporation (“Customer A”) and moved from the development phase of the project to its production phase. As a result, during the year ended December 31, 2022, the Company recognized development services revenues and related development costs that had been previously deferred, in the amounts of $317 thousand and $180 thousand, respectively. The amounts were recognized based on the expected manufacturing term of the product, which the Company estimates at 7 years.
     
    In addition, following the commencement of the production phase, the Company recognized product revenues of $221 thousands during the year ended December 31, 2022 from the sale of units of the product developed in the context of these development services.

 

  b. Revenues by geographical area (based on the location of customers)

 

The following is a summary of revenues within geographic areas:

 

   2022   2021 
   Year ended on
December 31,		 
   2022   2021 
   USD in thousands 
United States   553    273 
United Kingdom   65    48 
Israel   -    19 
Other   47    47 
 Revenue   665    387 

 

  c. Major customers

 

Set forth below is a breakdown of Company’s revenue by major customers (major customer –revenues from these customers constituted at least 10% of total revenues in a certain year):

 

 SCHEDULE OF MAJOR CUSTOMER BREAKDOWN OF COMPANY’S REVENUE

   Year ended on 
   December 31, 
   2022   2021 
   USD in thousands 
Customer A   538    - 
           
Customer B   -    199 
           
Customer C   65    48 

 

F-24

 

 

  d. Contract fulfillment assets and Contract liabilities:

 

   2022   2021 
   December 31, 
   2022   2021 
   USD in thousands 
Contract fulfillment assets:   1,495    1,675 
Contract liabilities   3,644    2,420 

 

Contract liabilities include advance payments, which are primarily related to advanced billings for development services.

 

The change in contract fulfillment assets:

 

   2022   2021 
   December 31, 
   2022   2021 
   USD in thousands 
         
Balance at beginning of year   1,675    1,130 
Additions during the year   -    545 
Contract costs recognized during the period   (180)   - 
Balance at end of year   1,495    1,675 

 

The change in contract liabilities:

 

   2022   2021 
   December 31, 
   2022   2021 
   USD in thousands 
         
Balance at beginning of year   2,420    848 
Deferred revenue relating to new sales   1,613    1,641 
Revenue recognized during the year   (389)   (69)
Balance at end of year   3,644    2,420 

 

Remaining Performance Obligations

 

Remaining Performance Obligations (“RPO”) represents contracted revenue that has not yet been recognized, which includes deferred revenue and amounts that will be recognized as revenue in future periods. As of December 31, 2022, the total RPO amounted to $3,644 thousand, which the Company expects to recognize over the expected manufacturing term of the product under development.

 

F-25

 

 

SCOUTCAM INC.

 

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 11 - LEASES

 

On December 31, 2022, the Group’s ROU assets and lease liabilities for operating leases totaled $307 thousand and $263 thousand, respectively.

 

On December 31, 2021, the Group’s ROU assets and lease liabilities for operating leases totaled $482 thousand and $459 thousand, respectively.

 

In December 2020, ScoutCam entered into a lease agreement for office space in Omer, Israel. The agreement is for 36 months beginning January 1, 2021. In March 2021, ScoutCam entered into a lease agreement for additional office space in Omer, Israel. The agreement is until December 31, 2023. Monthly lease payments under the agreements are approximately $12 thousand. ScoutCam subleases part of the office space to a third party for $3 thousand per month.

 

In December 2022, ScoutCam entered into a lease agreement for office space in Ramat Gan, Israel. The agreement is for 12 months beginning on December 14, 2022. The agreement expires on December 14, 2023, and the Company has an option to extend the lease period for an additional one year. The Company doesn’t expect to extend the lease period. Therefore, the Company has elected to use the practical expedient regarding short-term leases. Monthly lease payments under the agreements are $3 thousand.

 

In addition, the Company leases vehicles under various operating lease agreements.

 

Operating lease expenses were $264 thousand and $202 thousand for the years ended December 31, 2022 and 2021, respectively.

 

Supplemental cash flow information related to operating leases during the period presented was as follows:

 

   2022   2021 
   Year ended December 31, 
   2022   2021 
   USD in thousands 
Cash paid for amounts included in the measurement of lease liabilities:          
Operating cash flows from operating leases   261    202 

 

Lease term and discount rate related to operating leases as of the period presented were as follows:

 

   December 31, 
   2022   2021 
   USD in thousands 
Weighted-average remaining lease term (in years)   0.84    0.76 
Weighted-average discount rate   6%   6%

 

F-26

 

 

The maturities of lease liabilities under operating leases as of December 31, 2022 are as follows:

 

   USD in thousands 
2023   206 
2024   54 
2025   16 
Total undiscounted lease payments   276 
Less: Imputed interest   (13)
Total lease liabilities   263 

 

NOTE 12 – RESEARCH AND DEVELOPMENT EXPENSES:

 

   2022   2021 
   Year ended December 31, 
   2022   2021 
   USD in thousands 
Salaries and related expense   2,034    894 
Stock-based compensation   576    257 
Materials and subcontractors   1,030    655 
Depreciation   163    39 
Travel expenses   73    - 
Vehicle expenses   75    26 
Rent and maintenance and other expenses   246    131 
 Research and Development expenses   4,197    2,002 

 

NOTE 13 – GENERAL AND ADMINISTRATIVE EXPENSES:

 

   2022   2021 
   Year ended December 31, 
   2022   2021 
   USD in thousands 
Salaries and related expense   1,027    1,144 
Stock-based compensation   903    1,483 
Professional services   859    1,193 
Patents   292    798 
Depreciation   34    29 
Insurance   337    386 
Vehicle expenses   73    99 
Rent and maintenance and other expenses   181    120 
VAT provision (note 7e)   (129)   229 
 General and Administrative expenses   3,577    5,481 

 

NOTE 14 - SUBSEQUENT EVENTS:

 

On March 16, 2023, the Company consummated Stock Purchase Agreements for a private placement with (i) Moshe Arkin through his individual retirement account and (ii) The Phoenix Insurance Company Ltd. and Shotfut Menayot Israel – Phoenix Amitim, in connection with the sale and issuance of an aggregate amount of 3,294,117 units (collectively, the “Units”), at a purchase price of $4.25 per Unit, and for an aggregate purchase price of $14,000,000. Each Unit consists of: (i) one share of the Company’s common stock par value $0.001 per share (the “Common Stock”) and (ii) one warrant to purchase one share of Common Stock with an exercise price of $5.50 (the “Warrants”). The Warrants are immediately exercisable and will expire three years from the date of issuance and will be subject to customary adjustments.

 

F-27

 

 EX-3.2_1 2 ex3-2_1.htm

 

Exhibit 3.2.1

 

BYLAWS

OF

SCOUTCAM INC.

 

(effective as of July 27, 2021)

 

ARTICLE I

 

Meetings of Stockholders and Stockholder Matters

 

SECTION 1. Annual Meeting. An annual meeting of the stockholders of ScoutCam Inc., a Nevada corporation (hereinafter, the “Corporation”) for the election of directors to succeed only those whose terms expire in such year (the “Applicable Class”) and for the transaction of such other proper business as my properly come before the meeting shall be held at such time, date and place, either within or without the State of Nevada, as shall be designated by resolution of the Board of Directors. The Board of Directors may, in its sole discretion, determine that the meeting shall not be held at any place, but instead shall be held solely by means of remote communication as provided under the Nevada Revised Statutes (as amended from time to time, the “NRS”).

 

SECTION 2. Special Meetings. Special meetings of stockholders for any purpose or purposes may be called by the Board of Directors acting pursuant to a resolution approved by the affirmative vote of a majority of the Directors then in office. Only those matters set forth in the notice of the special meeting may be considered or acted upon at a special meeting of stockholders of the Corporation. No other person(s) may call a meeting of the stockholders. The Board of Directors may, in its sole discretion, determine that the meeting shall not be held at any place, but instead shall be held solely by means of remote communication as provided under the NRS.

 

SECTION 3. Notice of Meetings. Written notice of each meeting of the stockholders, which shall state the time, date and place of the meeting and in the case of a special meeting, the purpose or purposes for which it is called, shall, unless otherwise provided by applicable law, the Articles of Incorporation or these bylaws, be given not less than ten (10) nor more than sixty (60) days before the date of such meeting to each stockholder entitled to vote at such meeting, and, if mailed, it shall be deposited in the United States mail, postage prepaid, directed to the stockholder at such stockholder’s address as it appears on the records of the Corporation. Whenever notice is required to be given, a written waiver thereof signed by the person entitled thereto, whether before or after the time stated therein, shall be deemed equivalent to notice. Attendance of a person at a meeting shall constitute a waiver of notice of such meeting, except when the person attends a meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened.

 

SECTION 4. Adjournments. Any meeting of the stockholders may adjourn from time to time to reconvene at the same or some other place, and notice need not be given of any such adjourned meeting if the time and place thereof are announced at the meeting at which the adjournment is taken. At any such adjourned meeting at which a quorum may be present, the Corporation may transact any business which might have been transacted at the original meeting. If the adjournment is for more than thirty days, or if after the adjournment a new record date is fixed for the adjourned meeting, a notice of the adjourned meeting shall be given to each stockholder of record entitled to vote at the meeting.

 

SECTION 5. Quorum. Except as otherwise provided by Nevada law, the Articles of Incorporation or these bylaws, the holders of at least 33 1/3 percent of the voting power of all classes and series of stock entitled to vote at the meeting, present in person or by proxy, regardless of whether the proxy has authority to vote on all matters, will constitute a quorum at all meetings of the stockholders for the transaction of business. In the absence of a quorum, the holders of a majority of the shares present in person or represented by proxy and entitled to vote may adjourn the meeting from time to time in the manner described in Section 4 of this Article I.

 

SECTION 6. Organization. At each meeting of the stockholders, the Chairman of the Board, or in his or her absence or inability to act, the Chief Executive Officer or, in his or her absence, the President or, in his absence or inability to act, a Vice President or, in the absence or inability to act of such persons, any person designated by the Board of Directors, shall act as chairman of the meeting. The Secretary or, in his or her absence or inability to act, any person appointed by the chairman of the meeting shall act as secretary of the meeting and keep the minutes thereof. The chairman of any meeting of the stockholders shall determine the order of business and the procedures at the meeting, including such regulation of the manner of voting and the conduct of discussion as he or she deems to be appropriate. The chairman of any meeting of the stockholders shall have the power to adjourn the meeting to another place, if any, date and time. The date and time of the opening and closing of the polls for each matter upon which the stockholders will vote at the meeting shall be announced at the meeting.

 

 
- 2 -

 

SECTION 7. Notice of Stockholder Business and Nominations.

 

A. Annual Meetings of Stockholders.

 

Nominations of persons for election to the Applicable Class of Board of Directors and the proposal of business to be considered by the stockholders may be made at an annual meeting of the stockholders (a) pursuant to the Corporation’s notice of meeting or proxy materials with respect to such meeting, (b) by or at the direction of the Board of Directors or (c) by any stockholder of the Corporation who was a stockholder of record at the time of giving of notice thereof who is entitled to vote at the meeting, who has held continuously at least five percent (5%) or more of the outstanding shares of the Corporation’s common stock for at least one year prior to the date the Corporation receives the written notice and who complies with the notice procedures set forth in this paragraph C of Section 7.

 

B. Special Meetings of Stockholders.

 

Only such business, as was presented before the meeting in accordance to Section 2 above, shall be conducted at a special meeting of stockholders. The notice of such special meeting shall include the purpose for which the meeting is called. Nominations of candidates for election to the Applicable Class of Board of Directors may be made at a special meeting of the stockholders. Directors may be elected only by or at the direction of the Board of Directors.

 

C. Certain Matters Pertaining to Stockholder Business and Nominations.

 

(1) For nominations or other business to be properly brought by a stockholder before an annual meeting pursuant to clause (c) of paragraph A of this Section 7 or a special meeting pursuant to paragraph B of this Section 7, (1.) the stockholder must have given timely notice thereof in writing to the Secretary of the Corporation, (2.) such other business must otherwise be a proper matter for stockholder action under the NRS, (3.) if the stockholder, or the beneficial owner on whose behalf any such proposal or nomination is made, has provided the Corporation with a Solicitation Notice, as that term is defined in this paragraph C, such stockholder or beneficial owner must, in the case of a proposal, have delivered a proxy statement and form of proxy to holders of a sufficient percentage of the Corporation’s voting shares required by law to carry any such proposal, or, in the case of a nomination or nominations, have delivered a proxy statement and form of proxy to holders of a percentage of the Corporation’s voting shares reasonably believed by such stockholder or beneficial holder to be sufficient to elect the nominee or nominees proposed to be nominated by such stockholder, and must, in either case, have included in such materials the Solicitation Notice, and (4.) if no Solicitation Notice relating thereto has been timely provided pursuant to paragraph C of this Section 6, the stockholder or beneficial owner proposing such business or nomination must not have solicited a number of proxies sufficient to have required the delivery of such a Solicitation Notice under this Section.

 

To be timely, a stockholder’s notice pertaining to an annual meeting shall be delivered to the Secretary at the principal executive office of the Corporation not less than ninety (90) or more than one-hundred and twenty (120) days prior to the first anniversary (the “Anniversary”) of the date of the preceding year’s annual meeting; provided, however, that in the event that the date of the annual meeting is more than thirty (30) days before or more than thirty (30) days after the Anniversary, to be timely, notice by the stockholder must be so delivered not earlier than the close of business (at the principal executive office of the Corporation) on the one-hundred and twentieth (120th) day prior to such annual meeting and not later than the close of business on the later of (i) the ninetieth (90th) day prior to such annual meeting or (ii) the close of business on the tenth (10th) day following the day on which public announcement of the date of such meeting is first made by the Corporation. Such stockholder’s notice for an annual meeting or a special meeting shall set forth:

 

(a) as to each person whom the stockholder proposes to nominate for election or reelection as a director of the Corporation in accordance with the terms of these Bylaws:

 

(i) all information relating to such person that is required to be disclosed in solicitations of proxies for election of directors, or is otherwise required, in each case, pursuant to Regulation 14A under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (including such person’s written consent to being named in the proxy statement as a nominee and to serving as a director, if elected);

 

 
- 3 -

 

(ii) a description of all direct and indirect compensation and other material monetary agreements, arrangements and understandings during the past three (3) years, and any other material relationships, between or among such stockholder, the beneficial owner, if any, on whose behalf any such proposal or nomination is being made, and their respective affiliates and associates, on the one hand, and each proposed nominee, and his or her respective affiliates and associates, on the other hand, including, without limitation, all information that would be required to be disclosed pursuant to Item 404 of Regulation S-K promulgated under the Securities Act of 1933, as amended, if such stockholder, such beneficial owner, or any affiliate or associate thereof, were the “registrant” for purposes of such rule and the nominee were a director or executive officer of such registrant;

 

(iii) to the extent known by the stockholder, the name and address of any other securityholder of the Corporation who owns, beneficially or of record, any securities of the Corporation and who supports any nominee proposed by such stockholder; and

 

(iv) the questionnaire and the representation and agreement, completed and signed by such person, as required by paragraph D of this Section 7;

 

(b) as to any other business that the stockholder proposes to bring before the meeting, a brief description of the business desired to be brought before the meeting, including the text of any resolutions proposed for consideration, the reasons for conducting such business at the meeting, any material interest in such business of such stockholder and the beneficial owner, if any, on whose behalf the proposal is made, and to the extent known by the stockholder, the name and address of any other securityholder of the Corporation who owns, beneficially or of record, any securities of the Corporation and who supports any matter such stockholder intends to propose; and

 

(c) as to the stockholder giving the notice and the beneficial owner, if any, on whose behalf the nomination or proposal is made:

 

(i) the name and address of such stockholder, as they appear on the Corporation’s books, and of such beneficial owner;

 

(ii) (A) the class or series and number of shares of the Corporation’s capital stock which are, directly or indirectly, owned beneficially and of record by such stockholder and such beneficial owner, (B) any option, warrant, convertible security, stock appreciation right, or similar right with an exercise or conversion privilege or a settlement payment or mechanism at a price related to any class or series of the shares of the Corporation’s capital stock or with a value derived in whole or in part from the value of any class or series of the shares of the Corporation’s capital stock, whether or not such instrument or right shall be subject to settlement in the underlying class or series of the shares of capital stock of the Corporation (a “Derivative Instrument”) directly or indirectly owned beneficially by such stockholder and such beneficial owner as well as any other direct or indirect opportunity for such stockholder and such beneficial owner to profit or share in any profit derived from any increase or decrease in the value of shares of the Corporation, (C) any proxy, contract, arrangement, understanding, or relationship pursuant to which such stockholder has a right to vote any shares of any security of the Corporation, (D) any short interest in any security of the Corporation (for purposes of these Bylaws, a person shall be deemed to have a short interest in a security if such person directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, has the opportunity to profit or share in any profit derived from any decrease in the value of the subject security), (E) any rights to dividends on the shares of the Corporation owned beneficially by such stockholder that are separated or separable from the underlying shares of the Corporation, (F) any proportionate interest in shares of the Corporation or Derivative Instruments held, directly or indirectly, by a general or limited partnership in which such stockholder or beneficial owner (i) is a general partner or, (ii) directly or indirectly, beneficially owns an interest in such general partner, and (G) any performance-related fees (other than an asset-based fee) that such stockholder or beneficial owner is entitled to on any increase or decrease in the value of shares of the Corporation or Derivative Instruments as of the date of such notice, including, without limitation, any such interests held by members of such stockholder or beneficial owner’s immediate family sharing the same household (which information shall be supplemented by such stockholder and beneficial owner not later than ten (10) days after the record date for the meeting to disclose such ownership as of the record date; provided, however, that if such date is after the date of the meeting, not later than the day prior to the meeting);

 

 
- 4 -

 

(iii) any other information relating to such stockholder and beneficial owner, if any, that would be required to be disclosed in a proxy statement or other filings required to be made in connection with solicitations of proxies for, as applicable, the proposal and/or for the election of directors in a contested election pursuant to Regulation 14A under the Exchange Act and the rules and regulations promulgated thereunder;

 

(iv) a description of all agreements, arrangements and understandings between such stockholder and beneficial owner, if any, and any other person or persons (including their names) in connection with the proposal of such business by such stockholder; and

 

(v) a statement of whether or not either such stockholder or beneficial owner intends to deliver a proxy statement and form of proxy, in the case of a proposal, to holders of a sufficient percentage of the Corporation’s voting shares required by law to carry the proposal or, in the case of a nomination or nominations, to holders of a sufficient percentage of the Corporation’s voting shares to elect such nominee or nominees (an affirmative statement of such intent, a “Solicitation Notice”).

 

(2) In the event the Corporation calls a special meeting of the stockholders for the purpose of electing one or more directors of an Applicable Class to the Board of Directors, any such stockholder who has held continuously at least five percent (5%) or more of the outstanding shares of the Corporation’s common stock for at least one year prior to the date the Corporation, may nominate a person or persons (as the case may be), for election to such directorship(s) as specified in the Corporation’s notice of meeting, provided, however, that the stockholder’s notice required by paragraph C(1) of this Section 7 is delivered to the Secretary at the principal executive office of the Corporation not earlier than the ninetieth (90th) day prior to such special meeting nor later than the close of business on the later of (i) the sixtieth (60th) day prior to such special meeting, or (ii) the tenth (10th) day following the day on which public announcement is first made of the date of the special meeting and of the nominees proposed by the Board of Directors to be elected at such meeting.

 

D. General.

 

(1) Only such persons who are nominated in accordance with the procedures set forth in this Section 7 shall be eligible to serve as directors of the Corporation and only such business brought before a meeting of the stockholders in accordance with the procedures set forth in this Section 7 shall be conducted at such meeting. Except as otherwise provided by law, the Restated Articles of Incorporation or these Bylaws, the chairman of the meeting shall have the power and duty to determine whether a nomination or any business proposed to be brought before the meeting was made or proposed, as the case may be, in accordance with the procedures set forth in these Bylaws and, if any proposed nomination or business is not in compliance herewith, to declare that such defective proposal or nomination shall be disregarded.

 

(2) For purposes of this Section 7, “public announcement” shall mean disclosure in a press release reported by the Dow Jones News Service, Associated Press or comparable national news service or in a document publicly filed by the Corporation with the Securities and Exchange Commission pursuant to Section 13, 14 or 15(d) of the Exchange Act.

 

(3) Notwithstanding the foregoing provisions of this Section 7, a stockholder shall also comply with all applicable requirements of the Exchange Act and the rules and regulations thereunder with respect to the matters set forth herein. Nothing in this Section 7 shall be deemed to affect any rights (i) of the stockholders of the Corporation to request inclusion of proposals in the Corporation’s proxy statement pursuant to Rule 14a-8 under the Exchange Act or (ii) of the holders of any series of Preferred Stock then outstanding to elect directors under specified circumstances.

 

 
- 5 -

 

(4) In addition to the requirements set forth elsewhere in these Bylaws, to be eligible to be a nominee for election or reelection as a director of the Corporation, a person must deliver, in accordance with the time periods prescribed for delivery of notice under Section 7(C) of this Article I, to the Secretary at the principal executive office of the Corporation a completed and signed questionnaire with respect to the background and qualification of such person and the background of any other person or entity on whose behalf the nomination is being made (which questionnaire shall be provided by the Secretary upon written request) and a written representation and agreement (in the form provided by the Secretary upon written request) that such person (i) is not and will not become a party to (A) any agreement, arrangement or understanding with, and has not given any commitment or assurance to, any other person or entity as to how such person, if elected as a director of the Corporation, will act or vote on any issue or question (a “Voting Commitment”) that has not been disclosed to the Corporation or (B) any Voting Commitment that could limit or interfere with such person’s ability to comply, if elected as a director of the Corporation, with such person’s fiduciary duties under applicable law, (ii) is not and will not become a party to any agreement, arrangement or understanding with any other person or entity, other than the Corporation, with respect to any direct or indirect compensation, reimbursement or indemnification in connection with service or action as a director of the Corporation, and (iii) in such person’s individual capacity and on behalf of any other person or entity on whose behalf the nomination is being made, would be in compliance, if elected as a director of the Corporation, and will comply with, applicable law and all applicable publicly disclosed corporate governance, code of conduct and ethics, conflict of interest, corporate opportunities, trading and any other policies and guidelines of the Corporation applicable to directors.

 

(5) Notwithstanding the foregoing provisions of this Section 7, unless otherwise required by law, if a stockholder of the Corporation (or a qualified representative of the stockholder) does not appear in person at the annual or special meeting of the stockholders of the Corporation to make its nomination or propose any other matter, such nomination shall be disregarded and such other proposed matter shall not be transacted, even if proxies in respect of such vote have been received by the Corporation. For purposes of this Article I, to be considered a “qualified representative” of the stockholder, a person must be (i) a duly authorized officer, manager or partner of such stockholder or (ii) must be authorized by a writing executed by such stockholder or an electronic transmission delivered by such stockholder to act for such stockholder as proxy at the meeting of the stockholders, and such person must produce such writing or electronic transmission, or a reliable reproduction of the writing or electronic transmission, at the commencement of the meeting of the stockholders.

 

SECTION 8. Voting; Proxies. Unless otherwise provided by NRS or in the Articles of Incorporation, each stockholder entitled to vote at any meeting of stockholders shall be entitled to one vote for each share of capital stock which has voting power upon the matter in question held by such stockholder either (i) on the date fixed pursuant to the provisions of Section 9 of Article I of these bylaws as the record date for the determination of the stockholders to be entitled to notice of or to vote at such meeting; or (ii) if no record date is fixed, then at the close of business on the day next preceding the day on which notice is given. Each stockholder entitled to vote at any meeting of the stockholders may authorize another person or persons to act for him by proxy. Any such proxy shall be delivered to the secretary of such meeting at or prior to the time designated in the order of business for so delivering such proxies. At all meetings of the stockholders for the election of directors, a plurality of the votes cast shall be sufficient to elect. On all other matters, except as otherwise required by Nevada law or the Articles of Incorporation, a majority of the votes cast at a meeting of the stockholders shall be necessary to authorize any corporate action to be taken by vote of the stockholders. Unless required by NRS, or determined by the chairman of the meeting to be advisable, the vote on any question other than the election of directors need not be by written ballot. On a vote by written ballot, each written ballot shall be signed by the stockholder voting, or by his proxy if there be such proxy, and shall state the number of shares voted.

 

SECTION 9. Fixing of Record Date for Stockholder Meetings. In order that the Corporation may determine the stockholders entitled to notice of or to vote at any meeting of stockholders or any adjournment thereof, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors, and which record date shall not be more than 60 nor less than 10 days before the date of such meeting. If no record date is fixed by the Board of Directors, the record date for determining stockholders entitled to notice of or to vote at a meeting of stockholders shall be the close of business on the day next preceding the day on which notice is given, or if notice is waived, at the close of business on the day next preceding the day on which the meeting is held. A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; provided, however, that the Board of Directors may fix a new record date for the adjourned meeting.

 

SECTION 10. Fixing a Record Date for Other Purposes. In order that the Corporation may determine the stockholders entitled to receive payment of any dividend or other distribution or allotment of any rights or the stockholders entitled to exercise any rights in respect of any change, conversion or exchange of stock, or for the purposes of any other lawful action, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted, and which record date shall not be more than 60 days prior to such action. If no record date is fixed, the record date for determining stockholders for any such purpose shall be at the close of business on the day on which the Board of Directors adopts the resolution relating thereto.

 

 
- 6 -

 

SECTION 11. List of Stockholders Entitled to Vote. The officer of the Corporation who has charge of the stock ledger of the Corporation shall prepare and make, at least 10 days before every meeting of the stockholders, a complete list of the stockholders entitled to vote at the meeting, arranged in alphabetical order, and showing the address of each stockholder and the number of shares registered in the name of each stockholder. Such list shall be open to the examination of any stockholder, for any purpose germane to the meeting, during ordinary business hours, for a period of at least ten days prior to the meeting, either at a place within the city where the meeting is to be held, which place shall be specified in the notice of the meeting, or, if not so specified, at the place where the meeting is to be held. The list shall also be produced and kept at the time and place of the meeting during the whole time thereof, and may be inspected by any stockholder of the Corporation who is present.

 

SECTION 12. Inspectors. The Board of Directors may, in advance of any meeting of stockholders, appoint one or more inspectors to act at such meeting or any adjournment thereof. If the inspectors shall not be so appointed or if any of them shall fail to appear or act, the chairman of the meeting shall appoint inspectors. Each inspector, before entering upon the discharge of his or her duties, shall take and sign an oath faithfully to execute the duties of inspector at such meeting with strict impartiality and according to the best of his or her ability. The inspectors shall determine the number of shares outstanding and the voting power of each, the number of shares represented at the meeting, the existence of a quorum, the validity and effect of proxies, and shall receive votes, ballots or consents, hear and determine all challenges and questions arising in connection with the right to vote, count and tabulate all votes, ballots or consents, determine the result, and do such acts as are proper to conduct the election or vote with fairness to all stockholders. On request of the chairman of the meeting or any stockholder entitled to vote thereat, the inspectors shall make a report in writing of any challenge, question or matter determined by them and shall execute a certificate of any fact found by them. No director or candidate for the office of director shall act as an inspector of an election of directors. Inspectors need not be stockholders.

 

SECTION 13. Action Without Meeting. Unless otherwise prohibited under exchange rules, any action required by statute to be taken at a meeting of the shareholders, or any action which may be taken at a meeting of the stockholders, may be taken without a meeting if a consent in writing, setting forth the action so taken, shall be signed by stockholders representing a majority of shares entitled to vote with respect to the subject matter thereof and such consent shall have the same force and effect as a unanimous vote of the stockholders. The consent may be in more than one counterpart so long as each stockholder signs one of the counterparts. The signed consent, or a signed copy shall be placed in the minute book.

 

SECTION 14. Stock Ledger. The stock ledger of the Corporation shall be the only evidence as to who are the stockholders entitled to examine the stock ledger, the list required by Section 11 of this Article I, the books of the Corporation, or to vote in person or by proxy at any meeting of the stockholders.

 

ARTICLE II

 

Board of Directors

 

SECTION 1. General Powers. The business and affairs of the Corporation shall be managed by or under the direction of a Board of Directors. The Board of Directors may exercise all such authority and powers of the Corporation and do all such lawful acts and things as are not, by NRS or the Articles of Incorporation, directed or required to be exercised or done by the stockholders.

 

SECTION 2. Number, Qualification. The Board of Directors shall consist of such number of Directors (not less than three (3) nor more than ten (10)) as may be fixed from time to time by affirmative vote of a majority of the directors then in office.

 

The Board of Directors of the Corporation shall be divided into three classes, with the term of office of the first class to expire at the first annual meeting of the stockholders following the initial classification of directors and until their successors are duly elected and qualified, the term of office of the second class to expire at the second annual meeting of the stockholders following the initial classification of directors and until their successors are duly elected and qualified, and the term of office of the third class to expire at the third annual meeting of the stockholders following the initial classification of directors and until their successors are duly elected and qualified. At each annual meeting of the stockholders, directors elected to succeed those directors whose terms expire shall be elected for a term of office to expire at the third succeeding annual meeting of the stockholders after their election and until their successors are duly elected and qualified, and if authorized by a resolution of the Board of Directors, directors may be elected to fill any vacancy on the Board of Directors, regardless of how such vacancy was created.

 

 
- 7 -

 

The Chairman of the Board of Directors and any Vice Chairman appointed to act in the absence of the Chairman, if any, shall be elected by and from the Board of Directors. The Chairman shall preside at all meetings of the Board of Directors at which he or she is present and shall have such authority and perform such duties as may be prescribed by these Bylaws or from time to time be determined by the Board of Directors.

 

SECTION 3. Newly Created Directorships and Vacancies. Except as otherwise fixed by or pursuant to provisions of the Articles of Incorporation relating to the rights of the holders of any class or series of stock having a preference over common stock as to dividends or upon liquidation to elect additional directors under specified circumstances, newly created directorships resulting from any increase in the number of directors and any vacancies on the Board of Directors resulting from death, resignation, disqualification, removal or other cause shall be filled by the affirmative vote of a majority of the remaining directors then in office. Any director elected in accordance with the preceding sentence shall hold office for the remainder of the full term and until such director’s successor shall have been duly elected and qualified. No decrease in the number of directors constituting the Board of Directors shall shorten the term of any director then in office.

 

SECTION 4. Removal and Resignation. Any director may resign at any time upon written notice to the Corporation. Any such resignation shall take effect at the time specified therein or, if the time when it shall become effective shall not be specified therein, immediately upon its receipt; and, unless otherwise specified therein, the acceptance of such resignation shall not be necessary to make it effective. Any director, or the entire Board of Directors, may be removed from office at any time only for cause and only by the affirmative vote of the holders of at least seventy percent (70%) of the voting power of all of the then outstanding shares of capital stock of the Corporation entitled to vote at an election of directors, voting together as a single class.

 

SECTION 5. Regular Meetings. Regular meetings of the Board of Directors may be held at such places within or without the State of Nevada and at such times as the Board of Directors may from time to time determine. Notice of regular meetings of the Board of Directors need not be given except as otherwise required by the NRS or these bylaws.

 

SECTION 6. Special Meetings. Special meetings of the Board of Directors may be held at any time or place within or without the State of Nevada whenever called by the Chairman of the Board of Directors, the President or by a majority of the entire Board of Directors.

 

SECTION 7. Notice of Meetings. Notice of each special meeting of the Board of Directors (and of each regular meeting for which notice shall be required) shall be given by the Secretary as hereinafter provided in this Section 7, in which notice shall be stated the time and place of the meeting. Except as otherwise required by Nevada law or these bylaws, such notice need not state the purpose(s) of such meeting. Notice of each such meeting shall be mailed, postage prepaid, to each director, addressed to such director at such director’s residence or usual place of business, by registered mail, return receipt requested delivered at least two (2) days before the day on which such meeting is to be held, or shall be sent addressed to such director at such place by electronic mail, or wireless, or be delivered to such director personally, by facsimile or by telephone, at least 24 hours before the time at which such meeting is to be held. A written waiver of notice, signed by the director entitled to notice, whether before or after the time stated therein, shall be deemed equivalent to notice. Notice of any such meeting need not be given to any director who shall, either before or after the meeting, submit a signed waiver of notice or who shall attend such meeting without protesting, prior to or at its commencement, the lack of notice to him.

 

SECTION 8. Quorum and Manner of Acting. Except as hereinafter provided, a majority of the Board of Directors shall be present in person or by means of a conference telephone or similar communications equipment which allows all persons participating in the meeting to hear each other at the same time at any meeting of the Board of Directors in order to constitute a quorum for the transaction of business at such meeting; and, except as otherwise required by NRS, the Articles of Incorporation or these bylaws, the act of a majority of the directors present at any meeting at which a quorum is present shall be the act of the Board of Directors. In the absence of a quorum at any meeting of the Board of Directors, a majority of the directors present thereat may adjourn such meeting to another time and place. Notice of the time and place of any such adjourned meeting shall be given to the directors who were not present at the time of the adjournment and, unless such time and place were announced at the meeting at which the adjournment was taken, to the other directors. At any adjourned meeting at which a quorum is present, any business may be transacted which might have been transacted at the meeting as originally called. The directors shall act only as a Board and the individual directors shall have no power as such.

 

SECTION 9. Action Without a Meeting. Any action required or permitted to be taken at any meeting of the Board of Directors may be taken without a meeting if all members of the Board consent thereto in writing, and the writing or writings are filed with the minutes of the proceedings of the Board of Directors.

 

 
- 8 -

 

SECTION 10. Telephonic Participation. Members of the Board of Directors may participate in a meeting of the Board by means of a conference telephone or similar communications equipment allowing all persons participating in the meeting to hear each other at the same time. Participation in such a meeting shall constitute presence in person at such meeting.

 

SECTION 11. Conduct of Meetings. At any meeting of the Board of Directors, business shall be transacted in such order and manner as the Board of Directors may from time to time determine and publicized among all directors, and all matters shall be determined by the vote of a majority of the directors present, except as otherwise provided herein, under the Restated Articles of Incorporation or required by law.

 

SECTION 12. Compensation. The Board of Directors or any designated committee shall have authority to fix the compensation, including fees and reimbursement of expenses, of directors for services to the Corporation in any capacity, provided that directors who are serving the Corporation as employees and who receive compensation for their services as such, shall not receive any salary or other compensation for their services as directors of the Corporation.

 

SECTION 13. Committees. The Board of Directors, by vote of a majority of the directors then in office, may elect from its number one or more committees, including, without limitation, a an Audit Committee, Compensation Committee and a Corporate Governance and Nominating Committee, and may delegate thereto some or all of its powers except those which by law, by the Articles of Incorporation or by these bylaws may not be delegated. Except as the Board of Directors may otherwise determine, any such committee may make rules for the conduct of its business, but unless otherwise provided by the Board of Directors or in such rules, its business shall be conducted so far as possible in the same manner as is provided by these bylaws for the Board of Directors. All members of such committees shall hold such offices at the pleasure of the Board of Directors. The Board of Directors may abolish any such committee at any time. Any committee to which the Board of Directors delegates any of its powers or duties shall keep records of its meetings and shall report its action to the Board of Directors.

 

ARTICLE III

 

Officers

 

SECTION 1. Number. The officers of the Corporation shall be elected by the Board of Directors and shall consist of a Chairman of the Board, a Chief Executive Officer, a President, Chief Financial Officer, Chief Technology Officer, one or more Vice Presidents, a Secretary, a Treasurer, and such other officers and assistant officers as may be deemed necessary or desirable by the Board of Directors. Any number of offices may be held by the same person. In its discretion, the Board of Directors may choose not to fill any office for any period that it may deem advisable unless otherwise required by Nevada law.

 

SECTION 2. Election and Term of Office. The officers of the Corporation shall be elected annually by the Board of Directors at its first meeting held after each annual meeting of stockholders or as soon thereafter as conveniently may be. The Chief Executive Officer shall appoint persons to other officers as he or she deems desirable and such appointments, if any, shall serve at the pleasure of the Board of Directors. Each officer shall hold office until a successor is duly elected and qualified or until his or her earlier death, resignation or removal as hereinafter provided.

 

SECTION 3. Resignations. Any officer may resign at any time upon written notice to the Corporation. Any such resignation shall take effect at the time specified therein or, if the time when it shall become effective shall not be specified therein, immediately upon its receipt; and, unless otherwise specified therein, the acceptance of such resignation shall not be necessary to make it effective.

 

SECTION 4. Removal. Any officer or agent of the Corporation may be removed, either with or without cause, at any time, by the Board of Directors at any meeting of the Board of Directors or, except in the case of an officer or agent elected or appointed by the Board of Directors, by the Chief Executive Officer, but any such removal shall be without prejudice to the contract rights, if any, of the person so removed.

 

 
- 9 -

 

SECTION 5. Vacancies. Any vacancy occurring in any office of the Corporation by death, resignation, removal or otherwise, may be filled for the unexpired portion of the term of the office which shall be vacant by the Board of Directors at any special or regular meeting.

 

SECTION 6. Powers and Duties of Executive Officers. The officers of the Corporation shall have such powers and duties in the management of the Corporation as may be prescribed in a resolution by the Board of Directors and, to the extent not so provided, as generally pertain to their respective offices, subject to the control of the Board of Directors. The Board of Directors may require any officer, agent or employee to give security for the faithful performance of his or her duties.

 

SECTION 7. The Chairman of the Board. The Chairman of the Board shall, if present, preside at each meeting of the stockholders and of the Board of Directors. Such person shall perform all duties incident to the office of Chairman of the Board and such other duties as may from time to time be assigned to such person by the Board of Directors.

 

SECTION 8. The Chief Executive Officer. The Chief Executive Officer shall have the general and active supervision and direction over the business operations and affairs of the Corporation and over the other officers, agents and employees and shall see that their duties are properly performed. At the request of the Chairman of the Board, or in the case of his absence or inability to act, the Chief Executive Officer shall perform the duties of the Chairman of the Board and when so acting shall have all the powers of, and be subject to all the restrictions upon the Chairman of the Board. Such person shall perform all duties incident to the office of Chief Executive Officer and such other duties as may from time to time be assigned to such person by the Board of Directors.

 

SECTION 9. The President. The President shall have general and active supervision and direction over the business operations and affairs of the Corporation and over its several officers, agents and employees, subject, however, to the direction of the Chief Executive Officer and the control of the Board of Directors. In general, the President shall have such other powers and shall perform such other duties as usually pertain to the office of President or as from time to time may be assigned to him by the Board of Directors or the Chief Executive Officer.

 

SECTION 10. Vice Presidents. Each Vice President shall have such powers and perform such duties as from time to time may be assigned to him by the Board of Directors or the Chief Executive Officer.

 

SECTION 11. The Treasurer. The Treasurer shall (a) have charge and custody of, and be responsible for, all the funds and securities of the Corporation; (b) keep full and accurate accounts of receipts and disbursements in books belonging to the Corporation; (c) cause all monies and other valuables to be deposited to the credit of the Corporation in such depositories as may be designated by the Board; (d) receive, and give receipts for, monies due and payable to the Corporation from any source whatsoever; (e) disburse the funds of the Corporation and supervise the investment of its funds as ordered or authorized by the Board, taking proper vouchers therefor; and (f) in general, have all the powers and perform all the duties incident to the office of Treasurer and such other duties as from time to time may be assigned to him by the Board of Directors or the Chief Executive Officer.

 

SECTION 12. The Secretary. The Secretary shall (a) record the proceedings of the meetings of the stockholders and directors in a minute book to be kept for that purpose; (b) see that all notices are duly given in accordance with the provisions of these bylaws and as required by law; (c) be custodian of the records and the seal of the Corporation and affix and attest the seal to all stock certificates of the Corporation (unless the seal of the Corporation on such certificates shall be a facsimile, as hereinafter provided) and affix and attest the seal to all other documents to be executed on behalf of the Corporation under its seal; (d) see that the books, reports, statements, certificates and other documents and records required by law to be kept and filed are properly kept and filed; and (e) in general, have all the powers and perform all the duties incident to the office of Secretary and such other duties as from time to time may be assigned to him by the Board of Directors or the Chief Executive Officer.

 

SECTION 13. Officers’ Bonds or Other Security. The Board of Directors may secure the fidelity of any or all of its officers or agents by bond or otherwise, in such amount and with such surety or sureties as the Board of Directors may require.

 

SECTION 14. Compensation. The compensation of the officers of the Corporation for their services as such officers shall be fixed from time to time by the Board of Directors; provided, however, that the Board of Directors may delegate to the Chief Executive Officer or the President the power to fix the compensation of officers and agents appointed by the Chairman of the Board or the President, as the case may be. An officer of the Corporation shall not be prevented from receiving compensation by reason of the fact that such person is also a director of the Corporation.

 

 
- 10 -

 

ARTICLE IV

 

Shares of Stock

 

SECTION 1. Stock Certificates. Every holder of stock in the Corporation shall be entitled to have a certificate signed by or in the name of the Corporation by the Chairman of the Board or the President or a Vice President, and by the Treasurer or an Assistant Treasurer, or the Secretary or an Assistant Secretary, certifying the number of shares owned by such holder in the Corporation. Any of or all the signatures on the certificate may be a facsimile. In case any officer, transfer agent or registrar who has signed or whose facsimile signature has been placed upon such certificate shall have ceased to be such officer, transfer agent or registrar before such certificate is issued, it may nevertheless be issued by the Corporation with the same effect as if he were such officer, transfer agent or registrar at the date of issue.

 

SECTION 2. Books of Account and Record of Stockholders. The books and records of the Corporation may be kept at such places, within or without the State of Nevada, as the Board of Directors may from time to time determine. The stock record books and the blank stock certificate books shall be kept by the Secretary or by any other officer or agent designated by the Board of Directors.

 

SECTION 3. Transfer of Shares. Transfers of shares of stock of the Corporation shall be made on the stock records of the Corporation only upon authorization by the registered holder thereof, or by his attorney hereunto authorized by power of attorney duly executed and filed with the Secretary or with a transfer agent or transfer clerk, and on surrender of the certificate or certificates for such shares properly endorsed or accompanied by a duly executed stock transfer power and the payment of all taxes thereon. Except as otherwise provided by Nevada law, the Corporation shall be entitled to recognize the exclusive right of a person in whose name any share or shares stand on the record of stockholders as the owner of such share or shares for all purposes, including, without limitation, the rights to receive dividends or other distributions, and to vote as such owner, and the Corporation may hold any such stockholder of record liable for calls and assessments and the Corporation shall not be bound to recognize any equitable or legal claim to or interest in any such share or shares on the part of any other person whether or not it shall have express or other notice thereof. Whenever any transfers of shares shall be made for collateral security and not absolutely, and both the transferor and transferee request the Corporation to do so, such fact shall be stated in the entry of the transfer.

 

SECTION 4. Regulations. The Board of Directors may make such additional rules and regulations, not inconsistent with these bylaws, as it may deem expedient concerning the issue, transfer and registration of certificates for shares of stock of the Corporation. It may appoint, or authorize any officer or officers to appoint, one or more transfer agents or one or more transfer clerks and one or more registrars and may require all certificates for shares of stock to bear the signature or signatures of any of them.

 

SECTION 5. Lost, Stolen or Destroyed Stock Certificates. The holder of any certificate representing shares of stock of the Corporation shall immediately notify the Corporation of any loss, destruction or mutilation of such certificate, and the Corporation may issue a new certificate of stock in the place of any certificate theretofore issued by it, alleged to have been lost, stolen or destroyed, and the Board of Directors may, in its discretion, require the owner of the lost, stolen or destroyed certificate, or his legal representative, to give the Corporation a bond sufficient, as the Board in its absolute discretion shall determine, to indemnify the Corporation against any claim that may be made against it on account of the alleged loss, theft or destruction of any such certificate or the issuance of such new certificate. Anything herein to the contrary notwithstanding, the Board of Directors, in its absolute discretion, may refuse to issue any such new certificate, except pursuant to judicial proceedings under the laws of the State of Nevada.

 

 
- 11 -

 

ARTICLE V

INDEMNIFICATION OF DIRECTORS AND OFFICERS

 

SECTION 1. Right to Indemnification.

 

Each person who was or is made a party or is threatened to be made a party to or is otherwise involved (including, without limitation, as a witness) in any action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that he is or was a director or an officer of the Corporation or is or was serving at the request of the Corporation as a director, officer, or trustee of another corporation, or of a partnership, joint venture, trust or other enterprise, including service with respect to an employee benefit plan (hereinafter an “Indemnitee”), whether the basis of such action, suit or proceeding is alleged action in an official capacity as a director, officer or trustee or in any other capacity while serving as a director, officer or trustee, shall be indemnified and held harmless by the Corporation to the fullest extent permitted by law, as the same exists or may hereafter be amended (but, in the case of any such amendment, only to the extent that such amendment permits the Corporation to provide broader indemnification rights than such law permitted the Corporation to provide prior to such amendment), against all expense, liability and loss (including attorneys’ fees, judgments, fines, ERISA excise taxes or penalties and amounts paid in settlement) reasonably incurred or suffered by such Indemnitee in connection therewith; provided, however, that, except as provided in Section 3 of this Article V with respect to proceedings to enforce rights to indemnification or an advancement of expenses or as otherwise required by law, the Corporation shall not be required to indemnify or advance expenses to any such Indemnitee in connection with an action, suit or proceeding (or part thereof) initiated by such Indemnitee unless such action, suit or proceeding (or part thereof) was authorized by the Board of Directors of the Corporation.

 

SECTION 2. Right to Advancement of Expenses.

 

In addition to the right to indemnification conferred in Section 1 of this Article V, an Indemnitee shall also have the right to be paid by the Corporation the expenses (including attorney’s fees) incurred in defending any such proceeding in advance of its final disposition; provided, however, that, if the NRS then requires, an advancement of expenses incurred by an Indemnitee in his capacity as a director or officer (and not in any other capacity in which service was or is rendered by such Indemnitee, including, without limitation, service to an employee benefit plan) shall be made only upon delivery to the Corporation of an undertaking, by or on behalf of such Indemnitee, to repay all amounts so advanced if it shall ultimately be determined by final judicial decision from which there is no further right to appeal that such Indemnitee is not entitled to be indemnified for such expenses under this Section 2.

 

SECTION 3. Right of Indemnitees to Bring Suit.

 

If a claim under Section 1 or 2 of this Article V is not paid in full by the Corporation within sixty (60) days after a written claim has been received by the Corporation, except in the case of a claim for an advancement of expenses, in which case the applicable period shall be twenty (20) days, the Indemnitee may at any time thereafter bring suit against the Corporation to recover the unpaid amount of the claim. If successful in whole or in part in any such suit, or in a suit brought by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the Indemnitee shall also be entitled to be paid the expenses of prosecuting or defending such suit. In any suit brought by the Indemnitee to enforce a right to indemnification hereunder (but not in a suit brought by the Indemnitee to enforce a right to an advancement of expenses) it shall be a defense that the Indemnitee has not met any applicable standard for indemnification set forth in the NRS. In any suit brought by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the Corporation shall be entitled to recover such expenses upon a final adjudication that, the Indemnitee has not met any applicable standard for indemnification set forth in the NRS. Neither the failure of the Corporation (including its directors who are not parties to such action, a committee of such directors, independent legal counsel, or its stockholders) to have made a determination prior to the commencement of such suit that indemnification of the Indemnitee is proper in the circumstances because the Indemnitee has met the applicable standard of conduct set forth in the NRS, nor an actual determination by the Corporation (including its directors who are not parties to such action, a committee of such directors, independent legal counsel, or its stockholders) that the Indemnitee has not met such applicable standard of conduct, shall create a presumption that the Indemnitee has not met the applicable standard of conduct or, in the case of such a suit brought by the Indemnitee, be a defense to such suit. In any suit brought by the Indemnitee to enforce a right to indemnification or to an advancement of expenses hereunder, or brought by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the burden of proving that the Indemnitee is not entitled to be indemnified, or to such advancement of expenses, under this Article V or otherwise shall be on the Corporation.

 

SECTION 4. Non-Exclusivity of Rights.

 

The rights to indemnification and to the advancement of expenses conferred in this Article V shall not be exclusive of any other right which any person may have or hereafter acquire under any statute, the Restated Certificate of Incorporation as amended from time to time, these Bylaws, any agreement, any vote of stockholders or directors as permitted by the NRS or otherwise.

 

 
- 12 -

 

SECTION 5. Insurance.

 

The Corporation may maintain insurance, at its expense, to protect itself and any director, officer, employee or agent of (i) the Corporation or (ii) another corporation, partnership, joint venture, trust or other enterprise, against any expense, liability or loss, whether or not the Corporation would have the power to indemnify such person against such expense, liability or loss under the NRS.

 

SECTION 6. Indemnity Agreements.

 

The Corporation may enter into indemnity agreements from time to time (i) with the persons who are members of its Board of Directors, (ii) with such officers, employees and agents of the Corporation and (iii) with such officers, directors, employees and agents of subsidiaries or affiliates of the Corporation. Such indemnity agreements may provide in substance that the Corporation will indemnify such persons to the full extent as contemplated by this Article V or permitted by law and the Restated Articles of Incorporation, and may include any other substantive or procedural provisions regarding indemnification as are not inconsistent with the laws of the State of Nevada. The provisions of such indemnity agreements shall prevail to the extent that they limit or condition or differ from the provisions of this Article V.

 

SECTION 7. Indemnification of Employees and Agents of the Corporation.

 

The Corporation may, to the extent authorized from time to time by the Board of Directors, grant rights to indemnification and to the advancement of expenses to any employee or agent of the Corporation to the fullest extent of the provisions of this Article V with respect to the indemnification and advancement of expenses of directors and officers of the Corporation.

 

SECTION 8. Nature of Rights.

 

The rights conferred upon Indemnitees in this Article V shall be contract rights and such rights shall continue as to an Indemnitee who has ceased to be a director, officer, employee, agent or trustee and shall inure to the benefit of the Indemnitee’s heirs, executors and administrators. Any amendment, alteration or repeal of this Article V that adversely affects any right of an Indemnitee or its successors shall be prospective only and shall not limit, eliminate, or impair any such right with respect to any action, suit or proceeding involving any occurrence or alleged occurrence of any action or omission to act that took place prior to such amendment, alteration or repeal.

 

SECTION 9. Severability.

 

If any word, clause, provision or provisions of this Article V shall be held to be invalid, illegal or unenforceable for any reason whatsoever: (i) the validity, legality and enforceability of the remaining provisions of this Article V (including, without limitation, each portion of any section of this Article containing any such provision held to be invalid, illegal or unenforceable, that is not itself held to be invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby; and (ii) to the fullest extent possible, the provisions of this Article V (including, without limitation, each such portion of any section of this Article V containing any such provision held to be invalid, illegal or unenforceable) shall be construed so as to give effect to the intent manifested by the provision held invalid, illegal or unenforceable.

 

ARTICLE VI

 

General Provisions

 

SECTION 1. Registered Office. The registered office and registered agent of the Corporation will be as specified in the Articles of Incorporation of the Corporation.

 

SECTION 2. Other Offices. The Corporation may also have such offices, both within or without the State of Nevada, as the Board of Directors may from time to time determine or the business of the Corporation may require.

 

SECTION 3. Fiscal Year. The fiscal year of the Corporation shall be so determined by the Board of Directors.

 

 
- 13 -

 

SECTION 4. Voting Securities Owned by Corporation. Voting securities in any other corporation held by the Corporation shall be voted by the Chief Executive Officer, unless the Board of Directors specifically confers authority to vote with respect thereto, which authority may be general or confined to specific instances, upon some other person or officer. Any person authorized to vote securities shall have the power to appoint proxies, with general power of substitution.

 

SECTION 5. Inspection of Books and Records. Any stockholder of record, in person or by attorney or other agent, shall, upon written demand under oath stating the purpose thereof, have the right during the usual hours for business to inspect for any proper purpose the Corporation’s stock ledger, a list of its stockholders, and its other books and records, and to make copies or extracts therefrom. A proper purpose shall mean any purpose reasonably related to such person’s interest as a stockholder. In every instance where an attorney or other agent shall be the person who seeks the right to inspection, the demand under oath shall be accompanied by a power of attorney or such other writing which authorizes the attorney or other agent to so act on behalf of the stockholder. The demand under oath shall be directed to the Corporation at its registered office in the State of Nevada or at its principal place of business.

 

SECTION 6. Section Headings. Section headings in these bylaws are for convenience of reference only and shall not be given any substantive effect in limiting or otherwise construing any provision herein.

 

SECTION 7. Inconsistent Provisions. In the event that any provision of these bylaws is or becomes inconsistent with any provision of the Articles of Incorporation, the general corporation law of the State of Nevada or any other applicable law, the provision of these bylaws shall not be given any effect to the extent of such inconsistency but shall otherwise be given full force and effect.

 

ARTICLE VII

 

Amendments

 

These bylaws, may be adopted, amended or repealed, and new bylaws made, by the Board of Directors of the Corporation, but the stockholders of the Corporation may make additional bylaws and may alter and repeal any bylaws, whether adopted by them or otherwise, by affirmative vote of the holders of at least sixty-six percent (66%) of the voting power of all of the then outstanding shares of capital stock of the Corporation entitled to be voted at the meeting, present in person or represented by proxy.

 

I, the undersigned, being the Secretary of ScoutCam Inc., DO HEREBY CERTIFY the foregoing to be the bylaws of the Corporation, as adopted by consent to action in lieu of a special meeting of the Board of Directors of the Corporation, dated June __, 2021.

 

 

 

 EX-4.1 3 ex4-1.htm

 

Exhibit 4.1

 

DESCRIPTION OF THE REGISTRANT’S SECURITIES

REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES

EXCHANGE ACT OF 1934

 

ScoutCam Inc. has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), our shares of common stock, par value $0.001 (the “Common Stock”). The following is a summary of some of the terms of our Common Stock based on our Amended and Restated Articles of Incorporation (the “Articles of Incorporation”) and our Amended and Restated Bylaws (the “Bylaws”). The following summary is not complete and is subject to, and is qualified in its entirety by reference to, the provisions of our Articles of Incorporation, our Bylaws as well as the Nevada Revised Statutes (“NRS”) and any other documents referenced in the summary and from which the summary is derived.

 

Name of exchange on which registered

 

Our Common Stock is quoted on the OTC Market, OTCQB Tier, under the symbol “SCTC”. Prior to December 30, 2019, our Common Stock was quoted under the symbol “INLL”.

 

Registration

 

ScoutCam Inc. was incorporated on March 22, 2013 in the State of Nevada under the name Intellisense Solutions Inc.

 

Common Stock

 

We are authorized to issue up to a total of 300,000,000 shares of Common Stock. Holders of our Common Stock are entitled to one vote for each share held on all matters submitted to a vote of our stockholders.

 

As of December 31, 2022, there were 7,121,737 shares of Common Stock issued and outstanding and there were approximately 36 holders of record of our Common Stock.

 

Voting Rights

 

Holders of Common Stock are entitled to one vote per share on all matters voted on generally by the stockholders, including the election of directors, and the holders of Common Stock possess all voting power of our stockholders. Holders of Common Stock do not have cumulative voting rights.

 

Liquidation Rights

 

If any, upon any liquidation, dissolution or winding up of the affairs of the Company, whether voluntary or involuntary, holders of shares of Common Stock are entitled to share equally and ratably in the assets of the Company to be distributed among the holders of outstanding shares of Common Stock.

 

Dividends

 

In general, the holders of outstanding shares of our Common Stock are entitled to receive dividends out of funds legally available therefor at such times and in such amounts as our board of directors may from time to time determine. As a Nevada corporation, we are subject to the limitations of Nevada law, which allows us to pay dividends unless, after such dividend, we would not be able to pay our debts as they become due in the usual course of business or our total assets would be less than the sum of our total liabilities plus any amount that would be needed if we were to be dissolved at the time of the dividend payment to satisfy the preferential rights of stockholders whose preferential rights are superior to those receiving the dividend.

 

Changing our Articles of Incorporation and Bylaws

 

Our Articles of Incorporation may be amended or repealed in the manner prescribed by the NRS, and all rights conferred upon stockholders are granted subject to this reservation. Additionally, the affirmative vote of the holders of at least sixty-six percent (66%) of the voting power of all the then outstanding shares of Capital Stock entitled to be voted at the meeting, present in person or represented by proxy, shall be required to amend, alter or repeal, or adopt any provision inconsistent with, Articles IV through XIII of our Articles of Incorporation, and in addition to the affirmative vote of the holders of any class or series of the shares of capital stock required by law.

 

 
- 2 -

 

Our bylaws may be adopted, amended or repealed, and new bylaws made, by the Board of Directors, but our stockholders may make additional bylaws and may alter and repeal any bylaws, whether adopted by them or otherwise, by affirmative vote of the holders of at least sixty-six percent (66%) of the voting power of all of the then outstanding shares of Capital Stock entitled to be voted at the meeting, present in person or represented by proxy.

 

Board of Directors

 

Directors shall be divided into three classes. The initial first, second and third class directors shall serve terms of office expiring at the first, second and third annual meeting of stockholders following the initial classification of directors, respectively, and until their respective successors are duly elected and qualified. At each annual meeting of stockholders, directors elected to succeed those directors whose terms expire shall be elected for a term of office to expire at the third succeeding annual meeting of stockholders after their election and until their successors are duly elected and qualified. The Board of Directors is authorized to assign directors already in office to such classes as it may determine at the time the classification becomes effective.

 

In any election of directors, the persons (i) in contested elections receiving a plurality of the votes cast, up to the number of directors to be elected in such election, shall be deemed elected or (ii) in uncontested elections receiving a majority of the votes shall be deemed elected. The stockholders are expressly prohibited from cumulating their votes in any election of our directors. Each director shall hold office until his or her successor is elected and qualified or until his or her earlier resignation or removal.

 

Anti-Takeover Effects of Nevada Law and Our Articles of Incorporation and Bylaws

 

General. Certain provisions of our Articles of Incorporation and our Bylaws, and certain provisions of the NRS could make our acquisition by a third party, a change in our incumbent management, or a similar change of control more difficult. These provisions, which are summarized below, may reduce our vulnerability to an unsolicited proposal for the restructuring or sale of all or substantially all of our assets or an unsolicited takeover attempt. The summary of the provisions set forth below does not purport to be complete and is qualified in its entirety by reference to our Articles of Incorporation and our Bylaws and the applicable provisions of the NRS.

 

Advance Notice Requirements. Stockholders wishing to nominate or re-nominate persons for election to our Board of Directors at an annual meeting or to propose any business to be considered by our stockholders at an annual meeting must comply with certain advance notice and other requirements set forth in our Bylaws. Likewise, if our Board of Directors has determined that directors shall be elected at a special meeting of stockholders, stockholders wishing to nominate or re-nominate persons for election to our board of directors at such special meeting must comply with certain advance notice and other requirements set forth in our Bylaws.

 

Special Meetings. Our Bylaws provide that special meetings of stockholders may only be called by the Board of Directors acting pursuant to a resolution approved by the affirmative vote by a majority of the directors then in office.

 

Board Vacancies. Any vacancy on our board of directors, howsoever resulting, may be filled by a majority vote of the directors then in office even if less than a quorum is present. Any director elected to fill a vacancy shall hold office for a term expiring at the next annual meeting of stockholders, at which their successors are elected or appointed and the term of the class to which he or she has been elected expires, or until his or her earlier resignation or removal.

 

Removal of Directors. Our Bylaws provide that any director, or the entire Board of Directors, may be removed from office at any time only for cause and only by the affirmative vote of the holders of at least seventy percent (70%) of the voting power of all of the then outstanding shares of capital stock of the Corporation entitled to vote at an election of directors, voting together as a single class. NRS 78.335 generally requires the vote of stockholders representing not less than two-thirds of the voting power of the issued and outstanding stock entitled to vote in order to remove an incumbent director.

 

 
- 3 -

 

Nevada Anti-Takeover Statutes. Nevada’s “acquisition of controlling interest” statutes (NRS 78.378 through 78.3793, inclusive) contain provisions governing the acquisition of a controlling interest in certain Nevada corporations. These “control share” laws provide generally that any person that acquires a “controlling interest” in certain Nevada corporations may be denied voting rights, unless a majority of the disinterested stockholders of the corporation elects to restore such voting rights. These laws will apply to us as of a particular date if we were to have 200 or more stockholders of record (at least 100 of whom have addresses in Nevada appearing on our stock ledger at all times during the 90 days immediately preceding that date) and do business in the State of Nevada directly or through an affiliated corporation, unless our articles of incorporation or bylaws in effect on the tenth day after the acquisition of a controlling interest provide otherwise. These laws provide that a person acquires a “controlling interest” whenever a person acquires shares of a subject corporation that, but for the application of these provisions of the NRS, would enable that person to exercise (1) one-fifth or more, but less than one-third, (2) one-third or more, but less than a majority or (3) a majority or more, of all of the voting power of the corporation in the election of directors. Once an acquirer crosses one of these thresholds, shares which it acquired in the transaction taking it over the threshold and within the 90 days immediately preceding the date when the acquiring person acquired or offered to acquire a controlling interest become “control shares” to which the voting restrictions described above apply. Our Articles of Incorporation include a provision electing that the Company be governed by these laws. These laws may have a chilling effect on certain transactions by for example discouraging companies or persons interested in acquiring a significant interest in or control of us, regardless of whether such transactions may be in the interest of our stockholders, unless our Articles of Incorporation or Bylaws are amended to provide that these provisions generally do not apply to us or to an acquisition of a controlling interest, or if our disinterested stockholders do not confer voting rights in the control shares. However, at this time, we do not believe we have 100 stockholders of record resident of Nevada and we do not conduct business in Nevada directly or through an affiliated corporation. Therefore, the provisions of the control share acquisition act are believed not to apply to acquisitions of our shares at this time and will not until such time as these requirements have been met.

 

Nevada’s “combinations with interested stockholders” statutes (NRS 78.411 through 78.444, inclusive) provide that specified types of business “combinations” between certain Nevada corporations and any person deemed to be an “interested stockholder” of the corporation are prohibited for two years after such person first becomes an “interested stockholder” unless the corporation’s board of directors approves the combination (or the transaction by which such person becomes an “interested stockholder”) in advance, or unless the combination is approved by the board of directors and sixty percent of the corporation’s voting power not beneficially owned by the interested stockholder, its affiliates and associates. Furthermore, in the absence of prior approval certain restrictions may apply even after such two-year period. For purposes of these statutes, an “interested stockholder” is any person who is (1) the beneficial owner, directly or indirectly, of 10% or more of the voting power of the outstanding voting shares of the corporation, or (2) an affiliate or associate of the corporation and at any time within the two previous years was the beneficial owner, directly or indirectly, of 10% or more of the voting power of the then-outstanding shares of the corporation. The definition of the term “combination” is sufficiently broad to cover most significant transactions between a corporation and an “interested stockholder”. These laws generally apply to Nevada corporations with 200 or more stockholders of record. Our Articles of Incorporation include a provision electing that the Company not be governed by these laws.

 

In addition, NRS 78.139 also provides that directors may resist a change or potential change in control of the corporation if the board of directors determines that the change or potential change is opposed to or not in the best interest of the corporation upon consideration of any relevant facts, circumstances, contingencies or constituencies pursuant to NRS 78.138(4).

 

Transfer Agent

 

The transfer agent and registrar for our Common Stock is Securities Transfer Corporation. The transfer agent and registrar’s address is 2901 N. Dallas Parkway, Suite 380, Plano, Texas 75093. The transfer agent’s telephone number is (469) 633-0101.

 

 

 EX-10.3 4 ex10-3.htm

 

Exhibit 10.3

 

 

 

ScoutCam inc.

2020 Share Incentive Plan

 

 

 

Unless otherwise defined, terms used herein shall have the meaning ascribed to them in Section 2 hereof.

 

1.PURPOSE; TYPES OF AWARDS; CONSTRUCTION.

 

1.1. Purpose. The purpose of this 2020 Share Incentive Plan (as amended on July 5, 2022, this “Plan”) is to afford an incentive to Service Providers of ScoutCam Inc., a Nevada registered company (together with any successor corporation thereto, the “Corporation”), or any Affiliate of the Corporation, which now exists or hereafter is organized or acquired by the Corporation or its Affiliates, to continue as Service Providers, to increase their efforts on behalf of the Corporation or its Affiliates and to promote the success of the Corporation’s business, by providing such Service Providers with opportunities to acquire a proprietary interest in the Corporation by the issuance of Shares or restricted Shares (“Restricted Shares”) of the Corporation, and by the grant of options to purchase Shares (“Options”), Restricted Share Units (“RSUs”) and other Share-based Awards pursuant to Sections 11 through 13 of this Plan.

 

1.2. Types of Awards. This Plan is intended to enable the Corporation to issue Awards under various tax regimes, including:

 

(i) pursuant and subject to the provisions of Section 102 of the Ordinance (or the corresponding provision of any subsequently enacted statute, as amended from time to time), and all regulations and interpretations adopted by any competent authority, including the Israel Tax Authority (the “ITA”), including the Income Tax Rules (Tax Benefits in Stock Issuance to Employees) 5763-2003 or such other rules so adopted from time to time (the “Rules”) (such Awards that are intended to be (as set forth in the Award Agreement) and which qualify as such under Section 102 of the Ordinance and the Rules, “102 Awards”);

 

(ii) pursuant to Section 3(i) of the Ordinance or the corresponding provision of any subsequently enacted statute, as amended from time to time (such Awards, “3(i) Awards”);

 

(iii) Incentive Stock Options within the meaning of Section 422 of the Code, or the corresponding provision of any subsequently enacted United States federal tax statute, as amended from time to time, to be granted to Employees who are deemed to be residents of the United States, for purposes of taxation, or are otherwise subject to U.S. Federal income tax (such Awards that are intended to be (as set forth in the Award Agreement) and which qualify as an incentive stock option within the meaning of Section 422(b) of the Code, “Incentive Stock Options”); and

 

(iv) Options not intended to be (as set forth in the Award Agreement) or which do not qualify as an Incentive Stock Option to be granted to Service Providers who are deemed to be residents of the United States for purposes of taxation, or are otherwise subject to U.S. Federal income tax (“Nonqualified Stock Options”).

 

In addition to the issuance of Awards under the relevant tax regimes in the United States of America and the State of Israel, and without derogating from the generality of Section 25, this Plan contemplates issuances to Grantees in other jurisdictions or under other tax regimes with respect to which the Committee is empowered, but is not required, to make the requisite adjustments in this Plan and set forth the relevant conditions in an appendix to this Plan or in the Corporation’s agreement with the Grantee in order to comply with the requirements of such other tax regimes.

 

1.3. Corporation Status. This Plan contemplates the issuance of Awards by the Corporation, both as a private and public company.

 

 
2

 

1.4. Construction. To the extent any provision herein conflicts with the conditions of any relevant tax law, rule or regulation which are relied upon for tax relief in respect of a particular Award to a Grantee, the Committee is empowered, but is not required, hereunder to determine that the provisions of such law, rule or regulation shall prevail over those of this Plan and to interpret and enforce such prevailing provisions. With respect to 102 Awards, if and to the extent any action or the exercise or application of any provision hereof or authority granted hereby is conditioned or subject to obtaining a ruling or tax determination from the ITA, to the extent required by applicable law, then the taking of any such action or the exercise or application of such section or authority with respect to 102 Awards shall be conditioned upon obtaining such ruling or tax determination, and, if obtained, shall be subject to any condition set forth therein; it being clarified that there is no obligation to apply for any such ruling or tax determination (which shall be in the sole discretion of the Committee) and no assurance is made that if applied any such ruling or tax determination will be obtained (or the conditions thereof).

 

2.DEFINITIONS.

 

2.1. Terms Generally. Except when otherwise indicated by the context, (i) the singular shall include the plural and the plural shall include the singular; (ii) any pronoun shall include the corresponding masculine, feminine and neuter forms; (iii) any definition of or reference to any agreement, instrument or other document herein shall be construed as referring to such agreement, instrument or other document as from time to time amended, restated, supplemented or otherwise modified (subject to any restrictions on such amendments, restatements, supplements or modifications set forth therein or herein), (iv) references to any law, constitution, statute, treaty, regulation, rule or ordinance, including any section or other part thereof shall refer to it as amended from time to time and shall include any successor thereof, (v) reference to a “company” or “entity” shall include a, partnership, corporation, limited liability company, association, trust, unincorporated organization, or a government or agency or political subdivision thereof, and reference to a “person” shall mean any of the foregoing or an individual, (vi) the words “herein”, “hereof” and “hereunder”, and words of similar import, shall be construed to refer to this Plan in its entirety, and not to any particular provision hereof, (vii) all references herein to Sections shall be construed to refer to Sections to this Plan; (viii) the words “include”, “includes” and “including” shall be deemed to be followed by the phrase “without limitation”; and (ix) use of the term “or” is not intended to be exclusive.

 

2.2. Defined Terms. The following terms shall have the meanings ascribed to them in this Section 2:

 

2.3. “Affiliate” shall mean, with respect to any person, any other person that, directly or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with, such person (with the term “control” or “controlled by” within the meaning of Rule 405 of Regulation C under the Securities Act), including, without limitation, any Parent or Subsidiary, or Employer.

 

2.4. “Applicable Law” shall mean any applicable law, rule, regulation, statute, pronouncement, policy, interpretation, judgment, order or decree of any federal, provincial, state or local governmental, regulatory or adjudicative authority or agency, of any jurisdiction, and the rules and regulations of any stock exchange, over-the-counter market or trading system on which the Corporation’s shares are then traded or listed.

 

2.5. “Award” shall mean any Option, Restricted Share, RSUs, Shares or any other Share-based award granted under this Plan.

 

2.6. “Board” shall mean the Board of Directors of the Corporation.

 

2.7. “Bylaws” – shall mean ScoutCam Inc.’s by-laws.

 

2.8. “Change in Board Event” shall mean any time at which individuals who, as of the Effective Date, constitute the Board (the “Incumbent Board”) cease for any reason to constitute at least a majority of the Board; provided, however, that any individual becoming a director subsequent to the Effective Date whose election, or nomination for election by the Corporation’s shareholders, was approved by a vote of at least a majority of the directors then comprising the Incumbent Board shall be considered as though such individual were a member of the Incumbent Board, but excluding, for this purpose, any such individual whose initial assumption of office occurs as a result of an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents by or on behalf of a Person other than the Board.

 

 
3

 

2.9. “Charter”- shall mean ScoutCam Inc.’s Certificate of Incorporation.

 

2.10. “Code” shall mean the United States Internal Revenue Code of 1986, and any applicable regulations promulgated thereunder, all as amended.

 

2.11. “Committee” shall mean a committee established or appointed by the Board to administer this Plan, subject to Section 3.1.

 

2.12. “Controlling Shareholder” shall have the meaning set forth in Section 32(9) of the Ordinance.

 

2.13. “Disability” shall mean (i) the inability of a Grantee to engage in any substantial gainful activity or to perform the major duties of the Grantee’s position with the Corporation or its Affiliates by reason of any medically determinable physical or mental impairment which has lasted or can be expected to last for a continuous period of not less than 12 months (or such other period as determined by the Committee), as determined by a qualified doctor acceptable to the Corporation, (ii) if applicable, a “permanent and total disability” as defined in Section 22(e)(3) of the Code or Section 409A(a)(2)(c)(i) of the Code, as amended from time to time, or (iii) as defined in a policy of the Corporation that the Committee deems applicable to this Plan, or that makes reference to this Plan, for purposes of this definition. Notwithstanding the foregoing, for Awards that are subject to Section 409A of the Code, Disability shall mean that a Participant is disabled under Section 409A(a)(2)(C)(i) or (ii) of the Code.

 

2.14. “Employee” shall mean any person treated as an employee (including an officer or a director who is also treated as an employee) in the records of the Corporation or any of its Affiliates (and in the case of 102 Awards, subject to Section 9.3 or in the case of Incentive Stock Options, who is an employee for purposes of Section 422 of the Code); provided, however, that neither service as a director nor payment of a director’s fee shall be sufficient to constitute employment for purposes of this Plan. The Corporation shall determine in good faith and in the exercise of its discretion whether an individual has become or has ceased to be an Employee and the effective date of such individual’s employment or termination of employment, as the case may be. For purposes of a person’s rights, if any, under this Plan as of the time of the Corporation’s determination, all such determinations by the Corporation shall be final, binding and conclusive, notwithstanding that the Corporation or any court of law or governmental agency subsequently makes a contrary determination.

 

2.15. “Employer” means, for purpose of a 102 Trustee Award, the Corporation or an Affiliate, Subsidiary or Parent thereof, which is an “employing company” within the meaning and subject to the conditions of Section 102(a) of the Ordinance.

 

2.16. “employment”, “employed” and words of similar import shall be deemed to refer to the employment of Employees or to the services of any other Service Provider, as the case may be.

 

2.17. “exercise” “exercised” and words of similar import, when referring to an Award that does not require exercise or that is settled upon vesting (such as may be the case with RSUs or Restricted Shares, if so determined in their terms), shall be deemed to refer to the vesting of such an Award (regardless of whether or not the wording included reference to vesting of such an Awards explicitly).

 

2.18. “Exercise Period” shall mean the period, commencing on the date of grant of an Award, during which an Award shall be exercisable, subject to any vesting provisions thereof (including any acceleration thereof, if any) and subject to the termination provisions hereof.

 

2.19. “Exercise Price” shall mean the exercise price for each Share covered by an Option or the purchase price for each Share covered by any other Award.

 

 
4

 

2.20. “Fair Market Value” shall mean, as of any date, the value of a Share or other securities, property or rights as determined by the Board, in its discretion, subject to the following: (i) if, on such date, the Shares are listed on any securities exchange, the average closing sales price per Share on which the Shares are principally traded over the thirty (30) day calendar period preceding the subject date (utilizing all trading days during such 30 calendar day period), as reported in The Wall Street Journal or such other source as the Corporation deems reliable; (ii) if, on such date, the Shares are then quoted in an over-the-counter market, the average of the closing bid and asked prices for the Shares in that market during the thirty (30) day calendar period preceding the subject date (utilizing all trading days during such 30 calendar day period), as reported in The Wall Street Journal or such other source as the Corporation deems reliable; or (iii) if, on such date, the Shares are not then listed on a securities exchange or quoted in an over-the-counter market, or in case of any other securities, property or rights, such value as the Committee, in its sole discretion, shall determine, with full authority to determine the method for making such determination and which determination shall be conclusive and binding on all parties, and shall be made after such consultations with outside legal, accounting and other experts as the Committee may deem advisable; provided, however, that, if applicable, the Fair Market Value of the Shares shall be determined in a manner that is intended to satisfy the applicable requirements of and subject to Section 409A of the Code, and with respect to Incentive Stock Options, in a manner that is intended to satisfy the applicable requirements of and subject to Section 422 of the Code, subject to Section 422(c)(7) of the Code. The Committee shall maintain a written record of its method of determining such value. If the Shares are listed or quoted on more than one established stock exchange or over-the-counter market, the Committee shall determine the principal such exchange or market and utilize the price of the Shares on that exchange or market (determined as per the method described in clauses (i) or (ii) above, as applicable) for the purpose of determining Fair Market Value.

 

2.21. “Grantee” shall mean a person who has been granted an Award(s) under this Plan.

 

2.22. “Ordinance” shall mean the Israeli Income Tax Ordinance (New Version) 1961, and the regulations and rules (including the Rules) promulgated thereunder, all as amended from time to time.

 

2.23. “Parent” shall mean any company (other than the Corporation), which now exists or is hereafter organized, (i) in an unbroken chain of companies ending with the Corporation if, at the time of granting an Award, each of the companies (other than the Corporation) owns stock possessing fifty percent (50%) or more of the total combined voting power of all classes of stock in one of the other companies in such chain, or (ii) if applicable and for purposes of Incentive Stock Options, that is a “parent corporation” of the Corporation, as defined in Section 424(e) of the Code.

 

2.24. “Retirement” shall mean a Grantee’s retirement pursuant to Applicable Law or in accordance with the terms of any tax-qualified retirement plan maintained by the Corporation or any of its Affiliates in which the Grantee participates or is subject to.

 

2.25. “Securities Act” shall mean the U.S. Securities Act of 1933, and the rules and regulations promulgated thereunder, all as amended from time to time.

 

2.26. “Service Provider” shall mean an Employee, director, officer, consultant, advisor and any other person or entity who provides services to the Corporation or any Parent, Subsidiary or Affiliate thereof. Service Providers shall include prospective Service Providers to whom Awards are granted in connection with written offers of an employment or other service relationship with the Corporation or any Parent, Subsidiary or any Affiliates thereof, provided, however, that such employment or service shall have actually commenced.

 

“Shares” shall mean shares of common stock, par value US$0.001 per share, of the Corporation (as adjusted for stock split, reverse stock split, bonus shares, combination or other recapitalization events), or shares of such other class of shares of the Corporation as shall be designated by the Board in respect of the relevant Award(s). “Shares” include any securities, property or rights issued or distributed with respect thereto.

 

 
5

 

2.27. “Subsidiary” shall mean any company (other than the Corporation), which now exists or is hereafter organized or acquired by the Corporation, (i) in an unbroken chain of companies beginning with the Corporation if, at the time of granting an Award, each of the companies other than the last company in the unbroken chain owns stock possessing fifty percent (50%) or more of the total combined voting power of all classes of stock in one of the other companies in such chain, or (ii) if applicable and for purposes of Incentive Stock Options, that is a “subsidiary corporation” of the Corporation, as defined in Section 424(f) of the Code.

 

2.28. “tax(es)” shall mean (a) all federal, state, local or foreign taxes, charges, fees, imposts, levies or other assessments, including all income, capital gains, alternative or add-on minimum, transfer, value added tax, real and personal property, withholding, payroll, employment, escheat, social security, disability, national security, health tax, wealth surtax, stamp, registration and estimated taxes, customs duties, fees, assessments and charges of any similar kind whatsoever (including under Section 280G of the Code) or other tax of any kind whatsoever, (b) all interest, indexation differentials, penalties, fines, additions to tax or additional amounts imposed by any taxing authority in connection with any item described in clause (a), (c) any transferee or successor liability in respect of any items described in clauses (a) or (b) payable by reason of contract, assumption, transferee liability, successor liability, operation of Applicable Law, or as a result of any express or implied obligation to assume Taxes or to indemnify any other person, and (d) any liability for the payment of any amounts of the type described in clause (a) or (b) payable as a result of being a member of an affiliated, consolidated, combined, unitary or aggregate or other group for any taxable period, including under U.S. Treasury Regulations Section 1.1502-6(a) (or any predecessor or successor thereof of any analogous or similar provision under Law) or otherwise.

 

2.29. “Ten Percent Shareholder” shall mean a Grantee who, at the time an Award is granted to the Grantee, owns shares possessing more than ten percent (10%) of the total combined voting power of all classes of shares of the Corporation or any Parent or Subsidiary, within the meaning of Section 422(b)(6) of the Code.

 

2.30. “Trustee” shall mean the trustee appointed by the Committee to hold the Awards (and, in relation with 102 Trustee Awards, approved by the ITA), if so appointed.

 

2.31. Other Defined Terms. The following terms shall have the meanings ascribed to them in the Sections set forth below:

 

Term   Section
102 Awards   1.2(i)
102 Capital Gains Track Awards   9.1
102 Non-Trustee Awards   9.2
102 Ordinary Income Track Awards   9.1
102 Trustee Awards   9.1
3(i) Awards   1.2(ii)
Award Agreement   6
Cause   6.6.4.4
Corporation   1.1
Effective Date   24.1
Election   9.2
Eligible 102 Grantees   9.3.1
Incentive Stock Options   1.2(iii)
Information   16.4
ITA   1.1(i)
Market Stand-Off   17
Market Stand-Off Period   17
Merger/Sale   14.2
Nonqualified Stock Options   1.2(iv)
Plan   1.1
Pool   5.1
Recapitalization   14.1
Required Holding Period   9.5
Restricted Period   11.2
Restricted Share Agreement   11
Restricted Share Unit Agreement   12
Restricted Shares   1.1
RSUs   1.1
Rules   1.11.2(i)
Securities   17.1
Successor Corporation   14.2.1
Withholding Obligations   18.5

 

 
6

 

3.ADMINISTRATION.

 

3.1. To the extent permitted under Applicable Law, the Charter, the Bylaws and any other governing document of the Corporation, this Plan shall be administered by the Committee. In the event that the Board does not appoint or establish a committee to administer this Plan, this Plan shall be administered by the Board, and, accordingly, any and all references herein to the Committee shall be construed as references to the Board. In the event that an action necessary for the administration of this Plan is required under Applicable Law to be taken by the Board without the right of delegation, or if such action or power was explicitly reserved by the Board in appointing, establishing and empowering the Committee, then such action shall be so taken by the Board. In any such event, all references herein to the Committee shall be construed as references to the Board. Even if such a Committee was appointed or established, the Board may take any actions that are stated to be vested in the Committee, and shall not be restricted or limited from exercising all rights, powers and authorities under this Plan or Applicable Law.

 

3.2. The Board shall appoint the members of the Committee, may from time to time remove members from, or add members to, the Committee, and shall fill vacancies in the Committee, however caused, provided that the composition of the Committee shall at all times be in compliance with any mandatory requirements of Applicable Law, the Charter, the Bylaws and any other governing document of the Corporation. The Committee may select one of its members as its Chairman and shall hold its meetings at such times and places as it shall determine. The Committee may appoint a Secretary, who shall keep records of its meetings, and shall make such rules and regulations for the conduct of its business as it shall deem advisable and subject to mandatory requirements of Applicable Law.

 

3.3. Subject to the terms and conditions of this Plan, any mandatory provisions of Applicable Law and any provisions of any Corporation policy required under mandatory provisions of Applicable Law, and in addition to the Committee’s powers contained elsewhere in this Plan, the Committee shall have full authority, in its discretion, from time to time and at any time, to determine any of the following, or to recommend to the Board any of the following if it is not authorized to take such action according to Applicable Law:

 

(i) eligible Grantees,

 

(ii) grants of Awards and setting the terms and provisions of Award Agreements (which need not be identical) and any other agreements or instruments under which Awards are made, including the number of Shares underlying each Award and the class of Shares underlying each Award (if more than one class was designated by the Board),

 

 
7

 

(iii) the time or times at which Awards shall be granted.

 

(iv) the terms, conditions and restrictions applicable to each Award (which need not be identical) and any Shares acquired upon the exercise or (if applicable) vesting thereof, including (1) designating Awards under Section 1.2; (2) the vesting schedule, the acceleration thereof and terms and conditions upon which Awards may be exercised or become vested, (3) the Exercise Price, (4) the method of payment for Shares purchased upon the exercise or (if applicable) vesting of the Awards, (5) the method for satisfaction of any tax withholding obligation arising in connection with the Awards or such Shares, including by the withholding or delivery of Shares, (6) the time of the expiration of the Awards, (7) the effect of the Grantee’s termination of employment with the Corporation or any of its Affiliates, and (8) all other terms, conditions and restrictions applicable to the Award or the Shares not inconsistent with the terms of this Plan,

 

(v) to accelerate, continue, extend or defer the exercisability of any Award or the vesting thereof, including with respect to the period following a Grantee’s termination of employment or other service.

 

(vi) the interpretation of this Plan and any Award Agreement and the meaning, interpretation and applicability of terms referred to in Applicable Law,

 

(vii) policies, guidelines, rules and regulations relating to and for carrying out this Plan, and any amendment, supplement or rescission thereof, as it may deem appropriate,

 

(viii) to adopt supplements to, or alternative versions of, this Plan, including, without limitation, as it deems necessary or desirable to comply with the laws of, or to accommodate the tax regime or custom of, foreign jurisdictions whose citizens or residents may be granted Awards,

 

(ix) the Fair Market Value of the Shares or other securities, property or rights,

 

(x) the tax track (capital gains, ordinary income track or any other track available under the Section 102 of the Ordinance) for the purpose of 102 Awards,

 

(xi) the authorization and approval of conversion, substitution, cancellation or suspension under and in accordance with this Plan of any or all Awards or Shares,

 

(xii) unless otherwise provided under the terms of this Plan, the amendment, modification, waiver or supplement of the terms of any outstanding Award (including, without limitation, reducing the Exercise Price of an Award), provided, however, that if such amendments increases the Exercise Price of an Award or reduces the number of Shares underlying an Award, then such amendments shall require the consent of the applicable Grantee, unless such amendment is made pursuant to the exercise of rights or authorities in accordance with Section 14.

 

(xiii) without limiting the generality of the foregoing, and subject to the provisions of Applicable Law, to grant to a Grantee, who is the holder of an outstanding Award, in exchange for the cancellation of such Award, a new Award having an Exercise Price lower than that provided in the Award so canceled and containing such other terms and conditions as the Committee may prescribe in accordance with the provisions of this Plan or to set a new Exercise Price for the same Award lower than that previously provided in the Award.

 

(xiv) to correct any defect, supply any omission or reconcile any inconsistency in this Plan or any Award Agreement and all other determinations and take such other actions with respect to this Plan or any Award as it may deem advisable to the extent not inconsistent with the provisions of this Plan or Applicable Law, and

 

(xv) any other matter which is necessary or desirable for, or incidental to, the administration of this Plan and any Award thereunder.

 

 
8

 

3.4. The authority granted hereunder includes the authority to modify Awards to eligible individuals who are foreign nationals or are individuals who are employed outside Israel to recognize differences in local law, tax policy or custom, in order to effectuate the purposes of this Plan but without amending this Plan.

 

3.5. The Board and the Committee shall be free at all times to make such determinations and take such actions as they deem fit. The Board and the Committee need not take the same action or determination with respect to all Awards, with respect to certain types of Awards, with respect to all Service Providers or any certain type of Service Providers and actions and determinations may differ as among the Grantees, and as between the Grantees and any other holders of securities of the Corporation.

 

3.6. All decisions, determinations, and interpretations of the Committee, the Board and the Corporation under this Plan shall be final and binding on all Grantees (whether before or after the issuance of Shares pursuant to Awards), unless otherwise determined by the Committee, the Board or the Corporation, respectively. The Committee shall have the authority (but not the obligation) to determine the interpretation and applicability of Applicable Law to any Grantee or any Awards. No member of the Committee or the Board shall be liable to any Grantee for any action taken or determination made in good faith with respect to this Plan or any Award granted hereunder.

 

3.7. Any officer or authorized signatory of the Corporation shall have the authority to act on behalf of the Corporation with respect to any matter, right, obligation, determination or election which is the responsibility of or which is allocated to the Corporation herein, provided such person has apparent authority with respect to such matter, right, obligation, determination or election. Such person or authorized signatory shall not be liable to any Grantee for any action taken or determination made in good faith with respect to this Plan or any Award granted hereunder.

 

4.ELIGIBILITY.

 

Awards may be granted to Service Providers of the Corporation or any Affiliate thereof, taking into account, at the Committee’s discretion and without an obligation to do so, the qualification under each tax regime pursuant to which such Awards are granted, subject to the limitation on the granting of Incentive Stock Options set forth in Section 8.1. A person who has been granted an Award hereunder may be granted additional Awards, if the Committee shall so determine, subject to the limitations herein. However, eligibility in accordance with this Section 4 shall not entitle any person to be granted an Award, or, having been granted an Award, to be granted an additional Award.

 

Awards may differ in number of Shares covered thereby, the terms and conditions applying to them or on the Grantees or in any other respect (including, that there should not be any expectation (and it is hereby disclaimed) that a certain treatment, interpretation or position granted to one shall be applied to the other, regardless of whether or not the facts or circumstances are the same or similar).

 

5.SHARES.

 

5.1. The maximum aggregate number of Shares that may be issued pursuant to Awards under this Plan (the “Pool”) shall initially be 5,228,007 authorized but unissued Shares (except and as adjusted pursuant to Section 14.1 of this Plan), or such other number as the Board may determine from time to time (without the need to amend the Plan in case of such determination). However, except as adjusted pursuant to Section 14.1, in no event shall more than such number of Shares constituting the Pool, as adjusted in accordance with Section Error! Reference source not found., be available for issuance pursuant to the exercise of Incentive Stock Options.

 

 
9

 

5.2. Any Shares under the Pool that are not subject to outstanding or exercised Awards at the termination of this Plan shall cease to be reserved for the purpose of this Plan.

 

6.TERMS AND CONDITIONS OF AWARDS.

 

Each Award granted pursuant to this Plan shall be evidenced by a written or electronic agreement between the Corporation and the Grantee or a written or electronic notice delivered by the Corporation (the “Award Agreement”), in substantially such form or forms and containing such terms and conditions, as the Committee shall from time to time approve. The Award Agreement shall comply with and be subject to the following general terms and conditions and the provisions of this Plan (except for any provisions applying to Awards under different tax regimes), unless otherwise specifically provided in such Award Agreement, or the terms referred to in other Sections of this Plan applying to Awards under such applicable tax regimes, or terms prescribed by Applicable Law. Award Agreements need not be in the same form and may differ in the terms and conditions included therein.

 

6.1. Number of Shares. Each Award Agreement shall state the number of Shares covered by the Award.

 

6.2. Type of Award. Each Award Agreement may state the type of Award granted thereunder, provided that the tax treatment of any Award, whether or not stated in the Award Agreement, shall be as determined in accordance with Applicable Law.

 

6.3. Exercise Price. Each Award Agreement shall state the Exercise Price, if applicable. Subject to Sections 3, 7.2 and 8.2 and to the foregoing, the Committee may reduce the Exercise Price of any outstanding Award, on terms and subject to such conditions as it deems advisable. The Exercise Price shall also be subject to adjustment as provided in Section 14 hereof. The Exercise Price of any outstanding Award granted to a Grantee who is subject to U.S. federal income tax shall be determined in accordance with Section 409A of the Code.

 

6.4. Manner of Exercise. An Award may be exercised, as to any or all Shares as to which the Award has become exercisable, by written notice delivered in person or by mail (or such other methods of delivery prescribed by the Corporation) to the Chief Financial Officer of the Corporation or to such other person as determined by the Committee, or in any other manner as the Committee shall prescribe from time to time, specifying the number of Shares with respect to which the Award is being exercised (which may be equal to or lower than the aggregate number of Shares that have become exercisable at such time, subject to the last sentence of this Section), accompanied by payment of the aggregate Exercise Price for such Shares in the manner specified in the following sentence. The Exercise Price shall be paid in full with respect to each Share, at the time of exercise, either in (i) cash, (ii) if the Corporation’s shares are listed for trading on any securities exchange or over-the-counter market, and if the Committee so determines, all or part of the Exercise Price and any withholding taxes may be paid by the delivery (on a form prescribed by the Corporation) of an irrevocable direction to a securities broker approved by the Corporation to sell Shares and to deliver all or part of the sales proceeds to the Corporation or the Trustee, (iii) if the Corporation’s shares are listed for trading on any securities exchange or over-the-counter market, and if the Committee so determines, all or part of the Exercise Price and any withholding taxes may be paid by the delivery (on a form prescribed by the Corporation) of an irrevocable direction to pledge Shares to a securities broker or lender approved by the Corporation, as security for a loan, and to deliver all or part of the loan proceeds to the Corporation or the Trustee, or (iv) in such other manner as the Committee shall determine, which may include procedures for cashless exercise. The application of cashless exercise with respect to any 102 Awards shall be subject to obtaining a ruling from the ITA, to the extent required by applicable law.

 

6.5. Term and Vesting of Awards.

 

6.5.1. Each Award Agreement shall provide the vesting schedule for the Award as determined by the Committee. The Committee shall have the authority to determine the vesting schedule and accelerate the vesting of any outstanding Award at such time and under such circumstances as it, in its sole discretion, deems appropriate. Unless otherwise resolved by the Committee and stated in the Award Agreement, and subject to Sections 6.6 and 6.7 hereof, Awards shall vest and become exercisable under the following schedule: twenty-five percent (25%) of the Shares covered by the Award, on the first anniversary of the vesting commencement date determined by the Committee (and in the absence of such determination, of date on which such Award was granted), and six and one-quarter percent (6.25%) of the Shares covered by the Award at the end of each subsequent three-month period thereafter over the course of the following three (3) years; provided that the Grantee remains continuously as a Service Provider of the Corporation or its Affiliates throughout such vesting dates.

 

 
10

 

6.5.2. The Award Agreement may contain performance goals and measurements (which, in case of 102 Trustee Awards, may, if then required, be subject to obtaining a specific tax ruling or determination from the ITA), and the provisions with respect to any Award need not be the same as the provisions with respect to any other Award. Such performance goals may include, but are not limited to, sales, earnings before interest and taxes, return on investment, earnings per share, any combination of the foregoing or rate of growth of any of the foregoing, as determined by the Committee. The Committee may adjust performance goals pursuant to Awards previously granted to take into account changes in law and accounting and tax rules and to make such adjustments as the Committee deems necessary or appropriate to reflect the inclusion or the exclusion of the impact of extraordinary or unusual items, events or circumstances.

 

6.5.3. The Exercise Period of an Award will be seven years from the date of grant of the Award, unless otherwise determined by the Committee and stated in the Award Agreement, but subject to the vesting provisions described above and the early termination provisions set forth in Sections 6.6 and 6.7 hereof. At the expiration of the Exercise Period, any Award, or any part thereof, that has not been exercised within the term of the Award and the Shares covered thereby not paid for in accordance with this Plan and the Award Agreement shall terminate and become null and void, and all interests and rights of the Grantee in and to the same shall expire.

 

6.6. Termination.

 

6.6.1. Unless otherwise determined by the Committee, and subject to Section 6.7 hereof, an Award may not be exercised unless the Grantee is then a Service Provider of the Corporation or an Affiliate thereof or, in the case of an Incentive Stock Option, an employee of a company or a parent or subsidiary company of such company issuing or assuming the Option in a transaction to which Section 424(a) of the Code applies, and unless the Grantee has remained continuously so employed since the date of grant of the Award and throughout the vesting dates.

 

6.6.2. In the event that the employment or service of a Grantee shall terminate (other than by reason of death, Disability or Retirement), all Awards of such Grantee that are unvested at the time of such termination shall terminate on the date of such termination, and all Awards of such Grantee that are vested and exercisable at the time of such termination may be exercised within up to three (3) years after the date of such termination (or such different period as the Committee shall prescribe), but in any event no later than the date of expiration of the Award’s term as set forth in the Award Agreement or pursuant to this Plan; provided, however, that if the Corporation (or the Subsidiary or Affiliate, when applicable) shall terminate the Grantee’s employment or service for Cause (as defined below) (whether occurring prior to or after termination of employment or service), all Awards theretofore granted to such Grantee (whether vested or not) shall terminate, unless otherwise determined by the Committee, and any Shares issued upon exercise or (if applicable) vesting of Awards (including other Shares or securities issued or distributed with respect thereto), whether held by the Grantee or by the Trustee for the Grantee’s benefit, shall be deemed to be irrevocably offered for sale to the Corporation, any of its Affiliates or any person designated by the Corporation to purchase, at the Corporation’s election and subject to Applicable Law, either for no consideration, for the par value of such Shares (if shares bear a par value) or against payment of the Exercise Price previously received by the Corporation for such Shares upon their issuance, as the Committee deems fit, upon written notice to the Grantee at any time prior to, at or after the Grantee’s termination of employment or service. Such Shares or other securities shall be sold and transferred within 30 days from the date of the Corporation’s notice of its election to exercise its right. If the Grantee fails to transfer such Shares or other securities to the Corporation, the Corporation, at the decision of the Committee, shall be entitled to forfeit or repurchase such Shares and to authorize any person to execute on behalf of the Grantee any document necessary to effect such transfer, whether or not the share certificates are surrendered. The Corporation shall have the right and authority to affect the above either by: (i) repurchasing all of such Shares or other securities held by the Grantee or by the Trustee for the benefit of the Grantee, or designate the purchaser of all or any part of such Shares or other securities, for the Exercise Price paid for such Shares, the par value of such Shares (if shares bear a par value) or for no payment or consideration whatsoever, as the Committee deems fit; (ii) forfeiting all or any party of such Shares or other securities; (iii) redeeming all or any party of such Shares or other securities, for the Exercise Price paid for such Shares, the par value of such Shares (if shares bear a par value) or for no payment or consideration whatsoever, as the Committee deems fit; (iv) taking action in order to have all or any party of such Shares or other securities converted into deferred shares entitling their holder only to their par value (if shares bear a par value) upon liquidation of the Corporation; or (v) taking any other action which may be required in order to achieve similar results; all as shall be determined by the Committee, at its sole and absolute discretion, and the Grantee is deemed to irrevocably empower the Corporation or any person which may be designated by it to take any action by, in the name of or on behalf of the Grantee to comply with and give effect to such actions (including, voting such shares, filling in, signing and delivering share transfer deeds, etc.).

 

 
11

 

6.6.3. Notwithstanding anything to the contrary, the Committee, in its absolute discretion, may, on such terms and conditions as it may determine appropriate, extend the periods for which Awards held by any Grantee may continue to vest and be exercisable; it being clarified that such Awards may lose their entitlement to certain tax benefits under Applicable Law (including, without limitation, qualification of an Award as an Incentive Stock Option) as a result of the modification of such Awards and/or in the event that the Award is exercised beyond the later of: (i) three (3) months after the date of termination of the employment or service relationship; or (ii) the applicable period under Section 6.7 below with respect to a termination of the employment or service relationship because of the death, Disability or Retirement of Grantee.

 

6.6.4. For purposes of this Plan:

 

6.6.4.1. A termination of employment or service of a Grantee shall not be deemed to occur (except to the extent required by the Code with respect to the Incentive Stock Option status of an Option) in case of (i) a transition or transfer of a Grantee among the Corporation and its Affiliates, (ii) a change in the capacity in which the Grantee is employed or renders service to the Corporation or any of its Affiliates or a change in the identity of the employing or engagement entity among the Corporation and its Affiliates, provided, in case of the foregoing clauses (i) and (ii) above, that the Grantee has remained continuously employed by and/or in the service of the Corporation and its Affiliates since the date of grant of the Award and throughout the vesting period; or (iii) if the Grantee takes any unpaid leave as set forth in Section 6.8.

 

6.6.4.2. An entity or an Affiliate thereof assuming an Award or issuing in substitution thereof in a transaction to which Section 424(a) of the Code applies or in a Merger/Sale in accordance with Section 14 shall be deemed as an Affiliate of the Corporation for purposes of this Section 6.6, unless the Committee determines otherwise.

 

6.6.4.3. In the case of a Grantee whose principal employer or service recipient is a Subsidiary or Affiliate, the Grantee’s employment shall also be deemed terminated for purposes of this Section 6.6 as of the date on which such principal employer or service recipient ceases to be a Subsidiary or Affiliate.

 

6.6.4.4. The term “Cause” shall mean (irrespective of, and in addition to, any definition included in any other agreement or instrument applicable to the Grantee, and unless otherwise determined by the Committee) any of the following: (i) any theft, fraud, embezzlement, dishonesty, willful misconduct, breach of fiduciary duty for personal profit, falsification of any documents or records of the Corporation or any of its Affiliates, felony or similar act by the Grantee (whether or not related to the Grantee’s relationship with the Corporation); (ii) an act of moral turpitude by the Grantee, or any act that causes significant injury to, or is otherwise adversely affecting, the reputation, business, assets, operations or business relationship of the Corporation (or a Subsidiary or Affiliate, when applicable); (iii) any breach by the Grantee of any material agreement with or of any material duty of the Grantee to the Corporation or any Subsidiary or Affiliate thereof (including breach of confidentiality, non-disclosure, non-use, non-competition or non-solicitation covenants towards the Corporation or any of its Affiliates) or failure to abide by code of conduct or other policies (including, without limitation, policies relating to confidentiality and reasonable workplace conduct); (iv) any act which constitutes a breach of a Grantee’s fiduciary duty towards the Corporation or an Affiliate or Subsidiary, including disclosure of confidential or proprietary information thereof or acceptance or solicitation to receive unauthorized or undisclosed benefits, irrespective of their nature, or funds, or promises to receive either, from individuals, consultants or corporate entities that the Corporation or a Subsidiary does business with; (v) the Grantee’s unauthorized use, misappropriation, destruction, or diversion of any tangible or intangible asset or corporate opportunity of the Corporation or any of its Affiliates (including, without limitation, the improper use or disclosure of confidential or proprietary information); or (vi) any circumstances that constitute grounds for termination for cause under the Grantee’s employment or service agreement with the Corporation or Affiliate, to the extent applicable. For the avoidance of doubt, the determination as to whether a termination is for Cause for purposes of this Plan, shall be made in good faith by the Committee and shall be final and binding on the Grantee.

 

 
12

 

6.7. Death, Disability or Retirement of Grantee.

 

6.7.1. If a Grantee shall die while employed by, or performing service for, the Corporation or its Affiliates, or within the three (3) years period (or such longer period of time as determined by the Board, in its discretion) after the date of termination of such Grantee’s employment or service (or within such different period as the Committee may have provided pursuant to Section 6.6 hereof), or if the Grantee’s employment or service shall terminate by reason of Disability, all Awards theretofore granted to such Grantee may (to the extent otherwise vested and exercisable and unless earlier terminated in accordance with their terms) be exercised by the Grantee or by the Grantee’s estate or by a person who acquired the legal right to exercise such Awards by bequest or inheritance, or by a person who acquired the legal right to exercise such Awards in accordance with applicable law in the case of Disability of the Grantee, as the case may be, at any time within three (3) years (or such longer period of time as determined by the Committee, in its discretion) after the death or Disability of the Grantee (or such different period as the Committee shall prescribe), but in any event no later than the date of expiration of the Award’s term as set forth in the Award Agreement or pursuant to this Plan. In the event that an Award granted hereunder shall be exercised as set forth above by any person other than the Grantee, written notice of such exercise shall be accompanied by a certified copy of letters testamentary or proof satisfactory to the Committee of the right of such person to exercise such Award.

 

6.7.2. In the event that the employment or service of a Grantee shall terminate on account of such Grantee’s Retirement, all Awards of such Grantee that are exercisable at the time of such Retirement may, unless earlier terminated in accordance with their terms, be exercised at any time within the three (3) years period after the date of such Retirement (or such different period as the Committee shall prescribe).

 

6.8. Suspension of Vesting. Unless the Committee provides otherwise, vesting of Awards granted hereunder shall be suspended during any unpaid leave of absence, other than in the case of any (i) leave of absence which was pre-approved by the Corporation explicitly for purposes of continuing the vesting of Awards, or (ii) transfers between locations of the Corporation or any of its Affiliates, or between the Corporation and any of its Affiliates, or any respective successor thereof. For clarity, for purposes of this Plan, military leave, statutory maternity or paternity leave or sick leave are not deemed unpaid leave of absence, unless otherwise determined by the Committee.

 

6.9. Securities Law Restrictions. Except as otherwise provided in the applicable Award Agreement or other agreement between the Service Provider and the Corporation, if the exercise of an Award following the termination of the Service Provider’s employment or service (other than for Cause) would be prohibited at any time solely because the issuance of Shares would violate the registration requirements under the Securities Act or equivalent requirements under equivalent laws of other applicable jurisdictions, then the Award shall remain exercisable and terminate on the earlier of (i) the expiration of a period of three (3) months (or such longer period of time as determined by the Board, in its discretion) after the termination of the Service Provider’s employment or service during which the exercise of the Award would not be in such violation, or (ii) the expiration of the term of the Award as set forth in the Award Agreement or pursuant to this Plan. In addition, unless otherwise provided in a Grantee’s Award Agreement, if the sale of any Shares received upon exercise or (if applicable) vesting of an Award following the termination of the Grantee’s employment or service (other than for Cause) would violate the Corporation’s insider trading policy, then the Award shall terminate on the earlier of (i) the expiration of a period equal to the applicable post-termination exercise period after the termination of the Grantee’s employment or service during which the exercise of the Award would not be in violation of the Corporation’s insider trading policy, or (ii) the expiration of the term of the Award as set forth in the applicable Award Agreement or pursuant to this Plan.

 

 
13

 

6.10. Other Provisions. The Award Agreement evidencing Awards under this Plan shall contain such other terms and conditions not inconsistent with this Plan as the Committee may determine, at or after the date of grant, including provisions in connection with the restrictions on transferring the Awards or Shares covered by such Awards, which shall be binding upon the Grantees and any purchaser, assignee or transferee of any Awards, and other terms and conditions as the Committee shall deem appropriate.

 

7.NONQUALIFIED STOCK OPTIONS.

 

Awards granted pursuant to this Section 7 are intended to constitute Nonqualified Stock Options and shall be subject to the general terms and conditions specified in Section 6 hereof and other provisions of this Plan, except for any provisions of this Plan applying to Awards under different tax laws or regulations. In the event of any inconsistency or contradictions between the provisions of this Section 7 and the other terms of this Plan, this Section 7 shall prevail. However, if for any reason the Awards granted pursuant to this Section 7 (or portion thereof) does not qualify as an Incentive Stock Option, then, to the extent of such non- qualification, such Option (or portion thereof) shall be regarded as a Nonqualified Stock Option granted under this Plan. In no event will the Board, the Corporation or any Parent or Subsidiary or any of their respective employees or directors have any liability to Participant (or any other person) due to the failure of the Option to qualify for any reason as an Incentive Stock Option.

 

7.1. Certain Limitations on Eligibility for Nonqualified Stock Options. Nonqualified Stock Options may not be granted to a Service Provider who is deemed to be a resident of the United States for purposes of taxation or who is otherwise subject to United States federal income tax unless the Shares underlying such Options constitute “service recipient stock” under Section 409A of the Code or unless such Options comply with the payment requirements of Section 409A of the Code.

 

7.2. Exercise Price. The Exercise Price of a Nonqualified Stock Option shall not be less than 100% of the Fair Market Value of a Share on the date of grant of such Option unless the Committee specifically indicates that the Awards will have a lower Exercise Price and the Award complies with Section 409A of the Code. Notwithstanding the foregoing, a Nonqualified Stock Option may be granted with an exercise price lower than the minimum exercise price set forth above if such Award is granted pursuant to an assumption or substitution for another option in a manner qualifying under the provisions of that complies with Section 424(a) of the Code or 1.409A-1(b)(5)(v)(D) of the U.S. Treasury Regulations or any successor guidance.

 

8.INCENTIVE STOCK OPTIONS.

 

Awards granted pursuant to this Section 8 are intended to constitute Incentive Stock Options and shall be granted subject to the following special terms and conditions, the general terms and conditions specified in Section 6 hereof and other provisions of this Plan, except for any provisions of this Plan applying to Awards under different tax laws or regulations. In the event of any inconsistency or contradictions between the provisions of this Section 8 and the other terms of this Plan, this Section 8 shall prevail.

 

8.1. Eligibility for Incentive Stock Options. Incentive Stock Options may be granted only to Employees of the Corporation, or to Employees of a Parent or Subsidiary, determined as of the date of grant of such Options. An Incentive Stock Option granted to a prospective Employee upon the condition that such person become an Employee shall be deemed granted effective on the date such person commences employment, with an exercise price determined as of such date in accordance with Section 8.2.

 

 
14

 

8.2. Exercise Price. The Exercise Price of an Incentive Stock Option shall not be less than one hundred percent (100%) of the Fair Market Value of the Shares covered by the Awards on the date of grant of such Option or such other price as may be determined pursuant to the Code. Notwithstanding the foregoing, an Incentive Stock Option may be granted with an exercise price lower than the minimum exercise price set forth above if such Award is granted pursuant to an assumption or substitution for another option in a manner that complies with the provisions of Section 424(a) of the Code.

 

8.3. Date of Grant. Notwithstanding any other provision of this Plan to the contrary, no Incentive Stock Option may be granted under this Plan after 10 years from the date this Plan is adopted, or the date this Plan is approved by the shareholders, whichever is earlier.

 

8.4. Exercise Period. No Incentive Stock Option shall be exercisable after the expiration of ten (10) years after the effective date of grant of such Award, subject to Section 8.6. No Incentive Stock Option granted to a prospective Employee may become exercisable prior to the date on which such person commences employment.

 

8.5. $100,000 Per Year Limitation. The aggregate Fair Market Value (determined as of the date the Incentive Stock Option is granted) of the Shares with respect to which all Incentive Stock Options granted under this Plan and all other “incentive stock option” plans of the Corporation, or of any Parent or Subsidiary, become exercisable for the first time by each Grantee during any calendar year shall not exceed one hundred thousand United States dollars ($100,000) with respect to such Grantee. To the extent that the aggregate Fair Market Value of Shares with respect to which such Incentive Stock Options and any other such incentive stock options are exercisable for the first time by any Grantee during any calendar year exceeds one hundred thousand United States dollars ($100,000), such options shall be treated as Nonqualified Stock Options. The foregoing shall be applied by taking options into account in the order in which they were granted. If the Code is amended to provide for a different limitation from that set forth in this Section 8.5, such different limitation shall be deemed incorporated herein effective as of the date and with respect to such Awards as required or permitted by such amendment to the Code. If an Option is treated as an Incentive Stock Option in part and as a Nonqualified Stock Option in part by reason of the limitation set forth in this Section 8.5, the Grantee may designate which portion of such Option the Grantee is exercising. In the absence of such designation, the Grantee shall be deemed to have exercised the Incentive Stock Option portion of the Option first. Separate certificates representing each such portion may be issued upon the exercise of the Option.

 

8.6. Ten Percent Shareholder. In the case of an Incentive Stock Option granted to a Ten Percent Shareholder, notwithstanding the foregoing provisions of this Section 8.6, (i) the Exercise Price shall not be less than one hundred and ten percent (110%) of the Fair Market Value of a Share on the date of grant of such Incentive Stock Option, and (ii) the Exercise Period shall not exceed five (5) years from the effective date of grant of such Incentive Stock Option.

 

8.7. Payment of Exercise Price. Each Award Agreement evidencing an Incentive Stock Option shall state each alternative method by which the Exercise Price thereof may be paid.

 

8.8. Leave of Absence. Notwithstanding Section 6.8, a Grantee’s employment shall not be deemed to have terminated if the Grantee takes any leave as set forth in Section 6.8(i); provided, however, that if any such leave exceeds three (3) months, on the day that is three (3) months following the commencement of such leave any Incentive Stock Option held by the Grantee shall cease to be treated as an Incentive Stock Option and instead shall be treated thereafter as a Nonqualified Stock Option, unless the Grantee’s right to return to employment is guaranteed by statute or contract.

 

8.9. Exercise Following Termination for Disability. Notwithstanding anything else in this Plan to the contrary, Incentive Stock Options that are not exercised within three (3) months following termination of the Grantee’s employment with the Corporation or its Parent or Subsidiary or a corporation or a Parent or Subsidiary of such corporation issuing or assuming an Option in a transaction to which Section 424(a) of the Code applies, or within one year in case of termination of the Grantee’s employment with the Corporation or its Parent or Subsidiary due to a Disability (within the meaning of Section 22(e)(3) of the Code), shall be deemed to be Nonqualified Stock Options.

 

 
15

 

8.10. Adjustments to Incentive Stock Options. Any Awards Agreement providing for the grant of Incentive Stock Options shall indicate that adjustments made pursuant to this Plan with respect to Incentive Stock Options could constitute a “modification” of such Incentive Stock Options (as that term is defined in Section 424(h) of the Code) or could cause adverse tax consequences for the holder of such Incentive Stock Options and that the holder should consult with his or her tax advisor regarding the consequences of such “modification” on his or her income tax treatment with respect to the Incentive Stock Option.

 

8.11. Notice to Corporation of Disqualifying Disposition. Each Grantee who receives an Incentive Stock Option must agree to notify the Corporation in writing immediately after the Grantee makes a Disqualifying Disposition of any Shares received pursuant to the exercise of Incentive Stock Options. A “Disqualifying Disposition” is any disposition (including any sale) of such Shares before the later of (i) two years after the date the Grantee was granted the Incentive Stock Option, or (ii) one year after the date the Grantee acquired Shares by exercising the Incentive Stock Option. If the Grantee dies before such Shares are sold, these holding period requirements do not apply and no disposition of the Shares will be deemed a Disqualifying Disposition.

 

9.102 AWARDS.

 

Awards granted pursuant to this Section 9 are intended to constitute 102 Awards and shall be granted subject to the following special terms and conditions, the general terms and conditions specified in Section 6 hereof and other provisions of this Plan, except for any provisions of this Plan applying to Awards under different tax laws or regulations. In the event of any inconsistency or contradictions between the provisions of this Section 9 and the other terms of this Plan, this Section 9 shall prevail.

 

9.1. Tracks. Awards granted pursuant to this Section 9 are intended to be granted pursuant to Section 102 of the Ordinance pursuant to either (i) Section 102(b)(2) or (3) thereof (as applicable), under the capital gain track (“102 Capital Gain Track Awards”), or (ii) Section 102(b)(1) thereof under the ordinary income track (“102 Ordinary Income Track Awards”, and together with 102 Capital Gain Track Awards, “102 Trustee Awards”). 102 Trustee Awards shall be granted subject to the special terms and conditions contained in this Section 9, the general terms and conditions specified in Section 6 hereof and other provisions of this Plan, except for any provisions of this Plan applying to Options under different tax laws or regulations.

 

9.2. Election of Track. Subject to Applicable Law, the Corporation may grant only one type of 102 Trustee Awards at any given time to all Grantees who are to be granted 102 Trustee Awards pursuant to this Plan, and shall file an election with the ITA regarding the type of 102 Trustee Awards it elects to grant before the date of grant of any 102 Trustee Awards (the “Election”). Such Election shall also apply to any other securities, including bonus shares, received by any Grantee as a result of holding the 102 Trustee Awards. The Corporation may change the type of 102 Trustee Awards that it elects to grant only after the expiration of at least 12 months from the end of the year in which the first grant was made in accordance with the previous Election, or as otherwise provided by Applicable Law. Any Election shall not prevent the Corporation from granting Awards, pursuant to Section 102(c) of the Ordinance without a Trustee (“102 Non-Trustee Awards”).

 

9.3. Eligibility for Awards.

 

9.3.1. Subject to Applicable Law, 102 Awards may only be granted to an “employee” within the meaning of Section 102(a) of the Ordinance (which as of the date of the adoption of this Plan means (i) individuals employed by an Israeli company being the Corporation or any of its Affiliates, and (ii) individuals who are serving and are engaged personally (and not through an entity) as “office holders” by such an Israeli company), but may not be granted to a Controlling Shareholder (“Eligible 102 Grantees”). Eligible 102 Grantees may receive only 102 Awards, which may either be granted to a Trustee or granted under Section 102 of the Ordinance without a Trustee.

 

 
16

 

9.4. 102 Award Grant Date.

 

9.4.1. Each 102 Award will be deemed granted on the date determined by the Committee, subject to Section 9.4.2, provided that (i) the Grantee has signed all documents required by the Corporation or pursuant to Applicable Law, and (ii) with respect to 102 Trustee Award, the Corporation has provided all applicable documents to the Trustee in accordance with the guidelines published by the ITA, and if an agreement is not signed and delivered by the Grantee within 90 days from the date determined by the Committee (subject to Section 9.4.2), then such 102 Trustee Award shall be deemed granted on such later date as such agreement is signed and delivered and on which the Corporation has provided all applicable documents to the Trustee in accordance with the guidelines published by the ITA. In the case of any contradiction, this provision and the date of grant determined pursuant hereto shall supersede and be deemed to amend any date of grant indicated in any corporate resolution or Award Agreement.

 

9.4.2. Unless otherwise permitted by the Ordinance, any grants of 102 Trustee Awards that are made on or after the date of the adoption of this Plan or an amendment to this Plan, as the case may be, that may become effective only at the expiration of thirty (30) days after the filing of this Plan or any amendment thereof (as the case may be) with the ITA in accordance with the Ordinance shall be conditional upon the expiration of such 30-day period, such condition shall be read and is incorporated by reference into any corporate resolutions approving such grants and into any Award Agreement evidencing such grants (whether or not explicitly referring to such condition), and the date of grant shall be at the expiration of such 30-day period, whether or not the date of grant indicated therein corresponds with this Section. In the case of any contradiction, this provision and the date of grant determined pursuant hereto shall supersede and be deemed to amend any date of grant indicated in any corporate resolution or Award Agreement.

 

9.5. 102 Trustee Awards.

 

9.5.1. Each 102 Trustee Award, each Share issued pursuant to the exercise of any 102 Trustee Award, and any rights granted thereunder, including bonus shares, shall be issued to and registered in the name of the Trustee and shall be held in trust for the benefit of the Grantee for the requisite period prescribed by the Ordinance (the “Required Holding Period”). In the event that the requirements under Section 102 of the Ordinance to qualify an Award as a 102 Trustee Award are not met, then the Award may be treated as a 102 Non-Trustee Award or 3(i) Award, all in accordance with the provisions of the Ordinance. After expiration of the Required Holding Period, the Trustee may release such 102 Trustee Awards and any such Shares, provided that (i) the Trustee has received an acknowledgment from the ITA that the Grantee has paid any applicable taxes due pursuant to the Ordinance, or (ii) the Trustee and/or the Corporation and/or the Employer withholds all applicable taxes and compulsory payments due pursuant to the Ordinance arising from the 102 Trustee Awards and/or any Shares issued upon exercise or (if applicable) vesting of such 102 Trustee Awards. The Trustee shall not release any 102 Trustee Awards or Shares issued upon exercise or (if applicable) vesting thereof prior to the payment in full of the Grantee’s tax and compulsory payments arising from such 102 Trustee Awards and/or Shares or the withholding referred to in (ii) above.

 

9.5.2. Each 102 Trustee Award shall be subject to the relevant terms of the Ordinance, the Rules and any determinations, rulings or approvals issued by the ITA, which shall be deemed an integral part of the 102 Trustee Awards and shall prevail over any term contained in this Plan or Award Agreement that is not consistent therewith. Any provision of the Ordinance, the Rules and any determinations, rulings or approvals by the ITA not expressly specified in this Plan or Award Agreement that are necessary to receive or maintain any tax benefit pursuant to Section 102 of the Ordinance shall be binding on the Grantee. Any Grantee granted a 102 Trustee Awards shall comply with the Ordinance and the terms and conditions of the trust agreement entered into between the Corporation and the Trustee. The Grantee shall execute any and all documents that the Corporation and/or its Affiliates and/or the Trustee determine from time to time to be necessary in order to comply with the Ordinance and the Rules.

 

 
17

 

9.5.3. During the Required Holding Period, the Grantee shall not release from trust or sell, assign, transfer or give as collateral, the Shares issuable upon the exercise or (if applicable) vesting of a 102 Trustee Awards and/or any securities issued or distributed with respect thereto, until the expiration of the Required Holding Period. Notwithstanding the above, if any such sale, release or other action occurs during the Required Holding Period it may result in adverse tax consequences to the Grantee under Section 102 of the Ordinance and the Rules, which shall apply to and shall be borne solely by such Grantee. Subject to the foregoing, the Trustee may, pursuant to a written request from the Grantee, but subject to the terms of this Plan, release and transfer such Shares to a designated third party, provided that both of the following conditions have been fulfilled prior to such release or transfer: (i) payment has been made to the ITA of all taxes and compulsory payments required to be paid upon the release and transfer of the Shares, and confirmation of such payment has been received by the Trustee and the Corporation, and (ii) the Trustee has received written confirmation from the Corporation that all requirements for such release and transfer have been fulfilled according to the terms of the Corporation’s corporate documents, any agreement governing the Shares, this Plan, the Award Agreement and any Applicable Law.

 

9.5.4. If a 102 Trustee Award is exercised or (if applicable) vested, the Shares issued upon such exercise or (if applicable) vesting shall be issued in the name of the Trustee for the benefit of the Grantee.

 

9.5.5. Upon or after receipt of a 102 Trustee Award, if required, the Grantee may be required to sign an undertaking to release the Trustee from any liability with respect to any action or decision duly taken and executed in good faith by the Trustee in relation to this Plan, or any 102 Trustee Awards or Share granted to such Grantee thereunder.

 

9.6. 102 Non-Trustee Awards. The foregoing provisions of this Section 9 relating to 102 Trustee Awards shall not apply with respect to 102 Non-Trustee Awards, which shall, however, be subject to the relevant provisions of Section 102 of the Ordinance and the applicable Rules. The Committee may determine that 102 Non-Trustee Awards, the Shares issuable upon the exercise or (if applicable) vesting of a 102 Non-Trustee Awards and/or any securities issued or distributed with respect thereto, shall be allocated or issued to the Trustee, who shall hold such 102 Non-Trustee Awards and all accrued rights thereon (if any), in trust for the benefit of the Grantee and/or the Corporation, as the case may be, until the full payment of tax arising from the 102 Non-Trustee Awards, the Shares issuable upon the exercise or (if applicable) vesting of a 102 Non-Trustee Awards and/or any securities issued or distributed with respect thereto. The Corporation may choose, alternatively, to force the Grantee to provide it with a guarantee or other security, to the satisfaction of each of the Trustee and the Corporation, until the full payment of the applicable taxes.

 

9.7. Written Grantee Undertaking. To the extent and with respect to any 102 Trustee Award, and as required by Section 102 of the Ordinance and the Rules, by virtue of the receipt of such Award, the Grantee is deemed to have provided, undertaken and confirm the following written undertaking (and such undertaking is deemed incorporated into any documents signed by the Grantee in connection with the employment or service of the Grantee and/or the grant of such Award), and which undertaking shall be deemed to apply and relate to all 102 Trustee Awards granted to the Grantee, whether under this Plan or other plans maintained by the Corporation, and whether prior to or after the date hereof.

 

9.7.1. The Grantee shall comply with all terms and conditions set forth in Section 102 of the Ordinance with regard to the “Capital Gain Track” or the “Ordinary Income Track”, as applicable, and the applicable rules and regulations promulgated thereunder, as amended from time to time;

 

9.7.2. The Grantee is familiar with, and understands the provisions of, Section 102 of the Ordinance in general, and the tax arrangement under the “Capital Gain Track” or the “Ordinary Income Track” in particular, and its tax consequences; the Grantee agrees that the 102 Trustee Awards and Shares that may be issued upon exercise or (if applicable) vesting of the 102 Trustee Awards (or otherwise in relation to the 102 Trustee Awards), will be held by the Trustee appointed pursuant to Section 102 of the Ordinance for at least the duration of the “Holding Period” (as such term is defined in Section 102) under the “Capital Gain Track” or the “Ordinary Income Track”, as applicable. The Grantee understands that any release of such 102 Trustee Awards or Shares from trust, or any sale of the Share prior to the termination of the Holding Period, as defined above, will result in taxation at marginal tax rate, in addition to deductions of appropriate social security, health tax contributions or other compulsory payments; and

 

9.7.3. The Grantee agrees to the trust agreement signed between the Corporation, the Employer and the Trustee appointed pursuant to Section 102 of the Ordinance.

 

 
18

 

10.3(i) AWARDS.

 

Awards granted pursuant to this Section 10 are intended to constitute 3(i) Awards and shall be granted subject to the general terms and conditions specified in Section 6 hereof and other provisions of this Plan, except for any provisions of this Plan applying to Awards under different tax laws or regulations. In the event of any inconsistency or contradictions between the provisions of this Section 10 and the other terms of this Plan, this Section 10 shall prevail.

 

10.1. To the extent required by the Ordinance or the ITA or otherwise deemed by the Committee to be advisable, the 3(i) Awards and/or any shares or other securities issued or distributed with respect thereto granted pursuant to this Plan shall be issued to a Trustee nominated by the Committee in accordance with the provisions of the Ordinance or the terms of a trust agreement, as applicable. In such event, the Trustee shall hold such Awards and/or other securities issued or distributed with respect thereto in trust, until exercised or (if applicable) vested by the Grantee and the full payment of tax arising therefrom, pursuant to the Corporation’s instructions from time to time as set forth in a trust agreement, which will have been entered into between the Corporation and the Trustee. If determined by the Board or the Committee, and subject to such trust agreement, the Trustee will also hold the shares issuable upon exercise or (if applicable) vesting of the 3(i) Awards, as long as they are held by the Grantee. If determined by the Board or the Committee, and subject to such trust agreement, the Trustee shall be responsible for withholding any taxes to which a Grantee may become liable upon issuance of Shares, whether due to the exercise or (if applicable) vesting of Awards.

 

10.2. Shares pursuant to a 3(i) Award shall not be issued, unless the Grantee delivers to the Corporation payment in cash or by bank check or such other form acceptable to the Committee of all withholding taxes due, if any, on account of the Grantee acquired Shares under the Award or gives other assurance satisfactory to the Committee of the payment of those withholding taxes.

 

11.RESTRICTED SHARES.

 

The Committee may award Restricted Shares to any eligible Grantee, including under Section 102 of the Ordinance. Each Award of Restricted Shares under this Plan shall be evidenced by a written agreement between the Corporation and the Grantee (the “Restricted Share Agreement”), in such form as the Committee shall from time to time approve. The Restricted Shares shall be subject to all applicable terms of this Plan, which in the case of Restricted Shares granted under Section 102 of the Ordinance shall include Section 9 hereof, and may be subject to any other terms that are not inconsistent with this Plan. The provisions of the various Restricted Shares Agreements entered into under this Plan need not be identical. The Restricted Share Agreement shall comply with and be subject to Section 6 and the following terms and conditions, unless otherwise specifically provided in such Agreement and not inconsistent with this Plan, or Applicable Law:

 

11.1. Purchase Price. Section 6.4 shall not apply. Each Restricted Share Agreement shall state an amount of Exercise Price to be paid by the Grantee, if any, in consideration for the issuance of the Restricted Shares and the terms of payment thereof, which may include payment in cash or, subject to the Committee’s approval, by issuance of promissory notes or other evidence of indebtedness on such terms and conditions as determined by the Committee.

 

11.2. Restrictions. Restricted Shares may not be sold, assigned, transferred, pledged, hypothecated or otherwise disposed of, except by will or the laws of descent and distribution (in which case they shall be transferred subject to all restrictions then or thereafter applicable thereto), until such Restricted Shares shall have vested (the period from the date on which the Award is granted until the date of vesting of the Restricted Share thereunder being referred to herein as the “Restricted Period”). The Committee may also impose such additional or alternative restrictions and conditions on the Restricted Shares, as it deems appropriate, including the satisfaction of performance criteria (which, in case of 102 Trustee Awards, may be subject to obtaining a specific tax ruling or determination from the ITA). Such performance criteria may include, but are not limited to, sales, earnings before interest and taxes, return on investment, earnings per share, any combination of the foregoing or rate of growth of any of the foregoing, as determined by the Committee or pursuant to the provisions of any Corporation policy required under mandatory provisions of Applicable Law. Certificates for shares issued pursuant to Restricted Share Awards, if issued, shall bear an appropriate legend referring to such restrictions, and any attempt to dispose of any such shares in contravention of such restrictions shall be null and void and without effect. Such certificates may, if so determined by the Committee, be held in escrow by an escrow agent appointed by the Committee, or, if a Restricted Share Award is made pursuant to Section 102 of the Ordinance, by the Trustee. In determining the Restricted Period of an Award the Committee may provide that the foregoing restrictions shall lapse with respect to specified percentages of the awarded Restricted Shares on successive anniversaries of the date of such Award. To the extent required by the Ordinance or the ITA, the Restricted Shares issued pursuant to Section 102 of the Ordinance shall be issued to the Trustee in accordance with the provisions of the Ordinance and the Restricted Shares shall be held for the benefit of the Grantee for at least the Required Holding Period.

 

 
19

 

11.3. Forfeiture; Repurchase. Subject to such exceptions as may be determined by the Committee, if the Grantee’s continuous employment with or service to the Corporation or any Affiliate thereof shall terminate for any reason prior to the expiration of the Restricted Period of an Award or prior to the timely payment in full of the Exercise Price of any Restricted Shares, any Shares remaining subject to vesting or with respect to which the purchase price has not been paid in full, shall thereupon be forfeited, transferred to, and redeemed, repurchased or cancelled by, as the case may be, in any manner as set forth in Section 6.6.2(i) through (v), subject to Applicable Law and the Grantee shall have no further rights with respect to such Restricted Shares.

 

11.4. Ownership. During the Restricted Period the Grantee shall possess all incidents of ownership of such Restricted Shares, subject to Section Error! Reference source not found. and Section 11.2, including the right to vote and receive dividends with respect to such Shares. All securities, if any, received by a Grantee with respect to Restricted Shares as a result of any stock split, stock dividend, combination of shares, or other similar transaction shall be subject to the restrictions applicable to the original Award.

 

12.RESTRICTED SHARE UNITS.

 

An RSU is an Award covering a number of Shares that is settled, if vested and (if applicable) exercised, by issuance of those Shares. An RSU may be awarded to any eligible Grantee, including under Section 102 of the Ordinance. The Award Agreement relating to the grant of RSUs under this Plan (the “Restricted Share Unit Agreement”), shall be in such form as the Committee shall from time to time approve. The RSUs shall be subject to all applicable terms of this Plan, which in the case of RSUs granted under Section 102 of the Ordinance shall include Section 9 hereof, and may be subject to any other terms that are not inconsistent with this Plan. The provisions of the various Restricted Share Unit Agreements entered into under this Plan need not be identical. RSUs may be granted in consideration of a reduction in the recipient’s other compensation.

 

12.1. Exercise Price. No payment of Exercise Price shall be required as consideration for RSUs, unless included in the Award Agreement or as required by Applicable Law, and Section 6.4 shall apply, if applicable.

 

12.2. Shareholders’ Rights. The Grantee shall not possess or own any ownership rights in the Shares underlying the RSUs and no rights as a shareholder shall exist prior to the actual issuance of Shares in the name of the Grantee.

 

12.3. Settlements of Awards. Settlement of vested RSUs shall be made in the form of Shares or cash (in case of 102 Trustee Awards, the settlement shall be made in the form of shares only). Distribution to a Grantee of an amount (or amounts) from settlement of vested RSUs can be deferred to a date after settlement as determined by the Committee. The amount of a deferred distribution may be increased by an interest factor or by dividend equivalents. Until the grant of RSUs is settled, the number of Shares underlying such RSUs shall be subject to adjustment pursuant hereto.

 

 
20

 

12.4. Section 409A Restrictions. Notwithstanding anything to the contrary set forth herein, any RSUs granted under this Plan that are not exempt from the requirements of Section 409A of the Code shall contain such restrictions or other provisions so that such RSUs will comply with the requirements of Section 409A of the Code, if applicable to the Corporation. Such restrictions, if any, shall be determined by the Committee and contained in the Restricted Share Unit Agreement evidencing such RSU. For example, such restrictions may include a requirement that any Shares that are to be issued in a year following the year in which the RSU vests must be issued in accordance with a fixed, pre-determined schedule.

 

13.OTHER SHARE OR SHARE-BASED AWARDS.

 

13.1. The Committee may grant other Awards under this Plan pursuant to which Shares (which may, but need not, be Restricted Shares pursuant to Section 11 hereof), cash (in settlement of Share-based Awards) or a combination thereof, are or may in the future be acquired or received, or Awards denominated in stock units, including units valued on the basis of measures other than market value.

 

13.2. The Committee may also grant stock appreciation rights without the grant of an accompanying option, which rights shall permit the Grantees to receive, at the time of any exercise of such rights, cash equal to the amount by which the Fair Market Value of the Shares in respect to which the right was granted is so exercised exceeds the exercise price thereof. The exercise price of any such stock appreciation right granted to a Grantee who is subject to U.S. federal income tax shall be determined in compliance with Section 7.2.

 

13.3. Such other Share-based Awards as set forth above may be granted alone, in addition to, or in tandem with any Award of any type granted under this Plan (without any obligation or assurance that that such Share-based Awards will be entitled to tax benefits under Applicable Law or to the same tax treatment as other Awards under this Plan).

 

14.EFFECT OF CERTAIN CHANGES.

 

14.1. General.

 

14.1.1. In the event of a division or subdivision of the outstanding share capital of the Corporation, any distribution of bonus shares (stock split), consolidation or combination of share capital of the Corporation (reverse stock split), reclassification with respect to the Shares or any similar recapitalization events (each, a “Recapitalization”), a merger (including, a reverse merger and a reverse triangular merger), consolidation, amalgamation or like transaction of the Corporation with or into another corporation, a reorganization (which may include a combination or exchange of shares, spin-off or other corporate divestiture or division, or other similar occurrences, the Committee shall have the authority to make, without the need for a consent of any holder of an Award, such adjustments as determined by the Committee to be appropriate, in its discretion, in order to adjust (i) the number and class of shares reserved and available for grants of Awards, (ii) the number and class of shares covered by outstanding Awards, (iii) the Exercise Price per share covered by any Award, (iv) the terms and conditions concerning vesting and exercisability and the term and duration of the outstanding Awards, (v) the type or class of security, asset or right underlying the Award (which need not be only that of the Corporation, and may be that of the surviving corporation or any affiliate thereof or such other entity party to any of the above transactions), and (vi) any other terms of the Award that in the opinion of the Committee should be adjusted. Any fractional shares resulting from such adjustment shall be treated as determined by the Committee, and in the absence of such determination shall be rounded to the nearest whole share, and the Corporation shall have no obligation to make any cash or other payment with respect to such fractional shares. No adjustment shall be made by reason of the distribution of subscription rights or rights offering to outstanding shares or other issuance of shares by the Corporation, unless the Committee determines otherwise. The adjustments determined pursuant to this Section 14.1 (including a determination that no adjustment is to be made) shall be final, binding and conclusive.

 

 
21

 

14.1.2. Notwithstanding anything to the contrary included herein, in the event of a distribution of cash dividend by the Corporation to all holders of Shares, the Committee shall have the authority to determine, without the need for a consent of any holder of an Award, that the Exercise Price of any Award, which is outstanding and unexercised on the record date of such distribution, shall be reduced by an amount equal to the per Share gross dividend amount distributed by the Corporation, and the Committee may determine that the Exercise Price following such reduction shall be not less than the par value of a Share. The application of this Section with respect to any 102 Awards shall be subject to obtaining a ruling from the ITA, to the extent required by applicable law and subject to the terms and conditions of any such ruling.

 

14.2. Merger/Sale of Corporation. In the event of (i) a sale of all or substantially all of the assets of the Corporation, or a sale (including an exchange) of all or substantially all of the shares of the Corporation, to any person, or a purchase by a shareholder of the Corporation or by an Affiliate of such shareholder, of all the shares of the Corporation held by all or substantially all other shareholders or by other shareholders who are not Affiliated with such acquiring party; (ii) a merger (including, a reverse merger and a reverse triangular merger), consolidation, amalgamation or like transaction of the Corporation with or into another corporation; (iii) a scheme of arrangement for the purpose of effecting such sale, merger, consolidation, amalgamation or other transaction; (iv) approval by the shareholders of the Corporation of a complete liquidation or dissolution of the Corporation, (v) Change in Board Event, or (vi) such other transaction or set of circumstances that is determined by the Board, in its discretion, to be a transaction subject to the provisions of this Section 14.2 excluding any of the foregoing transactions in clauses (i) through (iv) if the Board determines that such transaction should be excluded from the definition hereof and the applicability of this Section 14.2 (such transaction, a “Merger/Sale”), then, without derogating from the general authority and power of the Board or the Committee under this Plan, without the Grantee’s consent and action and without any prior notice requirement, the Committee may make any determination as to the treatment of Awards, in its sole and absolute discretion, as provided herein:

 

14.2.1. Unless otherwise determined by the Committee, any Award then outstanding shall be assumed or be substituted by the Corporation, or by the successor corporation in such Merger/Sale or by any parent or Affiliate thereof, as determined by the Committee in its discretion (the “Successor Corporation”), under terms as determined by the Committee or the terms of this Plan applied by the Successor Corporation to such assumed or substituted Awards.

 

For the purposes of this Section 14.2.1, the Award shall be considered assumed or substituted if, following a Merger/Sale, the Award confers on the holder thereof the right to purchase or receive, for each Share underlying an Award immediately prior to the Merger/Sale, either (i) the consideration (whether shares or other securities, cash or other property, or rights, or any combination thereof) distributed to or received by holders of Shares in the Merger/Sale for each Share held on the effective date of the Merger/Sale (and if holders were offered a choice or several types of consideration, the type of consideration as determined by the Committee, which need not be the same type for all Grantees), or (ii) regardless of the consideration received by the holders of Shares in the Merger/Sale, solely shares or any type of Awards (or their equivalent) of the Successor Corporation at a value to be determined by the Committee in its discretion, or a certain type of consideration (whether shares or other securities, cash or other property, or rights, or any combination thereof) as determined by the Committee. Any of the consideration referred to in the foregoing clauses (i) and (ii) shall be subject to the same vesting and expiration terms of the Awards applying immediately prior to the Merger/Sale, unless determined by the Committee, in its discretion, that the consideration shall be subject to different vesting and expiration terms, or other terms, and the Committee may determine that it be subject to other or additional terms. The foregoing shall not limit the Committee’s authority to determine that in lieu of such assumption or substitution of Awards for Awards of the Successor Corporation, such Award will be substituted for shares or other securities, cash or other property, or rights, or any combination thereof, including as set forth in Section 14.2.2 hereunder.

 

14.2.2. Regardless of whether or not Awards are assumed or substituted, the Committee may (but shall not be obligated to):

 

14.2.2.1. provide for the Grantee to have the right to exercise the Award in respect of Shares covered by the Award which would otherwise be exercisable or vested, under such terms and conditions as the Committee shall determine, and the cancellation of all unexercised Awards (whether vested or unvested) upon or immediately prior to the closing of the Merger/Sale, unless the Committee provides for the Grantee to have the right to exercise the Award, or otherwise for the acceleration of vesting of such Award, as to all or part of the Shares covered by the Award which would not otherwise be exercisable or vested, under such terms and conditions as the Committee shall determine;

 

 
22

 

14.2.2.2. provide for the cancellation of each outstanding Award at or immediately prior to the closing of such Merger/Sale, and if and to the extent payment shall be made to the Grantee of an amount in shares or other securities of the Corporation, the acquiror or of a corporation or other business entity which is a party to the Merger/Sale, cash or other property, or rights, or any combination thereof, as determined by the Committee to be fair in the circumstances, and subject to such terms and conditions as determined by the Committee. The Committee shall have full authority to select the method for determining the payment (being the intrinsic (“spread”) value of the option, Black-Scholes model or any other method). Inter alia, and without limitation of the following determination being made in other circumstances, the Committee’s determination may provide that payment shall be set to zero if the value of the Shares is determined to be less than the Exercise Price, or in respect of Shares covered by the Award which would not otherwise be exercisable or vested, or that payment may be made only in excess of the Exercise Price; and/or

 

14.2.2.3. provide that the terms of any Award shall be otherwise amended, modified or terminated, as determined by the Committee to be fair in the circumstances.

 

14.2.3. The Committee may determine: (i) that any payments made in respect of Awards shall be made or delayed to the same extent that payment of consideration to the holders of the Shares in connection with the Merger/Sale is made or delayed as a result of escrows, indemnification, earn outs, holdbacks or any other contingencies or conditions; (ii) the terms and conditions applying to the payment made or payable to the Grantees, including participation in escrow, indemnification, releases, earn-outs, holdbacks or any other contingencies; and (iii) that any terms and conditions applying under the applicable definitive transaction agreements shall apply to the Grantees (including, appointment and engagement of a shareholders or sellers representative, payment of fees or other costs and expenses associated with such services, indemnifying such representative, and authorization to such representative within the scope of such representative’s authority in the applicable definitive transaction agreements).

 

14.2.4. The Committee may determine to suspend the Grantee’s rights to exercise any vested portion of an Award for a period of time prior to the signing or consummation of a Merger/Sale transaction.

 

14.2.5. Without limiting the generality of this Section 14, if the consideration in exchange for Awards in a Merger/Sale includes any securities and due receipt thereof by any Grantee (or by the Trustee for the benefit of such Grantee) may require under applicable law (i) the registration or qualification of such securities or of any person as a broker or dealer or agent with respect to such securities; or (ii) the provision to any Grantee of any information under the Securities Act or any other securities laws, then the Committee may determine that the Grantee shall be paid in lieu thereof, against surrender of the Shares or cancellation of any other Awards, an amount in cash or other property, or rights, or any combination thereof, as determined by the Committee to be fair in the circumstances, and subject to such terms and conditions as determined by the Committee. Nothing herein shall entitle any Grantee to receive any form of consideration that such Grantee would be ineligible to receive as a result of such Grantee’s failure to satisfy (in the Committee’s sole determination) any condition, requirement or limitation that is generally applicable to the Corporation’s shareholders, or that is otherwise applicable under the terms of the Merger/Sale, and in such case, the Committee shall determine the type of consideration and the terms applying to such Grantees.

 

14.2.6. Neither the authorities and powers of the Committee under this Section 14.2, nor the exercise or implementation thereof, shall (i) be restricted or limited in any way by any adverse consequences (tax or otherwise) that may result to any holder of an Award, and (ii) as, inter alia, being a feature of the Award upon its grant, be deemed to constitute a change or an amendment of the rights of such holder under this Plan, nor shall any such adverse consequences (as well as any adverse tax consequences that may result from any tax ruling or other approval or determination of any relevant tax authority) be deemed to constitute a change or an amendment of the rights of such holder under this Plan, and may be effected without consent of any Grantee and without any liability to the Corporation or its Affiliates, or to their respective officers, directors, employees and representatives, and the respective successors and assigns of any of the foregoing. The Committee need not take the same action with respect to all Awards or with respect to all Service Providers. The Committee may take different actions with respect to the vested and unvested portions of an Award. The Committee may determine an amount or type of consideration to be received or distributed in a Merger/Sale which may differ as among the Grantees, and as between the Grantees and any other holders of shares of the Corporation.

 

 
23

 

14.2.7. The Committee may determine that upon a Merger/Sale any Shares held by Grantees (or for Grantee’s benefit) are sold in accordance with instructions issued by the Committee in connection with such Merger/Sale, which shall be final, conclusive and binding on all Grantees.

 

14.2.8. All of the Committee’s determinations pursuant to this Section 14 shall be at its sole and absolute discretion, and shall be final, conclusive and binding on all Grantees (including, for clarity, as it relates to Shares issued upon exercise or vesting of any Awards or that are Awards, unless otherwise determined by the Committee) and without any liability to the Corporation or its Affiliates, or to their respective officers, directors, employees, shareholders and representatives, and the respective successors and assigns of any of the foregoing, in connection with the method of treatment, chosen course of action or determinations made hereunder.

 

14.2.9. If determined by the Committee, the Grantees shall be subject to the definitive agreement(s) in connection with the Merger/Sale as applying to holders of Shares including, such terms, conditions, representations, undertakings, liabilities, limitations, releases, indemnities, appointing and indemnifying shareholders/sellers representative, participating in transaction expenses, shareholders/sellers representative expense fund and escrow arrangement, in each case as determined by the Committee. Each Grantee shall execute (and authorizes any person designated by the Corporation to so execute, as well as (if applicable) the Trustee holding any Shares for the Grantee’s behalf) such separate agreement(s) or instruments as may be requested by the Corporation, the Successor Corporation or the acquiror in connection with such in such Merger/Sale or otherwise under or for the purpose of implementing this Section 14.2, and in the form required by them. The execution of such separate agreement(s) may be a condition to the receipt of assumed or substituted Awards, payment in lieu of the Award, the exercise of any Award or otherwise to be entitled to benefit from shares or other securities, cash or other property, or rights, or any combination thereof, pursuant to this Section 14.2 (and the Corporation (and, if applicable, the Trustee) may exercise its authorization above and sign such agreement on behalf of the Grantee or subject the Grantee to the provisions of such agreements).

 

14.3. Reservation of Rights. Except as expressly provided in this Section 14 (if any), the Grantee of an Award hereunder shall have no rights by reason of any Recapitalization of shares of any class, any increase or decrease in the number of shares of any class, or any dissolution, liquidation, reorganization (which may include a combination or exchange of shares, spin-off or other corporate divestiture or division, or other similar occurrences), or Merger/Sale. Any issue by the Corporation of shares of any class, or securities convertible into shares of stock of any class, shall not affect, and no adjustment by reason thereof shall be made with respect to, the number, type or price of shares subject to an Award. The grant of an Award pursuant to this Plan shall not affect in any way the right or power of the Corporation to make adjustments, reclassifications, reorganizations or changes of its capital or business structures or to merge or to consolidate or to dissolve, liquidate or sell, or transfer all or part of its business or assets or engage in any similar transactions.

 

15.NON-TRANSFERABILITY OF AWARDS; SURVIVING BENEFICIARY.

 

15.1. All Awards granted under this Plan by their terms shall not be transferable, other than by will or by the laws of descent and distribution, unless otherwise determined by the Committee or under this Plan, provided that with respect to Shares issued upon exercise, Shares issued upon the vesting of Awards or Awards that are Shares, the restrictions on transfer shall be the restrictions referred to in Section 16 (Conditions upon Issuance of Shares) hereof. Subject to the above provisions, the terms of such Award, this Plan and any applicable Award Agreement shall be binding upon the beneficiaries, executors, administrators, heirs and successors of such Grantee. Awards may be exercised or otherwise realized, during the lifetime of the Grantee, only by the Grantee or by his guardian or legal representative, to the extent provided for herein. Any transfer of an Award not permitted hereunder (including transfers pursuant to any decree of divorce, dissolution or separate maintenance, any property settlement, any separation agreement or any other agreement with a spouse) and any grant of any interest in any Award to, or creation in any way of any direct or indirect interest in any Award by, any party other than the Grantee shall be null and void and shall not confer upon any party or person, other than the Grantee, any rights. A Grantee may file with the Committee a written designation of a beneficiary, who shall be permitted to exercise such Grantee’s Award or to whom any benefit under this Plan is to be paid, in each case, in the event of the Grantee’s death before he or she fully exercises his or her Award or receives any or all of such benefit, on such form as may be prescribed by the Committee and may, from time to time, amend or revoke such designation. If no designated beneficiary survives the Grantee, the executor or administrator of the Grantee’s estate shall be deemed to be the Grantee’s beneficiary. Notwithstanding the foregoing, upon the request of the Grantee and subject to Applicable Law the Committee, at its sole discretion, may permit the Grantee to transfer the Award to a trust whose beneficiaries are the Grantee and/or the Grantee’s immediate family members (all or several of them).

 

 
24

 

15.2. Notwithstanding any other provisions of the Plan to the contrary, no Incentive Stock Option may be sold, transferred, pledged, assigned or otherwise alienated or hypothecated, other than by will or by the laws of descent and distribution or in accordance with a beneficiary designation pursuant to Section 15.1. Further, all Incentive Stock Options granted to a Grantee shall be exercisable during his or her lifetime only by such Grantee.

 

15.3. As long as the Shares are held by the Trustee in favor of the Grantee, all rights possessed by the Grantee over the Shares are personal, and may not be transferred, assigned, pledged or mortgaged, other than by will or laws of descent and distribution.

 

15.4. If and to the extent a Grantee is entitled to transfer an Award and/or Shares underlying an Award in accordance with the terms of the Plan and any other applicable agreements, such transfer shall be subject (in addition, to any other conditions or terms applying thereto) to receipt by the Corporation from such proposed transferee of a written instrument, on a form reasonably acceptable to the Corporation, pursuant to which such proposed transferee agrees to be bound by all provisions of the Plan and any other applicable agreements, including without limitation, any restrictions on transfer of the Award and/or Shares set forth herein (however, failure to so deliver such instrument to the Corporation as set forth above shall not derogate from all such provisions applying on any transferee).

 

15.5. The provisions of this Section 15 shall apply to the Grantee and to any purchaser, assignee or transferee of any Shares.

 

16.CONDITIONS UPON ISSUANCE OF SHARES; GOVERNING PROVISIONS.

 

16.1. Legal Compliance. The grant of Awards and the issuance of Shares upon exercise or settlement of Awards shall be subject to compliance with all Applicable Law as determined by the Corporation, including, applicable requirements of federal, state and foreign law with respect to such securities. The Corporation shall have no obligations to issue Shares pursuant to the exercise or settlement of an Award and Awards may not be exercised or settled, if the issuance of Shares upon exercise or settlement would constitute a violation of any Applicable Law as determined by the Corporation, including, applicable federal, state or foreign securities laws or other law or regulations or the requirements of any stock exchange or market system upon which the Shares may then be listed. In addition, no Award may be exercised unless (i) a registration statement under the Securities Act or equivalent law in another jurisdiction shall at the time of exercise or settlement of the Award be in effect with respect to the shares issuable upon exercise of the Award, or (ii) in the opinion of legal counsel to the Corporation, the shares issuable upon exercise of the Award may be issued in accordance with the terms of an applicable exemption from the registration requirements of the Securities Act or equivalent law in another jurisdiction. The inability of the Corporation to obtain authority from any regulatory body having jurisdiction, if any, deemed by the Corporation to be necessary to the lawful issuance and sale of any Shares hereunder, and the inability to issue Shares hereunder due to non-compliance with any Corporation policies with respect to the sale of Shares, shall relieve the Corporation of any liability in respect of the failure to issue or sell such Shares as to which such requisite authority or compliance shall not have been obtained or achieved. As a condition to the exercise of an Award, the Corporation may require the person exercising such Award to satisfy any qualifications that may be necessary or appropriate, to evidence compliance with any Applicable Law or regulation and to make any representation or warranty with respect thereto as may be requested by the Corporation, including to represent and warrant at the time of any such exercise that the Shares are being purchased only for investment and without any present intention to sell or distribute such Shares, all in form and content specified by the Corporation.

 

 
25

 

16.2. Provisions Governing Shares. Shares issued pursuant to an Award shall be subject to this Plan (unless otherwise determined by the Committee), and shall be subject to the Charter and Bylaws of the Corporation, any limitation, restriction or obligation included in any shareholders agreement applicable to all or substantially all of the holders of shares (regardless of whether or not the Grantee is a formal party to such shareholders agreement), any other governing documents of the Corporation, all policies, manuals and internal regulations adopted by the Corporation from time to time, in each case, as may be amended from time to time, including any provisions included therein concerning restrictions or limitations on disposition of Shares (such as, but not limited to, right of first refusal and lock up/market stand-off) or grant of any rights with respect thereto, forced sale and bring along/drag along provisions, any provisions concerning restrictions on the use of inside information and other provisions deemed by the Corporation to be appropriate in order to ensure compliance with Applicable Law. Each Grantee shall execute (and authorizes any person designated by the Corporation to so execute, as well as (if applicable) the Trustee holding any Shears for the Grantee’s behalf) such separate agreement(s) as may be requested by the Corporation relating to matters set forth in or otherwise for the purpose of implementing this Section 16.2. The execution of such separate agreement(s) may be a condition by the Corporation to the exercise of any Award and the Corporation (and, if applicable, the Trustee) may exercise its authorization above and sign such agreement on behalf of the Grantee or subject the Grantee to the provisions of such agreements.

 

16.3. Share Purchase Transactions; Forced Sale. In the event that the Board approves a Merger/Sale effected by way of a forced or compulsory sale or in the event of a transaction for the sale of all shares of the Corporation, then, without derogating from such provisions and in addition thereto, the Grantee shall be obligated, and shall be deemed to have agreed to the offer to effect the Merger/Sale (and the Shares held by or for the benefit of the Grantee shall be included in the shares of the Corporation approving the terms of such Merger/Sale for the purpose of satisfying the required majority), and shall sell all of the Shares held by or for the benefit of the Grantee on the terms and conditions applying to the holders of Shares, in accordance with the instructions then issued by the Board, whose determination shall be final. No Grantee shall contest, bring any claims or demands, or exercise any appraisal rights related to any of the foregoing. Each Grantee shall execute (and authorizes any person designated by the Corporation to so execute, as well as (if applicable) the Trustee holding any Shares for the Grantee’s behalf) such documents and agreements, as may be requested by the Corporation relating to matters set forth in or otherwise for the purpose of implementing this Section 16.3. The execution of such separate agreement(s) may be a condition by the Corporation to the exercise of any Award and the Corporation (and, if applicable, the Trustee) may exercise its authorization above and sign such agreement on behalf of the Grantee or subject the Grantee to the provisions of such agreements.

 

16.4. Data Privacy; Data Transfer. Information related to Grantees and Awards hereunder, as shall be received from Grantee or others, and/or held by, the Corporation or its Affiliates from time to time, and which information may include sensitive and personal information related to Grantees (“Information”), will be used by the Corporation or its Affiliates (or third parties appointed by any of them, including the Trustee) to comply with any applicable legal requirement, or for administration of the Plan as they deems necessary or advisable, or for the respective business purposes of the Corporation or its Affiliates (including in connection with transactions related to any of them). The Corporation and its Affiliates shall be entitled to transfer the Information among the Corporation or its Affiliates, and to third parties for the purposes set forth above, which may include persons located abroad (including, any person administering the Plan or providing services in respect of the Plan or in order to comply with legal requirements, or the Trustee, their respective officers, directors, employees and representatives, and the respective successors and assigns of any of the foregoing), and any person so receiving Information shall be entitled to transfer it for the purposes set forth above. The Corporation shall use commercially reasonable efforts to ensure that the transfer of such Information shall be limited to the reasonable and necessary scope. By receiving an Award hereunder, Grantee acknowledges and agrees that the Information is provided at Grantee’s free will and Grantee consents to the storage and transfer of the Information as set forth above.

 

 
26

 

17.MARKET STAND-OFF

 

17.1. In connection with any underwritten public offering of equity securities of the Corporation pursuant to an effective registration statement filed under the Securities Act or equivalent law in another jurisdiction, the Grantee shall not directly or indirectly, without the prior written consent of the Corporation or its underwriters, (i) lend, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any Shares or other Awards, any securities of the Corporation (whether or not such Shares were acquired under this Plan), or any securities convertible into or exercisable or exchangeable (directly or indirectly) for Shares or securities of the Corporation and any other shares or securities issued or distributed in respect thereto or in substitution thereof (collectively, “Securities”), or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the Securities, whether any such transaction described in the foregoing clauses (i) or (ii) is to be settled by delivery of Securities, in cash or otherwise. The foregoing provisions of this Section 17.1 shall not apply to the sale of any shares to an underwriter pursuant to an underwriting agreement. Such restrictions (the “Market Stand-Off”) shall be in effect for such period of time (the “Market Stand-Off Period”): (A) following the first public filing of the registration statement relating to the underwritten public offering until the expiration of up to 180 days following the effective date of such registration statement relating to the Corporation’s public offering; or (B) such other period as shall be requested by the Corporation or the underwriters. Notwithstanding anything herein to the contrary, if the underwriter(s) and the Corporation agree on a termination date of the Market Stand-Off Period in the event of failure to consummate a certain public offering, then such termination shall apply also to the Market Stand-Off Period hereunder with respect to that particular public offering.

 

17.2. In the event of a subdivision of the outstanding share capital of the Corporation, the distribution of any securities (whether or not of the Corporation), whether as bonus shares or otherwise, and whether as dividend or otherwise, a recapitalization, a reorganization (which may include a combination or exchange of shares or a similar transaction affecting the Corporation’s outstanding securities without receipt of consideration), a consolidation, a spin-off or other corporate divestiture or division, a reclassification or other similar occurrence, any new, substituted or additional securities which are by reason of such transaction distributed with respect to any Shares subject to the Market Stand-Off, or into which such Shares thereby become convertible, shall immediately be subject to the Market Stand-Off.

 

17.3. In order to enforce the Market Stand-Off, the Corporation may impose stop-transfer instructions with respect to the Shares acquired under this Plan until the end of the applicable Market Stand- Off period.

 

17.4. The underwriters in connection with a registration statement so filed are intended third party beneficiaries of this Section 17 and shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto. Each Grantee shall execute such separate agreement(s) as may be requested by the Corporation or the underwriters in connection with such registration statement and in the form required by them, relating to Market Stand-Off (which need not be identical to the provisions of this Section 17, and may include such additional provisions and restrictions as the underwriters deem advisable) or that are necessary to give further effect thereto. The execution of such separate agreement(s) may be a condition by the Corporation to the exercise of any Award.

 

17.5. Without derogating from the above provisions of this Section 17 or elsewhere in this Plan, the provisions of this Section 17 shall apply to the Grantee and the Grantee’s heirs, legal representatives, successors, assigns, and to any purchaser, assignee or transferee of any Awards or Shares.

 

 
27

 

18.AGREEMENT REGARDING TAXES; DISCLAIMER.

 

18.1. If the Corporation shall so require, as a condition of exercise or (if applicable) vesting of an Award, the release of Shares by the Trustee or the expiration of the Restricted Period, a Grantee shall agree that, no later than the date of such occurrence, the Grantee will pay to the Corporation (or the Trustee, as applicable) or make arrangements satisfactory to the Corporation and the Trustee (if applicable) regarding payment of any applicable taxes and compulsory payments of any kind required by Applicable Law to be withheld or paid.

 

18.2. TAX LIABILITY. ALL TAX CONSEQUENCES UNDER ANY APPLICABLE LAW WHICH MAY ARISE FROM THE GRANT OF ANY AWARDS OR THE EXERCISE OR (IF APPLICABLE) VESTING THEREOF, THE SALE OR DISPOSITION OF ANY SHARES GRANTED HEREUNDER OR ISSUED UPON EXERCISE OR (IF APPLICABLE) THE VESTING OF ANY AWARD, THE ASSUMPTION, SUBSTITUTION, CANCELLATION OR PAYMENT IN LIEU OF AWARDS OR FROM ANY OTHER ACTION IN CONNECTION WITH THE FOREGOING (INCLUDING WITHOUT LIMITATION ANY TAXES AND COMPULSORY PAYMENTS, SUCH AS SOCIAL SECURITY OR HEALTH TAX PAYABLE BY THE GRANTEE OR THE COMPANY IN CONNECTION THEREWITH) SHALL BE BORNE AND PAID SOLELY BY THE GRANTEE, AND THE GRANTEE SHALL INDEMNIFY THE COMPANY, ITS SUBSIDIARIES AND AFFILIATES AND THE TRUSTEE, AND SHALL HOLD THEM HARMLESS AGAINST AND FROM ANY LIABILITY FOR ANY SUCH TAX OR PAYMENT OR ANY PENALTY, INTEREST OR INDEXATION THEREON. EACH GRANTEE AGREES TO, AND UNDERTAKES TO COMPLY WITH, ANY RULING, SETTLEMENT, CLOSING AGREEMENT OR OTHER SIMILAR AGREEMENT OR ARRANGEMENT WITH ANY TAX AUTHORITY IN CONNECTION WITH THE FOREGOING WHICH IS APPROVED BY THE COMPANY.

 

18.3. NO TAX ADVICE. THE GRANTEE IS ADVISED TO CONSULT WITH A TAX ADVISOR WITH RESPECT TO THE TAX CONSEQUENCES OF RECEIVING, EXERCISING OR DISPOSING OF AWARDS HEREUNDER. THE COMPANY DOES NOT ASSUME ANY RESPONSIBILITY TO ADVISE THE GRANTEE ON SUCH MATTERS, WHICH SHALL REMAIN SOLELY THE RESPONSIBILITY OF THE GRANTEE.

 

18.4. TAX TREATMENT. THE COMPANY AND ITS AFFILIATES (INCLUDING THE EMPLOYER) DO NOT UNDERTAKE OR ASSUME ANY LIABILITY OR RESPONSIBILITY TO THE EFFECT THAT ANY AWARD SHALL QUALIFY WITH ANY PARTICULAR TAX REGIME OR RULES APPLYING TO PARTICULAR TAX TREATMENT, OR BENEFIT FROM ANY PARTICULAR TAX TREATMENT OR TAX ADVANTAGE OF ANY TYPE AND THE COMPANY AND ITS AFFILIATES (INCLUDING THE EMPLOYER) SHALL BEAR NO LIABILITY IN CONNECTION WITH THE MANNER IN WHICH ANY AWARD IS TREATED FOR TAX PURPOSES, REGARDLESS OF WHETHER THE AWARD WAS GRANTED OR WAS INTENDED TO QUALIFY UNDER ANY PARTICULAR TAX REGIME OR TREATMENT. THIS PROVISION SHALL SUPERSEDE ANY TYPE OF AWARDS OR TAX QUALIFICATION INDICATED IN ANY CORPORATE RESOLUTION OR AWARD AGREEMENT, WHICH SHALL AT ALL TIMES BE SUBJECT TO THE REQUIREMENTS OF APPLICABLE LAW. THE COMPANY AND ITS AFFILIATES (INCLUDING THE EMPLOYER) DO NOT UNDERTAKE AND SHALL NOT BE REQUIRED TO TAKE ANY ACTION IN ORDER TO QUALIFY ANY AWARD WITH THE REQUIREMENT OF ANY PARTICULAR TAX TREATMENT AND NO INDICATION IN ANY DOCUMENT TO THE EFFECT THAT ANY AWARD IS INTENDED TO QUALIFY FOR ANY TAX TREATMENT SHALL IMPLY SUCH AN UNDERTAKING. THE COMPANY AND ITS AFFILIATES (INCLUDING THE EMPLOYER) DO NOT UNDERTAKE TO REPORT FOR TAX PURPOSES ANY AWARD IN ANY PARTICULAR MANNER, INCLUDING IN ANY MANNER CONSISTENT WITH ANY PARTICULAR TAX TREATMENT. NO ASSURANCE IS MADE BY THE COMPANY OR ANY OF ITS AFFILIATES (INCLUDING THE EMPLOYER) THAT ANY PARTICULAR TAX TREATMENT ON THE DATE OF GRANT WILL CONTINUE TO EXIST OR THAT THE AWARD WOULD QUALIFY AT THE TIME OF EXERCISE, VESTING OR DISPOSITION THEREOF WITH ANY PARTICULAR TAX TREATMENT. THE COMPANY AND ITS AFFILIATES (INCLUDING THE EMPLOYER) SHALL NOT HAVE ANY LIABILITY OR OBLIGATION OF ANY NATURE IN THE EVENT THAT AN AWARD DOES NOT QUALIFY FOR ANY PARTICULAR TAX TREATMENT, REGARDLESS WHETHER THE COMPANY COULD HAVE OR SHOULD HAVE TAKEN ANY ACTION TO CAUSE SUCH QUALIFICATION TO BE MET AND SUCH QUALIFICATION REMAINS AT ALL TIMES AND UNDER ALL CIRCUMSTANCES AT THE RISK OF THE GRANTEE. THE COMPANY DOES NOT UNDERTAKE OR ASSUME ANY LIABILITY TO CONTEST A DETERMINATION OR INTERPRETATION (WHETHER WRITTEN OR UNWRITTEN) OF ANY TAX AUTHORITIES, INCLUDING IN RESPECT OF THE QUALIFICATION UNDER ANY PARTICULAR TAX REGIME OR RULES APPLYING TO PARTICULAR TAX TREATMENT. IF THE AWARDS DO NOT QUALIFY UNDER ANY PARTICULAR TAX TREATMENT IT COULD RESULT IN ADVERSE TAX CONSEQUENCES TO THE GRANTEE.

 

 
28

 

18.5. The Corporation or any Subsidiary or Affiliate (including the Employer) may take such action as it may deem necessary or appropriate, in its discretion, for the purpose of or in connection with withholding of any taxes and compulsory payments which the Trustee, the Corporation or any Subsidiary or Affiliate (including the Employer) (or any applicable agent thereof) is required by any Applicable Law to withhold in connection with any Awards, including, without limitations, any income tax, social benefits, social insurance, health tax, pension, payroll tax, fringe benefits, excise tax, payment on account or other tax-related items related to the Participant’s participation in the Plan and applicable by law to the Participant (collectively, “Withholding Obligations”). Such actions may include (i) requiring a Grantees to remit to the Corporation or the Employer in cash an amount sufficient to satisfy such Withholding Obligations and any other taxes and compulsory payments, payable by the Corporation or the Employer in connection with the Award or the exercise or (if applicable) the vesting thereof; (ii) subject to Applicable Law, allowing the Grantees to surrender Shares to the Corporation, in an amount that at such time, reflects a value that the Committee determines to be sufficient to satisfy such Withholding Obligations; (iii) withholding Shares otherwise issuable upon the exercise of an Award at a value which is determined by the Corporation to be sufficient to satisfy such Withholding Obligations; or (iv) any combination of the foregoing. The Corporation shall not be obligated to allow the exercise or vesting of any Award by or on behalf of a Grantee until all tax consequences arising therefrom are resolved in a manner acceptable to the Corporation.

 

18.6. Each Grantee shall notify the Corporation in writing promptly and in any event within ten (10) days after the date on which such Grantee first obtains knowledge of any tax authority inquiry, audit, assertion, determination, investigation, or question relating in any manner to the Awards granted or received hereunder or Shares issued thereunder and shall continuously inform the Corporation of any developments, proceedings, discussions and negotiations relating to such matter, and shall allow the Corporation and its representatives to participate in any proceedings and discussions concerning such matters. Upon request, a Grantee shall provide to the Corporation any information or document relating to any matter described in the preceding sentence, which the Corporation, in its discretion, requires.

 

18.7. With respect to 102 Non-Trustee Options, if the Grantee ceases to be employed by the Corporation, Parent, Subsidiary or any Affiliate (including the Employer), the Grantee shall extend to the Corporation and/or the Employer a security or guarantee for the payment of taxes due at the time of sale of Shares, all in accordance with the provisions of Section 102 of the Ordinance and the Rules.

 

18.8. If a Grantee makes an election under Section 83(b) of the Code to be taxed with respect to an Award as of the date of transfer of Shares rather than as of the date or dates upon which the Grantee would otherwise be taxable under Section 83(a) of the Code, such Grantee shall deliver a copy of such election to the Corporation upon or prior to the filing such election with the U.S. Internal Revenue Service. Neither the Corporation nor any Affiliate (including the Employer) shall have any liability or responsibility relating to or arising out of the filing or not filing of any such election or any defects in its construction.

 

19.RIGHTS AS A SHAREHOLDER; VOTING AND DIVIDENDS.

 

19.1. Subject to Section 11.4, a Grantee shall have no rights as a shareholder of the Corporation with respect to any Shares covered by an Award until the Grantee shall have exercised or (as applicable) vests in the Award, paid any Exercise Price therefor and becomes the record holder of the subject Shares. In the case of 102 Awards, the Trustee shall have no rights as a shareholder of the Corporation with respect to the Shares covered by such Award until the Trustee becomes the record holder for such Shares for the Grantee’s benefit, and the Grantee shall not be deemed to be a shareholder and shall have no rights as a shareholder of the Corporation with respect to the Shares covered by the Award until the date of the release of such Shares from the Trustee to the Grantee and the transfer of record ownership of such Shares to the Grantee (provided, however, that the Grantee shall be entitled to receive from the Trustee any cash dividend or distribution made on account of the Shares held by the Trustee for such Grantee’s benefit, subject to any tax withholding and compulsory payment). No adjustment shall be made for dividends (ordinary or extraordinary, whether in shares or other securities, cash or other property, or rights, or any combination thereof) or distribution of other rights for which the record date is prior to the date on which the Grantee or Trustee (as applicable) becomes the record holder of the Shares covered by an Award, except as provided in Section 14 hereof.

 

 
29

 

19.2. With respect to all Awards issued in the form of Shares hereunder or upon the exercise or (if applicable) the vesting of Awards hereunder, any and all voting rights attached to such Shares shall be subject to Section Error! Reference source not found., and the Grantee shall be entitled to receive dividends distributed with respect to such Shares, subject to the provisions of the Corporation’s Charter and Bylaws, as amended from time to time, and subject to any Applicable Law.

 

19.3. The Corporation may, but shall not be obligated to, register or qualify the sale of Shares under any applicable securities law or any other Applicable Law.

 

20.NO REPRESENTATION BY COMPANY.

 

By granting the Awards, the Corporation is not, and shall not be deemed as, making any representation or warranties to the Grantee regarding the Corporation, its business affairs, its prospects or the future value of its Shares and such representations and warranties are hereby disclaimed. The Corporation shall not be required to provide to any Grantee any information, documents or material in connection with the Grantee’s considering an exercise of an Award. To the extent that any information, documents or materials are provided, the Corporation shall have no liability with respect thereto. Any decision by a Grantee to exercise an Award shall solely be at the risk of the Grantee.

 

21.NO RETENTION RIGHTS.

 

Nothing in this Plan, any Award Agreement or in any Award granted or agreement entered into pursuant hereto shall confer upon any Grantee the right to continue in the employ of, or be in the service of the Corporation or any Subsidiary or Affiliate thereof as a Service Provider or to be entitled to any remuneration or benefits not set forth in this Plan or such agreement, or to interfere with or limit in any way the right of the Corporation or any such Subsidiary or Affiliate to terminate such Grantee’s employment or service (including, any right of the Corporation or any of its Affiliates to immediately cease the Grantee’s employment or service or to shorten all or part of the notice period, regardless of whether notice of termination was given by the Corporation or its Affiliates or by the Grantee). Awards granted under this Plan shall not be affected by any change in duties or position of a Grantee, subject to Sections 6.6 through 6.8. No Grantee shall be entitled to claim and the Grantee hereby waives any claim against the Corporation or any Subsidiary or Affiliate that he or she was prevented from continuing to vest Awards as of the date of termination of his or her employment with, or services to, the Corporation or any Subsidiary or Affiliate. No Grantee shall be entitled to any compensation in respect of the Awards which would have vested had such Grantee’s employment or engagement with the Corporation (or any Subsidiary or Affiliate) not been terminated.

 

22.PERIOD DURING WHICH AWARDS MAY BE GRANTED.

 

Awards may be granted pursuant to this Plan from time to time within a period of ten (10) years from the Effective Date, which period may be extended from time to time by the Board. From and after such date (as extended) no grants of Awards may be made and this Plan shall continue to be in full force and effect with respect to Awards or Shares issued thereunder that remain outstanding.

 

23.AMENDMENT OF THIS PLAN AND AWARDS.

 

23.1. The Board at any time and from time to time may suspend, terminate, modify or amend this Plan, whether retroactively or prospectively. Any amendment effected in accordance with this Section shall be binding upon all Grantees and all Awards, whether granted prior to or after the date of such amendment, and without the need to obtain the consent of any Grantee. No termination or amendment of this Plan shall affect any then outstanding Award unless expressly provided by the Board.

 

 
30

 

23.2. Subject to changes in Applicable Law that would permit otherwise, without the approval of the Corporation’s shareholders, there shall be (i) no increase in the maximum aggregate number of Shares that may be issued under this Plan as Incentive Stock Options (except by operation of the provisions of Section 14.1), (ii) no change in the class of persons eligible to receive Incentive Stock Options, and (iii) no other amendment of this Plan that would require approval of the Corporation’s shareholders under any Applicable Law. Unless not permitted by Applicable Law, if the grant of an Award is subject to approval by shareholders, the date of grant of the Award shall be determined as if the Award had not been subject to such approval. Failure to obtain approval by the shareholders shall not in any way derogate from the valid and binding effect of any grant of an Award that is not an Incentive Stock Option.

 

23.3. The Board or the Committee at any time and from time to time may modify or amend any Award theretofore granted, including any Award Agreement, whether retroactively or prospectively.

 

24.APPROVAL.

 

24.1. This Plan shall take effect upon its adoption by the Board (the “Effective Date”).

 

24.2. Solely with respect to grants of Incentive Stock Options, this Plan shall also be subject to shareholders’ approval, within one year of the Effective Date, by a majority of the votes cast on the proposal at a meeting or a written consent of shareholders (however, if the grant of an Award is subject to approval by shareholders, the date of grant of the Award shall be determined as if the Award had not been subject to such approval). Failure to obtain such approval by the shareholders within such period shall not in any way derogate from the valid and binding effect of any grant of an Award, except that any Options previously granted under this Plan may not qualify as Incentive Stock Options but, rather, shall constitute Nonqualified Stock Options. Upon approval of this Plan by the shareholders of the Corporation as set forth above, all Incentive Stock Options granted under this Plan on or after the Effective Date shall be fully effective as if the shareholders of the Corporation had approved this Plan on the Effective Date.

 

24.3. 102 Awards are conditional upon the filing with or approval by the ITA, if required, as set forth in Section 9.49. Failure to so file or obtain such approval shall not in any way derogate from the valid and binding effect of any grant of an Award, which is not a 102 Award.

 

25.RULES PARTICULAR TO SPECIFIC COUNTRIES; SECTION 409A.

 

25.1. Notwithstanding anything herein to the contrary, the terms and conditions of this Plan may be supplemented or amended with respect to a particular country or tax regime by means of an appendix to this Plan, and to the extent that the terms and conditions set forth in any appendix conflict with any provisions of this Plan, the provisions of such appendix shall govern. Terms and conditions set forth in such appendix shall apply only to Awards granted to Grantees under the jurisdiction of the specific country or such other tax regime that is the subject of such appendix and shall not apply to Awards issued to a Grantee not under the jurisdiction of such country or such other tax regime. The adoption of any such appendix shall be subject to the approval of the Board or the Committee, and if determined by the Committee to be required in connection with the application of certain tax treatment, pursuant to applicable stock exchange rules or regulations or otherwise, then also the approval of the shareholders of the Corporation at the required majority.

 

25.2. This Section 25.2 shall only apply to Awards granted to Grantees who are subject to United States Federal income tax.

 

25.2.1 It is the intention of the Corporation that no Award shall be deferred compensation subject to Section 409A of the Code unless and to the extent that the Committee specifically determines otherwise as provided in Section 25.2.2, and the Plan and the terms and conditions of all Awards shall be interpreted and administered accordingly.

 

 
31

 

25.2.2 The terms and conditions governing any Awards that the Committee determines will be subject to Section 409A of the Code, including any rules for payment or elective or mandatory deferral of the payment or delivery of Shares or cash pursuant thereto, and any rules regarding treatment of such Awards in the event of a Change in Control, shall be set forth in the applicable Award Agreement and shall be intended to comply in all respects with Section 409A of the Code, and the Plan and the terms and conditions of such Awards shall be interpreted and administered accordingly.

 

25.2.3 The Corporation shall have complete discretion to interpret and construe the Plan and any Award Agreement in any manner that establishes an exemption from (or compliance with) the requirements of Section 409A of the Code. If for any reason, such as imprecision in drafting, any provision of the Plan and/or any Award Agreement does not accurately reflect its intended establishment of an exemption from (or compliance with) Code Section 409A, as demonstrated by consistent interpretations or other evidence of intent, such provision shall be considered ambiguous as to its exemption from (or compliance with) Section 409A of the Code and shall be interpreted by the Corporation in a manner consistent with such intent, as determined in the discretion of the Corporation. If, notwithstanding the foregoing provisions of this Section 25.2.3, any provision of the Plan or any such agreement would cause a Grantee to incur any additional tax or interest under Section 409A of the Code, the Corporation may reform such provision in a manner intended to avoid the incurrence by such Grantee of any such additional tax or interest; provided that the Corporation shall maintain, to the extent reasonably practicable, the original intent and economic benefit to the Grantee of the applicable provision without violating the provisions of Section 409A of the Code. For the avoidance of doubt, no provision of this Plan shall be interpreted or construed to transfer any liability for failure to comply with the requirements of Section 409A from any Grantee or any other individual to the Corporation or any of its affiliates, employees or agents.

 

25.2.4 Notwithstanding any other provision in the Plan, any Award Agreement, or any other written document establishing the terms and conditions of an Award, if any Grantee is a “specified employee,” within the meaning of Section 409A of the Code, as of the date of his or her “separation from service” (as defined under Section 409A of the Code), then, to the extent required by Treasury Regulation Section 1.409A-3(i)(2) (or any successor provision), any payment made to such Grantee on account of his or her separation from service shall not be made before a date that is six months after the date of his or her separation from service. The Committee may elect any of the methods of applying this rule that are permitted under Treasury Regulation Section 1.409A-3(i)(2)(ii) (or any successor provision).

 

25.2.5 Notwithstanding any other provision of this Section 25.2 to the contrary, although the Corporation intends to administer the Plan so that Awards will be exempt from, or will comply with, the requirements of Section 409A of the Code, the Corporation does not warrant that any Award under the Plan will qualify for favorable tax treatment under Section 409A of the Code or any other provision of federal, state, local, or non-United States law. The Corporation shall not be liable to any Grantee for any tax, interest, or penalties the Grantee might owe as a result of the grant, holding, vesting, exercise, or payment of any Award under the Plan.

 

26.GOVERNING LAW; JURISDICTION.

 

This Plan and all determinations made and actions taken pursuant hereto shall be governed by the laws of the State of Israel, except with respect to matters that are subject to tax laws, regulations and rules of any specific jurisdiction, which shall be governed by the respective laws, regulations and rules of such jurisdiction. Certain definitions, which refer to laws other than the laws of such jurisdiction, shall be construed in accordance with such other laws. The competent courts located in Tel-Aviv-Jaffa, Israel shall have exclusive jurisdiction over any dispute arising out of or in connection with this Plan and any Award granted hereunder. By signing any Award Agreement or any other agreement relating to an Award, each Grantee irrevocably submits to such exclusive jurisdiction.

 

 
32

 

27.NON-EXCLUSIVITY OF THIS PLAN.

 

The adoption of this Plan shall not be construed as creating any limitations on the power or authority of the Corporation to adopt such other or additional incentive or other compensation arrangements of whatever nature as the Corporation may deem necessary or desirable or preclude or limit the continuation of any other plan, practice or arrangement for the payment of compensation or fringe benefits to employees generally, or to any class or group of employees, which the Corporation or any Affiliate now has lawfully put into effect, including any retirement, pension, savings and stock purchase plan, insurance, death and disability benefits and executive short-term or long-term incentive plans.

 

28.MISCELLANEOUS.

 

28.1. Survival. The Grantee shall be bound by and the Shares issued upon exercise or (if applicable) the vesting of any Awards granted hereunder shall remain subject to this Plan after the exercise or (if applicable) the vesting of Awards, in accordance with the terms of this Plan, whether or not the Grantee is then or at any time thereafter employed or engaged by the Corporation or any of its Affiliates.

 

28.2. Additional Terms. Each Award awarded under this Plan may contain such other terms and conditions not inconsistent with this Plan as may be determined by the Committee, in its sole discretion.

 

28.3. Fractional Shares. No fractional Share shall be issuable upon exercise or vesting of any Award and the number of Shares to be issued shall be rounded down to the nearest whole Share, with any Share remaining at the last vesting date due to such rounding to be issued upon exercise at such last vesting date.

 

28.4. Severability. If any provision of this Plan, any Award Agreement or any other agreement entered into in connection with an Award shall be determined to be illegal or unenforceable by any court of law in any jurisdiction, the remaining provisions hereof and thereof shall be severable and enforceable in accordance with their terms, and all provisions shall remain enforceable in any other jurisdiction. In addition, if any particular provision contained in this Plan, any Award Agreement or any other agreement entered into in connection with an Award shall for any reason be held to be excessively broad as to duration, geographic scope, activity or subject, it shall be construed by limiting and reducing such provision as to such characteristic so that the provision is enforceable to fullest extent compatible with Applicable Law as it shall then appear.

 

28.5. Captions and Titles. The use of captions and titles in this Plan or any Award Agreement or any other agreement entered into in connection with an Award is for the convenience of reference only and shall not affect the meaning or interpretation of any provision of this Plan or such agreement.

 

* * *

 

 

 

 EX-10.4 5 ex10-4.htm

 

Exhibit 10.4

 

NOTICE OF OPTION GRANT

 

You have been granted the following options (the “Options”) to purchase shares of common stock par value US$ 0.001 each (the “Shares”) of ScoutCam Inc. (the “Company”), pursuant and subject to the terms and conditions of the Company’s 2020 Share Incentive Plan, a copy of which is attached hereto as Exhibit A (as may be amended from time to time, the “Plan”), and the additional terms and conditions contained herein. Unless otherwise defined, capitalized terms used herein shall have the meaning ascribed to them under the Plan.

 

Grantee:    
     
Date of Grant:    
such date being subject to Section 9.4 of the Plan and Section 10.2 of this Agreement
     
Intended Type of Award:       Incentive Stock Option (U.S.)
(☐ check one):       Nonqualified Stock Option (U.S.)
        Option designated as 102 Capital Gains Track Award (with Trustee) (Israel)
        Option designated as 102 Ordinary Income Track Award (with Trustee) (Israel)
        Option designated as 102 Non-Trustee Award (Israel)
        Option designated as 3(9) Award (Israel)
        Other
         
the above being subject to Section ‎9 of the Option Agreement, Section 18.4 of the Plan and applicable law
Exercise Price   (US$ / NIS / Other) «Grant__ExercisePrice» per Share
         
«Contact_FullName»    
     
Number of Shares underlying the Options:    
     
Vesting Commencement Date:    
     
Vesting Schedule:  

 

Subject to the terms of the Plan (including Sections 6.6 and 6.7 thereof), the Options shall vest and become exercisable under the following schedule: 33.33% of the Shares covered by the Options, on the first anniversary of the date on the Vesting Commencement Date, and 8.33% of the Shares covered by the Options at the end of each subsequent three-month period thereafter over the course of the subsequent 2 years; provided, in each case, that the Grantee remains continuously as a Service Provider of the Company or its Affiliates throughout each such vesting date; and, further, that the each of the outstanding Options shall immediately vest upon the occurrence of the following: (i) the sale of all or substantially al of the assets of the Company, (ii) the sale of more than fifty percent (50%) of the outstanding common stock of the Company in a non-public sale, (iii) the dissolution or liquidation of the Company, or (iv) any merger, share exchange, consolidation or other reorganization or business combination of the Company if immediately after such transaction either (A) persons who were directors of the Company immediately prior such transaction do not constitute at least a majority of the directors of the surviving entity, or (B) persons who hold majority of the voting capital stock of the surviving entity are not persons who held a majority of the voting capital stock of the Company immediately prior to such transaction.

     
Exercise Period:   The date determined in accordance with and subject to Section ‎8 of the Option Agreement and the provisions of the Plan.
             

 

The Options are governed by this Notice of Option Grant and by the provisions of the Plan and the Option Agreement, both of which are attached to and made an integral part of this Notice. By signing the Option Agreement, the Grantee acknowledges receipt of copies of the Plan and the Option Agreement, represents that the Grantee read and is familiar with their provisions, and hereby accepts the Options subject to all of their terms and conditions.

 

 

 

 

THIS OPTION AGREEMENT AND THE SECURITIES ISSUABLE UPON EXERCISE OF THE OPTIONS HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) OR SUCH APPLICABLE LAWS OF OTHER JURISDICTIONS, OR QUALIFIED UNDER ANY SECURITIES LAW OR ANY OTHER JURISDICTION, AND, SUBJECT TO THEIR TERMS, MAY NOT BE OFFERED, SOLD, TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED UNLESS THERE IS AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR SUCH APPLICABLE LAWS OF OTHER JURISDICTIONS COVERING THIS AGREEMENT AND/OR SUCH SECURITIES, OR THE HOLDER RECEIVES AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY STATING THAT SUCH OFFERING, SALE, TRANSFER, ASSIGNMENT, PLEDGE OR HYPOTHECATION IS EXEMPT FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF THE SECURITIES ACT AND THE QUALIFICATION REQUIREMENTS UNDER APPLICABLE LAW.

 

OPTION AGREEMENT

 

The Company has granted to the Grantee named in the Notice of Option Grant (“Notice”) to which this Option Agreement (this “Agreement”) is attached Options upon the terms and conditions set forth in the Notice and this Agreement. The Options have been granted pursuant to and shall in all respects be subject to the terms and conditions of the Notice, this Agreement and the Plan, the provisions of which are incorporated herein by reference and made an integral part of this Agreement.

 

By signing this Agreement, the Grantee: (a) represents that the Grantee has received copies of, and has read and is familiar with the terms and conditions of, the Notice, the Plan and this Agreement, (b) accepts that the Options, the Shares issued upon the exercise thereof and/or any securities issued or distributed with respect thereto are subject to all of the terms and conditions of the Notice, the Plan this Agreement, the Trust Agreement (as defined below) and any other documents ancillary hereto or thereto, and (c) agrees to accept as binding, conclusive and final all decisions and interpretations of the Board or the Committee upon any questions arising under the Notice, the Plan or this Agreement (whether before or after the issuance of Shares pursuant to the Options). While certain terms and conditions are included in this Agreement, such terms and conditions shall not in any way derogate from the applicability of all other terms and conditions set forth in the Plan. The Grantee acknowledges that the terms and conditions of the Plan may be amended from time to time as set forth therein, and therefore, any reference to the Plan shall be deemed to refer to the Plan as amended from time to time, including any amendments adopted after the date of grant. Unless otherwise stated, in the event of any inconsistency or contradiction between any of the terms of this Agreement and the provisions of the Plan, the terms and provisions of this Agreement shall prevail.

 

1. No Disposition of Options. The Options shall not be sold, pledged or otherwise transferred (whether by operation of law or otherwise), and shall not be subject to sale under execution, attachment, levy or similar process (each of the foregoing, a “Transfer”) other than by will or by the laws of descent and distribution.

 

2. Issuance and Disposition of Shares.

 

2.1. Legal Compliance. The Company shall have no obligations to issue Shares pursuant to the exercise or settlement of Options and Options may not be exercised or settled (even if vested), if the issuance of Shares upon exercise or settlement would constitute a violation of any Applicable Laws as determined by the Company, including, applicable federal, state or foreign securities laws or other law or regulations or the requirements of any stock exchange or market system upon which the Shares may then be listed. THE GRANTEE IS CAUTIONED THAT THE OPTIONS MAY NOT BE EXERCISED UNLESS THE FOREGOING CONDITIONS AND THOSE SET FORTH IN THE PLAN ARE SATISFIED. ACCORDINGLY, THE OPTIONEE MAY NOT BE ABLE TO EXERCISE THE OPTIONS WHEN DESIRED EVEN THOUGH THE OPTION IS VESTED.

 

 

 

 

2.2. Provisions Governing Shares. Shares issued upon exercise of Options shall be subject to the restrictions referred to in Section 16 of the Plan (Conditions upon Issuance of Shares; Governing Provisions) and in this Agreement, the Articles of Incorporation of the Company, any limitation, restriction or obligation included in any stockholders agreement applicable to all or substantially all of the holders of Shares (regardless of whether or not the Grantee is a formal party to such stockholders agreement), any other governing documents of the Company, and all policies, manuals and internal regulations adopted by the Company from time to time, in each case, as may be amended from time to time, including, without limitation, any provisions included therein concerning restrictions or limitations on disposition of Shares (such as, but not limited to, right of first refusal and lock-up/market stand-off) or grant of any rights with respect thereto, forced sale and bring along provisions, any provisions concerning a restrictions on the use of inside information and other provisions deemed by the Company to be appropriate in order to ensure compliance with Applicable Laws and with the requirements of any transaction entered into or proposed to be entered into by the Company. By exercising an Option the Grantee is deemed to have undertaken to comply with all the foregoing provisions. The Grantee shall execute (and authorizes any person designated by the Company to so execute, as well as (if applicable) the Trustee holding any Shares for the Grantee’s behalf) such separate agreement(s) as may be requested by the Company relating to matters set forth in or otherwise for the purpose of implementing this Section ‎2.2. The execution of such separate agreement(s) may be a condition by the Company to the exercise of any Award and the Company (and, if applicable, the Trustee) may exercise its authorization above and sign such agreement on behalf of the Grantee or subject the Grantee to the provisions of such agreements.

 

2.3. Waiver. As a material precondition to the Company’s grant of Options and issuance of any Shares under the Plan, the Grantee hereby irrevocably waives any right of first refusal, pre-emptive, co-sale, participation rights or other similar rights with respect to any prior or future Transfer of any shares in the Company by other stockholders or the issuance of securities by the Company, if such right was so provided in any agreement between the Company and any of its stockholders, in the Articles of Incorporation or in any other governing document of the Company. The Grantee acknowledges and agrees that the Company and its stockholders are entitled to rely on this irrevocable waiver.

 

2.4. Additional or Substituted Securities. In the event that in connection with the declaration of a share dividend (bonus shares), a share split, a reverse share split, a reorganization (which may include a combination or exchange of shares), a consolidation, a spin-off or other corporate divestiture or division, a recapitalization, a reclassification or other similar occurrence affecting the Company’s outstanding securities without receipt of consideration (or in consideration for the par value, if shares bear par value), any new, substituted or additional securities or other property (other than cash dividend) are distributed by reason of such occurrence with respect to any Shares which are subject to this Section ‎2, or into which such Shares thereby become convertible, then such substituted or additional securities or other property (if distributed) shall immediately be subject to this Section ‎2. Any adjustments to reflect the distribution of such securities or other property shall be conclusively determined by the Company. The terms and conditions contained herein and in the Plan in respect of the Option and/or the Shares shall apply to any new, substituted or additional securities or other property resulting from the above adjustments.

 

2.5. Market Stand-Off. As a material precondition to the grant of Options and the issuance of any Shares in accordance with the Plan, and without limitation of Section 17 of the Plan, the Grantee hereby executes a market stand-off undertaking in the form attached hereto as Exhibit B.

 

 

 

 

2.6. Data Privacy; Data Transfer. Information related to the Grantee and Award(s) hereunder, as shall be received from Grantee or others, and/or held by, the Company or its Affiliates from time to time, and which information may include sensitive and personal information related to the Grantee (“Information”), will be used by the Company or its Affiliates (or third parties appointed by any of them, including the Trustee) to comply with any applicable legal requirement, or for administration of the Plan as they deems necessary or advisable, or for the respective business purposes of the Company or its Affiliates (including in connection with transactions related to any of them). The Company and its Affiliates shall be entitled to transfer the Information among the Company or its Affiliates and to third parties for the purposes set forth above, which may include persons located abroad (including, any person administering the Plan or providing services in respect of the Plan or in order to comply with legal requirements, or the Trustee, their respective officers, directors, employees and representatives, and the respective successors and assigns of any of the foregoing), and any person so receiving Information shall be entitled to transfer it for the purposes set forth above. The Company shall use commercially reasonable efforts to ensure that the transfer of such Information shall be limited to the reasonable and necessary scope. By receiving an Award hereunder, Grantee acknowledges and agrees that the Information is provided at Grantee’s free will and that Grantee hereby consents to the storage and transfer of the Information as set forth above.

 

3. Exercise Procedures.

 

3.1. The Grantee may exercise Options that have become exercisable by giving a signed written notice to the Company, delivered in person or by mail (or such other methods of delivery prescribed by the Company) to the Chief Financial Officer of the Company or to such other person as determined by the Committee, or in any other manner as the Committee shall prescribe from time to time. The exercise notice shall be in a form prescribed by the Company from time to time. The Grantee shall specify in the notice the election to exercise Options, the number of Shares for which it is being exercised (which may be equal to or lower than the aggregate number of Shares that have become exercisable at such time, subject to the last sentence of this Section), accompanied by payment of the aggregate Exercise Price for such Shares in the manner permitted by the Plan. In the event that Options are being exercised by the representative of the Grantee, if permitted under the Plan, the notice shall be accompanied by proof (satisfactory to the Company) of the representative’s right to exercise such Options.

 

3.2. After receiving a proper and duly executed notice of exercise in the form prescribed by the Company, the Company shall cause to be issued a certificate or certificates for the Shares as to which the Options have been exercised, registered in the name of the person exercising such Options, except that in case of Options designated as 102 Trustee Awards, the Shares shall be issued to and in the name of the Trustee for the benefit of the Grantee. The issuance shall be subject to the payment of any and all applicable taxes and compulsory payments by the Grantee. Subject to Section 19 of the Plan, the Grantee shall have no rights as a stockholder with respect to any Shares subject to Options until the Grantee shall have duly exercised the Options, paid the full Exercise Price therefor, if required, paid all applicable taxes and compulsory payments therefor and becomes the record holder of the subject Shares.

 

3.3. Without derogating from the provision of the Plan, in the event that the Company or, with respect to 102 Trustee Awards, the Trustee, determines that it is required to withhold any tax as a result of the exercise of Options, the Grantee, as a condition to the exercise of Options, shall make arrangements satisfactory to the Company and the Trustee, if applicable, to enable it to satisfy all withholding requirements. The Grantee shall also make arrangements satisfactory to the Company and the Trustee, if applicable, to enable it to satisfy any withholding requirements that may arise in connection with the vesting or disposition of Shares acquired pursuant to the grant of an Option under the Plan. Furthermore, the Grantee shall indemnify the Company and the Trustee, if applicable, and hold them harmless against and from any and all liability for any such tax or interest or penalty thereon, including without limitation, liabilities relating to withholding.

 

4. Payment of Exercise Price. The Exercise Price shall be paid in cash or in such other manner as determined in accordance with the Plan.

 

5. Repurchase Right. Grantee agrees that all Shares issued pursuant to the exercise of the Options shall be subject to certain repurchase rights in favor of the Company or its assigns as provided in the Plan.

 

 

 

 

6. Restricted Securities. Grantee acknowledges and understands that, unless the issuance of Shares that may be acquired upon exercise of the Options is registered under the Securities Act of 1934, as amended (the “Securities Act”), before any exercise of the Options, the Shares acquired upon exercise of the Options will be characterized as “restricted securities” under the federal securities laws, as the shares will be acquired from the Company in a transaction not involving a public offering, and that under such laws and applicable regulations the Shares may not be resold without registration under the Securities Act, except in certain limited circumstances. The Grantee represents to the Company that he or she is either familiar with Rule 144 promulgated under the Securities Act, as presently in effect, and understands the resale limitations imposed thereby and by the Securities Act, or has sought counsel from someone with such knowledge. The Grantee acknowledges that if an exemption from registration or qualification is available, it may be conditioned on various requirements, including, but not limited to, the time and manner of sale, the holding period for the Shares, and on requirements relating to the Company that are outside the Grantee’s control, and which the Company is under no obligation to satisfy and may not be able to satisfy. Prior to any transfer of the Shares by the Grantee, the Company retains the right to request and receive from the Grantee an opinion of counsel that the proposed transfer may be completed in compliance with all applicable federal and state securities laws.

 

7. Legend. Unless the issuance of Shares that may be acquired upon exercise of the Options is registered under the Securities Act, the Company may at any time place legends referencing the restriction imposed on the Shares (including, without limitation, right of first refusal and right of repurchase) and any applicable federal, state or foreign securities law restrictions on all certificates representing Shares subject to the provisions of this Agreement. The Grantee shall, at the request of the Company, promptly present to the Company any and all certificates representing Shares acquired pursuant to Options in the possession of the Grantee in order to carry out the provisions of this Section. Unless otherwise specified by the Company, legends placed on such certificates may include, but shall not be limited to, the following:

 

7.1. THE SECURITIES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) OR SUCH APPLICABLE LAWS OF OTHER JURISDICTIONS, OR QUALIFIED UNDER ANY SECURITIES LAW OR ANY OTHER JURISDICTION, AND, SUBJECT TO THEIR TERMS, MAY NOT BE OFFERED, SOLD, TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED UNLESS THERE IS AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR SUCH APPLICABLE LAWS OF OTHER JURISDICTIONS COVERING SUCH SECURITIES, OR THE COMPANY RECEIVES AN OPINION OF COUNSEL, SATISFACTORY TO THE COMPANY, STATING THAT SUCH OFFERING, SALE, TRANSFER, ASSIGNMENT, PLEDGE OR HYPOTHECATION IS EXEMPT FROM THE REGISTRATION OR PROSPECTUS DELIVERY REQUIREMENTS OF THE SECURITIES ACT OR THE QUALIFICATION REQUIREMENTS UNDER APPLICABLE LAW.

 

7.2. THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO THE COMPANY’S ARTICLES OF INCORPORATION, THE COMPANY’S SHARE INCENTIVE PLAN AND THE OPTION AGREEMENT WITH THE COMPANY, EACH AS AMENDED FROM TIME TO TIME, A COPY OF WHICH IS ON FILE AT THE PRINCIPAL OFFICE OF THIS COMPANY.

 

8. Term and Expiration. The Options shall expire in accordance with the Plan, including in case the Grantee’s employment or service terminates for any reason.

 

9. Tax Matters and Consultation.

 

9.1. THE GRANTEE IS ADVISED TO CONSULT WITH A TAX ADVISOR WITH RESPECT TO THE TAX CONSEQUENCES OF RECEIVING OR EXERCISING OPTIONS HEREUNDER. THE COMPANY DOES NOT ASSUME ANY RESPONSIBILITY TO ADVISE THE GRANTEE ON SUCH MATTERS, WHICH SHALL REMAIN SOLELY THE RESPONSIBILITY OF THE GRANTEE. Without derogating from Section 18 of the Plan, and notwithstanding anything to the contrary, including the indication under “Intended Type of Award” above, the Company shall be under no duty to ensure, and no representation or commitment is made, that the Options qualify or will qualify under any particular tax treatment (such as Section 102, ISO or any other treatment), nor shall the Company be required to take any action for the qualification of any Option under such tax treatment. If the Options do not qualify under any particular tax treatment it could result in adverse tax consequences to the Grantee. By signing below, Grantee agrees that the Company and its Affiliates and their respective employees, directors, officers and stockholders shall not be liable for any tax, penalty, interest or cost incurred by Grantee as a result of such determination, nor will any of them have any liability of any kind or nature in the event that, for any reason whatsoever, an Option does not qualify for any particular tax treatment.

 

 

 

 

9.2. Without limitation of the foregoing, with respect to Incentive Stock Option and Nonqualified Stock Option, there is no guarantee that the Internal Revenue Service (“IRS”) will determine that the Exercise Price of these Options represent the fair market value thereof as of the Date of Grant in compliance with the requirements of Section 409A of the Code. If the IRS determines that the Exercise Price is less than such fair market value it could result in adverse tax consequences to Grantee.

 

9.3. In case of Incentive Stock Options, adjustments made pursuant to the Plan with respect to Incentive Stock Options could constitute a “modification” of such Incentive Stock Options (as that term is defined in Section 424(h) of the Code) or could cause adverse tax consequences for the Grantee and the Grantee should consult with his or her tax advisor regarding the consequences of such “modification” on his or her income tax treatment with respect to the Incentive Stock Option.

 

10. Section 102 Awards.

 

10.1. Eligibility for Awards. Subject to Applicable Law, 102 Awards may only be granted to an “employee” within the meaning of Section 102(a) of the Ordinance (which as of the date hereof means (i) individuals employed by an Israeli company being the Company or any of its Affiliates, and (ii) individuals who are serving and are engaged personally (and not through an entity) as “office holders” by such an Israeli company), but may not be granted to a Controlling Shareholder (“Eligible 102 Grantees”). Eligible 102 Grantees may receive only 102 Awards, which may either be granted to a Trustee or granted under Section 102 of the Ordinance without a Trustee.

 

10.2. 102 Award Grant Date.

 

10.2.1. Each 102 Award will be deemed granted on the date determined by the Committee, subject to Section ‎10.2.2, provided that (i) the Grantee has signed all documents required by the Company or pursuant to Applicable Law, and (ii) with respect to 102 Trustee Awards, the Company has provided all applicable documents to the Trustee in accordance with the guidelines published by the ITA, and if this Agreement is not signed and delivered by the Grantee within 90 days from the date determined by the Committee (subject to Section ‎10.2.2), then such 102 Trustee Award shall be deemed granted on such later date as this Agreement is signed and delivered and on which the Company has provided all applicable documents to the Trustee in accordance with the guidelines published by the ITA. In the case of any contradiction, this provision and the date of grant determined pursuant hereto shall supersede and be deemed to amend any date of grant indicated in the Notice or in any corporate resolution or any agreement.

 

10.2.2. Unless otherwise permitted by the Ordinance, any grants of 102 Trustee Awards that are made on or after the date of the adoption of this Plan or an amendment to this Plan, as the case may be, that may become effective only at the expiration of thirty (30) days after the filing of this Plan or any amendment thereof (as the case may be) with the ITA in accordance with the Ordinance shall be conditional upon the expiration of such 30-day period, such condition shall be read and is incorporated by reference into any corporate resolutions approving such grants and into this Agreement and any agreement evidencing such grants (whether or not explicitly referring to such condition), and the date of grant shall be at the expiration of such 30-day period, whether or not the date of grant indicated therein corresponds with this Section ‎10.2. In the case of any contradiction, this provision and the date of grant determined pursuant hereto shall supersede and be deemed to amend any date of grant indicated in the Notice or in any corporate resolution or any agreement.

 

 

 

 

10.3. To the extent and with respect to 102 Trustee Awards, the Grantee acknowledges, undertakes and confirms that: (i) the Grantee fully understands that Section 102 Ordinance and the rules and regulations enacted thereunder apply to the Options, and (ii) the Grantee understands the provisions of Section 102 of the Ordinance, the tax track chosen thereunder and the implications thereof. If applicable, the terms of such Options shall also be subject to the terms of the Trust Agreement made between the Company and the Trustee for the benefit of the Grantee (as amended, the “Trust Agreement”), and the Grantee shall sign all documents requested by the Company or the Trustee, in accordance with and under the Trust Agreement. A copy of the Trust Agreement is available for the Grantee’s review, during normal working hours, at the Company’s offices.

 

10.4. Grantee Undertaking. Without derogating from the generality of the foregoing, to the extent and with respect to any Options that are 102 Capital Gain Track Awards, and as required by Section 102 of the Ordinance and the Rules, the Grantee acknowledges, undertakes and confirms in writing the following (which shall be apply and relate to all Awards granted to the Grantee, whether under this Plan or other plans maintained by the Company, and whether prior to or after the date hereof, if any):

 

10.4.1. The Grantee shall comply with all terms and conditions set forth in Section 102 of the Ordinance with regard to the “Capital Gain Track” and the applicable rules and regulations promulgated thereunder, as amended from time to time;

 

10.4.2. The Grantee is familiar with, and understands the provisions of, Section 102 of the Ordinance in general, and the tax arrangement under the “Capital Gain Track” in particular, and its tax consequences; the Grantee agrees that the Options and Shares that may be issued upon exercise of the Options (or otherwise in relation to the Options), will be held by a trustee appointed pursuant to Section 102 of the Ordinance for at least the duration of the Holding Period, as defined in Section 102 under the “Capital Gain Track”. The Grantee understands that any release of such Options or Shares from trust, or any sale of the Share prior to the termination of the Holding Period, will result in taxation at marginal tax rates, in addition to deductions of appropriate social security, health tax contributions or other compulsory payments; and

 

10.4.3. The Grantee agrees to the trust agreement signed between the Company, his employing company and the trustee appointed pursuant to Section 102 of the Ordinance and shall sign all documents requested by the Company or the Trustee, in accordance with and under the trust agreement.

 

 

11. Plan Termination or Amendment. The Board may terminate or amend the Plan or the Options at any time, subject to the Plan and any such amendment shall apply on the Grantee and this Option Agreement (including the Options and Shares issuable or issued pursuant thereto), without any required consent of the Grantee. Except as set forth above, this Agreement shall not be amended without the consent of the parties hereto.

 

12. Miscellaneous.

 

12.1. Further Assurances. The Grantee shall perform such further acts and execute such further documents as may reasonably be necessary by the Company to carry out and give full effect to the provisions of this Agreement and the Plan.

 

12.2. Fractional Shares. No fractional Share shall be issuable upon exercise or vesting of any Options and the number of Shares to be issued shall be rounded down to the nearest whole Share, with any Share remaining at the last vesting date due to such rounding to be issued upon exercise at such last vesting date.

 

12.3. Entire Agreement. This Agreement (together with the Notice and all Exhibits) and the Plan constitutes the full and entire understanding and agreement between the parties with regard to the subject matters hereof and thereof, and supersede all prior agreements and understandings, both written and oral (with no concession being made as to the existence of any such agreements and understandings).

 

12.4. Governing Law; Jurisdiction. This Agreement shall be governed by and construed according to the laws of the State of Israel, without regard to the conflict of law provisions thereof. Any dispute arising under or proceeding in relation to this Agreement shall be resolved exclusively in the competent court in Tel Aviv-Jaffa, and each of the parties hereby irrevocably submits to the exclusive jurisdiction of such court.

 

12.5. Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original and enforceable against the parties, and all of which together shall be considered one and the same agreement, it being understood that all parties need not sign the same counterpart. The exchange of an executed Agreement (in counterparts or otherwise) by facsimile transmission, electronic transmission or electronic signature shall be sufficient to bind the parties to the terms and conditions of this Agreement, as an original.

 

- Signature Pages Following -

 

 

 

 

IN WITNESS WHEREOF, the parties have duly executed and delivered this OPTION AGREEMENT as of the date last written below.

 

ScoutCam LTD  
   
Signed Electronically  
By: «Contact_Contact_FullName»  
Date of Signature: Manager_SIGN  
   
Grantee  
   
Signed Electronically  
By: «Contact_FullName»  
ID No.: : «Contact_IDSSN»  
Date of Signature: Employee_SIGN  

 

 

 

 

EXHIBIT A

 

THE PLAN

 

 

 

 

Market Stand-Off Undertaking

To: «Contact_FullName»

ScoutCam Inc. (the “Company”); and

The underwriters

 

Dear Sirs:

 

In connection with any underwritten public offering of equity securities of the Company pursuant to an effective registration statement filed under the U.S. Securities Act of 1933, as amended, or equivalent law in another jurisdiction, and in recognition of the benefit that such an offering will confer upon the undersigned as a stockholder of the Company, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the undersigned agrees with the Company and each underwriter, during the Lock Up Period (as defined below), that the undersigned will not, without the prior written consent of the Company or the underwriters (or the lead underwriter, as the underwriters shall agree among themselves), directly or indirectly, (i) lend, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant for the sale of, or otherwise dispose of or transfer any shares of the Company or any securities convertible into or exchangeable or exercisable for shares or securities of the Company, whether now owned or hereafter acquired by the undersigned or with respect to which the undersigned has or hereafter acquires the power of disposition (including, without limitation, awards under any Company share or equity plan) and any shares or other securities issued or distributed with respect to or in substitution of any of the foregoing (collectively, the “Lock Up Securities”), (ii) exercise any right with respect to the registration of any of the Lock Up Securities, or file or cause to be filed any registration statement in connection therewith, under the U.S. Securities Act of 1933, as amended, or equivalent law in another jurisdiction, or (iii) enter into any swap or any other agreement or any transaction that transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of the Lock Up Securities, whether any such swap or transaction in this clause (iii) or (i) above is to be settled by delivery of shares or other securities of the Company, in cash or otherwise. The foregoing provisions shall not apply to the sale of any shares to an underwriter pursuant to an underwriting agreement.

 

The restrictions contained in this letter shall be in effect for such period of time (the “Lock Up Period”): (A) until the expiration of 90 days following the effective date of such registration statement relating to any other public offering;; or (B) as shall be requested by the Company or the underwriter(s). Notwithstanding anything herein to the contrary, if the underwriter(s) and the Company agreed on a termination date of the Lock Up Period in the event of failure to consummation a certain public offering, then such termination shall apply also to the Lock Up Period hereunder with respect to that particular public offering.

 

In the event of a subdivision of the outstanding share capital of the Company, the distribution of any securities (whether or not of the Company), whether as bonus shares or otherwise, and whether as dividend or otherwise, a recapitalization, a reorganization (which may include a combination or exchange of shares or a similar transaction affecting the Company’s outstanding securities without receipt of consideration), a consolidation, a spin-off or other corporate divestiture or division, a reclassification or other similar occurrence, any new, substituted or additional securities which are by reason of such transaction distributed with respect to any Lock Up Securities, or into which such Lock Up Securities thereby become convertible, shall immediately be subject to the provisions and restrictions contained herein.

 

The undersigned agrees that, prior to engaging in any transaction or taking any other action that is subject to the terms of this letter during the Lock Up Period, it will give notice thereof to the Company and will not consummate such transaction or take any such action unless it has received written confirmation from the Company that the Lock Up Period has expired.

 

 

 

 

The Company may impose and the undersigned agrees and consents to the entry of stop transfer instructions with the Company’s transfer agent and registrar against the transfer of the Lock Up Securities except in compliance with the foregoing restrictions.

 

The undersigned understands that the Company and the underwriters are relying upon this letter in proceeding toward consummation of the offering. The underwriters in connection with a registration statement so filed are intended third party beneficiaries of this letter and shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto. The undersigned shall execute (and hereby empowers the Company as its proxy and attorney-in-fact to do so in his/her name) such separate agreement(s) as may be requested by the Company or the underwriters in connection with such registration statement and in the form required by them (which need not be identical to the provisions of this letter, and may include such additional provisions and restrictions as the underwriter(s) deem advisable) or that are necessary to give further effect thereto. The execution of such separate agreement(s) may be a condition by the Company to the exercise of any award under the Company’s share incentive plan(s).

 

This letter is irrevocable and shall be binding upon the undersigned’s heirs, legal representatives, successors, assigns, and the purchaser or transferee of any Lock Up Securities. The Company, may, at its discretion, and without any further consent, release or remove some or all of the restrictions contained in this letter, or allow certain exceptions to such restrictions (whether in general or in any specific case, and such relief or exceptions need not be the same or identical among to all persons bound by them).

 

This letter shall not derogate from any provision or restriction contained in any Company’s share incentive plan(s), agreement between the undersigned the Company or the underwriters, or any restriction or limitation pursuant to applicable law.

 

  Very truly yours,
   
  Signed Electronically
  By : «Contact_FullName»
  ID No.: : «Contact_IDSSN»
  Date of Signature: Employee_SIGN

 

 

 

 EX-10.5 6 ex10-5.htm

 

Exhibit 10.5

 

NOTICE OF RESTRICTED SHARE UNITS GRANT

 

You have been granted the following Restricted Share Units (the “RSUs”) to purchase shares of common stock par value US$ 0.001 each (the “Shares”) of ScoutCam Inc. (the “Company”), pursuant and subject to the terms and conditions of the Company’s 2020 Share Incentive Plan, a copy of which is attached hereto as Exhibit A (as may be amended from time to time, the “Plan”), and the additional terms and conditions contained herein. Unless otherwise defined, capitalized terms used herein shall have the meaning ascribed to them under the Plan.

 

Grantee:  
Date of Grant:  

 

such date being subject to Section 9.4 of the Plan and Section 10.2 of this Agreement

 

Intended Type of
Award:
(🗸check one): ______ RSU designated as 102 Capital Gains Track Award (with Trustee) (Israel)
  ______ RSU designated as 102 Non-Trustee Award (Israel)/ RSU designated as
  ______3(9) Award (Israel)
  ______ Other

 

the above being subject to Section 9 of the Restricted Share Unit Agreement, Section 18.4 of the Plan and applicable law

 

Number
RSUs Granted:  
 
Vesting
Commencement Date:  

 

Vesting Schedule:

Subject to the terms of the Plan (including Sections 6.6 and 6.7 thereof), the RSUs shall vest and become exercisable under the following schedule: 33.33% of the Shares covered by the RSUs, on the first anniversary of the date on the Vesting Commencement Date, and 8.33% of the Shares covered by the RSUs at the end of each subsequent three- month period thereafter over the course of the subsequent 2 years; provided, in each case, that the Grantee remains continuously as a Service Provider of the Company or its Affiliates throughout each such vesting date; and, further, that the each of the outstanding RSUs shall immediately vest upon the occurrence of the following: (i) the sale of all or substantially all of the assets of the Company, (ii) the sale of more than fifty percent (50%) of the outstanding common stock of the Company in a non-public sale, (iii) the dissolution or liquidation of the Company, or (iv) any merger, share exchange, consolidation or other reorganization or business combination of the Company if immediately after such transaction either (A) persons who were directors of the Company immediately prior to such transaction do not constitute at least a majority of the directors of the surviving entity, or (B) persons who hold a majority of the voting capital stock of the surviving entity are not persons who held a majority of the voting capital stock of the Company immediately prior to such transaction.

   
Exercise Period: The date determined in accordance with and subject to Section 8 of the Restricted Share Unit Agreement and the provisions of the Plan.

 

The RSUs are governed by this Notice of Restricted Share Units Grant and by the provisions of the Plan and the Restricted Share Unit Agreement, both of which are attached to and made an integral part of this Notice. By signing the Award Agreement, the Grantee acknowledges receipt of copies of the Plan and the Restricted Share Unit Agreement, represents that the Grantee read and is familiar with their provisions, and hereby accepts the RSUs subject to all of their terms and conditions.

 

1

 

 

THIS AWARD AGREEMENT AND THE SECURITIES ISSUABLE UPON VESTING OF THE RSUS HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) OR SUCH APPLICABLE LAWS OF OTHER JURISDICTIONS, OR QUALIFIED UNDER ANY SECURITIES LAW OR ANY OTHER JURISDICTION, AND, SUBJECT TO THEIR TERMS, MAY NOT BE OFFERED, SOLD, TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED UNLESS THERE IS AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR SUCH APPLICABLE LAWS OF OTHER JURISDICTIONS COVERING THIS AGREEMENT AND/OR SUCH SECURITIES, OR THE HOLDER RECEIVES AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY STATING THAT SUCH OFFERING, SALE, TRANSFER, ASSIGNMENT, PLEDGE OR HYPOTHECATION IS EXEMPT FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF THE SECURITIES ACT AND THE QUALIFICATION REQUIREMENTS UNDER APPLICABLE LAW.

 

RESTRICTED SHARE

UNIT AGREEMENT

 

The Company has granted to the Grantee named in the Notice of Restricted Shares Units Grant (“Notice”) to which this Restricted Share Unit Agreement (this “Agreement”) is attached RSUs upon the terms and conditions set forth in the Notice and this Agreement. The RSUs have been granted pursuant to and shall in all respects be subject to the terms and conditions of the Notice, this Agreement and the Plan, the provisions of which are incorporated herein by reference and made an integral part of this Agreement.

 

By signing this Agreement, the Grantee: (a) represents that the Grantee has received copies of, and has read and is familiar with the terms and conditions of, the Notice, the Plan and this Agreement, (b) accepts that the RSUs, the Shares issued upon the vest thereof and/or any securities issued or distributed with respect thereto are subject to all of the terms and conditions of the Notice, the Plan this Agreement, the Trust Agreement (as defined below) and any other documents ancillary hereto or thereto, and (c) agrees to accept as binding, conclusive and final all decisions and interpretations of the Board or the Committee upon any questions arising under the Notice, the Plan or this Agreement (whether before or after the issuance of Shares pursuant to the RSUs). While certain terms and conditions are included in this Agreement, such terms and conditions shall not in any way derogate from the applicability of all other terms and conditions set forth in the Plan. The Grantee acknowledges that the terms and conditions of the Plan may be amended from time to time as set forth therein, and therefore, any reference to the Plan shall be deemed to refer to the Plan as amended from time to time, including any amendments adopted after the date of grant. Unless otherwise stated, in the event of any inconsistency or contradiction between any of the terms of this Agreement and the provisions of the Plan, the terms and provisions of this Agreement shall prevail.

 

1. No Disposition of Awards. The RSUs shall not be sold, pledged or otherwise transferred (whether by operation of law or otherwise), and shall not be subject to sale under execution, attachment, levy or similar process (each of the foregoing, a “Transfer”) other than by will or by the laws of descent and distribution.

 

2. Issuance and Disposition of Shares.

 

2.1. Legal Compliance. The Company shall have no obligations to issue Shares pursuant to the settlement of RSUs and RSUs may not be settled (even if vested), if the issuance of Shares upon settlement would constitute a violation of any Applicable Laws as determined by the Company, including, applicable federal, state or foreign securities laws or other law or regulations or the requirements of any stock exchange or market system upon which the Shares may then be listed. THE GRANTEE IS CAUTIONED THAT THE RSUS MAY NOT BE SETTLED UNLESS THE FOREGOING CONDITIONS AND THOSE SET FORTH IN THE PLAN ARE SATISFIED.

 

2.2. Provisions Governing Shares. Shares issued upon vesting of RSUs shall be subject to the restrictions referred to in Section 16 of the Plan (Conditions upon Issuance of Shares; Governing Provisions) and in this Agreement, the Articles of Incorporation of the Company, any limitation, restriction or obligation included in any stockholders agreement applicable to all or substantially all of the holders of Shares (regardless of whether or not the Grantee is a formal party to such stockholders agreement), any other governing documents of the Company, and all policies, manuals and internal regulations adopted by the Company from time to time, in each case, as may be amended from time to time, including, without limitation, any provisions included therein concerning restrictions or limitations on disposition of Shares (such as, but not limited to, right of first refusal and lock-up/market stand-off) or grant of any rights with respect thereto, forced sale and bring along provisions, any provisions concerning a restrictions on the use of inside information and other provisions deemed by the Company to be appropriate in order to ensure compliance with Applicable Laws and with the requirements of any transaction entered into or proposed to be entered into by the Company. The Grantee is deemed to have undertaken to comply with all the foregoing provisions. The Grantee shall execute (and authorizes any person designated by the Company to so execute, as well as (if applicable) the Trustee holding any Shares for the Grantee’s behalf) such separate agreement(s) as may be requested by the Company relating to matters set forth in or otherwise for the purpose of implementing this Section 2.2. The execution of such separate agreement(s) may be a condition by the Company to the exercise of any Award and the Company (and, if applicable, the Trustee) may exercise its authorization above and sign such agreement on behalf of the Grantee or subject the Grantee to the provisions of such agreements.

 

2

 

 

2.3. Waiver. As a material precondition to the Company’s grant of RSUs and issuance of any Shares under the Plan, the Grantee hereby irrevocably waives any right of first refusal, pre-emptive, co-sale, participation rights or other similar rights with respect to any prior or future Transfer of any shares in the Company by other stockholders or the issuance of securities by the Company, if such right was so provided in any agreement between the Company and any of its stockholders, in the Articles of Incorporation or in any other governing document of the Company. The Grantee acknowledges and agrees that the Company and its stockholders are entitled to rely on this irrevocable waiver.

 

2.4. Additional or Substituted Securities. In the event that in connection with the declaration of a share dividend (bonus shares), a share split, a reverse share split, a reorganization (which may include a combination or exchange of shares), a consolidation, a spin-off or other corporate divestiture or division, a recapitalization, a reclassification or other similar occurrence affecting the Company’s outstanding securities without receipt of consideration (or in consideration for the par value, if shares bear par value), any new, substituted or additional securities or other property (other than cash dividend) are distributed by reason of such occurrence with respect to any Shares which are subject to this Section 2, or into which such Shares thereby become convertible, then such substituted or additional securities or other property (if distributed) shall immediately be subject to this Section 2. Any adjustments to reflect the distribution of such securities or other property shall be conclusively determined by the Company. The terms and conditions contained herein and in the Plan in respect of the RSU and/or the Shares shall apply to any new, substituted or additional securities or other property resulting from the above adjustments.

 

2.5. Market Stand-Off. As a material precondition to the grant of RSUs and the issuance of any Shares in accordance with the Plan, and without limitation of Section 17 of the Plan, the Grantee hereby executes a market stand-off undertaking in the form attached hereto as Exhibit B.

 

2.6. Data Privacy; Data Transfer. Information related to the Grantee and Award(s) hereunder, as shall be received from Grantee or others, and/or held by, the Company or its Affiliates from time to time, and which information may include sensitive and personal information related to the Grantee (“Information”), will be used by the Company or its Affiliates (or third parties appointed by any of them, including the Trustee) to comply with any applicable legal requirement, or for administration of the Plan as they deems necessary or advisable, or for the respective business purposes of the Company or its Affiliates (including in connection with transactions related to any of them). The Company and its Affiliates shall be entitled to transfer the Information among the Company or its Affiliates and to third parties for the purposes set forth above, which may include persons located abroad (including, any person administering the Plan or providing services in respect of the Plan or in order to comply with legal requirements, or the Trustee, their respective officers, directors, employees and representatives, and the respective successors and assigns of any of the foregoing), and any person so receiving Information shall be entitled to transfer it for the purposes set forth above. The Company shall use commercially reasonable efforts to ensure that the transfer of such Information shall be limited to the reasonable and necessary scope. By receiving an Award hereunder, Grantee acknowledges and agrees that the Information is provided at Grantee’s free will and that Grantee hereby consents to the storage and transfer of the Information as set forth above.

 

3

 

 

3. Issuance of Shares.

 

3.1. As soon as practicable following the vesting date, subject to payment of applicable taxes and execution of any document required by the Company, the Company shall cause to be issued a certificate or certificates for the Shares as to which the RSUs have been vested, registered in the name of the Grantee, except that in case of RSUs designated as 102 Trustee Awards, the Shares shall be issued to and in the name of the Trustee for the benefit of the Grantee. The issuance shall be subject to the payment of any and all applicable taxes and compulsory payments by the Grantee. Subject to Section 19 of the Plan, the Grantee shall have no rights as a stockholder with respect to any Shares subject to RSUs until the Grantee shall have duly paid all applicable taxes and compulsory payments therefor and the Shares are allotted pursuant to vesting of RSUs and the Grantee becomes the record holder of the subject Shares.

 

3.2. Without derogating from the provision of the Plan, in the event that the Company or, with respect to 102 Trustee Awards, the Trustee, determines that it is required to withhold any tax as a result of the vesting of RSUs, the Grantee shall make arrangements satisfactory to the Company and the Trustee, if applicable, to enable it to satisfy all withholding requirements. The Grantee shall also make arrangements satisfactory to the Company and the Trustee, if applicable, to enable it to satisfy any withholding requirements that may arise in connection with the vesting or disposition of Shares acquired pursuant to the grant of an RSU under the Plan. Furthermore, the Grantee shall indemnify the Company and the Trustee, if applicable, and hold them harmless against and from any and all liability for any such tax or interest or penalty thereon, including without limitation, liabilities relating to withholding.

 

4. Restricted Securities. Grantee acknowledges and understands that, unless the issuance of Shares that may be acquired upon vesting of the RSUs is registered under the Securities Act of 1934, as amended (the “Securities Act”), the Shares acquired upon vesting of the RSUs will be characterized as “restricted securities” under the federal securities laws, as the shares will be acquired from the Company in a transaction not involving a public offering, and that under such laws and applicable regulations the Shares may not be resold without registration under the Securities Act, except in certain limited circumstances. The Grantee represents to the Company that he or she is either familiar with Rule 144 promulgated under the Securities Act, as presently in effect, and understands the resale limitations imposed thereby and by the Securities Act, or has sought counsel from someone with such knowledge. The Grantee acknowledges that if an exemption from registration or qualification is available, it may be conditioned on various requirements, including, but not limited to, the time and manner of sale, the holding period for the Shares, and on requirements relating to the Company that are outside the Grantee’s control, and which the Company is under no obligation to satisfy and may not be able to satisfy. Prior to any transfer of the Shares by the Grantee, the Company retains the right to request and receive from the Grantee an opinion of counsel that the proposed transfer may be completed in compliance with all applicable federal and state securities laws.

 

4

 

 

5. Legend. Unless the issuance of Shares that may be acquired upon vesting of the RSUs is registered under the Securities Act, the Company may at any time place legends referencing the restriction imposed on the Shares (including, without limitation, right of first refusal and right of repurchase) and any applicable federal, state or foreign securities law restrictions on all certificates representing Shares subject to the provisions of this Agreement. The Grantee shall, at the request of the Company, promptly present to the Company any and all certificates representing Shares acquired pursuant to RSUs in the possession of the Grantee in order to carry out the provisions of this Section. Unless otherwise specified by the Company, legends placed on such certificates may include, but shall not be limited to, the following:

 

5.1. THE SECURITIES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) OR SUCH APPLICABLE LAWS OF OTHER JURISDICTIONS, OR QUALIFIED UNDER ANY SECURITIES LAW OR ANY OTHER JURISDICTION, AND, SUBJECT TO THEIR TERMS, MAY NOT BE OFFERED, SOLD, TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED UNLESS THERE IS AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR SUCH APPLICABLE LAWS OF OTHER JURISDICTIONS COVERING SUCH SECURITIES, OR THE COMPANY RECEIVES AN OPINION OF COUNSEL, SATISFACTORY TO THE COMPANY, STATING THAT SUCH OFFERING, SALE, TRANSFER, ASSIGNMENT, PLEDGE OR HYPOTHECATION IS EXEMPT FROM THE REGISTRATION OR PROSPECTUS DELIVERY REQUIREMENTS OF THE SECURITIES ACT OR THE QUALIFICATION REQUIREMENTS UNDER APPLICABLE LAW.

 

5.2. THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO THE COMPANY’S ARTICLES OF INCORPORATION, THE COMPANY’S SHARE INCENTIVE PLAN AND THE RESTRICTED SHARE UNIT AGREEMENT WITH THE COMPANY, EACH AS AMENDED FROM TIME TO TIME, A COPY OF WHICH IS ON FILE AT THE PRINCIPAL OFFICE OF THIS COMPANY.

 

6. Term and Expiration. The RSUs shall expire in accordance with the Plan, including in case the Grantee’s employment or service terminates for any reason.

 

7. Tax Matters and Consultation.

 

7.1. THE GRANTEE IS ADVISED TO CONSULT WITH A TAX ADVISOR WITH RESPECT TO THE TAX CONSEQUENCES OF RECEIVING OR RSUS HEREUNDER. THE COMPANY DOES NOT ASSUME ANY RESPONSIBILITY TO ADVISE THE GRANTEE ON SUCH MATTERS, WHICH SHALL REMAIN SOLELY THE RESPONSIBILITY OF THE GRANTEE. Without derogating from Section 18 of the Plan, and notwithstanding anything to the contrary, including the indication under “Intended Type of Award” above, the Company shall be under no duty to ensure, and no representation or commitment is made, that the RSUs qualify or will qualify under any particular tax treatment (such as Section 102 or any other treatment), nor shall the Company be required to take any action for the qualification of any RSU under such tax treatment. If the RSUs do not qualify under any particular tax treatment it could result in adverse tax consequences to the Grantee. By signing below, Grantee agrees that the Company and its Affiliates and their respective employees, directors, officers and stockholders shall not be liable for any tax, penalty, interest or cost incurred by Grantee as a result of such determination, nor will any of them have any liability of any kind or nature in the event that, for any reason whatsoever, an RSU does not qualify for any particular tax treatment.

 

8. Section 102 Awards.

 

8.1. Eligibility for Awards. Subject to Applicable Law, 102 Awards may only be granted to an “employee” within the meaning of Section 102(a) of the Ordinance (which as of the date hereof means (i) individuals employed by an Israeli company being the Company or any of its Affiliates, and (ii) individuals who are serving and are engaged personally (and not through an entity) as “office holders” by such an Israeli company), but may not be granted to a Controlling Shareholder (“Eligible 102 Grantees”). Eligible 102 Grantees may receive only 102 Awards, which may either be granted to a Trustee or granted under Section 102 of the Ordinance without a Trustee.

 

5

 

 

8.2. 102 Award Grant Date.

 

8.2.1. Each 102 Award will be deemed granted on the date determined by the Committee, subject to Section 10.2.2, provided that (i) the Grantee has signed all documents required by the Company or pursuant to Applicable Law, and (ii) with respect to 102 Trustee Awards, the Company has provided all applicable documents to the Trustee in accordance with the guidelines published by the ITA, and if this Agreement is not signed and delivered by the Grantee within 90 days from the date determined by the Committee (subject to Section 10.2.2), then such 102 Trustee Award shall be deemed granted on such later date as this Agreement is signed and delivered and on which the Company has provided all applicable documents to the Trustee in accordance with the guidelines published by the ITA. In the case of any contradiction, this provision and the date of grant determined pursuant hereto shall supersede and be deemed to amend any date of grant indicated in the Notice or in any corporate resolution or any agreement.

 

8.2.2. Unless otherwise permitted by the Ordinance, any grants of 102 Trustee Awards that are made on or after the date of the adoption of this Plan or an amendment to this Plan, as the case may be, that may become effective only at the expiration of thirty (30) days after the filing of this Plan or any amendment thereof (as the case may be) with the ITA in accordance with the Ordinance shall be conditional upon the expiration of such 30-day period, such condition shall be read and is incorporated by reference into any corporate resolutions approving such grants and into this Agreement and any agreement evidencing such grants (whether or not explicitly referring to such condition), and the date of grant shall be at the expiration of such 30-day period, whether or not the date of grant indicated therein corresponds with this Section 10.2. In the case of any contradiction, this provision and the date of grant determined pursuant hereto shall supersede and be deemed to amend any date of grant indicated in the Notice or in any corporate resolution or any agreement.

 

8.3. To the extent and with respect to 102 Trustee Awards, the Grantee acknowledges, undertakes and confirms that: (i) the Grantee fully understands that Section 102 Ordinance and the rules and regulations enacted thereunder apply to the RSUs, and (ii) the Grantee understands the provisions of Section 102 of the Ordinance, the tax track chosen thereunder and the implications thereof. If applicable, the terms of such RSUs shall also be subject to the terms of the Trust Agreement made between the Company and the Trustee for the benefit of the Grantee (as amended, the “Trust Agreement”), and the Grantee shall sign all documents requested by the Company or the Trustee, in accordance with and under the Trust Agreement. A copy of the Trust Agreement is available for the Grantee’s review, during normal working hours, at the Company’s offices.

 

8.4. Grantee Undertaking. Without derogating from the generality of the foregoing, to the extent and with respect to any RSUs that are 102 Capital Gain Track Awards, and as required by Section 102 of the Ordinance and the Rules, the Grantee acknowledges, undertakes and confirms in writing the following (which shall be apply and relate to all Awards granted to the Grantee, whether under this Plan or other plans maintained by the Company, and whether prior to or after the date hereof, if any):

 

8.4.1. The Grantee shall comply with all terms and conditions set forth in Section 102 of the Ordinance with regard to the “Capital Gain Track” and the applicable rules and regulations promulgated thereunder, as amended from time to time;

 

6

 

 

8.4.2. The Grantee is familiar with, and understands the provisions of, Section 102 of the Ordinance in general, and the tax arrangement under the “Capital Gain Track” in particular, and its tax consequences; the Grantee agrees that the RSUs and Shares that may be issued upon vesting of the RSUs (or otherwise in relation to the RSUs), will be held by a trustee appointed pursuant to Section 102 of the Ordinance for at least the duration of the Holding Period, as defined in Section 102 under the “Capital Gain Track”. The Grantee understands that any release of such RSUs or Shares from trust, or any sale of the Share prior to the termination of the Holding Period, will result in taxation at marginal tax rates, in addition to deductions of appropriate social security, health tax contributions or other compulsory payments; and

 

8.4.3. The Grantee agrees to the trust agreement signed between the Company, his employing company and the trustee appointed pursuant to Section 102 of the Ordinance and shall sign all documents requested by the Company or the Trustee, in accordance with and under the trust agreement.

 

9. Plan Termination or Amendment. The Board may terminate or amend the Plan or the RSUs at any time, subject to the Plan and any such amendment shall apply on the Grantee and this Restricted Share Unit Agreement (including the RSUs and Shares issuable or issued pursuant thereto), without any required consent of the Grantee. Except as set forth above, this Agreement shall not be amended without the consent of the parties hereto.

 

10. Miscellaneous.

 

10.1. Further Assurances. The Grantee shall perform such further acts and execute such further documents as may reasonably be necessary by the Company to carry out and give full effect to the provisions of this Agreement and the Plan.

 

10.2. Fractional Shares. No fractional Share shall be issuable upon vesting of any RSUs and the number of Shares to be issued shall be rounded down to the nearest whole Share, with any Share remaining at the last vesting date due to such rounding to be issued upon exercise at such last vesting date.

 

10.3. Entire Agreement. This Agreement (together with the Notice and all Exhibits) and the Plan constitutes the full and entire understanding and agreement between the parties with regard to the subject matters hereof and thereof, and supersede all prior agreements and understandings, both written and oral (with no concession being made as to the existence of any such agreements and understandings).

 

10.4. Governing Law; Jurisdiction. This Agreement shall be governed by and construed according to the laws of the State of Israel, without regard to the conflict of law provisions thereof. Any dispute arising under or proceeding in relation to this Agreement shall be resolved exclusively in the competent court in Tel Aviv-Jaffa, and each of the parties hereby irrevocably submits to the exclusive jurisdiction of such court.

 

10.5. Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original and enforceable against the parties, and all of which together shall be considered one and the same agreement, it being understood that all parties need not sign the same counterpart. The exchange of an executed Agreement (in counterparts or otherwise) by facsimile transmission, electronic transmission or electronic signature shall be sufficient to bind the parties to the terms and conditions of this Agreement, as an original.

 

- Signature Pages Following -

 

7

 

 

IN WITNESS WHEREOF, the parties have duly executed and delivered this RESTRICTED SHARE UNIT AGREEMENT as of the date last written below.

 

Signed Electronically:

 

SCOUTCAM INC.

Name: Tatiana Yosef  
Date of Signature: Manager_SIGN  

 

GRANTEE

Name:    

I.D. NO.:    
Date of Signature: Employee_SIGN  

 

8

 

 

EXHIBIT A

 

THE PLAN

 

9

 

 

Market Stand-Off Undertaking

To:

ScoutCam Inc. (the “Company”); and

The underwriters

 

Dear Sirs:

 

In connection with any underwritten public offering of equity securities of the Company pursuant to an effective registration statement filed under the U.S. Securities Act of 1933, as amended, or equivalent law in another jurisdiction, and in recognition of the benefit that such an offering will confer upon the undersigned as a stockholder of the Company, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the undersigned agrees with the Company and each underwriter, during the Lock Up Period (as defined below), that the undersigned will not, without the prior written consent of the Company or the underwriters (or the lead underwriter, as the underwriters shall agree among themselves), directly or indirectly, (i) lend, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant for the sale of, or otherwise dispose of or transfer any shares of the Company or any securities convertible into or exchangeable or exercisable for shares or securities of the Company, whether now owned or hereafter acquired by the undersigned or with respect to which the undersigned has or hereafter acquires the power of disposition (including, without limitation, awards under any Company share or equity plan) and any shares or other securities issued or distributed with respect to or in substitution of any of the foregoing (collectively, the “Lock Up Securities”), (ii) exercise any right with respect to the registration of any of the Lock Up Securities, or file or cause to be filed any registration statement in connection therewith, under the U.S. Securities Act of 1933, as amended, or equivalent law in another jurisdiction, or (iii) enter into any swap or any other agreement or any transaction that transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of the Lock Up Securities, whether any such swap or transaction in this clause (iii) or (i) above is to be settled by delivery of shares or other securities of the Company, in cash or otherwise. The foregoing provisions shall not apply to the sale of any shares to an underwriter pursuant to an underwriting agreement.

 

The restrictions contained in this letter shall be in effect for such period of time (the “Lock Up Period”): (A) until the expiration of 90 days following the effective date of such registration statement relating to any other public offering;; or (B) as shall be requested by the Company or the underwriter(s). Notwithstanding anything herein to the contrary, if the underwriter(s) and the Company agreed on a termination date of the Lock Up Period in the event of failure to consummation a certain public offering, then such termination shall apply also to the Lock Up Period hereunder with respect to that particular public offering.

 

In the event of a subdivision of the outstanding share capital of the Company, the distribution of any securities (whether or not of the Company), whether as bonus shares or otherwise, and whether as dividend or otherwise, a recapitalization, a reorganization (which may include a combination or exchange of shares or a similar transaction affecting the Company’s outstanding securities without receipt of consideration), a consolidation, a spin-off or other corporate divestiture or division, a reclassification or other similar occurrence, any new, substituted or additional securities which are by reason of such transaction distributed with respect to any Lock Up Securities, or into which such Lock Up Securities thereby become convertible, shall immediately be subject to the provisions and restrictions contained herein.

 

The undersigned agrees that, prior to engaging in any transaction or taking any other action that is subject to the terms of this letter during the Lock Up Period, it will give notice thereof to the Company and will not consummate such transaction or take any such action unless it has received written confirmation from the Company that the Lock Up Period has expired.

 

The Company may impose and the undersigned agrees and consents to the entry of stop transfer instructions with the Company’s transfer agent and registrar against the transfer of the Lock Up Securities except in compliance with the foregoing restrictions.

 

10

 

 

The undersigned understands that the Company and the underwriters are relying upon this letter in proceeding toward consummation of the offering. The underwriters in connection with a registration statement so filed are intended third party beneficiaries of this letter and shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto. The undersigned shall execute (and hereby empowers the Company as its proxy and attorney-in-fact to do so in his/her name) such separate agreement(s) as may be requested by the Company or the underwriters in connection with such registration statement and in the form required by them (which need not be identical to the provisions of this letter, and may include such additional provisions and restrictions as the underwriter(s) deem advisable) or that are necessary to give further effect thereto. The execution of such separate agreement(s) may be a condition by the Company to the exercise of any award under the Company’s share incentive plan(s).

 

This letter is irrevocable and shall be binding upon the undersigned’s heirs, legal representatives, successors, assigns, and the purchaser or transferee of any Lock Up Securities. The Company, may, at its discretion, and without any further consent, release or remove some or all of the restrictions contained in this letter, or allow certain exceptions to such restrictions (whether in general or in any specific case, and such relief or exceptions need not be the same or identical among to all persons bound by them).

 

This letter shall not derogate from any provision or restriction contained in any Company’s share incentive plan(s), agreement between the undersigned the Company or the underwriters, or any restriction or limitation pursuant to applicable law.

 

Very truly yours,

 

Signed Electronically:

 

GRANTEE

 

Name:    

I.D. NO.:   
Date of Signature: Employee_SIGN 

 

11

 

 EX-10.23 7 ex10-23.htm

 

Exhibit 10.23

 

Employment Agreement

 

Of September 20, 2022

 

Between: ScoutCam Ltd., Company No. 515950400

 

Of 7A Gan Hata’asiya St., Omer, Israel

 

And: Jacob Avinu, identity no. ***

 

Address: *** (the “Employee”)

 

Employment and Compensation

 

1.The Parties wish to enter into an employment agreement for an unfixed period, in accordance with the conditions and provisions of this Employment Agreement. The date of commencement of the Employee’s employment, his job, his direct supervisor and other issues relating to the conditions of the Employee’s employment, including consideration, are set out in Appendix A, which is attached hereto.

 

2.In the performance of his job, the Employee shall devote all of his time, attention, ability and effort exclusively for the performance of his duties at the Company and he undertakes not to engage, either as an employee or otherwise, in any business, commercial or professional activities, either for consideration or otherwise, during the term of his employment, without receiving the Company’s prior written consent to such. The provisions of this section shall not derogate from the Employee’s undertakings as set out in Appendix B which is attached hereto.

 

3.Each party shall be entitled to rescind this Agreement at any time, by giving prior notice as set out in Appendix A below, and subject to any law.

 

4.Notwithstanding the provisions of section 3 above, and without derogating from its rights under this Agreement or under any law, the Company shall be entitled to terminate the employment of the Employee without prior notice, upon the occurrence of one of the following cases: (a) breach of the Employee’s fiduciary duty, intentional damage to the Company’s property, dealing in competing activity or any breach of Appendix B below; or (b) a fundamental breach of the provisions of this Agreement on condition that the Employee has not remedied the breach (to the extent that it can be remedied) within 7 days of receipt of a warning from the Company; or (c) indictment of the Employee for a criminal offense (except for a fine-related offense) or for involvement in sexual harassment incidentally to the Employee’s employment at the Company; or (d) the Employee has put himself in a position of conflict of interests; or (e) any other circumstance in respect of which it is legally permissible to fire an employee without the giving of prior notice.

 

 

 

 

5.The Employee shall not have a right of lien over the assets, equipment or any other of the Company’s property that might be in his possession. The Employee shall return all of the Company’s property that is in his possession not later than the date of termination of employer-employee relations, prior to his taking any unpaid leave or within 7 days of receipt of a demand to do so from the Company.

 

6.The provisions of this Agreement shall not derogate from any right afforded to the Employee under any law, extension order, collective agreement, employment contract or any other contract relating to the conditions of his employment.

 

Confidentiality, Prohibition of Competition and Title to Inventions

 

7.Together with the execution of this Agreement, the Employee shall sign an undertaking to the Company regarding confidentiality, prohibition of unfair competition, and title to inventions, which is attached hereto as Appendix B.

 

Representations and Undertakings of the Employee

 

The Employee declares and undertakes as follows:

 

8.He has the ability, skills and knowledge that are necessary for the performance of his Job pursuant to this Agreement and he does not suffer from any physical or mental health deficiency that might unreasonably prevent or impede him in the performance of his job and his other obligations under this Agreement.

 

9.He is not bound by any undertaking or other agreement whatsoever that might restrict or prevent him from entering into this Agreement and performing his undertakings hereunder. By executing this Agreement and performing his job, he is not and will not be in breach of, or in a conflict of interests with: (1) the rights of his previous employers or his undertakings to them; or (2) his undertakings under any other document to which he is a party or which binds him.

 

10.He shall give notice to the Company, immediately, of any matter or subject in respect of which he or his close family might have a personal interest or that might generate a conflict of interests with his job and employment at the Company.

 

11.He shall not receive any beneficial interest from any third party, directly or indirectly, with respect to his employment. Should the Employee breach this undertaking, then without derogating from the rest of the Company’s rights, the beneficial interest or the value thereof shall be the property of the Company alone, and the Employee hereby grants the Company leave to deduct the value of the beneficial interest from any sum that may be owing to the Employee from it. This section shall not apply to gifts or benefits of a marginal value.

 

 

 

 

12.In the context of his employment, he shall not act in contravention of the signature rights that are prescribed by the Company.

 

13.Employee acknowledges and agrees that from time to time Employee may be required by the Company to travel and stay abroad as part of Employee’s obligations under this Agreement. Employee hereby acknowledges and agrees that while Employee is abroad as part of Employee’s obligations under this Agreement, Employee shall serve as a senior representative of the Company, a position which requires a special degree of personal trust, as defined in the Working Hours and Rest Law, 1951 (the “Working Hours and Rest Law”). Therefore, in these special circumstances, the provisions of the Working Hours and Rest Law shall not apply to the Employee’s employment under this Agreement. Employee acknowledges that while Employee is abroad as part of Employee’s obligations under this Agreement, Employee shall be required to work “overtime” hours, including during late hours and during “weekly hours of rest”, and that Employee shall not be granted any additional compensation with regard to such “overtime” hours. Employee acknowledges that the monetary implications of this provision have been taken into account by the parties to this Agreement in their decision on the compensation specified in Appendix A and by the Employee in the Employee’s decision to engage in this Agreement.

 

14.For the purpose of performance of his job, the Company may provide the Employee with a computer, hardware, software, an email address and/or mobile telephone as the case may be (“Computers”) which shall be the exclusive property of the Company. Subject to the Company’s procedures in this regard, and without derogating from his undertakings and the performance of his job pursuant to this Agreement, the Employee shall be entitled to make reasonable, private use of the Computers provided that the Employee shall not be entitled to store private files on the Computers (except for private folders that are prominently marked as such) and shall not be entitled to store Company files on private storage measures. It is clarified that the professional email address shall be used for professional purposes only, whilst the Employee shall be entitled, for private purposes, to use external email services (such as gmail).

 

15.The Employee is aware and agrees that: (1) the Company may allow other employees and third parties to make use of the Computers; (2) in order to preserving its legitimate interests, the Company may monitor the activities on the Computers, including the usage log and the contents of email and internet correspondence, which shall be admissible as evidence in legal proceedings; (3) in light of the Employee’s undertakings above, the Employee shall not have a right to privacy with respect to the contents of the Computers, with the exception of private folder that have been prominently marked as such.

 

16.The Employee is aware and agrees that the information about him and about the conditions of his employment which may be accrued and documented by the Company (the “Information”) may be provided to third parties, including outside of Israel, on condition that: (a) such transfer is effected for the purpose of the performance of some relevant legal provision or for the purpose of the Company’s business (including any transactions related thereto); (b) no information shall be provided beyond what is necessary and reasonable; (c) the party to which the information is provided shall undertake to the Company, to the extent that such is possible and relevant, that it shall maintain the privacy of the information at a level of protection that is at least that which is employed by the Company with respect to the information.

 

 

 

 

17.In the event of rescission of this Agreement, for any reason whatsoever, the Employee shall cooperate with the Company and shall make best endeavors to assist in the orderly transition of his job at the Company, and in the orderly overlap between him and the person or persons due to replace him in his job.

 

General Provisions

 

18.This Agreement and the Appendixes hereto constitute the full agreement between the Parties and prevail over any prior agreement, offer, understanding, correspondence, content, conversation or arrangement, whether in writing or oral, if any, between the Parties, with respect to the conditions of the Employee’s employment. Any matter not expressly regulated in this Agreement shall be in accordance with the law. Any amendment and/or addition to this Agreement shall bind the Parties to this Agreement and shall only be in force if it is in writing and signed by the Parties.

 

19.Israeli law shall apply to this Agreement. The competent courts / tribunals in the city of Tel Aviv Yafo shall have exclusive jurisdiction with respect to any matter stemming from this Agreement or with respect to this Agreement.

 

20.All notices must be sent by one party to the other by registered mail, by email or by hand delivery to the address at the top of this Agreement or to such other address as a Party may notify. Any notice shall be deemed to have been received by the recipient: if sent by registered mail – 4 business days after dispatch; if sent by email – one business day after dispatch provided that an automatic confirmation is obtained from the server that the notice reached its destination; if delivered by hand – upon delivery provided that a “certificate of delivery” is received.

 

The Employee declares that: (1) he has read carefully and has understood all of the provisions of the Agreement and the Appendixes hereto; (2) he has been given a reasonable opportunity to consult with third parties, including with an advocate; (3) he has signed this Agreement with full volition and consent. 

 

In witness whereof, the Parties have hereunto set their hands:

 

The Employee: /s/ Jacob Avinu The Company: /s/ Yehu Ofer
       /s/ Tanya Yosef

 

 

 

 

Appendix A – Conditions of Employment

 

1.Date of Commencement, Job and Supervisor – The Employee’s employment shall commence on November 15, 2022, full time, in the position of SVP Product or such other similar position, whatever its title may be. The Employee shall report directly to the CEO.

 

2. Working Hours - Employee shall be employed on a 5-day workweek basis. Employee’s working hours shall be in accordance with the Company’s policy, as in effect from time to time. On the date of signature of this Agreement the normal working hours of the Company are 8 am to 5pm, except on one shorter workday as determined by the Company. On the date of signature of this Agreement, the shorter weekly worday is Thursday. The Company may instruct the Employee to work overtime. Employee’s entitlement to breaks will be in accordance with any applicable law. The employees’ rest day shall be Saturday.

 

3.Prior Notice – 45 days in advance. Notice shall be given in writing however, even if notice is not given in writing as aforesaid, the Employee shall be deemed to have resigned if he gives clear notice in such regard.

 

4.Salary – A gross salary of NIS 40,746 (the “Base Salary”). An additional global payment of NIS 11,194 per month for up to 40 overtime hours at an hourly rate of 125% and NIS 8,060 per month for up to 24 overtime hours at an hourly rate of 150% (the “Global Overtime Payment”) – up to 64 overtime hours in total (the “Quota”). Employee will be entitled to full Global Overtime Payment even if the entire Quota was not met.

 

The parties estimate that the Quota reflects the actual overtime hours that Employee nay work and therefore, the Global Overtime Payment is sufficient to cover all overtime work. The Company undertakes the Global Overtime Payment shall be raised together with any Base Salary increase.

 

The parties agree that the Global Overtime Payment be treated, for all intents and purposes, as salary payment and therefore the Base Salary and the Global Overtime Payment shall be collectively referred to as the “Salary”. Any payment or benefit under this Appendix A, other than the Salary, shall not be considered as a salary for any purpose whatsoever, and the Employee shall not maintain or claim otherwise. The Salary shall be payable on such dates as required by law.

 

5.Pension Arrangements – The Company shall insure the Employee under a pension arrangement of his choice (insurance fund, pension fund or a combination of the two), in accordance with the rates and conditions that are set out below:

 

  5.1. Insurance fund (“executive insurance”) – in accordance with the following components:

 

  5.1.1. Insurance for loss of capacity to work – the Company shall, at its own expense and from an insurer of its choice, purchase coverage in the event of loss of capacity to work with the usual and acceptable conditions, at the rate that is necessary for the insurance of 75% of the Salary. The Company’s payment for insurance for loss of capacity to work shall not, in any event, be greater than 2.5% of the Salary.

 

 

 

 

  5.1.2. The Company’s provisions for severance pay - 81/3% of the Salary.
     
  5.1.3. The Company’s provisions for compensation – the difference between 6.5% of the Salary and the Company’s payment for insurance for loss of capacity to work, provided that in any event, the Company’s provisions for compensation shall not be less than 5% of the Salary.
     
  5.1.4. The Employee’s provisions for compensation – 6% of the Salary.

 

  5.2. Pension fund – in accordance with the following components: The Company’s provisions for severance pay – 8.33% of the Salary; the Company’s provisions for compensation - 6.5% of the Salary; the Employee’s provisions for compensation - 6% of the Salary.

 

6.Release of Pension Funds – The Parties adopt the provisions of the General Authorization regarding Employer Payments into Pension Funds and Insurance Funds in lieu of Severance Pay, which was issued pursuant to the Severance Pay Law, 5723-1963, as is in force from time to time, a copy of which is attached to this Agreement as Appendix C. The Company hereby waives its right to a refund of the monies that it paid to the Pension Fund and/or to an executive insurance policy unless the Employee’s right to severance pay is repudiated in a judgment pursuant to sections 16 and 17 of the Severance Pay Law, 5723-1963 (in accordance with the provisions thereof), or if the Employee withdraws monies from the pension fund and/or executive insurance policy, other than due to an “entitling event”. For this purpose, an “entitling event”: death, disability or retirement at age sixty or above. The Employee declares, confirms and undertakes that the Company’s provisions for the executive insurance policy or pension fund shall stand in place of all of the severance pay owing to him if any, pursuant to section 14 of the Severance Pay Law, 5723-1963, and in accordance with the General Authorization referred to above.

 

7.Study Fund – The Company and the Employee shall maintain a study fund for the Employee to which the Company shall contribute, on a monthly basis, an amount equal to 7.5% of Salary to Study Fund (as defined below) (the “Company Portion”) and the Employee shall contribute on a monthly basis an amount equal to 2.5% of Salary to Study Fund (the “Employee Portion”). Provided that the contributions according to this section will made for an amount of NIS 45,000 (the “Salary to Study Fund”). The Employee hereby instructs the Company to transfer the Employee Portion to the selected Study Fund. In the event that the Company Portion and Employee Portion exceed the maximum tax-exempt ceiling for Study Fund contributions, the exceeding amounts shall be recognized as ordinary income for tax purposes, on the date of their contribution to the selected Study Fund.

 

 

 

 

8. Vacation – The Employee shall be entitled to leave of 23 days of work for each period of twelve (12) months of employment (the “Annual Quota”) but in any event, not less than that which is set out in the Annual Leave Law, 5711-1951, as such may be from time to time (the “Annual Leave Law”). However, the Employee shall be entitled to accrue vacation days in a quantity of not more than twice the Annual Quota (the “Accrual Quota”). Vacation days beyond the Accrual Quota shall be deleted without the Employee being given compensation for such. The dates for taking vacations shall be prescribed by the Company at its discretion, in accordance with its possibilities and needs, and where possible, taking into account the Employee’s wishes. The Company shall be entitled to decide on a uniform annual leave period for all or some of its employees, with respect to some or all of their annual leave quota, as it may see fit.
   
9. Sick Pay– The Employee shall be entitled to the payment of sick pay in accordance with the provisions of the Sick Pay Law, 5736-1976. Notwithstanding the aforesaid, you will be entitled to your full Salary from the first day of your sick leave .
   
10. Convalescence Pay – The Employee shall be entitled to payment of convalescence pay in accordance with the Extension Order regarding Payment of Convalescence Pay.
   
11. Company Car – In place of travel expenses, the Company shall provide the Employee with a company car, for the purposes of the Employee’s job capacity. The Company shall pay for all ordinary expenses in connection with the Car, including licensing fees, insurance, gasoline and repairs; however, the Company shall not pay for traffic tickets or infractions, toll road fees or any other penalties or fines. It is agreed that the Company shall bear all taxes associated with this car.
   
12. The Employee: (1) will ensure the Car is in good shape and will verify the conditions of the insurance policy will be fulfilled and satisfied (including instructions and requirements in connection with the protection of the Car); (2) use the Car in accordance with the Company’s policies, which will be effective from time to time; and (3) in the event the Employee’s employment with the Company shall expire, either by termination of employment or otherwise, the Employee shall return the Car to the Company with the keys to the Car as well as other related licenses and documents in connection with the Car, in accordance with the framework of this Agreement.
   
13. Options - Subject to the approval of such grant by the compensation committee and board of directors of the Company, the Employee shall be granted options to purchase 100,000 shares of common stock of ScoutCam, Inc.
   
  Vesting period - 33.33% on the first anniversary of the Commencement Date, and 8.33% at the end of each subsequent three-month period thereafter over the course of the subsequent 2 years.

 

 

 

 

Exercise price - US $4.5 per option.

 

14. Signing Bonus - The Employee shall receive a signing bonus in the framework of his first pay slip to be provided following the Commencement Date, in the aggregate (gross) amount of NIS 50,000 (the “Signing Bonus”). The Employee shall be required to repay the Signing Bonus in full in the event of termination of employment of the Employee for any reason prior to the first year anniversary of the Commencement Date.
   
15. Performance Bonus - The Employee shall be entitled, after the first year anniversary of the Commencement Date, to a performance bonus in the aggregate (gross) amount of NIS 120,000, pursuant to certain objectives, which will be set by the CEO of the Company.
   
16. Options/RSU Compensation - the company will consider, according to its sole discretion, after the first- and second-year anniversary of the Commencement Date, to grant the employee additional options / RSU pursuant to certain objectives, subject to the approval of such grant by the CEO and board of directors of the Company.
   
17. Taxes and Mandatory Payments – All of the taxes and benefits under this Agreement shall be gross sums. The Company shall deduct taxes and other mandatory payments as required by the law.

 

The Employee: /s/ Jacob Avinu The Company: /s/ Yehu Ofer
                            /s/ Tanya Yosef

 

 

 

 

Appendix B – Deed of Undertaking

 

This Deed of Undertaking was executed on September 20, 2022 by Jacob Avinu, identity card no. 039058391, of Nativ HaShayara 75, Israel (hereinafter: the “Employee”).

 

Since the Employee wishes to enter into an employment agreement with ScoutCam Ltd. (the “Company”) and since the preservation of the Confidential Information (as defined below), the Company’s rights in Inventions (as defined below) and in all of the intellectual property rights auxiliary to such, are essential to the Company, the Employee is executing this Undertaking as a condition of his employment by the Company, and he undertakes to perform it verbatim.

 

In this Deed of Undertaking, all of the Employee’s undertakings to the Company shall be made to any parent companies, subsidiaries, sister companies and related companies to the Company, directly or indirectly, and the substitutes or transferees of such companies.

 

Confidential Information

 

1.The Employee recognizes the fact that he has and that he will have access to information that is confidential in nature (whether marked as such or not), that is related to the Company, including with respect to its commercial secrets, professional knowledge, technology, products (including products under development), research and development, experiments, formulas and processes, inventions, business, assets, financial condition, contracts and undertakings, obligations, operations, marketing and sales promotion issues, plans (including business and financial plans), strategies, procedures, forecasts, customers, suppliers, business partners and third parties to whom the Company has undertaken to keep information confidential and information relating to its employees, consultants, office bearers, directors and shareholders (all hereinafter jointly: the “Confidential Information”). The Confidential Information might be in any form whatsoever, including in writing, oral or on a magnetic or electronic medium. Confidential Information shall not include information that has come into the public domain as a result of a breach of this Deed of Undertaking by the Employee or information which the Employee is required to disclose pursuant to the legal demand of a competent authority, on condition that: (a) the Employee gives notice to the Company of such demand, immediately; (b) the Employee cooperates with the Company, if necessary, in order to reduce the scope of the demand; (c) the Employee does not disclose it beyond his duty to disclose in accordance with the aforesaid demand.

 

2.During the term of his employment and at all times thereafter, without any limitation in time, the Employee shall strictly preserve the Confidential Information and shall ensure its confidentiality, and shall not disclose the Confidential Information to any person or entity and shall not use the Confidential Information other than for the Company’s benefit. The Employee recognizes and understands that his work at the Company and his access to the Confidential Information give rise to a relationship of trust with respect to such Confidential Information.

 

 

 

 

3.The Employee declares that he has been made aware that all of the rights in the Confidential Information are the exclusive property of the Company (or of the third party to which the Company has undertaken to keep the Information confidential). Without derogating from the generality of the aforesaid, the Employee agrees that all of the Confidential Information that was prepared, collected, processed, received, kept or was in his use with respect to his employment in the Company (the “Material”) shall be the exclusive property of the Company and shall be deemed to be Confidential Information. Everything relating to the Material, including originals, copies and summaries, shall be transferred by the Employee to the Company upon termination of the term of his employment or at any time prior to such at the Company’s demand, without the Employee keeping any copies of the above and without the Employee having a right of lien over them. The Employee shall not remove the Material from the Company, unless such is required by virtue of his job and for the purpose of his employment, and unless such is permitted in accordance with the Company’s procedures. If the Material is removed from the Company’s offices as set out above, the Director shall take all of the necessary measures in order to maintain absolute confidentiality of the Material and shall return such to its place immediately after such use.

 

4.Unless there is a lawful permit or approval for such, the Employee shall not use nor disclose Confidential Information or commercial secrets belonging to any third parties including to previous employers, towards which the Employee has a duty of confidentiality or non-use (including any academic institution or any related entity).

 

Unfair Competition and Prohibited Solicitation

 

5. The Employee undertakes that during the course of his employment at the Company, he shall not contract, set up, open or be in any way involved, directly or indirectly, either as an employee, owner, partner, agent, shareholder, director, adviser or in any other many, any business, occupation, employment or any other activity that is in competition with the Company’s business.
   
  The Employee undertakes that during the period of 12 months following termination of his employment at the Company for any reason whatsoever, he shall not contract, set up, open or be in any way involved, directly or indirectly, either as an employee, owner, partner, agent, shareholder, director, adviser or in any other many, any business, occupation, employment or any other activity that is in which might reasonably include or require use of the Confidential Information. The Employee hereby confirms that it is reasonable that any engagement, set-up, opening or involvement, directly or indirectly, whether as an employee, owner, partner, agent, shareholder, director, adviser or in any other capacity, of any business, profession, employment or any other activity that is in competition with the Company’s business, as such was during the term of the Employee’s employment, or with the Company’s business as planned during the term of his employment, might require the use of all or part of the Confidential Information.

 

 

 

 

The Employee agrees that in light of his position at the Company and his exposure to the Confidential Information, the provisions of this section 5 are reasonable and necessary for the purpose of lawfully protecting the Confidential Information, which constitutes a principal asset of the Company and he undertakes to perform such as a condition of his employment by the Company. The Employee declares that he has carefully read the provisions of this undertaking, that he understands the outcome of this undertaking and agrees to the provisions hereof, and that he has assessed the advantages and disadvantages involved in entry into this undertaking for himself.

 

The Employee hereby declares that he is aware that part of his Salary contains additional consideration that is being provided for the Employee’s undertaking under this non-competition stipulation. Without derogating from the aforesaid, the Employee declares that he has the financial capability to enter into this non-competition undertaking.

 

6.The Employee undertakes that during the course of his employment at the Company and for a period of 12 months thereafter, he shall not solicit, persuade or try to persuade any employee of the Company to cease his employment at the Company or to reduce the scope of his employment at the Company, and that he shall not employ such an employee. Furthermore, the Employee shall not solicit, persuade, try to solicit or try to persuade, directly or indirectly, any consultant, service provider, agent, distributor, customer or supplier of the Company to terminate, reduce or alter their relationship with Company. All of the above shall apply both directly and indirectly.

 

Title to Inventions

 

7.The Employee shall give notice and shall transfer to the Company or to whomever is appointed for such on its behalf with all inventions, improvements, enhancements, formulas, processes, techniques, professional knowledge and technological information, whether able to be registered as a patent, as copyright or any similar law or not, which come into being, are invented, made, developed or raised as an idea or implemented, or which may be deduced by the Employee alone or jointly with others, during the course of the Employee’s employment at the Company (including after business hours, on weekends , or during vacations) (all of the aforesaid shall hereinafter be defined as: “Inventions” or the “Invention”), immediately upon discovery, receipt, generation or invention thereof, as the case may be.

 

8.The Employee agrees that any Inventions, as of the date of their invention or creation shall be the Inventions of the Company, shall be the exclusive property of the Company 0and its transferees, and the Company and its transferees shall be the exclusive owners of all of the property, rights and interests in the patents, copyright, commercial secrets and all of the other rights of any kind whatsoever, including moral rights with respect to the Inventions. The Employee hereby irrevocably and unconditionally assigns all of the rights set out below with respect to all of the Inventions to the Company: (1) all property, rights and interests in patents, patent applications and patent rights, extensions or expansions thereof; (2) rights related to a work, including copyright or applications for copyright, moral rights (as defined below) and proprietary rights in design; (3) rights related to the protection of commercial secrets and confidential information; (4) designs and the rights related thereto; (5) other proprietary rights related to intangible assets including trademarks, service marks and the implementation thereof, commercial names and packaging, and all of the goodwill related to them; (6) any property, rights and interests in any Invention; and (7) rights to sue for breach of any of the rights set out above and the right to revenues, royalties and other payments for the rights set out above. The Employee hereby waives all of the moral rights (as defined below) that it might have with respect to the Inventions, even after termination of his employment at the Company, and agrees never to sue with respect to such rights. “Moral rights” shall mean any right of an author to claim that his name be mentioned on his work, any right to object to any change in the work and any similar right that exists under any law in any country in the world, or under any treaty.

 

 

 

 

9.The Employee has attached hereto as Appendix B1, a list of all of the Inventions, enhancements, improvements, formulas, processes, techniques, professional knowledge and technological information, whether able to be registered as a patent, as copyright or under any similar law, or not, and whether in fact implemented or not, original works and commercial secrets created or conceived or belonging to the Employee (whether generated by the Employee alone or jointly with others), which: (1) were developed by the Employee prior to his contract with the Company (hereinafter jointly: the “Previous Inventions”); (2) are related to the existing or planned business, products or research and development of the Company; and (3) are not assigned in favor of the Company pursuant to this Agreement; or, if the aforesaid Appendix B1 is missing or not attached at all, the Employee hereby declares that no such Previous Inventions exist.

 

10.The Employee undertakes that during the term of his employment at the Company and thereafter, he shall take all of the actions reasonably necessary or required by the Company and he shall assist the Company, at its expense, in any way that it may request, in order to register, preserve, protect and enforce the Inventions in all countries around the world. These actions shall include, inter alia, the execution of documents and assistance in legal proceedings. The Employee hereby irrevocably authorizes and appoints the Company or a person appointed on its behalf as attorney for the Employee to act in his stead and in his place, to sign any document, to submit it and to do any other action on behalf of the Employee which may be permitted under any law in order to enable the registration, preservation, protection and enforcement of the Inventions in all countries around the world.

 

11.The Employee shall not be entitled with respect to the above to any monetary or other consideration apart from that set out expressly in his Employment Agreement or beyond the provisions of any other special agreement or arrangement in this regard made in writing and signed by the Company. Without derogating from the generality of the aforesaid, the Employee irrevocably confirms that the consideration paid to the Employee under the express conditions of this Employment Agreement shall be in lieu of any right that the Employee might have been entitled to receive by law for payment for the Inventions and the Employee hereby waives any right to receive royalties or any other payment for the Inventions, including under section 134 of the Patents Law, 5727-1967. With respect to the above, no arrangement, contract or agreement made orally or in writing shall have any effect unless such is in writing and lawfully signed by the Company.

 

 

 

 

General

 

12.The Employee declares that in the performance of his undertakings under this Deed of Undertaking, and his function as an employee of the Company, he is not in breach of any undertaking regarding the assignment of inventions, non-competition, confidentiality or any similar undertaking towards, or right of, any previous employer (including any academic institution or any related entity). The Employee recognizes the fact that the Company has relied on this declaration in its decision to employ him at the Company.

 

13.The Employee agrees that the provisions of this undertaking which constitute an integral part of the conditions of his employment, are reasonable and necessary for the purpose of protecting the legitimate interests of the Company with respect to the subject of this undertaking.

 

14.The Employee recognizes that in the event of breach of any of the provisions of this Deed of Undertaking, the Company might suffer damages that cannot be remedied and therefore, in the event of a breach of this Deed of Undertaking, the Company shall be entitled to an injunction in order to enforce this Deed of Undertaking (without derogating from the other remedies to which the Company might be entitled in such a case, under any law).

 

15.Should it be ruled by any competent judicial instance that any of the provisions of this Deed of Undertaking are not valid or enforceable, in any way whatsoever, such provision shall be enforced to the extent possible in accordance with the intention of the Company and the Employee. If such provision cannot be enforced in accordance with such intention, the provision shall be deemed to have been amended so that those parts of it which are held, as aforesaid, to be invalid or unenforceable, may be deleted therefrom, only in such country or region in which the decision that the provision is invalid or unenforceable as aforesaid has been handed down, in accordance with the local law. In addition, if it is held that a particular provision contained in this undertaking is too broad in terms of the time periods, geographical scope, actions or subject matter set out herein, it shall be interpreted such that the provision shall be limited and restricted with respect to such characteristic, so that the provision shall be enforceable to the greatest extent possible that is suitable to the applicable law as may be in force at such time.

 

16.The provisions of this undertaking shall remain in full force even after termination of the employment between the Company and the Employee, for any reason whatsoever. This undertaking shall not in any way derogate from the undertakings and liabilities of the Employee under any law.

 

 

 

 

17.The Employee hereby agrees that following termination of the employment between the Company and the Employee, the Company shall be entitled to give notice to the Employee’s new employer of the Employee’s rights and obligations pursuant to this Deed of Undertaking.

 

18.This Deed of Undertaking constitutes the full agreement between the Company and the Employee with respect to the subject of this Deed of Undertaking. Any addition, amendment or waiver of any undertaking pursuant to this Deed of Undertaking shall only be valid if in writing and signed by the Company as well. The Company’s waiver of the Employee’s undertaking shall constitute a one-time waiver and shall not constitute a precedent or serve for the drawing of inferences to similar, different or other cases.

 

19.This Deed of Undertaking and the rights and obligations hereunder shall be valid towards the substitutes, transferees and legal representatives of the Employee and the Company. The Company shall be entitled to assign all or part of its rights under this Deed of Undertaking. The Employee shall not convert, assign or otherwise transfer the duties imposed upon him under this Deed of Undertaking other than with the prior written consent of the Company.

 

The Employee: /s/ Jacob Avinu The Company: /s/ Yehu Ofer
       /s/ Tanya Yosef

 

 

 

 

Appendix C

 

General Authorization (Consolidated Version) regarding Employer Payments into Pension Funds and Insurance Funds in lieu of Severance Pay

 

Pursuant to the Severance Pay Law, 5723-1963

 

By virtue of my authority pursuant to section 14 of the Severance Pay Law, 5723-1963, (hereinafter: the “Law”), I authorize that payments made by the Employer as of the date of publication of this Certificate, for the Employee, into a comprehensive pension in an annuity fund which is not an insurance fund as defined in the Income Tax (Rules for Approval of and Management of Pension Funds) Regulations, 5724-1964 (hereinafter: a “Pension Fund”), or into an executive insurance policy which includes the ability to pay an annuity or a combination of payments into an annuity plan and a plan which is not an annuity plan, into such insurance fund (hereinafter: an “Insurance Fund”), including payments made by combining payments into a Pension Fund and an Insurance Fund, whether the Insurance Fund contains an annuity plan or not (hereinafter: “Employer Payments”) shall stand in lieu of the severance pay owing on the Salary out of which the aforesaid payments are made, and for the period paid (hereinafter: the “Severance Salary”), provided that all of the above exist:

 

1. Employer’s payments –

 

(a)Into a Pension Fund shall be no less than 141/3% of the Severance Salary or 12% of the Severance Salary if the Employer also makes payments for the Employee, in addition to the above, for supplementation of severance pay into a severance pay pension fund or an Insurance Fund in the Employee’s name in the rate of 21/3% of the Severance Salary. Where the Employer has not paid the aforesaid 21/3% in addition to the 12%, the Employer’s payments shall stand in lieu of 72% of the Employee’s severance pay only;

 

(b)Into an Insurance Fund are no less than one of the following:

 

(1)131/3% of the Severance Salary, if the Employer pays for the Employee, in addition to the above, for monthly salary assurance in the event of loss of capacity to work, under a plan approved by the Commissioner for Capital Markets, Insurance and Savings at the Ministry of Finance, in the rate required to assure 75% of the Severance Salary at least, or in the rate 21/2% of the Severance Salary, whichever is the lesser (hereinafter: “Payment for Insurance of Loss of Capacity to Work”);

 

(2)11% of the Severance Salary, if the Employer also makes payment for insurance for loss of capacity to work, in which case the Employer’s payments shall be in lieu of 72% of the Employee’s severance pay, only; should the Employer make payments to supplement severance pay in addition to the above into a Pension Fund or Insurance Fund for severance pay in the Employee’s name, in the rate of 21/3% of the Severance Salary, the Employer’s payments shall be in lieu of 100% of the Employee’s severance pay.

 

 

 

 

2.No more than 3 months after the commencement of the Employer’s payments, a written agreement is entered into between the Employer and the Employee containing:

 

A.The Employee’s consent to an arrangement under this Authorization in a form setting out the Employer’s payments to the Pension Fund or Insurance Fund, as the case may be; such agreement shall also contain the wording of this Authorization;

 

B.A waiver by the Employer in advance of any right that it may have to restitution of the monies from its payments, unless the Employee’s right to severance pay is repudiated in a judgment under sections 16 and 17 of the Law, and to the extent so repudiated, or that the Employee has withdrawn monies from the Pension Fund or the Insurance Fund not due to an entitling event; in this regard, “entitling event” – death, disability or retirement at the age of 60 or more.

 

C.This Authorization shall not derogate from an employee’s right to severance pay under the Law, under a collective agreement, extension order or employment contract, in respect of salary above the exempt salary.

 

(Eliyahu Yishai)

 

The Employee: /s/ Jacob Avinu The Company: /s/ Yehu Ofer
                            /s/ Tanya Yosef

 

 

 

 EX-31.1 8 ex31-1.htm

 

Exhibit 31.1

 

CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER

PURSUANT TO RULE 13a-14(a)

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Yehu Ofer, certify that:

 

1. I have reviewed this Annual Report on Form 10-K for the year ended December 31, 2022 of ScoutCam Inc.;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the year end covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the year end presented in this report;
   
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
   
a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the year end in which this report is being prepared;
   
b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
   
c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the year end covered by this report based on such evaluation; and
   
d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
   
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
   
a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
   
b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: March 28, 2023  
   
/s/ Yehu Ofer  
Yehu Ofer  
Chief Executive Officer  
(Principal Executive Officer)  

  

 

 

 

CERTIFICATION OF THE CHIEF FINANCIAL OFFICER

PURSUANT TO RULE 13a-14(a)

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Tanya Yosef, certify that:

 

1. I have reviewed this Annual Report on Form 10-K for the year ended December 31, 2022, of ScoutCam Inc.;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the year end covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the year end presented in this report;
   
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
   
a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the year end in which this report is being prepared;
   
b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
   
c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the year end covered by this report based on such evaluation; and
   
d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
   
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
   
a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
   
b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: March 28, 2023  
   
/s/ Tanya Yosef  
Tanya Yosef  
Chief Financial Officer  
(Principal Financial Officer)  

  

 

 

 EX-32.1 9 ex32-1.htm

 

Exhibit 32.1

 

CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER

PURSUANT TO

18 U.S.C. § 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Annual Report of ScoutCam Inc. (the “Company”) on Form 10-K for the year ended December 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Yehu Ofer, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

 

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
   
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: March 28, 2023

 

/s/ Yehu Ofer  
Yehu Ofer  
Chief Executive Officer  
(Principal Executive Officer)  

 

 

 

 

CERTIFICATION OF THE CHIEF FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. § 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Annual Report of ScoutCam Inc. (the “Company”) on Form 10-K for the year ended December 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Tanya Yosef, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

 

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
   
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: March 28, 2023

 

/s/ Tanya Yosef  
Tanya Yosef  
Chief Financial Officer  
(Principal Financial Officer)  

 

 

 

 GRAPHIC 10 form10-k_001.jpg begin 644 form10-k_001.jpg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end GRAPHIC 11 report_001.jpg begin 644 report_001.jpg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end EX-101.SCH 12 sctc-20221231.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Consolidated Statements of Changes in Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - GENERAL link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - SHORT-TERM DEPOSITS link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - INVENTORY link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - PROPERTY AND EQUIPMENT, NET link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - OTHER ACCRUED EXPENSES link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - RELATED PARTIES link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - EQUITY link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - REVENUES AND ENTITY WIDE DISCLOSURES link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - LEASES link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - GENERAL AND ADMINISTRATIVE EXPENSES link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - INVENTORY (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - OTHER ACCRUED EXPENSES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - INCOME TAXES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - RELATED PARTIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - REVENUES AND ENTITY WIDE DISCLOSURES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - GENERAL AND ADMINISTRATIVE EXPENSES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - GENERAL (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT ANNUAL DEPRECIATION RATES (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - SHORT-TERM DEPOSITS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - SCHEDULE OF INVENTORY (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - INVENTORY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT NET (Details) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - SCHEDULE OF OTHER ACCRUED EXPENSES (Details) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - SCHEDULE OF COMPONENT OF DEFERRED TAX ASSET (Details) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - INCOME TAXES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - SCHEDULE OF BALANCES WITH RELATED PARTIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - RELATED PARTIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - SCHEDULE OF STOCK WARRANTS OUTSTANDING TO PURCHASE COMMON STOCK (Details) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - SCHEDULE OF SHARE-BASED PAYMENT,STOCK OPTIONS, VALUATION ASSUMPTIONS (Details) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000050 - Disclosure - SCHEDULE OF DISAGGREGATION OF REVENUE (Details) link:presentationLink link:calculationLink link:definitionLink 00000051 - Disclosure - SCHEDULE OF DISAGGREGATION OF REVENUE (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000052 - Disclosure - SCHEDULE OF REVENUES WITHIN GEOGRAPHIC AREAS (Details) link:presentationLink link:calculationLink link:definitionLink 00000053 - Disclosure - SCHEDULE OF MAJOR CUSTOMER BREAKDOWN OF COMPANY’S REVENUE (Details) link:presentationLink link:calculationLink link:definitionLink 00000054 - Disclosure - SCHEDULE OF CONTRACT FULFILLMENT ASSETS AND CONTRACT LIABILITIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000055 - Disclosure - REVENUES AND ENTITY WIDE DISCLOSURES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000056 - Disclosure - SCHEDULE OF SUPPLEMENTAL CASH FLOW INFORMATION RELATED TO OPERATING LEASES (Details) link:presentationLink link:calculationLink link:definitionLink 00000057 - Disclosure - SCHEDULE OF LEASE TERM AND DISCOUNT RATE RELATED TO OPERATING LEASES (Details) link:presentationLink link:calculationLink link:definitionLink 00000058 - Disclosure - SCHEDULE OF MATURITIES LEASE LIABILITIES UNDER OPERATING LEASES (Details) link:presentationLink link:calculationLink link:definitionLink 00000059 - Disclosure - LEASES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000060 - Disclosure - SCHEDULE OF RESEARCH AND DEVELOPMENT EXPENSES (Details) link:presentationLink link:calculationLink link:definitionLink 00000061 - Disclosure - SCHEDULE OF GENERAL AND ADMINISTRATIVE EXPENSES (Details) link:presentationLink link:calculationLink link:definitionLink 00000062 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 13 sctc-20221231_cal.xml XBRL CALCULATION FILE EX-101.DEF 14 sctc-20221231_def.xml XBRL DEFINITION FILE EX-101.LAB 15 sctc-20221231_lab.xml XBRL LABEL FILE Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Long-Lived Tangible Asset [Axis] Machinery and Equipment [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Office Equipment [Member] Computer Equipment [Member] Leasehold Improvements [Member] Leasehold Improvements Office Furniture And Equipment [Member] Income Tax Authority [Axis] Foreign Tax Authority [Member] Domestic Tax Authority [Member] Income Tax Authority, Name [Axis] Israel Tax Authority [Member] Tax Period [Axis] Tax Year 2021 [Member] Income Statement Location [Axis] General and Administrative Expense [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Agreement [Member] Related Party [Axis] Directors [Member] Smartec R and D Ltd [Member] Medigus Ltd [Member] Sale of Stock [Axis] Private Placement [Member] Title of Individual [Axis] Board of Directors [Member] Warrant A [Member] Warrant B [Member] Consultant [Member] Warrant [Member] Letter Agreement [Member] Legal Entity [Axis] Investment C [Member] Investors C [Member] Plan Name [Axis] 2020 Share Incentive Plan [Member] Employees, Consultants, Directors and Other Service Providers [Member] Award Type [Axis] Equity Option [Member] Option Indexed to Issuer's Equity, Type [Axis] Share-Based Payment Arrangement, Option [Member] Related Party Transaction [Axis] Prof Goldwasser [Member] Board of Directors Chairman [Member] Officer [Member] Employee and Directors [Member] Restricted Stock Units (RSUs) [Member] Restricted Stock [Member] Warrant March 2021 [Member] Product and Service [Axis] Service [Member] Product [Member] Customer A [Member] Related Development Costs [Member] Geographical [Axis] UNITED STATES UNITED KINGDOM ISRAEL Other [Member] Customer [Axis] Customer B [Member] Customer C [Member] Lease Agreement [Member] Stock Purchase Agreements [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity public float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference ICFR Auditor Attestation Flag Auditor Firm ID Auditor Name Auditor Location Statement of Financial Position [Abstract] Assets CURRENT ASSETS: Cash and cash equivalents Short terms deposits Accounts receivable Inventory Other current assets Total current assets NON-CURRENT ASSETS: Contract fulfillment assets Property and equipment, net Operating lease right-of-use assets Severance pay asset Total non-current assets TOTAL ASSETS Liabilities and shareholders’ equity CURRENT LIABILITIES: Accounts payable Contract liabilities - short term Operating lease liabilities - short term Accrued compensation expenses Related parties Other accrued expenses Total current liabilities NON-CURRENT LIABILITIES: Contract liabilities - long term Operating lease liabilities - long term Liability for severance pay Total non-current liabilities TOTAL LIABILITIES SHAREHOLDERS’ EQUITY: Common stock, $0.001 par value; 300,000,000 shares authorized as of December 31, 2022 and December 31, 2021, 7,121,737 shares issued and outstanding as of December 31, 2022 and December 31, 2021 Additional paid-in capital Accumulated deficit TOTAL SHAREHOLDERS’ EQUITY TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY Common stock, par value Common Stock, Shares Authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] REVENUES COST OF REVENUES GROSS LOSS RESEARCH AND DEVELOPMENT EXPENSES SALES AND MARKETING EXPENSES GENERAL AND ADMINISTRATIVE EXPENSES OPERATING LOSS OTHER INCOME FINANCING INCOME (EXPENSES), NET LOSS BEFORE TAXES ON INCOME TAXES ON INCOME NET LOSS Net loss per share (basic and diluted, in USD) Weighted average common shares (basic and diluted, in thousands) Statement [Table] Statement [Line Items] Balance Balance, shares Stock based compensation (see note 9) Net loss Issuance of shares and warrants (see note 9) Issuance of shares and warrants,shares Exercise of warrants (see note 9) Exercise of warrants, shares Round up of shares due to reverse stock split (see note 9) Round up shares due to reverse stock split, shares Balance Balance, shares Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Adjustments to reconcile net loss to net cash used in operating activities: Depreciation Stock based compensation Profit (loss) from exchange differences on cash and cash equivalents Profit from exchange differences from operating lease liabilities Severance pay asset and liability Interest income in respect of deposits CHANGES IN OPERATING ASSET AND LIABILITY: Decrease (increase) in accounts receivable Decrease (increase) in inventory Increase (decrease) in operating lease liability Decrease (increase) in ROU asset Decrease (increase) in other current assets Increase in account payables Increase (decrease) in contract fulfillment assets Increase in contract liabilities Increase (decrease) in accrued compensation expenses Increase in related parties Increase in other accrued expenses Net cash flows used in operating activities CASH FLOWS FROM INVESTING ACTIVITIES: Purchase of property and equipment Withdrawal of short terms deposits Investment in short terms deposits Net cash flows provided by (used in) investing activities CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from issuance of shares and warrants Proceeds from exercise of warrants Issuance expenses Net cash flows provided by financing activities INCREASE IN CASH AND CASH EQUIVALENTS BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR PROFITS FROM EXCHANGE DIFFERENCES ON CASH AND CASH EQUIVALENTS BALANCE OF CASH AND CASH EQUIVALENTS AT END OF YEAR  Non cash activities Right-of-use assets obtained in exchange for operating lease liabilities Increase in property and equipment through a decrease in advances to suppliers Organization, Consolidation and Presentation of Financial Statements [Abstract] GENERAL Accounting Policies [Abstract] SIGNIFICANT ACCOUNTING POLICIES Debt Disclosure [Abstract] SHORT-TERM DEPOSITS Inventory Disclosure [Abstract] INVENTORY Property, Plant and Equipment [Abstract] PROPERTY AND EQUIPMENT, NET Other Liabilities Disclosure [Abstract] OTHER ACCRUED EXPENSES Income Tax Disclosure [Abstract] INCOME TAXES Related Party Transactions [Abstract] RELATED PARTIES Equity [Abstract] EQUITY Revenue from Contract with Customer [Abstract] REVENUES AND ENTITY WIDE DISCLOSURES Leases LEASES Research and Development [Abstract] RESEARCH AND DEVELOPMENT EXPENSES General And Administrative Expenses GENERAL AND ADMINISTRATIVE EXPENSES Subsequent Events [Abstract] SUBSEQUENT EVENTS Basis of preparation Use of estimates Functional currency Cash and Cash Equivalents Short-term bank deposits Accounts receivable Property and equipment Severance pay Stock-Based Compensation Inventories Revenue recognition Cost of revenues Research and development costs Income taxes Legal contingencies Basic and diluted net loss per common stock Leases SCHEDULE OF PROPERTY AND EQUIPMENT ANNUAL DEPRECIATION RATES SCHEDULE OF INVENTORY SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT NET SCHEDULE OF OTHER ACCRUED EXPENSES SCHEDULE OF COMPONENT OF DEFERRED TAX ASSET SCHEDULE OF BALANCES WITH RELATED PARTIES Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] SCHEDULE OF STOCK WARRANTS OUTSTANDING TO PURCHASE COMMON STOCK SCHEDULE OF STOCK OPTION ACTIVITY SCHEDULE OF SHARE-BASED PAYMENT,STOCK OPTIONS, VALUATION ASSUMPTIONS SCHEDULE OF DISAGGREGATION OF REVENUE SCHEDULE OF REVENUES WITHIN GEOGRAPHIC AREAS SCHEDULE OF MAJOR CUSTOMER BREAKDOWN OF COMPANY’S REVENUE SCHEDULE OF CONTRACT FULFILLMENT ASSETS AND CONTRACT LIABILITIES SCHEDULE OF SUPPLEMENTAL CASH FLOW INFORMATION RELATED TO OPERATING LEASES SCHEDULE OF LEASE TERM AND DISCOUNT RATE RELATED TO OPERATING LEASES SCHEDULE OF MATURITIES LEASE LIABILITIES UNDER OPERATING LEASES SCHEDULE OF RESEARCH AND DEVELOPMENT EXPENSES SCHEDULE OF GENERAL AND ADMINISTRATIVE EXPENSES Stockholders' equity, reverse stock split Retained Earnings (Accumulated Deficit) Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Property and equipment annual depreciation rates Property, plant and equipment, description Accounts receivable, allowance for credit loss Monthly salary percentage Interest rate Maturity term Raw materials and supplies Work in progress Finished goods  Inventory Net Inventory impairment Total property and equipment, gross Less: accumulated deprecation Total property and equipment, net Depreciation expenses Internal Revenue Services Accrued expenses Total other accrued expenses  Operating loss carryforward Net deferred tax asset before valuation allowance Valuation allowance Net deferred tax Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Line Items] Effective income tax rate reconciliation, at federal statutory income tax rate Valuation allowance Accumulated tax loss carryforward Income tax expense (benefit) Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Line Items] Balances with related parties Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary, Sale of Stock [Line Items] Issuance of units Issuance of unit, price per unit Compensation expense Consulting expense Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Line Items] Warrant issuance date Warrant expiration date Warrant exercise price per share Number of shares of common stock underlying warrants Options, Outstanding at beginning of period Weighted average exercise price, Outstanding at beginning of period Weighted average remaning contractual term (years) beginning of the period Aggregate Intrinsic Value, Outstanding at beginning of period Options, outstanding, granted Weighted average exercise price, Granted Options, outstanding, cancelled Weighted average exercise price, Cancelled Weighted average remaning contractual term (years) Options, Outstanding at ending of period Weighted average exercise price, Outstanding at end of period Aggregate Intrinsic Value, Outstanding at end of period Options, Exercisable at end of period Weighted average exercise price, Exercisable at end of period Weighted average remaning contractual term (years) exercisable at end of the period Aggregate Intrinsic Value, Exercisable at end of period Weighted average grant date fair value per share, begining of period Weighted average grant date fair value per share, granted Weighted average grant date fair value per share,vested Weighted average grant date fair value per share, unvested and outstanding ending balance Weighted average grant date fair value per share, unvested and outstanding ending balance Underlying value of ordinary shares Exercise price Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Term of the options (years) Risk-free interest rate minimum Risk-free interest rate maximum Common stock shares authorized Stock issued during period, shares, new issues Shares issued, price per share Sale of stock, description Proceeds from Issuance of Private Placement Warrant exercisable, shares Warrant exerise price per share Warrants and rights outstanding, term Warrant exercise price percentage Exercise of warrants required to invest return for shares of common stock Exercise of warrants required to invest return for shares of common stock Number of warrants exercised Number of unexercised warrants Warrants and rights outstanding, maturity date Proceeds from issuance of securities offered Proceeds from issuance after deducting issuance costs Conversion price Number of shares conversion Number of shares issued Proceeds from issuance of common stock Common stock percent Share based compensation arrangement Options grants in period gross Stock option vested term Weighted average exercise price Stock option award cost not yet recognized Stock option award weighted average period Option to purchase Expenses recorded regarding Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award Compensation expense Share-based compensation arrangement by share-based payment award, options, vested in period, fair value Share-based compensation arrangement by share-based payment award, options, vested in period, fair value Estimated average period Disaggregation of Revenue [Table] Disaggregation of Revenue [Line Items] Revenues Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table] Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] Development expense Revenues from development services Estimated useful life  Revenue Contract fulfillment assets: Contract liabilities Balance at beginning of year Additions during the year Contract costs recognized during the period Balance at end of year Balance at beginning of year Deferred revenue relating to new sales Revenue recognized during the year Balance at end of year Remaining performance obligations Schedule Of Supplemental Cash Flow Information Related To Operating Leases Operating cash flows from operating leases Schedule Of Lease Term And Discount Rate Related To Operating Leases Weighted-average remaining lease term (in years) Weighted-average discount rate 2023 2024 2025 Total undiscounted lease payments Less: Imputed interest Total lease liabilities Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Operating lease, right-of-use asset Operating lease, liability Lessee, operating lease, description Operating lease, payments Sublease income Operating lease expense Salaries and related expense Stock-based compensation Materials and subcontractors Depreciation Travel expenses Vehicle expenses Rent and maintenance and other expenses  Research and Development expenses Schedule Of General And Administrative Expenses Salaries and related expense Stock-based compensation Professional services Patents Depreciation Insurance Vehicle expenses Rent and maintenance and other expenses VAT provision (note 7e)  General and Administrative expenses Subsequent Event [Table] Subsequent Event [Line Items] Purchase price Aggregate purchase price Common stock par value, per share Exercise price Warrant exercisable term Severance pay asset Liability for severance pay. Financing income expenses net. Issuance of shares and warrants. Exercise of warrants. Round up shares due to reverse stock split. Issuance of shares and warrants, shares. Exercise of warrants shares. Interest income in respect of deposits. Withdrawal short-t erm deposits. Proceeds from issuance of shares and warrants. Issuance expenses. Severance pay asset and liability. Gain or loss on exchange from operating lease liability. Increase decrease in right-of-use asset. Payments investment to short-term deposits. Non cash related to increase in property and equipment through a decrease in advances to suppliers. Termination of right-of-use assets in exchange for cancellation of operating lease obligations. Short Term Bank Deposit [Policy Text Block] Schedule of property and equipment annual depreciation rates [Table Text Block] Severance pay [Policy Text Block] Monthly salary percentage. Property plant and equipment annual depreciation rates. Internal revenue service. Accrued expenses, current. Medigus Ltd [Member] Smartec R and D Ltd [Member] Benad Goldwasser [Member] Chairman [Member] Warrant, issuance date. Warrant March 2021 [Member] 2020 Share Incentive Plan [Member] Employees, Consultants, Directors and Other Service Providers [Member] Board of Directors [Member] Share based compensation arrangement by share based payment award options granted weighted average remaining contractual term 1. Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Share-based payment award options cancelled number of shares. Share-based payment award options cancelled weighted average grant date fair value. Weighted average remaining contractual term. Warrant A [Member] Warrant B [Member] Consultant [Member] Warrant exercise price percentage. Exercise of warrants required to invest return for shares of common stock. Exercise of warrants required not to invest return for shares of common stock. Number of warrants exercised. Number of warrants unexercised. Letter Agreement [Member] Investors C [Member] Customer A [Member] Customer B [Member] Related Development Costs [Member] Customers B [Member] Deferred revenue relating to new sales. Contract with customer asset contract costs. Contract with customer liability revenue recognized development services. Lease Agreement [Member] Schedule of lease term and discount rate related to operating leases [Table Text Block]. Schedule of Research and Development Expense [Table Text Block] Schedule of general and administrative expense [Table Text Block] Stock Purchase Agreements [Member] Materials and Sub-contractors. Rent and maintenance and other expenses. Vehicle expenses. Patents. General and Administrative Disclosure [Text Block] Investment C [Member] Common stock exceeding percentage. Agreement [Member] Directors [Member] Prof Goldwasser [Member] Customer C [Member] Employee and Directors [Member] Development expense Amount of general and administrative expense classified as vehicle expenses. Amount of general and administrative expense classified as depreciation. Assets, Current Assets, Noncurrent Assets [Default Label] Liabilities, Current Liabilities, Noncurrent Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity Gross Profit Operating Income (Loss) Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Shares, Outstanding Foreign Currency Transaction Gain (Loss), before Tax GainOrLossOnExchangeFromOperatingLeaseLiability SeverancePayAssetAndLiability InterestIncomeInRespectOfDeposits Increase (Decrease) in Accounts Receivable Increase (Decrease) in Inventories Increase (Decrease) in Other Current Assets Increase (Decrease) in Contract with Customer, Asset Increase (Decrease) in Accounts Receivable, Related Parties Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment PaymentsInvestmentToShortTermDeposits Net Cash Provided by (Used in) Investing Activities IssuanceExpenses Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Research, Development, and Computer Software Disclosure [Text Block] GeneralAndAdministrativeDisclosureTextBlock Accounts Receivable [Policy Text Block] Lessee, Leases [Policy Text Block] Inventory, Net Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Operating Loss Carryforwards, Valuation Allowance Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageRemainingContractualTerm ExerciseOfWarrantsRequiredNotToInvestReturnForSharesOfCommonStock Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Lessee, Operating Lease, Liability, to be Paid Lessee, Operating Lease, Liability, Undiscounted Excess Amount Depreciation, Nonproduction Labor and Related Expense DepreciationIncludedInGeneralAndAdministartiveExpenses VehicleExpensesIncludedInGeneralAndAdministartiveExpenses Other General and Administrative Expense EX-101.PRE 16 sctc-20221231_pre.xml XBRL PRESENTATION FILE XML 17 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Mar. 28, 2023
Jun. 30, 2022
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Dec. 31, 2022    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2022    
Current Fiscal Year End Date --12-31    
Entity File Number 333-188920    
Entity Registrant Name SCOUTCAM INC.    
Entity Central Index Key 0001577445    
Entity Tax Identification Number 47-4257143    
Entity Incorporation, State or Country Code NV    
Entity Address, Address Line One Suite 7A and 3B    
Entity Address, Address Line Two Industrial Park    
Entity Address, Address Line Three P.O. Box 3030    
Entity Address, City or Town Omer    
Entity Address, Country IL    
Entity Address, Postal Zip Code 8496500    
City Area Code +972    
Local Phone Number 73 370-4691    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity public float     $ 19,220
Entity Common Stock, Shares Outstanding   10,432,518  
Documents Incorporated by Reference None    
ICFR Auditor Attestation Flag false    
Auditor Firm ID 1197    
Auditor Name Brightman Almagor Zohar & Co.    
Auditor Location Tel Aviv, Israel    
XML 18 R2.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
CURRENT ASSETS:    
Cash and cash equivalents $ 10,099 $ 8,581
Short terms deposits 3,047 11,013
Accounts receivable 60 8
Inventory 630 167
Other current assets 281 443
Total current assets 14,117 20,212
NON-CURRENT ASSETS:    
Contract fulfillment assets 1,495 1,675
Property and equipment, net 648 781
Operating lease right-of-use assets 307 482
Severance pay asset 328 396
Total non-current assets 2,778 3,334
TOTAL ASSETS 16,895 23,546
CURRENT LIABILITIES:    
Accounts payable 297 103
Contract liabilities - short term 1,426 346
Operating lease liabilities - short term 199 256
Accrued compensation expenses 365 355
Related parties 58 39
Other accrued expenses 214 210
Total current liabilities 2,559 1,309
NON-CURRENT LIABILITIES:    
Contract liabilities - long term 2,218 2,074
Operating lease liabilities - long term 64 203
Liability for severance pay 268 344
Total non-current liabilities 2,550 2,621
TOTAL LIABILITIES 5,109 3,930
SHAREHOLDERS’ EQUITY:    
Common stock, $0.001 par value; 300,000,000 shares authorized as of December 31, 2022 and December 31, 2021, 7,121,737 shares issued and outstanding as of December 31, 2022 and December 31, 2021 7 7
Additional paid-in capital 36,541 34,903
Accumulated deficit (24,762) (15,294)
TOTAL SHAREHOLDERS’ EQUITY 11,786 19,616
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY $ 16,895 $ 23,546
XML 19 R3.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Balance Sheets (Parenthetical) - $ / shares
Dec. 31, 2022
Dec. 31, 2021
Statement of Financial Position [Abstract]    
Common stock, par value $ 0.001 $ 0.001
Common Stock, Shares Authorized 300,000,000 300,000,000
Common stock, shares issued 7,121,737 7,121,737
Common stock, shares outstanding 7,121,737 7,121,737
XML 20 R4.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Income Statement [Abstract]    
REVENUES $ 665 $ 387
COST OF REVENUES 1,631 1,108
GROSS LOSS (966) (721)
RESEARCH AND DEVELOPMENT EXPENSES 4,197 2,002
SALES AND MARKETING EXPENSES 699 908
GENERAL AND ADMINISTRATIVE EXPENSES 3,577 5,481
OPERATING LOSS (9,439) (9,112)
OTHER INCOME 30 8
FINANCING INCOME (EXPENSES), NET (59) 117
LOSS BEFORE TAXES ON INCOME (9,468) (8,987)
TAXES ON INCOME
NET LOSS $ (9,468) $ (8,987)
Net loss per share (basic and diluted, in USD) $ (1.33) $ (1.44)
Weighted average common shares (basic and diluted, in thousands) 7,122 6,240
XML 21 R5.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Changes in Shareholders' Equity - USD ($)
shares in Thousands, $ in Thousands
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Balance at Dec. 31, 2020 $ 4 $ 10,267 $ (6,307) $ 3,964
Balance, shares at Dec. 31, 2020 4,084      
Stock based compensation (see note 9) 2,030 2,030
Net loss (8,987) (8,987)
Issuance of shares and warrants (see note 9) $ 2 19,116 19,118
Issuance of shares and warrants,shares 2,469      
Exercise of warrants (see note 9) $ 1 3,490 3,491
Exercise of warrants, shares 568      
Round up of shares due to reverse stock split (see note 9) [1] [1] [1]
Round up shares due to reverse stock split, shares 1      
Balance at Dec. 31, 2021 $ 7 34,903 (15,294) 19,616
Balance, shares at Dec. 31, 2021 7,122      
Stock based compensation (see note 9) 1,638 1,638
Net loss (9,468) (9,468)
Balance at Dec. 31, 2022 $ 7 $ 36,541 $ (24,762) $ 11,786
Balance, shares at Dec. 31, 2022 7,122      
[1] Represents an amount less than $1 thousand
XML 22 R6.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (9,468) $ (8,987)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 251 114
Stock based compensation 1,638 2,030
Profit (loss) from exchange differences on cash and cash equivalents 269 (130)
Profit from exchange differences from operating lease liabilities (49)
Severance pay asset and liability (8) (25)
Interest income in respect of deposits (34) (13)
CHANGES IN OPERATING ASSET AND LIABILITY:    
Decrease (increase) in accounts receivable (52) 9
Decrease (increase) in inventory (463) 77
Increase (decrease) in operating lease liability (233) 20
Decrease (increase) in ROU asset 261 (43)
Decrease (increase) in other current assets 162 (126)
Increase in account payables 194 24
Increase (decrease) in contract fulfillment assets 180 (545)
Increase in contract liabilities 1,224 1,572
Increase (decrease) in accrued compensation expenses 10 (14)
Increase in related parties 19 86
Increase in other accrued expenses 4 65
Net cash flows used in operating activities (6,095) (5,886)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchase of property and equipment (118) (595)
Withdrawal of short terms deposits 14,500
Investment in short terms deposits (6,500) (11,000)
Net cash flows provided by (used in) investing activities 7,882 (11,595)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds from issuance of shares and warrants 19,118
Proceeds from exercise of warrants 3,491
Issuance expenses (50)
Net cash flows provided by financing activities 22,559
INCREASE IN CASH AND CASH EQUIVALENTS 1,787 5,078
BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR 8,581 3,373
PROFITS FROM EXCHANGE DIFFERENCES ON CASH AND CASH EQUIVALENTS (269) 130
BALANCE OF CASH AND CASH EQUIVALENTS AT END OF YEAR 10,099 8,581
 Non cash activities    
Right-of-use assets obtained in exchange for operating lease liabilities 155 524
Increase in property and equipment through a decrease in advances to suppliers $ 31
XML 23 R7.htm IDEA: XBRL DOCUMENT v3.23.1
GENERAL
 12 Months Ended
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
GENERAL

NOTE 1 – GENERAL:

 

  a. ScoutCam Inc. (the “Company”), formerly known as Intellisense Solutions Inc., (“Intellisense”), was incorporated under the laws of the State of Nevada on March 22, 2013. Prior to the closing of the Exchange Agreement (as defined below), the Company was a non-operating “shell company”.
     
    The Company’s wholly-owned subsidiary, ScoutCam Ltd. (“ScoutCam”), was formed in the State of Israel on January 3, 2019, as a wholly-owned subsidiary of Medigus Ltd. (“Medigus”), an Israeli company traded on the Nasdaq Capital Market, and commenced operations on March 1, 2019.
     
    In December 2019, Medigus and ScoutCam consummated an asset transfer agreement, under which Medigus transferred and assigned certain assets and intellectual property rights related to its miniaturized imaging business to ScoutCam.
     
    On December 30, 2019, Intellisense and Medigus consummated a securities exchange agreement (the “Exchange Agreement”), pursuant to which Medigus delivered 100% of its holdings in ScoutCam to Intellisense in exchange for shares of Intellisense’s common stock representing 60% of the issued and outstanding share capital of Intellisense immediately upon the consummation of the Exchange Agreement.
     
    As of December 31, 2022, Medigus beneficially owned 27.02% of the Company’s outstanding common stock.
     
    The Company, through ScoutCam, is engaged in the development, production and marketing of innovative Predictive Maintenance (PdM) and Condition Based Monitoring (CBM) technologies, providing visual sensing and AI-based video analytics solutions for critical systems in the aviation, maritime, industrial non-destructing-testing industries, transportation, and energy industries. Some of the Company’s products utilize our micro visualization technology in medical devices for complex and minimally invasive medical procedures. Company’s technology includes proven video technologies and products amalgamated into a first-of-its-kind, FDA-cleared minimally invasive surgical device. The Company’s video-based sensors, embedded software and AI algorithms are being deployed in hard-to-reach locations and harsh environments across a variety of PdM and CBM use cases. The Company’s solution allows maintenance and operations teams visibility into areas which are inaccessible under normal circumstances, or where the operating ambience otherwise is not suitable for continuous real-time monitoring’ and has various applications which have relevancy in wide range of industry segments, that utilize complicated mechanics requiring ongoing monitoring and predictive maintenance applications.

 

 

SCOUTCAM INC.

 

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 1 – GENERAL (continued):

 

  b.

On August 9, 2021, the Company amended its Articles of Incorporation to effect a nine-to-one reverse stock split of its outstanding Common Stock.

     
    As a result of the reverse stock split, every nine shares of the Company’s outstanding Common Stock were combined and reclassified into one share of the Company’s Common Stock. No fractional shares were issued in connection with or following the reverse split. The amount of authorized capital of the Company’s Common Stock and par value of such shares remained unchanged.
     
    All share, stock option and per share information in these consolidated financial statements have been adjusted to reflect the reverse stock split on a retroactive basis.
     

 

.

 c.

Since incorporation of ScoutCam and through December 31, 2022, the Company accumulated a deficit of approximately $25 million and its activities have been funded mainly by its shareholders. The Company’s management believes the Company’ cash and cash resources as of December 31, 2022 as well as its proceeds from issuance of common stock and warrants in the private offering as detailed in Note 14, will allow the Company to fund its operating plan through at least the next 12 months. However, the Company expects to continue to incur significant research and development and other costs related to its ongoing operations and in order to continue its future operations, the Company will need to obtain additional funding until becoming profitable.

 

 

SCOUTCAM INC.

 

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

 
XML 24 R8.htm IDEA: XBRL DOCUMENT v3.23.1
SIGNIFICANT ACCOUNTING POLICIES
 12 Months Ended
Dec. 31, 2022
Accounting Policies [Abstract]  
SIGNIFICANT ACCOUNTING POLICIES

NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES:

 

  a. Basis of preparation:

 

The consolidated financial statements have been prepared in accordance with United States Generally Accepted Accounting Principles in the United States (“U.S. GAAP”) applied on a consistent basis.

 

  b. Use of estimates

 

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. The Company evaluates its assumptions on an ongoing basis, including those related to contingencies and inventory impairment, as well as estimates used in applying its revenue recognition policy. Actual results may differ from these estimates.

 

  c. Functional currency

 

A majority of ScoutCam’s revenues are generated in U.S. dollars. The substantial majority of ScoutCam costs are incurred in U.S. dollars and New Israeli Shekels (“NIS”). ScoutCam management believes that the U.S. dollar is the currency of the primary economic environment in which ScoutCam operates. Thus, the functional currency of ScoutCam is the U.S. dollar.

 

Transactions and balances originally denominated in U.S. dollars are presented at their original amounts. Balances in non-U.S. dollar currencies are translated into U.S. dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For non-U.S. dollar transactions and other items in the statements of operations (indicated below), the following exchange rates are used: (i) for transactions exchange rates at transaction dates and (ii) for other items (derived from non-monetary balance sheet items such as depreciation and amortization) historical exchange rates. Currency transaction gains and losses are presented in financial income or expenses, as appropriate.

 

  d. Cash and Cash Equivalents

 

The Company considers as cash equivalents all short-term, highly liquid investments, which include short-term bank deposits with original maturities of three months or less from the date of purchase that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash.

 

  e. Short-term bank deposits

 

Bank deposits with maturities of more than three months but less than one year are included in short-term bank deposits. Such short-term bank deposits are stated at cost which approximates fair market value.

 

 

SCOUTCAM INC.

 

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (continued):

 

  f. Accounts receivable

 

Accounts receivable are presented in the Company’s consolidated balance sheets net of allowance for doubtful accounts. The Company estimates the collectability of its accounts receivable balances and adjusts its allowance for doubtful accounts accordingly.

 

When revenue recognition criteria are not met for a sale transaction that has been billed, the Company does not recognize deferred revenues or the related account receivable.

 

As of December 31, 2022 and 2021, no allowance for doubtful accounts was recorded.

 

  g. Property and equipment

 

Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation is calculated on a straight-line basis over the estimated useful lives.

 

The annual depreciation rates are as follows:

 

   % 
Machinery and laboratory equipment   10%-15%
Office furniture and equipment   10%
Computers and computer software   33%
Leasehold improvements   Over the shorter of the lease term (including options if any) or useful life 

 

  h. Severance pay

 

Israeli labor law generally requires payment of severance pay upon dismissal of an employee or upon termination of employment in certain other circumstances. Pursuant to Section 14 of the Severance Compensation Act, 1963 (“Section 14”), all of the ScoutCam’s employees in Israel are entitled to a monthly contribution, at a rate of 8.33% of their monthly salary, made in their name with insurance companies. Contributions under Section 14 relieve ScoutCam from any future severance payment obligation with respect to those employees. The aforementioned contributions are not recorded as an asset on the Company’s balance sheet and there is no liability recorded, as the Company does not have a future obligation to make any additional payments.

 

The asset and the liability for severance pay presented in the balance sheets reflects employees that began employment prior to automatic application of Section 14.

 

The severance pay liability of ScoutCam to its employees that began employment prior to automatic application of Section 14 is based upon the number of years of service and the latest monthly salary of such employees and is partly covered by regular deposits with recognized pension funds and deposits with severance pay funds. Under labor laws, these deposits are in the employees’ names and, subject to certain limitations, are the property of the employees. ScoutCam records the obligation as if it were payable at each balance sheet date on an undiscounted basis.

 

 

SCOUTCAM INC.

 

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (continued):

 

  i. Stock-Based Compensation

 

The Company measures and recognizes compensation expense for its equity classified stock-based awards granted under its plan based on estimated fair values on the grant dates. The Company calculates the estimated fair value of option awards on the grant date using the Black-Scholes option-pricing model. The Black-Scholes option-pricing model requires a number of assumptions, of which the most significant are the stock price volatility and the expected option term. The Company’s expected dividend rate is zero since the Company does not currently pay cash dividends on its stocks and does not anticipate doing so in the foreseeable future. Each of the above factors requires the Company to use judgment and make estimates in determining the percentages and time periods used for the calculation. If the Company were to use different percentages or time periods, the estimated fair value of option awards could be materially different. The Company recognizes stock-based compensation cost for option awards on an accelerated basis over the employee’s requisite service period, net of estimated forfeitures.

 

  j. Inventories

 

Inventories include raw materials, inventory in process and finished products and are valued at the lower of cost or net realizable value.

 

Inventories are stated at a lower of cost, determined by the first-in, first-out method, or market based on net realizable value. Costs of purchased raw materials and inventory in process include costs of design, raw materials, direct labor, other direct costs and fixed production overheads.

 

The inventories are adjusted for estimated excess and obsolescence and written down to net realizable value based upon estimates of future demand, technology developments and market conditions.

 

  k. Revenue recognition

 

  a) Revenue measurement

 

The Company’s revenues are measured according to the ASC 606, “Revenue from Contracts with Customers” (“ASC 606”). Under ASC 606, revenues are measured according to the amount of consideration that the Company expects to be entitled to receive in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties. Revenues are presented net of VAT.

 

  b) Revenue recognition

 

The Company recognizes revenue when a customer obtains control over promised goods or services. For each performance obligation, the Company determines at contract inception whether it satisfies the performance obligation over time or satisfies the performance obligation at a point in time.

 

Performance obligations are satisfied over time if one of the following criteria is met:

 

 

SCOUTCAM INC.

 

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (continued):

 

(a) the customer simultaneously receives and consumes the benefits provided by the Company’s performance; (b) the Company’s performance creates or enhances an asset that the customer controls as the asset is created or enhanced; or (c) the Company’s performance does not create an asset with an alternative use for the Company and the Company has an enforceable right to payment for performance completed to date.

 

If a performance obligation is not satisfied over time, a Company satisfies the performance obligation at a point in time.

 

The transaction price is allocated to each distinct performance obligations on a relative standalone selling price (“SSP”) basis and revenue is recognized for each performance obligation when control has passed. In most cases, the Company is able to establish SSP based on the observable prices of services sold separately in comparable circumstances to similar customers and for products based on the Company’s best estimates of the price at which the Company would have sold the product regularly on a stand-alone basis. The Company reassesses the SSP on a periodic basis or when facts and circumstances change.

 

Product Revenue

 

Revenues from product sales are recognized at a point in time when the customer obtains control of the Company’s product, typically upon shipment to the customer. Indirect taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from revenues.

 

Service Revenue

 

The Company also generates revenues from development services. Revenue from development services is recognized over the period of the applicable service contract. To the extent development services are not distinct from the performance obligation relating to the subsequent mass production phase of the prototype under development, revenue from these services is deferred until commencement of the production phase of the project and are then recognized over the expected term production.

 

 

SCOUTCAM INC.

 

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (continued):

 

  l. Cost of revenues

 

Cost of revenue consists of products purchased from sub-contractors, raw materials for in-house assembly line, shipping and handling costs to customers, salary, employee-related expenses, depreciation and overhead expenses.

 

Cost of revenues are expensed commensurate with the recognition of the respective revenues. Costs deferred in respect of deferral of revenues are recorded as contract fulfilment assets on the Company’s balance sheet and are written down to the extent the contract is expected to incur losses.

 

  m. Research and development costs

 

Research and development costs are expensed as incurred and includes salaries and employee-related expenses, overhead expenses, material, and third-party contractors’ charges.

 

  n. Income taxes

 

Income taxes are accounted for using the asset and liability approach under ASC-740, “Income Taxes”. The asset and liability approach requires the recognition of taxes payable or refundable for the current year and deferred tax liabilities and assets for the future tax consequences of events that have been recognized in the Company’s financial statements or tax returns.

 

The measurement of current and deferred tax liabilities and assets is based on provisions of the relevant tax law. The measurement of deferred tax assets is reduced, if necessary, by the amount of any tax benefits that, based on available evidence, are not expected to be realized.

 

Uncertain tax positions are accounted for in accordance with the provisions of ASC 740-10, under which a company may recognize the tax benefit from an uncertain tax position claimed or expected to be claimed on a tax return only if it is more likely than not that the tax position will be sustained on examination by the taxation authorities, based on the technical merits of the position, at the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement. Interest and penalties, if any, related to unrecognized tax benefits are recognized in tax expense. The Company and ScoutCam provide a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value.

 

  o. Legal contingencies

 

From time to time, the Company and its subsidiary become involved in legal proceedings or are subject to claims arising in their ordinary course of business. Such matters are generally subject to many uncertainties and outcomes are not predictable with assurance. The Company accrues for contingencies when the loss is probable and can reasonably estimate the amount of any such loss.

 

 

SCOUTCAM INC.

 

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 2 — SIGNIFICANT ACCOUNTING POLICIES (continued):

 

  p. Basic and diluted net loss per common stock:

 

Basic net loss per common stock is computed by dividing net loss, as adjusted, to include the weighted average number of shares of common stock outstanding during the year.

 

Diluted net loss per common stock is computed by dividing net loss, as adjusted, by the weighted average number of shares of common stock outstanding during the year, plus the number of shares of common stock that would have been outstanding if all potentially dilutive shares of common stock had been issued, using the treasury stock method, in accordance with ASC 260-10 “Earnings per Share”.

 

All outstanding stock options and warrants have been excluded from the calculation of the diluted loss per share for the years ended December 31, 2022 and December 31, 2021, since all such securities have an anti-dilutive effect.

 

  q. Leases

 

In accordance with ASC 842, the Company determines whether an arrangement is or contains a lease based on the facts and circumstances present at inception of an arrangement. An arrangement is or contains a lease if the arrangement conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

 

Arrangements that are determined to be leases at inception are recognized in long-term right-of-use assets (“ROU”) assets and short and long-term lease liabilities in the consolidated balance sheet at lease commencement. Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future fixed lease payments over the lease term at commencement date. As most of the Company’s leases do not provide an implicit rate, the Company applies its incremental borrowing rate based on the economic environment at commencement date in determining the present value of future payments. Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for operating leases or payments are recognized on a straight-line basis over the lease term.

 

The Company has elected not to recognize on the balance sheet leases with terms of 12 months or less.

 

 

SCOUTCAM INC.

 

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

 
XML 25 R9.htm IDEA: XBRL DOCUMENT v3.23.1
SHORT-TERM DEPOSITS
 12 Months Ended
Dec. 31, 2022
Debt Disclosure [Abstract]  
SHORT-TERM DEPOSITS

NOTE 3 - SHORT-TERM DEPOSITS

 

Short term investments as of December 31, 2022 include bank deposit bearing annual interest rates of 4%, with maturities of up to 12 months.

 
XML 26 R10.htm IDEA: XBRL DOCUMENT v3.23.1
INVENTORY
 12 Months Ended
Dec. 31, 2022
Inventory Disclosure [Abstract]  
INVENTORY

NOTE 4 - INVENTORY:

 

   2022   2021 
   December 31, 
   2022   2021 
   USD in thousands 
Raw materials and supplies   438    99 
Work in progress   148    2 
Finished goods   44    66 
 Inventory Net   630    167 

 

During the years 2022 and 2021, no impairment occurred.

 
XML 27 R11.htm IDEA: XBRL DOCUMENT v3.23.1
PROPERTY AND EQUIPMENT, NET
 12 Months Ended
Dec. 31, 2022
Property, Plant and Equipment [Abstract]  
PROPERTY AND EQUIPMENT, NET

NOTE 5 - PROPERTY AND EQUIPMENT, NET:

 

Property, plant and equipment, net consisted of the following:

 

   2022   2021 
   December 31, 
   2022   2021 
   USD in thousands 
Cost:          
Machinery and laboratory equipment   619    578 
Leasehold improvements, office furniture and equipment   351    316 
Computers and computer software   182    140 
Total property and equipment, gross   1,152    1,034 
Less: accumulated deprecation   (504)   (253)
Total property and equipment, net   648    781 

 

Depreciation expenses were $251 thousand and $114 thousand for the years ended December 31, 2022 and 2021, respectively.

 

 

SCOUTCAM INC.

 

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

 
XML 28 R12.htm IDEA: XBRL DOCUMENT v3.23.1
OTHER ACCRUED EXPENSES
 12 Months Ended
Dec. 31, 2022
Other Liabilities Disclosure [Abstract]  
OTHER ACCRUED EXPENSES

NOTE 6 – OTHER ACCRUED EXPENSES:

 

   2022   2021 
   December 31, 
   2022   2021 
   USD in thousands 
Internal Revenue Services   -    40 
Accrued expenses   214    170 
Total other accrued expenses    214    210 

 
XML 29 R13.htm IDEA: XBRL DOCUMENT v3.23.1
INCOME TAXES
 12 Months Ended
Dec. 31, 2022
Income Tax Disclosure [Abstract]  
INCOME TAXES

NOTE 7 - INCOME TAXES:

 

  a. Basis of taxation

 

1.Tax rates applicable to the income of the Israeli subsidiary:

 

ScoutCam is taxed according to Israeli tax laws.

 

The Israeli corporate tax rate from the year 2018 and onwards is 23%.

 

  2.Tax rates applicable to the income of the U.S. company:

 

    The Company is taxed according to U.S. tax laws.
     
    The U.S. corporate tax rate from the year 2018 and onwards is 21%.

 

  b.

Deferred income taxes:

     
    Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s deferred tax assets are as follows:

   2022   2021 
   December 31, 
   2022   2021 
   USD in thousands 
Operating loss carryforward   26,295    15,582 
           
Net deferred tax asset before valuation allowance   

6,069

    

3,595

 
Valuation allowance   (6,069)   (3,595)
Net deferred tax   -    - 

 

    As of December 31, 2022, the Company has provided a full valuation allowance of $6,069 thousand in respect of deferred tax assets resulting from tax loss carryforward and other temporary differences. Management currently believes that because the Company has a history of losses, it is more likely than not that the deferred tax regarding the loss carryforward and other temporary differences will not be realized in the foreseeable future.
     
  c. Available carryforward tax losses:
     
    As of December 31, 2022, the Company has an accumulated tax loss carryforward of approximately $26,295 thousand. Carryforward tax losses in Israel are of unlimited duration. Under the Tax Cut and Jobs Act of 2017, or the Tax Act (subject to modifications under the Coronavirus Aid, Relief, and Economic Security Act), federal net operating losses (NOL) incurred in taxable years ending after December 31, 2017 and in future years may be carried forward indefinitely, but the deductibility of such federal net operating losses is limited. It is uncertain if and to what extent various states will conform to the newly enacted federal tax law.
     

 

 

 

 

In addition, under Section 382 of the Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, if a corporation undergoes an “ownership change,” which is generally defined as a greater than 50 percentage point change, by value, in its equity ownership over a three-year period, the corporation’s ability to use its pre-change NOL carryforwards and other pre-change tax attributes to offset its post-change income or taxes may be limited. Such limitations may result in the expiration of net operating losses before utilization.

     
  d. The main reconciling item between the statutory tax rate of the Company and the effective tax rate is the recognition of valuation allowance in respect of deferred taxes relating to accumulated net operating losses carried forward due to the uncertainty of the realization of such deferred taxes.

 

  e.

As of December 31, 2021, ScoutCam owed NIS 740 thousand, (approximately $229 thousand) in additional taxes to the Israel Tax Authority following a VAT audit in Israel for 2019-2021.

     
    On November 18, 2021, ScoutCam filed an appeal to the Israeli Tax Authority on the finding of the VAT audit.
     
    Due to the uncertainty regarding the outcome of the appeal, the financial statements as of December 31, 2021 included a provision related to the additional taxes of $229 thousand, which was included in general and administrative expenses in the statement of operation report.
     
    In July 2022, ScoutCam reached an agreement with the Israeli Tax Authority, according to which the amount due in additional taxes was reduced to NIS 340 thousand (approximately $100 thousand).

 

 

SCOUTCAM INC.

 

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

 
XML 30 R14.htm IDEA: XBRL DOCUMENT v3.23.1
RELATED PARTIES
 12 Months Ended
Dec. 31, 2022
Related Party Transactions [Abstract]  
RELATED PARTIES

NOTE 8 – RELATED PARTIES:

 

  a. Related Parties Balances:

 

   December 31, 
   2022   2021 
   USD in thousands 
Directors (directors’ accrued compensation)   48    - 
Smartec R&D Ltd. (see note 8c)   10    - 
Medigus   -    39 
    58    39 

 

  b. On May 18, 2020, the Company allocated in a private issuance to M. Arkin (1999) Ltd. (“Arkin”) a total of 229,569 units (as described in note 9c) at a purchase price of $8.712 per unit (“Arkin Transaction”).
     
    In connection with the Arkin Transaction, the Company, Medigus and Arkin entered into a voting agreement, pursuant to which Arkin and Medigus each agreed to vote their respective shares of common stock in favor of the election of the opposite party’s designated representative(s), as applicable, to the Board (“Voting Agreement”). Each of Arkin’s and Medigus’ rights under the Voting Agreement are contingent upon, inter alia, such party maintaining a certain beneficial ownership threshold in the Company’ as follows:
     
    (a) One person designated by Arkin is to be elected, for as long as Arkin, continues to beneficially own at least eight percent of the issued and outstanding capital stock of the Company.
     
    (b) Three persons designated by Medigus are to be elected, for as long as Medigus, continues to beneficially own at least thirty five percent of the issued and outstanding capital stock of the Company.
     
    (c) Two persons designated by Medigus are to be elected for as long as Medigus, continues to beneficially own less than thirty five percent and more than twenty percent of the issued and outstanding capital stock of the Company.
     
   

(d) One person designated by Medigus is to be elected for as long as Medigus, continues to beneficially own less than twenty percent and more than eight percent of the issued and outstanding capital stock of the Company.

     
  c. During 2021 and 2022 the Company received development services from Smartec R&D Ltd., a company owned by the Company’s CTO.
     
    Total compensation for the fiscal years ended December 31, 2021 and December 31, 2022 was $82 thousands and $117 thousands, respectively.
     
  d. During 2021 the Company received financial consultant services from Anona De Finance Ltd., a company owned by one of the Company’s directors.
     
    Total expenses for the fiscal years ended December 31, 2021 was approximately $37 thousands.

 

 

SCOUTCAM INC.

 

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

 
XML 31 R15.htm IDEA: XBRL DOCUMENT v3.23.1
EQUITY
 12 Months Ended
Dec. 31, 2022
Equity [Abstract]  
EQUITY

NOTE 9 - EQUITY:

 

Increase of the authorized share capital

 

On January 20, 2021, the Company’s Board of Directors approved an increase of the authorized share capital of the Company by an additional 225,000,000 shares of common stock par value $0.001 per share, such that the authorized share capital of the Company following such increase shall be consisting of 300,000,000 shares of common stock.

 

a.Private placement:

 

  1. In December 2019, the Company allocated in a private placement, a total of 379,269 units at a purchase price of $8.712 per unit. Each unit was comprised of two shares of common stock par value $0.001 per share, one Warrant A (as described below) and two Warrants B (as described below). The immediate proceeds (gross) from the issuance of the units amounted to approximately $3.3 million.

 

Each Warrant A was exercisable into one share of common stock of the Company at an exercise price of $5.355 per share during the 12 month period following the allocation. Each Warrant B is exercisable into one share of common stock of the Company at an exercise price of $8.037 per share during the 18 month period following the allocation.

 

In addition, Shrem Zilberman Group Ltd. (the “Consultant”) will be entitled to receive the amount representing 3% of any exercise price of each Warrant A or Warrant B that may be exercised in the future. In the event the total proceeds received as a result of exercise of warrants will be less than $2 million at the time of their expiration, the Consultant will be required to invest $250,000 in the Company in return for shares of common stock of Company. As of December 31, 2021, holders of the foregoing warrants have exercised in excess of $2 million and, accordingly, the Consultant is not required to invest $250,000 in the Company.

 

During 2020, 332,551 Warrants A were exercised, and 46,718 unexercised Warrants A expired on December 30, 2020.

 

The Consultant received $53 thousand following the exercise of 332,551 Warrants A.

 

During the second quarter of 2021, 185,271 Warrants B were exercised, and 573,256 unexercised Warrants B expired on June 30, 2021.

 

The Consultant received $45 thousand following the exercise of 185,271 Warrants B.

 

  2. On March 3, 2020, the Company issued in a private placement a total of 108,880 units at a purchase price of $8.712 per unit.

 

Each unit was comprised of two shares of common stock par value $0.001 per share, one Warrant A (as described below) and two Warrants B (as described below).

 

Each Warrant A was exercisable into one share of common stock of the Company at an exercise price of $5.355 per share during the 12 month period following the allocation.

 

Each Warrant B is exercisable into one share of common stock of the Company at an exercise price of $8.037 per share during the 18 month period following the allocation.

 

The gross proceeds from the issuance of all securities offered amounted to approximately $948 thousands. After deducting issuance costs, the Company received proceeds of approximately $909 thousand.

 

 

SCOUTCAM INC.

 

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 9 – EQUITY (continued):

 

During 2021, 108,880 Warrants A were exercised.

 

217,760 unexercised Warrants B expired on September 3, 2021.

 

  3. On May 18, 2020, the Company allocated in a private placement to Arkin a total of 229,569 units at a purchase price of $8.712 per unit.

 

Each unit was comprised of two shares of common stock par value $0.001 per share, one Warrant A (as described below) and two Warrants B (as described below).

 

Each Warrant A was exercisable into one share of common stock of the Company at an exercise price of $5.355 per share during the 18 month period following the allocation.

 

Each Warrant B is exercisable into one share of common stock of the Company at an exercise price of $8.037 per share during the 24 month period following the allocation.

 

The gross proceeds from the issuance of all securities offered amounted to approximately $2 million. After deducting issuance costs, the Company received proceeds of approximately $1.9 million.

 

During February 2021, 37,349 Warrants A were exercised.

 

During November 2021, 192,220 Warrants A were exercised.

 

  4.

On June 23, 2020, (the “Conversion Date”), the Company entered into a side letter agreement with Medigus whereby the parties agreed to convert, at a conversion price of $4.356 per share, an outstanding line of credit previously extended by Medigus to ScoutCam, which as of the Conversion Date had $381,136 outstanding, into (a) 87,497 shares of the Company’s common stock, (b) to 43,749 Warrant A (as described below), and (c) 87,497 Warrant B (as described below). As the conversion price represented the same unit price as in the March 2020 and May 2020 private placements, no finance expenses have been recorded in statement of operations as a result of the conversion.

 

Each Warrant A is exercisable into one share of common stock of the Company at an exercise price of $5.355 per share during the 12 months period following the allocation.

 

Each Warrant B is exercisable into one share of common stock of the Company at an exercise price of $8.037 per share during the 18 months period following the allocation.

 

During June 2021, 43,749 Warrants A were exercised.

 

On December 23, 2021, 87,497 unexercised Warrants B expired.

 

  5. On March 29, 2021, the Company issued to certain investors, including Arkin, a major stockholder of the Company, of which Mori Arkin, a director of the company, is the owner, 2,469,156 units in exchange for an aggregate purchase price of $20 million. Each such unit consists of (i) one share of common stock and (ii) one warrant to purchase one share of common stock with an exercise price of $10.35 per share. Each such warrant is exercisable until the close of business on March 31, 2026. Pursuant to the terms of the foregoing warrants, following April 1, 2024, if the closing price of Company common stock equal or exceeds 135% of the aforementioned exercise price (subject to appropriate adjustments for stock splits, stock dividends, stock combinations and other similar transactions after the issue date of the warrants) for any thirty (30) consecutive trading days, the Company may force the exercise of the warrants, in whole or in part, by delivering to these investors a notice of forced exercise.

 

 

SCOUTCAM INC.

 

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 9 – EQUITY (continued):

 

As of December 31, 2022, the Company had the following outstanding warrants to purchase common stock:

 

Warrant  Issuance Date  Expiration Date  Exercise Price
Per Share ($)		   Number of Shares
of common stock
Underlying
Warrants		 
               
March 2021 Warrant  March 29, 2021  March 31, 2026   10.350    2,469,156 
               2,469,156 

 

b.Stock-based compensation to employees, directors and service providers:

 

In February 2020, the Company’s Board of Directors approved the 2020 Share Incentive Plan (the “Plan”).

 

The Plan initially included a pool of 580,890 shares of common stock for grant to Company employees, consultants, directors and other service providers. On March 15, 2020, the Company’s Board of Directors approved an increase to the Company’s option pool pursuant to the Plan by an additional 64,099 shares of common stock. On June 22, 2020, the Company’s Board of Directors approved an increase to the Company’s option pool pursuant to the Plan by an additional 401,950 shares of common stock. During the second quarter of 2021, the Company’s Board of Directors approved an increase to the Company’s option pool pursuant to the Plan by an additional 777,778 shares of common stock.

 

The Plan is designed to enable the Company to grant options to purchase shares of common stock and RSUs under various and different tax regimes including, without limitation: (i) pursuant and subject to Section 102 of the Israeli Tax Ordinance or any provision which may amend or replace it and any regulations, rules, orders or procedures promulgated thereunder and to designate them as either grants made through a trustee or not through a trustee; and (ii) pursuant and subject to Section 3 (i) of the Israeli Tax Ordinance.

 

During 2021, the Company granted 648,712 options pursuant to the Plan.

 

During 2022, the Company granted 479,000 options pursuant to the Plan.

 

Options granted generally have a contractual term of seven years and vest over a period of three to four years.

 

 

SCOUTCAM INC.

 

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 9 – EQUITY (continued):

 

Stock Option Activity

 

The following summarizes stock option activity:

 

   Amount of options   Weighted average exercise price   Weighted Average Remaining Contractual Term (years)   Aggregate Intrinsic Value (in thousands) 
       $       $ in thousands 
Outstanding - December 31, 2020   737,049    2.61    6.23    2,446 
Granted   648,712    4.09    -    - 
Forfeited   (132,207)   3.34    -    - 
Outstanding - December 31, 2021   1,253,554    3.31    5.65    5,884 
                     
Granted   479,000    4.50    -    - 
Forfeited   (172,514)   3.57    -    - 
Outstanding - December 31, 2022   1,560,040    3.64    5.17    2,116 
                     
Options Exercisable - December 31, 2022   838,994    3.10    4.24    1,595 

 

As of December 31, 2022, the aggregate intrinsic value of options granted is calculated as the difference between the exercise price and the closing price on the same date.

 

The Company estimates the fair value of stock option awards on the grant date using the Black-Scholes option pricing model. The weighted-average grant date fair value per option granted during the year ended December 31, 2022 was $2.76. The fair value of each award is estimated using Black-Scholes option-pricing model based on the following assumptions:

 

  

Year ended

December 31, 2022

  

Year ended

December 31, 2021

 
Underlying value of shares ($)   5.00-7.20    7.65-10.35 
Exercise price ($)   4.5    2.61-7.2 
Expected volatility (%)   40%    46%-49% 
Term of the options (years)   7    7 
Risk-free interest rate (%)   1.98%-3.95%    0.78%-1.51% 

 

Volatility is derived from the historical volatility of publicly traded set of peer companies. The risk-free interest rates used in the Black-Scholes calculations are based on the prevailing U.S. Treasury yield as determined by the U.S. Federal Reserve. The Company has not paid dividends and does not anticipate paying dividends in the foreseeable future. Accordingly, no dividend yield was assumed for purposes of estimating the fair value of the Company’s stock-based compensation. The weighted average expected life of options was estimated individually in respect of each grant.

 

The unrecognized compensation expense calculated under the fair-value method for stock options expected to vest as of December 31, 2022 is approximately $1.45 million and is expected to be recognized over a weighted-average period of 1.41 years.

 

During 2022 and 2021 the Company’s Board of Directors authorized the grant of options to purchase 45,000 shares of common stock of the Company and 83,334 shares of common stock of the Company, respectively, to Prof. Goldwasser, the Chairman of the Board. Total expenses recorded regarding this grant, for the year ended December 31, 2022, and December 31, 2021, are $367 thousand and $255 thousand, respectively.

 

During 2021 the Company’s Board of Directors authorized the grant of options to purchase 75,855 shares of common stock of the Company to directors of the Company. Total expenses recorded regarding this grant, for the year ended December 31, 2022, and December 31, 2021, are $213 thousand and $221 thousand, respectively.

 

During 2022 and 2021 the Company’s Board of Directors authorized the grant of options to purchase 400,000 shares of common stock of the Company and 335,987 shares of common stock of the Company, respectively, to certain officers of the Company. Total expenses recorded regarding this grant, for the year ended December 31, 2022, and December 31, 2021, are $523 thousand and $871 thousand, respectively.

 

Compensation expense recorded by the Company in respect of its stock-based employees, directors and service providers compensation awards in accordance with ASC 718-10 for the year ended December 31, 2022 and 2021 amounted to $1,487 thousands and $2,030 thousands, respectively.

 

 

c.Restricted stock unit (“RSU”) to employees and service providers:

 

During the year ended December 31, 2022, the Company granted 110,000 RSUs pursuant to the Plan.

 

Each RSU will vest based on continued service which is generally over three years. The grant date fair value of the award will be recognized as stock-based compensation expense over the requisite service period. The fair value of restricted stock units was estimated on the date of grant based on the fair value of the Company’s common stock.

 

The cost of the benefit embodied in the RSU granted during 2022, based on their fair value as at the grant date, is estimated to be approximately $748 thousand. These amounts will be recognized in the statements of operations over the vesting period.

 

The following table summarizes RSU activity for December 31, 2022:

 

   Amount of RSU  

Weighted

Average Grant

Date Fair

Value

per Share

   Weighted Average Remaining Contractual Term (years) 
       $     
Outstanding - December 31, 2021   -    -    - 
Granted   110,000    6.8    - 
Forfeited   (60,000)   7.2    - 
Unvested and Outstanding - December 31, 2022   50,000    6.32    6.44 

 

The unrecognized compensation expense calculated under the fair-value method for RSU expected to vest as of December 31, 2022 is approximately $164 thousand and is expected to be recognized over a weighted-average period of 1.15 years.

 

During 2022 the Company’s Board of Directors authorized the grant of options to purchase 90,000 shares of common stock of the Company to certain officers of the Company. Total expenses recorded regarding this grant, for the year ended December 31, 2022, are $127 thousand.

 

 

SCOUTCAM INC.

 

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

 
XML 32 R16.htm IDEA: XBRL DOCUMENT v3.23.1
REVENUES AND ENTITY WIDE DISCLOSURES
 12 Months Ended
Dec. 31, 2022
Revenue from Contract with Customer [Abstract]  
REVENUES AND ENTITY WIDE DISCLOSURES

NOTE 10 – REVENUES AND ENTITY WIDE DISCLOSURES:

 

ASC 280, “Segment Reporting,” establishes standards for reporting information about operating segments. The Company manages its business based on one operating segment, as described in Note 1.

 

a.Disaggregation of revenue

 SCHEDULE OF DISAGGREGATION OF REVENUE

   Year ended on
December 31,		 
   2022   2021 
   USD in thousands 
Development Services (customer A) (*)   317    - 
Products   348    387 
    665    387 

 

  (*) During the second quarter of 2022, the Company completed the development of the product relating to a customer-specific project for a Fortune 500 multinational healthcare corporation (“Customer A”) and moved from the development phase of the project to its production phase. As a result, during the year ended December 31, 2022, the Company recognized development services revenues and related development costs that had been previously deferred, in the amounts of $317 thousand and $180 thousand, respectively. The amounts were recognized based on the expected manufacturing term of the product, which the Company estimates at 7 years.
     
    In addition, following the commencement of the production phase, the Company recognized product revenues of $221 thousands during the year ended December 31, 2022 from the sale of units of the product developed in the context of these development services.

 

  b. Revenues by geographical area (based on the location of customers)

 

The following is a summary of revenues within geographic areas:

 

   2022   2021 
   Year ended on
December 31,		 
   2022   2021 
   USD in thousands 
United States   553    273 
United Kingdom   65    48 
Israel   -    19 
Other   47    47 
 Revenue   665    387 

 

  c. Major customers

 

Set forth below is a breakdown of Company’s revenue by major customers (major customer –revenues from these customers constituted at least 10% of total revenues in a certain year):

 

 SCHEDULE OF MAJOR CUSTOMER BREAKDOWN OF COMPANY’S REVENUE

   Year ended on 
   December 31, 
   2022   2021 
   USD in thousands 
Customer A   538    - 
           
Customer B   -    199 
           
Customer C   65    48 

 

 

  d. Contract fulfillment assets and Contract liabilities:

 

   2022   2021 
   December 31, 
   2022   2021 
   USD in thousands 
Contract fulfillment assets:   1,495    1,675 
Contract liabilities   3,644    2,420 

 

Contract liabilities include advance payments, which are primarily related to advanced billings for development services.

 

The change in contract fulfillment assets:

 

   2022   2021 
   December 31, 
   2022   2021 
   USD in thousands 
         
Balance at beginning of year   1,675    1,130 
Additions during the year   -    545 
Contract costs recognized during the period   (180)   - 
Balance at end of year   1,495    1,675 

 

The change in contract liabilities:

 

   2022   2021 
   December 31, 
   2022   2021 
   USD in thousands 
         
Balance at beginning of year   2,420    848 
Deferred revenue relating to new sales   1,613    1,641 
Revenue recognized during the year   (389)   (69)
Balance at end of year   3,644    2,420 

 

Remaining Performance Obligations

 

Remaining Performance Obligations (“RPO”) represents contracted revenue that has not yet been recognized, which includes deferred revenue and amounts that will be recognized as revenue in future periods. As of December 31, 2022, the total RPO amounted to $3,644 thousand, which the Company expects to recognize over the expected manufacturing term of the product under development.

 

 

SCOUTCAM INC.

 

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

 
XML 33 R17.htm IDEA: XBRL DOCUMENT v3.23.1
LEASES
 12 Months Ended
Dec. 31, 2022
Leases  
LEASES

NOTE 11 - LEASES

 

On December 31, 2022, the Group’s ROU assets and lease liabilities for operating leases totaled $307 thousand and $263 thousand, respectively.

 

On December 31, 2021, the Group’s ROU assets and lease liabilities for operating leases totaled $482 thousand and $459 thousand, respectively.

 

In December 2020, ScoutCam entered into a lease agreement for office space in Omer, Israel. The agreement is for 36 months beginning January 1, 2021. In March 2021, ScoutCam entered into a lease agreement for additional office space in Omer, Israel. The agreement is until December 31, 2023. Monthly lease payments under the agreements are approximately $12 thousand. ScoutCam subleases part of the office space to a third party for $3 thousand per month.

 

In December 2022, ScoutCam entered into a lease agreement for office space in Ramat Gan, Israel. The agreement is for 12 months beginning on December 14, 2022. The agreement expires on December 14, 2023, and the Company has an option to extend the lease period for an additional one year. The Company doesn’t expect to extend the lease period. Therefore, the Company has elected to use the practical expedient regarding short-term leases. Monthly lease payments under the agreements are $3 thousand.

 

In addition, the Company leases vehicles under various operating lease agreements.

 

Operating lease expenses were $264 thousand and $202 thousand for the years ended December 31, 2022 and 2021, respectively.

 

Supplemental cash flow information related to operating leases during the period presented was as follows:

 

   2022   2021 
   Year ended December 31, 
   2022   2021 
   USD in thousands 
Cash paid for amounts included in the measurement of lease liabilities:          
Operating cash flows from operating leases   261    202 

 

Lease term and discount rate related to operating leases as of the period presented were as follows:

 

   December 31, 
   2022   2021 
   USD in thousands 
Weighted-average remaining lease term (in years)   0.84    0.76 
Weighted-average discount rate   6%   6%

 

 

The maturities of lease liabilities under operating leases as of December 31, 2022 are as follows:

 

   USD in thousands 
2023   206 
2024   54 
2025   16 
Total undiscounted lease payments   276 
Less: Imputed interest   (13)
Total lease liabilities   263 

 
XML 34 R18.htm IDEA: XBRL DOCUMENT v3.23.1
RESEARCH AND DEVELOPMENT EXPENSES
 12 Months Ended
Dec. 31, 2022
Research and Development [Abstract]  
RESEARCH AND DEVELOPMENT EXPENSES

NOTE 12 – RESEARCH AND DEVELOPMENT EXPENSES:

 

   2022   2021 
   Year ended December 31, 
   2022   2021 
   USD in thousands 
Salaries and related expense   2,034    894 
Stock-based compensation   576    257 
Materials and subcontractors   1,030    655 
Depreciation   163    39 
Travel expenses   73    - 
Vehicle expenses   75    26 
Rent and maintenance and other expenses   246    131 
 Research and Development expenses   4,197    2,002 

 
XML 35 R19.htm IDEA: XBRL DOCUMENT v3.23.1
GENERAL AND ADMINISTRATIVE EXPENSES
 12 Months Ended
Dec. 31, 2022
General And Administrative Expenses  
GENERAL AND ADMINISTRATIVE EXPENSES

NOTE 13 – GENERAL AND ADMINISTRATIVE EXPENSES:

 

   2022   2021 
   Year ended December 31, 
   2022   2021 
   USD in thousands 
Salaries and related expense   1,027    1,144 
Stock-based compensation   903    1,483 
Professional services   859    1,193 
Patents   292    798 
Depreciation   34    29 
Insurance   337    386 
Vehicle expenses   73    99 
Rent and maintenance and other expenses   181    120 
VAT provision (note 7e)   (129)   229 
 General and Administrative expenses   3,577    5,481 

 
XML 36 R20.htm IDEA: XBRL DOCUMENT v3.23.1
SUBSEQUENT EVENTS
 12 Months Ended
Dec. 31, 2022
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS

NOTE 14 - SUBSEQUENT EVENTS:

 

On March 16, 2023, the Company consummated Stock Purchase Agreements for a private placement with (i) Moshe Arkin through his individual retirement account and (ii) The Phoenix Insurance Company Ltd. and Shotfut Menayot Israel – Phoenix Amitim, in connection with the sale and issuance of an aggregate amount of 3,294,117 units (collectively, the “Units”), at a purchase price of $4.25 per Unit, and for an aggregate purchase price of $14,000,000. Each Unit consists of: (i) one share of the Company’s common stock par value $0.001 per share (the “Common Stock”) and (ii) one warrant to purchase one share of Common Stock with an exercise price of $5.50 (the “Warrants”). The Warrants are immediately exercisable and will expire three years from the date of issuance and will be subject to customary adjustments.
XML 37 R21.htm IDEA: XBRL DOCUMENT v3.23.1
SIGNIFICANT ACCOUNTING POLICIES (Policies)
 12 Months Ended
Dec. 31, 2022
Accounting Policies [Abstract]  
Basis of preparation

 

  a. Basis of preparation:

 

The consolidated financial statements have been prepared in accordance with United States Generally Accepted Accounting Principles in the United States (“U.S. GAAP”) applied on a consistent basis.
Use of estimates

 

  b. Use of estimates

 

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. The Company evaluates its assumptions on an ongoing basis, including those related to contingencies and inventory impairment, as well as estimates used in applying its revenue recognition policy. Actual results may differ from these estimates.
Functional currency

 

  c. Functional currency

 

A majority of ScoutCam’s revenues are generated in U.S. dollars. The substantial majority of ScoutCam costs are incurred in U.S. dollars and New Israeli Shekels (“NIS”). ScoutCam management believes that the U.S. dollar is the currency of the primary economic environment in which ScoutCam operates. Thus, the functional currency of ScoutCam is the U.S. dollar.

 

Transactions and balances originally denominated in U.S. dollars are presented at their original amounts. Balances in non-U.S. dollar currencies are translated into U.S. dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For non-U.S. dollar transactions and other items in the statements of operations (indicated below), the following exchange rates are used: (i) for transactions exchange rates at transaction dates and (ii) for other items (derived from non-monetary balance sheet items such as depreciation and amortization) historical exchange rates. Currency transaction gains and losses are presented in financial income or expenses, as appropriate.
Cash and Cash Equivalents

 

  d. Cash and Cash Equivalents

 

The Company considers as cash equivalents all short-term, highly liquid investments, which include short-term bank deposits with original maturities of three months or less from the date of purchase that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash.
Short-term bank deposits

 

  e. Short-term bank deposits

 

Bank deposits with maturities of more than three months but less than one year are included in short-term bank deposits. Such short-term bank deposits are stated at cost which approximates fair market value.

 

 

SCOUTCAM INC.

 

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (continued):
Accounts receivable

 

  f. Accounts receivable

 

Accounts receivable are presented in the Company’s consolidated balance sheets net of allowance for doubtful accounts. The Company estimates the collectability of its accounts receivable balances and adjusts its allowance for doubtful accounts accordingly.

 

When revenue recognition criteria are not met for a sale transaction that has been billed, the Company does not recognize deferred revenues or the related account receivable.

 

As of December 31, 2022 and 2021, no allowance for doubtful accounts was recorded.
Property and equipment

 

  g. Property and equipment

 

Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation is calculated on a straight-line basis over the estimated useful lives.

 

The annual depreciation rates are as follows:

 

   % 
Machinery and laboratory equipment   10%-15%
Office furniture and equipment   10%
Computers and computer software   33%
Leasehold improvements   Over the shorter of the lease term (including options if any) or useful life 
Severance pay

 

  h. Severance pay

 

Israeli labor law generally requires payment of severance pay upon dismissal of an employee or upon termination of employment in certain other circumstances. Pursuant to Section 14 of the Severance Compensation Act, 1963 (“Section 14”), all of the ScoutCam’s employees in Israel are entitled to a monthly contribution, at a rate of 8.33% of their monthly salary, made in their name with insurance companies. Contributions under Section 14 relieve ScoutCam from any future severance payment obligation with respect to those employees. The aforementioned contributions are not recorded as an asset on the Company’s balance sheet and there is no liability recorded, as the Company does not have a future obligation to make any additional payments.

 

The asset and the liability for severance pay presented in the balance sheets reflects employees that began employment prior to automatic application of Section 14.

 

The severance pay liability of ScoutCam to its employees that began employment prior to automatic application of Section 14 is based upon the number of years of service and the latest monthly salary of such employees and is partly covered by regular deposits with recognized pension funds and deposits with severance pay funds. Under labor laws, these deposits are in the employees’ names and, subject to certain limitations, are the property of the employees. ScoutCam records the obligation as if it were payable at each balance sheet date on an undiscounted basis.

 

 

SCOUTCAM INC.

 

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (continued):
Stock-Based Compensation

 

  i. Stock-Based Compensation

 

The Company measures and recognizes compensation expense for its equity classified stock-based awards granted under its plan based on estimated fair values on the grant dates. The Company calculates the estimated fair value of option awards on the grant date using the Black-Scholes option-pricing model. The Black-Scholes option-pricing model requires a number of assumptions, of which the most significant are the stock price volatility and the expected option term. The Company’s expected dividend rate is zero since the Company does not currently pay cash dividends on its stocks and does not anticipate doing so in the foreseeable future. Each of the above factors requires the Company to use judgment and make estimates in determining the percentages and time periods used for the calculation. If the Company were to use different percentages or time periods, the estimated fair value of option awards could be materially different. The Company recognizes stock-based compensation cost for option awards on an accelerated basis over the employee’s requisite service period, net of estimated forfeitures.
Inventories

 

  j. Inventories

 

Inventories include raw materials, inventory in process and finished products and are valued at the lower of cost or net realizable value.

 

Inventories are stated at a lower of cost, determined by the first-in, first-out method, or market based on net realizable value. Costs of purchased raw materials and inventory in process include costs of design, raw materials, direct labor, other direct costs and fixed production overheads.

 

The inventories are adjusted for estimated excess and obsolescence and written down to net realizable value based upon estimates of future demand, technology developments and market conditions.
Revenue recognition

 

  k. Revenue recognition

 

  a) Revenue measurement

 

The Company’s revenues are measured according to the ASC 606, “Revenue from Contracts with Customers” (“ASC 606”). Under ASC 606, revenues are measured according to the amount of consideration that the Company expects to be entitled to receive in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties. Revenues are presented net of VAT.

 

  b) Revenue recognition

 

The Company recognizes revenue when a customer obtains control over promised goods or services. For each performance obligation, the Company determines at contract inception whether it satisfies the performance obligation over time or satisfies the performance obligation at a point in time.

 

Performance obligations are satisfied over time if one of the following criteria is met:

 

 

SCOUTCAM INC.

 

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (continued):

 

(a) the customer simultaneously receives and consumes the benefits provided by the Company’s performance; (b) the Company’s performance creates or enhances an asset that the customer controls as the asset is created or enhanced; or (c) the Company’s performance does not create an asset with an alternative use for the Company and the Company has an enforceable right to payment for performance completed to date.

 

If a performance obligation is not satisfied over time, a Company satisfies the performance obligation at a point in time.

 

The transaction price is allocated to each distinct performance obligations on a relative standalone selling price (“SSP”) basis and revenue is recognized for each performance obligation when control has passed. In most cases, the Company is able to establish SSP based on the observable prices of services sold separately in comparable circumstances to similar customers and for products based on the Company’s best estimates of the price at which the Company would have sold the product regularly on a stand-alone basis. The Company reassesses the SSP on a periodic basis or when facts and circumstances change.

 

Product Revenue

 

Revenues from product sales are recognized at a point in time when the customer obtains control of the Company’s product, typically upon shipment to the customer. Indirect taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from revenues.

 

Service Revenue

 

The Company also generates revenues from development services. Revenue from development services is recognized over the period of the applicable service contract. To the extent development services are not distinct from the performance obligation relating to the subsequent mass production phase of the prototype under development, revenue from these services is deferred until commencement of the production phase of the project and are then recognized over the expected term production.

 

 

SCOUTCAM INC.

 

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (continued):
Cost of revenues

 

  l. Cost of revenues

 

Cost of revenue consists of products purchased from sub-contractors, raw materials for in-house assembly line, shipping and handling costs to customers, salary, employee-related expenses, depreciation and overhead expenses.

 

Cost of revenues are expensed commensurate with the recognition of the respective revenues. Costs deferred in respect of deferral of revenues are recorded as contract fulfilment assets on the Company’s balance sheet and are written down to the extent the contract is expected to incur losses.
Research and development costs

 

  m. Research and development costs

 

Research and development costs are expensed as incurred and includes salaries and employee-related expenses, overhead expenses, material, and third-party contractors’ charges.
Income taxes

 

  n. Income taxes

 

Income taxes are accounted for using the asset and liability approach under ASC-740, “Income Taxes”. The asset and liability approach requires the recognition of taxes payable or refundable for the current year and deferred tax liabilities and assets for the future tax consequences of events that have been recognized in the Company’s financial statements or tax returns.

 

The measurement of current and deferred tax liabilities and assets is based on provisions of the relevant tax law. The measurement of deferred tax assets is reduced, if necessary, by the amount of any tax benefits that, based on available evidence, are not expected to be realized.

 

Uncertain tax positions are accounted for in accordance with the provisions of ASC 740-10, under which a company may recognize the tax benefit from an uncertain tax position claimed or expected to be claimed on a tax return only if it is more likely than not that the tax position will be sustained on examination by the taxation authorities, based on the technical merits of the position, at the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement. Interest and penalties, if any, related to unrecognized tax benefits are recognized in tax expense. The Company and ScoutCam provide a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value.
Legal contingencies

 

  o. Legal contingencies

 

From time to time, the Company and its subsidiary become involved in legal proceedings or are subject to claims arising in their ordinary course of business. Such matters are generally subject to many uncertainties and outcomes are not predictable with assurance. The Company accrues for contingencies when the loss is probable and can reasonably estimate the amount of any such loss.

 

 

SCOUTCAM INC.

 

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 2 — SIGNIFICANT ACCOUNTING POLICIES (continued):
Basic and diluted net loss per common stock

 

  p. Basic and diluted net loss per common stock:

 

Basic net loss per common stock is computed by dividing net loss, as adjusted, to include the weighted average number of shares of common stock outstanding during the year.

 

Diluted net loss per common stock is computed by dividing net loss, as adjusted, by the weighted average number of shares of common stock outstanding during the year, plus the number of shares of common stock that would have been outstanding if all potentially dilutive shares of common stock had been issued, using the treasury stock method, in accordance with ASC 260-10 “Earnings per Share”.

 

All outstanding stock options and warrants have been excluded from the calculation of the diluted loss per share for the years ended December 31, 2022 and December 31, 2021, since all such securities have an anti-dilutive effect.
Leases

 

  q. Leases

 

In accordance with ASC 842, the Company determines whether an arrangement is or contains a lease based on the facts and circumstances present at inception of an arrangement. An arrangement is or contains a lease if the arrangement conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

 

Arrangements that are determined to be leases at inception are recognized in long-term right-of-use assets (“ROU”) assets and short and long-term lease liabilities in the consolidated balance sheet at lease commencement. Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future fixed lease payments over the lease term at commencement date. As most of the Company’s leases do not provide an implicit rate, the Company applies its incremental borrowing rate based on the economic environment at commencement date in determining the present value of future payments. Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for operating leases or payments are recognized on a straight-line basis over the lease term.

 

The Company has elected not to recognize on the balance sheet leases with terms of 12 months or less.
XML 38 R22.htm IDEA: XBRL DOCUMENT v3.23.1
SIGNIFICANT ACCOUNTING POLICIES (Tables)
 12 Months Ended
Dec. 31, 2022
Accounting Policies [Abstract]  
SCHEDULE OF PROPERTY AND EQUIPMENT ANNUAL DEPRECIATION RATES

The annual depreciation rates are as follows:

 

   % 
Machinery and laboratory equipment   10%-15%
Office furniture and equipment   10%
Computers and computer software   33%
Leasehold improvements   Over the shorter of the lease term (including options if any) or useful life 
XML 39 R23.htm IDEA: XBRL DOCUMENT v3.23.1
INVENTORY (Tables)
 12 Months Ended
Dec. 31, 2022
Inventory Disclosure [Abstract]  
SCHEDULE OF INVENTORY

 

   2022   2021 
   December 31, 
   2022   2021 
   USD in thousands 
Raw materials and supplies   438    99 
Work in progress   148    2 
Finished goods   44    66 
 Inventory Net   630    167 
XML 40 R24.htm IDEA: XBRL DOCUMENT v3.23.1
PROPERTY AND EQUIPMENT, NET (Tables)
 12 Months Ended
Dec. 31, 2022
Property, Plant and Equipment [Abstract]  
SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT NET

Property, plant and equipment, net consisted of the following:

 

   2022   2021 
   December 31, 
   2022   2021 
   USD in thousands 
Cost:          
Machinery and laboratory equipment   619    578 
Leasehold improvements, office furniture and equipment   351    316 
Computers and computer software   182    140 
Total property and equipment, gross   1,152    1,034 
Less: accumulated deprecation   (504)   (253)
Total property and equipment, net   648    781 
XML 41 R25.htm IDEA: XBRL DOCUMENT v3.23.1
OTHER ACCRUED EXPENSES (Tables)
 12 Months Ended
Dec. 31, 2022
Other Liabilities Disclosure [Abstract]  
SCHEDULE OF OTHER ACCRUED EXPENSES

 

   2022   2021 
   December 31, 
   2022   2021 
   USD in thousands 
Internal Revenue Services   -    40 
Accrued expenses   214    170 
Total other accrued expenses    214    210 
XML 42 R26.htm IDEA: XBRL DOCUMENT v3.23.1
INCOME TAXES (Tables)
 12 Months Ended
Dec. 31, 2022
Income Tax Disclosure [Abstract]  
SCHEDULE OF COMPONENT OF DEFERRED TAX ASSET

   2022   2021 
   December 31, 
   2022   2021 
   USD in thousands 
Operating loss carryforward   26,295    15,582 
           
Net deferred tax asset before valuation allowance   

6,069

    

3,595

 
Valuation allowance   (6,069)   (3,595)
Net deferred tax   -    - 
XML 43 R27.htm IDEA: XBRL DOCUMENT v3.23.1
RELATED PARTIES (Tables)
 12 Months Ended
Dec. 31, 2022
Related Party Transactions [Abstract]  
SCHEDULE OF BALANCES WITH RELATED PARTIES a.Related Parties Balances:

 

   December 31, 
   2022   2021 
   USD in thousands 
Directors (directors’ accrued compensation)   48    - 
Smartec R&D Ltd. (see note 8c)   10    - 
Medigus   -    39 
    58    39 
XML 44 R28.htm IDEA: XBRL DOCUMENT v3.23.1
EQUITY (Tables)
 12 Months Ended
Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
SCHEDULE OF STOCK WARRANTS OUTSTANDING TO PURCHASE COMMON STOCK

As of December 31, 2022, the Company had the following outstanding warrants to purchase common stock:

 

Warrant  Issuance Date  Expiration Date  Exercise Price
Per Share ($)		   Number of Shares
of common stock
Underlying
Warrants		 
               
March 2021 Warrant  March 29, 2021  March 31, 2026   10.350    2,469,156 
               2,469,156 
SCHEDULE OF STOCK OPTION ACTIVITY

The following summarizes stock option activity:

 

   Amount of options   Weighted average exercise price   Weighted Average Remaining Contractual Term (years)   Aggregate Intrinsic Value (in thousands) 
       $       $ in thousands 
Outstanding - December 31, 2020   737,049    2.61    6.23    2,446 
Granted   648,712    4.09    -    - 
Forfeited   (132,207)   3.34    -    - 
Outstanding - December 31, 2021   1,253,554    3.31    5.65    5,884 
                     
Granted   479,000    4.50    -    - 
Forfeited   (172,514)   3.57    -    - 
Outstanding - December 31, 2022   1,560,040    3.64    5.17    2,116 
                     
Options Exercisable - December 31, 2022   838,994    3.10    4.24    1,595 
SCHEDULE OF SHARE-BASED PAYMENT,STOCK OPTIONS, VALUATION ASSUMPTIONS

 

  

Year ended

December 31, 2022

  

Year ended

December 31, 2021

 
Underlying value of shares ($)   5.00-7.20    7.65-10.35 
Exercise price ($)   4.5    2.61-7.2 
Expected volatility (%)   40%    46%-49% 
Term of the options (years)   7    7 
Risk-free interest rate (%)   1.98%-3.95%    0.78%-1.51% 
Restricted Stock [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
SCHEDULE OF STOCK OPTION ACTIVITY

The following table summarizes RSU activity for December 31, 2022:

 

   Amount of RSU  

Weighted

Average Grant

Date Fair

Value

per Share

   Weighted Average Remaining Contractual Term (years) 
       $     
Outstanding - December 31, 2021   -    -    - 
Granted   110,000    6.8    - 
Forfeited   (60,000)   7.2    - 
Unvested and Outstanding - December 31, 2022   50,000    6.32    6.44 
XML 45 R29.htm IDEA: XBRL DOCUMENT v3.23.1
REVENUES AND ENTITY WIDE DISCLOSURES (Tables)
 12 Months Ended
Dec. 31, 2022
Revenue from Contract with Customer [Abstract]  
SCHEDULE OF DISAGGREGATION OF REVENUE

 SCHEDULE OF DISAGGREGATION OF REVENUE

   Year ended on
December 31,		 
   2022   2021 
   USD in thousands 
Development Services (customer A) (*)   317    - 
Products   348    387 
    665    387 

 

  (*) During the second quarter of 2022, the Company completed the development of the product relating to a customer-specific project for a Fortune 500 multinational healthcare corporation (“Customer A”) and moved from the development phase of the project to its production phase. As a result, during the year ended December 31, 2022, the Company recognized development services revenues and related development costs that had been previously deferred, in the amounts of $317 thousand and $180 thousand, respectively. The amounts were recognized based on the expected manufacturing term of the product, which the Company estimates at 7 years.
     
    In addition, following the commencement of the production phase, the Company recognized product revenues of $221 thousands during the year ended December 31, 2022 from the sale of units of the product developed in the context of these development services.
SCHEDULE OF REVENUES WITHIN GEOGRAPHIC AREAS

The following is a summary of revenues within geographic areas:

 

   2022   2021 
   Year ended on
December 31,		 
   2022   2021 
   USD in thousands 
United States   553    273 
United Kingdom   65    48 
Israel   -    19 
Other   47    47 
 Revenue   665    387 
SCHEDULE OF MAJOR CUSTOMER BREAKDOWN OF COMPANY’S REVENUE

Set forth below is a breakdown of Company’s revenue by major customers (major customer –revenues from these customers constituted at least 10% of total revenues in a certain year):

 

 SCHEDULE OF MAJOR CUSTOMER BREAKDOWN OF COMPANY’S REVENUE

   Year ended on 
   December 31, 
   2022   2021 
   USD in thousands 
Customer A   538    - 
           
Customer B   -    199 
           
Customer C   65    48 
SCHEDULE OF CONTRACT FULFILLMENT ASSETS AND CONTRACT LIABILITIES

 

   2022   2021 
   December 31, 
   2022   2021 
   USD in thousands 
Contract fulfillment assets:   1,495    1,675 
Contract liabilities   3,644    2,420 
 

The change in contract fulfillment assets:

 

   2022   2021 
   December 31, 
   2022   2021 
   USD in thousands 
         
Balance at beginning of year   1,675    1,130 
Additions during the year   -    545 
Contract costs recognized during the period   (180)   - 
Balance at end of year   1,495    1,675 

 

The change in contract liabilities:

 

   2022   2021 
   December 31, 
   2022   2021 
   USD in thousands 
         
Balance at beginning of year   2,420    848 
Deferred revenue relating to new sales   1,613    1,641 
Revenue recognized during the year   (389)   (69)
Balance at end of year   3,644    2,420 
 

XML 46 R30.htm IDEA: XBRL DOCUMENT v3.23.1
LEASES (Tables)
 12 Months Ended
Dec. 31, 2022
Leases  
SCHEDULE OF SUPPLEMENTAL CASH FLOW INFORMATION RELATED TO OPERATING LEASES

Supplemental cash flow information related to operating leases during the period presented was as follows:

 

   2022   2021 
   Year ended December 31, 
   2022   2021 
   USD in thousands 
Cash paid for amounts included in the measurement of lease liabilities:          
Operating cash flows from operating leases   261    202 
SCHEDULE OF LEASE TERM AND DISCOUNT RATE RELATED TO OPERATING LEASES

Lease term and discount rate related to operating leases as of the period presented were as follows:

 

   December 31, 
   2022   2021 
   USD in thousands 
Weighted-average remaining lease term (in years)   0.84    0.76 
Weighted-average discount rate   6%   6%
SCHEDULE OF MATURITIES LEASE LIABILITIES UNDER OPERATING LEASES

The maturities of lease liabilities under operating leases as of December 31, 2022 are as follows:

 

   USD in thousands 
2023   206 
2024   54 
2025   16 
Total undiscounted lease payments   276 
Less: Imputed interest   (13)
Total lease liabilities   263 
XML 47 R31.htm IDEA: XBRL DOCUMENT v3.23.1
RESEARCH AND DEVELOPMENT EXPENSES (Tables)
 12 Months Ended
Dec. 31, 2022
Research and Development [Abstract]  
SCHEDULE OF RESEARCH AND DEVELOPMENT EXPENSES

 

   2022   2021 
   Year ended December 31, 
   2022   2021 
   USD in thousands 
Salaries and related expense   2,034    894 
Stock-based compensation   576    257 
Materials and subcontractors   1,030    655 
Depreciation   163    39 
Travel expenses   73    - 
Vehicle expenses   75    26 
Rent and maintenance and other expenses   246    131 
 Research and Development expenses   4,197    2,002 
XML 48 R32.htm IDEA: XBRL DOCUMENT v3.23.1
GENERAL AND ADMINISTRATIVE EXPENSES (Tables)
 12 Months Ended
Dec. 31, 2022
General And Administrative Expenses  
SCHEDULE OF GENERAL AND ADMINISTRATIVE EXPENSES

 

   2022   2021 
   Year ended December 31, 
   2022   2021 
   USD in thousands 
Salaries and related expense   1,027    1,144 
Stock-based compensation   903    1,483 
Professional services   859    1,193 
Patents   292    798 
Depreciation   34    29 
Insurance   337    386 
Vehicle expenses   73    99 
Rent and maintenance and other expenses   181    120 
VAT provision (note 7e)   (129)   229 
 General and Administrative expenses   3,577    5,481 
XML 49 R33.htm IDEA: XBRL DOCUMENT v3.23.1
GENERAL (Details Narrative) - USD ($)
$ in Thousands
Aug. 09, 2021
Dec. 31, 2022
Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]      
Stockholders' equity, reverse stock split nine-to-one    
Retained Earnings (Accumulated Deficit)   $ (24,762) $ (15,294)
XML 50 R34.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF PROPERTY AND EQUIPMENT ANNUAL DEPRECIATION RATES (Details)
 12 Months Ended
Dec. 31, 2022
Machinery and Equipment [Member] | Minimum [Member]  
Property, Plant and Equipment [Line Items]  
Property and equipment annual depreciation rates 10.00%
Machinery and Equipment [Member] | Maximum [Member]  
Property, Plant and Equipment [Line Items]  
Property and equipment annual depreciation rates 15.00%
Office Equipment [Member]  
Property, Plant and Equipment [Line Items]  
Property and equipment annual depreciation rates 10.00%
Computer Equipment [Member]  
Property, Plant and Equipment [Line Items]  
Property and equipment annual depreciation rates 33.00%
Leasehold Improvements [Member]  
Property, Plant and Equipment [Line Items]  
Property, plant and equipment, description Over the shorter of the lease term (including options if any) or useful life
XML 51 R35.htm IDEA: XBRL DOCUMENT v3.23.1
SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Accounting Policies [Abstract]    
Accounts receivable, allowance for credit loss $ 0 $ 0
Monthly salary percentage 8.33%  
XML 52 R36.htm IDEA: XBRL DOCUMENT v3.23.1
SHORT-TERM DEPOSITS (Details Narrative)
 12 Months Ended
Dec. 31, 2022
Debt Disclosure [Abstract]  
Interest rate 4.00%
Maturity term 12 months
XML 53 R37.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF INVENTORY (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Inventory Disclosure [Abstract]    
Raw materials and supplies $ 438 $ 99
Work in progress 148 2
Finished goods 44 66
 Inventory Net $ 630 $ 167
XML 54 R38.htm IDEA: XBRL DOCUMENT v3.23.1
INVENTORY (Details Narrative) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Inventory Disclosure [Abstract]    
Inventory impairment $ 0 $ 0
XML 55 R39.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT NET (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Property, Plant and Equipment [Line Items]    
Total property and equipment, gross $ 1,152 $ 1,034
Less: accumulated deprecation (504) (253)
Total property and equipment, net 648 781
Machinery and Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Total property and equipment, gross 619 578
Leasehold Improvements Office Furniture And Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Total property and equipment, gross 351 316
Computer Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Total property and equipment, gross $ 182 $ 140
XML 56 R40.htm IDEA: XBRL DOCUMENT v3.23.1
PROPERTY AND EQUIPMENT, NET (Details Narrative) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Property, Plant and Equipment [Abstract]    
Depreciation expenses $ 251 $ 114
XML 57 R41.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF OTHER ACCRUED EXPENSES (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Other Liabilities Disclosure [Abstract]    
Internal Revenue Services $ 40
Accrued expenses 214 170
Total other accrued expenses  $ 214 $ 210
XML 58 R42.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF COMPONENT OF DEFERRED TAX ASSET (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Income Tax Disclosure [Abstract]    
Operating loss carryforward $ 26,295 $ 15,582
Net deferred tax asset before valuation allowance 6,069 3,595
Valuation allowance (6,069) (3,595)
Net deferred tax
XML 59 R43.htm IDEA: XBRL DOCUMENT v3.23.1
INCOME TAXES (Details Narrative)
₪ in Thousands, $ in Thousands
 1 Months Ended 12 Months Ended
Dec. 31, 2021
USD ($)
Dec. 31, 2021
ILS (₪)
Jul. 31, 2022
USD ($)
Jul. 31, 2022
ILS (₪)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Operating Loss Carryforwards [Line Items]            
Valuation allowance $ 3,595       $ 6,069 $ 3,595
Accumulated tax loss carryforward 15,582       26,295 15,582
Income tax expense (benefit)        
General and Administrative Expense [Member]            
Operating Loss Carryforwards [Line Items]            
Income tax expense (benefit)           $ 229
Israel Tax Authority [Member]            
Operating Loss Carryforwards [Line Items]            
Income tax expense (benefit)     $ 100      
Israel Tax Authority [Member] | Agreement [Member]            
Operating Loss Carryforwards [Line Items]            
Income tax expense (benefit) | ₪       ₪ 340    
Israel Tax Authority [Member] | Tax Year 2021 [Member]            
Operating Loss Carryforwards [Line Items]            
Income tax expense (benefit) $ 229 ₪ 740        
Foreign Tax Authority [Member]            
Operating Loss Carryforwards [Line Items]            
Effective income tax rate reconciliation, at federal statutory income tax rate         23.00%  
Domestic Tax Authority [Member]            
Operating Loss Carryforwards [Line Items]            
Effective income tax rate reconciliation, at federal statutory income tax rate         21.00%  
XML 60 R44.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF BALANCES WITH RELATED PARTIES (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Related Party Transaction [Line Items]    
Balances with related parties $ 58 $ 39
Directors [Member]    
Related Party Transaction [Line Items]    
Balances with related parties 48
Smartec R and D Ltd [Member]    
Related Party Transaction [Line Items]    
Balances with related parties 10
Medigus Ltd [Member]    
Related Party Transaction [Line Items]    
Balances with related parties $ 39
XML 61 R45.htm IDEA: XBRL DOCUMENT v3.23.1
RELATED PARTIES (Details Narrative) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 12 Months Ended
May 18, 2020
Mar. 03, 2020
Dec. 31, 2019
Dec. 31, 2022
Dec. 31, 2021
Subsidiary, Sale of Stock [Line Items]          
Compensation expense       $ 117 $ 82
Consulting expense         $ 37
Private Placement [Member]          
Subsidiary, Sale of Stock [Line Items]          
Issuance of units 229,569 108,880 379,269    
Issuance of unit, price per unit $ 8.712 $ 8.712 $ 8.712    
XML 62 R46.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF STOCK WARRANTS OUTSTANDING TO PURCHASE COMMON STOCK (Details)
 12 Months Ended
Dec. 31, 2022
$ / shares
shares
Warrant March 2021 [Member]  
Accumulated Other Comprehensive Income (Loss) [Line Items]  
Warrant issuance date Mar. 29, 2021
Warrant expiration date Mar. 31, 2026
Warrant exercise price per share | $ / shares $ 10.350
Number of shares of common stock underlying warrants 2,469,156
Warrant [Member]  
Accumulated Other Comprehensive Income (Loss) [Line Items]  
Number of shares of common stock underlying warrants 2,469,156
XML 63 R47.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF STOCK OPTION ACTIVITY (Details) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]      
Options, Outstanding at beginning of period 1,253,554 737,049  
Weighted average exercise price, Outstanding at beginning of period $ 3.31 $ 2.61  
Weighted average remaning contractual term (years) beginning of the period     6 years 2 months 23 days
Aggregate Intrinsic Value, Outstanding at beginning of period $ 5,884 $ 2,446  
Options, outstanding, granted 479,000 648,712  
Weighted average exercise price, Granted $ 4.50 $ 4.09  
Options, outstanding, cancelled (172,514) (132,207)  
Weighted average exercise price, Cancelled $ 3.57 $ 3.34  
Weighted average remaning contractual term (years) 5 years 2 months 1 day 5 years 7 months 24 days  
Options, Outstanding at ending of period 1,560,040 1,253,554 737,049
Weighted average exercise price, Outstanding at end of period $ 3.64 $ 3.31 $ 2.61
Aggregate Intrinsic Value, Outstanding at end of period $ 2,116 $ 5,884 $ 2,446
Options, Exercisable at end of period 838,994    
Weighted average exercise price, Exercisable at end of period $ 3.10    
Weighted average remaning contractual term (years) exercisable at end of the period 4 years 2 months 26 days    
Aggregate Intrinsic Value, Exercisable at end of period $ 1,595    
Restricted Stock Units (RSUs) [Member]      
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]      
Options, Outstanding at beginning of period    
Options, outstanding, granted 110,000    
Options, outstanding, cancelled (60,000)    
Options, Outstanding at ending of period 50,000  
Weighted average grant date fair value per share, begining of period    
Weighted average grant date fair value per share, granted 6.8    
Weighted average grant date fair value per share,vested 7.2    
Weighted average grant date fair value per share, unvested and outstanding ending balance $ 6.32  
Weighted average grant date fair value per share, unvested and outstanding ending balance 6 years 5 months 8 days    
XML 64 R48.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF SHARE-BASED PAYMENT,STOCK OPTIONS, VALUATION ASSUMPTIONS (Details) - $ / shares
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Exercise price $ 4.5  
Term of the options (years) 7 years 7 years
Minimum [Member]    
Underlying value of ordinary shares $ 5.00 $ 7.65
Exercise price   $ 2.61
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum   46.00%
Risk-free interest rate minimum 1.98% 0.78%
Maximum [Member]    
Underlying value of ordinary shares $ 7.20 $ 10.35
Exercise price   $ 7.2
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum   49.00%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 40.00%  
Risk-free interest rate maximum 3.95% 1.51%
XML 65 R49.htm IDEA: XBRL DOCUMENT v3.23.1
EQUITY (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Dec. 23, 2021
Mar. 29, 2021
Jun. 23, 2020
Jun. 22, 2020
May 18, 2020
Mar. 15, 2020
Mar. 03, 2020
Nov. 30, 2021
Jun. 30, 2021
Feb. 28, 2021
Feb. 29, 2020
Dec. 31, 2019
Jun. 30, 2021
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Jan. 20, 2021
Subsidiary, Sale of Stock [Line Items]                                  
Common stock shares authorized                           300,000,000 300,000,000    
Common stock, par value                           $ 0.001 $ 0.001    
Proceeds from exercise of warrants                           $ 3,491,000    
Share based compensation arrangement Options grants in period gross                           479,000 648,712    
Weighted average exercise price                           $ 4.50 $ 4.09    
Expenses recorded regarding                           $ 576,000 $ 257,000    
Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award                           90,000      
Compensation expense                           $ 1,638,000 $ 2,030,000    
Share-based compensation arrangement by share-based payment award, options, vested in period, fair value                           $ 127,000      
Share-Based Payment Arrangement, Option [Member]                                  
Subsidiary, Sale of Stock [Line Items]                                  
Option to purchase                             75,855    
Share-Based Payment Arrangement, Option [Member] | Prof Goldwasser [Member]                                  
Subsidiary, Sale of Stock [Line Items]                                  
Option to purchase                           45,000 83,334    
Expenses recorded regarding                           $ 367,000 $ 255,000    
Equity Option [Member]                                  
Subsidiary, Sale of Stock [Line Items]                                  
Weighted average exercise price                           $ 2.76      
Stock option award cost not yet recognized                           $ 1,450,000      
Stock option award weighted average period                           1 year 4 months 28 days      
Restricted Stock Units (RSUs) [Member]                                  
Subsidiary, Sale of Stock [Line Items]                                  
Share based compensation arrangement Options grants in period gross                           110,000      
Share-based compensation arrangement by share-based payment award, options, vested in period, fair value                           $ 748,000      
Share-based compensation arrangement by share-based payment award, options, vested in period, fair value                           $ 164,000      
Estimated average period                           1 year 1 month 24 days      
2020 Share Incentive Plan [Member]                                  
Subsidiary, Sale of Stock [Line Items]                                  
Share based compensation arrangement Options grants in period gross                           479,000 648,712    
Stock option vested term                           7 years      
2020 Share Incentive Plan [Member] | Minimum [Member]                                  
Subsidiary, Sale of Stock [Line Items]                                  
Stock option vested term                           3 years      
2020 Share Incentive Plan [Member] | Maximum [Member]                                  
Subsidiary, Sale of Stock [Line Items]                                  
Stock option vested term                           4 years      
Letter Agreement [Member] | Medigus Ltd [Member]                                  
Subsidiary, Sale of Stock [Line Items]                                  
Conversion price     $ 4.356                            
Warrant A [Member]                                  
Subsidiary, Sale of Stock [Line Items]                                  
Warrant exercisable, shares     1   1   1             1      
Warrant exerise price per share     $ 5.355   $ 5.355   $ 5.355             $ 5.355      
Warrants and rights outstanding, term     12 months   18 months   12 months                    
Proceeds from exercise of warrants                         $ 45,000     $ 53,000  
Number of warrants exercised               192,220 43,749 37,349     185,271   108,880 332,551  
Number of unexercised warrants                               46,718  
Warrants and rights outstanding, maturity date                               Dec. 30, 2020  
Warrant A [Member] | Letter Agreement [Member] | Medigus Ltd [Member]                                  
Subsidiary, Sale of Stock [Line Items]                                  
Warrant exercisable, shares     43,749                            
Warrant B [Member]                                  
Subsidiary, Sale of Stock [Line Items]                                  
Warrant exercisable, shares     1,000   1   1             1      
Warrant exerise price per share     $ 8.037   $ 8.037   $ 8.037             $ 8.037      
Warrants and rights outstanding, term     18 months   24 months   18 months               18 months    
Number of warrants exercised                         185,271        
Number of unexercised warrants 87,497                       573,256   217,760    
Warrants and rights outstanding, maturity date                 Jun. 30, 2021       Jun. 30, 2021   Sep. 03, 2021    
Warrant B [Member] | Letter Agreement [Member] | Medigus Ltd [Member]                                  
Subsidiary, Sale of Stock [Line Items]                                  
Warrant exercisable, shares     87,497                            
Warrant [Member]                                  
Subsidiary, Sale of Stock [Line Items]                                  
Sale of stock, description         Each unit was comprised of two shares of common stock par value $0.001 per share, one Warrant A (as described below) and two Warrants B (as described below)                        
Proceeds from issuance of securities offered         $ 2,000,000   $ 948,000                    
Proceeds from issuance after deducting issuance costs         $ 1,900,000   $ 909,000                    
Common Stock [Member] | Letter Agreement [Member] | Medigus Ltd [Member]                                  
Subsidiary, Sale of Stock [Line Items]                                  
Number of shares conversion     $ 381,136                            
Number of shares issued     87,497                            
Private Placement [Member]                                  
Subsidiary, Sale of Stock [Line Items]                                  
Stock issued during period, shares, new issues         229,569   108,880         379,269          
Shares issued, price per share         $ 8.712   $ 8.712         $ 8.712          
Sale of stock, description             Each unit was comprised of two shares of common stock par value $0.001 per share, one Warrant A (as described below) and two Warrants B (as described below)         Each unit was comprised of two shares of common stock par value $0.001 per share, one Warrant A (as described below) and two Warrants B (as described below)          
Proceeds from Issuance of Private Placement                       $ 3,300,000          
Board of Directors [Member]                                  
Subsidiary, Sale of Stock [Line Items]                                  
Common stock shares authorized                                 225,000,000
Common stock, par value                                 $ 0.001
Board of Directors [Member] | 2020 Share Incentive Plan [Member]                                  
Subsidiary, Sale of Stock [Line Items]                                  
Share based compensation arrangement Options grants in period gross           64,099                      
Consultant [Member]                                  
Subsidiary, Sale of Stock [Line Items]                                  
Warrant exercise price percentage                           3.00%      
Proceeds from exercise of warrants                           $ 2,000,000 $ 2,000,000    
Exercise of warrants required to invest return for shares of common stock                           250,000      
Exercise of warrants required to invest return for shares of common stock                             250,000    
Investment C [Member]                                  
Subsidiary, Sale of Stock [Line Items]                                  
Stock issued during period, shares, new issues   2,469,156                              
Investors C [Member]                                  
Subsidiary, Sale of Stock [Line Items]                                  
Sale of stock, description   Each such unit consists of (i) one share of common stock and (ii) one warrant to purchase one share of common stock with an exercise price of $10.35 per share                              
Warrant exerise price per share   $ 10.35                              
Warrants and rights outstanding, maturity date   Mar. 31, 2026                              
Proceeds from issuance of common stock   $ 20,000,000                              
Common stock percent   135.00%                              
Employees, Consultants, Directors and Other Service Providers [Member] | 2020 Share Incentive Plan [Member]                                  
Subsidiary, Sale of Stock [Line Items]                                  
Share based compensation arrangement Options grants in period gross       401,950             580,890   777,778        
Board of Directors Chairman [Member] | Share-Based Payment Arrangement, Option [Member]                                  
Subsidiary, Sale of Stock [Line Items]                                  
Expenses recorded regarding                           $ 213,000 221,000    
Officer [Member]                                  
Subsidiary, Sale of Stock [Line Items]                                  
Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award                           400,000      
Employee and Directors [Member]                                  
Subsidiary, Sale of Stock [Line Items]                                  
Compensation expense                           $ 1,487,000 $ 2,030,000    
XML 66 R50.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF DISAGGREGATION OF REVENUE (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Disaggregation of Revenue [Line Items]    
Revenues $ 665 $ 387
Service [Member]    
Disaggregation of Revenue [Line Items]    
Revenues [1] 317
Product [Member]    
Disaggregation of Revenue [Line Items]    
Revenues $ 348 $ 387
[1] During the second quarter of 2022, the Company completed the development of the product relating to a customer-specific project for a Fortune 500 multinational healthcare corporation (“Customer A”) and moved from the development phase of the project to its production phase. As a result, during the year ended December 31, 2022, the Company recognized development services revenues and related development costs that had been previously deferred, in the amounts of $317 thousand and $180 thousand, respectively. The amounts were recognized based on the expected manufacturing term of the product, which the Company estimates at 7 years.
XML 67 R51.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF DISAGGREGATION OF REVENUE (Details) (Parenthetical) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Jun. 30, 2022
Dec. 31, 2022
Dec. 31, 2021
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]      
Revenues from development services   $ 1,631 $ 1,108
Estimated useful life   7 years  
Service [Member]      
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]      
Revenues from development services   $ 317  
Related Development Costs [Member]      
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]      
Revenues from development services   180  
Product [Member]      
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]      
Revenues from development services   $ 221  
Customer A [Member]      
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]      
Development expense $ 500    
XML 68 R52.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF REVENUES WITHIN GEOGRAPHIC AREAS (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Disaggregation of Revenue [Line Items]    
 Revenue $ 665 $ 387
UNITED STATES    
Disaggregation of Revenue [Line Items]    
 Revenue 553 273
UNITED KINGDOM    
Disaggregation of Revenue [Line Items]    
 Revenue 65 48
ISRAEL    
Disaggregation of Revenue [Line Items]    
 Revenue 19
Other [Member]    
Disaggregation of Revenue [Line Items]    
 Revenue $ 47 $ 47
XML 69 R53.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF MAJOR CUSTOMER BREAKDOWN OF COMPANY’S REVENUE (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Disaggregation of Revenue [Line Items]    
Revenues $ 665 $ 387
Customer A [Member]    
Disaggregation of Revenue [Line Items]    
Revenues 538
Customer B [Member]    
Disaggregation of Revenue [Line Items]    
Revenues 199
Customer C [Member]    
Disaggregation of Revenue [Line Items]    
Revenues $ 65 $ 48
XML 70 R54.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF CONTRACT FULFILLMENT ASSETS AND CONTRACT LIABILITIES (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Revenue from Contract with Customer [Abstract]    
Contract fulfillment assets: $ 1,495 $ 1,675
Contract liabilities 3,644 2,420
Balance at beginning of year 1,675 1,130
Additions during the year 545
Contract costs recognized during the period (180)
Balance at end of year 1,495 1,675
Balance at beginning of year 2,420 848
Deferred revenue relating to new sales 1,613 1,641
Revenue recognized during the year (389) (69)
Balance at end of year $ 3,644 $ 2,420
XML 71 R55.htm IDEA: XBRL DOCUMENT v3.23.1
REVENUES AND ENTITY WIDE DISCLOSURES (Details Narrative)
$ in Thousands
Dec. 31, 2022
USD ($)
Revenue from Contract with Customer [Abstract]  
Remaining performance obligations $ 3,644
XML 72 R56.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF SUPPLEMENTAL CASH FLOW INFORMATION RELATED TO OPERATING LEASES (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Leases    
Operating cash flows from operating leases $ 261 $ 202
XML 73 R57.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF LEASE TERM AND DISCOUNT RATE RELATED TO OPERATING LEASES (Details)
Dec. 31, 2022
Dec. 31, 2021
Leases    
Weighted-average remaining lease term (in years) 10 months 2 days 9 months 3 days
Weighted-average discount rate 6.00% 6.00%
XML 74 R58.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF MATURITIES LEASE LIABILITIES UNDER OPERATING LEASES (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Leases    
2023 $ 206  
2024 54  
2025 16  
Total undiscounted lease payments 276  
Less: Imputed interest (13)  
Total lease liabilities $ 263 $ 459
XML 75 R59.htm IDEA: XBRL DOCUMENT v3.23.1
LEASES (Details Narrative) - USD ($)
$ in Thousands
 12 Months Ended
Jan. 02, 2022
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Operating lease, right-of-use asset   $ 307 $ 482  
Operating lease, liability   263 459  
Operating lease, payments   261 202  
Sublease income   3    
Operating lease expense   $ 264 $ 202  
Lease Agreement [Member]        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Lessee, operating lease, description   In December 2022, ScoutCam entered into a lease agreement for office space in Ramat Gan, Israel. The agreement is for 12 months beginning on December 14, 2022.   In December 2020, ScoutCam entered into a lease agreement for office space in Omer, Israel. The agreement is for 36 months beginning January 1, 2021
Operating lease, payments $ 12      
Sublease income $ 3      
XML 76 R60.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF RESEARCH AND DEVELOPMENT EXPENSES (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Research and Development [Abstract]    
Salaries and related expense $ 2,034 $ 894
Stock-based compensation 576 257
Materials and subcontractors 1,030 655
Depreciation 163 39
Travel expenses 73
Vehicle expenses 75 26
Rent and maintenance and other expenses 246 131
 Research and Development expenses $ 4,197 $ 2,002
XML 77 R61.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF GENERAL AND ADMINISTRATIVE EXPENSES (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
General And Administrative Expenses    
Salaries and related expense $ 1,027 $ 1,144
Stock-based compensation 903 1,483
Professional services 859 1,193
Patents 292 798
Depreciation 34 29
Insurance 337 386
Vehicle expenses 73 99
Rent and maintenance and other expenses 181 120
VAT provision (note 7e) (129) 229
 General and Administrative expenses $ 3,577 $ 5,481
XML 78 R62.htm IDEA: XBRL DOCUMENT v3.23.1
SUBSEQUENT EVENTS (Details Narrative) - USD ($)
Mar. 16, 2023
Dec. 31, 2022
Dec. 31, 2021
Subsequent Event [Line Items]      
Common stock par value, per share   $ 0.001 $ 0.001
Stock Purchase Agreements [Member] | Subsequent Event [Member]      
Subsequent Event [Line Items]      
Issuance of units 3,294,117    
Purchase price $ 4.25    
Aggregate purchase price $ 14,000,000    
Stock Purchase Agreements [Member] | Subsequent Event [Member] | Common Stock [Member]      
Subsequent Event [Line Items]      
Common stock par value, per share $ 0.001    
Stock Purchase Agreements [Member] | Subsequent Event [Member] | Warrant [Member]      
Subsequent Event [Line Items]      
Exercise price $ 5.50    
Warrant exercisable term 3 years    
XML 79 form10-k_htm.xml IDEA: XBRL DOCUMENT 0001577445 2022-01-01 2022-12-31 0001577445 2022-06-30 0001577445 2023-03-28 0001577445 2022-12-31 0001577445 2021-12-31 0001577445 2021-01-01 2021-12-31 0001577445 us-gaap:CommonStockMember 2021-12-31 0001577445 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001577445 us-gaap:RetainedEarningsMember 2021-12-31 0001577445 us-gaap:CommonStockMember 2020-12-31 0001577445 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001577445 us-gaap:RetainedEarningsMember 2020-12-31 0001577445 2020-12-31 0001577445 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001577445 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001577445 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001577445 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001577445 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001577445 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001577445 us-gaap:CommonStockMember 2022-12-31 0001577445 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001577445 us-gaap:RetainedEarningsMember 2022-12-31 0001577445 2021-08-08 2021-08-09 0001577445 srt:MinimumMember us-gaap:MachineryAndEquipmentMember 2022-01-01 2022-12-31 0001577445 srt:MaximumMember us-gaap:MachineryAndEquipmentMember 2022-01-01 2022-12-31 0001577445 us-gaap:OfficeEquipmentMember 2022-01-01 2022-12-31 0001577445 us-gaap:ComputerEquipmentMember 2022-01-01 2022-12-31 0001577445 us-gaap:LeaseholdImprovementsMember 2022-01-01 2022-12-31 0001577445 us-gaap:MachineryAndEquipmentMember 2022-12-31 0001577445 us-gaap:MachineryAndEquipmentMember 2021-12-31 0001577445 SCTC:LeaseholdImprovementsOfficeFurnitureAndEquipmentMember 2022-12-31 0001577445 SCTC:LeaseholdImprovementsOfficeFurnitureAndEquipmentMember 2021-12-31 0001577445 us-gaap:ComputerEquipmentMember 2022-12-31 0001577445 us-gaap:ComputerEquipmentMember 2021-12-31 0001577445 us-gaap:ForeignCountryMember 2022-01-01 2022-12-31 0001577445 us-gaap:DomesticCountryMember 2022-01-01 2022-12-31 0001577445 us-gaap:IsraelTaxAuthorityMember us-gaap:TaxYear2021Member 2021-12-30 2021-12-31 0001577445 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-12-31 0001577445 us-gaap:IsraelTaxAuthorityMember SCTC:AgreementMember 2022-07-01 2022-07-31 0001577445 us-gaap:IsraelTaxAuthorityMember 2022-07-01 2022-07-31 0001577445 SCTC:DirectorsMember 2022-12-31 0001577445 SCTC:DirectorsMember 2021-12-31 0001577445 SCTC:SmartecRAndDLtdMember 2022-12-31 0001577445 SCTC:SmartecRAndDLtdMember 2021-12-31 0001577445 SCTC:MedigusLtdMember 2022-12-31 0001577445 SCTC:MedigusLtdMember 2021-12-31 0001577445 us-gaap:PrivatePlacementMember 2020-05-17 2020-05-18 0001577445 us-gaap:PrivatePlacementMember 2020-05-18 0001577445 SCTC:BoardOfDirectorsMember 2021-01-20 0001577445 us-gaap:PrivatePlacementMember 2019-12-01 2019-12-31 0001577445 us-gaap:PrivatePlacementMember 2019-12-31 0001577445 SCTC:WarrantAMember 2022-12-31 0001577445 SCTC:WarrantBMember 2022-12-31 0001577445 SCTC:WarrantBMember 2021-12-31 0001577445 SCTC:ConsultantMember 2022-01-01 2022-12-31 0001577445 SCTC:ConsultantMember 2021-01-01 2021-12-31 0001577445 SCTC:WarrantAMember 2020-01-01 2020-12-31 0001577445 SCTC:WarrantAMember 2020-12-31 0001577445 SCTC:WarrantBMember 2021-04-01 2021-06-30 0001577445 SCTC:WarrantBMember 2021-06-30 0001577445 SCTC:WarrantAMember 2021-04-01 2021-06-30 0001577445 us-gaap:PrivatePlacementMember 2020-03-02 2020-03-03 0001577445 us-gaap:PrivatePlacementMember 2020-03-03 0001577445 SCTC:WarrantAMember 2020-03-03 0001577445 SCTC:WarrantBMember 2020-03-03 0001577445 us-gaap:WarrantMember 2020-03-02 2020-03-03 0001577445 SCTC:WarrantAMember 2021-01-01 2021-12-31 0001577445 SCTC:WarrantBMember 2021-01-01 2021-12-31 0001577445 us-gaap:WarrantMember 2020-05-17 2020-05-18 0001577445 SCTC:WarrantAMember 2020-05-18 0001577445 SCTC:WarrantBMember 2020-05-18 0001577445 SCTC:WarrantAMember 2021-02-01 2021-02-28 0001577445 SCTC:WarrantAMember 2021-11-01 2021-11-30 0001577445 SCTC:LetterAgreementMember SCTC:MedigusLtdMember 2020-06-23 0001577445 us-gaap:CommonStockMember SCTC:LetterAgreementMember SCTC:MedigusLtdMember 2020-06-21 2020-06-23 0001577445 SCTC:WarrantAMember SCTC:LetterAgreementMember SCTC:MedigusLtdMember 2020-06-23 0001577445 SCTC:WarrantBMember SCTC:LetterAgreementMember SCTC:MedigusLtdMember 2020-06-23 0001577445 SCTC:WarrantAMember 2020-06-23 0001577445 SCTC:WarrantBMember 2020-06-23 0001577445 SCTC:WarrantAMember 2021-06-01 2021-06-30 0001577445 SCTC:WarrantBMember 2021-12-22 2021-12-23 0001577445 SCTC:InvestmentCMember 2021-03-28 2021-03-29 0001577445 SCTC:InvestorsCMember 2021-03-28 2021-03-29 0001577445 SCTC:InvestorsCMember 2021-03-29 0001577445 SCTC:EmployeesConsultantsDirectorsAndOtherServiceProvidersMember SCTC:TwoThousandAndTwentyShareIncentivePlanMember 2020-02-01 2020-02-29 0001577445 SCTC:BoardOfDirectorsMember SCTC:TwoThousandAndTwentyShareIncentivePlanMember 2020-03-14 2020-03-15 0001577445 SCTC:EmployeesConsultantsDirectorsAndOtherServiceProvidersMember SCTC:TwoThousandAndTwentyShareIncentivePlanMember 2020-06-22 2020-06-22 0001577445 SCTC:EmployeesConsultantsDirectorsAndOtherServiceProvidersMember SCTC:TwoThousandAndTwentyShareIncentivePlanMember 2021-04-01 2021-06-30 0001577445 SCTC:TwoThousandAndTwentyShareIncentivePlanMember 2021-01-01 2021-12-31 0001577445 SCTC:TwoThousandAndTwentyShareIncentivePlanMember 2022-01-01 2022-12-31 0001577445 srt:MinimumMember SCTC:TwoThousandAndTwentyShareIncentivePlanMember 2022-01-01 2022-12-31 0001577445 srt:MaximumMember SCTC:TwoThousandAndTwentyShareIncentivePlanMember 2022-01-01 2022-12-31 0001577445 us-gaap:StockOptionMember 2022-01-01 2022-12-31 0001577445 us-gaap:StockOptionMember 2022-12-31 0001577445 us-gaap:EmployeeStockOptionMember SCTC:ProfGoldwasserMember 2022-12-31 0001577445 us-gaap:EmployeeStockOptionMember SCTC:ProfGoldwasserMember 2021-12-31 0001577445 us-gaap:EmployeeStockOptionMember SCTC:ProfGoldwasserMember 2022-01-01 2022-12-31 0001577445 us-gaap:EmployeeStockOptionMember SCTC:ProfGoldwasserMember 2021-01-01 2021-12-31 0001577445 us-gaap:EmployeeStockOptionMember 2021-12-31 0001577445 srt:BoardOfDirectorsChairmanMember us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0001577445 srt:BoardOfDirectorsChairmanMember us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001577445 srt:OfficerMember 2022-01-01 2022-12-31 0001577445 SCTC:EmployeeAndDirectorsMember 2022-01-01 2022-12-31 0001577445 SCTC:EmployeeAndDirectorsMember 2021-01-01 2021-12-31 0001577445 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-12-31 0001577445 us-gaap:RestrictedStockUnitsRSUMember 2022-12-31 0001577445 us-gaap:RestrictedStockMember 2022-01-01 2022-12-31 0001577445 SCTC:WarrantMarchTwoThousandTwentyOneMember 2022-01-01 2022-12-31 0001577445 SCTC:WarrantMarchTwoThousandTwentyOneMember 2022-12-31 0001577445 us-gaap:WarrantMember 2022-12-31 0001577445 2020-01-01 2020-12-31 0001577445 us-gaap:RestrictedStockUnitsRSUMember 2021-12-31 0001577445 srt:MinimumMember 2022-12-31 0001577445 srt:MaximumMember 2022-12-31 0001577445 srt:MinimumMember 2021-12-31 0001577445 srt:MaximumMember 2021-12-31 0001577445 srt:MinimumMember 2022-01-01 2022-12-31 0001577445 srt:MaximumMember 2022-01-01 2022-12-31 0001577445 srt:MinimumMember 2021-01-01 2021-12-31 0001577445 srt:MaximumMember 2021-01-01 2021-12-31 0001577445 us-gaap:ServiceMember 2022-01-01 2022-12-31 0001577445 us-gaap:ServiceMember 2021-01-01 2021-12-31 0001577445 us-gaap:ProductMember 2022-01-01 2022-12-31 0001577445 us-gaap:ProductMember 2021-01-01 2021-12-31 0001577445 SCTC:CustomerAMember 2022-04-01 2022-06-30 0001577445 us-gaap:ServiceMember 2022-01-01 2022-12-31 0001577445 SCTC:RelatedDevelopmentCostsMember 2022-01-01 2022-12-31 0001577445 us-gaap:ProductMember 2022-01-01 2022-12-31 0001577445 country:US 2022-01-01 2022-12-31 0001577445 country:US 2021-01-01 2021-12-31 0001577445 country:GB 2022-01-01 2022-12-31 0001577445 country:GB 2021-01-01 2021-12-31 0001577445 country:IL 2022-01-01 2022-12-31 0001577445 country:IL 2021-01-01 2021-12-31 0001577445 SCTC:OtherMember 2022-01-01 2022-12-31 0001577445 SCTC:OtherMember 2021-01-01 2021-12-31 0001577445 SCTC:CustomerAMember 2022-01-01 2022-12-31 0001577445 SCTC:CustomerAMember 2021-01-01 2021-12-31 0001577445 SCTC:CustomerBMember 2022-01-01 2022-12-31 0001577445 SCTC:CustomerBMember 2021-01-01 2021-12-31 0001577445 SCTC:CustomerCMember 2022-01-01 2022-12-31 0001577445 SCTC:CustomerCMember 2021-01-01 2021-12-31 0001577445 SCTC:LeaseAgreementMember 2020-01-01 2020-12-31 0001577445 SCTC:LeaseAgreementMember 2022-01-01 2022-01-02 0001577445 SCTC:LeaseAgreementMember 2022-01-01 2022-12-31 0001577445 us-gaap:SubsequentEventMember SCTC:StockPurchaseAgreementsMember 2023-03-15 2023-03-16 0001577445 us-gaap:SubsequentEventMember SCTC:StockPurchaseAgreementsMember 2023-03-16 0001577445 us-gaap:CommonStockMember us-gaap:SubsequentEventMember SCTC:StockPurchaseAgreementsMember 2023-03-16 0001577445 us-gaap:WarrantMember us-gaap:SubsequentEventMember SCTC:StockPurchaseAgreementsMember 2023-03-16 0001577445 us-gaap:WarrantMember us-gaap:SubsequentEventMember SCTC:StockPurchaseAgreementsMember 2023-03-15 2023-03-16 iso4217:USD shares iso4217:USD shares pure iso4217:ILS 0001577445 false FY -24762000 P3Y P3Y 10-K true 2022-12-31 --12-31 2022 false 333-188920 SCOUTCAM INC. NV 47-4257143 Suite 7A and 3B Industrial Park P.O. Box 3030 Omer IL 8496500 +972 73 370-4691 No No Yes Yes Non-accelerated Filer true false false false 19220000 10432518 None 1197 Brightman Almagor Zohar & Co. Tel Aviv, Israel 10099000 8581000 3047000 11013000 60000 8000 630000 167000 281000 443000 14117000 20212000 1495000 1675000 648000 781000 307000 482000 328000 396000 2778000 3334000 16895000 23546000 297000 103000 1426000 346000 199000 256000 365000 355000 58000 39000 214000 210000 2559000 1309000 2218000 2074000 64000 203000 268000 344000 2550000 2621000 5109000 3930000 0.001 0.001 300000000 300000000 7121737 7121737 7121737 7121737 7000 7000 36541000 34903000 -24762000 -15294000 11786000 19616000 16895000 23546000 665000 387000 1631000 1108000 -966000 -721000 4197000 2002000 699000 908000 3577000 5481000 -9439000 -9112000 30000 8000 -59000 117000 -9468000 -8987000 -9468000 -8987000 -1.33 -1.44 7122000 6240000 7122000 7000 34903000 -15294000 19616000 1638000 1638000 -9468000 -9468000 7122000 7000 36541000 -24762000 11786000 4084000 4000 10267000 -6307000 3964000 4084000 4000 10267000 -6307000 3964000 2469000 2000 19116000 19118000 568000 1000 3490000 3491000 2030000 2030000 1000 -8987000 -8987000 7122000 7000 34903000 -15294000 19616000 7122000 7000 34903000 -15294000 19616000 -9468000 -8987000 251000 114000 1638000 2030000 -269000 130000 49000 8000 25000 34000 13000 52000 -9000 463000 -77000 -233000 20000 261000 -43000 -162000 126000 194000 24000 -180000 545000 1224000 1572000 10000 -14000 -19000 -86000 4000 65000 -6095000 -5886000 118000 595000 14500000 6500000 11000000 7882000 -11595000 19118000 3491000 50000 22559000 1787000 5078000 8581000 3373000 -269000 130000 10099000 8581000 155000 524000 31000 <p id="xdx_80C_eus-gaap--NatureOfOperations_zsYalrco8Ux1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 – <span id="xdx_825_z79SxFmFVUhe">GENERAL</span>:</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <table cellpadding="0" cellspacing="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>a</b>.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ScoutCam Inc. (the “Company”), formerly known as Intellisense Solutions Inc., (“Intellisense”), was incorporated under the laws of the State of Nevada on March 22, 2013. Prior to the closing of the Exchange Agreement (as defined below), the Company was a non-operating “shell company”.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s wholly-owned subsidiary, ScoutCam Ltd. (“ScoutCam”), was formed in the State of Israel on January 3, 2019, as a wholly-owned subsidiary of Medigus Ltd. (“Medigus”), an Israeli company traded on the Nasdaq Capital Market, and commenced operations on March 1, 2019. </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2019, Medigus and ScoutCam consummated an asset transfer agreement, under which Medigus transferred and assigned certain assets and intellectual property rights related to its miniaturized imaging business to ScoutCam. </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 30, 2019, Intellisense and Medigus consummated a securities exchange agreement (the “Exchange Agreement”), pursuant to which Medigus delivered 100% of its holdings in ScoutCam to Intellisense in exchange for shares of Intellisense’s common stock representing 60% of the issued and outstanding share capital of Intellisense immediately upon the consummation of the Exchange Agreement. </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022, Medigus beneficially owned 27.02% of the Company’s outstanding common stock. </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company, through ScoutCam, is engaged in the development, production and marketing of innovative Predictive Maintenance (PdM) and Condition Based Monitoring (CBM) technologies, providing visual sensing and AI-based video analytics solutions for critical systems in the aviation, maritime, industrial non-destructing-testing industries, transportation, and energy industries. Some of the Company’s products utilize our micro visualization technology in medical devices for complex and minimally invasive medical procedures. Company’s technology includes proven video technologies and products amalgamated into a first-of-its-kind, FDA-cleared minimally invasive surgical device. The Company’s video-based sensors, embedded software and AI algorithms are being deployed in hard-to-reach locations and harsh environments across a variety of PdM and CBM use cases. The Company’s solution allows maintenance and operations teams visibility into areas which are inaccessible under normal circumstances, or where the operating ambience otherwise is not suitable for continuous real-time monitoring’ and has various applications which have relevancy in wide range of industry segments, that utilize complicated mechanics requiring ongoing monitoring and predictive maintenance applications. </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SCOUTCAM INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 – GENERAL</b> (continued)<b>:</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>b.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 9, 2021, the Company amended its Articles of Incorporation to effect a <span id="xdx_900_eus-gaap--StockholdersEquityReverseStockSplit_c20210808__20210809_zPI7HM1fCr7a" title="Stockholders' equity, reverse stock split">nine-to-one</span> reverse stock split of its outstanding Common Stock.</span></p></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">As a result of the reverse stock split, every nine shares of the Company’s outstanding Common Stock were combined and reclassified into one share of the Company’s Common Stock. No fractional shares were issued in connection with or following the reverse split. The amount of authorized capital of the Company’s Common Stock and par value of such shares remained unchanged.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All share, stock option and per share information in these consolidated financial statements have been adjusted to reflect the reverse stock split on a retroactive basis.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>c.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since incorporation of ScoutCam and through December 31, 2022, the Company accumulated a deficit of approximately $<span id="xdx_908_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_pn3n3_dxL_c20221231_zAwAVp3P6jOh" title="::XDX::-24762"><span style="-sec-ix-hidden: xdx2ixbrl0416">25 </span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million and its activities have been funded mainly by its shareholders. The Company’s management believes the Company’ cash and cash resources as of December 31, 2022 as well as its proceeds from issuance of common stock and warrants in the private offering as detailed in Note 14, will allow the Company to fund its operating plan through at least the next 12 months. However, the Company expects to continue to incur significant research and development and other costs related to its ongoing operations and in order to continue its future operations, the Company will need to obtain additional funding until becoming profitable.</span></p></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SCOUTCAM INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.6pt; text-align: justify; text-indent: -49.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> nine-to-one <p id="xdx_80A_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zVfE8eiHcr4c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.6pt; text-align: justify; text-indent: -49.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 – <span id="xdx_82E_zyUYRny0KSOk">SIGNIFICANT ACCOUNTING POLICIES</span>:</b></span></p> <p id="xdx_841_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zcFDaxWJkEN8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.6pt; text-align: justify; text-indent: -49.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>a.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zqHMYMwCNxBl">Basis of preparation</span>:</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements have been prepared in accordance with United States Generally Accepted Accounting Principles in the United States (“U.S. GAAP”) applied on a consistent basis.</span></p> <p id="xdx_84A_eus-gaap--UseOfEstimates_zpciYLHYkDXf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>b.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_z6iqiCJacFki">Use of estimates</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. The Company evaluates its assumptions on an ongoing basis, including those related to contingencies and inventory impairment, as well as estimates used in applying its revenue recognition policy. Actual results may differ from these estimates.</span></p> <p id="xdx_846_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zcbOrOrpRy6b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>c.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_znhOjMC9fga9">Functional currency</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A majority of ScoutCam’s revenues are generated in U.S. dollars. The substantial majority of ScoutCam costs are incurred in U.S. dollars and New Israeli Shekels (“NIS”). ScoutCam management believes that the U.S. dollar is the currency of the primary economic environment in which ScoutCam operates. Thus, the functional currency of ScoutCam is the U.S. dollar.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions and balances originally denominated in U.S. dollars are presented at their original amounts. Balances in non-U.S. dollar currencies are translated into U.S. dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For non-U.S. dollar transactions and other items in the statements of operations (indicated below), the following exchange rates are used: (i) for transactions exchange rates at transaction dates and (ii) for other items (derived from non-monetary balance sheet items such as depreciation and amortization) historical exchange rates. Currency transaction gains and losses are presented in financial income or expenses, as appropriate.</span></p> <p id="xdx_840_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zGEdNf2eF5Bb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>d.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zbPwLcPYcGMj">Cash and Cash Equivalents</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company considers as cash equivalents all short-term, highly liquid investments, which include short-term bank deposits with original maturities of three months or less from the date of purchase that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash.</span></p> <p id="xdx_843_ecustom--ShortTermBankDepositPolicyTextBlock_zZjU8SPZ0g4h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>e.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zloki840hfl9">Short-term bank deposits</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bank deposits with maturities of more than three months but less than one year are included in short-term bank deposits. Such short-term bank deposits are stated at cost which approximates fair market value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SCOUTCAM INC. </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.6pt; text-align: justify; text-indent: -49.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES</b> (continued)<b>:</b></span></p> <p id="xdx_840_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zw4kyDtafAqd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>f.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zScio6yDpLqf">Accounts receivable</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts receivable are presented in the Company’s consolidated balance sheets net of allowance for doubtful accounts. The Company estimates the collectability of its accounts receivable balances and adjusts its allowance for doubtful accounts accordingly.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When revenue recognition criteria are not met for a sale transaction that has been billed, the Company does not recognize deferred revenues or the related account receivable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022 and 2021, <span id="xdx_902_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_do_c20221231_zjil5dADqc88" title="Accounts receivable, allowance for credit loss"><span id="xdx_908_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_do_c20211231_zKI2y6Cgi5ha" title="Accounts receivable, allowance for credit loss">no</span></span> allowance for doubtful accounts was recorded.</span></p> <p id="xdx_847_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zQnccRB3TgV4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>g.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_z6KCgc1vitS6">Property and equipment</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation is calculated on a straight-line basis over the estimated useful lives.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_893_ecustom--ScheduleOfPropertyAndEquipmentAnnualDepreciationRatesTableTextBlock_zXzEPYn8LmFd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The annual depreciation rates are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span id="xdx_8B4_zt2qGwapDJ27" style="display: none">SCHEDULE OF PROPERTY AND EQUIPMENT ANNUAL DEPRECIATION RATES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Machinery and laboratory equipment</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_ecustom--PropertyPlantAndEquipmentAnnualDepreciationRates_pid_dp_uPure_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MinimumMember_z77iNftVBjz" title="Property and equipment annual depreciation rates">10</span>%-<span id="xdx_903_ecustom--PropertyPlantAndEquipmentAnnualDepreciationRates_pid_dp_uPure_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MaximumMember_zRqOJXP0ZjC" title="Property and equipment annual depreciation rates">15</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; width: 70%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office furniture and equipment</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 26%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_ecustom--PropertyPlantAndEquipmentAnnualDepreciationRates_pid_dp_uPure_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_z3FXMWa0CDBj" title="Property and equipment annual depreciation rates">10</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computers and computer software</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_ecustom--PropertyPlantAndEquipmentAnnualDepreciationRates_pid_dp_uPure_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zq0yFNskzPa1" title="Property and equipment annual depreciation rates">33</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold improvements</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zEZjqWJImgV8" title="Property, plant and equipment, description">Over the shorter of the lease term (including options if any) or useful life</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8AF_znX2hE6D4m9k" style="display: none; margin-top: 0; margin-bottom: 0"> </p> <p id="xdx_840_ecustom--SeverancePayPolicyTextBlock_zzCoCrB0Yek7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>h.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zE8u4HotDKCc">Severance pay</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israeli labor law generally requires payment of severance pay upon dismissal of an employee or upon termination of employment in certain other circumstances. Pursuant to Section 14 of the Severance Compensation Act, 1963 (“Section 14”), all of the ScoutCam’s employees in Israel are entitled to a monthly contribution, at a rate of <span id="xdx_904_ecustom--MonthlySalaryPercentage_pid_dp_uPure_c20220101__20221231_zUzE8AAzLdjc" title="Monthly salary percentage">8.33</span>% of their monthly salary, made in their name with insurance companies. Contributions under Section 14 relieve ScoutCam from any future severance payment obligation with respect to those employees. The aforementioned contributions are not recorded as an asset on the Company’s balance sheet and there is no liability recorded, as the Company does not have a future obligation to make any additional payments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The asset and the liability for severance pay presented in the balance sheets reflects employees that began employment prior to automatic application of Section 14.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The severance pay liability of ScoutCam to its employees that began employment prior to automatic application of Section 14 is based upon the number of years of service and the latest monthly salary of such employees and is partly covered by regular deposits with recognized pension funds and deposits with severance pay funds. Under labor laws, these deposits are in the employees’ names and, subject to certain limitations, are the property of the employees. ScoutCam records the obligation as if it were payable at each balance sheet date on an undiscounted basis.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SCOUTCAM INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.6pt; text-align: justify; text-indent: -49.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES</b> (continued)<b>:</b></span></p> <p id="xdx_844_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zksmPwjacWna" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>i.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_z3zixqKLtrEc">Stock-Based Compensation</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company measures and recognizes compensation expense for its equity classified stock-based awards granted under its plan based on estimated fair values on the grant dates. The Company calculates the estimated fair value of option awards on the grant date using the Black-Scholes option-pricing model. The Black-Scholes option-pricing model requires a number of assumptions, of which the most significant are the stock price volatility and the expected option term. The Company’s expected dividend rate is zero since the Company does not currently pay cash dividends on its stocks and does not anticipate doing so in the foreseeable future. Each of the above factors requires the Company to use judgment and make estimates in determining the percentages and time periods used for the calculation. If the Company were to use different percentages or time periods, the estimated fair value of option awards could be materially different. The Company recognizes stock-based compensation cost for option awards on an accelerated basis over the employee’s requisite service period, net of estimated forfeitures.</span></p> <p id="xdx_847_eus-gaap--InventoryPolicyTextBlock_zq4aklG9Mfti" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>j.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zm7wIGAiHbG9">Inventories</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories include raw materials, inventory in process and finished products and are valued at the lower of cost or net realizable value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Inventories are stated at a lower of cost, determined by the first-in, first-out method, or market based on net realizable value</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. Costs of purchased raw materials and inventory in process include costs of design, raw materials, direct labor, other direct costs and fixed production overheads.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The inventories are adjusted for estimated excess and obsolescence and written down to net realizable value based upon estimates of future demand, technology developments and market conditions.</span></p> <p id="xdx_841_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zALCsEopztmd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>k.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zdbcZqI4SkOl">Revenue recognition</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue measurement</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s revenues are measured according to the ASC 606, “Revenue from Contracts with Customers” (“ASC 606”). Under ASC 606, revenues are measured according to the amount of consideration that the Company expects to be entitled to receive in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties. Revenues are presented net of VAT.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue recognition</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes revenue when a customer obtains control over promised goods or services. For each performance obligation, the Company determines at contract inception whether it satisfies the performance obligation over time or satisfies the performance obligation at a point in time.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Performance obligations are satisfied over time if one of the following criteria is met:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SCOUTCAM INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.6pt; text-align: justify; text-indent: -49.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES</b> (continued)<b>:</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) the customer simultaneously receives and consumes the benefits provided by the Company’s performance; (b) the Company’s performance creates or enhances an asset that the customer controls as the asset is created or enhanced; or (c) the Company’s performance does not create an asset with an alternative use for the Company and the Company has an enforceable right to payment for performance completed to date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If a performance obligation is not satisfied over time, a Company satisfies the performance obligation at a point in time.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The transaction price is allocated to each distinct performance obligations on a relative standalone selling price (“SSP”) basis and revenue is recognized for each performance obligation when control has passed. In most cases, the Company is able to establish SSP based on the observable prices of services sold separately in comparable circumstances to similar customers and for products based on the Company’s best estimates of the price at which the Company would have sold the product regularly on a stand-alone basis. The Company reassesses the SSP on a periodic basis or when facts and circumstances change.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Product Revenue</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues from product sales are recognized at a point in time when the customer obtains control of the Company’s product, typically upon shipment to the customer. Indirect taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from revenues.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Service Revenue</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company also generates revenues from development services. Revenue from development services is recognized over the period of the applicable service contract. To the extent development services are not distinct from the performance obligation relating to the subsequent mass production phase of the prototype under development, revenue from these services is deferred until commencement of the production phase of the project and are then recognized over the expected term production.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SCOUTCAM INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.6pt; text-align: justify; text-indent: -49.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES</b> (continued)<b>:</b></span></p> <p id="xdx_84C_eus-gaap--CostOfSalesPolicyTextBlock_zIgrXqqeVuU4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>l.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zZOUo0f2bq6c">Cost of revenues</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost of revenue consists of products purchased from sub-contractors, raw materials for in-house assembly line, shipping and handling costs to customers, salary, employee-related expenses, depreciation and overhead expenses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost of revenues are expensed commensurate with the recognition of the respective revenues. Costs deferred in respect of deferral of revenues are recorded as contract fulfilment assets on the Company’s balance sheet and are written down to the extent the contract is expected to incur losses.</span></p> <p id="xdx_849_eus-gaap--ResearchAndDevelopmentExpensePolicy_zId2KWg6Z7Q3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>m.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zKNG3pV7gYR4">Research and development costs</span> </b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development costs are expensed as incurred and includes salaries and employee-related expenses, overhead expenses, material, and third-party contractors’ charges.</span></p> <p id="xdx_847_eus-gaap--IncomeTaxPolicyTextBlock_zH5g77M8oBc6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>n.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zlUunTcRLAB7">Income taxes</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income taxes are accounted for using the asset and liability approach under ASC-740, “Income Taxes”. The asset and liability approach requires the recognition of taxes payable or refundable for the current year and deferred tax liabilities and assets for the future tax consequences of events that have been recognized in the Company’s financial statements or tax returns.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The measurement of current and deferred tax liabilities and assets is based on provisions of the relevant tax law. The measurement of deferred tax assets is reduced, if necessary, by the amount of any tax benefits that, based on available evidence, are not expected to be realized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Uncertain tax positions are accounted for in accordance with the provisions of ASC 740-10, under which a company may recognize the tax benefit from an uncertain tax position claimed or expected to be claimed on a tax return only if it is more likely than not that the tax position will be sustained on examination by the taxation authorities, based on the technical merits of the position, at the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement. Interest and penalties, if any, related to unrecognized tax benefits are recognized in tax expense. </span>The Company and ScoutCam provide a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p id="xdx_848_eus-gaap--CommitmentsAndContingenciesPolicyTextBlock_zlwcat3eNGs7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>o.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zBRH1nBY1zse">Legal contingencies</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From time to time, the Company and its subsidiary become involved in legal proceedings or are subject to claims arising in their ordinary course of business. Such matters are generally subject to many uncertainties and outcomes are not predictable with assurance. The Company accrues for contingencies when the loss is probable and can reasonably estimate the amount of any such loss.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SCOUTCAM INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 — SIGNIFICANT ACCOUNTING POLICIES </b>(continued):</span></p> <p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_znaMzv7DnJIc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>p.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zjrDfhTmlGBh">Basic and diluted net loss per common stock</span>:</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic net loss per common stock is computed by dividing net loss, as adjusted, to include the weighted average number of shares of common stock outstanding during the year.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diluted net loss per common stock is computed by dividing net loss, as adjusted, by the weighted average number of shares of common stock outstanding during the year, plus the number of shares of common stock that would have been outstanding if all potentially dilutive shares of common stock had been issued, using the treasury stock method, in accordance with ASC 260-10 “Earnings per Share”.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All outstanding stock options and warrants have been excluded from the calculation of the diluted loss per share for the years ended December 31, 2022 and December 31, 2021, since all such securities have an anti-dilutive effect.</span></p> <p id="xdx_842_eus-gaap--LesseeLeasesPolicyTextBlock_zflQp9nwnOCi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>q.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zFnKpU7ryeta">Leases</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with ASC 842, the Company determines whether an arrangement is or contains a lease based on the facts and circumstances present at inception of an arrangement. An arrangement is or contains a lease if the arrangement conveys the right to control the use of an identified asset for a period of time in exchange for consideration.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Arrangements that are determined to be leases at inception are recognized in long-term right-of-use assets (“ROU”) assets and short and long-term lease liabilities in the consolidated balance sheet at lease commencement. Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future fixed lease payments over the lease term at commencement date. As most of the Company’s leases do not provide an implicit rate, the Company applies its incremental borrowing rate based on the economic environment at commencement date in determining the present value of future payments. Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for operating leases or payments are recognized on a straight-line basis over the lease term.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has elected not to recognize on the balance sheet leases with terms of 12 months or less.</span></p> <p id="xdx_85E_zb86KgoTOSU" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SCOUTCAM INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zcFDaxWJkEN8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.6pt; text-align: justify; text-indent: -49.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>a.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zqHMYMwCNxBl">Basis of preparation</span>:</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements have been prepared in accordance with United States Generally Accepted Accounting Principles in the United States (“U.S. GAAP”) applied on a consistent basis.</span></p> <p id="xdx_84A_eus-gaap--UseOfEstimates_zpciYLHYkDXf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>b.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_z6iqiCJacFki">Use of estimates</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. The Company evaluates its assumptions on an ongoing basis, including those related to contingencies and inventory impairment, as well as estimates used in applying its revenue recognition policy. Actual results may differ from these estimates.</span></p> <p id="xdx_846_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zcbOrOrpRy6b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>c.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_znhOjMC9fga9">Functional currency</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A majority of ScoutCam’s revenues are generated in U.S. dollars. The substantial majority of ScoutCam costs are incurred in U.S. dollars and New Israeli Shekels (“NIS”). ScoutCam management believes that the U.S. dollar is the currency of the primary economic environment in which ScoutCam operates. Thus, the functional currency of ScoutCam is the U.S. dollar.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions and balances originally denominated in U.S. dollars are presented at their original amounts. Balances in non-U.S. dollar currencies are translated into U.S. dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For non-U.S. dollar transactions and other items in the statements of operations (indicated below), the following exchange rates are used: (i) for transactions exchange rates at transaction dates and (ii) for other items (derived from non-monetary balance sheet items such as depreciation and amortization) historical exchange rates. Currency transaction gains and losses are presented in financial income or expenses, as appropriate.</span></p> <p id="xdx_840_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zGEdNf2eF5Bb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>d.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zbPwLcPYcGMj">Cash and Cash Equivalents</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company considers as cash equivalents all short-term, highly liquid investments, which include short-term bank deposits with original maturities of three months or less from the date of purchase that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash.</span></p> <p id="xdx_843_ecustom--ShortTermBankDepositPolicyTextBlock_zZjU8SPZ0g4h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>e.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zloki840hfl9">Short-term bank deposits</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bank deposits with maturities of more than three months but less than one year are included in short-term bank deposits. Such short-term bank deposits are stated at cost which approximates fair market value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SCOUTCAM INC. </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.6pt; text-align: justify; text-indent: -49.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES</b> (continued)<b>:</b></span></p> <p id="xdx_840_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zw4kyDtafAqd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>f.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zScio6yDpLqf">Accounts receivable</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts receivable are presented in the Company’s consolidated balance sheets net of allowance for doubtful accounts. The Company estimates the collectability of its accounts receivable balances and adjusts its allowance for doubtful accounts accordingly.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When revenue recognition criteria are not met for a sale transaction that has been billed, the Company does not recognize deferred revenues or the related account receivable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022 and 2021, <span id="xdx_902_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_do_c20221231_zjil5dADqc88" title="Accounts receivable, allowance for credit loss"><span id="xdx_908_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_do_c20211231_zKI2y6Cgi5ha" title="Accounts receivable, allowance for credit loss">no</span></span> allowance for doubtful accounts was recorded.</span></p> 0 0 <p id="xdx_847_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zQnccRB3TgV4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>g.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_z6KCgc1vitS6">Property and equipment</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation is calculated on a straight-line basis over the estimated useful lives.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_893_ecustom--ScheduleOfPropertyAndEquipmentAnnualDepreciationRatesTableTextBlock_zXzEPYn8LmFd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The annual depreciation rates are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span id="xdx_8B4_zt2qGwapDJ27" style="display: none">SCHEDULE OF PROPERTY AND EQUIPMENT ANNUAL DEPRECIATION RATES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Machinery and laboratory equipment</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_ecustom--PropertyPlantAndEquipmentAnnualDepreciationRates_pid_dp_uPure_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MinimumMember_z77iNftVBjz" title="Property and equipment annual depreciation rates">10</span>%-<span id="xdx_903_ecustom--PropertyPlantAndEquipmentAnnualDepreciationRates_pid_dp_uPure_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MaximumMember_zRqOJXP0ZjC" title="Property and equipment annual depreciation rates">15</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; width: 70%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office furniture and equipment</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 26%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_ecustom--PropertyPlantAndEquipmentAnnualDepreciationRates_pid_dp_uPure_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_z3FXMWa0CDBj" title="Property and equipment annual depreciation rates">10</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computers and computer software</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_ecustom--PropertyPlantAndEquipmentAnnualDepreciationRates_pid_dp_uPure_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zq0yFNskzPa1" title="Property and equipment annual depreciation rates">33</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold improvements</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zEZjqWJImgV8" title="Property, plant and equipment, description">Over the shorter of the lease term (including options if any) or useful life</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8AF_znX2hE6D4m9k" style="display: none; margin-top: 0; margin-bottom: 0"> </p> <p id="xdx_893_ecustom--ScheduleOfPropertyAndEquipmentAnnualDepreciationRatesTableTextBlock_zXzEPYn8LmFd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The annual depreciation rates are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span id="xdx_8B4_zt2qGwapDJ27" style="display: none">SCHEDULE OF PROPERTY AND EQUIPMENT ANNUAL DEPRECIATION RATES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Machinery and laboratory equipment</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_ecustom--PropertyPlantAndEquipmentAnnualDepreciationRates_pid_dp_uPure_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MinimumMember_z77iNftVBjz" title="Property and equipment annual depreciation rates">10</span>%-<span id="xdx_903_ecustom--PropertyPlantAndEquipmentAnnualDepreciationRates_pid_dp_uPure_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MaximumMember_zRqOJXP0ZjC" title="Property and equipment annual depreciation rates">15</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; width: 70%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office furniture and equipment</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 26%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_ecustom--PropertyPlantAndEquipmentAnnualDepreciationRates_pid_dp_uPure_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_z3FXMWa0CDBj" title="Property and equipment annual depreciation rates">10</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computers and computer software</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_ecustom--PropertyPlantAndEquipmentAnnualDepreciationRates_pid_dp_uPure_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zq0yFNskzPa1" title="Property and equipment annual depreciation rates">33</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold improvements</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zEZjqWJImgV8" title="Property, plant and equipment, description">Over the shorter of the lease term (including options if any) or useful life</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 0.10 0.15 0.10 0.33 Over the shorter of the lease term (including options if any) or useful life <p id="xdx_840_ecustom--SeverancePayPolicyTextBlock_zzCoCrB0Yek7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>h.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zE8u4HotDKCc">Severance pay</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israeli labor law generally requires payment of severance pay upon dismissal of an employee or upon termination of employment in certain other circumstances. Pursuant to Section 14 of the Severance Compensation Act, 1963 (“Section 14”), all of the ScoutCam’s employees in Israel are entitled to a monthly contribution, at a rate of <span id="xdx_904_ecustom--MonthlySalaryPercentage_pid_dp_uPure_c20220101__20221231_zUzE8AAzLdjc" title="Monthly salary percentage">8.33</span>% of their monthly salary, made in their name with insurance companies. Contributions under Section 14 relieve ScoutCam from any future severance payment obligation with respect to those employees. The aforementioned contributions are not recorded as an asset on the Company’s balance sheet and there is no liability recorded, as the Company does not have a future obligation to make any additional payments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The asset and the liability for severance pay presented in the balance sheets reflects employees that began employment prior to automatic application of Section 14.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The severance pay liability of ScoutCam to its employees that began employment prior to automatic application of Section 14 is based upon the number of years of service and the latest monthly salary of such employees and is partly covered by regular deposits with recognized pension funds and deposits with severance pay funds. Under labor laws, these deposits are in the employees’ names and, subject to certain limitations, are the property of the employees. ScoutCam records the obligation as if it were payable at each balance sheet date on an undiscounted basis.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SCOUTCAM INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.6pt; text-align: justify; text-indent: -49.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES</b> (continued)<b>:</b></span></p> 0.0833 <p id="xdx_844_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zksmPwjacWna" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>i.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_z3zixqKLtrEc">Stock-Based Compensation</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company measures and recognizes compensation expense for its equity classified stock-based awards granted under its plan based on estimated fair values on the grant dates. The Company calculates the estimated fair value of option awards on the grant date using the Black-Scholes option-pricing model. The Black-Scholes option-pricing model requires a number of assumptions, of which the most significant are the stock price volatility and the expected option term. The Company’s expected dividend rate is zero since the Company does not currently pay cash dividends on its stocks and does not anticipate doing so in the foreseeable future. Each of the above factors requires the Company to use judgment and make estimates in determining the percentages and time periods used for the calculation. If the Company were to use different percentages or time periods, the estimated fair value of option awards could be materially different. The Company recognizes stock-based compensation cost for option awards on an accelerated basis over the employee’s requisite service period, net of estimated forfeitures.</span></p> <p id="xdx_847_eus-gaap--InventoryPolicyTextBlock_zq4aklG9Mfti" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>j.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zm7wIGAiHbG9">Inventories</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories include raw materials, inventory in process and finished products and are valued at the lower of cost or net realizable value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Inventories are stated at a lower of cost, determined by the first-in, first-out method, or market based on net realizable value</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. Costs of purchased raw materials and inventory in process include costs of design, raw materials, direct labor, other direct costs and fixed production overheads.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The inventories are adjusted for estimated excess and obsolescence and written down to net realizable value based upon estimates of future demand, technology developments and market conditions.</span></p> <p id="xdx_841_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zALCsEopztmd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>k.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zdbcZqI4SkOl">Revenue recognition</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue measurement</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s revenues are measured according to the ASC 606, “Revenue from Contracts with Customers” (“ASC 606”). Under ASC 606, revenues are measured according to the amount of consideration that the Company expects to be entitled to receive in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties. Revenues are presented net of VAT.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue recognition</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes revenue when a customer obtains control over promised goods or services. For each performance obligation, the Company determines at contract inception whether it satisfies the performance obligation over time or satisfies the performance obligation at a point in time.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Performance obligations are satisfied over time if one of the following criteria is met:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SCOUTCAM INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.6pt; text-align: justify; text-indent: -49.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES</b> (continued)<b>:</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) the customer simultaneously receives and consumes the benefits provided by the Company’s performance; (b) the Company’s performance creates or enhances an asset that the customer controls as the asset is created or enhanced; or (c) the Company’s performance does not create an asset with an alternative use for the Company and the Company has an enforceable right to payment for performance completed to date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If a performance obligation is not satisfied over time, a Company satisfies the performance obligation at a point in time.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The transaction price is allocated to each distinct performance obligations on a relative standalone selling price (“SSP”) basis and revenue is recognized for each performance obligation when control has passed. In most cases, the Company is able to establish SSP based on the observable prices of services sold separately in comparable circumstances to similar customers and for products based on the Company’s best estimates of the price at which the Company would have sold the product regularly on a stand-alone basis. The Company reassesses the SSP on a periodic basis or when facts and circumstances change.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Product Revenue</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues from product sales are recognized at a point in time when the customer obtains control of the Company’s product, typically upon shipment to the customer. Indirect taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from revenues.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Service Revenue</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company also generates revenues from development services. Revenue from development services is recognized over the period of the applicable service contract. To the extent development services are not distinct from the performance obligation relating to the subsequent mass production phase of the prototype under development, revenue from these services is deferred until commencement of the production phase of the project and are then recognized over the expected term production.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SCOUTCAM INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.6pt; text-align: justify; text-indent: -49.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES</b> (continued)<b>:</b></span></p> <p id="xdx_84C_eus-gaap--CostOfSalesPolicyTextBlock_zIgrXqqeVuU4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>l.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zZOUo0f2bq6c">Cost of revenues</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost of revenue consists of products purchased from sub-contractors, raw materials for in-house assembly line, shipping and handling costs to customers, salary, employee-related expenses, depreciation and overhead expenses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost of revenues are expensed commensurate with the recognition of the respective revenues. Costs deferred in respect of deferral of revenues are recorded as contract fulfilment assets on the Company’s balance sheet and are written down to the extent the contract is expected to incur losses.</span></p> <p id="xdx_849_eus-gaap--ResearchAndDevelopmentExpensePolicy_zId2KWg6Z7Q3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>m.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zKNG3pV7gYR4">Research and development costs</span> </b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development costs are expensed as incurred and includes salaries and employee-related expenses, overhead expenses, material, and third-party contractors’ charges.</span></p> <p id="xdx_847_eus-gaap--IncomeTaxPolicyTextBlock_zH5g77M8oBc6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>n.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zlUunTcRLAB7">Income taxes</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income taxes are accounted for using the asset and liability approach under ASC-740, “Income Taxes”. The asset and liability approach requires the recognition of taxes payable or refundable for the current year and deferred tax liabilities and assets for the future tax consequences of events that have been recognized in the Company’s financial statements or tax returns.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The measurement of current and deferred tax liabilities and assets is based on provisions of the relevant tax law. The measurement of deferred tax assets is reduced, if necessary, by the amount of any tax benefits that, based on available evidence, are not expected to be realized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Uncertain tax positions are accounted for in accordance with the provisions of ASC 740-10, under which a company may recognize the tax benefit from an uncertain tax position claimed or expected to be claimed on a tax return only if it is more likely than not that the tax position will be sustained on examination by the taxation authorities, based on the technical merits of the position, at the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement. Interest and penalties, if any, related to unrecognized tax benefits are recognized in tax expense. </span>The Company and ScoutCam provide a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p id="xdx_848_eus-gaap--CommitmentsAndContingenciesPolicyTextBlock_zlwcat3eNGs7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>o.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zBRH1nBY1zse">Legal contingencies</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From time to time, the Company and its subsidiary become involved in legal proceedings or are subject to claims arising in their ordinary course of business. Such matters are generally subject to many uncertainties and outcomes are not predictable with assurance. The Company accrues for contingencies when the loss is probable and can reasonably estimate the amount of any such loss.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SCOUTCAM INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 — SIGNIFICANT ACCOUNTING POLICIES </b>(continued):</span></p> <p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_znaMzv7DnJIc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>p.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zjrDfhTmlGBh">Basic and diluted net loss per common stock</span>:</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic net loss per common stock is computed by dividing net loss, as adjusted, to include the weighted average number of shares of common stock outstanding during the year.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diluted net loss per common stock is computed by dividing net loss, as adjusted, by the weighted average number of shares of common stock outstanding during the year, plus the number of shares of common stock that would have been outstanding if all potentially dilutive shares of common stock had been issued, using the treasury stock method, in accordance with ASC 260-10 “Earnings per Share”.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All outstanding stock options and warrants have been excluded from the calculation of the diluted loss per share for the years ended December 31, 2022 and December 31, 2021, since all such securities have an anti-dilutive effect.</span></p> <p id="xdx_842_eus-gaap--LesseeLeasesPolicyTextBlock_zflQp9nwnOCi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>q.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zFnKpU7ryeta">Leases</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with ASC 842, the Company determines whether an arrangement is or contains a lease based on the facts and circumstances present at inception of an arrangement. An arrangement is or contains a lease if the arrangement conveys the right to control the use of an identified asset for a period of time in exchange for consideration.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Arrangements that are determined to be leases at inception are recognized in long-term right-of-use assets (“ROU”) assets and short and long-term lease liabilities in the consolidated balance sheet at lease commencement. Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future fixed lease payments over the lease term at commencement date. As most of the Company’s leases do not provide an implicit rate, the Company applies its incremental borrowing rate based on the economic environment at commencement date in determining the present value of future payments. Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for operating leases or payments are recognized on a straight-line basis over the lease term.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has elected not to recognize on the balance sheet leases with terms of 12 months or less.</span></p> <p id="xdx_80B_eus-gaap--ShortTermDebtTextBlock_zXlHVKrudf5l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 3 - <span id="xdx_823_zCvAhhV7P388">SHORT-TERM DEPOSITS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Short term investments as of December 31, 2022 include bank deposit bearing annual interest rates of <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20221231_z2IHnR4nOSGh" title="Interest rate">4</span>%, with maturities of up to <span id="xdx_90A_eus-gaap--DebtInstrumentTerm_dtM_c20220101__20221231_zZTzdzQtAdn2" title="Maturity term">12</span> months.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0.04 P12M <p id="xdx_806_eus-gaap--InventoryDisclosureTextBlock_zeMOjFhhJsY2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.6pt; text-align: justify; text-indent: -49.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 4 - <span id="xdx_826_zwtuuEzcVuVc">INVENTORY</span>:</b></span></p> <p id="xdx_89F_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zm7GreD43SBc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_8B8_zm6qsqOwqy91" style="display: none">SCHEDULE OF INVENTORY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_492_20221231_zxeM76iCWsTe" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49F_20211231_zpAZqjoLQGdl" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD in thousands</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_405_eus-gaap--InventoryRawMaterialsAndSupplies_iI_pn3n3_maINz3CT_zh45JFdcVcmc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Raw materials and supplies</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">438</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_404_eus-gaap--InventoryWorkInProcess_iI_pn3n3_maINz3CT_zKAqdU3zbzo6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Work in progress</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">148</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_400_eus-gaap--InventoryFinishedGoods_iI_pn3n3_maINz3CT_zKVLBhMltFy" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finished goods</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">66</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--InventoryNet_iTI_pn3n3_mtINz3CT_zDvKc8ExGRMd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"> Inventory Net</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">630</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">167</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8AA_z0JrK0KnWyQk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the years 2022 and 2021, <span id="xdx_908_eus-gaap--InventoryWriteDown_pn3n3_do_c20220101__20221231_zRsCwhW8Q1Nb" title="Inventory impairment"><span id="xdx_908_eus-gaap--InventoryWriteDown_pn3n3_do_c20210101__20211231_z0PyLPhYmjO6" title="Inventory impairment">no</span></span> impairment occurred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zm7GreD43SBc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_8B8_zm6qsqOwqy91" style="display: none">SCHEDULE OF INVENTORY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_492_20221231_zxeM76iCWsTe" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49F_20211231_zpAZqjoLQGdl" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD in thousands</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_405_eus-gaap--InventoryRawMaterialsAndSupplies_iI_pn3n3_maINz3CT_zh45JFdcVcmc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Raw materials and supplies</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">438</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_404_eus-gaap--InventoryWorkInProcess_iI_pn3n3_maINz3CT_zKAqdU3zbzo6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Work in progress</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">148</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_400_eus-gaap--InventoryFinishedGoods_iI_pn3n3_maINz3CT_zKVLBhMltFy" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finished goods</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">66</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--InventoryNet_iTI_pn3n3_mtINz3CT_zDvKc8ExGRMd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"> Inventory Net</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">630</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">167</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 438000 99000 148000 2000 44000 66000 630000 167000 0 0 <p id="xdx_80B_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zXnlmPKp8Yif" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.6pt; text-align: justify; text-indent: -49.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 5 - <span id="xdx_824_zm2zaxFM1RR">PROPERTY AND EQUIPMENT, NET</span>:</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.6pt; text-align: justify; text-indent: -49.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_893_eus-gaap--PropertyPlantAndEquipmentTextBlock_zjftIWZMz2Ii" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property, plant and equipment, net consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.6pt; text-align: justify; text-indent: -49.6pt"><span id="xdx_8BE_zostC1GfZWH7" style="display: none">SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT NET</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_498_20221231_zmZHyGOpCCbl" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_496_20211231_zTSR4rBVx647" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD in thousands</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zJO12LxZHAeb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Machinery and laboratory equipment</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">619</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">578</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LeaseholdImprovementsOfficeFurnitureAndEquipmentMember_zPOQAwg0IGyg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold improvements, office furniture and equipment</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">351</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">316</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zWfvysDq4kg7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computers and computer software</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">182</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">140</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maPPAENz0YO_zK6gvFP68hwl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total property and equipment, gross</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,152</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,034</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40D_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENz0YO_zJVMQZO0tTbf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less: accumulated deprecation</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(504</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(253</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENz0YO_z79XzlaL3rte" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total property and equipment, net</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">648</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">781</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A7_zHqSbzizjpTa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation expenses were $<span id="xdx_90D_eus-gaap--Depreciation_pn3n3_c20220101__20221231_zBHeQxu3qEW6" title="Depreciation expenses">251</span> thousand and $<span id="xdx_906_eus-gaap--Depreciation_pn3n3_c20210101__20211231_zkdZ0ysED0Je" title="Depreciation expenses">114</span> thousand for the years ended December 31, 2022 and 2021, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.6pt; text-align: justify; text-indent: -49.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SCOUTCAM INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.6pt; text-align: justify; text-indent: -49.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_893_eus-gaap--PropertyPlantAndEquipmentTextBlock_zjftIWZMz2Ii" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property, plant and equipment, net consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.6pt; text-align: justify; text-indent: -49.6pt"><span id="xdx_8BE_zostC1GfZWH7" style="display: none">SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT NET</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_498_20221231_zmZHyGOpCCbl" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_496_20211231_zTSR4rBVx647" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD in thousands</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zJO12LxZHAeb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Machinery and laboratory equipment</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">619</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">578</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LeaseholdImprovementsOfficeFurnitureAndEquipmentMember_zPOQAwg0IGyg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold improvements, office furniture and equipment</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">351</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">316</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zWfvysDq4kg7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computers and computer software</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">182</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">140</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maPPAENz0YO_zK6gvFP68hwl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total property and equipment, gross</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,152</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,034</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40D_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENz0YO_zJVMQZO0tTbf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less: accumulated deprecation</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(504</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(253</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENz0YO_z79XzlaL3rte" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total property and equipment, net</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">648</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">781</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 619000 578000 351000 316000 182000 140000 1152000 1034000 504000 253000 648000 781000 251000 114000 <p id="xdx_80E_eus-gaap--OtherLiabilitiesDisclosureTextBlock_z2niD5VMH2m8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.6pt; text-align: justify; text-indent: -49.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 6 – <span id="xdx_829_zIKJpjrepWgf">OTHER ACCRUED EXPENSES</span>:</b></span></p> <p id="xdx_89E_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_z0URkmQldem6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.6pt; text-align: justify; text-indent: -49.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_zP1g6QBxj6lj" style="display: none">SCHEDULE OF OTHER ACCRUED EXPENSES</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49F_20221231_zNCaxNWgRo8c" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_495_20211231_zRjLStJopgni" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD in thousands</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_406_ecustom--InternalRevenueService_iI_pn3n3_maALFVDzrl7_maOALCzJQJ_zIEtobuQa47f" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Internal Revenue Services</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0528">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_400_ecustom--AccruedExpensesCurrent_iI_pn3n3_maOALCzJQJ_z6bKUrLBcmz5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">214</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">170</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_405_eus-gaap--OtherAccruedLiabilitiesCurrent_iTI_pn3n3_mtOALCzJQJ_z60mc0y4kD2j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total other accrued expenses </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">214</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">210</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A3_z8dY2DdDGTkh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_z0URkmQldem6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.6pt; text-align: justify; text-indent: -49.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_zP1g6QBxj6lj" style="display: none">SCHEDULE OF OTHER ACCRUED EXPENSES</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49F_20221231_zNCaxNWgRo8c" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_495_20211231_zRjLStJopgni" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD in thousands</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_406_ecustom--InternalRevenueService_iI_pn3n3_maALFVDzrl7_maOALCzJQJ_zIEtobuQa47f" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Internal Revenue Services</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0528">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_400_ecustom--AccruedExpensesCurrent_iI_pn3n3_maOALCzJQJ_z6bKUrLBcmz5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">214</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">170</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_405_eus-gaap--OtherAccruedLiabilitiesCurrent_iTI_pn3n3_mtOALCzJQJ_z60mc0y4kD2j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total other accrued expenses </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">214</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">210</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 40000 214000 170000 214000 210000 <p id="xdx_807_eus-gaap--IncomeTaxDisclosureTextBlock_zKp7nziq8Sf2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 7 - <span id="xdx_822_zlLOwMXMLsXh">INCOME TAXES</span></b>:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis of taxation</b></span></td></tr> </table> <p style="text-align: center; margin-top: 0; margin-bottom: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 1in"/><td style="width: 0.25in">1.</td><td style="text-align: justify">Tax rates applicable to the income of the Israeli subsidiary:</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in">ScoutCam is taxed according to Israeli tax laws.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in">The Israeli corporate tax rate from the year 2018 and onwards is <span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zDkklGCBGDAi" title="Effective income tax rate reconciliation, at federal statutory income tax rate">23</span>%.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; text-align: justify"> <td style="width: 1in"> </td> <td style="width: 0.25in; text-align: justify">2.</td><td style="text-align: justify">Tax rates applicable to the income of the U.S. company:</td> </tr></table> <p style="text-align: center; margin-top: 0; margin-bottom: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is taxed according to U.S. tax laws.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The U.S. corporate tax rate from the year 2018 and onwards is <span id="xdx_90C_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zq6dO976xsC8" title="Effective income tax rate reconciliation, at federal statutory income tax rate">21</span>%.</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Deferred income taxes:</b></span></p></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s deferred tax assets are as follows:</span></td></tr> </table> <p id="xdx_896_eus-gaap--SummaryOfOperatingLossCarryforwardsTextBlock_z121l4l9ipL3" style="text-align: center; margin-top: 0; margin-bottom: 0"><span id="xdx_8BF_zawolLZnQopk" style="display: none">SCHEDULE OF COMPONENT OF DEFERRED TAX ASSET</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.75in"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20221231_z8b3MR4zzKa3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20211231_zNl9DGw4dpu1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40F_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_z9v36auV4kF9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left; padding-bottom: 2.5pt">Operating loss carryforward</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">26,295</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,582</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DeferredTaxAssetsGross_iI_zPzuKwYFSqcg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Net deferred tax asset before valuation allowance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p style="margin: 0">6,069</p></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">3,595</p></td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--OperatingLossCarryforwardsValuationAllowance_iNI_pn3n3_di_zUA6sARZ0Gt4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6,069</span></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,595</span></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_zzaWFo4Z3P3e" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0554">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0555">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A4_zoqXObOM213e" style="text-align: center; margin-top: 0; margin-bottom: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022, the Company has provided a full valuation allowance of $<span id="xdx_909_eus-gaap--DeferredTaxAssetsGross_iI_pn3n3_c20221231_zvRztr3xZkTb" title="Valuation allowance">6,069</span> thousand <span>in respect of deferred tax assets resulting from tax loss carryforward and other temporary differences. Management currently believes that because the Company has a history of losses, it is more likely than not that the deferred tax regarding the loss carryforward and other temporary differences will not be realized in the foreseeable future.</span></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">c.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Available carryforward tax losses:</b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">As of December 31, 2022, the Company has an accumulated tax loss carryforward of approximately $<span id="xdx_909_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_c20221231_zBNpAi2FWuh" title="Accumulated tax loss carryforward">26,295</span> thousand. Carryforward tax losses in Israel are of unlimited duration. Under the Tax Cut and Jobs Act of 2017, or the Tax Act (subject to modifications under the Coronavirus Aid, Relief, and Economic Security Act), federal net operating losses (NOL) incurred in taxable years ending after December 31, 2017 and in future years may be carried forward indefinitely, but the deductibility of such federal net operating losses is limited. It is uncertain if and to what extent various states will conform to the newly enacted federal tax law.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p></td> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, under Section 382 of the Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, if a corporation undergoes an “ownership change,” which is generally defined as a greater than 50 percentage point change, by value, in its equity ownership over a three-year period, the corporation’s ability to use its pre-change NOL carryforwards and other pre-change tax attributes to offset its post-change income or taxes may be limited. Such limitations may result in the expiration of net operating losses before utilization.</span></p></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">d.</td> <td style="font: 10pt Times New Roman, Times, Serif">The main reconciling item between the statutory tax rate of the Company and the effective tax rate is the recognition of valuation allowance in respect of deferred taxes relating to accumulated net operating losses carried forward due to the uncertainty of the realization of such deferred taxes.</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2021, ScoutCam owed NIS <span id="xdx_90F_eus-gaap--IncomeTaxExpenseBenefit_pn3n3_uNIS_c20211230__20211231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--IsraelTaxAuthorityMember__us-gaap--TaxPeriodAxis__us-gaap--TaxYear2021Member_zZfgJP6MgdRj" title="Income tax liability">740</span> thousand, (approximately $<span id="xdx_905_eus-gaap--IncomeTaxExpenseBenefit_pn3n3_uUSD_c20211230__20211231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--IsraelTaxAuthorityMember__us-gaap--TaxPeriodAxis__us-gaap--TaxYear2021Member_zyTOZ06GrNRl" title="Income tax liability">229</span> thousand) in additional taxes to the Israel Tax Authority following a VAT audit in Israel for 2019-2021.</span></p></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 18, 2021, ScoutCam filed an appeal to the Israeli Tax Authority on the finding of the VAT audit.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due to the uncertainty regarding the outcome of the appeal, the financial statements as of December 31, 2021 included a provision related to the additional taxes of $<span id="xdx_906_eus-gaap--IncomeTaxExpenseBenefit_pn3n3_uUSD_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zf4hLM4Cf5Jf" title="Provision for tax">229</span> thousand, which was included in general and administrative expenses in the statement of operation report.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In July 2022, ScoutCam reached an agreement with the Israeli Tax Authority, according to which the amount due in additional taxes was reduced to NIS <span id="xdx_901_eus-gaap--IncomeTaxExpenseBenefit_pn3n3_uNIS_c20220701__20220731__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--IsraelTaxAuthorityMember__us-gaap--TypeOfArrangementAxis__custom--AgreementMember_zXZgd3Nd1wr6" title="Income tax expense (benefit)">340</span> thousand (approximately $<span id="xdx_90E_eus-gaap--IncomeTaxExpenseBenefit_pn3n3_uUSD_c20220701__20220731__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--IsraelTaxAuthorityMember_z2PYwfbgC9Vg" title="Income tax expense (benefit)">100</span> thousand).</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SCOUTCAM INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0.23 0.21 <p id="xdx_896_eus-gaap--SummaryOfOperatingLossCarryforwardsTextBlock_z121l4l9ipL3" style="text-align: center; margin-top: 0; margin-bottom: 0"><span id="xdx_8BF_zawolLZnQopk" style="display: none">SCHEDULE OF COMPONENT OF DEFERRED TAX ASSET</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.75in"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20221231_z8b3MR4zzKa3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20211231_zNl9DGw4dpu1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40F_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_z9v36auV4kF9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left; padding-bottom: 2.5pt">Operating loss carryforward</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">26,295</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,582</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DeferredTaxAssetsGross_iI_zPzuKwYFSqcg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Net deferred tax asset before valuation allowance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p style="margin: 0">6,069</p></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">3,595</p></td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--OperatingLossCarryforwardsValuationAllowance_iNI_pn3n3_di_zUA6sARZ0Gt4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6,069</span></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,595</span></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_zzaWFo4Z3P3e" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0554">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0555">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 26295000 15582000 6069000 3595000 6069000 3595000 6069000 26295000 740000 229000 229000 340000 100000 <p id="xdx_80E_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zZMZIPAbqQ6g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.6pt; text-align: justify; text-indent: -49.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 8 – <span id="xdx_82D_zLiUtZ6yszw4">RELATED PARTIES</span></b>:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.6pt; text-align: justify; text-indent: -49.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_893_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zwZDblvQinRa" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Related Parties Balances:</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B5_zdePU12Ti8Me" style="display: none">SCHEDULE OF BALANCES WITH RELATED PARTIES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.75in"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD in thousands</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Directors (directors’ accrued compensation)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pn3n3_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorsMember_zruzBXnECQKc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balances with related parties">48</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pn3n3_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorsMember_z1o8uZnzXAQc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balances with related parties"><span style="-sec-ix-hidden: xdx2ixbrl0577">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smartec R&amp;D Ltd. (see note 8c)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pn3n3_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SmartecRAndDLtdMember_zSAF6iGvDTu1" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Balances with related parties"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pn3n3_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SmartecRAndDLtdMember_zRsQAU8NHHD" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Balances with related parties"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0581">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medigus</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_980_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pn3n3_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MedigusLtdMember_zE9fXw9HtfV5" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balances with related parties"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0583">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_982_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pn3n3_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MedigusLtdMember_zhm9HRaS6ewj" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balances with related parties"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pn3n3_c20221231_zvtqLjuW8PTh" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balances with related parties"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pn3n3_c20211231_z8RZRAeME4f4" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balances with related parties"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A2_zi8BW7CjCg9f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b/></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 18, 2020, the Company allocated in a private issuance to M. Arkin (1999) Ltd. (“Arkin”) a total of <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20200517__20200518__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_znqFuxI0muMf" title="Issuance of units">229,569</span> units (as described in note 9c) at a purchase price of $<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20200518__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zDd6TgXT3908" title="Issuance of unit, price per unit">8.712</span> per unit (“Arkin Transaction”).</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In connection with the Arkin Transaction, the Company, Medigus and Arkin entered into a voting agreement, pursuant to which Arkin and Medigus each agreed to vote their respective shares of common stock in favor of the election of the opposite party’s designated representative(s), as applicable, to the Board (“Voting Agreement”). Each of Arkin’s and Medigus’ rights under the Voting Agreement are contingent upon, inter alia, such party maintaining a certain beneficial ownership threshold in the Company’ as follows:</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) One person designated by Arkin is to be elected, for as long as Arkin, continues to beneficially own at least eight percent of the issued and outstanding capital stock of the Company.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) Three persons designated by Medigus are to be elected, for as long as Medigus, continues to beneficially own at least thirty five percent of the issued and outstanding capital stock of the Company.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) Two persons designated by Medigus are to be elected for as long as Medigus, continues to beneficially own less than thirty five percent and more than twenty percent of the issued and outstanding capital stock of the Company.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) One person designated by Medigus is to be elected for as long as Medigus, continues to beneficially own less than twenty percent and more than eight percent of the issued and outstanding capital stock of the Company.</span></p></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During 2021 and 2022 the Company received development services from Smartec R&amp;D Ltd., a company owned by the Company’s CTO.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total compensation for the fiscal years ended December 31, 2021 and December 31, 2022 was $<span id="xdx_90B_eus-gaap--CompensationExpenseExcludingCostOfGoodAndServiceSold_pn3n3_c20210101__20211231_zCHsqLgfVZIk" title="Compensation expense">82</span> thousands and $<span id="xdx_90C_eus-gaap--CompensationExpenseExcludingCostOfGoodAndServiceSold_pn3n3_c20220101__20221231_zTyQDztwIDJ" title="Compensation expense">117</span> thousands, respectively.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d. </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During 2021 the Company received financial consultant services from Anona De Finance Ltd., a company owned by one of the Company’s directors.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total expenses for the fiscal years ended December 31, 2021 was approximately $<span id="xdx_90B_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_c20210101__20211231_zFgfQ2HUjBNk" title="Consulting expense">37</span> thousands.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SCOUTCAM INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Related Parties Balances:</b></span><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B5_zdePU12Ti8Me" style="display: none">SCHEDULE OF BALANCES WITH RELATED PARTIES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.75in"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD in thousands</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Directors (directors’ accrued compensation)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pn3n3_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorsMember_zruzBXnECQKc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balances with related parties">48</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pn3n3_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorsMember_z1o8uZnzXAQc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balances with related parties"><span style="-sec-ix-hidden: xdx2ixbrl0577">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smartec R&amp;D Ltd. (see note 8c)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pn3n3_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SmartecRAndDLtdMember_zSAF6iGvDTu1" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Balances with related parties"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pn3n3_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SmartecRAndDLtdMember_zRsQAU8NHHD" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Balances with related parties"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0581">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medigus</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_980_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pn3n3_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MedigusLtdMember_zE9fXw9HtfV5" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balances with related parties"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0583">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_982_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pn3n3_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MedigusLtdMember_zhm9HRaS6ewj" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balances with related parties"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pn3n3_c20221231_zvtqLjuW8PTh" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balances with related parties"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pn3n3_c20211231_z8RZRAeME4f4" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balances with related parties"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 48000 10000 39000 58000 39000 229569 8.712 82000 117000 37000 <p id="xdx_801_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zTXIKjPtj623" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 9 - <span id="xdx_823_z1GxZE0S2Xv8">EQUITY</span>:</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Increase of the authorized share capital</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 20, 2021, the Company’s Board of Directors approved an increase of the authorized share capital of the Company by an additional <span id="xdx_905_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20210120__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_zKW295bGw4Ki" title="Common stock, share authorized">225,000,000</span> shares of common stock par value $<span id="xdx_902_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_uUSDPShares_c20210120__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_zYXaO1AWk2U5" title="Common stock, par value">0.001</span> per share, such that the authorized share capital of the Company following such increase shall be consisting of <span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20221231_zQI7RfQlksN5" title="Common stock shares authorized">300,000,000</span> shares of common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>a.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Private placement:</b></span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2019, the Company allocated in a private placement, a total of <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20191201__20191231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zNZwFveXTSI" title="Number of shares issued">379,269</span> units at a purchase price of $<span id="xdx_90A_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20191231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zZDa5qthdgxe" title="Shares issued, price per share">8.712</span> per unit. <span id="xdx_90F_eus-gaap--SaleOfStockDescriptionOfTransaction_c20191201__20191231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z4hMPX2yuFbc" title="Warranr description">Each unit was comprised of two shares of common stock par value $0.001 per share, one Warrant A (as described below) and two Warrants B (as described below)</span>. The immediate proceeds (gross) from the issuance of the units amounted to approximately $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn5n6_c20191201__20191231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zfhCmSAy8dpk">3.3</span> million.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each Warrant A was exercisable into <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_dc_c20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantAMember_zPFVY6McbEh8" title="Warrant exercisable, shares">one</span> share of common stock of the Company at an exercise price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantAMember_zkhvm3Fg98uj" title="Warrant exerise price per share">5.355</span> per share during the 12 month period following the allocation. Each Warrant B is exercisable into <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_dc_c20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantBMember_z4KAhJQZ8A85" title="Warrant exercisable, shares">one</span> share of common stock of the Company at an exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantBMember_zF7x62B6BqIg" title="Warrant exerise price per share">8.037</span> per share during the <span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtM_c20211231__us-gaap--StatementEquityComponentsAxis__custom--WarrantBMember_zn4Z6MJBSj8e" title="Warrants and rights outstanding, term">18</span> month period following the allocation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, Shrem Zilberman Group Ltd. (the “Consultant”) will be entitled to receive the amount representing <span id="xdx_906_ecustom--WarrantExercisePricePercentage_dp_uPure_c20220101__20221231__srt--TitleOfIndividualAxis__custom--ConsultantMember_znMyNvlVqLT4" title="Warrant exercise price percentage">3%</span> of any exercise price of each Warrant A or Warrant B that may be exercised in the future. In the event the total proceeds received as a result of exercise of warrants will be less than $<span id="xdx_909_eus-gaap--ProceedsFromWarrantExercises_pn6n6_c20220101__20221231__srt--TitleOfIndividualAxis__custom--ConsultantMember_zqDjJrlaqer" title="Proceeds from warrant exercises">2</span> million at the time of their expiration, the Consultant will be required to invest $<span id="xdx_903_ecustom--ExerciseOfWarrantsRequiredToInvestReturnForSharesOfCommonStock_pp0p0_c20220101__20221231__srt--TitleOfIndividualAxis__custom--ConsultantMember_zDBS5ssmicsl" title="Exercise of warrants required to invest return for shares of common stock">250,000</span> in the Company in return for shares of common stock of Company. As of December 31, 2021, holders of the foregoing warrants have exercised in excess of $<span id="xdx_908_eus-gaap--ProceedsFromWarrantExercises_pn6n6_c20210101__20211231__srt--TitleOfIndividualAxis__custom--ConsultantMember_zgveDAD8cek6" title="Proceeds from warrant exercises">2</span> million and, accordingly, the Consultant is not required to invest $<span id="xdx_902_ecustom--ExerciseOfWarrantsRequiredNotToInvestReturnForSharesOfCommonStock_pp0p0_c20210101__20211231__srt--TitleOfIndividualAxis__custom--ConsultantMember_zbTaAQbcdmlh" title="Exercise of warrants required to invest return for shares of common stock">250,000</span> in the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During 2020, <span id="xdx_90F_ecustom--NumberOfWarrantsExercised_pid_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__custom--WarrantAMember_zmYcSb1qxAAi" title="Number of warrants exercised">332,551</span> Warrants A were exercised, and <span id="xdx_905_ecustom--NumberOfWarrantsUnexercised_pid_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__custom--WarrantAMember_zmbPicSgYrC5" title="Number of warrants unexercised">46,718</span> unexercised Warrants A expired on <span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_pid_c20201231__us-gaap--StatementEquityComponentsAxis__custom--WarrantAMember_zowKBA3C0vHc" title="Warrant expiration">December 30, 2020</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Consultant received $<span id="xdx_907_eus-gaap--ProceedsFromWarrantExercises_pn3n3_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__custom--WarrantAMember_zdg4jIZzt9m9" title="Proceeds from exercise of warrants">53</span> thousand following the exercise of <span id="xdx_90A_ecustom--NumberOfWarrantsExercised_pid_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__custom--WarrantAMember_zz0IqHfR4eqg" title="Number of warrant exercised">332,551</span> Warrants A.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the second quarter of 2021, <span id="xdx_907_ecustom--NumberOfWarrantsExercised_pid_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__custom--WarrantBMember_zOJJbkOhNrj1" title="Number of warrants exercised">185,271</span> Warrants B were exercised, and <span id="xdx_90A_ecustom--NumberOfWarrantsUnexercised_pid_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__custom--WarrantBMember_z2UQvAp6Yol5" title="Number of warrants unexercised">573,256</span> unexercised Warrants B expired on <span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_pid_dd_c20210630__us-gaap--StatementEquityComponentsAxis__custom--WarrantBMember_zSsjNTmBpY9g" title="Warrant expiration">June 30, 2021</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Consultant received $<span id="xdx_904_eus-gaap--ProceedsFromWarrantExercises_pn3n3_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__custom--WarrantAMember_zuKbnmpUPmNj" title="Proceeds from exercise of warrants">45</span> thousand following the exercise of <span id="xdx_90D_ecustom--NumberOfWarrantsExercised_pid_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__custom--WarrantAMember_zL4k8Kif6Gza" title="Number of warrants exercised">185,271</span> Warrants B.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 3, 2020, the Company issued in a private placement a total of <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20200302__20200303__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zNpKGP4YDKr2" title="Stock issued during period, shares, new issues">108,880</span> units at a purchase price of $<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20200303__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zpGiylZXguh1" title="Shares issued, price per share">8.712</span> per unit.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--SaleOfStockDescriptionOfTransaction_c20200302__20200303__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zAUmUlOMvxX3" title="Warrant description">Each unit was comprised of two shares of common stock par value $0.001 per share, one Warrant A (as described below) and two Warrants B (as described below)</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each Warrant A was exercisable into <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_dc_c20200303__us-gaap--StatementEquityComponentsAxis__custom--WarrantAMember_zTVMpZrQ0SAc" title="Warrant exercisable, shares">one</span> share of common stock of the Company at an exercise price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20200303__us-gaap--StatementEquityComponentsAxis__custom--WarrantAMember_zKNRgZVdAD01" title="Warrant exerise price per share">5.355</span> per share during the <span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtM_c20200303__us-gaap--StatementEquityComponentsAxis__custom--WarrantAMember_zd3sUi6z8ARd" title="Warrants and rights outstanding, term">12</span> month period following the allocation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each Warrant B is exercisable into <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_dc_c20200303__us-gaap--StatementEquityComponentsAxis__custom--WarrantBMember_zI6302DVVmkk" title="Class of warrant or right, number of securities called by each warrant or right">one</span> share of common stock of the Company at an exercise price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20200303__us-gaap--StatementEquityComponentsAxis__custom--WarrantBMember_zlsvYvFMrmCe" title="Warrant exerise price per share">8.037</span> per share during the <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtM_c20200303__us-gaap--StatementEquityComponentsAxis__custom--WarrantBMember_zmCDOPPNctP8" title="Warrants and rights outstanding, term">18</span> month period following the allocation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The gross proceeds from the issuance of all securities offered amounted to approximately $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn3n3_c20200302__20200303__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrHyBKX14Sjd" title="Proceeds from issuance of securities offered">948</span> thousands. After deducting issuance costs, the Company received proceeds of approximately $<span id="xdx_904_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn3n3_c20200302__20200303__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOGQm5o1KDzf" title="Proceeds from issuance after deducting issuance costs">909</span> thousand.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SCOUTCAM INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.6pt; text-align: justify; text-indent: -49.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 9 – EQUITY </b>(continued):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During 2021, <span id="xdx_909_ecustom--NumberOfWarrantsExercised_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--WarrantAMember_zDAU5g3HOL8f" title="Number of share warrants exercised">108,880</span> Warrants A were exercised.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_ecustom--NumberOfWarrantsUnexercised_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--WarrantBMember_zAAvMe6E7oJb" title="Number of unexercised warrants">217,760</span> unexercised Warrants B expired on <span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_pid_c20211231__us-gaap--StatementEquityComponentsAxis__custom--WarrantBMember_zfRw9wXfNUBi" title="Warrant expiration">September 3, 2021</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 18, 2020, the Company allocated in a private placement to Arkin a total of <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20200517__20200518__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zz746JjxuIBd" title="Stock issued during period, shares, new issues">229,569</span> units at a purchase price of $<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20200518__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zfzE8ioaNaZ2" title="Shares issued, price per share">8.712</span> per unit.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--SaleOfStockDescriptionOfTransaction_c20200517__20200518__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zEbhCdJ3Qycc" title="Sale of stock description">Each unit was comprised of two shares of common stock par value $0.001 per share, one Warrant A (as described below) and two Warrants B (as described below)</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each Warrant A was exercisable into <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_dc_c20200518__us-gaap--StatementEquityComponentsAxis__custom--WarrantAMember_zB93znQoC0Xd" title="Warrant exercisable, shares">one</span> share of common stock of the Company at an exercise price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20200518__us-gaap--StatementEquityComponentsAxis__custom--WarrantAMember_z4T7xG8r4qd" title="Warrant exerise price per share">5.355</span> per share during the <span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtM_c20200518__us-gaap--StatementEquityComponentsAxis__custom--WarrantAMember_zO0Bzkxg53n9" title="Warrants and rights outstanding, term">18</span> month period following the allocation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each Warrant B is exercisable into <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_dc_c20200518__us-gaap--StatementEquityComponentsAxis__custom--WarrantBMember_zcQcZLWvtXVc" title="Warrant exercisable, shares">one</span> share of common stock of the Company at an exercise price of $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20200518__us-gaap--StatementEquityComponentsAxis__custom--WarrantBMember_zRtgorGGZq3j" title="Warrant exerise price per share">8.037</span> per share during the <span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtM_c20200518__us-gaap--StatementEquityComponentsAxis__custom--WarrantBMember_zoW5AesnNTP4" title="Warrants and rights outstanding, term">24</span> month period following the allocation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The gross proceeds from the issuance of all securities offered amounted to approximately $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn6n6_c20200517__20200518__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zLdUvNpWpNZe" title="Proceeds from issuance of securities offered">2</span> million. After deducting issuance costs, the Company received proceeds of approximately $<span id="xdx_905_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20200517__20200518__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pn5n6" title="Proceeds from issuance after deducting issuance costs">1.9</span> million.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During February 2021, <span id="xdx_905_ecustom--NumberOfWarrantsExercised_pid_c20210201__20210228__us-gaap--StatementEquityComponentsAxis__custom--WarrantAMember_z9TaaTMV2b09" title="Number of share warrants exercised">37,349</span> Warrants A were exercised.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During November 2021, <span id="xdx_90C_ecustom--NumberOfWarrantsExercised_pid_c20211101__20211130__us-gaap--StatementEquityComponentsAxis__custom--WarrantAMember_zKwPCCwOUl48" title="Number of share warrants exercised">192,220</span> Warrants A were exercised.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 23, 2020, (the “Conversion Date”), the Company entered into a side letter agreement with Medigus whereby the parties agreed to convert, at a conversion price of $<span id="xdx_90F_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_uUSDPShares_c20200623__us-gaap--TypeOfArrangementAxis__custom--LetterAgreementMember__dei--LegalEntityAxis__custom--MedigusLtdMember_zPMYOGeg8XUk" title="Conversion price">4.356</span> per share, an outstanding line of credit previously extended by Medigus to ScoutCam, which as of the Conversion Date had $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_pid_c20200621__20200623__us-gaap--TypeOfArrangementAxis__custom--LetterAgreementMember__dei--LegalEntityAxis__custom--MedigusLtdMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zReFhvlAMlA4" title="Number of shares conversion">381,136</span> outstanding, into (a) <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20200621__20200623__us-gaap--TypeOfArrangementAxis__custom--LetterAgreementMember__dei--LegalEntityAxis__custom--MedigusLtdMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwA2LBrVKo94" title="Number of shares issued">87,497</span> shares of the Company’s common stock, (b) to <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20200623__us-gaap--TypeOfArrangementAxis__custom--LetterAgreementMember__dei--LegalEntityAxis__custom--MedigusLtdMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantAMember_zusqwOybrLPe" title="Number of warrants issued">43,749</span> Warrant A (as described below), and (c) <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20200623__us-gaap--TypeOfArrangementAxis__custom--LetterAgreementMember__dei--LegalEntityAxis__custom--MedigusLtdMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantBMember_zZks8GKYVIg2" title="Number of warrants issued">87,497</span> Warrant B (as described below). As the conversion price represented the same unit price as in the March 2020 and May 2020 private placements, no finance expenses have been recorded in statement of operations as a result of the conversion.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each Warrant A is exercisable into <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_dc_c20200623__us-gaap--StatementEquityComponentsAxis__custom--WarrantAMember_zCIVnwAxuWI7" title="Warrant exercisable, shares">one</span> share of common stock of the Company at an exercise price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20200623__us-gaap--StatementEquityComponentsAxis__custom--WarrantAMember_zRBmPIqzs4Uh" title="Warrant exerise price per share">5.355</span> per share during the <span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtM_c20200623__us-gaap--StatementEquityComponentsAxis__custom--WarrantAMember_zObjvKU2Sot2" title="Warrants and rights outstanding, term">12</span> months period following the allocation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each Warrant B is exercisable into <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_dc_c20200623__us-gaap--StatementEquityComponentsAxis__custom--WarrantBMember_zLjvObGslgme" title="Warrant exercisable, shares">one</span> share of common stock of the Company at an exercise price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20200623__us-gaap--StatementEquityComponentsAxis__custom--WarrantBMember_z5zK5ZwyJePg" title="Warrant exerise price per share">8.037</span> per share during the <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtM_c20200623__us-gaap--StatementEquityComponentsAxis__custom--WarrantBMember_zNcO0qpE5EM5" title="Warrants and rights outstanding, term">18</span> months period following the allocation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During June 2021, <span id="xdx_90B_ecustom--NumberOfWarrantsExercised_pid_c20210601__20210630__us-gaap--StatementEquityComponentsAxis__custom--WarrantAMember_z5T0MYhWBsq" title="Number of warrants exercised">43,749</span> Warrants A were exercised.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 23, 2021, <span id="xdx_905_ecustom--NumberOfWarrantsUnexercised_pid_c20211222__20211223__us-gaap--StatementEquityComponentsAxis__custom--WarrantBMember_zijgbjbWnzEa">87,497</span> unexercised Warrants B expired.</span></p></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 29, 2021, the Company issued to certain investors, including Arkin, a major stockholder of the Company, of which Mori Arkin, a director of the company, is the owner, <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210328__20210329__srt--TitleOfIndividualAxis__custom--InvestmentCMember_zSO1rGp7rrWe" title="Stock issued during period, shares, new issues">2,469,156</span> units in exchange for an aggregate purchase price of $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn6n6_c20210328__20210329__srt--TitleOfIndividualAxis__custom--InvestorsCMember_zZ5JorljekKh" title="Proceeds from issuance of common stock">20</span> million. <span id="xdx_901_eus-gaap--SaleOfStockDescriptionOfTransaction_c20210328__20210329__srt--TitleOfIndividualAxis__custom--InvestorsCMember_zgQlMgiXGDIh" title="Sale of stock, description">Each such unit consists of (i) one share of common stock and (ii) one warrant to purchase one share of common stock with an exercise price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20210329__srt--TitleOfIndividualAxis__custom--InvestorsCMember_zN4gOOdbp9s3" title="Warrant exerise price per share">10.35</span> per share</span>. Each such warrant is exercisable until the close of business on <span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20210329__srt--TitleOfIndividualAxis__custom--InvestorsCMember_zAcHyLpQbPv1" title="Warrants and rights outstanding, maturity date">March 31, 2026</span>. Pursuant to the terms of the foregoing warrants, following April 1, 2024, if the closing price of Company common stock equal or exceeds <span id="xdx_901_ecustom--CommonStockExceedingPercentage_iI_pid_c20210329__srt--TitleOfIndividualAxis__custom--InvestorsCMember_zS4j3ohI13th" title="Common stock percent">135%</span> of the aforementioned exercise price (subject to appropriate adjustments for stock splits, stock dividends, stock combinations and other similar transactions after the issue date of the warrants) for any thirty (30) consecutive trading days, the Company may force the exercise of the warrants, in whole or in part, by delivering to these investors a notice of forced exercise.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SCOUTCAM INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.6pt; text-align: justify; text-indent: -49.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 9 – EQUITY </b>(continued):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_ziYEHtRkbDyc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022, the Company had the following outstanding warrants to purchase common stock:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.6pt; text-align: justify; text-indent: -49.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B8_z9in7h7WBcWa" style="display: none">SCHEDULE OF STOCK WARRANTS OUTSTANDING TO PURCHASE COMMON STOCK</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance Date</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expiration Date</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise Price<br/> Per Share ($)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of Shares<br/> of common stock<br/> Underlying <br/> Warrants</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 36%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 2021 Warrant</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 12%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_ecustom--WarrantAndRightsOutstandingIssuanceDate_dd_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantMarchTwoThousandTwentyOneMember_zj7CV0iZRa92" title="Warrant issuance date">March 29, 2021</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 12%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantMarchTwoThousandTwentyOneMember_zYa4d8x09vA" title="Warrant expiration date">March 31, 2026</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantMarchTwoThousandTwentyOneMember_zkLNxscv8AQ7" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 12%; text-align: right" title="Warrant exercise price per share"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.350</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantMarchTwoThousandTwentyOneMember_zV62ra2uMkck" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Number of shares of common stock underlying warrants"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,469,156</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zv4puIP8LVde" style="font: bold 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares of common stock underlying warrants"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,469,156</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8AA_ziYSiPIRQcyl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>b.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock-based compensation to employees, directors and service providers:</b></span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 49.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 53.85pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February 2020, the Company’s Board of Directors approved the 2020 Share Incentive Plan (the “Plan”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 53.85pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 53.85pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Plan initially included a pool of <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20200201__20200229__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyShareIncentivePlanMember__srt--TitleOfIndividualAxis__custom--EmployeesConsultantsDirectorsAndOtherServiceProvidersMember_zQMU0saIhifa" title="Share based compensation arrangement Options grants in period gross">580,890</span> shares of common stock for grant to Company employees, consultants, directors and other service providers. On March 15, 2020, the Company’s Board of Directors approved an increase to the Company’s option pool pursuant to the Plan by an additional <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20200314__20200315__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyShareIncentivePlanMember__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_zZXVPZ0GYbLh" title="Share based compensation arrangement Options grants in period gross">64,099</span> shares of common stock. On June 22, 2020, the Company’s Board of Directors approved an increase to the Company’s option pool pursuant to the Plan by an additional <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20200622__20200622__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyShareIncentivePlanMember__srt--TitleOfIndividualAxis__custom--EmployeesConsultantsDirectorsAndOtherServiceProvidersMember_zqmhpqv1IJhi" title="Share based compensation arrangement Options grants in period gross, additional">401,950</span> shares of common stock. During the second quarter of 2021, the Company’s Board of Directors approved an increase to the Company’s option pool pursuant to the Plan by an additional <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210401__20210630__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyShareIncentivePlanMember__srt--TitleOfIndividualAxis__custom--EmployeesConsultantsDirectorsAndOtherServiceProvidersMember_zKfXg27zaRX" title="Share based compensation arrangement Options grants in period gross, additional">777,778</span> shares of common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 53.85pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 53.85pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Plan is designed to enable the Company to grant options to purchase shares of common stock and RSUs under various and different tax regimes including, without limitation: (i) pursuant and subject to Section 102 of the Israeli Tax Ordinance or any provision which may amend or replace it and any regulations, rules, orders or procedures promulgated thereunder and to designate them as either grants made through a trustee or not through a trustee; and (ii) pursuant and subject to Section 3 (i) of the Israeli Tax Ordinance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 53.85pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 53.85pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During 2021, the Company granted <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210101__20211231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyShareIncentivePlanMember_zALqE7Qs40Jc" title="Share based compensation arrangement Options grants in period gross">648,712</span> options pursuant to the Plan.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 53.85pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 53.85pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During 2022, the Company granted <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyShareIncentivePlanMember_z7mZ30JMSg4c" title="Share based compensation arrangement Options grants in period gross">479,000</span> options pursuant to the Plan.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options granted generally have a contractual term of <span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1_dc_c20220101__20221231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyShareIncentivePlanMember_zQJtOH0Yypod" title="Stock option granted contractual term">seven years</span> and vest over a period of <span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1_dtYxL_c20220101__20221231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyShareIncentivePlanMember__srt--RangeAxis__srt--MinimumMember_zNb7MZ914chi" title="Stock option vested term::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl0773">three</span></span> to <span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1_dc_c20220101__20221231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyShareIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_zvKNGHxsCcf6" title="Stock option vested term">four years</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SCOUTCAM INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.6pt; text-align: justify; text-indent: -49.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 9 – EQUITY </b>(continued):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock Option Activity</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zsuVCKl2u98e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following summarizes stock option activity:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B1_z4QotXm3cH4a" style="display: none">SCHEDULE OF STOCK OPTION ACTIVITY</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount of options</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted average exercise price</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted Average Remaining Contractual Term (years)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aggregate Intrinsic Value (in thousands)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$ in thousands</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 44%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding - December 31, 2020</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20210101__20211231_zEgU1z9bo6z5" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Options, Outstanding at beginning of period"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">737,049</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20210101__20211231_zSTfuZjtsqkf" title="Weighted average exercise price, Outstanding at beginning of period">2.61</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200101__20201231_zjaISoMxMoE8" title="Weighted average remaning contractual term (years) beginning of the period">6.23</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20210101__20211231_z8yvb1uJ6Ok8" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Aggregate Intrinsic Value, Outstanding at beginning of period"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,446</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210101__20211231_zyZxxYlMjdj4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options, Granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">648,712</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20210101__20211231_zZsNUEaIb27c" title="Weighted average exercise price, Granted">4.09</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20210101__20211231_zSiMrbiEamDk" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options, Cancelled"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(132,207</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20210101__20211231_zlGINIqk2EW5" title="Weighted average exercise price, Cancelled">3.34</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding - December 31, 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231_zbZFiKNyiWHe" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options, Outstanding at beginning of period"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,253,554</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20220101__20221231_zjpox4lhCZW7" title="Weighted average exercise price, Outstanding at beginning of period">3.31</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_zUh7aAdES2y6" title="Weighted average remaning contractual term (years)">5.65</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20220101__20221231_zhseySOCsa2b" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value, Outstanding at beginning of period"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,884</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231_zq9Ct9WxYNP6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options, Granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">479,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220101__20221231_zb9TBTEazu51" title="Weighted average exercise price, Granted">4.50</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20221231_zcxxk6GS1ve2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options, Cancelled"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(172,514</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220101__20221231_zaTZLnLqJTZ3" title="Weighted average exercise price, Cancelled">3.57</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding - December 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20221231_zhQ4Ls68tYC4" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options, Exercisable at end of period"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,560,040</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20220101__20221231_z52XQ0whzYL7" title="Weighted average exercise price, Outstanding at end of period">3.64</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zgQZQQvCLorf" title="Weighted average remaning contractual term (years)">5.17</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20220101__20221231_zXv3CrXMgeBh" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value, Outstanding at end of period"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,116</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options Exercisable - December 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20221231_zRElvcZWY6y2" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options, Exercisable at end of period"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">838,994</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20221231_z3u6DfqgDcv3" title="Weighted average exercise price, Exercisable at end of period">3.10</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231_zL8TozOYNKS7" title="Weighted average remaning contractual term (years) exercisable at end of the period">4.24</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20221231_zWHu5UGQ9Pvf" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value, Exercisable at end of period"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,595</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8AF_zDGj18wZD0g8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022, the aggregate intrinsic value of options granted is calculated as the difference between the exercise price and the closing price on the same date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company estimates the fair value of stock option awards on the grant date using the Black-Scholes option pricing model. The weighted-average grant date fair value per option granted during the year ended December 31, 2022 was $<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zcvgaOFT797b" title="Weighted average exercise price">2.76</span>. The fair value of each award is estimated using Black-Scholes option-pricing model based on the following assumptions:</span></p> <p id="xdx_896_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_zmP61lYQrrM9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B8_zbNTChQMRqUb" style="display: none">SCHEDULE OF SHARE-BASED PAYMENT,STOCK OPTIONS, VALUATION ASSUMPTIONS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2022</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2021</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underlying value of shares ($)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--SharePrice_iI_pid_c20221231__srt--RangeAxis__srt--MinimumMember_zrn4LsP5drV6" title="Underlying value of ordinary shares">5.00</span>-<span id="xdx_904_eus-gaap--SharePrice_iI_pid_c20221231__srt--RangeAxis__srt--MaximumMember_zbfsVPO6YV6j" title="Underlying value of ordinary shares">7.20</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--SharePrice_iI_pid_c20211231__srt--RangeAxis__srt--MinimumMember_zI8CHFdg26f7" title="Underlying value of ordinary shares">7.65</span>-<span id="xdx_904_eus-gaap--SharePrice_iI_pid_c20211231__srt--RangeAxis__srt--MaximumMember_z8aWHWJx6kCc" title="Underlying value of ordinary shares">10.35</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise price ($)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20221231_zy05DHoYkPlb" title="Exercise price">4.5</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20211231__srt--RangeAxis__srt--MinimumMember_z7jGn4U8a0Id" title="Exercise price">2.61</span>-<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20211231__srt--RangeAxis__srt--MaximumMember_zbUHg0xMt76i" title="Exercise price">7.2</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected volatility (%)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zr41fUZjQWS5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_z3IDXoKUubpb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40%</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20210101__20211231__srt--RangeAxis__srt--MinimumMember_zMoqbt9z52wd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">46%</span>-<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20210101__20211231__srt--RangeAxis__srt--MaximumMember_zxMbnPreTmyf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49%</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Term of the options (years)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231_zeoj6eTww0K6" title="Term of the options (years)">7</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231_zVQzG7gY5whg" title="Term of the options (years)">7</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free interest rate (%)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_z97wTSI82Y4j" title="Risk-free interest rate minimum">1.98</span>%-<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zc3lL3zLTkC" title="Risk-free interest rate maximum">3.95%</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20210101__20211231__srt--RangeAxis__srt--MinimumMember_zeKNgL71Msz1" title="Risk-free interest rate minimum">0.78%</span>-<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20210101__20211231__srt--RangeAxis__srt--MaximumMember_zQXFN1EqTK49" title="Risk-free interest rate maximum">1.51%</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8AA_zVsA2tfXaITi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Volatility is derived from the historical volatility of publicly traded set of peer companies. The risk-free interest rates used in the Black-Scholes calculations are based on the prevailing U.S. Treasury yield as determined by the U.S. Federal Reserve. The Company has not paid dividends and does not anticipate paying dividends in the foreseeable future. Accordingly, no dividend yield was assumed for purposes of estimating the fair value of the Company’s stock-based compensation. The weighted average expected life of options was estimated individually in respect of each grant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The unrecognized compensation expense calculated under the fair-value method for stock options expected to vest as of December 31, 2022 is approximately $<span id="xdx_908_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn4n6_c20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zLgoaAQY1kMe" title="Stock option award cost not yet recognized">1.45</span> million and is expected to be recognized over a weighted-average period of <span id="xdx_905_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zFTr0stkXxMl" title="Stock option award weighted average period">1.41</span> years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During 2022 and 2021 the Company’s Board of Directors authorized the grant of options to purchase <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20221231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--RelatedPartyTransactionAxis__custom--ProfGoldwasserMember_zowL1JJTvNrh" title="Option to purchase">45,000</span> shares of common stock of the Company and <span><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--RelatedPartyTransactionAxis__custom--ProfGoldwasserMember_zVgwg3UGEisf" title="Option to purchase">83,334</span></span> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock of the Company, respectively, to Prof. Goldwasser, the Chairman of the Board. </span>Total expenses recorded regarding this grant, for the year ended December 31, 2022, and December 31, 2021, are $<span id="xdx_90B_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20220101__20221231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--RelatedPartyTransactionAxis__custom--ProfGoldwasserMember_z8S0FAttq6zl" title="Expenses recorded regarding">367</span> thousand and $<span id="xdx_90B_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--RelatedPartyTransactionAxis__custom--ProfGoldwasserMember_zj2yps4P61Ik" title="Expenses recorded regarding">255</span> thousand, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">During 2021 the Company’s Board of Directors authorized the grant of options to purchase <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_z5ERF0Tm274j" title="Option to purchase">75,855</span> shares of common stock of the Company to directors of the Company. Total expenses recorded regarding this grant, for the year ended December 31, 2022, and December 31, 2021, are $<span id="xdx_90F_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20220101__20221231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zAkzbDoFJNLb" title="Expenses recorded regarding">213</span> thousand and $<span id="xdx_90E_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20210101__20211231__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zRPzCJezXzL5" title="Expenses recorded regarding">221</span> thousand, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During 2022 and 2021 the Company’s Board of Directors authorized the grant of options to purchase <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_pid_c20220101__20221231__srt--TitleOfIndividualAxis__srt--OfficerMember_zVtFR4aicaef">400,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock of the Company and <span id="xdx_909_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20210101__20211231__srt--TitleOfIndividualAxis__srt--OfficerMember_zKa9vdIifcR9">335,987 shares of common stock of the Company, respectively, to certain officers of the Company. Total expenses recorded regarding this grant, for the year ended December 31, 2022, and December 31, 2021, are $523 thousand and $871 thousand, respectively.</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Compensation expense recorded by the Company in respect of its stock-based employees, directors and service providers compensation awards in accordance with ASC 718-10 for the year ended December 31, 2022 and 2021 amounted to $<span id="xdx_900_eus-gaap--ShareBasedCompensation_pn3n3_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeeAndDirectorsMember_zLTyO2w4Cba9" title="Compensation expense">1,487</span> thousands and $<span id="xdx_900_eus-gaap--ShareBasedCompensation_pn3n3_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeeAndDirectorsMember_zmJNUxu2nnci" title="Compensation expense">2,030</span> thousands, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>c.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Restricted stock unit (“RSU”) to employees and service providers:</b></span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2022, the Company granted <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zGoPYbVGpPtj" title="Share based compensation arrangement Options grants in period gross">110,000</span> RSUs pursuant to the Plan.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each RSU will vest based on continued service which is generally over three years. The grant date fair value of the award will be recognized as stock-based compensation expense over the requisite service period. The fair value of restricted stock units was estimated on the date of grant based on the fair value of the Company’s common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The cost of the benefit embodied in the RSU granted during 2022, based on their fair value as at the grant date, is estimated to be approximately $<span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pn3n3_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zuqRdmvW68H9" title="Share-based compensation arrangement by share-based payment award, options, vested in period, fair value">748</span> thousand. These amounts will be recognized in the statements of operations over the vesting period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zcGzB813wBb3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes RSU activity for December 31, 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B6_znJjfw0u3GPb" style="display: none">SCHEDULE OF STOCK OPTION ACTIVITY</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount of RSU</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average Grant</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date Fair</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>per Share</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted Average Remaining Contractual Term (years)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding - December 31, 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zoq2tYQ8dUx8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options, Outstanding at beginning of period"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0891">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zuC9A26JXaGg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average grant date fair value per share, begining of period"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0893">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; width: 58%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zZPRZFHsOkI4" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Options, outstanding, granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">110,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z8NzXtkrDSP7" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Weighted average grant date fair value per share, granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.8</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zBIrLMxme1Z9" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options, outstanding, cancelled"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(60,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zCAiakXAkwEj" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average grant date fair value per share,vested"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.2</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unvested and Outstanding - December 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zkeESZ4bnxoe" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options, Outstanding at ending of period"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zzcNhB78v2Oh" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average grant date fair value per share, unvested and outstanding ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.32</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageRemainingContractualTerm_iE_pid_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zZTeEB1zHVvg" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average grant date fair value per share, unvested and outstanding ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.44</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/> <p id="xdx_8A9_zi0ag3qcek98" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The unrecognized compensation expense calculated under the fair-value method for RSU expected to vest as of December 31, 2022 is approximately $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iI_pn3n3_c20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zDu3Fa1qqeTj" title="Share-based compensation arrangement by share-based payment award, options, vested in period, fair value">164</span> thousand and is expected to be recognized over a weighted-average period of <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zlRexWJOZcSk" title="Estimated average period">1.15</span> years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During 2022 the Company’s Board of Directors authorized the grant of options to purchase <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_pid_c20220101__20221231_zmEaV9dQKGal">90,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock of the Company to certain officers of the Company. </span>Total expenses recorded regarding this grant, for the year ended December 31, 2022, are $<span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pn3n3_c20220101__20221231_z1hd9KkZhiL1" title="Share-based compensation arrangement by share-based payment award, options, vested in period, fair value">127</span> thousand.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SCOUTCAM INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 225000000 0.001 300000000 379269 8.712 Each unit was comprised of two shares of common stock par value $0.001 per share, one Warrant A (as described below) and two Warrants B (as described below) 3300000 1 5.355 1 8.037 P18M 0.03 2000000 250000 2000000 250000 332551 46718 2020-12-30 53000 332551 185271 573256 2021-06-30 45000 185271 108880 8.712 Each unit was comprised of two shares of common stock par value $0.001 per share, one Warrant A (as described below) and two Warrants B (as described below) 1 5.355 P12M 1 8.037 P18M 948000 909000 108880 217760 2021-09-03 229569 8.712 Each unit was comprised of two shares of common stock par value $0.001 per share, one Warrant A (as described below) and two Warrants B (as described below) 1 5.355 P18M 1 8.037 P24M 2000000 1900000 37349 192220 4.356 381136 87497 43749 87497 1 5.355 P12M 1000 8.037 P18M 43749 87497 2469156 20000000 Each such unit consists of (i) one share of common stock and (ii) one warrant to purchase one share of common stock with an exercise price of $10.35 per share 10.35 2026-03-31 1.35 <p id="xdx_899_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_ziYEHtRkbDyc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022, the Company had the following outstanding warrants to purchase common stock:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.6pt; text-align: justify; text-indent: -49.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B8_z9in7h7WBcWa" style="display: none">SCHEDULE OF STOCK WARRANTS OUTSTANDING TO PURCHASE COMMON STOCK</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance Date</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expiration Date</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise Price<br/> Per Share ($)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of Shares<br/> of common stock<br/> Underlying <br/> Warrants</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 36%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 2021 Warrant</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 12%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_ecustom--WarrantAndRightsOutstandingIssuanceDate_dd_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantMarchTwoThousandTwentyOneMember_zj7CV0iZRa92" title="Warrant issuance date">March 29, 2021</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 12%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantMarchTwoThousandTwentyOneMember_zYa4d8x09vA" title="Warrant expiration date">March 31, 2026</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantMarchTwoThousandTwentyOneMember_zkLNxscv8AQ7" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 12%; text-align: right" title="Warrant exercise price per share"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.350</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__custom--WarrantMarchTwoThousandTwentyOneMember_zV62ra2uMkck" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Number of shares of common stock underlying warrants"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,469,156</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zv4puIP8LVde" style="font: bold 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares of common stock underlying warrants"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,469,156</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 2021-03-29 2026-03-31 10.350 2469156 2469156 580890 64099 401950 777778 648712 479000 P7Y P4Y <p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zsuVCKl2u98e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following summarizes stock option activity:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B1_z4QotXm3cH4a" style="display: none">SCHEDULE OF STOCK OPTION ACTIVITY</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount of options</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted average exercise price</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted Average Remaining Contractual Term (years)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aggregate Intrinsic Value (in thousands)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$ in thousands</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 44%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding - December 31, 2020</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20210101__20211231_zEgU1z9bo6z5" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Options, Outstanding at beginning of period"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">737,049</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20210101__20211231_zSTfuZjtsqkf" title="Weighted average exercise price, Outstanding at beginning of period">2.61</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200101__20201231_zjaISoMxMoE8" title="Weighted average remaning contractual term (years) beginning of the period">6.23</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20210101__20211231_z8yvb1uJ6Ok8" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Aggregate Intrinsic Value, Outstanding at beginning of period"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,446</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210101__20211231_zyZxxYlMjdj4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options, Granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">648,712</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20210101__20211231_zZsNUEaIb27c" title="Weighted average exercise price, Granted">4.09</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20210101__20211231_zSiMrbiEamDk" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options, Cancelled"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(132,207</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20210101__20211231_zlGINIqk2EW5" title="Weighted average exercise price, Cancelled">3.34</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding - December 31, 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231_zbZFiKNyiWHe" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options, Outstanding at beginning of period"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,253,554</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20220101__20221231_zjpox4lhCZW7" title="Weighted average exercise price, Outstanding at beginning of period">3.31</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_zUh7aAdES2y6" title="Weighted average remaning contractual term (years)">5.65</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20220101__20221231_zhseySOCsa2b" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value, Outstanding at beginning of period"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,884</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231_zq9Ct9WxYNP6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options, Granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">479,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220101__20221231_zb9TBTEazu51" title="Weighted average exercise price, Granted">4.50</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20221231_zcxxk6GS1ve2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options, Cancelled"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(172,514</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220101__20221231_zaTZLnLqJTZ3" title="Weighted average exercise price, Cancelled">3.57</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding - December 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20221231_zhQ4Ls68tYC4" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options, Exercisable at end of period"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,560,040</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20220101__20221231_z52XQ0whzYL7" title="Weighted average exercise price, Outstanding at end of period">3.64</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zgQZQQvCLorf" title="Weighted average remaning contractual term (years)">5.17</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20220101__20221231_zXv3CrXMgeBh" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value, Outstanding at end of period"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,116</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options Exercisable - December 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20221231_zRElvcZWY6y2" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options, Exercisable at end of period"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">838,994</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20221231_z3u6DfqgDcv3" title="Weighted average exercise price, Exercisable at end of period">3.10</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231_zL8TozOYNKS7" title="Weighted average remaning contractual term (years) exercisable at end of the period">4.24</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20221231_zWHu5UGQ9Pvf" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value, Exercisable at end of period"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,595</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 737049 2.61 P6Y2M23D 2446000 648712 4.09 132207 3.34 1253554 3.31 P5Y7M24D 5884000 479000 4.50 172514 3.57 1560040 3.64 P5Y2M1D 2116000 838994 3.10 P4Y2M26D 1595000 2.76 <p id="xdx_896_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_zmP61lYQrrM9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B8_zbNTChQMRqUb" style="display: none">SCHEDULE OF SHARE-BASED PAYMENT,STOCK OPTIONS, VALUATION ASSUMPTIONS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2022</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2021</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underlying value of shares ($)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--SharePrice_iI_pid_c20221231__srt--RangeAxis__srt--MinimumMember_zrn4LsP5drV6" title="Underlying value of ordinary shares">5.00</span>-<span id="xdx_904_eus-gaap--SharePrice_iI_pid_c20221231__srt--RangeAxis__srt--MaximumMember_zbfsVPO6YV6j" title="Underlying value of ordinary shares">7.20</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--SharePrice_iI_pid_c20211231__srt--RangeAxis__srt--MinimumMember_zI8CHFdg26f7" title="Underlying value of ordinary shares">7.65</span>-<span id="xdx_904_eus-gaap--SharePrice_iI_pid_c20211231__srt--RangeAxis__srt--MaximumMember_z8aWHWJx6kCc" title="Underlying value of ordinary shares">10.35</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise price ($)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20221231_zy05DHoYkPlb" title="Exercise price">4.5</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20211231__srt--RangeAxis__srt--MinimumMember_z7jGn4U8a0Id" title="Exercise price">2.61</span>-<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20211231__srt--RangeAxis__srt--MaximumMember_zbUHg0xMt76i" title="Exercise price">7.2</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected volatility (%)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zr41fUZjQWS5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_z3IDXoKUubpb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40%</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20210101__20211231__srt--RangeAxis__srt--MinimumMember_zMoqbt9z52wd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">46%</span>-<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20210101__20211231__srt--RangeAxis__srt--MaximumMember_zxMbnPreTmyf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49%</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Term of the options (years)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231_zeoj6eTww0K6" title="Term of the options (years)">7</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231_zVQzG7gY5whg" title="Term of the options (years)">7</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free interest rate (%)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_z97wTSI82Y4j" title="Risk-free interest rate minimum">1.98</span>%-<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zc3lL3zLTkC" title="Risk-free interest rate maximum">3.95%</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20210101__20211231__srt--RangeAxis__srt--MinimumMember_zeKNgL71Msz1" title="Risk-free interest rate minimum">0.78%</span>-<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20210101__20211231__srt--RangeAxis__srt--MaximumMember_zQXFN1EqTK49" title="Risk-free interest rate maximum">1.51%</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 5.00 7.20 7.65 10.35 4.5 2.61 7.2 0.40 0.46 0.49 P7Y P7Y 0.0198 0.0395 0.0078 0.0151 1450000 P1Y4M28D 45000 83334 367000 255000 75855 213000 221000 400000 1487000 2030000 110000 748000 <p id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zcGzB813wBb3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes RSU activity for December 31, 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B6_znJjfw0u3GPb" style="display: none">SCHEDULE OF STOCK OPTION ACTIVITY</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount of RSU</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average Grant</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date Fair</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>per Share</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted Average Remaining Contractual Term (years)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding - December 31, 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zoq2tYQ8dUx8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options, Outstanding at beginning of period"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0891">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zuC9A26JXaGg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average grant date fair value per share, begining of period"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0893">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; width: 58%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zZPRZFHsOkI4" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Options, outstanding, granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">110,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z8NzXtkrDSP7" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Weighted average grant date fair value per share, granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.8</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zBIrLMxme1Z9" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options, outstanding, cancelled"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(60,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zCAiakXAkwEj" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average grant date fair value per share,vested"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.2</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unvested and Outstanding - December 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zkeESZ4bnxoe" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options, Outstanding at ending of period"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zzcNhB78v2Oh" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average grant date fair value per share, unvested and outstanding ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.32</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageRemainingContractualTerm_iE_pid_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zZTeEB1zHVvg" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average grant date fair value per share, unvested and outstanding ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.44</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/> 110000 6.8 60000 7.2 50000 6.32 P6Y5M8D 164000 P1Y1M24D 90000 127000 <p id="xdx_80D_eus-gaap--RevenueFromContractWithCustomerTextBlock_z90zXPQksUd1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 10 – <span id="xdx_82D_zD2NaG2wgl5c">REVENUES AND ENTITY WIDE DISCLOSURES</span>:</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC 280, “Segment Reporting,” establishes standards for reporting information about operating segments. The Company manages its business based on one operating segment, as described in Note 1.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>a.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>Disaggregation of revenue</b></span></td></tr></table> <p id="xdx_89D_eus-gaap--DisaggregationOfRevenueTableTextBlock_z0cDHvkgMbRk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b><span style="display: none">SCHEDULE OF DISAGGREGATION OF REVENUE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.75in"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year ended on <br/> December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD in thousands</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Development Services (customer A) (*)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20221231__srt--ProductOrServiceAxis__us-gaap--ServiceMember_fKCop_zaxWPCRCwPGd" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Revenues"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">317</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20211231__srt--ProductOrServiceAxis__us-gaap--ServiceMember_fKCop_zgs6V5GjNx7h" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Revenues"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0922">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Products</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20221231__srt--ProductOrServiceAxis__us-gaap--ProductMember_zUUKf8gMzsRj" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Revenues"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">348</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20211231__srt--ProductOrServiceAxis__us-gaap--ProductMember_zt49ZMRK31mc" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Revenues"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">387</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20221231_z00u3iP4xv41" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Revenues"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">665</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20211231_zT8UNHD1odQf" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Revenues"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">387</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <table cellpadding="0" cellspacing="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span id="xdx_F0B_z15N4osjkuBi" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(*)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1D_zkOi78S6av12" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the second quarter of 2022, the Company completed the development of the product relating to a customer-specific project for a Fortune <span class="xdx_phnt_RGlzY2xvc3VyZSAtICBTQ0hFRFVMRSBPRiBESVNBR0dSRUdBVElPTiBPRiBSRVZFTlVFIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_903_ecustom--DevelopmentExpense_c20220401__20220630__srt--TitleOfIndividualAxis__custom--CustomerAMember_zLrl2EBiGByf" title="Development expense">500</span> multinational healthcare corporation (“Customer A”) and moved from the development phase of the project to its production phase. As a result, during the year ended December 31, 2022, the Company recognized development services revenues and related development costs that had been previously deferred, in the amounts of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtICBTQ0hFRFVMRSBPRiBESVNBR0dSRUdBVElPTiBPRiBSRVZFTlVFIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_902_eus-gaap--CostOfRevenue_pn3n3_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--ServiceMember_zJnLP0MgUEu3" title="Revenues from development services">317</span> thousand and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtICBTQ0hFRFVMRSBPRiBESVNBR0dSRUdBVElPTiBPRiBSRVZFTlVFIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_903_eus-gaap--CostOfRevenue_pn3n3_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelatedDevelopmentCostsMember_zCZIhGvZHhHa" title="Revenues from development services">180</span> thousand, respectively. The amounts were recognized based on the expected manufacturing term of the product, which the Company estimates at <span class="xdx_phnt_RGlzY2xvc3VyZSAtICBTQ0hFRFVMRSBPRiBESVNBR0dSRUdBVElPTiBPRiBSRVZFTlVFIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_c20220101__20221231_zAJwLSuagEU4" title="Estimated useful life">7 years</span>.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, following the commencement of the production phase, the Company recognized product revenues of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtICBTQ0hFRFVMRSBPRiBESVNBR0dSRUdBVElPTiBPRiBSRVZFTlVFIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--CostOfRevenue_pn3n3_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--ProductMember_zjgdZtwmkMa6">221 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">thousands during the year ended December 31, 2022 from the sale of units of the product developed in the context of these development services.</span></td></tr> </table> <p id="xdx_8A7_zfcpHU4lR9l2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>b.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Revenues by geographical area (based on the location of customers)</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.4pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89C_eus-gaap--RevenueFromExternalCustomersByGeographicAreasTableTextBlock_zFTv5ZR7D0Ul" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following is a summary of revenues within geographic areas:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B3_zNXQ5135dgw3" style="display: none">SCHEDULE OF REVENUES WITHIN GEOGRAPHIC AREAS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.75in"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_498_20220101__20221231_z6P75j7yzWBh" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_498_20210101__20211231_zTGZowwFLvdb" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year ended on <br/> December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD in thousands</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--StatementGeographicalAxis__country--US_zXM69xDvCM4f" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United States</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">553</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">273</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--StatementGeographicalAxis__country--GB_zwKZmaxqge15" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United Kingdom</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">48</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--StatementGeographicalAxis__country--IL_zGMmDHJk9Egf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0950">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--StatementGeographicalAxis__custom--OtherMember_zQk3yRGjG2u4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_ze9Omtxh7azl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"> Revenue</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">665</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">387</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8AE_zeU9mfnpTIAj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>c.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Major customers</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_897_eus-gaap--ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_zWNVzxLfYOed" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set forth below is a breakdown of Company’s revenue by major customers (major customer –revenues from these customers constituted at least 10% of total revenues in a certain year):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B3_zedaQ7piT6u2">SCHEDULE OF MAJOR CUSTOMER BREAKDOWN OF COMPANY’S REVENUE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.75in"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year ended on</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD in thousands</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer A</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerAMember_zklhey6Hdfg1" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Revenues"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">538</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20211231__srt--MajorCustomersAxis__custom--CustomerAMember_zU8e5yR1wfnc" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Revenues"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0963">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer B</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerBMember_zubGpEM2wYX8" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Revenues"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0965">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20211231__srt--MajorCustomersAxis__custom--CustomerBMember_z2dHw8QhmjSc" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Revenues"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">199</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer C</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerCMember_z7RVLlbgj6Ic" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Revenues"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20211231__srt--MajorCustomersAxis__custom--CustomerCMember_zYwzKHOJgNKd" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Revenues"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">48</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8AC_zxjG0gxA7FM" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>d.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contract fulfillment assets and Contract liabilities:</b></span></td></tr> </table> <p id="xdx_899_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_gL3CWCAALTTB-SOP_zKHIA2x0s8D" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_zETGhGIR7RH3" style="display: none">SCHEDULE OF CONTRACT FULFILLMENT ASSETS AND CONTRACT LIABILITIES</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.75in"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_495_20221231_z2e4qOoiLBvd" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49E_20211231_z2PPX3ApHgV7" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD in thousands</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_400_eus-gaap--ContractWithCustomerAssetNet_iI_zANK1Jocx9n3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract fulfillment assets:</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,495</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,675</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_ze0HDwiKeRU2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,644</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,420</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A5_zkfGwSz9SXKg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract liabilities include advance payments, which are primarily related to advanced billings for development services.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span id="xdx_C09_gL3CWCAALTTB-SOP_zmoycMI9cQKg"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <div id="xdx_C05_gL3CWCAALTTB-SOP_zr71Gx5DsNFb"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The change in contract fulfillment assets:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"/> <table cellpadding="0" cellspacing="0" id="xdx_30F_134_zdwhuRQiCIVf" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.75in" summary="xdx: Disclosure - SCHEDULE OF CONTRACT FULFILLMENT ASSETS AND CONTRACT LIABILITIES (Details)"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_493_20220101__20221231_ziykXgMlL1Re" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49E_20210101__20211231_zt4UPiAZtzr2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD in thousands</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_eus-gaap--ContractWithCustomerAssetNet_iS_pn3n3_z9MOXT9CQqvd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance at beginning of year</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,675</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,130</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_eus-gaap--ContractWithCustomerAssetPurchase_pn3n3_zawNeljGbyU5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additions during the year</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0987">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">545</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_405_ecustom--ContractWithCustomerAssetContractCosts_pn3n3_ziGyqfcLz241" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract costs recognized during the period</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(180</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0991">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_eus-gaap--ContractWithCustomerAssetNet_iE_pn3n3_zwYBkbFwPSk5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance at end of year</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,495</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,675</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The change in contract liabilities:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <table cellpadding="0" cellspacing="0" id="xdx_303_134_zYXu9wgzw7fc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.75in" summary="xdx: Disclosure - SCHEDULE OF CONTRACT FULFILLMENT ASSETS AND CONTRACT LIABILITIES (Details)"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49E_20220101__20221231_zqbpiIlJJCEg" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49B_20210101__20211231_zefdtLCLXwM6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD in thousands</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_400_eus-gaap--ContractWithCustomerLiability_iS_pn3n3_zYEgCqh86k11" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance at beginning of year</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,420</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">848</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_406_ecustom--ContractWithCustomerLiabilityDeferredRevenueRelatingToNewSales_pn3n3_zr3DFrWDEIPd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred revenue relating to new sales</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,613</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,641</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_403_ecustom--ContractWithCustomerLiabilityRevenueRecognizedDevelopmentServices_pn3n3_z8uC049mPW63" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue recognized during the year</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(389</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(69</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_407_eus-gaap--ContractWithCustomerLiability_iE_pn3n3_zg1wSQY5Dna9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance at end of year</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,644</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,420</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_C07_gL3CWCAALTTB-SOP_z9ZQMJvo7zOb"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Remaining Performance Obligations</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Remaining Performance Obligations (“RPO”) represents contracted revenue that has not yet been recognized, which includes deferred revenue and amounts that will be recognized as revenue in future periods. As of December 31, 2022, the total RPO amounted to $<span id="xdx_901_eus-gaap--RevenueRemainingPerformanceObligation_iI_pn3n3_c20221231_zbwqcc3sNXs8" title="Remaining performance obligations">3,644</span> thousand, which the Company expects to recognize over the expected manufacturing term of the product under development.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SCOUTCAM INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89D_eus-gaap--DisaggregationOfRevenueTableTextBlock_z0cDHvkgMbRk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b><span style="display: none">SCHEDULE OF DISAGGREGATION OF REVENUE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.75in"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year ended on <br/> December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD in thousands</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Development Services (customer A) (*)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20221231__srt--ProductOrServiceAxis__us-gaap--ServiceMember_fKCop_zaxWPCRCwPGd" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Revenues"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">317</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20211231__srt--ProductOrServiceAxis__us-gaap--ServiceMember_fKCop_zgs6V5GjNx7h" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Revenues"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0922">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Products</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20221231__srt--ProductOrServiceAxis__us-gaap--ProductMember_zUUKf8gMzsRj" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Revenues"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">348</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20211231__srt--ProductOrServiceAxis__us-gaap--ProductMember_zt49ZMRK31mc" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Revenues"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">387</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20221231_z00u3iP4xv41" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Revenues"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">665</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20211231_zT8UNHD1odQf" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Revenues"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">387</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <table cellpadding="0" cellspacing="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span id="xdx_F0B_z15N4osjkuBi" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(*)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1D_zkOi78S6av12" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the second quarter of 2022, the Company completed the development of the product relating to a customer-specific project for a Fortune <span class="xdx_phnt_RGlzY2xvc3VyZSAtICBTQ0hFRFVMRSBPRiBESVNBR0dSRUdBVElPTiBPRiBSRVZFTlVFIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_903_ecustom--DevelopmentExpense_c20220401__20220630__srt--TitleOfIndividualAxis__custom--CustomerAMember_zLrl2EBiGByf" title="Development expense">500</span> multinational healthcare corporation (“Customer A”) and moved from the development phase of the project to its production phase. As a result, during the year ended December 31, 2022, the Company recognized development services revenues and related development costs that had been previously deferred, in the amounts of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtICBTQ0hFRFVMRSBPRiBESVNBR0dSRUdBVElPTiBPRiBSRVZFTlVFIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_902_eus-gaap--CostOfRevenue_pn3n3_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--ServiceMember_zJnLP0MgUEu3" title="Revenues from development services">317</span> thousand and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtICBTQ0hFRFVMRSBPRiBESVNBR0dSRUdBVElPTiBPRiBSRVZFTlVFIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_903_eus-gaap--CostOfRevenue_pn3n3_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelatedDevelopmentCostsMember_zCZIhGvZHhHa" title="Revenues from development services">180</span> thousand, respectively. The amounts were recognized based on the expected manufacturing term of the product, which the Company estimates at <span class="xdx_phnt_RGlzY2xvc3VyZSAtICBTQ0hFRFVMRSBPRiBESVNBR0dSRUdBVElPTiBPRiBSRVZFTlVFIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_c20220101__20221231_zAJwLSuagEU4" title="Estimated useful life">7 years</span>.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, following the commencement of the production phase, the Company recognized product revenues of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtICBTQ0hFRFVMRSBPRiBESVNBR0dSRUdBVElPTiBPRiBSRVZFTlVFIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--CostOfRevenue_pn3n3_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--ProductMember_zjgdZtwmkMa6">221 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">thousands during the year ended December 31, 2022 from the sale of units of the product developed in the context of these development services.</span></td></tr> </table> 317000 348000 387000 665000 387000 500000 317000 180000 P7Y 221000 <p id="xdx_89C_eus-gaap--RevenueFromExternalCustomersByGeographicAreasTableTextBlock_zFTv5ZR7D0Ul" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following is a summary of revenues within geographic areas:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B3_zNXQ5135dgw3" style="display: none">SCHEDULE OF REVENUES WITHIN GEOGRAPHIC AREAS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.75in"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_498_20220101__20221231_z6P75j7yzWBh" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_498_20210101__20211231_zTGZowwFLvdb" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year ended on <br/> December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD in thousands</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--StatementGeographicalAxis__country--US_zXM69xDvCM4f" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United States</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">553</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">273</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--StatementGeographicalAxis__country--GB_zwKZmaxqge15" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United Kingdom</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">48</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--StatementGeographicalAxis__country--IL_zGMmDHJk9Egf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0950">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--StatementGeographicalAxis__custom--OtherMember_zQk3yRGjG2u4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_ze9Omtxh7azl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"> Revenue</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">665</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">387</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 553000 273000 65000 48000 19000 47000 47000 665000 387000 <p id="xdx_897_eus-gaap--ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_zWNVzxLfYOed" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set forth below is a breakdown of Company’s revenue by major customers (major customer –revenues from these customers constituted at least 10% of total revenues in a certain year):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B3_zedaQ7piT6u2">SCHEDULE OF MAJOR CUSTOMER BREAKDOWN OF COMPANY’S REVENUE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.75in"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year ended on</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD in thousands</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer A</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerAMember_zklhey6Hdfg1" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Revenues"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">538</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20211231__srt--MajorCustomersAxis__custom--CustomerAMember_zU8e5yR1wfnc" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Revenues"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0963">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer B</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerBMember_zubGpEM2wYX8" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Revenues"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0965">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20211231__srt--MajorCustomersAxis__custom--CustomerBMember_z2dHw8QhmjSc" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Revenues"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">199</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer C</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerCMember_z7RVLlbgj6Ic" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Revenues"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210101__20211231__srt--MajorCustomersAxis__custom--CustomerCMember_zYwzKHOJgNKd" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Revenues"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">48</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 538000 199000 65000 48000 <p id="xdx_899_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_gL3CWCAALTTB-SOP_zKHIA2x0s8D" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_zETGhGIR7RH3" style="display: none">SCHEDULE OF CONTRACT FULFILLMENT ASSETS AND CONTRACT LIABILITIES</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.75in"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_495_20221231_z2e4qOoiLBvd" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49E_20211231_z2PPX3ApHgV7" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD in thousands</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_400_eus-gaap--ContractWithCustomerAssetNet_iI_zANK1Jocx9n3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract fulfillment assets:</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,495</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,675</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_ze0HDwiKeRU2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,644</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,420</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The change in contract fulfillment assets:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"/> <table cellpadding="0" cellspacing="0" id="xdx_30F_134_zdwhuRQiCIVf" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.75in" summary="xdx: Disclosure - SCHEDULE OF CONTRACT FULFILLMENT ASSETS AND CONTRACT LIABILITIES (Details)"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_493_20220101__20221231_ziykXgMlL1Re" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49E_20210101__20211231_zt4UPiAZtzr2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD in thousands</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_eus-gaap--ContractWithCustomerAssetNet_iS_pn3n3_z9MOXT9CQqvd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance at beginning of year</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,675</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,130</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_eus-gaap--ContractWithCustomerAssetPurchase_pn3n3_zawNeljGbyU5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additions during the year</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0987">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">545</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_405_ecustom--ContractWithCustomerAssetContractCosts_pn3n3_ziGyqfcLz241" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract costs recognized during the period</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(180</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0991">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_eus-gaap--ContractWithCustomerAssetNet_iE_pn3n3_zwYBkbFwPSk5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance at end of year</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,495</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,675</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The change in contract liabilities:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <table cellpadding="0" cellspacing="0" id="xdx_303_134_zYXu9wgzw7fc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.75in" summary="xdx: Disclosure - SCHEDULE OF CONTRACT FULFILLMENT ASSETS AND CONTRACT LIABILITIES (Details)"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49E_20220101__20221231_zqbpiIlJJCEg" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49B_20210101__20211231_zefdtLCLXwM6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD in thousands</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_400_eus-gaap--ContractWithCustomerLiability_iS_pn3n3_zYEgCqh86k11" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance at beginning of year</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,420</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">848</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_406_ecustom--ContractWithCustomerLiabilityDeferredRevenueRelatingToNewSales_pn3n3_zr3DFrWDEIPd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred revenue relating to new sales</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,613</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,641</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_403_ecustom--ContractWithCustomerLiabilityRevenueRecognizedDevelopmentServices_pn3n3_z8uC049mPW63" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue recognized during the year</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(389</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(69</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_407_eus-gaap--ContractWithCustomerLiability_iE_pn3n3_zg1wSQY5Dna9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance at end of year</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,644</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,420</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table>   1495000 1675000 3644000 2420000 1675000 1130000 545000 -180000 1495000 1675000 2420000 848000 1613000 1641000 -389000 -69000 3644000 2420000 3644000 <p id="xdx_803_eus-gaap--LesseeOperatingLeasesTextBlock_zWf7EniP6ihb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.6pt; text-align: justify; text-indent: -49.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 11 - <span id="xdx_822_z57P32zbdeA3">LEASES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 31, 2022, the Group’s ROU assets and lease liabilities for operating leases totaled $<span id="xdx_909_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20221231_zq3ORVV5WVMf" title="Operating lease, right-of-use asset">307</span> thousand and $<span id="xdx_908_eus-gaap--OperatingLeaseLiability_iI_pn3n3_c20221231_zLAAn1OnEyc5" title="Operating lease, liability">263</span> thousand, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 31, 2021, the Group’s ROU assets and lease liabilities for operating leases totaled $<span id="xdx_901_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20211231_zD2Gmc1an6Vf" title="Operating lease, right-of-use asset">482</span> thousand and $<span id="xdx_900_eus-gaap--OperatingLeaseLiability_iI_pn3n3_c20211231_zXr99p6D95L1" title="Operating lease, liability">459</span> thousand, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--LesseeOperatingLeaseDescription_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_zr8HrEMjQHOc" title="Lessee, operating lease, description">In December 2020, ScoutCam entered into a lease agreement for office space in Omer, Israel. The agreement is for 36 months beginning January 1, 2021</span>. In March 2021, ScoutCam entered into a lease agreement for additional office space in Omer, Israel. The agreement is until December 31, 2023. Monthly lease payments under the agreements are approximately $<span id="xdx_90F_eus-gaap--OperatingLeasePayments_pn3n3_c20220101__20220102__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_zRtHL8bpO3Q9" title="Operating lease, payments">12</span> thousand. ScoutCam subleases part of the office space to a third party for $<span id="xdx_90B_eus-gaap--SubleaseIncome_pn3n3_c20220101__20220102__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_zaLCLzp7rri9" title="Sublease, payments">3</span> thousand per month.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--LesseeOperatingLeaseDescription_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_z4NbGLl9qIqg" title="Lessee, operating lease, description">In December 2022, ScoutCam entered into a lease agreement for office space in Ramat Gan, Israel. The agreement is for 12 months beginning on December 14, 2022.</span> <span>The agreement expires on December 14, 2023, and the Company has an option to extend the lease period for an additional one year. </span>The Company doesn’t expect to extend the lease period. <span style="background-color: white">Therefore, the Company has elected to use the practical expedient regarding short-term leases. </span> Monthly lease payments under the agreements are $<span id="xdx_900_eus-gaap--SubleaseIncome_pn3n3_c20220101__20221231_zCYoNsAUpK2a" title="Sublease income">3</span> thousand.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In addition, the Company leases vehicles under various operating lease agreements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating lease expenses were $<span id="xdx_90B_eus-gaap--OperatingLeaseExpense_pn3n3_c20220101__20221231_z9nh1ALFco05" title="Operating lease expense">264</span> thousand and $<span id="xdx_908_eus-gaap--OperatingLeaseExpense_pn3n3_c20210101__20211231_zDpbCex0EkFh" title="Operating lease expense">202</span> thousand for the years ended December 31, 2022 and 2021, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89C_eus-gaap--ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_zv3s0Gp74cUi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplemental cash flow information related to operating leases during the period presented was as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B4_zhwYkLhKd9Aa" style="display: none">SCHEDULE OF SUPPLEMENTAL CASH FLOW INFORMATION RELATED TO OPERATING LEASES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.75in"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49C_20220101__20221231_z2ZHt10cW7Bc" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_497_20210101__20211231_zR3XPX8wgwxd" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year ended December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD in thousands</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeasePayments_pn3n3_zyiUSLVRyH17" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating cash flows from operating leases</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">261</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">202</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A8_zqe4VCaTDfU5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_ecustom--ScheduleOfLeaseTermAndDiscountRateRelatedToOperatingLeasesTableTextBlock_zLI3m8rMCwU5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease term and discount rate related to operating leases as of the period presented were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B4_zJf1m0QVtHP7" style="display: none">SCHEDULE OF LEASE TERM AND DISCOUNT RATE RELATED TO OPERATING LEASES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.75in"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD in thousands</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted-average remaining lease term (in years)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231_zeKtanFOhxPk" title="Weighted-average remaining lease term (in years)">0.84</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20211231_zAZdxQ9UoDM7" title="Weighted-average remaining lease term (in years)">0.76</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted-average discount rate</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20221231_ziovQcMNkug2" title="Weighted-average discount rate">6</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20211231_zrAkUH8HgO5" title="Weighted-average discount rate">6</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> </table> <p id="xdx_8A4_zjmsQ4D992y9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_890_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zrnqQ6s3Lbz8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The maturities of lease liabilities under operating leases as of December 31, 2022 are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_znpOlhghPzy5" style="display: none">SCHEDULE OF MATURITIES LEASE LIABILITIES UNDER OPERATING LEASES</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"/> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49D_20221231_zuaKEbsTQSak" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD in thousands</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPz8To_zfJSP6vIQugl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">206</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPz8To_zTdNEAtTCTqa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maLOLLPz8To_zVc602u6HAze" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPz8To_zIlalCIDDPi3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total undiscounted lease payments</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">276</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zLS4uUB5VnBl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less: Imputed interest</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(13</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_401_eus-gaap--OperatingLeaseLiability_iI_pn3n3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total lease liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">263</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A8_z6eiZYrGg1Le" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 307000 263000 482000 459000 In December 2020, ScoutCam entered into a lease agreement for office space in Omer, Israel. The agreement is for 36 months beginning January 1, 2021 12000 3000 In December 2022, ScoutCam entered into a lease agreement for office space in Ramat Gan, Israel. The agreement is for 12 months beginning on December 14, 2022. 3000 264000 202000 <p id="xdx_89C_eus-gaap--ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_zv3s0Gp74cUi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplemental cash flow information related to operating leases during the period presented was as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B4_zhwYkLhKd9Aa" style="display: none">SCHEDULE OF SUPPLEMENTAL CASH FLOW INFORMATION RELATED TO OPERATING LEASES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.75in"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49C_20220101__20221231_z2ZHt10cW7Bc" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_497_20210101__20211231_zR3XPX8wgwxd" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year ended December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD in thousands</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeasePayments_pn3n3_zyiUSLVRyH17" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating cash flows from operating leases</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">261</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">202</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 261000 202000 <p id="xdx_891_ecustom--ScheduleOfLeaseTermAndDiscountRateRelatedToOperatingLeasesTableTextBlock_zLI3m8rMCwU5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease term and discount rate related to operating leases as of the period presented were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B4_zJf1m0QVtHP7" style="display: none">SCHEDULE OF LEASE TERM AND DISCOUNT RATE RELATED TO OPERATING LEASES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.75in"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD in thousands</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted-average remaining lease term (in years)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231_zeKtanFOhxPk" title="Weighted-average remaining lease term (in years)">0.84</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20211231_zAZdxQ9UoDM7" title="Weighted-average remaining lease term (in years)">0.76</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted-average discount rate</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20221231_ziovQcMNkug2" title="Weighted-average discount rate">6</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20211231_zrAkUH8HgO5" title="Weighted-average discount rate">6</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> </table> P0Y10M2D P0Y9M3D 0.06 0.06 <p id="xdx_890_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zrnqQ6s3Lbz8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The maturities of lease liabilities under operating leases as of December 31, 2022 are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_znpOlhghPzy5" style="display: none">SCHEDULE OF MATURITIES LEASE LIABILITIES UNDER OPERATING LEASES</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"/> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49D_20221231_zuaKEbsTQSak" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD in thousands</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPz8To_zfJSP6vIQugl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">206</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPz8To_zTdNEAtTCTqa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maLOLLPz8To_zVc602u6HAze" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPz8To_zIlalCIDDPi3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total undiscounted lease payments</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">276</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zLS4uUB5VnBl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less: Imputed interest</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(13</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_401_eus-gaap--OperatingLeaseLiability_iI_pn3n3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total lease liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">263</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 206000 54000 16000 276000 13000 263000 <p id="xdx_803_eus-gaap--ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_zGM2tKt488r1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.6pt; text-align: justify; text-indent: -49.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 12 – <span id="xdx_825_zUBD2vlU1gGe">RESEARCH AND DEVELOPMENT EXPENSES</span>:</b></span></p> <p id="xdx_898_ecustom--ScheduleOfResearchAndDevelopmentExpenseTableTextBlock_zRYRNeCqfXGg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.6pt; text-align: justify; text-indent: -49.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b><span id="xdx_8BE_zuuHE6V7pae7" style="display: none">SCHEDULE OF RESEARCH AND DEVELOPMENT EXPENSES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_491_20220101__20221231_zke8xrOzCG89" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49F_20210101__20211231_zOqo5B58t8A1" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year ended December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD in thousands</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_eus-gaap--SalariesAndWages_pn3n3_maRADEzp1i_zIAVIAW0pYMh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Salaries and related expense</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,034</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">894</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_404_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_maRADEzp1i_z07LfdXVvLVf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based compensation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">576</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">257</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_403_ecustom--MaterialsAndSubcontractors_pn3n3_maRADEzp1i_zWbYDyyhV5fl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Materials and subcontractors</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,030</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">655</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40C_eus-gaap--DepreciationNonproduction_pn3n3_maRADEzp1i_zzN4VEHalEBd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">163</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_eus-gaap--TravelAndEntertainmentExpense_pn3n3_maRADEzp1i_znVrA7ik0x5a" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Travel expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1080">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_ecustom--VehicleExpenses_pn3n3_maRADEzp1i_z6escGEmnwN6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vehicle expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">75</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40C_ecustom--RentAndMaintenanceAndOtherExpenses_pn3n3_maRADEzp1i_zhb1hQ1xMxb8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rent and maintenance and other expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">246</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">131</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpense_iT_pn3n3_mtRADEzp1i_zL2tZgsRHHAc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"> Research and Development expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,197</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,002</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8AE_zXB7S1yVzY84" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_898_ecustom--ScheduleOfResearchAndDevelopmentExpenseTableTextBlock_zRYRNeCqfXGg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.6pt; text-align: justify; text-indent: -49.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b><span id="xdx_8BE_zuuHE6V7pae7" style="display: none">SCHEDULE OF RESEARCH AND DEVELOPMENT EXPENSES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_491_20220101__20221231_zke8xrOzCG89" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49F_20210101__20211231_zOqo5B58t8A1" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year ended December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD in thousands</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_eus-gaap--SalariesAndWages_pn3n3_maRADEzp1i_zIAVIAW0pYMh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Salaries and related expense</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,034</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">894</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_404_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_maRADEzp1i_z07LfdXVvLVf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based compensation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">576</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">257</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_403_ecustom--MaterialsAndSubcontractors_pn3n3_maRADEzp1i_zWbYDyyhV5fl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Materials and subcontractors</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,030</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">655</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40C_eus-gaap--DepreciationNonproduction_pn3n3_maRADEzp1i_zzN4VEHalEBd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">163</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_eus-gaap--TravelAndEntertainmentExpense_pn3n3_maRADEzp1i_znVrA7ik0x5a" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Travel expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1080">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_ecustom--VehicleExpenses_pn3n3_maRADEzp1i_z6escGEmnwN6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vehicle expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">75</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40C_ecustom--RentAndMaintenanceAndOtherExpenses_pn3n3_maRADEzp1i_zhb1hQ1xMxb8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rent and maintenance and other expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">246</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">131</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpense_iT_pn3n3_mtRADEzp1i_zL2tZgsRHHAc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"> Research and Development expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,197</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,002</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 2034000 894000 576000 257000 1030000 655000 163000 39000 73000 75000 26000 246000 131000 4197000 2002000 <p id="xdx_801_ecustom--GeneralAndAdministrativeDisclosureTextBlock_zmyETG6Kpx8k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-indent: -63.8pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 13 – <span id="xdx_821_zn6PZKLRwSHg">GENERAL AND ADMINISTRATIVE EXPENSES</span>:</b></span></p> <p id="xdx_89F_ecustom--ScheduleOfGeneralAndAdministrativeExpenseTableTextBlock_zDVoxzDGKNv1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.6pt; text-align: justify; text-indent: -49.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_znnqtnwhFMm2" style="display: none">SCHEDULE OF GENERAL AND ADMINISTRATIVE EXPENSES</span><b> </b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49C_20220101__20221231_zOrVcGhKemug" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_499_20210101__20211231_zclIF3p82pEj" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year ended December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD in thousands</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_405_eus-gaap--LaborAndRelatedExpense_pn3n3_maGAAEzAKv_ziLwCmKROsjd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Salaries and related expense</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,027</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,144</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_ecustom--ShareBasedCompensationIncludedInGeneralAndAdministartiveExpenses_pn3n3_maGAAEzAKv_zqA3fQL33It4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based compensation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">903</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,483</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_401_eus-gaap--ProfessionalAndContractServicesExpense_pn3n3_maGAAEzAKv_zcNsv2SO1vc6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Professional services</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">859</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,193</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_409_ecustom--Patents_pn3n3_maGAAEzAKv_zghsPt6E9Pl8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patents</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">292</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">798</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40B_ecustom--DepreciationIncludedInGeneralAndAdministartiveExpenses_pn3n3_maGAAEzAKv_z8pEDt9YPkn9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_eus-gaap--GeneralInsuranceExpense_pn3n3_maGAAEzAKv_zoOX4vhwW46a" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insurance</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">337</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">386</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_409_ecustom--VehicleExpensesIncludedInGeneralAndAdministartiveExpenses_pn3n3_maGAAEzAKv_zU6QD3EnJ2d1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vehicle expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_404_eus-gaap--OtherGeneralAndAdministrativeExpense_pn3n3_maGAAEzAKv_zWm7H0HUHMZ1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rent and maintenance and other expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">181</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">120</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_409_eus-gaap--IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_pn3n3_maGAAEzAKv_zFpKxPLItN65" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">VAT provision (note 7e)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(129</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">229</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_401_eus-gaap--GeneralAndAdministrativeExpense_iT_pn3n3_mtGAAEzAKv_zUZ7o5gtd6Zd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"> General and Administrative expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,577</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,481</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8AC_zWHO9ayFuNk1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_89F_ecustom--ScheduleOfGeneralAndAdministrativeExpenseTableTextBlock_zDVoxzDGKNv1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.6pt; text-align: justify; text-indent: -49.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_znnqtnwhFMm2" style="display: none">SCHEDULE OF GENERAL AND ADMINISTRATIVE EXPENSES</span><b> </b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49C_20220101__20221231_zOrVcGhKemug" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_499_20210101__20211231_zclIF3p82pEj" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year ended December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD in thousands</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_405_eus-gaap--LaborAndRelatedExpense_pn3n3_maGAAEzAKv_ziLwCmKROsjd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Salaries and related expense</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,027</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,144</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_ecustom--ShareBasedCompensationIncludedInGeneralAndAdministartiveExpenses_pn3n3_maGAAEzAKv_zqA3fQL33It4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based compensation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">903</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,483</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_401_eus-gaap--ProfessionalAndContractServicesExpense_pn3n3_maGAAEzAKv_zcNsv2SO1vc6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Professional services</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">859</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,193</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_409_ecustom--Patents_pn3n3_maGAAEzAKv_zghsPt6E9Pl8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patents</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">292</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">798</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40B_ecustom--DepreciationIncludedInGeneralAndAdministartiveExpenses_pn3n3_maGAAEzAKv_z8pEDt9YPkn9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_eus-gaap--GeneralInsuranceExpense_pn3n3_maGAAEzAKv_zoOX4vhwW46a" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insurance</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">337</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">386</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_409_ecustom--VehicleExpensesIncludedInGeneralAndAdministartiveExpenses_pn3n3_maGAAEzAKv_zU6QD3EnJ2d1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vehicle expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_404_eus-gaap--OtherGeneralAndAdministrativeExpense_pn3n3_maGAAEzAKv_zWm7H0HUHMZ1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rent and maintenance and other expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">181</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">120</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_409_eus-gaap--IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_pn3n3_maGAAEzAKv_zFpKxPLItN65" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">VAT provision (note 7e)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(129</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">229</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_401_eus-gaap--GeneralAndAdministrativeExpense_iT_pn3n3_mtGAAEzAKv_zUZ7o5gtd6Zd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"> General and Administrative expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,577</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,481</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 1027000 1144000 903000 1483000 859000 1193000 292000 798000 34000 29000 337000 386000 73000 99000 181000 120000 -129000 229000 3577000 5481000 <p id="xdx_80A_eus-gaap--SubsequentEventsTextBlock_z5hUxQgfaiqa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 14 - <span id="xdx_820_z9UEiPzBpaLj">SUBSEQUENT EVENTS</span>:</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 16, 2023, the Company consummated Stock Purchase Agreements for a private placement with (i) Moshe Arkin through his individual retirement account and (ii) The Phoenix Insurance Company Ltd. and Shotfut Menayot Israel – Phoenix Amitim, in connection with the sale and issuance of an aggregate amount of <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230315__20230316__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zxnqBFRCJWSd" title="Issuance of units">3,294,117</span> units (collectively, the “Units”), at a purchase price of $<span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20230316__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_znMgmWkv4lc8" title="Purchase price">4.25</span> per Unit, and for an aggregate purchase price of $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230315__20230316__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zh94mjbDcJma" title="Aggregate purchase price">14,000,000</span>. Each Unit consists of: (i) one share of the Company’s common stock par value $<span id="xdx_908_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_uUSDPShares_c20230316__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zy75ajedHap8" title="Common stock par value, per share">0.001</span> per share (the “Common Stock”) and (ii) one warrant to purchase one share of Common Stock with an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20230316__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zU1pXz8jkjE2" title="Exercise price">5.50</span> (the “Warrants”). The Warrants are immediately exercisable and will expire three<span id="xdx_906_eus-gaap--LineOfCreditFacilityExpirationPeriod_dxL_c20230315__20230316__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVxSoIsiKzX3" title="Warrant exercisable term::XDX::P3Y"/><span style="-sec-ix-hidden: xdx2ixbrl1137"/> years from the date of issuance and will be subject to customary adjustments.</span></p> 3294117 4.25 14000000 0.001 5.50 Represents an amount less than $1 thousand During the second quarter of 2022, the Company completed the development of the product relating to a customer-specific project for a Fortune 500 multinational healthcare corporation (“Customer A”) and moved from the development phase of the project to its production phase. As a result, during the year ended December 31, 2022, the Company recognized development services revenues and related development costs that had been previously deferred, in the amounts of $317 thousand and $180 thousand, respectively. The amounts were recognized based on the expected manufacturing term of the product, which the Company estimates at 7 years. EXCEL 80 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 81 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 82 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 83 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 150 287 1 true 56 0 false 5 false false R1.htm 00000001 - Document - Cover Sheet http://Scoutcam.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Consolidated Balance Sheets Sheet http://Scoutcam.com/role/BalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://Scoutcam.com/role/BalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Consolidated Statements of Operations Sheet http://Scoutcam.com/role/StatementsOfOperations Consolidated Statements of Operations Statements 4 false false R5.htm 00000005 - Statement - Consolidated Statements of Changes in Shareholders' Equity Sheet http://Scoutcam.com/role/StatementsOfChangesInShareholdersEquity Consolidated Statements of Changes in Shareholders' Equity Statements 5 false false R6.htm 00000006 - Statement - Consolidated Statements of Cash Flows Sheet http://Scoutcam.com/role/StatementsOfCashFlows Consolidated Statements of Cash Flows Statements 6 false false R7.htm 00000007 - Disclosure - GENERAL Sheet http://Scoutcam.com/role/General GENERAL Notes 7 false false R8.htm 00000008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES Sheet http://Scoutcam.com/role/SignificantAccountingPolicies SIGNIFICANT ACCOUNTING POLICIES Notes 8 false false R9.htm 00000009 - Disclosure - SHORT-TERM DEPOSITS Sheet http://Scoutcam.com/role/Short-termDeposits SHORT-TERM DEPOSITS Notes 9 false false R10.htm 00000010 - Disclosure - INVENTORY Sheet http://Scoutcam.com/role/Inventory INVENTORY Notes 10 false false R11.htm 00000011 - Disclosure - PROPERTY AND EQUIPMENT, NET Sheet http://Scoutcam.com/role/PropertyAndEquipmentNet PROPERTY AND EQUIPMENT, NET Notes 11 false false R12.htm 00000012 - Disclosure - OTHER ACCRUED EXPENSES Sheet http://Scoutcam.com/role/OtherAccruedExpenses OTHER ACCRUED EXPENSES Notes 12 false false R13.htm 00000013 - Disclosure - INCOME TAXES Sheet http://Scoutcam.com/role/IncomeTaxes INCOME TAXES Notes 13 false false R14.htm 00000014 - Disclosure - RELATED PARTIES Sheet http://Scoutcam.com/role/RelatedParties RELATED PARTIES Notes 14 false false R15.htm 00000015 - Disclosure - EQUITY Sheet http://Scoutcam.com/role/Equity EQUITY Notes 15 false false R16.htm 00000016 - Disclosure - REVENUES AND ENTITY WIDE DISCLOSURES Sheet http://Scoutcam.com/role/RevenuesAndEntityWideDisclosures REVENUES AND ENTITY WIDE DISCLOSURES Notes 16 false false R17.htm 00000017 - Disclosure - LEASES Sheet http://Scoutcam.com/role/Leases LEASES Notes 17 false false R18.htm 00000018 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES Sheet http://Scoutcam.com/role/ResearchAndDevelopmentExpenses RESEARCH AND DEVELOPMENT EXPENSES Notes 18 false false R19.htm 00000019 - Disclosure - GENERAL AND ADMINISTRATIVE EXPENSES Sheet http://Scoutcam.com/role/GeneralAndAdministrativeExpenses GENERAL AND ADMINISTRATIVE EXPENSES Notes 19 false false R20.htm 00000020 - Disclosure - SUBSEQUENT EVENTS Sheet http://Scoutcam.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 20 false false R21.htm 00000021 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://Scoutcam.com/role/SignificantAccountingPoliciesPolicies SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 21 false false R22.htm 00000022 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://Scoutcam.com/role/SignificantAccountingPoliciesTables SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://Scoutcam.com/role/SignificantAccountingPolicies 22 false false R23.htm 00000023 - Disclosure - INVENTORY (Tables) Sheet http://Scoutcam.com/role/InventoryTables INVENTORY (Tables) Tables http://Scoutcam.com/role/Inventory 23 false false R24.htm 00000024 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables) Sheet http://Scoutcam.com/role/PropertyAndEquipmentNetTables PROPERTY AND EQUIPMENT, NET (Tables) Tables http://Scoutcam.com/role/PropertyAndEquipmentNet 24 false false R25.htm 00000025 - Disclosure - OTHER ACCRUED EXPENSES (Tables) Sheet http://Scoutcam.com/role/OtherAccruedExpensesTables OTHER ACCRUED EXPENSES (Tables) Tables http://Scoutcam.com/role/OtherAccruedExpenses 25 false false R26.htm 00000026 - Disclosure - INCOME TAXES (Tables) Sheet http://Scoutcam.com/role/IncomeTaxesTables INCOME TAXES (Tables) Tables http://Scoutcam.com/role/IncomeTaxes 26 false false R27.htm 00000027 - Disclosure - RELATED PARTIES (Tables) Sheet http://Scoutcam.com/role/RelatedPartiesTables RELATED PARTIES (Tables) Tables http://Scoutcam.com/role/RelatedParties 27 false false R28.htm 00000028 - Disclosure - EQUITY (Tables) Sheet http://Scoutcam.com/role/EquityTables EQUITY (Tables) Tables http://Scoutcam.com/role/Equity 28 false false R29.htm 00000029 - Disclosure - REVENUES AND ENTITY WIDE DISCLOSURES (Tables) Sheet http://Scoutcam.com/role/RevenuesAndEntityWideDisclosuresTables REVENUES AND ENTITY WIDE DISCLOSURES (Tables) Tables http://Scoutcam.com/role/RevenuesAndEntityWideDisclosures 29 false false R30.htm 00000030 - Disclosure - LEASES (Tables) Sheet http://Scoutcam.com/role/LeasesTables LEASES (Tables) Tables http://Scoutcam.com/role/Leases 30 false false R31.htm 00000031 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES (Tables) Sheet http://Scoutcam.com/role/ResearchAndDevelopmentExpensesTables RESEARCH AND DEVELOPMENT EXPENSES (Tables) Tables http://Scoutcam.com/role/ResearchAndDevelopmentExpenses 31 false false R32.htm 00000032 - Disclosure - GENERAL AND ADMINISTRATIVE EXPENSES (Tables) Sheet http://Scoutcam.com/role/GeneralAndAdministrativeExpensesTables GENERAL AND ADMINISTRATIVE EXPENSES (Tables) Tables http://Scoutcam.com/role/GeneralAndAdministrativeExpenses 32 false false R33.htm 00000033 - Disclosure - GENERAL (Details Narrative) Sheet http://Scoutcam.com/role/GeneralDetailsNarrative GENERAL (Details Narrative) Details http://Scoutcam.com/role/GeneralAndAdministrativeExpensesTables 33 false false R34.htm 00000034 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT ANNUAL DEPRECIATION RATES (Details) Sheet http://Scoutcam.com/role/ScheduleOfPropertyAndEquipmentAnnualDepreciationRatesDetails SCHEDULE OF PROPERTY AND EQUIPMENT ANNUAL DEPRECIATION RATES (Details) Details 34 false false R35.htm 00000035 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://Scoutcam.com/role/SignificantAccountingPoliciesDetailsNarrative SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://Scoutcam.com/role/SignificantAccountingPoliciesTables 35 false false R36.htm 00000036 - Disclosure - SHORT-TERM DEPOSITS (Details Narrative) Sheet http://Scoutcam.com/role/Short-termDepositsDetailsNarrative SHORT-TERM DEPOSITS (Details Narrative) Details http://Scoutcam.com/role/Short-termDeposits 36 false false R37.htm 00000037 - Disclosure - SCHEDULE OF INVENTORY (Details) Sheet http://Scoutcam.com/role/ScheduleOfInventoryDetails SCHEDULE OF INVENTORY (Details) Details 37 false false R38.htm 00000038 - Disclosure - INVENTORY (Details Narrative) Sheet http://Scoutcam.com/role/InventoryDetailsNarrative INVENTORY (Details Narrative) Details http://Scoutcam.com/role/InventoryTables 38 false false R39.htm 00000039 - Disclosure - SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT NET (Details) Sheet http://Scoutcam.com/role/ScheduleOfPropertyPlantAndEquipmentNetDetails SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT NET (Details) Details 39 false false R40.htm 00000040 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details Narrative) Sheet http://Scoutcam.com/role/PropertyAndEquipmentNetDetailsNarrative PROPERTY AND EQUIPMENT, NET (Details Narrative) Details http://Scoutcam.com/role/PropertyAndEquipmentNetTables 40 false false R41.htm 00000041 - Disclosure - SCHEDULE OF OTHER ACCRUED EXPENSES (Details) Sheet http://Scoutcam.com/role/ScheduleOfOtherAccruedExpensesDetails SCHEDULE OF OTHER ACCRUED EXPENSES (Details) Details 41 false false R42.htm 00000042 - Disclosure - SCHEDULE OF COMPONENT OF DEFERRED TAX ASSET (Details) Sheet http://Scoutcam.com/role/ScheduleOfComponentOfDeferredTaxAssetDetails SCHEDULE OF COMPONENT OF DEFERRED TAX ASSET (Details) Details 42 false false R43.htm 00000043 - Disclosure - INCOME TAXES (Details Narrative) Sheet http://Scoutcam.com/role/IncomeTaxesDetailsNarrative INCOME TAXES (Details Narrative) Details http://Scoutcam.com/role/IncomeTaxesTables 43 false false R44.htm 00000044 - Disclosure - SCHEDULE OF BALANCES WITH RELATED PARTIES (Details) Sheet http://Scoutcam.com/role/ScheduleOfBalancesWithRelatedPartiesDetails SCHEDULE OF BALANCES WITH RELATED PARTIES (Details) Details 44 false false R45.htm 00000045 - Disclosure - RELATED PARTIES (Details Narrative) Sheet http://Scoutcam.com/role/RelatedPartiesDetailsNarrative RELATED PARTIES (Details Narrative) Details http://Scoutcam.com/role/RelatedPartiesTables 45 false false R46.htm 00000046 - Disclosure - SCHEDULE OF STOCK WARRANTS OUTSTANDING TO PURCHASE COMMON STOCK (Details) Sheet http://Scoutcam.com/role/ScheduleOfStockWarrantsOutstandingToPurchaseCommonStockDetails SCHEDULE OF STOCK WARRANTS OUTSTANDING TO PURCHASE COMMON STOCK (Details) Details 46 false false R47.htm 00000047 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details) Sheet http://Scoutcam.com/role/ScheduleOfStockOptionActivityDetails SCHEDULE OF STOCK OPTION ACTIVITY (Details) Details 47 false false R48.htm 00000048 - Disclosure - SCHEDULE OF SHARE-BASED PAYMENT,STOCK OPTIONS, VALUATION ASSUMPTIONS (Details) Sheet http://Scoutcam.com/role/ScheduleOfShare-basedPaymentstockOptionsValuationAssumptionsDetails SCHEDULE OF SHARE-BASED PAYMENT,STOCK OPTIONS, VALUATION ASSUMPTIONS (Details) Details 48 false false R49.htm 00000049 - Disclosure - EQUITY (Details Narrative) Sheet http://Scoutcam.com/role/EquityDetailsNarrative EQUITY (Details Narrative) Details http://Scoutcam.com/role/EquityTables 49 false false R50.htm 00000050 - Disclosure - SCHEDULE OF DISAGGREGATION OF REVENUE (Details) Sheet http://Scoutcam.com/role/ScheduleOfDisaggregationOfRevenueDetails SCHEDULE OF DISAGGREGATION OF REVENUE (Details) Details 50 false false R51.htm 00000051 - Disclosure - SCHEDULE OF DISAGGREGATION OF REVENUE (Details) (Parenthetical) Sheet http://Scoutcam.com/role/ScheduleOfDisaggregationOfRevenueDetailsParenthetical SCHEDULE OF DISAGGREGATION OF REVENUE (Details) (Parenthetical) Details 51 false false R52.htm 00000052 - Disclosure - SCHEDULE OF REVENUES WITHIN GEOGRAPHIC AREAS (Details) Sheet http://Scoutcam.com/role/ScheduleOfRevenuesWithinGeographicAreasDetails SCHEDULE OF REVENUES WITHIN GEOGRAPHIC AREAS (Details) Details 52 false false R53.htm 00000053 - Disclosure - SCHEDULE OF MAJOR CUSTOMER BREAKDOWN OF COMPANY???S REVENUE (Details) Sheet http://Scoutcam.com/role/ScheduleOfMajorCustomerBreakdownOfCompanysRevenueDetails SCHEDULE OF MAJOR CUSTOMER BREAKDOWN OF COMPANY???S REVENUE (Details) Details 53 false false R54.htm 00000054 - Disclosure - SCHEDULE OF CONTRACT FULFILLMENT ASSETS AND CONTRACT LIABILITIES (Details) Sheet http://Scoutcam.com/role/ScheduleOfContractFulfillmentAssetsAndContractLiabilitiesDetails SCHEDULE OF CONTRACT FULFILLMENT ASSETS AND CONTRACT LIABILITIES (Details) Details 54 false false R55.htm 00000055 - Disclosure - REVENUES AND ENTITY WIDE DISCLOSURES (Details Narrative) Sheet http://Scoutcam.com/role/RevenuesAndEntityWideDisclosuresDetailsNarrative REVENUES AND ENTITY WIDE DISCLOSURES (Details Narrative) Details http://Scoutcam.com/role/RevenuesAndEntityWideDisclosuresTables 55 false false R56.htm 00000056 - Disclosure - SCHEDULE OF SUPPLEMENTAL CASH FLOW INFORMATION RELATED TO OPERATING LEASES (Details) Sheet http://Scoutcam.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesDetails SCHEDULE OF SUPPLEMENTAL CASH FLOW INFORMATION RELATED TO OPERATING LEASES (Details) Details 56 false false R57.htm 00000057 - Disclosure - SCHEDULE OF LEASE TERM AND DISCOUNT RATE RELATED TO OPERATING LEASES (Details) Sheet http://Scoutcam.com/role/ScheduleOfLeaseTermAndDiscountRateRelatedToOperatingLeasesDetails SCHEDULE OF LEASE TERM AND DISCOUNT RATE RELATED TO OPERATING LEASES (Details) Details 57 false false R58.htm 00000058 - Disclosure - SCHEDULE OF MATURITIES LEASE LIABILITIES UNDER OPERATING LEASES (Details) Sheet http://Scoutcam.com/role/ScheduleOfMaturitiesLeaseLiabilitiesUnderOperatingLeasesDetails SCHEDULE OF MATURITIES LEASE LIABILITIES UNDER OPERATING LEASES (Details) Details 58 false false R59.htm 00000059 - Disclosure - LEASES (Details Narrative) Sheet http://Scoutcam.com/role/LeasesDetailsNarrative LEASES (Details Narrative) Details http://Scoutcam.com/role/LeasesTables 59 false false R60.htm 00000060 - Disclosure - SCHEDULE OF RESEARCH AND DEVELOPMENT EXPENSES (Details) Sheet http://Scoutcam.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails SCHEDULE OF RESEARCH AND DEVELOPMENT EXPENSES (Details) Details 60 false false R61.htm 00000061 - Disclosure - SCHEDULE OF GENERAL AND ADMINISTRATIVE EXPENSES (Details) Sheet http://Scoutcam.com/role/ScheduleOfGeneralAndAdministrativeExpensesDetails SCHEDULE OF GENERAL AND ADMINISTRATIVE EXPENSES (Details) Details 61 false false R62.htm 00000062 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) Sheet http://Scoutcam.com/role/SubsequentEventsDetailsNarrative SUBSEQUENT EVENTS (Details Narrative) Details http://Scoutcam.com/role/SubsequentEvents 62 false false All Reports Book All Reports [dq-0542-Deprecated-Concept] Concept AccountsPayableRelatedPartiesCurrent in us-gaap/2022 used in 10 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. form10-k.htm 52, 53, 54, 8958, 8959, 10959, 10964, 10969, 10972, 10973 [dq-0542-Deprecated-Concept] Concept PropertyPlantAndEquipmentEstimatedUsefulLives in us-gaap/2022 used in 1 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. form10-k.htm 10065 [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 3 fact(s) appearing in ix:hidden were eligible for transformation: SCTC:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1, us-gaap:LineOfCreditFacilityExpirationPeriod, us-gaap:RetainedEarningsAccumulatedDeficit - form10-k.htm 48, 55, 65 form10-k.htm ex10-23.htm ex10-3.htm ex10-4.htm ex10-5.htm ex3-2_1.htm ex31-1.htm ex32-1.htm ex4-1.htm sctc-20221231.xsd sctc-20221231_cal.xml sctc-20221231_def.xml sctc-20221231_lab.xml sctc-20221231_pre.xml form10-k_001.jpg report_001.jpg http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 86 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form10-k.htm": { "axisCustom": 0, "axisStandard": 20, "baseTaxonomies": { "http://fasb.org/us-gaap/2022": 514, "http://xbrl.sec.gov/dei/2022": 36 }, "contextCount": 150, "dts": { "calculationLink": { "local": [ "sctc-20221231_cal.xml" ] }, "definitionLink": { "local": [ "sctc-20221231_def.xml" ] }, "inline": { "local": [ "form10-k.htm" ] }, "labelLink": { "local": [ "sctc-20221231_lab.xml" ] }, "presentationLink": { "local": [ "sctc-20221231_pre.xml" ] }, "schema": { "local": [ "sctc-20221231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 459, "entityCount": 1, "hidden": { "http://Scoutcam.com/20221231": 14, "http://fasb.org/us-gaap/2022": 27, "http://xbrl.sec.gov/dei/2022": 3, "total": 44 }, "keyCustom": 49, "keyStandard": 238, "memberCustom": 24, "memberStandard": 28, "nsprefix": "SCTC", "nsuri": "http://Scoutcam.com/20221231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://Scoutcam.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - INVENTORY", "menuCat": "Notes", "order": "10", "role": "http://Scoutcam.com/role/Inventory", "shortName": "INVENTORY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - PROPERTY AND EQUIPMENT, NET", "menuCat": "Notes", "order": "11", "role": "http://Scoutcam.com/role/PropertyAndEquipmentNet", "shortName": "PROPERTY AND EQUIPMENT, NET", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - OTHER ACCRUED EXPENSES", "menuCat": "Notes", "order": "12", "role": "http://Scoutcam.com/role/OtherAccruedExpenses", "shortName": "OTHER ACCRUED EXPENSES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - INCOME TAXES", "menuCat": "Notes", "order": "13", "role": "http://Scoutcam.com/role/IncomeTaxes", "shortName": "INCOME TAXES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - RELATED PARTIES", "menuCat": "Notes", "order": "14", "role": "http://Scoutcam.com/role/RelatedParties", "shortName": "RELATED PARTIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - EQUITY", "menuCat": "Notes", "order": "15", "role": "http://Scoutcam.com/role/Equity", "shortName": "EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - REVENUES AND ENTITY WIDE DISCLOSURES", "menuCat": "Notes", "order": "16", "role": "http://Scoutcam.com/role/RevenuesAndEntityWideDisclosures", "shortName": "REVENUES AND ENTITY WIDE DISCLOSURES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - LEASES", "menuCat": "Notes", "order": "17", "role": "http://Scoutcam.com/role/Leases", "shortName": "LEASES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES", "menuCat": "Notes", "order": "18", "role": "http://Scoutcam.com/role/ResearchAndDevelopmentExpenses", "shortName": "RESEARCH AND DEVELOPMENT EXPENSES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "SCTC:GeneralAndAdministrativeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - GENERAL AND ADMINISTRATIVE EXPENSES", "menuCat": "Notes", "order": "19", "role": "http://Scoutcam.com/role/GeneralAndAdministrativeExpenses", "shortName": "GENERAL AND ADMINISTRATIVE EXPENSES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "SCTC:GeneralAndAdministrativeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - Consolidated Balance Sheets", "menuCat": "Statements", "order": "2", "role": "http://Scoutcam.com/role/BalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - SUBSEQUENT EVENTS", "menuCat": "Notes", "order": "20", "role": "http://Scoutcam.com/role/SubsequentEvents", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)", "menuCat": "Policies", "order": "21", "role": "http://Scoutcam.com/role/SignificantAccountingPoliciesPolicies", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "SCTC:ScheduleOfPropertyAndEquipmentAnnualDepreciationRatesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)", "menuCat": "Tables", "order": "22", "role": "http://Scoutcam.com/role/SignificantAccountingPoliciesTables", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "SCTC:ScheduleOfPropertyAndEquipmentAnnualDepreciationRatesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - INVENTORY (Tables)", "menuCat": "Tables", "order": "23", "role": "http://Scoutcam.com/role/InventoryTables", "shortName": "INVENTORY (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)", "menuCat": "Tables", "order": "24", "role": "http://Scoutcam.com/role/PropertyAndEquipmentNetTables", "shortName": "PROPERTY AND EQUIPMENT, NET (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:OtherLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - OTHER ACCRUED EXPENSES (Tables)", "menuCat": "Tables", "order": "25", "role": "http://Scoutcam.com/role/OtherAccruedExpensesTables", "shortName": "OTHER ACCRUED EXPENSES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:OtherLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - INCOME TAXES (Tables)", "menuCat": "Tables", "order": "26", "role": "http://Scoutcam.com/role/IncomeTaxesTables", "shortName": "INCOME TAXES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - RELATED PARTIES (Tables)", "menuCat": "Tables", "order": "27", "role": "http://Scoutcam.com/role/RelatedPartiesTables", "shortName": "RELATED PARTIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - EQUITY (Tables)", "menuCat": "Tables", "order": "28", "role": "http://Scoutcam.com/role/EquityTables", "shortName": "EQUITY (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - REVENUES AND ENTITY WIDE DISCLOSURES (Tables)", "menuCat": "Tables", "order": "29", "role": "http://Scoutcam.com/role/RevenuesAndEntityWideDisclosuresTables", "shortName": "REVENUES AND ENTITY WIDE DISCLOSURES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "span", "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://Scoutcam.com/role/BalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "span", "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - LEASES (Tables)", "menuCat": "Tables", "order": "30", "role": "http://Scoutcam.com/role/LeasesTables", "shortName": "LEASES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "SCTC:ScheduleOfResearchAndDevelopmentExpenseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES (Tables)", "menuCat": "Tables", "order": "31", "role": "http://Scoutcam.com/role/ResearchAndDevelopmentExpensesTables", "shortName": "RESEARCH AND DEVELOPMENT EXPENSES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "SCTC:ScheduleOfResearchAndDevelopmentExpenseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "SCTC:GeneralAndAdministrativeDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "SCTC:ScheduleOfGeneralAndAdministrativeExpenseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - GENERAL AND ADMINISTRATIVE EXPENSES (Tables)", "menuCat": "Tables", "order": "32", "role": "http://Scoutcam.com/role/GeneralAndAdministrativeExpensesTables", "shortName": "GENERAL AND ADMINISTRATIVE EXPENSES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "SCTC:GeneralAndAdministrativeDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "SCTC:ScheduleOfGeneralAndAdministrativeExpenseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "span", "p", "td", "tr", "table", "us-gaap:NatureOfOperations", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-08-082021-08-09", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityReverseStockSplit", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000033 - Disclosure - GENERAL (Details Narrative)", "menuCat": "Details", "order": "33", "role": "http://Scoutcam.com/role/GeneralDetailsNarrative", "shortName": "GENERAL (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "td", "tr", "table", "us-gaap:NatureOfOperations", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-08-082021-08-09", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityReverseStockSplit", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "SCTC:ScheduleOfPropertyAndEquipmentAnnualDepreciationRatesTableTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-012022-12-31_us-gaap_MachineryAndEquipmentMember_srt_MinimumMember", "decimals": "INF", "first": true, "lang": null, "name": "SCTC:PropertyPlantAndEquipmentAnnualDepreciationRates", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000034 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT ANNUAL DEPRECIATION RATES (Details)", "menuCat": "Details", "order": "34", "role": "http://Scoutcam.com/role/ScheduleOfPropertyAndEquipmentAnnualDepreciationRatesDetails", "shortName": "SCHEDULE OF PROPERTY AND EQUIPMENT ANNUAL DEPRECIATION RATES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "SCTC:ScheduleOfPropertyAndEquipmentAnnualDepreciationRatesTableTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-012022-12-31_us-gaap_MachineryAndEquipmentMember_srt_MinimumMember", "decimals": "INF", "first": true, "lang": null, "name": "SCTC:PropertyPlantAndEquipmentAnnualDepreciationRates", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "span", "span", "p", "us-gaap:TradeAndOtherAccountsReceivablePolicy", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000035 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "menuCat": "Details", "order": "35", "role": "http://Scoutcam.com/role/SignificantAccountingPoliciesDetailsNarrative", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "span", "p", "us-gaap:TradeAndOtherAccountsReceivablePolicy", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:ShortTermDebtTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000036 - Disclosure - SHORT-TERM DEPOSITS (Details Narrative)", "menuCat": "Details", "order": "36", "role": "http://Scoutcam.com/role/Short-termDepositsDetailsNarrative", "shortName": "SHORT-TERM DEPOSITS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:ShortTermDebtTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsAndSupplies", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000037 - Disclosure - SCHEDULE OF INVENTORY (Details)", "menuCat": "Details", "order": "37", "role": "http://Scoutcam.com/role/ScheduleOfInventoryDetails", "shortName": "SCHEDULE OF INVENTORY (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsAndSupplies", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "span", "span", "p", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryWriteDown", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000038 - Disclosure - INVENTORY (Details Narrative)", "menuCat": "Details", "order": "38", "role": "http://Scoutcam.com/role/InventoryDetailsNarrative", "shortName": "INVENTORY (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "span", "p", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryWriteDown", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000039 - Disclosure - SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT NET (Details)", "menuCat": "Details", "order": "39", "role": "http://Scoutcam.com/role/ScheduleOfPropertyPlantAndEquipmentNetDetails", "shortName": "SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT NET (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - Consolidated Statements of Operations", "menuCat": "Statements", "order": "4", "role": "http://Scoutcam.com/role/StatementsOfOperations", "shortName": "Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:GrossProfit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000040 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details Narrative)", "menuCat": "Details", "order": "40", "role": "http://Scoutcam.com/role/PropertyAndEquipmentNetDetailsNarrative", "shortName": "PROPERTY AND EQUIPMENT, NET (Details Narrative)", "subGroupType": "details", "uniqueAnchor": null }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:OtherLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "SCTC:InternalRevenueService", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000041 - Disclosure - SCHEDULE OF OTHER ACCRUED EXPENSES (Details)", "menuCat": "Details", "order": "41", "role": "http://Scoutcam.com/role/ScheduleOfOtherAccruedExpensesDetails", "shortName": "SCHEDULE OF OTHER ACCRUED EXPENSES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:OtherLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "SCTC:InternalRevenueService", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000042 - Disclosure - SCHEDULE OF COMPONENT OF DEFERRED TAX ASSET (Details)", "menuCat": "Details", "order": "42", "role": "http://Scoutcam.com/role/ScheduleOfComponentOfDeferredTaxAssetDetails", "shortName": "SCHEDULE OF COMPONENT OF DEFERRED TAX ASSET (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:OperatingLossCarryforwardsValuationAllowance", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsGross", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000043 - Disclosure - INCOME TAXES (Details Narrative)", "menuCat": "Details", "order": "43", "role": "http://Scoutcam.com/role/IncomeTaxesDetailsNarrative", "shortName": "INCOME TAXES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember", "decimals": "-3", "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccountsPayableRelatedPartiesCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000044 - Disclosure - SCHEDULE OF BALANCES WITH RELATED PARTIES (Details)", "menuCat": "Details", "order": "44", "role": "http://Scoutcam.com/role/ScheduleOfBalancesWithRelatedPartiesDetails", "shortName": "SCHEDULE OF BALANCES WITH RELATED PARTIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31_custom_DirectorsMember", "decimals": "-3", "lang": null, "name": "us-gaap:AccountsPayableRelatedPartiesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000045 - Disclosure - RELATED PARTIES (Details Narrative)", "menuCat": "Details", "order": "45", "role": "http://Scoutcam.com/role/RelatedPartiesDetailsNarrative", "shortName": "RELATED PARTIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-012022-12-31_custom_WarrantMarchTwoThousandTwentyOneMember", "decimals": null, "first": true, "lang": "en-US", "name": "SCTC:WarrantAndRightsOutstandingIssuanceDate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000046 - Disclosure - SCHEDULE OF STOCK WARRANTS OUTSTANDING TO PURCHASE COMMON STOCK (Details)", "menuCat": "Details", "order": "46", "role": "http://Scoutcam.com/role/ScheduleOfStockWarrantsOutstandingToPurchaseCommonStockDetails", "shortName": "SCHEDULE OF STOCK WARRANTS OUTSTANDING TO PURCHASE COMMON STOCK (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-012022-12-31_custom_WarrantMarchTwoThousandTwentyOneMember", "decimals": null, "first": true, "lang": "en-US", "name": "SCTC:WarrantAndRightsOutstandingIssuanceDate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000047 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)", "menuCat": "Details", "order": "47", "role": "http://Scoutcam.com/role/ScheduleOfStockOptionActivityDetails", "shortName": "SCHEDULE OF STOCK OPTION ACTIVITY (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-012020-12-31", "decimals": null, "lang": "en-US", "name": "SCTC:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000048 - Disclosure - SCHEDULE OF SHARE-BASED PAYMENT,STOCK OPTIONS, VALUATION ASSUMPTIONS (Details)", "menuCat": "Details", "order": "48", "role": "http://Scoutcam.com/role/ScheduleOfShare-basedPaymentstockOptionsValuationAssumptionsDetails", "shortName": "SCHEDULE OF SHARE-BASED PAYMENT,STOCK OPTIONS, VALUATION ASSUMPTIONS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000049 - Disclosure - EQUITY (Details Narrative)", "menuCat": "Details", "order": "49", "role": "http://Scoutcam.com/role/EquityDetailsNarrative", "shortName": "EQUITY (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31_us-gaap_CommonStockMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - Consolidated Statements of Changes in Shareholders' Equity", "menuCat": "Statements", "order": "5", "role": "http://Scoutcam.com/role/StatementsOfChangesInShareholdersEquity", "shortName": "Consolidated Statements of Changes in Shareholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31_us-gaap_CommonStockMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000050 - Disclosure - SCHEDULE OF DISAGGREGATION OF REVENUE (Details)", "menuCat": "Details", "order": "50", "role": "http://Scoutcam.com/role/ScheduleOfDisaggregationOfRevenueDetails", "shortName": "SCHEDULE OF DISAGGREGATION OF REVENUE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-012022-12-31_us-gaap_ServiceMember", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CostOfRevenue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000051 - Disclosure - SCHEDULE OF DISAGGREGATION OF REVENUE (Details) (Parenthetical)", "menuCat": "Details", "order": "51", "role": "http://Scoutcam.com/role/ScheduleOfDisaggregationOfRevenueDetailsParenthetical", "shortName": "SCHEDULE OF DISAGGREGATION OF REVENUE (Details) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "link:footnote", "span", "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000052 - Disclosure - SCHEDULE OF REVENUES WITHIN GEOGRAPHIC AREAS (Details)", "menuCat": "Details", "order": "52", "role": "http://Scoutcam.com/role/ScheduleOfRevenuesWithinGeographicAreasDetails", "shortName": "SCHEDULE OF REVENUES WITHIN GEOGRAPHIC AREAS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-012022-12-31_country_US", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000053 - Disclosure - SCHEDULE OF MAJOR CUSTOMER BREAKDOWN OF COMPANY\u2019S REVENUE (Details)", "menuCat": "Details", "order": "53", "role": "http://Scoutcam.com/role/ScheduleOfMajorCustomerBreakdownOfCompanysRevenueDetails", "shortName": "SCHEDULE OF MAJOR CUSTOMER BREAKDOWN OF COMPANY\u2019S REVENUE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-012022-12-31_custom_CustomerAMember", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerAssetNet", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000054 - Disclosure - SCHEDULE OF CONTRACT FULFILLMENT ASSETS AND CONTRACT LIABILITIES (Details)", "menuCat": "Details", "order": "54", "role": "http://Scoutcam.com/role/ScheduleOfContractFulfillmentAssetsAndContractLiabilitiesDetails", "shortName": "SCHEDULE OF CONTRACT FULFILLMENT ASSETS AND CONTRACT LIABILITIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:ContractWithCustomerAssetNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueRemainingPerformanceObligation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000055 - Disclosure - REVENUES AND ENTITY WIDE DISCLOSURES (Details Narrative)", "menuCat": "Details", "order": "55", "role": "http://Scoutcam.com/role/RevenuesAndEntityWideDisclosuresDetailsNarrative", "shortName": "REVENUES AND ENTITY WIDE DISCLOSURES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueRemainingPerformanceObligation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000056 - Disclosure - SCHEDULE OF SUPPLEMENTAL CASH FLOW INFORMATION RELATED TO OPERATING LEASES (Details)", "menuCat": "Details", "order": "56", "role": "http://Scoutcam.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesDetails", "shortName": "SCHEDULE OF SUPPLEMENTAL CASH FLOW INFORMATION RELATED TO OPERATING LEASES (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R57": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "SCTC:ScheduleOfLeaseTermAndDiscountRateRelatedToOperatingLeasesTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000057 - Disclosure - SCHEDULE OF LEASE TERM AND DISCOUNT RATE RELATED TO OPERATING LEASES (Details)", "menuCat": "Details", "order": "57", "role": "http://Scoutcam.com/role/ScheduleOfLeaseTermAndDiscountRateRelatedToOperatingLeasesDetails", "shortName": "SCHEDULE OF LEASE TERM AND DISCOUNT RATE RELATED TO OPERATING LEASES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "SCTC:ScheduleOfLeaseTermAndDiscountRateRelatedToOperatingLeasesTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000058 - Disclosure - SCHEDULE OF MATURITIES LEASE LIABILITIES UNDER OPERATING LEASES (Details)", "menuCat": "Details", "order": "58", "role": "http://Scoutcam.com/role/ScheduleOfMaturitiesLeaseLiabilitiesUnderOperatingLeasesDetails", "shortName": "SCHEDULE OF MATURITIES LEASE LIABILITIES UNDER OPERATING LEASES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000059 - Disclosure - LEASES (Details Narrative)", "menuCat": "Details", "order": "59", "role": "http://Scoutcam.com/role/LeasesDetailsNarrative", "shortName": "LEASES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:SubleaseIncome", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - Consolidated Statements of Cash Flows", "menuCat": "Statements", "order": "6", "role": "http://Scoutcam.com/role/StatementsOfCashFlows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "SCTC:ScheduleOfResearchAndDevelopmentExpenseTableTextBlock", "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SalariesAndWages", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000060 - Disclosure - SCHEDULE OF RESEARCH AND DEVELOPMENT EXPENSES (Details)", "menuCat": "Details", "order": "60", "role": "http://Scoutcam.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails", "shortName": "SCHEDULE OF RESEARCH AND DEVELOPMENT EXPENSES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "SCTC:ScheduleOfResearchAndDevelopmentExpenseTableTextBlock", "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SalariesAndWages", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "SCTC:ScheduleOfGeneralAndAdministrativeExpenseTableTextBlock", "SCTC:GeneralAndAdministrativeDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LaborAndRelatedExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000061 - Disclosure - SCHEDULE OF GENERAL AND ADMINISTRATIVE EXPENSES (Details)", "menuCat": "Details", "order": "61", "role": "http://Scoutcam.com/role/ScheduleOfGeneralAndAdministrativeExpensesDetails", "shortName": "SCHEDULE OF GENERAL AND ADMINISTRATIVE EXPENSES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "SCTC:ScheduleOfGeneralAndAdministrativeExpenseTableTextBlock", "SCTC:GeneralAndAdministrativeDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LaborAndRelatedExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "span", "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000062 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)", "menuCat": "Details", "order": "62", "role": "http://Scoutcam.com/role/SubsequentEventsDetailsNarrative", "shortName": "SUBSEQUENT EVENTS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2023-03-152023-03-16_custom_StockPurchaseAgreementsMember_us-gaap_SubsequentEventMember", "decimals": "INF", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000007 - Disclosure - GENERAL", "menuCat": "Notes", "order": "7", "role": "http://Scoutcam.com/role/General", "shortName": "GENERAL", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES", "menuCat": "Notes", "order": "8", "role": "http://Scoutcam.com/role/SignificantAccountingPolicies", "shortName": "SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShortTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - SHORT-TERM DEPOSITS", "menuCat": "Notes", "order": "9", "role": "http://Scoutcam.com/role/Short-termDeposits", "shortName": "SHORT-TERM DEPOSITS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShortTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 56, "tag": { "SCTC_AccruedExpensesCurrent": { "auth_ref": [], "calculation": { "http://Scoutcam.com/role/ScheduleOfOtherAccruedExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued expenses, current.", "label": "Accrued expenses" } } }, "localname": "AccruedExpensesCurrent", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/ScheduleOfOtherAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "SCTC_AgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreement [Member]", "label": "Agreement [Member]" } } }, "localname": "AgreementMember", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "domainItemType" }, "SCTC_BoardOfDirectorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Board of Directors [Member]", "label": "Board of Directors [Member]" } } }, "localname": "BoardOfDirectorsMember", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "SCTC_CommonStockExceedingPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock exceeding percentage.", "label": "Common stock percent" } } }, "localname": "CommonStockExceedingPercentage", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative" ], "xbrltype": "percentItemType" }, "SCTC_ConsultantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Consultant [Member]", "label": "Consultant [Member]" } } }, "localname": "ConsultantMember", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "SCTC_ContractWithCustomerAssetContractCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Contract with customer asset contract costs.", "label": "Contract costs recognized during the period" } } }, "localname": "ContractWithCustomerAssetContractCosts", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/ScheduleOfContractFulfillmentAssetsAndContractLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "SCTC_ContractWithCustomerLiabilityDeferredRevenueRelatingToNewSales": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred revenue relating to new sales.", "label": "Deferred revenue relating to new sales" } } }, "localname": "ContractWithCustomerLiabilityDeferredRevenueRelatingToNewSales", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/ScheduleOfContractFulfillmentAssetsAndContractLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "SCTC_ContractWithCustomerLiabilityRevenueRecognizedDevelopmentServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contract with customer liability revenue recognized development services.", "label": "Revenue recognized during the year" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognizedDevelopmentServices", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/ScheduleOfContractFulfillmentAssetsAndContractLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "SCTC_CustomerAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer A [Member]", "label": "Customer A [Member]" } } }, "localname": "CustomerAMember", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/ScheduleOfDisaggregationOfRevenueDetailsParenthetical", "http://Scoutcam.com/role/ScheduleOfMajorCustomerBreakdownOfCompanysRevenueDetails" ], "xbrltype": "domainItemType" }, "SCTC_CustomerBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer B [Member]", "label": "Customer B [Member]" } } }, "localname": "CustomerBMember", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/ScheduleOfMajorCustomerBreakdownOfCompanysRevenueDetails" ], "xbrltype": "domainItemType" }, "SCTC_CustomerCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer C [Member]", "label": "Customer C [Member]" } } }, "localname": "CustomerCMember", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/ScheduleOfMajorCustomerBreakdownOfCompanysRevenueDetails" ], "xbrltype": "domainItemType" }, "SCTC_DepreciationIncludedInGeneralAndAdministartiveExpenses": { "auth_ref": [], "calculation": { "http://Scoutcam.com/role/ScheduleOfGeneralAndAdministrativeExpensesDetails": { "order": 5.0, "parentTag": "us-gaap_GeneralAndAdministrativeExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of general and administrative expense classified as depreciation.", "label": "DepreciationIncludedInGeneralAndAdministartiveExpenses", "verboseLabel": "Depreciation" } } }, "localname": "DepreciationIncludedInGeneralAndAdministartiveExpenses", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/ScheduleOfGeneralAndAdministrativeExpensesDetails" ], "xbrltype": "monetaryItemType" }, "SCTC_DevelopmentExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Development expense", "label": "Development expense" } } }, "localname": "DevelopmentExpense", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/ScheduleOfDisaggregationOfRevenueDetailsParenthetical" ], "xbrltype": "monetaryItemType" }, "SCTC_DirectorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Directors [Member]", "label": "Directors [Member]" } } }, "localname": "DirectorsMember", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/ScheduleOfBalancesWithRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "SCTC_DisclosureGeneralAndAdministrativeExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "General And Administrative Expenses", "verboseLabel": "Schedule Of General And Administrative Expenses" } } }, "localname": "DisclosureGeneralAndAdministrativeExpensesAbstract", "nsuri": "http://Scoutcam.com/20221231", "xbrltype": "stringItemType" }, "SCTC_DisclosureLeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases", "terseLabel": "Schedule Of Lease Term And Discount Rate Related To Operating Leases", "verboseLabel": "Schedule Of Supplemental Cash Flow Information Related To Operating Leases" } } }, "localname": "DisclosureLeasesAbstract", "nsuri": "http://Scoutcam.com/20221231", "xbrltype": "stringItemType" }, "SCTC_EmployeeAndDirectorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employee and Directors [Member]", "label": "Employee and Directors [Member]" } } }, "localname": "EmployeeAndDirectorsMember", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "SCTC_EmployeesConsultantsDirectorsAndOtherServiceProvidersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employees, Consultants, Directors and Other Service Providers [Member]", "label": "Employees, Consultants, Directors and Other Service Providers [Member]" } } }, "localname": "EmployeesConsultantsDirectorsAndOtherServiceProvidersMember", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "SCTC_ExerciseOfWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Exercise of warrants.", "label": "Exercise of warrants (see note 9)" } } }, "localname": "ExerciseOfWarrants", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/StatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "SCTC_ExerciseOfWarrantsRequiredNotToInvestReturnForSharesOfCommonStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Exercise of warrants required not to invest return for shares of common stock.", "label": "ExerciseOfWarrantsRequiredNotToInvestReturnForSharesOfCommonStock", "verboseLabel": "Exercise of warrants required to invest return for shares of common stock" } } }, "localname": "ExerciseOfWarrantsRequiredNotToInvestReturnForSharesOfCommonStock", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "SCTC_ExerciseOfWarrantsRequiredToInvestReturnForSharesOfCommonStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Exercise of warrants required to invest return for shares of common stock.", "label": "Exercise of warrants required to invest return for shares of common stock" } } }, "localname": "ExerciseOfWarrantsRequiredToInvestReturnForSharesOfCommonStock", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "SCTC_ExerciseOfWarrantsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise of warrants shares.", "label": "Exercise of warrants, shares" } } }, "localname": "ExerciseOfWarrantsShares", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/StatementsOfChangesInShareholdersEquity" ], "xbrltype": "sharesItemType" }, "SCTC_FinancingIncomeExpensesNet": { "auth_ref": [], "calculation": { "http://Scoutcam.com/role/StatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Financing income expenses net.", "label": "FINANCING INCOME (EXPENSES), NET" } } }, "localname": "FinancingIncomeExpensesNet", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "SCTC_GainOrLossOnExchangeFromOperatingLeaseLiability": { "auth_ref": [], "calculation": { "http://Scoutcam.com/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gain or loss on exchange from operating lease liability.", "label": "GainOrLossOnExchangeFromOperatingLeaseLiability", "negatedLabel": "Profit from exchange differences from operating lease liabilities" } } }, "localname": "GainOrLossOnExchangeFromOperatingLeaseLiability", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "SCTC_GeneralAndAdministrativeDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "General and Administrative Disclosure [Text Block]", "label": "GeneralAndAdministrativeDisclosureTextBlock", "verboseLabel": "GENERAL AND ADMINISTRATIVE EXPENSES" } } }, "localname": "GeneralAndAdministrativeDisclosureTextBlock", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/GeneralAndAdministrativeExpenses" ], "xbrltype": "textBlockItemType" }, "SCTC_IncreaseDecreaseInRightOfUseAsset": { "auth_ref": [], "calculation": { "http://Scoutcam.com/role/StatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in right-of-use asset.", "label": "Decrease (increase) in ROU asset" } } }, "localname": "IncreaseDecreaseInRightOfUseAsset", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "SCTC_InterestIncomeInRespectOfDeposits": { "auth_ref": [], "calculation": { "http://Scoutcam.com/role/StatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Interest income in respect of deposits.", "label": "InterestIncomeInRespectOfDeposits", "negatedLabel": "Interest income in respect of deposits" } } }, "localname": "InterestIncomeInRespectOfDeposits", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "SCTC_InternalRevenueService": { "auth_ref": [], "calculation": { "http://Scoutcam.com/role/ScheduleOfOtherAccruedExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Internal revenue service.", "label": "Internal Revenue Services" } } }, "localname": "InternalRevenueService", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/ScheduleOfOtherAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "SCTC_InvestmentCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Investment C [Member]", "label": "Investment C [Member]" } } }, "localname": "InvestmentCMember", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "SCTC_InvestorsCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Investors C [Member]", "label": "Investors C [Member]" } } }, "localname": "InvestorsCMember", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "SCTC_IssuanceExpenses": { "auth_ref": [], "calculation": { "http://Scoutcam.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance expenses.", "label": "IssuanceExpenses", "negatedLabel": "Issuance expenses" } } }, "localname": "IssuanceExpenses", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "SCTC_LeaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease Agreement [Member]", "label": "Lease Agreement [Member]" } } }, "localname": "LeaseAgreementMember", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/LeasesDetailsNarrative" ], "xbrltype": "domainItemType" }, "SCTC_LeaseholdImprovementsOfficeFurnitureAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leasehold Improvements Office Furniture And Equipment [Member]" } } }, "localname": "LeaseholdImprovementsOfficeFurnitureAndEquipmentMember", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/ScheduleOfPropertyPlantAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "SCTC_LetterAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Letter Agreement [Member]", "label": "Letter Agreement [Member]" } } }, "localname": "LetterAgreementMember", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "SCTC_LiabilityForSeverancePay": { "auth_ref": [], "calculation": { "http://Scoutcam.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Liability for severance pay.", "label": "Liability for severance pay" } } }, "localname": "LiabilityForSeverancePay", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "SCTC_MaterialsAndSubcontractors": { "auth_ref": [], "calculation": { "http://Scoutcam.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails": { "order": 3.0, "parentTag": "us-gaap_ResearchAndDevelopmentExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Materials and Sub-contractors.", "label": "Materials and subcontractors" } } }, "localname": "MaterialsAndSubcontractors", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails" ], "xbrltype": "monetaryItemType" }, "SCTC_MedigusLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Medigus Ltd [Member]", "label": "Medigus Ltd [Member]" } } }, "localname": "MedigusLtdMember", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative", "http://Scoutcam.com/role/ScheduleOfBalancesWithRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "SCTC_MonthlySalaryPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Monthly salary percentage.", "label": "Monthly salary percentage" } } }, "localname": "MonthlySalaryPercentage", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "SCTC_NoncashRelatedToIncreaseInPropertyAndEquipmentThroughADecreaseInAdvancesToSuppliers": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Non cash related to increase in property and equipment through a decrease in advances to suppliers.", "label": "Increase in property and equipment through a decrease in advances to suppliers" } } }, "localname": "NoncashRelatedToIncreaseInPropertyAndEquipmentThroughADecreaseInAdvancesToSuppliers", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "SCTC_NumberOfWarrantsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants exercised.", "label": "Number of warrants exercised" } } }, "localname": "NumberOfWarrantsExercised", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "SCTC_NumberOfWarrantsUnexercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants unexercised.", "label": "Number of unexercised warrants" } } }, "localname": "NumberOfWarrantsUnexercised", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "SCTC_OtherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other [Member]" } } }, "localname": "OtherMember", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/ScheduleOfRevenuesWithinGeographicAreasDetails" ], "xbrltype": "domainItemType" }, "SCTC_Patents": { "auth_ref": [], "calculation": { "http://Scoutcam.com/role/ScheduleOfGeneralAndAdministrativeExpensesDetails": { "order": 4.0, "parentTag": "us-gaap_GeneralAndAdministrativeExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Patents.", "label": "Patents" } } }, "localname": "Patents", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/ScheduleOfGeneralAndAdministrativeExpensesDetails" ], "xbrltype": "monetaryItemType" }, "SCTC_PaymentsInvestmentToShortTermDeposits": { "auth_ref": [], "calculation": { "http://Scoutcam.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments investment to short-term deposits.", "label": "PaymentsInvestmentToShortTermDeposits", "negatedLabel": "Investment in short terms deposits" } } }, "localname": "PaymentsInvestmentToShortTermDeposits", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "SCTC_ProceedsFromIssuanceOfSharesAndWarrants": { "auth_ref": [], "calculation": { "http://Scoutcam.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of shares and warrants.", "label": "Proceeds from issuance of shares and warrants" } } }, "localname": "ProceedsFromIssuanceOfSharesAndWarrants", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "SCTC_ProfGoldwasserMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prof Goldwasser [Member]", "label": "Prof Goldwasser [Member]" } } }, "localname": "ProfGoldwasserMember", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "SCTC_PropertyPlantAndEquipmentAnnualDepreciationRates": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Property plant and equipment annual depreciation rates.", "label": "Property and equipment annual depreciation rates" } } }, "localname": "PropertyPlantAndEquipmentAnnualDepreciationRates", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/ScheduleOfPropertyAndEquipmentAnnualDepreciationRatesDetails" ], "xbrltype": "percentItemType" }, "SCTC_RelatedDevelopmentCostsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Development Costs [Member]", "label": "Related Development Costs [Member]" } } }, "localname": "RelatedDevelopmentCostsMember", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/ScheduleOfDisaggregationOfRevenueDetailsParenthetical" ], "xbrltype": "domainItemType" }, "SCTC_RentAndMaintenanceAndOtherExpenses": { "auth_ref": [], "calculation": { "http://Scoutcam.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails": { "order": 7.0, "parentTag": "us-gaap_ResearchAndDevelopmentExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Rent and maintenance and other expenses.", "label": "Rent and maintenance and other expenses" } } }, "localname": "RentAndMaintenanceAndOtherExpenses", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails" ], "xbrltype": "monetaryItemType" }, "SCTC_RoundUpSharesDueToReverseStockSplit": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Round up shares due to reverse stock split.", "label": "Round up of shares due to reverse stock split (see note 9)" } } }, "localname": "RoundUpSharesDueToReverseStockSplit", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/StatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "SCTC_ScheduleOfGeneralAndAdministrativeExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of general and administrative expense [Table Text Block]", "label": "SCHEDULE OF GENERAL AND ADMINISTRATIVE EXPENSES" } } }, "localname": "ScheduleOfGeneralAndAdministrativeExpenseTableTextBlock", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/GeneralAndAdministrativeExpensesTables" ], "xbrltype": "textBlockItemType" }, "SCTC_ScheduleOfLeaseTermAndDiscountRateRelatedToOperatingLeasesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of lease term and discount rate related to operating leases [Table Text Block].", "label": "SCHEDULE OF LEASE TERM AND DISCOUNT RATE RELATED TO OPERATING LEASES" } } }, "localname": "ScheduleOfLeaseTermAndDiscountRateRelatedToOperatingLeasesTableTextBlock", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "SCTC_ScheduleOfPropertyAndEquipmentAnnualDepreciationRatesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of property and equipment annual depreciation rates [Table Text Block]", "label": "SCHEDULE OF PROPERTY AND EQUIPMENT ANNUAL DEPRECIATION RATES" } } }, "localname": "ScheduleOfPropertyAndEquipmentAnnualDepreciationRatesTableTextBlock", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "SCTC_ScheduleOfResearchAndDevelopmentExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Research and Development Expense [Table Text Block]", "label": "SCHEDULE OF RESEARCH AND DEVELOPMENT EXPENSES" } } }, "localname": "ScheduleOfResearchAndDevelopmentExpenseTableTextBlock", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/ResearchAndDevelopmentExpensesTables" ], "xbrltype": "textBlockItemType" }, "SCTC_SeverancePayAsset": { "auth_ref": [], "calculation": { "http://Scoutcam.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Severance pay asset", "label": "Severance pay asset" } } }, "localname": "SeverancePayAsset", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "SCTC_SeverancePayAssetAndLiability": { "auth_ref": [], "calculation": { "http://Scoutcam.com/role/StatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Severance pay asset and liability.", "label": "SeverancePayAssetAndLiability", "negatedLabel": "Severance pay asset and liability" } } }, "localname": "SeverancePayAssetAndLiability", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "SCTC_SeverancePayPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Severance pay [Policy Text Block]", "label": "Severance pay" } } }, "localname": "SeverancePayPolicyTextBlock", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "SCTC_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageRemainingContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageRemainingContractualTerm", "periodEndLabel": "Weighted average grant date fair value per share, unvested and outstanding ending balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageRemainingContractualTerm", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "SCTC_ShareBasedCompensationIncludedInGeneralAndAdministartiveExpenses": { "auth_ref": [], "calculation": { "http://Scoutcam.com/role/ScheduleOfGeneralAndAdministrativeExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_GeneralAndAdministrativeExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Stock-based compensation" } } }, "localname": "ShareBasedCompensationIncludedInGeneralAndAdministartiveExpenses", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/ScheduleOfGeneralAndAdministrativeExpensesDetails" ], "xbrltype": "monetaryItemType" }, "SCTC_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award options granted weighted average remaining contractual term 1.", "label": "Stock option vested term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative" ], "xbrltype": "durationItemType" }, "SCTC_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted average remaning contractual term (years) beginning of the period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "SCTC_ShortTermBankDepositPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Short Term Bank Deposit [Policy Text Block]", "label": "Short-term bank deposits" } } }, "localname": "ShortTermBankDepositPolicyTextBlock", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "SCTC_SmartecRAndDLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Smartec R and D Ltd [Member]", "label": "Smartec R and D Ltd [Member]" } } }, "localname": "SmartecRAndDLtdMember", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/ScheduleOfBalancesWithRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "SCTC_StockIssuedDuringPeriodSharesAndWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issuance of shares and warrants, shares.", "label": "Issuance of shares and warrants,shares" } } }, "localname": "StockIssuedDuringPeriodSharesAndWarrants", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/StatementsOfChangesInShareholdersEquity" ], "xbrltype": "sharesItemType" }, "SCTC_StockIssuedDuringPeriodValueOfSharesAndWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance of shares and warrants.", "label": "Issuance of shares and warrants (see note 9)" } } }, "localname": "StockIssuedDuringPeriodValueOfSharesAndWarrants", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/StatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "SCTC_StockPurchaseAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Purchase Agreements [Member]", "label": "Stock Purchase Agreements [Member]" } } }, "localname": "StockPurchaseAgreementsMember", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "SCTC_TwoThousandAndTwentyShareIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2020 Share Incentive Plan [Member]", "label": "2020 Share Incentive Plan [Member]" } } }, "localname": "TwoThousandAndTwentyShareIncentivePlanMember", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "SCTC_VehicleExpenses": { "auth_ref": [], "calculation": { "http://Scoutcam.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails": { "order": 6.0, "parentTag": "us-gaap_ResearchAndDevelopmentExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Vehicle expenses.", "label": "Vehicle expenses" } } }, "localname": "VehicleExpenses", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails" ], "xbrltype": "monetaryItemType" }, "SCTC_VehicleExpensesIncludedInGeneralAndAdministartiveExpenses": { "auth_ref": [], "calculation": { "http://Scoutcam.com/role/ScheduleOfGeneralAndAdministrativeExpensesDetails": { "order": 7.0, "parentTag": "us-gaap_GeneralAndAdministrativeExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of general and administrative expense classified as vehicle expenses.", "label": "VehicleExpensesIncludedInGeneralAndAdministartiveExpenses", "verboseLabel": "Vehicle expenses" } } }, "localname": "VehicleExpensesIncludedInGeneralAndAdministartiveExpenses", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/ScheduleOfGeneralAndAdministrativeExpensesDetails" ], "xbrltype": "monetaryItemType" }, "SCTC_WarrantAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrant A [Member]", "label": "Warrant A [Member]" } } }, "localname": "WarrantAMember", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "SCTC_WarrantAndRightsOutstandingIssuanceDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrant, issuance date.", "label": "Warrant issuance date" } } }, "localname": "WarrantAndRightsOutstandingIssuanceDate", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/ScheduleOfStockWarrantsOutstandingToPurchaseCommonStockDetails" ], "xbrltype": "dateItemType" }, "SCTC_WarrantBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrant B [Member]", "label": "Warrant B [Member]" } } }, "localname": "WarrantBMember", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "SCTC_WarrantExercisePricePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrant exercise price percentage.", "label": "Warrant exercise price percentage" } } }, "localname": "WarrantExercisePricePercentage", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative" ], "xbrltype": "percentItemType" }, "SCTC_WarrantMarchTwoThousandTwentyOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrant March 2021 [Member]", "label": "Warrant March 2021 [Member]" } } }, "localname": "WarrantMarchTwoThousandTwentyOneMember", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/ScheduleOfStockWarrantsOutstandingToPurchaseCommonStockDetails" ], "xbrltype": "domainItemType" }, "SCTC_WithdrawalShortTermDeposits": { "auth_ref": [], "calculation": { "http://Scoutcam.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Withdrawal short-t erm deposits.", "label": "Withdrawal of short terms deposits" } } }, "localname": "WithdrawalShortTermDeposits", "nsuri": "http://Scoutcam.com/20221231", "presentation": [ "http://Scoutcam.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "country_GB": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED KINGDOM" } } }, "localname": "GB", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfRevenuesWithinGeographicAreasDetails" ], "xbrltype": "domainItemType" }, "country_IL": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ISRAEL" } } }, "localname": "IL", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfRevenuesWithinGeographicAreasDetails" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfRevenuesWithinGeographicAreasDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://Scoutcam.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://Scoutcam.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r437" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://Scoutcam.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r437" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://Scoutcam.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r434", "r436", "r437" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://Scoutcam.com/role/Cover" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r434", "r436", "r437" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://Scoutcam.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r434", "r436", "r437" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://Scoutcam.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://Scoutcam.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://Scoutcam.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://Scoutcam.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r436" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://Scoutcam.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r434", "r436", "r437" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://Scoutcam.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://Scoutcam.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://Scoutcam.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://Scoutcam.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://Scoutcam.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r435" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://Scoutcam.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r423" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://Scoutcam.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r436" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://Scoutcam.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r436" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://Scoutcam.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r438" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://Scoutcam.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://Scoutcam.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r426" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://Scoutcam.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://Scoutcam.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://Scoutcam.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://Scoutcam.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://Scoutcam.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://Scoutcam.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://Scoutcam.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://Scoutcam.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r429" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://Scoutcam.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r425" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://Scoutcam.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://Scoutcam.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://Scoutcam.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r425" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://Scoutcam.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r442" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://Scoutcam.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://Scoutcam.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r425" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://Scoutcam.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://Scoutcam.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r439" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://Scoutcam.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r437" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://Scoutcam.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity public float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://Scoutcam.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r425" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://Scoutcam.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r425" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://Scoutcam.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r425" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://Scoutcam.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r425" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://Scoutcam.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://Scoutcam.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r440" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://Scoutcam.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://Scoutcam.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r434", "r436", "r437" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://Scoutcam.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://Scoutcam.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://Scoutcam.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r436" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://Scoutcam.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r430" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://Scoutcam.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r431" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://Scoutcam.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r424" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://Scoutcam.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r428" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://Scoutcam.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r427" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://Scoutcam.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r432" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://Scoutcam.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r433" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://Scoutcam.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://Scoutcam.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r441" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://Scoutcam.com/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_BoardOfDirectorsChairmanMember": { "auth_ref": [ "r456" ], "lang": { "en-us": { "role": { "label": "Board of Directors Chairman [Member]" } } }, "localname": "BoardOfDirectorsChairmanMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r177", "r411", "r465", "r517" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfMajorCustomerBreakdownOfCompanysRevenueDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r195", "r196", "r197", "r198", "r252", "r358", "r379", "r399", "r400", "r408", "r416", "r422", "r463", "r509", "r510", "r511", "r512", "r513", "r514" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative", "http://Scoutcam.com/role/ScheduleOfPropertyAndEquipmentAnnualDepreciationRatesDetails", "http://Scoutcam.com/role/ScheduleOfShare-basedPaymentstockOptionsValuationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r195", "r196", "r197", "r198", "r252", "r358", "r379", "r399", "r400", "r408", "r416", "r422", "r463", "r509", "r510", "r511", "r512", "r513", "r514" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative", "http://Scoutcam.com/role/ScheduleOfPropertyAndEquipmentAnnualDepreciationRatesDetails", "http://Scoutcam.com/role/ScheduleOfShare-basedPaymentstockOptionsValuationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r177", "r411", "r465", "r517" ], "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfMajorCustomerBreakdownOfCompanysRevenueDetails" ], "xbrltype": "domainItemType" }, "srt_OfficerMember": { "auth_ref": [ "r178" ], "lang": { "en-us": { "role": { "label": "Officer [Member]" } } }, "localname": "OfficerMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r174", "r361", "r409", "r420", "r459", "r460", "r465", "r516" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfDisaggregationOfRevenueDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r174", "r361", "r409", "r420", "r459", "r460", "r465", "r516" ], "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfDisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r195", "r196", "r197", "r198", "r250", "r252", "r281", "r282", "r283", "r357", "r358", "r379", "r399", "r400", "r408", "r416", "r422", "r458", "r463", "r510", "r511", "r512", "r513", "r514" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative", "http://Scoutcam.com/role/ScheduleOfPropertyAndEquipmentAnnualDepreciationRatesDetails", "http://Scoutcam.com/role/ScheduleOfShare-basedPaymentstockOptionsValuationAssumptionsDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r195", "r196", "r197", "r198", "r250", "r252", "r281", "r282", "r283", "r357", "r358", "r379", "r399", "r400", "r408", "r416", "r422", "r458", "r463", "r510", "r511", "r512", "r513", "r514" ], "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative", "http://Scoutcam.com/role/ScheduleOfPropertyAndEquipmentAnnualDepreciationRatesDetails", "http://Scoutcam.com/role/ScheduleOfShare-basedPaymentstockOptionsValuationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r175", "r176", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r410", "r421", "r465" ], "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfRevenuesWithinGeographicAreasDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r175", "r176", "r385", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r410", "r421", "r465" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfRevenuesWithinGeographicAreasDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r456", "r505" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative", "http://Scoutcam.com/role/ScheduleOfDisaggregationOfRevenueDetailsParenthetical" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative", "http://Scoutcam.com/role/ScheduleOfDisaggregationOfRevenueDetailsParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r16", "r419" ], "calculation": { "http://Scoutcam.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableRelatedPartiesCurrent": { "auth_ref": [ "r16", "r88", "r89", "r452" ], "calculation": { "http://Scoutcam.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Related parties", "verboseLabel": "Balances with related parties" } } }, "localname": "AccountsPayableRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/BalanceSheets", "http://Scoutcam.com/role/ScheduleOfBalancesWithRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r179", "r180" ], "calculation": { "http://Scoutcam.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r51", "r114" ], "calculation": { "http://Scoutcam.com/role/ScheduleOfPropertyPlantAndEquipmentNetDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less: accumulated deprecation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfPropertyPlantAndEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfStockWarrantsOutstandingToPurchaseCommonStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [ "r124", "r125", "r327", "r328", "r329", "r330", "r331", "r332" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfStockWarrantsOutstandingToPurchaseCommonStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r8" ], "calculation": { "http://Scoutcam.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r287", "r288", "r289", "r453", "r454", "r455", "r498" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/StatementsOfChangesInShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r73", "r74", "r254" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Stock based compensation (see note 9)" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/StatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r285" ], "calculation": { "http://Scoutcam.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_ResearchAndDevelopmentExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Expenses recorded regarding", "verboseLabel": "Stock-based compensation" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative", "http://Scoutcam.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r116", "r183", "r187" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Accounts receivable, allowance for credit loss" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative", "http://Scoutcam.com/role/IncomeTaxesDetailsNarrative", "http://Scoutcam.com/role/LeasesDetailsNarrative", "http://Scoutcam.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r91", "r95", "r115", "r131", "r165", "r168", "r172", "r185", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r314", "r316", "r322", "r419", "r461", "r462", "r507" ], "calculation": { "http://Scoutcam.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets [Default Label]", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r109", "r120", "r131", "r185", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r314", "r316", "r322", "r419", "r461", "r462", "r507" ], "calculation": { "http://Scoutcam.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CURRENT ASSETS:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsNoncurrent": { "auth_ref": [ "r131", "r185", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r314", "r316", "r322", "r461", "r462", "r507" ], "calculation": { "http://Scoutcam.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.", "label": "Assets, Noncurrent", "totalLabel": "Total non-current assets" } } }, "localname": "AssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NON-CURRENT ASSETS:" } } }, "localname": "AssetsNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r256", "r257", "r258", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r280", "r281", "r282", "r283", "r284" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative", "http://Scoutcam.com/role/EquityTables", "http://Scoutcam.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of preparation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r40" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/SignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r37", "r112", "r401" ], "calculation": { "http://Scoutcam.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r38" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r32", "r37", "r39" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "BALANCE OF CASH AND CASH EQUIVALENTS AT END OF YEAR", "periodStartLabel": "BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r32", "r87" ], "calculation": { "http://Scoutcam.com/role/StatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "INCREASE IN CASH AND CASH EQUIVALENTS" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r223" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Warrant exercise price per share", "terseLabel": "Exercise price", "verboseLabel": "Warrant exerise price per share" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative", "http://Scoutcam.com/role/ScheduleOfStockWarrantsOutstandingToPurchaseCommonStockDetails", "http://Scoutcam.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.", "label": "Warrant exercisable, shares" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r223" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Number of shares of common stock underlying warrants" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfStockWarrantsOutstandingToPurchaseCommonStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/LeasesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": { "auth_ref": [ "r54", "r386" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.", "label": "Legal contingencies" } } }, "localname": "CommitmentsAndContingenciesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r453", "r454", "r498" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative", "http://Scoutcam.com/role/StatementsOfChangesInShareholdersEquity", "http://Scoutcam.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value", "verboseLabel": "Common stock par value, per share" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/BalanceSheetsParenthetical", "http://Scoutcam.com/role/EquityDetailsNarrative", "http://Scoutcam.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "verboseLabel": "Common stock shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/BalanceSheetsParenthetical", "http://Scoutcam.com/role/EquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r7", "r58" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r7", "r419" ], "calculation": { "http://Scoutcam.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, $0.001 par value; 300,000,000 shares authorized as of December 31, 2022 and December 31, 2021, 7,121,737 shares issued and outstanding as of December 31, 2022 and December 31, 2021" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold": { "auth_ref": [ "r448" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit. Other employee benefit expense includes, but is not limited to, service component of net periodic benefit cost for defined benefit plan. Excludes compensation cost in cost of good and service sold.", "label": "Compensation expense" } } }, "localname": "CompensationExpenseExcludingCostOfGoodAndServiceSold", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/RelatedPartiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfPropertyAndEquipmentAnnualDepreciationRatesDetails", "http://Scoutcam.com/role/ScheduleOfPropertyPlantAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r464" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.", "label": "SCHEDULE OF CONTRACT FULFILLMENT ASSETS AND CONTRACT LIABILITIES" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/RevenuesAndEntityWideDisclosuresTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetNet": { "auth_ref": [ "r225", "r227", "r247" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "Contract fulfillment assets:", "periodEndLabel": "Balance at end of year", "periodStartLabel": "Balance at beginning of year" } } }, "localname": "ContractWithCustomerAssetNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfContractFulfillmentAssetsAndContractLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerAssetNetNoncurrent": { "auth_ref": [ "r225", "r227", "r247" ], "calculation": { "http://Scoutcam.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as noncurrent.", "label": "Contract fulfillment assets" } } }, "localname": "ContractWithCustomerAssetNetNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerAssetPurchase": { "auth_ref": [ "r188" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase from purchase of right to consideration in exchange for good or service transferred to customer when right is conditioned on passage of time.", "label": "Additions during the year" } } }, "localname": "ContractWithCustomerAssetPurchase", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfContractFulfillmentAssetsAndContractLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r225", "r226", "r247" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract liabilities", "periodEndLabel": "Balance at end of year", "periodStartLabel": "Balance at beginning of year" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfContractFulfillmentAssetsAndContractLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r225", "r226", "r247" ], "calculation": { "http://Scoutcam.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract liabilities - short term" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "auth_ref": [ "r225", "r226", "r247" ], "calculation": { "http://Scoutcam.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Contract liabilities - long term" } } }, "localname": "ContractWithCustomerLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r28", "r131", "r185", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r322", "r461" ], "calculation": { "http://Scoutcam.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "COST OF REVENUES", "verboseLabel": "Revenues from development services" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfDisaggregationOfRevenueDetailsParenthetical", "http://Scoutcam.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesPolicyTextBlock": { "auth_ref": [ "r466" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.", "label": "Cost of revenues" } } }, "localname": "CostOfSalesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r55", "r209" ], "lang": { "en-us": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Conversion price" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r21", "r208" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/Short-termDepositsDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Maturity term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/Short-termDepositsDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]" } } }, "localname": "DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfDisaggregationOfRevenueDetailsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r299" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Net deferred tax asset before valuation allowance", "verboseLabel": "Valuation allowance" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/IncomeTaxesDetailsNarrative", "http://Scoutcam.com/role/ScheduleOfComponentOfDeferredTaxAssetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r80", "r496" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Net deferred tax" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfComponentOfDeferredTaxAssetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepositsAssetsCurrent": { "auth_ref": [ "r446" ], "calculation": { "http://Scoutcam.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.", "label": "Short terms deposits" } } }, "localname": "DepositsAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r35", "r49" ], "calculation": { "http://Scoutcam.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "verboseLabel": "Depreciation expenses" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/PropertyAndEquipmentNetDetailsNarrative", "http://Scoutcam.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationNonproduction": { "auth_ref": [ "r35", "r49" ], "calculation": { "http://Scoutcam.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails": { "order": 4.0, "parentTag": "us-gaap_ResearchAndDevelopmentExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The expense recognized in the current period that allocates the cost of nonproduction tangible assets over their useful lives.", "label": "Depreciation, Nonproduction", "verboseLabel": "Depreciation" } } }, "localname": "DepreciationNonproduction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfDisaggregationOfRevenueDetails", "http://Scoutcam.com/role/ScheduleOfMajorCustomerBreakdownOfCompanysRevenueDetails", "http://Scoutcam.com/role/ScheduleOfRevenuesWithinGeographicAreasDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r246", "r409", "r410", "r411", "r412", "r413", "r414", "r415" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfDisaggregationOfRevenueDetails", "http://Scoutcam.com/role/ScheduleOfMajorCustomerBreakdownOfCompanysRevenueDetails", "http://Scoutcam.com/role/ScheduleOfRevenuesWithinGeographicAreasDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r465" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "SCHEDULE OF DISAGGREGATION OF REVENUE" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/RevenuesAndEntityWideDisclosuresTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r127", "r139", "r140", "r141", "r142", "r143", "r147", "r148", "r150", "r151", "r152", "r153", "r320", "r321", "r374", "r377", "r405" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Net loss per share (basic and diluted, in USD)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/StatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r41", "r42" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Basic and diluted net loss per common stock" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r501" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "PROFITS FROM EXCHANGE DIFFERENCES ON CASH AND CASH EQUIVALENTS" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r132", "r295", "r308" ], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective income tax rate reconciliation, at federal statutory income tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r18" ], "calculation": { "http://Scoutcam.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued compensation expenses" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r286" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Stock option award weighted average period" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r493" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Stock option award cost not yet recognized" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r58", "r107", "r124", "r125", "r126", "r134", "r135", "r136", "r138", "r144", "r146", "r155", "r186", "r224", "r287", "r288", "r289", "r304", "r305", "r319", "r327", "r328", "r329", "r330", "r331", "r332", "r347", "r380", "r381", "r382" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative", "http://Scoutcam.com/role/ScheduleOfStockWarrantsOutstandingToPurchaseCommonStockDetails", "http://Scoutcam.com/role/StatementsOfChangesInShareholdersEquity", "http://Scoutcam.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.", "label": "Foreign Tax Authority [Member]" } } }, "localname": "ForeignCountryMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r323", "r324", "r325", "r326" ], "calculation": { "http://Scoutcam.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), before Tax", "negatedLabel": "Profit (loss) from exchange differences on cash and cash equivalents" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r334" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Functional currency" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r29" ], "calculation": { "http://Scoutcam.com/role/ScheduleOfGeneralAndAdministrativeExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://Scoutcam.com/role/StatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "GENERAL AND ADMINISTRATIVE EXPENSES", "totalLabel": "General and Administrative expenses" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfGeneralAndAdministrativeExpensesDetails", "http://Scoutcam.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_GeneralInsuranceExpense": { "auth_ref": [ "r29" ], "calculation": { "http://Scoutcam.com/role/ScheduleOfGeneralAndAdministrativeExpensesDetails": { "order": 6.0, "parentTag": "us-gaap_GeneralAndAdministrativeExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The expense in the period incurred with respect to protection provided by insurance entities against risks other than risks associated with production (which are allocated to cost of sales).", "label": "Insurance" } } }, "localname": "GeneralInsuranceExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfGeneralAndAdministrativeExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r27", "r131", "r165", "r167", "r171", "r173", "r185", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r322", "r407", "r461" ], "calculation": { "http://Scoutcam.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "GROSS LOSS" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r24", "r90", "r93", "r100", "r165", "r167", "r171", "r173", "r375", "r407" ], "calculation": { "http://Scoutcam.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "LOSS BEFORE TAXES ON INCOME" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r193", "r194" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r194" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement." } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r76" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes." } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityNameAxis": { "auth_ref": [ "r76" ], "lang": { "en-us": { "role": { "documentation": "Information by name of taxing authority.", "label": "Income Tax Authority, Name [Axis]" } } }, "localname": "IncomeTaxAuthorityNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes." } } }, "localname": "IncomeTaxAuthorityNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r132", "r296", "r297", "r301", "r306", "r309", "r311", "r312", "r313" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r133", "r145", "r146", "r164", "r294", "r307", "r310", "r378" ], "calculation": { "http://Scoutcam.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income tax expense (benefit)", "negatedLabel": "TAXES ON INCOME" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/IncomeTaxesDetailsNarrative", "http://Scoutcam.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability": { "auth_ref": [ "r302" ], "calculation": { "http://Scoutcam.com/role/ScheduleOfGeneralAndAdministrativeExpensesDetails": { "order": 9.0, "parentTag": "us-gaap_GeneralAndAdministrativeExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of income tax expense (benefit) from continuing operations attributable to an adjustment of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity.", "label": "VAT provision (note 7e)" } } }, "localname": "IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfGeneralAndAdministrativeExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r123", "r292", "r293", "r297", "r298", "r300", "r303" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r34" ], "calculation": { "http://Scoutcam.com/role/StatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase in account payables" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r34" ], "calculation": { "http://Scoutcam.com/role/StatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Decrease (increase) in accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties": { "auth_ref": [ "r34" ], "calculation": { "http://Scoutcam.com/role/StatementsOfCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount due to the reporting entity for good and services provided to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, member of their immediate families, affiliates, or other parties with the ability to exert significant influence.", "label": "Increase (Decrease) in Accounts Receivable, Related Parties", "negatedLabel": "Increase in related parties" } } }, "localname": "IncreaseDecreaseInAccountsReceivableRelatedParties", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerAsset": { "auth_ref": [ "r450" ], "calculation": { "http://Scoutcam.com/role/StatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "Increase (Decrease) in Contract with Customer, Asset", "negatedLabel": "Increase (decrease) in contract fulfillment assets" } } }, "localname": "IncreaseDecreaseInContractWithCustomerAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r359", "r450" ], "calculation": { "http://Scoutcam.com/role/StatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase in contract liabilities" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "auth_ref": [ "r34" ], "calculation": { "http://Scoutcam.com/role/StatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Increase (decrease) in accrued compensation expenses" } } }, "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r34" ], "calculation": { "http://Scoutcam.com/role/StatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Decrease (increase) in inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CHANGES IN OPERATING ASSET AND LIABILITY:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [ "r450", "r503" ], "calculation": { "http://Scoutcam.com/role/StatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation for operating lease.", "label": "Increase (decrease) in operating lease liability" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": { "auth_ref": [ "r34" ], "calculation": { "http://Scoutcam.com/role/StatementsOfCashFlows": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid.", "label": "Increase in other accrued expenses" } } }, "localname": "IncreaseDecreaseInOtherAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "auth_ref": [ "r450" ], "calculation": { "http://Scoutcam.com/role/StatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in current assets classified as other.", "label": "Increase (Decrease) in Other Current Assets", "negatedLabel": "Decrease (increase) in other current assets" } } }, "localname": "IncreaseDecreaseInOtherCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r192" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "INVENTORY" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/Inventory" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r443" ], "calculation": { "http://Scoutcam.com/role/ScheduleOfInventoryDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryGross": { "auth_ref": [ "r445" ], "calculation": { "http://Scoutcam.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Inventory" } } }, "localname": "InventoryGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r118", "r402", "r419" ], "calculation": { "http://Scoutcam.com/role/ScheduleOfInventoryDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "totalLabel": "Inventory Net" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r111", "r117", "r154", "r189", "r191", "r192", "r360", "r403" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventories" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterialsAndSupplies": { "auth_ref": [ "r445" ], "calculation": { "http://Scoutcam.com/role/ScheduleOfInventoryDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed.", "label": "Raw materials and supplies" } } }, "localname": "InventoryRawMaterialsAndSupplies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcess": { "auth_ref": [ "r444" ], "calculation": { "http://Scoutcam.com/role/ScheduleOfInventoryDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.", "label": "Work in progress" } } }, "localname": "InventoryWorkInProcess", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWriteDown": { "auth_ref": [ "r190" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.", "label": "Inventory impairment" } } }, "localname": "InventoryWriteDown", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/InventoryDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_IsraelTaxAuthorityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government of Israel.", "label": "Israel Tax Authority [Member]" } } }, "localname": "IsraelTaxAuthorityMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_LaborAndRelatedExpense": { "auth_ref": [ "r448" ], "calculation": { "http://Scoutcam.com/role/ScheduleOfGeneralAndAdministrativeExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_GeneralAndAdministrativeExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.", "label": "Labor and Related Expense", "verboseLabel": "Salaries and related expense" } } }, "localname": "LaborAndRelatedExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfGeneralAndAdministrativeExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r50" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfPropertyAndEquipmentAnnualDepreciationRatesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r338" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "verboseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseDescription": { "auth_ref": [ "r339" ], "lang": { "en-us": { "role": { "documentation": "Description of lessee's operating lease.", "label": "Lessee, operating lease, description" } } }, "localname": "LesseeOperatingLeaseDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/LeasesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r504" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "SCHEDULE OF MATURITIES LEASE LIABILITIES UNDER OPERATING LEASES" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r345" ], "calculation": { "http://Scoutcam.com/role/ScheduleOfMaturitiesLeaseLiabilitiesUnderOperatingLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total undiscounted lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfMaturitiesLeaseLiabilitiesUnderOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r345" ], "calculation": { "http://Scoutcam.com/role/ScheduleOfMaturitiesLeaseLiabilitiesUnderOperatingLeasesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfMaturitiesLeaseLiabilitiesUnderOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r345" ], "calculation": { "http://Scoutcam.com/role/ScheduleOfMaturitiesLeaseLiabilitiesUnderOperatingLeasesDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfMaturitiesLeaseLiabilitiesUnderOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r345" ], "calculation": { "http://Scoutcam.com/role/ScheduleOfMaturitiesLeaseLiabilitiesUnderOperatingLeasesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfMaturitiesLeaseLiabilitiesUnderOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r345" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: Imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfMaturitiesLeaseLiabilitiesUnderOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r346" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "LEASES" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r17", "r131", "r185", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r315", "r316", "r317", "r322", "r406", "r461", "r507", "r508" ], "calculation": { "http://Scoutcam.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "TOTAL LIABILITIES" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r12", "r92", "r97", "r419", "r451", "r457", "r500" ], "calculation": { "http://Scoutcam.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "TOTAL LIABILITIES AND SHAREHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and shareholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r20", "r110", "r131", "r185", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r315", "r316", "r317", "r322", "r419", "r461", "r507", "r508" ], "calculation": { "http://Scoutcam.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CURRENT LIABILITIES:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r1", "r2", "r3", "r4", "r5", "r131", "r185", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r315", "r316", "r317", "r322", "r461", "r507", "r508" ], "calculation": { "http://Scoutcam.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Liabilities, Noncurrent", "totalLabel": "Total non-current liabilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NON-CURRENT LIABILITIES:" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityExpirationPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period remaining on line of credit facility before it terminates, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Warrant exercisable term" } } }, "localname": "LineOfCreditFacilityExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_MachineryAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery and Equipment [Member]" } } }, "localname": "MachineryAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfPropertyAndEquipmentAnnualDepreciationRatesDetails", "http://Scoutcam.com/role/ScheduleOfPropertyPlantAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r156", "r161" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "GENERAL" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/General" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r129" ], "calculation": { "http://Scoutcam.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash flows provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r129" ], "calculation": { "http://Scoutcam.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash flows provided by (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r32", "r33", "r36" ], "calculation": { "http://Scoutcam.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash flows used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r25", "r36", "r94", "r99", "r108", "r121", "r122", "r126", "r131", "r137", "r139", "r140", "r141", "r142", "r145", "r146", "r149", "r165", "r167", "r171", "r173", "r185", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r321", "r322", "r407", "r461" ], "calculation": { "http://Scoutcam.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://Scoutcam.com/role/StatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net loss", "totalLabel": "NET LOSS" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/StatementsOfCashFlows", "http://Scoutcam.com/role/StatementsOfChangesInShareholdersEquity", "http://Scoutcam.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non cash activities" } } }, "localname": "NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumedAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_OfficeEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.", "label": "Office Equipment [Member]" } } }, "localname": "OfficeEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfPropertyAndEquipmentAnnualDepreciationRatesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r165", "r167", "r171", "r173", "r407" ], "calculation": { "http://Scoutcam.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "OPERATING LOSS" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r502" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating lease expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/LeasesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r336" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Total lease liabilities", "verboseLabel": "Operating lease, liability" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/LeasesDetailsNarrative", "http://Scoutcam.com/role/ScheduleOfMaturitiesLeaseLiabilitiesUnderOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r336" ], "calculation": { "http://Scoutcam.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating lease liabilities - short term" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r336" ], "calculation": { "http://Scoutcam.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating lease liabilities - long term" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r337", "r341" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating cash flows from operating leases", "verboseLabel": "Operating lease, payments" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/LeasesDetailsNarrative", "http://Scoutcam.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r335" ], "calculation": { "http://Scoutcam.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating lease right-of-use assets", "verboseLabel": "Operating lease, right-of-use asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/BalanceSheets", "http://Scoutcam.com/role/LeasesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r344", "r418" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Weighted-average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfLeaseTermAndDiscountRateRelatedToOperatingLeasesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r343", "r418" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Weighted-average remaining lease term (in years)" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfLeaseTermAndDiscountRateRelatedToOperatingLeasesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r78" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating loss carryforward", "verboseLabel": "Accumulated tax loss carryforward" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/IncomeTaxesDetailsNarrative", "http://Scoutcam.com/role/ScheduleOfComponentOfDeferredTaxAssetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwardsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Loss Carryforwards [Line Items]" } } }, "localname": "OperatingLossCarryforwardsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwardsTable": { "auth_ref": [ "r79" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.", "label": "Operating Loss Carryforwards [Table]" } } }, "localname": "OperatingLossCarryforwardsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwardsValuationAllowance": { "auth_ref": [ "r77" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized.", "label": "Operating Loss Carryforwards, Valuation Allowance", "negatedLabel": "Valuation allowance" } } }, "localname": "OperatingLossCarryforwardsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfComponentOfDeferredTaxAssetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OptionIndexedToIssuersEquityTypeAxis": { "auth_ref": [ "r57", "r84", "r85", "r86" ], "lang": { "en-us": { "role": { "documentation": "Information by type of freestanding contracts issued by an entity that are indexed to, and potentially settled in, an entity's own stock.", "label": "Option Indexed to Issuer's Equity, Type [Axis]" } } }, "localname": "OptionIndexedToIssuersEquityTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_OptionIndexedToIssuersEquityTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding." } } }, "localname": "OptionIndexedToIssuersEquityTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r18" ], "calculation": { "http://Scoutcam.com/role/BalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://Scoutcam.com/role/ScheduleOfOtherAccruedExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other accrued expenses", "totalLabel": "Total other accrued expenses" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/BalanceSheets", "http://Scoutcam.com/role/ScheduleOfOtherAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r119", "r419" ], "calculation": { "http://Scoutcam.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherGeneralAndAdministrativeExpense": { "auth_ref": [ "r29" ], "calculation": { "http://Scoutcam.com/role/ScheduleOfGeneralAndAdministrativeExpensesDetails": { "order": 8.0, "parentTag": "us-gaap_GeneralAndAdministrativeExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of general and administrative expense classified as other.", "label": "Other General and Administrative Expense", "verboseLabel": "Rent and maintenance and other expenses" } } }, "localname": "OtherGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfGeneralAndAdministrativeExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Liabilities Disclosure [Abstract]" } } }, "localname": "OtherLiabilitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OtherLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for other liabilities.", "label": "OTHER ACCRUED EXPENSES" } } }, "localname": "OtherLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/OtherAccruedExpenses" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherNonoperatingIncome": { "auth_ref": [ "r128" ], "calculation": { "http://Scoutcam.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income related to nonoperating activities, classified as other.", "label": "OTHER INCOME" } } }, "localname": "OtherNonoperatingIncome", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r30" ], "calculation": { "http://Scoutcam.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchase of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PrivatePlacementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.", "label": "Private Placement [Member]" } } }, "localname": "PrivatePlacementMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative", "http://Scoutcam.com/role/RelatedPartiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r31" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from issuance of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "auth_ref": [ "r31" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.", "label": "Proceeds from Issuance of Private Placement" } } }, "localname": "ProceedsFromIssuanceOfPrivatePlacement", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "auth_ref": [ "r31" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.", "label": "Proceeds from issuance of securities offered" } } }, "localname": "ProceedsFromIssuanceOrSaleOfEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromWarrantExercises": { "auth_ref": [ "r449" ], "calculation": { "http://Scoutcam.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.", "label": "Proceeds from exercise of warrants" } } }, "localname": "ProceedsFromWarrantExercises", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative", "http://Scoutcam.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r409" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfDisaggregationOfRevenueDetails", "http://Scoutcam.com/role/ScheduleOfDisaggregationOfRevenueDetailsParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_ProfessionalAndContractServicesExpense": { "auth_ref": [], "calculation": { "http://Scoutcam.com/role/ScheduleOfGeneralAndAdministrativeExpensesDetails": { "order": 3.0, "parentTag": "us-gaap_GeneralAndAdministrativeExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Professional and contract service expense includes cost reimbursements for support services related to contracted projects, outsourced management, technical and staff support.", "label": "Professional services" } } }, "localname": "ProfessionalAndContractServicesExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfGeneralAndAdministrativeExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r52" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfPropertyAndEquipmentAnnualDepreciationRatesDetails", "http://Scoutcam.com/role/ScheduleOfPropertyPlantAndEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r53", "r387", "r388", "r389" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "PROPERTY AND EQUIPMENT, NET" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/PropertyAndEquipmentNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": { "auth_ref": [ "r48" ], "lang": { "en-us": { "role": { "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).", "label": "Property, plant and equipment, description" } } }, "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfPropertyAndEquipmentAnnualDepreciationRatesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r50", "r113" ], "calculation": { "http://Scoutcam.com/role/ScheduleOfPropertyPlantAndEquipmentNetDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Total property and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfPropertyPlantAndEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfPropertyAndEquipmentAnnualDepreciationRatesDetails", "http://Scoutcam.com/role/ScheduleOfPropertyPlantAndEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r52", "r98", "r376", "r419" ], "calculation": { "http://Scoutcam.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 }, "http://Scoutcam.com/role/ScheduleOfPropertyPlantAndEquipmentNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, net", "totalLabel": "Total property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/BalanceSheets", "http://Scoutcam.com/role/ScheduleOfPropertyPlantAndEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r52", "r387", "r388" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property and equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r52" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT NET" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/PropertyAndEquipmentNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r50" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfPropertyAndEquipmentAnnualDepreciationRatesDetails", "http://Scoutcam.com/role/ScheduleOfPropertyPlantAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Estimated useful life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfDisaggregationOfRevenueDetailsParenthetical" ], "xbrltype": "durationItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r251", "r350", "r351" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfBalancesWithRelatedPartiesDetails", "http://Scoutcam.com/role/ScheduleOfDisaggregationOfRevenueDetailsParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "auth_ref": [ "r89", "r350" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transactions with related party during the financial reporting period.", "label": "Consulting expense" } } }, "localname": "RelatedPartyTransactionAmountsOfTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/RelatedPartiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r106", "r350", "r351", "r506" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r106" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party." } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfBalancesWithRelatedPartiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r251", "r350", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r506" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfBalancesWithRelatedPartiesDetails", "http://Scoutcam.com/role/ScheduleOfDisaggregationOfRevenueDetailsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r348", "r349", "r351", "r352", "r353" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "RELATED PARTIES" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/RelatedParties" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Research and Development [Abstract]" } } }, "localname": "ResearchAndDevelopmentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r75", "r101", "r515" ], "calculation": { "http://Scoutcam.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://Scoutcam.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "RESEARCH AND DEVELOPMENT EXPENSES", "totalLabel": "Research and Development expenses" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails", "http://Scoutcam.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r75" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and development costs" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": { "auth_ref": [ "r102" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.", "label": "Research, Development, and Computer Software Disclosure [Text Block]", "verboseLabel": "RESEARCH AND DEVELOPMENT EXPENSES" } } }, "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ResearchAndDevelopmentExpenses" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r41" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/EquityTables" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative", "http://Scoutcam.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r9", "r60", "r96", "r383", "r384", "r419" ], "calculation": { "http://Scoutcam.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit", "verboseLabel": "Retained Earnings (Accumulated Deficit)" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/BalanceSheets", "http://Scoutcam.com/role/GeneralDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r107", "r134", "r135", "r136", "r138", "r144", "r146", "r186", "r287", "r288", "r289", "r304", "r305", "r319", "r380", "r382" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/StatementsOfChangesInShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r162", "r163", "r166", "r169", "r170", "r174", "r175", "r177", "r245", "r246", "r361" ], "calculation": { "http://Scoutcam.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "REVENUES", "terseLabel": "Revenue", "verboseLabel": "Revenues" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfDisaggregationOfRevenueDetails", "http://Scoutcam.com/role/ScheduleOfMajorCustomerBreakdownOfCompanysRevenueDetails", "http://Scoutcam.com/role/ScheduleOfRevenuesWithinGeographicAreasDetails", "http://Scoutcam.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r249", "r404" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r228", "r229", "r230", "r231", "r232", "r233", "r235", "r236", "r248", "r249" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "REVENUES AND ENTITY WIDE DISCLOSURES" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/RevenuesAndEntityWideDisclosures" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.", "label": "SCHEDULE OF REVENUES WITHIN GEOGRAPHIC AREAS" } } }, "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/RevenuesAndEntityWideDisclosuresTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRemainingPerformanceObligation": { "auth_ref": [ "r234" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.", "label": "Remaining performance obligations" } } }, "localname": "RevenueRemainingPerformanceObligation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/RevenuesAndEntityWideDisclosuresDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r342", "r418" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-use assets obtained in exchange for operating lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalariesAndWages": { "auth_ref": [ "r447" ], "calculation": { "http://Scoutcam.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_ResearchAndDevelopmentExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.", "label": "Salaries and related expense" } } }, "localname": "SalariesAndWages", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received on stock transaction after deduction of issuance costs.", "label": "Proceeds from issuance after deducting issuance costs" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockDescriptionOfTransaction": { "auth_ref": [ "r81", "r82", "r83" ], "lang": { "en-us": { "role": { "documentation": "Description of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination.", "label": "Sale of stock, description" } } }, "localname": "SaleOfStockDescriptionOfTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative", "http://Scoutcam.com/role/RelatedPartiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "SCHEDULE OF OTHER ACCRUED EXPENSES" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/OtherAccruedExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.", "label": "SCHEDULE OF SUPPLEMENTAL CASH FLOW INFORMATION RELATED TO OPERATING LEASES" } } }, "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r497" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/LeasesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable": { "auth_ref": [ "r64", "r65" ], "lang": { "en-us": { "role": { "documentation": "Schedule, table or text reflecting arrangements that are not equity-based payments, or pension and other postretirement benefits, with individual employees. The arrangements (for example, profit sharing, deferred bonuses or certain split-dollar life insurance arrangements) are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain amounts at designated future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period and the carrying amount as of the balance sheet date of the related liability.", "label": "Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]" } } }, "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfDisaggregationOfRevenueDetailsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r0", "r13", "r14", "r15" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "SCHEDULE OF INVENTORY" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/InventoryTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r52" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfPropertyAndEquipmentAnnualDepreciationRatesDetails", "http://Scoutcam.com/role/ScheduleOfPropertyPlantAndEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r88", "r89" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfBalancesWithRelatedPartiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.", "label": "SCHEDULE OF BALANCES WITH RELATED PARTIES" } } }, "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/RelatedPartiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.", "label": "SCHEDULE OF MAJOR CUSTOMER BREAKDOWN OF COMPANY\u2019S REVENUE" } } }, "localname": "ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/RevenuesAndEntityWideDisclosuresTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r253", "r255", "r256", "r257", "r258", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r280", "r281", "r282", "r283", "r284" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/EquityTables", "http://Scoutcam.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r67", "r68", "r70" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "SCHEDULE OF STOCK OPTION ACTIVITY" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/EquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r62", "r66" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "SCHEDULE OF STOCK WARRANTS OUTSTANDING TO PURCHASE COMMON STOCK" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/EquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingAndMarketingExpense": { "auth_ref": [], "calculation": { "http://Scoutcam.com/role/StatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.", "label": "SALES AND MARKETING EXPENSES" } } }, "localname": "SellingAndMarketingExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ServiceMember": { "auth_ref": [ "r409" ], "lang": { "en-us": { "role": { "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.", "label": "Service [Member]" } } }, "localname": "ServiceMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfDisaggregationOfRevenueDetails", "http://Scoutcam.com/role/ScheduleOfDisaggregationOfRevenueDetailsParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r34" ], "calculation": { "http://Scoutcam.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Stock based compensation", "verboseLabel": "Compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative", "http://Scoutcam.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.", "label": "Exercise price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfShare-basedPaymentstockOptionsValuationAssumptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfShare-basedPaymentstockOptionsValuationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfShare-basedPaymentstockOptionsValuationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk-free interest rate maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfShare-basedPaymentstockOptionsValuationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk-free interest rate minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfShare-basedPaymentstockOptionsValuationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/EquityTables", "http://Scoutcam.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r417" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Option to purchase" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r262" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Options, Exercisable at end of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r262" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Weighted average exercise price, Exercisable at end of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r266" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Options, outstanding, cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r264" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Options, outstanding, granted", "verboseLabel": "Share based compensation arrangement Options grants in period gross" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative", "http://Scoutcam.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r274" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Weighted average grant date fair value per share, granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock": { "auth_ref": [ "r69" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year.", "label": "SCHEDULE OF SHARE-BASED PAYMENT,STOCK OPTIONS, VALUATION ASSUMPTIONS" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/EquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r72" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "periodEndLabel": "Aggregate Intrinsic Value, Outstanding at end of period", "periodStartLabel": "Aggregate Intrinsic Value, Outstanding at beginning of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r260", "r261" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Options, Outstanding at ending of period", "periodStartLabel": "Options, Outstanding at beginning of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r260", "r261" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted average exercise price, Outstanding at end of period", "periodStartLabel": "Weighted average exercise price, Outstanding at beginning of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r276" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "verboseLabel": "Share-based compensation arrangement by share-based payment award, options, vested in period, fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward": { "auth_ref": [ "r494" ], "lang": { "en-us": { "role": { "documentation": "Number of shares purchased for issuance under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r256", "r257", "r258", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r280", "r281", "r282", "r283", "r284" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative", "http://Scoutcam.com/role/EquityTables", "http://Scoutcam.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r266" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Weighted average exercise price, Cancelled" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r264" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Weighted average exercise price, Granted", "verboseLabel": "Weighted average exercise price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative", "http://Scoutcam.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r259", "r278", "r279", "r280", "r281", "r284", "r290", "r291" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Underlying value of ordinary shares" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfShare-basedPaymentstockOptionsValuationAssumptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r280" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Term of the options (years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfShare-basedPaymentstockOptionsValuationAssumptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r72" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Aggregate Intrinsic Value, Exercisable at end of period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r72" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted average remaning contractual term (years) exercisable at end of the period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of non-vested options forfeited.", "label": "Weighted average grant date fair value per share,vested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of non-vested options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price", "periodEndLabel": "Weighted average grant date fair value per share, unvested and outstanding ending balance", "periodStartLabel": "Weighted average grant date fair value per share, begining of period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r71" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted average remaning contractual term (years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r276" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Estimated average period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "auth_ref": [ "r275" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.", "label": "Share-based compensation arrangement by share-based payment award, options, vested in period, fair value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Issuance of unit, price per unit", "terseLabel": "Purchase price", "verboseLabel": "Shares issued, price per share" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative", "http://Scoutcam.com/role/RelatedPartiesDetailsNarrative", "http://Scoutcam.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/StatementsOfChangesInShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermDebtTextBlock": { "auth_ref": [ "r56" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for short-term debt.", "label": "SHORT-TERM DEPOSITS" } } }, "localname": "ShortTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/Short-termDeposits" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r23", "r58", "r107", "r124", "r125", "r126", "r134", "r135", "r136", "r138", "r144", "r146", "r155", "r186", "r224", "r287", "r288", "r289", "r304", "r305", "r319", "r327", "r328", "r329", "r330", "r331", "r332", "r347", "r380", "r381", "r382" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative", "http://Scoutcam.com/role/ScheduleOfStockWarrantsOutstandingToPurchaseCommonStockDetails", "http://Scoutcam.com/role/StatementsOfChangesInShareholdersEquity", "http://Scoutcam.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfShare-basedPaymentstockOptionsValuationAssumptionsDetails", "http://Scoutcam.com/role/StatementsOfChangesInShareholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r134", "r135", "r136", "r155", "r361" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfShare-basedPaymentstockOptionsValuationAssumptionsDetails", "http://Scoutcam.com/role/StatementsOfChangesInShareholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r22", "r58", "r59", "r60", "r210" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Number of shares issued" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r6", "r7", "r58", "r60" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Issuance of units", "verboseLabel": "Stock issued during period, shares, new issues" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative", "http://Scoutcam.com/role/RelatedPartiesDetailsNarrative", "http://Scoutcam.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": { "auth_ref": [ "r58" ], "lang": { "en-us": { "role": { "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split.", "label": "Round up shares due to reverse stock split, shares" } } }, "localname": "StockIssuedDuringPeriodSharesReverseStockSplits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/StatementsOfChangesInShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r23", "r58", "r60" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Number of shares conversion" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r6", "r7", "r58", "r60" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Aggregate purchase price" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).", "label": "Equity Option [Member]" } } }, "localname": "StockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r7", "r10", "r11", "r47", "r419", "r451", "r457", "r500" ], "calculation": { "http://Scoutcam.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "TOTAL SHAREHOLDERS\u2019 EQUITY" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/BalanceSheets", "http://Scoutcam.com/role/StatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SHAREHOLDERS\u2019 EQUITY:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r63", "r130", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r224", "r318" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "EQUITY" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/Equity" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityReverseStockSplit": { "auth_ref": [ "r61" ], "lang": { "en-us": { "role": { "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.", "label": "Stockholders' equity, reverse stock split" } } }, "localname": "StockholdersEquityReverseStockSplit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/GeneralDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubleaseIncome": { "auth_ref": [ "r340", "r418" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of sublease income excluding finance and operating lease expense.", "label": "Sublease income" } } }, "localname": "SubleaseIncome", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/LeasesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r333", "r355" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r333", "r355" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r333", "r355" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r333", "r355" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r354", "r356" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Different names of stock transactions and the different attributes of each transaction.", "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]" } } }, "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative", "http://Scoutcam.com/role/RelatedPartiesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative", "http://Scoutcam.com/role/RelatedPartiesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Subsidiary, Sale of Stock [Line Items]" } } }, "localname": "SubsidiarySaleOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative", "http://Scoutcam.com/role/RelatedPartiesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock": { "auth_ref": [ "r79" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.", "label": "SCHEDULE OF COMPONENT OF DEFERRED TAX ASSET" } } }, "localname": "SummaryOfOperatingLossCarryforwardsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_TaxPeriodAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information about the period subject to enacted tax laws.", "label": "Tax Period [Axis]" } } }, "localname": "TaxPeriodAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_TaxPeriodDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identified tax period." } } }, "localname": "TaxPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_TaxYear2021Member": { "auth_ref": [ "r495" ], "lang": { "en-us": { "role": { "documentation": "Identified as tax year 2021.", "label": "Tax Year 2021 [Member]" } } }, "localname": "TaxYear2021Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "auth_ref": [ "r103", "r104", "r105", "r181", "r182", "r184" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for accounts receivable.", "label": "Accounts Receivable [Policy Text Block]", "verboseLabel": "Accounts receivable" } } }, "localname": "TradeAndOtherAccountsReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_TravelAndEntertainmentExpense": { "auth_ref": [ "r29" ], "calculation": { "http://Scoutcam.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails": { "order": 5.0, "parentTag": "us-gaap_ResearchAndDevelopmentExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expenses incurred for travel and entertainment during the period.", "label": "Travel expenses" } } }, "localname": "TravelAndEntertainmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r497" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative", "http://Scoutcam.com/role/IncomeTaxesDetailsNarrative", "http://Scoutcam.com/role/LeasesDetailsNarrative", "http://Scoutcam.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r43", "r44", "r45", "r157", "r158", "r159", "r160" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative", "http://Scoutcam.com/role/ScheduleOfStockWarrantsOutstandingToPurchaseCommonStockDetails", "http://Scoutcam.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstandingMaturityDate": { "auth_ref": [ "r499" ], "lang": { "en-us": { "role": { "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.", "label": "Warrant expiration date", "verboseLabel": "Warrants and rights outstanding, maturity date" } } }, "localname": "WarrantsAndRightsOutstandingMaturityDate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative", "http://Scoutcam.com/role/ScheduleOfStockWarrantsOutstandingToPurchaseCommonStockDetails" ], "xbrltype": "dateItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r499" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Warrants and rights outstanding, term" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/EquityDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r147", "r152" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted average common shares (basic and diluted, in thousands)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://Scoutcam.com/role/StatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "730", "Topic": "985", "URI": "https://asc.fasb.org/subtopic&trid=2197926", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(7)(d))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20,24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "https://asc.fasb.org/topic&trid=2126998", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130533-203044", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org/topic&trid=49130388", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28228-110885", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "https://asc.fasb.org/topic&trid=2175825", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/subtopic&trid=77888251", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "450", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r423": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r424": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r425": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r426": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r427": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r428": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r429": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r431": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r432": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r433": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r434": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r435": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r436": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r437": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r438": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r439": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r441": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r442": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "a", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r466": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "705", "URI": "https://asc.fasb.org/topic&trid=2122478", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905813&loc=d3e1205-110223", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r53": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org/topic&trid=2155823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r56": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "63", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=126970277&loc=d3e23176-110880", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.C)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "710", "URI": "https://asc.fasb.org/extlink&oid=6409733&loc=d3e19524-108361", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "710", "URI": "https://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569655-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90193-114008", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90198-114008", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 87 0001493152-23-009276-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-009276-xbrl.zip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̢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ⅅR7*X2">N:3<;<5A(Y-YS&2]Y M^Z740;?WZ'*H$R$L(>:6#3+QB_Z@;]]V>F '?;[.;6M7A@ZZD_WR6LQ#%U\X M8>XR!V&:F/JWHI'GK8^_S@J?SZS@VG"Z,A)Y: -6QE.LU89FIPT;X\>N\"8% MO53I-&HASIJ%L2)6"C MO!%HUHOS E-B4@#$8" M_:8IU_WE _W-SP7:P(8PF#J$P0'[//HLL8X0,^V'N8B,BSZ#'^29 MB.GA@<;KH-P0)@2&(A*R"^$[C(B!,7=!E7X$EQ+/QR ,/Q8\+:7X0E <1191 M:H]MT%3@@O2,<_N.YP-CG/.YY-NY,I?S_8"P+1N9*[(&XP#NHM,>1]B+#4[C ME%D'77B%-Y^9L&VK@?=<'I(QA<#R&<)+&7-W:5&J8JB,VVFO9F4F.,J!8&)7 M!+]CDD<[V2&P[E)_9D":1;[//>"JPAG4K5"E-=="^KG/.>>0&IN.0*8QYVK. M>_F<",9N<(U2Z.SG!7V2Z&9N"B":PGWP# KD9)+;KG.LD<[_>(LJI:N ME!93()K2S42ZX#2VS=2>H@-TZ5%E*E@"##.Q9ZIU*O2ZR.5C\ M)N/1GG.+-8U/P0X!4PV E-4P$\='1Y2/ Q?GK%/CD['"LLPB8@F?HJPJ7XM) M")I]U'.$+=M^#XR<2OOTB\TAAK>,T MQT2+@^"/3\'_?7QX1D#JK"<\$,35NSZJ/C'N>R3&'3^^4^;))[B]U4=>96E5 MURD?='?6BR3Z6@1UQ$('T0!_9!PL#9@Q8ET'7=9$H:G$PD#7>2XT8V59O MF"#6&F@%5WS.J#! M>0C.O:@*&=,'VC!\2QQ"K3)1@Z6-6/)P\13[#!F+D"=N1B[W6A/4FMH"=;"W MP;;LC#T<&^SX[$ZQO0\RQW3$NKCV%JS/24< NVM8:FNI^Z N,=FHL']:$\ < MU,0(;\7JCD^(US5+>B,L;X8;9.190C2!MJL1.,0_MTGWT\=,?.MG!\<\Z/,2X;CF8DR2VI4;8K*C$9.6&01G<"#)Y([!15. MJR '\<@)%%%OP6K25?>ABWJ,)-B\N7CXJ'@7_%E$V",ZO5%J]>'3Q\"[/S@5_%I+&8B%\'3,YRV,+@H M2 MX"(EES<%QN;AV+I;/1"R+,7:+E(,L)&;J@/+3<-HBMK&Q?Z]U%&7,!VF>3:% M@! YBW27^BOA'9%RD>)UBU#K8;NKMLKHZ@ MJB\LVAG]UIU"B'ET'M$MDN,19$>QTO[50L6P.175CA6JP -L+]!5&)SM7W_: MWK#L8DUF7!]FWM5-FO$I( FJDNO #-:=Y%Q?\N':F_?[[AN1;4NF+=?YXD;6C#"N-%O0/](18E%>WO78ZF]W_EGQL(DA@I\-LU* M4G6XM:9AXRWF[8M?:HKU6CA)W#\4XX%YA 06$L.+!37<&L(4 M8:!01N,T2[+1C*Y!A[XG$KI3.6ANH$,+L;P"56V*"A!, "J+(H5 FOI!\A\'1<9=QWRFJ.83"H"BQX+A 5JJ"Y #52I#0]5F4+ M&554(/$N=#S*=,^UR09P;(1^.*J@YC7M#-(?N?XRD00_/\EH,U)S#%RH1*"^ M6T^JH=\7:S=VQDDWA34H2FSS.B*=@Z8KK@@V']T_D2APT_)'BJ&CET= M_)6!_8+,M&V&==M3\XF-31W"AQ;73)M08X^!-!B$9)!< _,J,H8J< N%@^M< ME:0@9PCQC^6O!'#MM M*'\88K*;&5T"CG(4Q-F$$-,+ZLZ".X.Z-@3H.T4.KRMEN]PUVNI;#;2;41[L MB&J,==SB4,X)FK@U> MG.UGL*7WF_2-J,$-+!$!.#8M(U\R2)KR$& /3G![ "M+9L^#O4'KL5'&;!>> MW2[L#K$UANUNC9O9=TTH9HYYPB#IV U21/ X8QTRA4!4U"(JSG@JZE52I<&B M]&[&$E?<3+.^5W<]MP5%TW0]1$SLWMC8J+%QLO7&QILJ]X;$IY09"9)OSI5' M8A\[&('P*8F2NJHRM&BQR.$2-5$E\VY,\E43AH18T? QW8-R12X>[7N5RWVN MPK8=TM@B;![45R,K]U?E:M%K&=!2,HS?"Y0D]([F@8Y(-.[E1T9UTS.=SE@& M+:KM:=:94,VR$#\R''/4F@T$2ZE;3N'>H>*8%KR28*[O&*;MP:RNP:'4#7)5 M2--0+F$+9*RFC,,%1VS.;B3QNF@R'Z+86)YE\'.?9=!G&?3ZR!;J(Z=;KX^L M[OPT?0X;'L^!E"F'E\2U8,S\THU7U?'4]8D8H6'*Y!>PO N4-S;:VLSN#_;0 M)Z!3D*T#:-;H&>9'Q@W.(GS0Q0*'T?YA\%^MG\'OLA'[?PP(M!\9(^YJJ.H1 M.P#4#<./8N[%W+(LDK6^>BHV@Q#H2)085HQ#$@?4"RFT'M$X-%6\\.JSG!)0 M&77D34D+066J$W#_MG]:*K+=:WH/-#U:OX%EGL.H&YD%-E#:V%;>#N#./5BK MF=3704[873)8O B'P5O@=3/8L;!!C*?0-0S4L(OW0W\BKV\B)*WJ([FP,3T@4\!4#D3/I M+!Y'$RB7DTS;86:Q_JO M_#<'3B"X>>@F;8F$R> 9SC>&ZJ[,/82T^%)J8C M#FT.YL5OM,_>T^-(2XSBQ>7;UGD83*1 FYJXJ/4+U@TV!Z#=8P/(EKGM[?AL MS$7-RC22)"V/#F$PU++C&]4EA70-\/B':,;UVO9&M>W'6Z]M_T%LS/O(Y11= M$5BF-JP2S?U($!K<1M/JJ1/G%04#:E4I7&1]9.O1O;.\(\!/29'I2,IQA-T\E&8(^,R"QQLFWJ1!SX-KY2!6(5YH8"6XANHEOX89T(ED51-16< M]]4R<^V/L;G&%;;$()G9 MK+LL-PXJLGAN<&^WW&AH: UF;"?D$[W@2B=*ZT=))U&;NB*G(Y@>=E3!=C+VR_&$J;A1"MNDSN?N= MDV0\O9T53:XK$",%-SU%KPUYH%(LT>MX4/,TAG8_\<[!*_7N(5];3DMPXV9Z MD RRS,3CH_ZU(0^->$[.0[,_PM/S-HUA\XP*[#*Q$1QD.],LT*[#[JSL.07 MN():;\WG8;G\)M1ES\UNQ1AH*727I3,*C3NBB_NPFY!!1YR&'8R4T<<=M"PT M\B(:V.N&10JFF%-@2"Z-U!3]BE3ETA4"75AN3/+AIA+F5F/ZEAQO9R;L[E#N M/7S$@X,9B1=,GEMK$]K,AF8FG<2(3J0[Q;=_Q!F9>OFSUE. $% QLJ&I@G4J MQ;!4J)!,%@AQD99P6'43+54XGQBM#O<5S$0^,R4"+3IP=<=J4LADV /F;SN_ MT)KG7$H->OWK/!JCA>!2ZZ;A: L(A:WQ:C1- _,IZMH3A3YY711GH,_S3G5K M=\?=1 XJ'[K*79<#S,BT2K0:O22396$J2F?^$)51FDJQW1U46P>*O/5-)(E. MDAS*'\B6[^.)F_2T/OGZ>.)W9C ^X:LUNFEM&HC03A+/NB;7H^(6-#3<( 6' M6T+*Y*\$&_\E(ZK8C\A$-P-;)=G!C(BPB 6,??G LX7U6&T,%A]"VDYP5WNH M)X3OKA6HVH]P&/Q2Y3B+DRR77>WX;OMGR=2'9N+U-QU+L0P19.9'2%T2BSZ7 M_ H+^K1@J[TDH#65N1I4Y!8Q=<0!AE/7;@V;K?)F MK0.Y+:RZ>EZG\'#:&,^M ,H\YP+X\+B>688A,F_[^J=;GS&UNAK#+)7JSW31=YVO:%*9Y^K )'0 17S%5#1. MU=^57(B[PNJ$@5[!+>N6^COA"8I^9-RD:D2H8+[30GZ=J2@YKQ>K/Z+, MX89"P381.3JB-%I-[6*:2+;]R))EO#R>1AE[SLF$]1&&?4&@!!#60A6,E .J M$R@2@K04V$NT$AA$P]@#43(1,\[=1Z'_E:GP(LE24APTX ;O$ JZ(+Q'E^9] M0Y!$*XNKU;&X>7"4K6NA5L;X? ):N);RLT1/&$V))O%*1*SK[#.62+L,915- MT\4CH?EFQ$51/'/J-USQ:"LX NW4"EN- M$V/W,GZMW'.("Y)751GP6#;;>[[ZX=6U@.=D0FFR_,F8.662-J MNLX7U#E<2,T%5%&&06$#W2OX1\RX0HML2R8HZ@9%7>C)(I]+S%C@AUUYXQ0[ M\5T2/:&-]NG+YPOIFQM<[ M@%^0JT-IG8%NK3_GAR$,'[S5H;D<8Z)"O]."]'FP=[+O"8_!XW P#P7!8;C; MHJF0NC0.J=3![EYW__ABK76B1^-\YTJ6&-6IJZ1CB1L#!GNZWT&_/H EQWN] MC\V"$]@"E;26 %#Q>%]35%BNTZ8*EZ?,GGO.R=F^/L =T^ ,&,O9TI&B6#;A M)[JU)#D6;8C\GM*NB LM;]15-_9D[:*,MB M@O[4HUBE4G8",_]DGU%K;F2W#9'XG+[?>VHW#]7)4N=?3[EGX>48+JV+1=4% ML/9+=H8#,61^YME,)*4I,:;U]JRI-BV\3/2RBX+NI+YK0?!OSLJL]02;5$%. M)".8U^5"):2&S:;-8ITKZGV(;\B7=](14O)IZ!W0";G#DW'HEL?C)*W"9EUK MC)6/B12\.VU-,[XG##^*KB1"30*+4X1GBZ#*>;ZHP80_# "S]_JA\)S,-H^D M$NXQ\!-IU!0&1\(9D%![W*85]2F'O==A"K\//]]CK0$EZ90E*D(P#UG'1VV :6P6O MCD,LT ;Y4%O3\R+?]>W[.A_=($%76.#K/?V>YN6RL,!R3W\MY1Q_?V@<_O[Z MNB$%Q"EA\#M^>QM%,#@W).2-H3-G_Y!OB'[EG9+ D$9>#@@< M!Z;/L+>'4WB'XBJ;2T5I0F:[+9$QM$&PT5\176FVY /.95LUPY,F"HCCJ2)2 M#$KTO*X]0,)]'0R,M<[ *=J).L) >*^8HM/,S&'U/LM3.9NKC2!G450:@$K8 M!2(V'1^IH@NASD+RH@%#\%5?9W:R^1;5 ,&=%&\4;*N0M0IQ<8520WG,N*WL(I"F!-KI^KG.$W.Z;X=HN%J7UPGI]85>7UBSOG"? M6]C52?W @BF+)%Q9^R"PSO:;SX!([74LELC#+A59Y['G@K;=,$8B&$3S@$Y M#304!.] C/9MK;58BX@-;NI<,U?2Z<^*>2PX;@*X=!\B\AQC!36F,,%"C+"/ M-0%>UPVH=&=B,O%8GUDI&V]Y6=WM,9\=V>KMU'" ,#@+T2TMG&(OG[:+PY0, M2K-\=1VO4Z+L0T;GJMN$%BJOEI4)33K1F@993F".,,K-5O>.QVKL:EQ8E(Y# M0H=@ZHS>X,@K$PU=%(XT%*],1AU3;0!V+";)S7;@M3+EXL>GCU?*O/G J1W! M._3AG3T]>7IP_/.3I[Q[.YE(B&:_"!?0%7-_/-MG^CG>KVR9-A B32LPX,>2,TLY, MMS^R"UG1T01UA> BWFE8I:PC-2':YI*_&;*#V\"VM1MR=0A:"7";XK4FERO4V8DM+.]%P-I+L+(]0WL:6+OI5%S8 ME]UU(6)$'YZI*+6,-PQON!4L6,6^1/@]V9[D*N-J_+&:M#SL#U$?[*7 9J7 M?>XSYM;[S'EX@CGZW'=%Q8FO'7/6(ZV;(VU_+Y;5.5)#O:@U4TSHI_/5 M62S1P;:T?NI'A:O,-@X]>SB+:HBX!K&8$%H@T1>)5#OXIGA"F? "_7N!JG6>6L##A16 #+^THJVM_KEA"A-:+V;DF#O>HE775<1 M\C3Y)C0Y;21;J^(.5>D^68)JP,-FM/5AMHCI>?%&>?'9UO/B3W @$T_33S%' MJQ*.LG%9#9J_R);^ ILSXOI%G;ABZ\4WQX]M@N<5S%3,K>6)&:%6V,@VV@B:,QAJ@6PO&*]?IUC]4Z^B= ;T<4U"(S=@5JYF@=T&Z K<6<'!=T++$V M"QT_3GS5$RN.XI1V5U1I8U]8/)E$V@I:%$B(ML*Q;YH64S-&V7(CG _E*29K MZ50[*N:L*@Z&==/:F(6ZW_-8X&3ZT1)GUVFX:%LF&98F@#@\#"Y2"VU+><_< MC@'71)]H[BH75>C2LH/PCG,CB"YOR3F#4F'5; 8Z3B;X HDA<=.C5DU,(Y " MP5\R,#.G8ZJL(.1'7W^C3I,D]"BVU\#2H[:9.B>"<^I#G #G8:=D"OM/5*V[J5 MMC6 #V^; 7V#Y\ZT$L:NQ73.JB31AZV[5MXPX55A=0>RO$;YM4SQ"1?W9L*@ M0^<00-'QME^-9JB-4EF;I(WH%N6F*,9$=WJ/M[*OM#'Y$-G2#9DGIWWF29]Y MT@N\;11X]QF+5F=]NJ&LA9T"FQ)MD9#R#QS5$NU&5ZP+FMO*[[6(HRE,FPGS MKQ12F[NC@VB4#6 1!=M"<\6P'4[=ARCI>GZT67YT%S T?5/IN^(A;N\NRI9! MM;NN?+B-DDP. 4^4J.71Z:XS'ISCHZTSB'QXICB#\NGSE4H^7/W]-KQ<SR MS0'?9$\9>J8:&>2>C@ZW6*2>YB*XEDG"R4WM=I=VQ-W,=.7L+AZ=FS\!0Y4' MY.C2SZQQU'4[VOK2*=8EQ'I1J/#5Y#]XN@=S0;*1DQ!;5'IK;"[ MNX29+1@Q:1VQ8?P@E'^E3$DDS*/FW'/._.+",N>+)540+D-N,^Q5.1ZS\H4. MIA^X$_4:V3/NBJ]AT6?HC=J 86X.VK, 5N-1\2CXMXBR07!^I=*JL2RP [=W M%!:+6P_B3SFN@O=PQ-M#J+N,?_^UW:"2\S6+M>83#D0P<8O^AO5B6B]A!47P M)[#AX>)E6U]S^._M6'_<.]9[Q_IW*NE4BAR8GH:? MIS9D'[@_1?!+A(*,UPAOVS/I'N= M7AB=[.S.\.Y.:]2I&793MM0#K^NKY_83D][X2F\(=PYUOXN6\ IW=PQ4-2^S M^Z5)F"WF)D"C!C<'H4_MT=?F ]][KGN,E$3EH] MO0F_^-F=8Y-?$V%X]?[CF[P9M7+T_QS:N7_YC7-UGB M>$9K\N#X9.&]3.^ 6M%,B@RV, *&S[57)\L73'_1+SVDAP&_T7E MH[DL6%R%JA1C;#:TFB7T^*>=ZT4UZP0[IX$>VB%!%FAK3^L]UYY5S[!G4^-+ MD]F\M%I_X/"X3^CHQ9BW&!O<1S'6M@5U6;,CQ*A#$9]UF\;\K#^D#_J0'F_I M$3W>^B-Z?+HN@;Y YPOGE#Z0K#=H>4W%S8\,O/$$1CE&_&36.D5A.$H;+"?) M"G)U1F(J(G0D(8P*M6W5M6S:M48NQ=61F*FO%?"MG*A[+::J%$GPF\@_2VRH M5W,\5&L^B2NNMN/JY=]4BJTN"#KB%Y7B9;[=^QR-TK:ZX>RR"ICKT[/%^CK0 MD$A1E-K'6=^G0PT\6>^N(9<:-0U6A<8>*PH$=>QR[WUP$,?M;'H3\D[OAM?. M;O@O[ ;;$.Y;2)D^N[>7,]YRYF3[Y1QF3)_ M0JZ8]M._?E;0@1+Z>5 6;+*NI?7$&UBV#Y!!+JR>:4S,M\A;WC:9&>((P?=Z*O?%N^+35TM/Z_7.4G$$MB M>&@Y,9[=C#^;UO&LK>=>KK>==YYYP MKXS6T,XL)B?#E>F?U.J9J3N@$U(N=9ETVO2P9@3JDS1?!\1/2MHZ?FB%2AK?NONV M*1>9\WQRQQM\TU51H1#@0Y5C!+M(]<36N']M9MZ1AXL)(G&EF_+JLG5OP ^* MQ#QOM;0-C5O?WI2OTWYXDT88Q%*48P3C*'0B-<,3ERI?03'6X18T9V$EGAP% M%$?*OPF\:B\R>I'AO7:OMUYD^.."-#77&H.B"4SJ-,&[B6W;AM!^=! 3-B%@ M]/$AN[Z2M?89,E\NN(4<7H> ^S5PGNDI3-YH S?EFZ]GPM?<^YQD 3RBU)\_ M0,9T-ZL_]]XF:B;&U>[.GPJVM-K?2&'>W%)]H[*\FT1(#SG20X[TD"->9VB+ M($>6XXU\W[^_%]K)]K';&P*F3YX'[Z=D;CX#S:8H^_CI3?'3FR.<74N_5JUD M\S+ZT:OW;_ZDVKM?+W][]_+_ U!+ P04 " "P@'Q6)GQU=E:U "4L00 M"@ &5X,3 M,RYH=&WLO6MSVTB2+OR=$?P/.!UG)L0(6*V;;^T^CE#;[AF= MM\?NUY)W8C^")"AA# )< )3,^?4GKW4#0$D>RI8L;L1.6R0(%*JRLO+RY)._ M_OWL'W^\'@Y^_?N[X[?PWPC_[]>SD[,_WKW^]6?^+WS[LWS]ZV\?WOYW='KV MWW^\^S\_S?%+-$F+)JU^>OWK[Q_> MG[G/>S)+YEF^^N6Z)]*U=?;OE ?XT^N_%N-Z\>K7G_&&,"-__H?O0F..]NA_ M]_>?[^Z';U!EYQ?-)E_@U]]>O_MRD8VS9CC8W]L]_/7GWUYO['7NX=+\KR=/ MHM^S-)_^$GU/YDDB_I&*A2V<7M"+I,J M2_R;_?3Z=%(NFS?)/)(7CK)BLKMVUS^4"3C8.]B+3B^2*HU."AQH=IE&?^9) MT?%V6ZWVPVBU[[HO]:UDWV6RUT54Z>?VIR-.Z'@[*YB*M MKK(ZC:;I+"O2:0P/K^9UM*S3:03?I5D1U1>@>Z*+!/0'7![-TZ3(BO,HJ2=5 M-H;+FA(_GX/JA$=.FJPLH@/Z;3D#57JR\1.0_O?PYF:NLF*9XJR<'+W:/ M.C7H5TZ6?'"5\HH5905Z6!XZ32=EE>#KXA=%VB__?$N>O/NCS_^/'[[ M]N3]W_[/3WL_T=^G?QZ_T;]EK*)O]O?V_J+'RKC,I[<7M[9DP:RAKC#PYB_NU?\^G_+,M7(+MJ-_ZUHD]&$7P+:C^9S<#N MB>!FF=Y[.(#/8=B7V02>4Y67&=A%-0['F-HPCMTX2N!U+Y-I$E7I>5;#J0/# MF)3S15*LHIVF/$_Q: *-T5Q$^%&]G$S@R"HKN C>D!4OGCM5VI0Q'4QVN&_L M)>ZH8SCP*KK;\6R6Y5G2R#RED?.+.+JZR"87L&^NHO0+# U&7]%YELQ@F/CJ M974.9^"_<>+@?I/_668X^O$JO!5^G<'OS>-@29MR.)C >F;%,H4SM#U7> G. M)SROIA,WJZ(4)QH'4D3C%([C6<>XVP^#5Z73>5&5\[+ATUOF$7X/*^7?X*]5 MC=-41^-E#;9 #2.!5UK0N/# AY]>="PM+5&Y@+LTRR)KLI1%@V<%EAENL*BR MM$FJ%;P6+G3=H*T0/'TXD/G+ZGJ9@#B1S*#@TOSCKZILTL \RX<[=KT_AE]Z MLMJUQ#@S\KSS"KQ"O*A%*CA=)("'Y+M*TDXT\=J(+\4(%, MD.;= 86+G\!1"\IO41:D_\T-\ =\)H_K]'^6\#Y@.H!8DOJKFZ19-BFH6)!I MM2]F< )%#;P #0;^.V(5C(XEB.4R3UC!X6=T1BS@6-?/IJ"8^7C%AZ*-D,)N M:#!"^"@_N4<"#4KH'1F= ME>,_?TL+\).;FGS=IIQ\AF?):04O]FZ^R,M5FM:CZ.GS9X=/#O;V#O'LHH.3 M5/UP4-'-ZM*\5FMJHF"@]'COY-BA&\H^;RX2F HX<5P=,4[)O*O3)D+#X4+/ M6_I-='Q>I2FL3#-B06%[YW^6(+"S%=HD=']6(&OEA.P+^(2&&#MCQJM5F=F! M;SHS]&SW<*MNOINZ\?2-M5*B0]1$+5'9C$:)>A4*;XKA@*7.E44:SS<0QJTH M?C]1A!4^L1XH:V:QT\D_$?6GH4OG_#LZ.+ .PA2$[#\05+3YT0%HT/D:#F8I M*- D)]OK1C(XG8T .^;"I]W3W>AW&7[&)R&^Q7]X\,#N-"=/U'GPN)$$F#-< M1O;*KE_%G?'(7TCGJ#>W),D8#CIJ X: HFZ\R MD'";L)1.RPAOX@MK(%GRO/8VEJC)<."$36Z_GW&HT49V,QS8N)WM%GE?%OQF M&3W-T9_N)MEXE&%W[P;1XH>[%>[X94X*L-^GTTQE+HR>>9$ _+)*\_02HUU. M.$ EWY(,?)_K6LLGJ:23 ,1)[?C+^$ M5P+O2MZ)8I)X?LL6X"W,9\-\GC5P7PRKP(/+*XP\Q]%XV> GN,6KE .Z=!S/ MD\^IS!U\6L,<@>>&:SFG;4J3I^]"3G<*D\$JQ9OQ"5H2// ,KXR2Q0*T4?:% M%TYO@3'<5FC4!&83U4O\@GB9S!)-4D7K7)*+G(/':RZ2-YJK9K$.J2L)F][= MVUS0-PHC'E(8T8NEXV9=MB*)WF;KT1;M+ 9LCA*S,#4%\[-+5 ,HZHOE.,\F MFK39_-EP>%^EQX<8(6[G%=P O8$)_O"5'IV_X(-$[;V*_BO)E_#U 6-\"#K< MQB.I,#US0$7Z60>NZ';@ KG?I,SS9%'#6/1?)C-O<0=^]MH"!SK@ /["H-WW MDYMN=VYMYS/,/3,HJCTMXRI-/C\9IZ!1830+FFIW(S[CX=W_6>B"#7HSXXJ4 M"M.K"',#OT3'53+.)J^B]^ ZLL"]+U&,#CP4F?Z*H&[K9]C]V4;1M%O-?2O- M?22:NZB;:CGA?#6G\MF:@\=3I+M8.2$(@66!,I^!_FUJ:PPX1H;$*3R++T^N MX@@#T)Q0U;"[6$?H/\#EZ L%_ IQ0[8/( /9VAAJ$6%-X?-B'L [E&)UX19 M7[5'XML;6_A:8JJ6X!4A#BTK4@HS<*K:3V"0#=/W1@Q96U3P[ED>E9=D_[JP M"&.O4:Y=$@[T05K BT]2OK_OTBK M"7IJZ+HM%K"2DL6?=2PW9J9RZ;S\D*^BK(%?X%,FL"G(E<9I21J^@B4>G@$ZQJ1L<1)6Y->;&5NW1#N\5!O'"#+5^RHO_LR2>'=KN \=2*Y,!@\)BW D+SX+TT<86*3 MU#_H:;+#^%Q@( -'K1;Y$J.^&L.3/[WK^.C6>[R**+,K)DA1+HN.N_K)L7E2 M3_"L *-OEL[QS.7X0)$N$2\)A]N\IMO*?:G4(-.#B@RW&1P5Q83!HV0J:: + M81EH&U/0J]18W[2<\"=>A0*; 7@U'F,UW[8B0$"C6D9(0I5S8H1RL?ER$YNK2,@HXUF*FN6; "9]&0#_C8":JPMS?8U(6=+ MS>:[8!FR%ZS9QC.)OH$: +(Z- XRMYOUB7R*HGHBY^%_25SQOO!^[NNQ^R$9 M#8E)2=X"QR5?8+:F,9\'CXEIW+ EZXML$;M XSC*LSG%Q_,,7/&< $7R$,SI MUN4DDPM!JFJ0KV6!F1:^ &_%B7<'D]AM#VG MF7@!YJ5Q>MR7!F'5EUO R#%:[+X<)DMI L4FQ$#*>2F&':5;\1'399+C?(I" MN2K1N):[LCC)76/WTW*FSX)!#0?.-^3'F9]0HH!NB=( $XFZ*ILC8CCNVKNP MDD9:K+<&PHW(*UQ!,'-7?%MT(46LK3\Z'(3>$[T;JA\51-X0LF=>W,G_\36"!_'<=!IG!6YCFXT^906%Q4"%>6FTA: MAJ56<@CTA2S53O9EA#5>*A5HV^MO2UTX==&#O&GZ!0989Y?I-E_P0&T0AAV_ MY8J_X8",$4T5J&31L4FE@-WE?W5G_1]M"9/HVSR\^.C1"<@-T12;%9##70<] M8^I)'"0 F"7F=(E; 1K2QG06Q7STL$U GU"\(8ZFH,,GB)VBA*?Y2ZL;P!M@ M8T?@114HOBRI,APVFK]5F6.DK>92&O@K)TU()VNF&6\XG^=EH=?3*&,)Z_%0 M=DS@U-5_I5\S+HEM: >8A(C8Z&CO*?W;QB7?.,EXV";+BNMECB>- M"T".H[;^YIG\,ZG$7CA=CNL,YX1?6G!BU5W5@:S!+VWWUJWVUI&WMTPH=3CX M([ER=EAHOH5!5S3*?3/=V/#BMTW$TT%[1=7'\/;3<_Y"@8.@!2!1PX. M$I6BX#,%P!AS,+H $S?GQ]#FS$NT4:T5BU_*>,J*-C8")<::S?6 M2+$+[(C5656L/!N\MD9 H\L$4@)CY"(ISA&W>8G\"Q?IDPF\._J=L+J?4]HK M395P =NJ!K\J,AF//IA%S35?F!"1V#;<@!V\'$L5IYL/:=X$*+C=:+?::$^] MC8;Y@IX#C,2)4_;M0C[XY/03/L=4(MH3S:W;2R@%II _U?)W5)WG6,J/6UZB M30K,,UVF#=[52N!OI2^!KH)'143?HW)[2\906=4VC6-45"A(FPL'/W]^4X#R MDT.&;6[%ZW;B]?QNQ6L%9H&))Y"<%=.DOO#DS"O!M^7>JR?XVZUL/=BC[H5[ MU+TA@V@X '><=:\PE,$D4@Q@Q?G!17J5@#_+?7*A2K)Q7&P[&*;B'C(F8BL)UBGH4_>"_ M,=%D3+ZB)Y0><($$?$YQM+IRSDQ,A2@>?F<(]*GUB M<$\&\5 LD%W662D&CQ0HQ!9)X-Z:9I#2/YB6JNOE?&$R0;,9U4B4$W",:\:; M@LVUS!EP5""6!.]!#\(\18K( S/CE!:KFU8T@G GN/V)YQ MGM47PAVW6)19X6"[V%[''-H4D53(BV?#B+&+1C9T&[O[6YEY #)SX,L,IQ+! M MB(V"/F&)^3IV-+4.F CBSM&6S0K#5-+ =^AOGR=9,5OF5)1Q*:DX1) MT@I1 MFBQG&&F(IDM*3(M$R<(N+$DJSBHF<*4%W 89DGM2 N)TG!H"1T]QF,@E]R4"D2HDUD MP(-WS$H*L".F">FOV1_?/Q@.YG#914U%#$YIM/P"'F>JD1R23RVMB-L7))'E M4IB6%%I*)@CM9>*^LE5@BX L6%:MPB#;(8Y<7!_($I<1X1OBM$R-G!@,6:TD MWAX3]\%..MHY]+A1"#_ WP\'1WLOCW>2T<[!:&NV:3"ZX31A[X%9;BUS[@T[FJQ8V!7UFH\6[TOFQ0 M7'$S&)8W@X:,J6B_16W3<=[B?/ES9+>LG]/!>R!B USD;($U>#@@O#8W&<*N M57C#JU Q$-MYTC:+^!#4N8?O4/JF=9EGQ451L'$JQ#*I_!"$P$%:2XBT8@"Q MB5LCE0S(5I+79<]M1EHI5F'-Q;23_M?DMF>A^MYA6D:&_B>,&G4K'CMVR?-PPW=P]@U>A5I^#^.).XO,?\BS4B1U\)93!%E,VL% MWC]9,0![YGRCQQPR>*5N)2!.?B;9 2=%P2.F^W0J(4( $+32G6V^KZUSA:DZ M+^&XF25,>:TS/AS8HDE>&:?0[^J":;(](#>=D)3?($V/?U&B10&\<+'*I2D, M24VB8RH!CR!R;R?%>5W4S$Y5(/S*?AESAD$6?YZLX-&[T>_!!"61@M;%M*#> M&%I%NXI#)(7-1H'\XEG4/F+,K<(BSSSGE_(^[R*\L&L.IP?"FL99(3L0.P+>GP4,X M#9YVG :5=QK@.5![Y@OO"U2P9UA+D@HK6=PM6%91QPXH%+\3L*BI')'\+FE9 M+8>A$9'H!B4S'7Q['9S"/N& PQ4+MLS=NZ-;<=VTN#YSQ=7JE&$%CM9FQ;U:/XNFTS'.@8U&PS+[4#[BW\ M-^>.'\9<).NW,>5J^%.I2/-K"Z.^&]<8<"%(1+ZZ X*'@^V^VO2^\B!B[T2J MAX,_*<:U!I;*0;"84A@@%20,_(TZ"J9_B@I''$V7M+V$5TB%T8BQ;"J.0,$ M]N\6**#[ NP(L";6[ IS+"SP0D;^)=@=B7K_3-"STXX5R@DL!#FFL=#UOU3C MAG;/W4$.[B]:['"+%MNBQ3:.%CO:HL4>MBUSX$%X?D^R:CCX!Q?[D;KHUML* M9"<&&HJ6H#J^Q!]PP(4UL $"UZ8\E^H?P0[B?"D'*#NS@@)QCY6JP@9JX] 4 M,47VOU!"-P/#1;E@[.!.;1TBUQWB-<*WHJ7#M@ 2?Y' 'DL0_#_)2T*#UPF6 M4/)9L]"2-;\"TGD*7%=@KBK'4FRI>;R4FDF)6S5$SCE-DBN04J/1,S8,MI-%<5-4""B9'K)SJ&3V1L.O-1>'&(E M\%9X$D3N0: [3\3&":.XL18LKBF*U,9W7+Z;&EZOGG&&*'&*]4-&_<#;[ <+ M:-,$MT*E+RUZW>B&@^[AM?C^^T87]C[JO@9Q(<]])()D,PV"0X[9! :7T*"O M*ORFD'RS9BY%>K'R1I; 2##MG]WH9-9W\IEM#(,B7A!"[R!1B(.IA)%XM !T MG*_3T5;\PGPL.6MZ'O(8W;N*8L:99:UJ?C%A @7G-13VTO'['4<6$P(IN=M\ MFBK'#BJF/%EBUM1%AR3C\E)0.F;U1WJ6F,Y/X82W-LHVE_@0@A\'^W<:_!"0 M7U^AJ.)4$*G! /8WLIWH#&^G7IT'??!ME;BX3A:'F;9Y''7%4QP;Z#,;9_J MM)7%A_\7B!$<+*-H_^6S?4/VTNH"R]PO3L07+Z(^HZ.^2@JP5[Q2BC9B<9NI M> !"YY&/,89A'7Q.< O13E!CZ_@9(\4^%.45',)@4-1"%(;"PR:M$'0BB(P< M-E:P*_8@2$3_8&U88]VTCN%TFZA*!M7 QZ.]F/:B#_3 M7V05%BE4YC>F3S&> Y9R+?J#@7BXUR?HIM AY7$"FHAADWQY8D'][JW!Q!D. MU/-Q"P1N *S-W#B<5G L%#'>I*JFK%^V%=Q[+[@>Y,^2/ X'QY,^%A8J-<4N MG3XG))>6'AXZ5E(G(][-*DO)'!+4[)W90UL>N\T+U#-?H().LKW$/@8_%QMD M>ZP%!+&)WA%0&P-NI*2F;;Y63% 3:3IY?A*0JQT@7KN>214>&V\A+-7H/\5L M[+;@>QJK4V9V>"H%R\AB:%U+_3U1M 6:A%$C=4RY3U8AA@#I=@U-P52DE2CX MR >U:]R7GU2ELM$NLD5OQ9OSOL.!_\+XE:/T#5*EKVR!8TW>@'0H3DTH$]7D M*T7FW$'I^'8K;_8%[2:FN&"?*2/TH^QM((,Q&>/4G$#2#)].__?>[M[>/L4+ M:Z:I[*BUPP[7W*PV91N4$Y^O80T2:G#FU<7[ M+>@X;"#][33\9'0ES[&ALG=;2:S/[&)/5 XX3S,$:XZ7-! _:(][>//6V-[: MPGN!1WQ/1,[1%I&S1>1L')'S=(O(>@\2+%5.+2N>%^TT7 ?92N_*MX7;3S< M5QO1P8*T6\;\HB#D-]N&_!Z6%O%J%)KDRTY:C_I4"!88XA^F1P'U)8BE*T%) M;>=2&"M&[LB2!7/P'/\Q2ZGH9@[2B> =,!^%R%/X/VF322LVI]Z O=%RGH*- M+.8OT:G4&&8A6C 2<.IZ,'V"&(6LR.;+.38$2XIZAMZ=8(2FA-Y(OJ )+KWY MV-=.#M)YHV',,5_[M>5O0G3.-\08T"*LRIASA$DF%$2@1/064\7HQ#KS MQ^72/.^F:X,49'W."*.4-'6);HB;Z/.8,:*#%WM_\\K][5)A6UJY+=X.203T M?J#MQR-9-%BEB6_)S*O,9 M+MDFQ#T0'N0*F&H4^X3Z(*3IH*H(X;X-D6 M=&%+;KES;6]-:1 #'$D8. (S _)$VMHCYN$Z\PE5[BLO;^R.PCPX[AH-G @+ MK<:!N_EQ=H;7M2A]5P@'JZ@ZC8KTJ -QT"$9QT*99%,(BBLY+T#_M*)5'"G= MF?($VHE2=*7P/9CJ45U(/33!3.U;EW#J@G?AQL\N:3+:.1KUF7+ #;T=_8L/ M9IB790'*1")%Y^=8L->_]R?O2/7G/L.7-GV)F] ]L/(W(2KA8?A.+ MAV M)J&7MD*_V29W7AF)4&VLPS8UPL;1(NVT(%(0;MPK]*ED(Y \*>:36IK D1G0 MHO= J\/I D!@JK/C$1P07"!NGKIE^WP LL5MOC_@$3@<2*?-:*.--M/(]JPU ME*#C%.ZX^;:;WUA -AU5_PYA=">6Z\9NP]CNK=]+8JTO#_]BXNI=$>"VT/]$ M,5,G]GOS9W9$B7_2"*R-#%\7Y>>9N]5;'KW\RT;%"DV;:HXJWJS6V=OVF\C3 M#_PX_\-\8=$1X3M32/V.!>*F]]OD&\.IRN/@([5SF=TI*]W-U_5.OUOBR>^-;J0UFG@T>U3EQK4:U,_<5V9]WS M%7N8N^I1K-$AG,H/U)IX'.8$+8NLT'F52GW 0UBD9X]A>=Y@ZN2!K,?NL]VC MW:-'L2HV\/TPUF;_<9PVIM4LCP;[S3Z,]3DX>B0+E&LLY2&LRB/Q?-[!@#)B M9,'!8%)%$HL/Q%I[N7OX.':/P0#R:#P@X,-8*C:L>RQKC/C_8.N%'<$>DIGP M[''8;R=GQP]D07;W'TE8FZF45+$EQ?3)A]GL@2S2\T>[0)%RGV_7Z=ZL4UJ= MI]7/ITG^0'R?_:/'86:_+PO#?O&P#;C+1W$B(?':0UF41^'^_%F6^<-8D*>/ M8T$^!D7L#V-Q]A])K.TC$]C*6?-W+H-Z4 ;;R]VGCV.AM)\5#^[5@B"'X8-9 MD<<#SK;BWW&J\+BXPKR2S79!I*ZJD3&X-U]S3+=?8>)E^AAXUP2KWMIE95/KA*D9[TEZA 6$[^T^O# M74]1?]]SX]??7O_ZZ?7QVW^LIX:O8-PE.'GOJ M;*IGT.'A[G-3P6[: QV\P+KV.UXR>>@4.Z*138!?%.FWYD.XOEO2AN47175_ M-SHKF4,%GD1]$[ ;68,D&LP:%-!%,:_&15(U3(N=1K^M\N2J#CC*S[&Y&U&R M3,O)DMFR.S@"33,JYE@8#L9(PX8,;7635AU$'KO1B33Z1FICYBFT-,33$EZ_ M*!OEY"".=&U"%R5$VVSX0.QS[#!X1,.!'5+4,R)I*$L<(MRD EXV7\5"QS0E MDILJ)38S;".*?$U9$1E.=K^[';=^K)MJR>WF[ \-C3L]L.OUD>F'*6\*XHK" M*D.EU=*16_8O.^-9K>T(NY<:QPKC:I+/2#ODT3TC44JYY)DGU'O4?;*9X;KDE_$>13-*!'A$[GY)O/@W6SOEH>E?O,A?NW=P=SLO MCA!<<9] (:]QA18IR>RT8"=.? 46,B89(2ZFAKCUB6EQ*NMVF=;"LQ],D.T= MBCMEC%3=&BN-B#8.+M0>7>F7M)IDM1(M:F-5FGO9\D*I1XTT@@YSU%3 DZD[ MY%]ZNGOX]&9J% Z5PX?<\6YKM.<>">9+YB[N_)\@I;!/^'A&=@]A:,)B!N++TT;YC:2=A?\XD2%"BY[ M*C<)F[)V#D3%(P&QPO;*S-IV4OT"NT9UI>.V=MAV!#C&78^-Z?\RO1-=UNFM[4[S4+# MS*CP=^SW2Y>>:XU+M18+A2PJ!&R;PVVTK>G3]1NTI3+B*2>;G\?X;^%C,UI# MS$!CI+=[S6V:EVVO=R=_&XJSK]^Q'AG?9G?Q!ELCV[S?!F^:2L&BJ5.,[ZP_ M\O[^<^K#'48[CO9VGVTU^BU%(1LQ@RVW2]!.8WBNITVC_J'5\8%B)1)<@^"I MHQWI:Y&"%A'W*,.A8R1R%)AHB?T9-:M$#Y#^5'7.]W*:G\V3:>IR0^/0BJ7R M4DM3>OIMOL+OJ5L%CU$;#9J.36NOW@'-Z!#UHBW(/[RBK@S:QAP/\0 MPKX^E?5LF\K:IK(VGLIZODUEW0^;XWZ/;J,64787-I%MIE1I(*#Q3S43 146 M^= S_F'.D?LI0IN4H,L1^UMD*\6N,\P1%PX2\P?6?0)GRK4[;F0^B>EBFH(M M%R4%[X8#B3>GW,/*[5\UHH"V&$W&V1Z=04):-S>=L"PUSC5L#D'U, SS%/S8*9IXTA2%(EPR9XME-;E(:F?2HIO, MF7C.RF>_\W0D05MZ%'4@A7>N9^PKFRXLV&#':7?D-H!)*DX+=#32<3CVN6?) MA8S>73*Q/+V[5YA#RN 01U=_.- ?80\'MZT;O_0B M]!R*,#=PFOKJ*PP'-^D4+WUM7G!/(VE_=-L-9(8?22A3%AMV$/8)PN029A^= MP8D\>E&J#5OO3Q]\:XN'H78E+1W>_:04FV MJB<_:U2EWRV798^;%MFX&HSF%ALF;,N]Z>#XT]W]Z^4P6*;#IV0K;*7S/Y;. M3$XE:M>VP"Q.&TF@YWH033$Q"VF8$4?!3>AWH@F-,+-FHQQZQ:%<.&)LO'8X MP CXQD7L^5;$OI^(@8Q10@0;_0T'Y\L,S0!J]]>=\>.&/1S)U[:FDZ2J* K& MN!0G=3.5AG*@2*D](U@D($VIZB[0A:!-:\?@PS9[(/ -67.<,,3^/XL*3_R- MB]Y6\+ZCX&5R^$Y+#-X9N6#H =I\3@=1L$LU;AR[$F;.UMC@H@A#DY@VN"!* M*$:U ]"B$[T&$U9,0,(4K*29/;<@ON(G<5H,LU?S>8E-"MG^ \L<6X&R;\XM M/^ER[:[ZKR48Z%.U-Z\N2G 0)F"._CLM:A%[\LR,SZ)MX,2.WKB&/=Q*^G<, M#WVYH^C0[TE61@4H6M](H)NG(0'^D MISG%+?#*N])A1UL=]OT$33T1Q7EX/D157F)W<>J5+ Y\)9V=4FNR ?#FR,2R)5FY>WK;A]/W$#>5L6 M.2$(3<=DBR&U*JHC%,?8>^MQ@.&6SZ\O\^O/):_I $+/\-Z%D#5I= M7P:!MA/L8TVE"6L?PF8FC >!\-<@'?0W'G[?/I/33 *74[1GS?/&PW BJJ:# M,2]?<#.$BR$. P^->ID4)@IFX^@SL4IHIUM\>Y=R,.?3T<;#7MN]_QWW/FQ^ MV5[# >TOW5/G:9%6B0E6$1P1'+&2=F0 )R;39"V0$RXBOXM--P MAV\2,STR^0B*$F MWZ@&C-K3AMO\^[J41Z53S8TASI02:_A()Q\2YLZ2.H#;HQNZP& ,MM3M/H?= MV21;SZLT@2G$?KO\?L'[Z,34H 9D[.U73"^SHK M=877;=91X=6)33E:#+0 %C4:U,H!=3Z)(UF M+(PTYQV$ +8YS&]T8%XBN&,EAC(,JVD,_#7K#7N"4N9*4=@$.#)PX+3B:UW= MJI]MHI@]&9*JH'\@P5D/7GV^!:]NP:L;!Z^^V()7[XE^ON.PY1T:E3]PP1Y 0E[F$OQ!)3# 6M%!^'Z$FM.X(A9^!V+).<\G54,*+9 M/+;J\!NTT"KOXN% KV90#J(.P4V$(S4ZJ:LDS;6L[KR ]XC@\8:> *S,O 25 M@]G&F'**4IAH#RF0&'HI?.$^UU>J,K/54U$?A^("X'K.LX0IS\VB. M0MAG&\0QW14 MLAI#\YQ.L,AW$Z[G'3@R$7Z;GS%%YFWJ*('X\]M(/- CHY*=G%VF^2H@M(B< M@GC_2-_!TXX4#WQL\?$CO^*=WLF;;-FL(?JQ3<&$>U8FS0O/U+L1&.Q,[=$F M+Y'W<]E:8%GR3.,WSEV'@YG<5[0EDR2U="8E34"!G9>(%4Y02]XPD-2RC[;\ M&0]5L3P'Q4*!GMD,#J_*R9 A[P)7X)35JN,DZ=]"!&]#PAH04;AFUO7CUH%- MC!P89H)CC[)UL;/[ FU'C%JYEJAH5 H?@7?$P*7=@*43MX+Q@G4LE%KAB)@4 MS+(*#0=DORS@5,5OF=$+-%?1.*\:O@;]1-XCNLUK((V)?9JW"C 0LPP>SU?G M[H_N;/,+0.(;[/Y[N_6W%*S?AX+UZ/Y1L+[[X^1O)[^=_'%R]M];_M6'PK^Z M23%@HXV9T1RX-2C.#I>Q?0"J0:65A[98 30V%V(*3'Q)#)9-#R.4Y6UB"]0$ M:@JWNA.-5SB=)!LC'48GKM%/1;\."MTUS_D M: #)C^1-XX#A(3@*^0MV6FE M2Z5NU?2G]SN;4JX?SBXX@^!84AC."R2T/=9C$>-B%^0/PY&F$V[0239:!TM" MS+/F$N'52FQ0(.MF!ZP=(S]\,0>7I12BN]'?&6$52]B/S0X/[&!J . TU='D#4_V'LLKO2HM( M, BDIX6LFR![9"K9T?$J[B>Z0P]T);54<-&<$/M!Z(ARM$[P2(P^'XVHI)K( M0PL:)3<$ /B[] O^@/?X#D4>"(?'HR.=E"?PXM,1WR:QT;(J31H&4885B$@H MS-R=PX&C39'KR#(WHSMM[7<:/CKZYS"+'#F811J'@!NJ'X]U\/3:DZR:+.<( MN2+JR\H)+2)\$S9XGE2CS;NS!_=BCVS-U^]COCZ]?^;KZ=^//[X[W5JN#\5R MO>M(T%/J'$!T)K5I@/G33I=[%Z,[()";D=S6\'D'52U?\VG M:+>"$'*C[M]>_[6B3T:BY+,"C@#X!UMP3^.#@Q?QWMYS-RJ%$=IE(0^6(>VD M7R;I0C!TH-FG.&_!N!QL][X'01K%AMB$#T1Y8\Y9:8B9@7,: 6YSI.ZX+/J4 MOT(#GJE/X1/FZ"^B2<*0]';J;.2:D_(Z]E6&@[YWH9QN44H/ 2%9+NEL2P1Z MWV%0%%)*(UDG7([8F[I^=#R(_F^OWU556?VOZ*.2XX/MO*S@/WCFSL!I04OS MM]2SG$+LHQZCTQC$=313G##K4+!G(1A.]-H3V/\38:U^=%]U>9;W^L[^5[/[I_O=?;NXS].67'>]/^.W[^-WGQX__8$ M^[V=1A]^CX[_>?SQ[=:!>S .W";%Z%TRN0BSL;XQW0+PI)B)@+.<8#1)=%5A MU-MFH*NRR":6 -U#G+E9"P4-60 +LV9*C MC]A^3/>@*74G\Y,'MLF%5)SVA&]E@OM*K=3/U2R_9 MLE*2J:"53[L'@,->B[QW-N1+LH,S[D??>V/K@@*7,'RV92[MHD?H9Q M+3ASWU, A,20;6,\.7>C=TE;KC45V"@LOC<;(PKM3O)JS] LO:>V[ \E'PX!G84OY+_&IE&FC+!\ W<)4\7T$M=TT.'$E*DV)Z]C09%=X+-- M&!)&4\>^.QR,2B';;\;OH67O38D(,H! MX@S@T^[I;C1+IV0-*ID:* >SJ]=O:0,FV7MY;!%&TXWS-=]?..8/M;./:&?_ M(RD*L5-4W'AW'RO,*6Q)P)Y,Z3"9F7X,M05OV>.# 50D;(9Y'/LE@#&C?ESH MN9'5;*')8X1J9WFTXR?-N/E +:VCF?;?M]0#[V]D8-@763J+?B<60'#MH@\* M1F_!YNA@5'W CY5Q^2=@NU8DQ+S,::+[O$!+7-/R!V/QDE94!=-I'X9(ZG ) M,EP!ZO!E(JW2:$,7%Q%Z%)FM?%Z;M"LM:\*]9&(0(+^]P%X#V#:T+:GA:TPC M2)&."U<;<4?T^2(I,IY;;60A"V3&-!QT\/0X#2/4D)')%W?3&CC62=:Q=&I> MHR 724:_I9Z6[JQ3,U""--*##7Z2%A+I[N6&<91F) YPDYULA,G9BSBB)G19 M2_@,YK*6_54A)I!RI13EKA*.H$O_<5.&AVU0A- )P5BP,9[ G9\0LI,D$=E6 MI8"K!4MT (DU-S)'H%12F#\U%&P(B&B>'*7%YH4,K.N% MZP0YQ.&.$_#K34OV %N+'YU5F,A.:3W7+BCU1[W-BD9WL: 2([GYBD9WM*## M@;>BBSR=GAL"X)XE1D65,NNF7>QV25Y2ZV]7',("]8:G8^>J#P?NLN.%MUIU M:I]S.3+AJYOH?0?\:Q0RM6S!N \_?;K$:6"*^OJ" FBJ35A9B3VM:;+659VU M3Y;EUFHW-T,WEH@FAENK98XRP"<3//#D[#@..)RT$3%%>ZWKEV_>];M9S.JQ M&H@;Y")[MFM@A!N\*X8^4HF"_I=M+L6B2);GG3%Y/W_>05[RY.AP]_FWI<3K M8G[Y$1P*@O2YJ:(P*B N+^F-L'^:85@TU'%KK.N;%E>35>874;>>RZ0)VCO) MNZ;/X?9,6[J!DTP($-\8-XC)G\&^7W5)YHOM?"X1!=L>9#?Z%"9)0'.7^67' M-'#08GW$SHEKT&R8*,NSW6?TY;/=YY%6 GD' LX"5^"W;7N+\W L:)G17Z+F M"AZ]>C)#-!UX2X@6BG8.GOYE)$>K\1^ZXMJQ5@_,LHH&4. )S>1O,V]YN,_[ MA"6,&ENL$1FI&A"?9ERG5"G3"8N,R:/$^YEJ7R<=A0V0)=XRDNG-OM!_RR)] M GY4U;"3R*^-D4KSXMWQ?-TNXC)0OZX9.Q.8?R10%'X%:_ID#MON0OMM4=B7 M.0_PAO1KL FKVC11L*M#/Z?>@:LTJ>I7[3CQ<*"1HRJ=(_.^MA%C3E-$:K8J MS7H*S?P6=_CL$>F^C9M6!5$ITI08%>X)' OK>%*T_+Y'HC7 &:5*#^\BP! [YQ6Y- M 'J!XK^:2E6XJY:K%L:OBQW_D.P(XR"B=RXH#D9/L+/8(H!PO4; MRJ_LM@-6, 4XIO5-[L!>.*?,#>=%,%4XD>)SQU3MH9A5JL"EQ$K,8: 8SN4* M7[L6VB%I;*BV$L5)L$"P6594C9P5>-JQ+69^ND!C4>*$R.Q5SL<>SM7)=!'/ M,]DB,S [RBMX035+0_9XFI%;6,WXUIR3ZIB2COH:A^#<23@17YI;.SX<<*B* MV0&3*[6P\3LFBY^JH-CPFR5WLUFR#H[WCBYHCNW,/(6SG%:?>T["FM9.K";] M8C[@V*7=HUG7>0V1;KY?" '-.; M:)TCCH1LE>T&E.VA*%L;%&5CV^U+C8_%< M6CVU@TF,7>B) @HQY-H8+@K.*-6B[=/"25FA=M?V$3AF;V[-.W47L-/]*&X] MD\1<;Y,FO5%W#$,G*U7<)?G&!>:#\._+,IO&AEA?CP;I0"H]8;R&XIPD- @' M@@GRDV@V[RRYOL8W"I7+T;WO&7$?@Z?/[BYX*IOU<41+?]23AH"BGUK]P=9B M"@*0D@)RW!!>XL(VQ&2V*E3.'T__U&SI)ZCC;Q3=P4>$+$)$%2.'E#H7<%UW M52V-4KBF^:\8R@G\Y6<,)/Q/C@NG>#K^7EUG;@M6PB$FL5 ME\!VB':DL16";,:(7$QJ-IJF:=* B_X6X^Q"*5E%'],F8R=^%/N=(V4KZ&-, MO>62O,YT&L)03'F*VGOAP"3VKN(:7F]-&RWXZ!V"#@"N#U!!:P<4HLW$ZHN6 M"S:1O"BV)?P=#OJ&;%%CMBI%XN?78;%&;%\+C(M7O2C!IVU<@)0^V%J_!EA! MDV10/&2S)@'Q6)>EB?B,KNHJ&[2/HPLE;M NBZ&BWD%52@:Q5:'8-TDU-V&_ M"R=9/VH)@Z/PS$MT"SL:U6^298UI%G0W9GR I7EY-1H.#%-S.9DLJXJ=DXR! M=9:UV2_V[7P.B[_I?8!'3U,2^;,3D/#$T3R:Q5%Q[JUWO2T3M&)D%&;&W"#+ M15DXK!*(!YEY,RR*W0+_Z\A28&D)DVE\[:!>Y $85<.N1AG(I>P-&^_BZ1@9 M4#_8!+D9N\, +9](W,]63(=+/4X+6$@7]8_A%YYD)&(Q !X\DV?D;1'\+K$= MOGPL#A_>07)(N5X%5HG=G9!\MKM\#]%!RVH"IV_J4!2V 7.&K#>PF,*N80+& MFY%4$$<)VCT\7J>4/ 'YT=[D+KH0EU>07&/01U%B+QW1BU$'ZR:$+P9X*R>N M5J63-.O&,O%PW*>3M,%5F:4XZ:@RY) 9K2/](,#"3<>([4L^Y1FFG= MIZQ30E&YR>:5Z&M_7W<'B(2UYV07H=TF97YR$!SN@<9=P M$0T$;.I"X!?DGL,A[[OGLR3+&?TE0_&6 '5LZS6Z9+^]&1J!SS&_?@=SOBVE M9<)&VG<@ S,06N[^IUN!AF22ZA)-,/Q% =$CO/-DR2>]SY9M1 ;#Y:3)2V? M#;6:[BURPLITQ ']'M8C^N8Q MN S9INMA"$ M115N7W%]W59,M-&^8C)P.)COYBH-PE>)@I:W8G4E7GA6F0;$1;X2U9A5SO2L MG0\ZL?+L?Y;9U(LK.WKC%=ET.\Z[FJ1?XA+VBV-A@*KN7"23BPPF5/DXT:1: MY@T(#U5RU9T%4BV;$+1-8T%>I+C&\$_4M2[B*V0TR&K'K')M*CA$I1*CD\C9 M4!0[+V>-I^$ QIYH MLSTZ'P!2:']O"Q7:0H4V#Q7:WT*%[D=L<;,YA4-LZM2@IE;(,H:P5^@Y*4,W MA:LK,.GCT.,0D'+GL46HH++H)[CQNGTKXMH!9\18E=8H.2E'X+BLA8\P"8>H M*>YVF%&<4U8LZ3QRD,EN;/$5/I_K'"=PBG.A'X7'G$X"7)66(S,<6R+B79&Q MY3;K2[ZHH:]<,4%K+?>D4R96R]@?!TT/7/A 4N.B]"1'1HRT91-$#V-J^NG< MRFN-4$Q_+@V/3!";-O6?-J Z3E('*QE/M1W>0;/^=P_!>@UH*P_]R9SGW_8-GM-*MK/O+W6>/ M+_FVO_GC\8C:NPP'-XE7=F7P)*%N'3;*:!B2M/Z:2)-9;A6-XS?=)P&5]BQK M.3KT='#0NZBS);>=F8I4]9J\T=MFKR&Y'AQOPX$-QTLM>A))N;%)Z2^2B72: ML>0"C@MK.T>C]UQ0$R*=Q^[2VB+;*G7C[B>?*8:\ J.'HEMYFEPRV+JS8=*SW1?WXHQ\OO5K]?)KDZ3JBHOVC5NH2;6OW93H03K.N<]\T(H 9BEU D!MZ598%FT3^ M_NC-[;[8W+XXM! @@W%SZ;9JRID6DVR1Y*KQ*]\I@>\R/*LRJJ;L0V9< [P@ MH<;D%E.,J36B6(;I6A%F +>!(7?4N=[T'8A_O28C!AD!^U[G#KG_MMO@>VR# M(ZF0(#R3Y5(F_(_#H*R-85)D$<;$AC9'CQBGRAQSTBZ080:8>4;L4";9*F&_ M]7BT$AB*:LE.N\OBZX$:XL@!<=X(WS/R"ZRDAOH7,0+IXED31[,J68+Q MB!W4__UO#B'%R&537Y1P"C2KF I%9DN8A*S&2-ER@B4;%95VP]UG&7Q"^V6Z M%'X:SNHDQ)5 F(T9[/(@BF33\S6;VWCZ=?7\9&NZR\Z&^Z9YR01NFO3".J@@ M![X3M+:CH(KMAA>J*"_F(E45/O?/*VSY1Y,82=G5O"1J:E!68"J ?^2/P%2) M)!,):DW8'*?,$4X+ZM+B7TL"*##IFKO&R12Y U(L7Z=TE30:!.%%G(!&ZL;+ M&H]MXN@&(Q>9GQ>2;J49UN_]%^PP'7;(>[DQX(YG0V1*Q")$(?""SS%.ATQU M5OII?LNJ=06)4CN'U^.!V;&2L+2M/ >>9@479'G&7EF"X;,8.>^?4!/&$LM- M^>]E+?_ ]&':& \5/\(DU$1[MF*I3I&@-#>EQ&AOZB]RQCS)\F7%?B**"J\[Q\^#-N:Z'T+ND>*[*ZO,B3R:I/G@D M>7B583YF33,L=+6<>4U:6\JH"- K2T+ &.SC6E@^_&V7-H[L(MI5"A>28*<4 MK4\;E-VLH))0SWPG>/X$8QUD;:/V<%>2ZB\)P0;JUFF@1M64\F2*0'-O&&O05G\8QG;>F<0?1FQ3($+X@B?6 M1'A&$,Z)&LK1[3#D\PQEB8XW\Q=I)O]-R@7\HUD63FCD1LK_6M&GH,L-$?8;CL+0S-X,E&VUI>B*W M5MNUNKWHGS& ZRV@%+=]KI M&&)VT'_S9$I.[GE93E'5-1<]/$#Z ["?$BY&'&>%T@DZ<_8=?-+OC:'8WV(H MMAB*S6,H#K88B@=>I/O\;HITWZY/,$ MCO>*V6W^3ON:'=9&V?7L,CPYR,WN'?@/5-"*^900M6:RB;JO3&\CJE^1DB@C MY=[CN2)(T(/:/Z*Y<%_.K'Y0!Z>JS$J=:77DMR)(A@.I:Z(<_X*6)T_A7A7. M"&PE?&4)_H':PAO#)-:S9-*4UPT5]0FZ/39;U(BUK/,F&>YTY'G[K0'&)P.LFD MV.4%ETW3.J/<9@KX1#19I\M*Z])\3!7N9&:BCMUCJD6CLZ+$(_THLK^17,(5 M]1)+GZQI@X$G.47I\U4KY"@H-=-;J/6.L05O"[2P-MUZ\W*B6;(>IJ#.W"-: M@OW]?MD Z_X9?N-D#& W8WDR1V>9B@Y#M83^1XM]37QUCJ85GM(TK3%C+>F MIDQ:0>SQ^'/]2^%)%Z,(@WVF1+\.F0E M3GV*RQJ?=I5H7Y+"9C]&T56YS*F(!][^(AMG0EAD#GTLI,U7 MIGJ#TE)"=($CT>9G=)?+K,RU[AX;.,.D\Y %A M+9=@,W$]S[!TYRNI"CK?=545K=2AT-T-W$[CMWA;,]M:3,]X$6=# >.1"7$>M9M- MZ'9[]V:94Y>@S.[8X:"]V;H85S(F+##]S A+L>K9$+<6?&((9'$V?0L#G0DG M?O/$?7DC8BUOX6NG" $9Z^4XZA9C(\'K.&OZ9K!;YDU\YF9"O_YPZ8[4_)B= MYZ_)&Q]L\\;;O/'F\\:'V[SQP[;T]_?(U/_ 9NV?AC.=[?NS#KLB1>.@F)@6 M8K7!,BGM.!^&VL[#:2#966R/QPEV\(9CHFY<@)-A,>]*I3G=)AU*-R]H1A$- M%S#H,,)CE5Q9%))U,XBJRO%PX"0J+&N;FB$:8JPZ&F YV1WM@6EB* I@4J8[ M/9EKP[]H*+8(NPM20)DN,-UD"!9"JX^@3EW]$]O;IS.=>VW:'I&3?BL]W5+& MO\"!"/;/K3=\>[M[NOSFT]RA]7]ZC:_U]O;WDK?;L$J1#ZY23 '] GN[FB?Y M3Z^?6R'#4^'VX]VD:/SZ&P);WG]X__]_.O[CY/>3=V_Y3+KI_YV>?7CS_T4? M_CP[^?#^%/4D5HJTAQ?.@9T"9R;<\W%S8)G#P]WG;; ,;+*C36ZRSK66ATZQ MDH,,>ORB2._!6;I)$5("%@V:MQP-Q7,\I[@J-L^@^#G#[A4E_+XLA%D%OG++ MY6L?!AMT13E/BY0J353I#P>.UO<:PQM82:25KN;(< Y#/YPL! S)6?KOHX\ MKY64$NATL"%@C8W,A@QZ#, MC-LHH7LV^N\8K)')D5TF6;X;_5T)J;.9F0;!T3@FP'5K/QP\I] 5(MN=PH,1 M _'1ZN'%7TDE;U^# 8PTA(AN30EB 8K/SA/S%T*[0,S9K0$8P8(U@5>16N)^ M<32O&AAZM(Y%*5K60 M/L)O\DS!)3!'<',X(;-%(DE26VS',(01QCI,%9&6VTB80=X6OM25"59_W4)M M/JSPXCZ$%7XD;X6LG Y(M)5"(8S2L<=$Z/ MX"[IE,X15+S8A!"UM4,'H-3%,+I_SLT/M5,/:*>^,SD#(BFV M08F O)A22/WGE\=X) (.BAP].Q65WQ,X=?Z15)_3A@.E?$_:!&XK$8I/&YX: M]ZSM9-+0?J+P_!55]4VDC;1+:E?SV%5[26,N4[V@<9%@Y5T*-Y\GA79?#D/+PMQC9G+^X?JJLN8 MHM!/O9PO5+5Y-"Q\-//97BZD(@T35B!?8!_K$4XQ%U-K%]J-5+7'<^GSK70T M4H+G[>_B%#_9WQF/=IZ.=BY'.V_--9]V3T$T*^I2NQH./EIS5XT;"_$X7W+M MW;W03?O;P,N/&WAYDT@$ MB@)2+K.(@R(+2<6Z3?X:R07[&$\]MQ_V@8EGZ6!,*M )WT:6XUO*9J0K,VQD M\[N0"%"?Q&TLB'[$J7YR;P:WFJ=$6&%Q0+&:]DAJ[AGMK?G@B@.\Z1JFPA?@ MNFU\:Q[>@YUY#<#F< NPV0)L-@^P.=H";![V$7C[0%;OD=(3Q@)#/[H FPY1 M**#H)U0@AB(WZ@UN&91E&\3B@ER*:X_ 2+'9:JU2L,H8^\-1]R)TM UKWU8;')(V>*N! M9 *!:3+)WPA.YE)%PG?L6BUPBO*&>R5(XPX'C)W;WY,R5+\=J7TB,OU.09:1 M9KZL^JX(BO>H QHWSE-4'";7B6F?T?'?QY/;2O-_+LU'X=E&%0DJS^N/L7%0 MC6W@FT']2UK@8=;JDNYX.][Y9-NXD^Z.W0B.=5&>K1O?]9X;[R=RS-QWT"[# MK,F[Z*C[W;#-;X*];3ACT_+^E.3]?X-M%>_M[9&\1_^-G3XMD,!:=LGY.>)K MFJ[EZ9Y.GL/ZZ M.10@FHS+(;QIP.%O6.[[ 32\A6SO&DMA0_TSV+K@)KGZYM3!5QE#I#R,V^*Z MG7Y6L%=22W5EFJ13BA?-E[G)&4@=)%OR3KC<\LNJI80Q.[\RS8U;[SZ-0[(. M>PMG8B24JB7>A1E% QUIO>:277***0F1%N6\W(K M\#%P6=V?V7:"($HFX2%D!]:6T#LK(#,@K?'Z:!&,P[(ZK='GSO@<^"%MU%UX M4Y@??!>W]3R1O<-2X]U ]$DILF4AMQ)+'VO+M>ZVJYSS;B"+-[,YMH;W?VZ( M/"-#Y"PMR :AB,^I];,TC\+^H>%>N9&]"_>,.FZ)WN6:0$UG^M$QMV-3_AS$ MNVX0TF)&@<();>U?&]KJ &ZU(UA]@&O3&\T?+U=;VP&+@3'#&^P\'06^\W#0 MXZ!<\_C'5(WU0VW)Y[0E_TR4*W06B+H0IB0FJMA947E=\)?I+4GO)SG2^21T MY3P%NXP.=5O"'X2<%?ZO1P32^]PA%]A6VNY4VI@*[ ]#OG7,%DMW*-%I^ MF(5R;FHT1OVA%A-Q>ZO>BL:FKQL*TCYUQ9RT+V_8*:>[+$V4A'NU]@7%7SE] M0S\X.;X;= 4U&5@*/$A74)<8'4U@BL*X#7TW/S.@H)P605P:E[A4TSL.7RDV MP!.6)GV;@X.==(3+Z+S.*.[RB\?K"EZ_@\KYWH"AHRU@: L8VCQ@Z.D6,/2P MCW%AY#F>XA.IO)%"LVLQL\>&%<9Q*]G*1GVM.0 3@.@[M%EM:YV:G.'N0*B% M5R>M6BL,W?>,"9'(.8#\1+-,\W)JZM@UM]03+1D.]'8[B9;3(6$<5=+.**_F M^!UXY%[X1Q3;NS028N24]IJ$A<>QR;ZIS=QQ'*P]'M_"KP75+BDA^5%]8=YY MFBS,2?73_;!%ED7-CKNRE^Y.38:Y+_LSA MY9C(%Z4*>U',6O3=5**)[2KPJ1EXXU-DH**>MHKKL F=S_BX_I'VD8V&0$,W M]]&W:T&#ZK;J?9YJ)$P28N-B9R1.9UF*7R1(::K;5<;'!@N-B)N4,"PYI[FI8U"B+ -+M)AJW3"YHT-1GDS+Z@^\X8 M@@>SE,E :E:'1,3&L72OA']*,L/E2DSA4I3>)/N(5:J8MO[%&CGY/GR?VSK; M>U)G^TWJ+W]Z_?+^%=KN[QWU9E4P^L]\O[06NYZ+KV+7.KNQJ1(D[6<%"Z(]2H:=[(?>K9Q/6^1%2HQR0 M=XU!8!SY#SJK0(32M..U=J/V]]>JU;7T]L?BW<8O;:C@IELR501,D@O8-1R5.K9@?V[X/?R17[9[#"'*1:"?R!* [ MW*P6% /HV%#2J><<'-V"(=*8!8,]IB3=L*FQQVN5!IJSXUZ=P='8,8=F&37' MC=(\9!\_.3L.XG\=8S8Z/VOX%C4^B=_5B3&T,&?X@AW#W<&+K3;2J?=UT"GZ M]/J5@NR3O"YYEW(QI(&GFVY$+O?ZN"R6-1>#P>,!#_)TZ1NHOT#D[:V>+]B MJB>FYFTM&(O1]_R(*ZJ/G7:R*+"5EUYF)54H*K4'Y]2 55%Q)6W$-!SM2 M)]>B^Z$JD*G4[7MV*=Z^)C@[IDE!"R_A(%22:CG0HI.Z2M(\B[C=-KZ&'F/M MMJ)DY80-0@T&W7V(VB!$M$NYABG7>Q7GR3F3/]1E052C.QQ 1VU?EA^[\1N,791Y3J!36SS@'@>\LW,^ MS]6\\JT-O60X<*^AAXK=P+)AY46[K> EXI>&0]/3!]DWON!VW]'=V'U&I;/:CY HY7%8 M?;>6"L\^O+]6WQ%:?0@GX=-<^HCZR7M+Z6AML#5=Q3LY/?!)![%UC,F_UZ)# M#2]<)%B(CJW5F.-@6DZ6C#XP1=(=+>>#1J*AV6I,M1!8U8HZ=/1$N:"6]S)F M')+3T-2.3N*Z>K.>N &RBH.M5J08A!KG67UAW^?D[)A'2B4V3K_MC%K1V%F! M2_ F'AV8 :&PD?UR#ZMN0IJ@-0L6[?0MV$@:Z9*Y29$";\)ZJ2Y+^0DC:;@2 MOA:CU7VUSK>B(+4;G'$7VUT0C''=Y8ITU.BN_/P?Y^RUT\:QB2 M1S8 KAMRH*E/M HY]B> E0RLM\J;LCJ&>\PW!. MEYWX MU<"SUPF77E*6O"(,MM=V6W&YJQ08NL1-#ELNAGR;CG@OW++"$IC#O1&K/#M& M=-6Q[MV+#4A*RQF6D_\,1C3RX_X]&L2ZHD85FF1[CW!ZD@& MV\5:R*1,PTX3L(1U8E;[W"-$S4&9MDDJ["JDG]I*0%G?:$;H.;+Z7.\HOUQ3 M]NS^9N?J@A*I.)M<.H;Z-VMR&4XE24'_?4:QIQJ=-BV6.J9KB;MF*AA 6]U: MU=@(00O,"I[\,)I:%\\F5G>'@YLI^NC.]3Q7Z:Y7])U+_ WT_+,?4L>PKU**3SK MI)"' S^';/2Z/)Y.&025GR.:KE)\2QH5H/G4G-#G>^A$JO G]!&6,&C!SS@M MTEEF.O")$V0)UC8S*V0HLLC7HF+W87&"O5T%[(B:)!W>BO,K3Z3G9-,8G1IL.;\# 32< 0<0K;"9: MQ[))OB")WC*LK?.L:L6W!7+\L\BCZ\4Z'PMIJ>#2,"%3AX$&?CH#O>:+95Z7 MU4K[+%XS*A 9KA8Q+]X]S3^+::RE)BY!F=43^((S%R@87:9U(\F\GD5DID#] MS,(==.U[<"]8Y_^58U&C7NE>69*E+24(^FR)])G=Y?E4ZM<]T6":N7.Y1F9_ M-H-7&F9=6OPU&\FL$+."1898S;?VVH]T-A_TGLV]C<-Q2US2+K;@<$_#D'9= MYJG5C.IP) +$KY;H]G)+0W+Y,"_-&XCRQB;6**RF0?P.*<)A/YPCO)3H'V4, M/;K90ZA'V*. !D65OFT8J[C@>@I91U/Y@5 M&+2]..>X<[A^.J!9W\#$N#.B MKBQLVAH\60]&ZP40.@=/!W.*W2,1CMR4-A%>@4QF-!,\-:!?U'!1I4U@B[4F M@EFF<<8$,#Y+)L^/GF%JI'48$ I-#GOV.H@+]6L[P<4R,+;#;""7\HZI1!+< M]F+!D>>>C'PL^'Q-H-PG5'!>2(6AGP,P)E;'2>KC,]SS52? N.9R% J*5/\[ M=A<0Z5TPFTLKTSM9YI5(\AZ/]KX&D_!LBTG88A(VCTEXOL4D_(AFTN%N]);X MS=D16^L[^J>%ZT2P2J=C"?O\I'F.20;,+L9,]C7CD\;!V_RH+N-1Q28J%,W539>&GZ(YGD-,>,8XP?-&!9=64^ M>N>JNZLX>1BQQ^"(- BQF4+L!$!1=>%%*R MQX?8)\2*@33'&-^!=1\.C$IRW71GVIH(+ET1BZC^'\ M/4*R&,1/M\,4MO<"'U==QU\Z;1V@&JHCL;_)\:F:VT3ZUN0%U@?_[ZZQ[58X MOX=P/MV-/BU*@9-0MH$T\Z+I,;G(OM'CIMU_9)QZ9Q&>KQCQ(BM$FM50Z(8U MM2=VH/*%0#M3XM403D@:=Z*Y^&DZX6#5=)E3*YR40R 2XR A/R_!>)HE>)_@ MN,KP*,L3):AU]#3&SZX)F;N%%:[QXZ3M[J"EWX^X4>[AIN#.(KU%F]K-%EAT-^3<2[NZWJ6H_ 29!Q &XX./-0K=QR M2*-^9* %"5$SW@X?L*LYSPUM"_-GO5O*R:DYC[?$ M/%Q7ZO(_73T8R V7;U->/&_(H I^.)AI;,C?\XW6+(V_]\CYVW8D>)"' M"??$^2<[N<.!BMLG:Q#)B>(U5.SJ:;<./^17;URGVR741.$>O/XRJYJE\0,< M^\]M(NMN%J(8]CJCV'8F:NJ),29N?1 \N=+Y< U#*MBE1[J?VF=YR%P#J;7) M*ZET""HV")E:%"'1B-,D .T]JB>>I&M4K=^YBB9% +=\$KMC[J#^Y].=T5DY MT9 RO4H7K8EC7'K!+P7EAOU*C7+B+J2:#>TLY=$A\YU,E,H%GP\'!(YEB,>6 MF.)'\O>>(Y[Q#)]75SZBW9EQH?%2(!?C7Y@.SO-V5>V$G M\9AE&W.YU.(N>[4R4 6'%0O5U'R9GR^ @V .@1^EV6<*M9UB@2#0HP5.W@9KQ^@V D0>FD+/"R?9VAC>U C1=/X(C6"MIW29E)B>Q6)39[0@>B91/2:[X-%SZ24%9!3]# MI]._HT68:WHQP'-'#A'C#5??B,DM5*,/ ?(E6AC?3&JJ%UYJ@:(2I",O-=92 M+\QQ>NDD'Q7:T; I3#PG=I8DATIK:I.=(+P"16I$CQ"U(X@T&H,QYT.EJ L> M"VI\.3%P*L*BP9#0IJE+HMBU3MQ%"L[AA>X.=C+YAVI3=:3;7N%>N#.RV#5G MPE;[;T#['P;:GW6?$=< >*=.13?DCMTBQ9>' +SKU8]I@68Q_[(B/XY,78-E M>[[%LFVQ;)O'LKW88MGNB?*^8PJ$.W20MIU%KNLLLN$#NJ>QR/[>_>LLQ[^X7PK[+P;<4NM*CD7CU\$^-;EMJ;8-D\FW2W;W=SJAW=;%"6 457%.A@%/0]C9'&K7+P+59R!8J\T4M5*.Q">P\NY=$PO MYQXI7&:1SE]7+'@RZR"P^ZV$-3"Y&8=_D'.UYK3AD&@])0#:]Z(.JQ2R M(=5$]3R3KO9:H2Z%JAQW$@;N $A)L5W$0NK,T#P5G*06>#D6:W F5_K6WP), M)=P!V_SN0SW6#G8-?X-?1V.WA0,O-"<"*D%DLO.TFU!#UAWJRN5UF"3U!8H5 M;)IQ4GR.)A?IY',D!1A"C8>R/L>C!&Q#AB^5P9DI-2WN?C#L'UH_%6,!-IY' MRZ(-@/.[MCJI%'II4E?GU*I7RJW@O2NN\E:P5LDUY*UQT8GG K'*.FT/].Y M\-MVJMN@AP0]]N]?T./CN].SCR=OSMZ]O5WHX_3OQ_#3;>CC,88^SKA!E8L8 M3^AH^IBBU3YIK!X71%^J_3$,\,WVT+J^G%4ZMPL-U\QYS' 0G!VFEF%RZ\^O68.N1S* M+T_]Y;OX#%OWX#;NP;ZTROUS64TN$L13_0E"F4H7296QW:.P $G4Y[5"7#?$ M.(\$U&JBOU._DY[DEJ+['CCL<[7Q&9Q=@WAJ)S[QP%U?M^G4:CZ+$G+1B=G> MB#9Q&B*IQ@D\&704XC!F;M2M"=,HF15AY=V!(9H4_D9? N8O=4!#>I#@5;C& M8QAX07NTL.BP=D2>@%"]/02^3[!YZZIO8"]R4U<58EQL:5[=EFNGL5@-KI.2 MK%"QK9 :4.7M @DW\1\7JP4*G2E9OWXO"Z6YAB>VNK:.F5\H#[D<7VPCAP<6EEYY),"@6Z M6&R=AE\7O>U9JYB2 J39')=-8BH*;$QHS9Q2-G^&0QJYHEMM4I@T:RB=4;O0 M2-?(;MIE;<,!S#):I:3[)F 8P^LD$3#O'Y"A\YHM12S'/8*)IO6("K=;(X$R,';6V#<[( MYJMY&U"H![EDFF55X(QF!4H)17S!/-2?+C M@9,;"W/\?!S@76VE,&8W#?%\ M><6\,F3>!E<**+:_GXS3D8$ M)-$;C*/,B"2_IE.Z]N@HO+&TC0>1 SCV-0:I*B3A+A8.1C=/SU,JVP@;';CR M;GFS$YB.^8*$2O0=B:NE8))Q%I(EQL232W#C[2*CV K,\N C+LML:LKQL,,O M-\T0 9RXLT*,1O"*=>FLG*')<7(*#M\VTF675](R4_Y(SDD1&^QH^P9HMJ ) MU3/3J.F(1\@)"X/SN\8SBP/@/"7J]"54);24&4N9/+-IZ3*MIS5%!4:ZAX.. M62>D8:OJT8(48)_A"06S8QPY"B2D7:$$MK.0;)+HR(J"HMO@]]D?FQX9-MD8 MEF'>)$T<]]BG'8SPZU9@..A(W+III:](SQIBK_Z0 ,EA4&]N0,D:S0A+(GII MT7Y,O_ : /.++8!Y"V#>/(#YY1; _,"=OD-R^GXOJUF:@0F9OD*O8B'Q& G$ M! @*=M+8H*_5;%[;!S+K)ME'6R$JY,9689^ACZ',]@3/,.)KW"\ZN[G)H3G((X%9;F[*[2?[3[;/> >'MP' M?>=RY$6]?%,_S&6H84)N=U'"BU84XA(:FY:]UNFZ;\E+'J8*.R(5]N$*Y*N^ MR!82M&(VX9YM[1J.@I4MZQICGY+[H70)6:NEWMQ_;X_IA#I)BT@1ED\J&Y+8"TXQB MN-,>$1>YCH[S'-6IHA(M?,40G%(JT>T?Z]ZK(ZZ-786D]%446]V48!W6L$N; M6/[0T<5NO(&]&9DW"YG,8/D3(9Z5@$Y_>PPWI.1$Z/CK$J8+:V_%6WI,T+$M M#.8[P6 .?C 83/3I_6#$/\"XVB;0A^B3T761#T0&AM&NPV6AF/H;3 -CNYZ_$PG!WTW? 9OV(N8 M:=,!7 >9B>X ,>/T6K\6,A,L11U]#6J&)D5>0NERXB.W#]G6(+"4E3 MZY$04H(29G!2LID,"7JHK,K*)52D!([O(L>>6V%!- 2@80_ ECQM01L/5289 MM$%J#M'_X*J*CH%3BX(?E@NZW39'G5YTPZXX3F/=78F=B/RYJ%0IE-6CAP%Z M>CVYAK4=CX9FTB^@S/WX&?AY2_#3VB5#7 ;W8&^;P7W@Y^J1G*L3CJX?[;T\-AZP ?&V>@&"K0>8NR6WH6K4VXZB, QZL@]"ZC.Q_EI/L7A5 _.:;>\3&"P;EOLCHH< M/VBA:'WWY-R-?HSAEP183MP)=$*\8]. M>0\,EC[*7/0RANK0KH&'(NV ?XL $I9$L^P+F @8PTF?.%-53R[2Z?(N_-'] M^^N/;I,VWREIBKX\&=QW^A8]6C/[.GN@H-9W\N1L6-JU[B$00/GA!UO8P:Z<=[[DB08Q=9[ M][UE^OF3,;FJPJ=.T4^OB,'4T^$15E9R\K$KOT1<&^60E)*CK SR(29'5UX= M9M]P3^$X",6PA'.X]O-+R%5_B<[85&M88'@9&19S\*F7E6'U@&,5/>[J,UA5 M](MM_.JA;J"#S@U$M5"\BUA<,#673C(62P=_AF497L D8<-HO@ KC,IN%DS6 MS;M*?BG@)#20&C<,6E.@2(0XCJ1V@7*#@L>Q!$M:0T)WE&T&IB!2+DHA#]N64$JI]T/AP56K[$*: DQPL MB+"Y P';J"4$C'ZN) HKR_=!S&JK1>J[U.B5&72!Z@Q*RHQA:BSRV3!%2=&2 M^K\=+Z!]1S"-C6%9VO(@YU)%HZ>]GSID*CWM'"@[HZG2I-$P]#J#8;3UWK;> MV]U[;T?WSWM[]_OO[]Z%6'FI30O/\.3KU-YFZ)T>'N\^_;>>X MKJ82/X!5@Q*SOSLV2T4V'S<&2<\.X+#D".Y"-4 MWVZ:I[JNB>.T*,6U%!O ;_EYV;_YMS1;=;2#[9'A'3UTIW^I#^=,P.VOSE-D MLM4H04P!=QKQ<"#?$AN ?@H&%3@42")?R:_#68);@/H[A__1.C*&LSI-"WWNGS4+DAUSF=N( M3)K?HKBEU!* C+#@"6!?Q#APZY4M[HS &;W&O##+D&LX>:3=G%JTBI.%0IBI=]"EVQ%?3!7%!-U M*%;8U71V>BUMG'12EZT2+\F J'&&+%D6I*-[.>KK6[!#PMVLV M"$LV-G7'RN81G)AP#(/>R!9NK!!UI?X3.X](CKYU/#OY)\C>STS;" #W04 M'$!3U2"H6/(E4J5L.L"P=\_;#Q[L;;%?6^S7YK%?^UOLUSUI/[A9_^^@!?F 0:WCQJM/9."!*\5R,W->W/DW,[&CSP3W]!Z M^3:N. +&I)4RN-H[9KF_NM.&QQ1S@0XPG(QD&+@S%+OU/M.E$G4;=+B;>B/& M0L%[G5=E7=MIE:O=MD%=A[JU>]RLI)F[O@EP\%QL>MF:-4LOAW2$;#$DTJ<, MG+5+308F/&Z!G7,"P1KPCET0FE(X[PC,E_1!B/XFI]VE7A2V10,H9#ZS7@XT M![V7"U-(0"#0Z;>XZ45^XAUF]M;8&G??,?2>QDTWJ@2Y+.H?%%?Y^33)><<[ M.X=1L6&4#!WUQ#2+1[GD8!GJA"9+D*FLBQ*JLZ8KU<\L1F=M$UC!Y20/#BGY#Z_XH#(^C"L0SZVC%K\T@[ZE<'-,I5!D?F359#E'^9HX] ,]W=(Z0W08;<'8AT\WXQ\2ZWIR@G[! M>*C9UFUJ7"]V0PB2/%G6")JS'%<8@H,%$'(TG@O'';=Y?9\41R,W/(#4Y91. MP6_.9#^:_JB-/9XE^";OXZ#P\(5VPF?Y$7!'E_K!;[A_84TT$)L2HRSN@:T= M7JUYA^-:E%<2D;6O'[:V"[$%OBG8P2=7*SVX3)=+BLOM7['^%+8C&8$.(CX, M/*,596)$?APC,0W(+";"B],-*^X7 < / MFVXC6H!/%%H3()&T8ET; UU90N(BC.VQ-8PHGSEC5=DVEO[*W6X 'Z4 N4I$]CD;YM>2BELC MWF4S82UG?V*>&_BF8(60#6$GV)W=N^DX^>SQ&?Y=._Z.==#O9<41!C&:NH_N MW?W8R9>8#:>$')3#Z!2-##:#]9L3=R^Y=X0;SX M3(%>>@2-(O X,,^F&38F\0M["LB[CMSP!?OU%GF/V[05(=+HDZNF@ND@5T.F M5BSB2]LB(_SQ#N6;9N9)8'.0+SCCA8XF%V7&5.DU.@08F5DM6'"\V8J=Q&/P MU;4I+S_=R$E$1E;"G. =*9P%4JC@[A%;P^@>@#T)Z\VMLV8=B^C.IA6V]3,: MDW&2K^S"<_)1WTX",SNL:;/*J?T?&1AXIW+%&D*)$'%>YU8'!]=B)-2P $M MNV?[&XCMM4V.,%G:MQZVX8KEDA"GP'4"F!LM&[7B7R[RUC:3YARZ(2QN)WZ9 M"I.TQ,V4@Z0#UQ,WTQ(A>,-QGC2BZ+]XUVM,,]IG8%FL>PT'$2)_=P8U;7I8 MHII9$_9KH7O@NMIV-'1'CE':=; ,.-1NQ7^6;:G5&8V6TEF8&; UEB9D0D?& MPGBJ>FJ((RPK-+.E1NNV4>QT>S (;O<@FI4:2KD+\7=KG?KXFND";V74C1_N91R@?D!F\>J:S=>308J@5=V,U,DX;&EC;U8M84MU5J MCD'DH-KLE6RC75%PS7KQX]0"U]AA9NXF=5A[VR3V<7DZ24T]Y(1"WT97X3(W M[:C6F&Y*88^"L2P+_O&=.=2V (T;5M^)1N:]]=_Z[CW MVI+,(4T"2733'6Q9VMJ'=7S6L[Q2IXG4NR2@[J:&+--TM/,Z+Y80FR03,,1? MJ3Z\<0E1Y'R-9:P#>>ZSI/<10Y*>M9"D%I)T_Y"DYRTDZ3%8!_=N'("-*1IE M]F159M1[65#A#I"4.(!X77'_32^O&N.H@K,X@G.* M1 !*$&XSKW$56G.M%KV1N-+]&?3RH89*@2->@OTP9I=]!@91SF"P:AM(A7%O M<1M<_"B;+XML7F;C:$MR$^4"A/%$DQ >V;0DZ+Q$I$A)/1F-$6Q>1K-\DDYU M5GG>>13;.]&_>K_UYM0U>)HE__JI]ULI];?46?&QFI16[O_2(M<\]$43V8-=/XKCGJ05:%@(+],"^,\POF]I MN7&-NGTIJ<^@::-J#NQ<^M?81$[#,;[!U?DI+QX\T_/STZ]=^_@=*YH71M&X M2*6+EOK$JSL"?J^!+8)E)C$>^E=SDQD3H#?+R"]#6MEOM(>-F+QH) M@=P.^:=@?81G4<14Z>2ZD8U5)"S+,-1JT^3*%SX1%X<8,('HPQXE831>?E'! M?T;*=@IM1AF!76%]8!1XKN9F+X. M%0.VM$C(S0WIUCU3C%0Z/TO.',]:$E7!F25V=BRP!'"!U:ESM%XP/VTZ79RF MUAX>YT@ *CF>=(ZIKJ0L\W$%ONE:>YK=XRG!JT\C#!5;@/_G-G?#E71_$;SE M.%\8YJO@.C668#Z<7:D%B7>8]ONGN6GCUP\IS5]>+\UYTX'$#AN/.LM;2C9M M+!0/O 1KP>-SX5V%<' -R\(UJ5_"()UKR[Y8";- OBT)EW(U4SSO:8@^L5NT MK5KXWG;FJYWH=_8A-S?(B52/5G"U!M)K\K.NZW)H&+!3Q ALDXXFHN? ."R ML)*+8GR< Z3QYL9DE3+P9+%TL"9!$FKH9,LC$K4!A\9]A'O,B6?YR38=.('D MBBZLU/(HCJE(SQ!7E##Q']P62ZH\!8@K8S#AF4+-?ZZ88&OFI,C_Y#3G)(67 M9NS V=KR;W^_-PZ?L[10<>[>869!GIG-L9\(#\XK^9$?7F>\#&T),W1XY\O2*R'.; T.$1@^B0T0C828E MMOSP7.7BXE5:8R$"9WIU/46^?ZHQ*.-( S99:9UN=Z/-#7\T GA3/:(K6&;L M\M-,&&./Q5K4GFARV2%BA-,1MO/]!?SVVT!;6H7ZY13J:SC@"HTELU_\ -%O M7)EB0OH-Q2@6!Q4C49TD%Y1S%Q,6"^:PK@@YWJ"HR4Y\*VN,JNJ1DYX)($TN M,:+):C69<+4:E;AP4@R<.^3EM&EV"3>P'B7A(?JHJ33: 1 3F*]_]7ZC!E#@ M%+G@-8>A$_#Q$F9QLC0SA#A ^":1$\6,]4QG'*S 43(TB!"V3!M5L+( 5:/. MHX,0E$[(*4]3K>X'IU@<7:W2;9Z3!#&^>%D93!Q.57!A=::H6HE\=+B2"X!I M35B9N2HYDVL(U"(&"BZ(%05^[AS+[7N:E\T-6<':O!AF(@9#IS[C4*F/5YU5 MK8F"!9?"L+HHIYT,XW!E(65LV&&S0FTD5%HY7#,F23\!-8)-Q#!L L<@OTKE M9(6>N$%ZFMNX A;^"9*[G?GZ[&JAW<[F1I ]\C#K)59ON;!9LJ86?3IUB,RB M\=L1ARJB0XXJ%V4E746SC\]"E*S"7;7PKWI#2K#XWL@*X%'_L+0GM.DY7J]Y MPPM7HTG!:9[&(<2Y/M.Q"=1,?D\"QR]"1VB6B[/AXVB\*G#KY64J1JF+-]%W MSDH4U4^8PK6UP]\I=/0&_,SS%C_3XF?N'S_SHL7/?)4$RFZEA*?&:; -\E\I/7>WAM;F#LH%AI@3OW^FHJ\:EFFNH@ M'=8[%>XW0_=&2D69X/ -3:74%^P%^N(YY4IOY9UQC76[U>]CJ_^R$W6P(V_5 M_6H&N937\1&::NKE;8KRYY/J-J0 R2WV84 Y@H=J/$V4D!0+E< ]0.,9Q^@P M-71DZ,Q:O]$@HAU:H?1H%SR3&GP3X/:MBLZW_Z[93U6"=S?[XS"K>"].@-L; MS@N(U^6T!2*&URM70XPUG_!XN'Y5,+&*IQBI["U**G^Y(J=6TCRHI/EU)^J= MFK+"I@K(P+M95ZIIDL4N0;Q5;M\&:)%40H]-];M.L/B(=FP !'%PHN@#VJ[@ ME,*OX"\]Z50:Z,.ZI84W2!Z>KG%( :W8#)/TYCS_M!XBX! 66) Z#Y+H"@Z( M;W,OI,RBRZ/3U9S=9D9K6+8D.O^$'Z;.[S>%][N)C^]JT(C#G8TIL;WJ1;0S#B ME1.'KL3FI+299[9RP5).;=8"K(8TFE(LEN\//IQ)%(@G/TP!-LV2S$GB#Y&> M9,UJHE*XCA_$@V!,(? 2+71'/)D&+=A,^R<[*1RBL=V9-#O*;-M_J\:7R^G7 M9=NNXW%^SN>@NL7QPTJ'Y-CN9IY9]]IH003('1 L1&Q.AA8<)8GCNA['A'W& M3:YA(I='+;S(#6O1@ORKCR-_09S.]PJ(>(PZ^@71. ZI-8)F^T^C(6UO9G#L M_C5.%]23#-0$G)5RZC#O(C)"CV"+6W5OQ^'^,K@<9^Y5^.,E(N](W1V';+4W M2!1$.^G\89^"6* 8_RY("OEWR+:I)G#NI_+838<>['EWXN1S^PKM_6(ZET] M0#W5VWHPH8E1#L_9K\"6$)5;B>C'9N%BUY?"-:S49CC&7@S#^[8;*&^_FE@F:JOJ MT&V*T*6+Z-&8NVSB;41,&1/:>5K_>OL<^LAN(L:!T!:AB469[KKT%)&K6^)@ MT$JT%398P,66?WMNRE3=2-[%:"KJ%DX51B_E/_6=B5LNQ)*5\)7CZ\K87_0?W(T[/1'^]UAYVWOH'?TZFCC@VJ,U8'8C,@-A*U GCF8ZUJ"+CX$4ER^R I MDVI4$!;.FJ3X:S6C?TTT-PZ_A*$LA+;.Q'@]^$#^Y:*\TC)!(Z.$$V*%//?: MT;=?JEY5(2)S)O#KS8VM78^$I#'U3 ,A?NQVI)VX1V&HBQTX[W'%(5[/DG@8 M8DY!!1C4(%T#V\3Y?NY--,+N9HL]XG&6%.3WLI-/4>9D@B6_A 2FOW%'E0(# M=?'C"GYR1R=:43-*M.+1/K1-P H$@Q[+_B:K0A'7T^PT)9Q^Z)_&7' JV\DX MK4AQB+C)%3PQ2Y@\/#T#TZD:+PNJTPTU,,9*&(3*%K-;>&LRXKGA%O'+U/HO MAGI>?Q>F2YC;&)P0>B&PY?,":W>-AT&3XH(HLP1!8G/<*K'0*7/4 0N)EU,) MQ3%BG'X2E,R$"&?_,;?'!J\C7Y62I\#+C&E\A>E&V&/8]4OL.Z'/Y5;;Z$8I MNEVM8C'].2?!<3'Y=_.M3JYBI<)=7EFITXRIGE-A.@SU(L\F)G.$:\$$H)*. M];QFPFJ[?80;]32;IBZ ;-/ 2719X+_FD48G78&(/S=7,5'J M>T"XVRRV7J419>QB5G EW(,A5_A_S+@]9C6]R!$#QNU@_%)@B@%=3!L[]NLB'033,MP' M2Q?+S(7/T,BY=5,'.QK/*"TRT=M[W*'HA^9$/PVDUC&HFE]STE@"R=4(705[ MWS&P[H/DLII5L>E8FX$EQ@+:G+4XGPH^#T%% 0:?K[@58%E1%*1#@[/+Y?Z- M,^'812(V?X:1L;R@Y++_U[$L&%1^2K_T&T-J+%K36@M;N'[3VL@6M M?>->WYJ.?\NS%(*;"BPNM+JL'0 VO3&\ MG3=&#O/^JL"AQ&2Q-,^ ]Z1)ZX6YZPI)CO@KQD;R;@NX*6 ;7(4>T8/HL@>* MC'Y?Y^X%^ GEYL8T9ZKFI:_>=$SYE2)6T%J42QRGL\70G%O?F+"^6&+1?>QAO.H7W#_]L=^[7V;DO M&7M59^;SPBTK V"$SPAIW$,,>MF,C6TRZA(Z"%>I+I*F<#XXX0-5'DF@^*M: M[$W]'BR_5>IYUZ'/<<.X1I.NSXUCLL&0S3+?IL28(E :LJ*^ 3O&77(\H#H8 MR6&[8( ' 9'+FRAL!C.;\%I71,2[6*XIX(U#;24 [74/IAE2Q_\$>[5K)\ U MBO]6<^UB5PPR"AGT)%2R+BH:5"J&N\2SV4MM]]9Y?HG.71P45*/#/LTNE!O8 M3Z?C%0K:7MC[[F.\>O>\,NZ,WT;O!Q^ZPC_GNP^'@ M8V^$MW;I[N,[9;R/VZSW]RKL7Z,3#]OA %-[E)P!BP8M3H8H!C@O[:4BZ-JL MEGFM5P3YW%H35Z0)NH_=@Z5&CZK;O7F%@?@UT'B#!;>]D_UO#3E,R<1_6&<^ M!9N8L@[X/AC=1% O,C79-+FG5/'8/2UN]S94"+:47C&D-C&!34!!F: 0(9=> M,U?64W"0!..A^B8;[J<3QYMUQZ5A1I^ X>$BRT/NI&I6Y',7HS+YC*FGN:_P M1GD$)RX*I:FPU;4Z(DQ_4EU:RM]2[,F#0PL\;'^"C5M>EN@,JPVHQ;KWB6!E>4'JR7?!:7 '=DOPQ2])]'$%F3D&PT$CN4'NU!JU39+>9>OKV?Y$3S M13:7?3)E(3(&/ZI,ITW.V1T?IG,M$)6;7&+MHRK;%&XI;G7M(GE!W0,_>Z:A;9'?G!;QP/KE":8)NE7T&ER_,KV)-CS97 M\F"&/T4$"89Q90U@Y*>KJ9,+'#,HJ<[%6M\>@.$K&_T[58691VM,N&DB*,TG M%4%.-[<#7.2P/CB]+.:K^U"&I BWO(%^+.I].VI]G,/JD%#:F)* WO'F,N$!39RMK2-@7]%RRM(]2), 2B_=L2S+JNL=&HX+P&SH&$-"C9(+@1!BP)S MR!3Z21&_0[ND:3$K2CD0S.KXN>[C874?\=10Z1NVB0C$$(>1FHJ^*.:_7KDP M]9P\A0N%^0E50>FXETS#)[G$A(29.$J=U@F#HZAG84:$-XZ ..S,SD\GA)$K MJ$LY#NQY:^R>XZ U1K0)S,&LRA1$Q EA"O?Z>W\![_CQ9^Y?MIG[-G-__YG[ M5VWF_AOW7)^3YWKH@I2;&^\PRT>TTRQEV8D-<:):PI.#9L?-+ ) S(,W).IM;'.>I%6Y@.0W%8U9#W M5,%A6!X,LY$Q->I486*VF%_L]:VPGW>ET:H-_U+O)Z(-GC* U+C1 :.&CFT[ M-DF5,[>(DWR\"JSS<(8P2R/6),+OYF#NE%)N#1,\)ZBR=QF32;Y88TXTH2-# M_*>W2Z332O-/7.OA^95-DK@56DKB!HE9^!W) C:9(,M=2XDA,!\6>9FIO2M[ M>4L:-\<1MJIUW:!3AA5+1=UI=)H5)1*XG*[ L*:IF:)OO%K\I"XQ0EZP7G*; M_$>+6]:,>I.=1CPQXU1<".*6(=Q&@MG\GR9%(O\,P/:52?%S$"3#8!SL5ZZD MO)YH 0,::GQ>#9USDTMDC%SJ3%60.P[&[KQ$_Z 6?PK-W,_D78CNB7:!_8)F MWH4T*6[D7;B.4.!V/ O, J1,'[ 02SS 07_MH 3A;D0)),N/[L:"0#AAZU@U M3W#=U[KR@;7:#^[.$N!:<4CA\M=G"6@Q4-^L!<,< 233-S<.Q>F$O>;K?M]$ M^RQIL?*K45P/NS;G/8TDH &1X^W"R%A1&4=2RIW (B=RRRH A0# 2S$80HPXFWP*%[KV*/ANZ!I M;_8*"YJO(: (#1T8A]C)B246Y3\'1?$S.V/*(;*Y4:$@-"0PIAE$X\"L86;B MG@T%[KQL6KH05J294?G^HT:L2L1'?^SH96;)?YG'V4X+!26,E7?GE^/5 "5P MF_Y6-4*H>%T(-V!DI#!\2,M(NSN66HF Z,S4-1'M':)Y*TM!D942B;X+59OC M:9+-2B:R@+,Z87Z&H/T-KDF2H=TDAA#SX#E@0P.;\X/:"%9-,>?VW;B9>+=Y MDYL&;$!-=[03A+3AONV$%ZV=T-H)/YR=\)+LA+UDF8"94&07R1B>BG^RK0"J M3$T#[R49<150G$LJV69Z3$K>,:Z39C:[CHXL$U[^A.%P41EQ[6C4Z#<;:P_G MVCG7.G:6[:<$QTQH";&MA2"U@\OE#45);[5*2 ML6IC4T$I L^C44E97I&I4_JD#I.G32ZXJ"*V:MWPE#HJ&I&]C99)PU3XUVOB MB#2V*\8V&E3F;+N.H*"H3?@<7Q_2!*3&<=K=[LG^ZZ,'9]YPP3K8MEW-BAJJ M86+CJ,Y'Q7NRQ) *O61R4N3))M4V[9!73@IUH7<)?8"^%V*16GK*4OM'X2S8=;U^%V3+&U=N'5IG M1=U79C/4T!3[= !S1 Z%"]"W)0KR1 M/D$ZKY0R=E@;V!68YJ!UK\#4@R-8G_L?,5WYJDU7MNG*^T]7OOX!TY4M/OZ! M\/$_/SY\_(?.\#_=H[MAXT='G?[>D\'^OL.]MS#V[]-%_GGGV<[F1J_NCZ"1 M22:45A!IV"&QRA"FR P\9H^X8-?3W@%VF/)O< ^VV* M>E-M'AGLTRO+#S7%CK4:9N> $/;DUGY?[" T7LRWY)2TORKV?+$*] MNC+$) MPU'N[-5",ND8W(O739X-ESKXN>\7?-,>V?*8B,T-7",#^(LNP9@7+OHZJ>"V MHTB^CB/8AZC)E3 4R/3WEGDK3*#HG]OD)/G7NOXEP@K7LNE7$IO/:TWY*C ! MBD,0N;YPT+MD#CQW"XTQ/D,X\SYLXP]*&+51W#F95#PA-&&7R<(OEFFL0#X1 M>-J./HY^0)=1'N+R/'>I+HP#Q-99!1DZSV<@*(+&F_!E?CF'>YUGBSIB/':8 M&,6:RM,E:39Q/%V^'P![Q)B/6)4IEQ X?+W6)4MU!P::I+*7AFD?7.U@C9M? MBCC]0ZXKYP0!:HF:;5&GA8G+=F 9:(1%53RZKYA.16/02,E(Z&H#>=G"9_C5 M_\# E!$!4P:GIW8/V-2:)NY.WOZ?T58' MS\ITFE\Z&C%"T(C2P" 2JXQEM9; RWV3 &'_^5KULYHOLZDD'Q:9#_&M%OC[ M9[\\C2;)55D9E%<^S#U]JJ#UI@%)%,ZDY9K:75?&Q4WBWTI22, V/,%AM/B: M3! '9LS[4P/2*E<;[*J@7WF-64=*FLQ="+72D)2A;<:4 ;;++7Q\#J]IU9J<\Q1\/17X.L /VHS0A4N( !YXX("5W/7-^, MKZ@P/)U6C8FM"EXS/ZT5FVP;!5:"\SQ?E=4N+I?$#REIJ(\J7'0%9/!CA1%TRMGR QFU%"99]!WA(";+LG/@=DH4--M:U:W16X M7BC\%-YO;+#Y1.6K27'@8-7, M:.D;-4>HIS EH&U"9JD4T)0J7V&+MTI,VH:8"HMW=_N$GA'V-N#Y&Y;V78/LNW53O2[VK)5J#5I MMDH;C";9A$;WM$POR',7DC%'I.+BH?>]S;^Q)- -6(;7+9:AQ3+A^ZP[6/70B'$ /P% M&?UZ]>BN5H#EZE(1\-]Z"(9-C).087V1Z?SF"(LD$3;EML"N/#TD;J[L#5?V;D@GHGN<+/Q"ED]+NI8@/AYDGV!4)7;1CU*YUN9CT!#;"Y M<="3IJA<_=,Y.$#-$.T.^J/N_QQW^[O=473Z-NM#\C=\,.C!8[I^*/J'MJ-!C25]T_NL-= MO!C^WNKMFUO"EO[8'1V1[!08<'-(P..Y]0(4>]?G30ZQ[[QK'X)4T-#GF [Q9U=NE7<"G,=+_+?_W> M.WI/S]P?@)X>P( V-[9Z_=V#8]+8^/7@^ AN_J%WQ$_%&Y(BAW_MP:T^'!X? MC ;#3SJ6$8X9EJ@SBD:#W5[G(!IU=X^'L-PXIO?=S@$^$=8;KJ=5??O)KU^W M*VNVN8%WQF>%XZ55PE%MXT+ SGD+-Q@,^UT:S6&G!W;2X*![\*ERVYB^M\_A MG_=@Z3[T>_M\L3PSCGI'(YKYWEX/MEEW!,L#/^_L[\.^[1S)N^,OCH;'(W=[ MON7[P0%]]R&"G?+AH#N"J]]U>OW1$5WD5L4= YQ[WEHX;S@U9F7EJ\-N'R;N M4[RYT8/1PP:D;W#T?W3\Q SZ.U&W S?1ER23;10=#7B M%&/.O^AC^AM8:)P M-F-ZR/#X !8=UJ][='1 EA[LN /8_[ 3G/&'SZ4-M;DQ@EUQT!F&WW6&\.QW M_"?M+MDP4><8]A+M@YNVH!SRW@@/S7#P$8[4VV"![C_*]_2S],"S5@_<50\P M=T1_L+E!>V+O8V^W*Z3-YG#BTL-7(UAYVJC]T?&!;J=(?PA2AS^"XW (FPDO MI3-9528@%8?=W2ZUT8Y5,)/LA4TL(EXD,0M/)]1W[*Z+]@9PL_[@B 5TE\\, M/!N>U9.C#$/@@8X"POAMT/(!W@-+'[ M_\W_O#6"OL[F?^F-H*-AMW.$0M)O?MUF**E1 1EU8U0R&30@N >?NL-MV)*T M(9U@)PGL=Z?7,?!Y;:O"*/!F^_MT>-YWCKSM)'OS?XX[!Z@KO' M*/7QF(' !C^>;GY\T"5Y??")1CFH7NI>.,;+N9G]$6E#5*ZU.[O+R2#@$P_; MO_.NJX;8T:?#KM/#GS-W:D# $_L#/U6H8AOUTX<.?(9*5XZOGRP05S1>$%?[ M,MS#XR&(E2Z<=8Y_D!T (__]?9>L,;+SZ,>_=[PUB1(-_D0=#RNZ!PLT<&O@ M3>*UB^ F#3<4#,JU4)!W'1T?@OCI[G7]! 86(]Z-'P>6JEB+>_A/'$J/;;_= M ;S8$#["_30X.%93E%_&F0*AC,.MA68^C'.$)AO85O\V$GL(HKHWI-_1)(4V M?W ZV!+[[./AS33\_*U[-.D9N>*3,94'0YQTLPINT3P>TQ4R)\W'LNQ0[,)9A M%_;%$0_%G@ [^GYUMV([JD4-"W7;MW5KL%Y&D0$>[>&Q@!NS+_I[[^ _9@^^'G'-$7=/WIL MN-,=C0@8'(//X+88?W5$AWK?.9*Q=QE#QU0\UUM,$ O\SY>5N.;O.Q\;=,O@ M[4'O7PT38*!9MSL>BSW=X0 M3C06\Z$-*HLZ[(W^4[7GPE5QDW*S3F?3^ B=P4ZTUP73\D.O[V(#Y"@>#KOB MMV_I?/T./A@<*+SDN"]_;,.86 U;3ZV'ZBLXF6IIRQN$8%[P<8-;H/*%GV/J("K+L((G2_F(E]FW9>#TT!\'.;-F_3 MYO>?-O_E!TR;?U]NJS96K( F"6N_.BFS228M.1QAD:5;PH12E[EY"H;X+3$Q MQ?#$L7*P9-SD@T"'Z]M\(,82"WXG63DN4BYF:.#BX^K(*H"3LDE","AIJ.MS M5;[;DN4B"KOC?.X\;,D/@UZL7/Y)N%@JI+0)LH8F)EBZ(.]$S*--5>1:!FSH MG>K-7:5,&*[!:@>8E!B$-Q(,*9]FZ3[(D%@HH5SE>9I,D3L++U\@[QFWL4VN M"A!6_/$IUGBEYB[I7]S#A'ZC*40FUUS-E[Z5#WKF-VH$ PO1E(^5G:V[QM7+)L066"Z7;OI^-5&!:KI>CL$;+BHVY37A&2 ^?5]B M:F>UI*0Z5FV,7/EOM02-"7O=;#*^60K@F?*O2$]Q.R#DX *-(T]9Y5HG^+8* MKO3YSJOR!G<(OJD54EK[[G@!PMYC=1"T4G\NW6B%K?"&KG>U87/G@]N,FR$7 M%]O,3VL+X*I$LVL8S03N[NB0I88T6#Z]S=!,5H00G?K&'SNIG]&+8D M/+]V2)!\@;D!$$D^6R!E!1=^T';DRE@\OZAXTGFT]>SI-M?!)Z=+H5-AX,_< ME!QZD#D7[7,WMC)RA'G&5C%U-=D<=0ER?X!67Q* '.U]-(@"HFG4_'1NSN1/ M."Q4"V-9CT4,7NF&ETTNJ'/B,N'"3<>SZ@N^/4>'\&LL_7>>P1L+X[/Y*E^5 MTRMA0VVPI?A%)S"3TWRA"JC(QVF*ANU46=4=1A3#;B;KO#-]'' 27),1F[U_O8V^OV]T9MH5%;:"2J_5[;SLNZ9D7Z8Y]I-B6J/3#?0)BK*]9Q$(.5!8&@\7RP BE&Q:=KP M:(U_D?N]52GR0<>^5!]/2INP3H8>V=7(V6&1,?M&D5)C#NQ[2;Q&I=1!H<$K M7:\7-NWC:5B"FU?32W8BJ'[FC2>C_JLF;;QGO]&'[[VK3S=XHU- MI2A1X;I%^.!,$*ST/=J(K<*^FH\UW,/.\7. 3>W=)/BHNI\#9SV&E6W!2RN5 M@LZ7/*%*9L=PP)+=5' M28%ES'H8PC8P0RUOW"R9I$$:J;%-G+VIVQ!K=X!).6CTS<;FPX0)I;VH)3 U M0>H5B7[@*>VR>97,SE"FQ2%]*HRB MR!=@D5Q1F(\WGJ/HM<%YEV2T9+@2M>>'R*[% 7N?0G8#[37JTF'L^2"R&8HS MN,A5%%8DV/HC&ZYA@^"D9&(*FB@Q_4)@NIP\?\FM2/('8E][:#C/+RVIR$+?7U2'^Y3Z^.'> 3. MH^$8+G*Z4&VFY3(9G[-]8(T.IU2-DE:Q#ZYDMRCRXO]%PQ1)E'!SEOD*">@H M,@,& M:1O_W-MP03/65ZLC89)EYO7T= :H89V!!-_%.-1*^;&[OPZZ68DF^O MILDEMS&%@TAL?6OZ$E;LE4HC^#9'_:V>UA<-X+M9 A8>[+_U$(I8F KYH/[O M"H8M&>TP[1%IHC9 HAE27H1)B0$I-N:7W5FO:3L]TIW5!BL?)ECY_.GC"U9B M"?/=:) .A]U1MR_E&&\_:<5'&YO\5F*3][F)WEYM;A"P1A-3-IH6H(Y*E.\6 MQ!(&H1+XS2SY4[NF6P@+)YNDWU!6#]8X-I\:Z"2FG)1KM9N388)\>;:8?$79F (O6/*=8KL4)_[='(#9-"A MHQ&FXP T- L^I!5@9V+3*)X(DK"O+8&:J\C5((#A@D-*K"_]3IO ES!FI:== MI@Y2>JMA\#3X -JRJO;#N*)/6(8VJ)(F=RC)..;^#!@WL6W7W=!=&%IYMJ;" M:"\QNR(K_W1!8;G!=QI/:=7[0ZGW9]^#>L4[EQJE/PW!F7K.-&Y:1P%8[A;(#HZ1A$,AIH*P@-/W.?2RGU-K\7K*IV6GL\_4:!.=,C* MK& NQ;P:6F ::I_X96BM$6MYWYK83&FGRQDT4-XW/J:5!@5$?UHGP(14Y MR4QO;EPF5Z+5J!GCVI?D*,ZZ-\U=LZRT.8G$LZO+K'/JD4@2]+II%&)+N2>3 M 6<;SQ!@LS&1V3P"GJ3R'&8TG4<$YR)FQ<*- J'O<.%"6"W90IRB#0@7:$Y* M+L*?F*9AE[#RV J@D;-?&G6:5\&EOK)CW]YQ/.=Z%BKM)D/SCULF^>(X:;8$ M2SU9<9=(>+6\="2ASOZ)&\*&9?1ZYS4\JW & MDI",TG7D@KMYG">3VYS ='Z62'=-AS"LDJE>\RK;LN72N3_X#\1%VAK!W[P1 M#/;N\\=G[QYVA[W!WMULWKWCH6=K%)H.9&9]JT0:>\X*/D8S]_AN-NX==])# MA*]^!)N693#W.@0)KKK9ML[U&KJ6G-*"N,1VNM7BN*LT*0PNJ>L:Q.Y1M3^+ M??D=/QX+0I=K\F!J3[S-*0ZS3S6=F%>DZCM2$Z0&$8.B=T'1SJ]4FNRDO"I! M=EB_AQ:(6M.$'V3C^70%GW.?*_R%M$&J9@>K?5P::N9(WX-1C.U:3<_'+Y!G M:;7-#Z!MUH5<7CP^%=3YT.WOW;V_!'%1(=GA0:=/J&_61(\U -.F56Z71(_N MT=YZL>,BC/=XVR/5-9&$^$D)H?2OJR;4*.4*], < _OJ1,31+)]@8A[]CUEJ M-8U'@!;ILL@3823A,BI.P- ''.>G'W/$2+WBQE)&T_',N60G&3<5Y@@2?.9( M-!24HZDI'9$S 13_B<.OE+@+2M@-3-HO"_4,A1I2=@.YX)W1Y4C0X)M*:+H! M/.3+ 2X+]S6WK9,5-4TPC_0NS4EB2[@"D@0U1 US^*%1P MO[;8T18[>N_8T1=/6^SHMXQ& SWZ/*R=XI@KE2!5N':XP6*[J4O08X# M-4#\;A?)]!I(I"V;881$X4.*3*TUQ]C_N*!XN"B36?)7-EMAX/4,P]B@E.:K MV8FMJ^9!BK,GGE@UY R^8F^.)P#=TM$R!Y$F] G1EM0?( /1(C4D)M=0!KS< M>;8=,Z?5/#L6^^F53BR?'/D'61,!?!>.T:%8=&I9_53>" MLS;<77QQE-\AAOP*J0;M11A!=M%=\U2V7N31.]%^DDT1Y.+M%3LLRIS9V?&) M"LGQ76(;+VEK:VJR(^$,6_C5@\4 MMWKY".-6U*2J<_!8(TXMY.?K1YQ>?J&(4QCH(")EL1@H?(,8BV22DQ$0A#*B M+?RG9[,-4RT!B>T7"'KP5OSY9PQS5K?BRQ<[/[]J[82[;B]TQ BK"^JYDF3R MZ:RUSD(M8C8M\TH]G;5GQ05P-F^L63TXSI3$@X<)R5LEA4>XXUGR7R:M%//\ M(D< T#@IB?M9O*5%7H(Q3=2ULS1="IE20I2;F# TL<' U-YR/ -LUPNL_DLZ M%-'-_L3FQK4.Q7:31Q%A6R*S3A9(6;?(T(G4T-C<^W]-PY?4.P:Y^+\*/ M,F;R7 ?40B,4QR2%9YL;U[C1)ZME'#'!6>SSJW".EBM8B7X^YYMD\)C@A\*I M&7JN.H"FV*G+\1VX@]6SE% M-R)',O1#M;QL7D^987A$( M5Q!?%1&'@5&LK41$996A62:YEG*U6$PINB@%+T)M46/.$_KUU11<#*+V0JJM MG)J6$,$!@_YF:<(/2L@ZG(RDDVMHTZ<-+!RA[K/+LB&]'-Y+8%HU=521:Q07 MZBJ4U[3&$H85"=!8>!]ED6:+!DX8Y&VEJ2#'!-PTCB)6"#A.',7GZVF MB?3Z46HXSKL2&H9\_:;WO9TMRUJG.:S^%_40U]MI<[(>RYMV[R;HCTD:6 M4PWV;WX;/8MZH %$(V )YMPJEJ#/%*J.>5Z/IYVF!8J4H!RL@=P+3=: 8U^ M?%Z]2X& T>\^>:HJ#IYZ99MV>7+\-522]);//6&8:RFWSG[@7C8..NG?E I4 M%T6*!X3@E1,8 O$TX0>$UP0KZ_Z3J2I3G^Z\I)UW\U9Y^9+RKP^,1'SQM$4B MMDC$^TM2JZ#FC9QI].O:S IA+V:0FC&:XS&J>PCI55(71 MD#V^N7%*!?:^$EEZBS+OSWR2++'=)NL_;XF;'TB[E2N#6H1/B?;9^P4,ZF'] MY)X=T#NI-^$\*?7#A [B0F'WT:[#).ZB M/H-&0ZMOF*3[I4FJ%])^3YM%''M:?_;I_U%G1K3 M<&31/H/5-JWL'$<(;@/=-]AW)PWW5A-A2Z5%(LJ-M,2NH%EYGE);7635FG'@ M@;(@2"M @\A<#QT[:[''E31J9 3(+@9N<,XF %'=X9=_9C>"TDO MBN1TZ;E%7-A)[Z?O]I-V2*J\WB1/)>\R'J\*YA>1YK<$*]$C[%]:Y4GCBV/# M@LJ;D\%N7Y624I-T1DN0"$J8.-;*)<^XK%0B!UL9\%-BXF4*$O8W9%K\6WOP MKY*VX1F?G61GV(02'XQ;85G>:LW6NA\U(:>V?9T"A7MLZO8Q;TERCT:OKY($ M[7I%U)I-7'>L<*/$N'HV:LMY0NV_:P*1 E(WQ6!\FN)H_GXA!Y.-D MA;Z3Y9<#7;@26MF)2UYB7(MHCU#BEN RA@W(ZC*_ZCYB^)B:F,RJRVWGUNU4 MC)==Y-E$_-(Q-80>IZZ/B.-]#L*$:\?[)OK7\6_J'F(.Q!H/50F$]=L8S(LK M86<^Q7" <*(12TO:4\C^\B(#V4K!DJ7JT!2V2C[+QDJ,5"5QE DSFMC/BM99 M7&2Y-C!;6YI@9A\E*@J??8E]TB0FIDB7NMNE%"1%'E/.2%D[3LJ6N/ MD;#U&LJZ4Y>*%AERY0.FUPI.;N)L*+ L;W&$.6A8N16N:V.G=<.XE#B:HEC[ M8*8<3 6+'Q[=&@C?B('PLC&3)3LBD!XJZ!K)VN)P*RDDS;7A=2I1C]@ZN]1! M'4 ;!#6NF$])%)\I<2K4M;+Y8D%GNO;26-^4)G,AU;_&:JXQ0!G*)WU86Z:-34D;72VQN[=H@\R1C (+W" 7@"OR9H4M3^.JH';SADQ=; MV?;6\^W-C2VO=,9I6>9FR;9%5XFC1$P="K)SQS]H"&3>V[]P9-\WI!>C6W+\ M!-N 3ICCCC-?9?97!%8+;*N&NN>;'Z2\MNIPHEHCQU!E$"\OR.X)[QJ,PPM- M+]P&UN/\%4A7;='+=B[AL1.>P] )HF#%P*8#0'*48BI&L<=W8E) M#A1H/SZ@ MWKO!Q^ZP#VM^-[#>0>?W-]&_CX>]T5Z/0'F/M8:L!>)]28H6AF'XZ"/(?@T M2>C+4=$E0E>+I5_S-930R-)'N0X?B,(N4JZEXE(LU5Y9).G4%7I<5IN"S1*P M*XO2VYH6, 6JDEM3&;P1C5" 2!)24529A7,IT'OM:&4,V068WC<\A"Q^>_.= M:%=@5.2S9%+QQ$\L,-&"P^?Y8/38>3(/YJAVR]AT!O-1C :")8-)PYNQ7B=, M _E!X(L48-V@.2 ,34?I]$GG(KMX\F]LL1'+BH3]?\?358D9(SNBS0V<,9KA M258NL%!&FM)'TI.>Z<7KH#/':Q%$N179XV@(=Z*WL'BPW]=4A8OUXX@FW.=% MJI&FW)82)<8ORXHBO M_X#0A]94?R!3_>?'9ZKW!_TGW3]V#XY'O8^]HT^?3S;:VNH_IJV.\6!38+"F M/84W%),R0F:RI9I2U))$4]I2_YY?ZR>C\#1P*1;4C8F7;'77 269%J6TAQADI89!\TH M9)PB](DRF-)Q16.*V7R5V%(,"9=1ID42H!Q*\P.CT%8 @SH-7P)C=MB#+?7- M8K"EF4_4G:78468ZO=*^,-*&HZ3(_%F1KQ9X4_>+V/2X;\@*^M8O\_P2S'(* MVE$E-SA@2V[.P[6M!@0F+5[2I40U8XS+E>3]E,D%7"#=\:B* _RX\3ERU_'$ M9/-R5:!;$<,\)U1E-$%#7].D[K4I0?Q7.E[1DE-CER?H-U+GFWQ^1G\@\D!W M!=[_WM.7C\2<;K7\0VGY7QZ?EO_0&^'"=_K=P7'+!?[-:.HOGB[[!8>2+FY42W3I5.!VP^[WAJ 9;L'O]4] M^(+VX'[!61+<@RRR>1/V<_ ;]"L6Y@:M"$*=_)F:6&\2X4XEU#FE<\,F[5'( M!>H2^&227SKVA'F*OUAB#>U4E LSJW$S.AH?*P1R'9>2I8!?Z) (>P3 M/4;"[X;4VKX2.";B0=9N]8,#?A[CCG[)U@KZZ.+]B<72.VU":]_480%3 7(]G5,C+#I-VIP34U\X1/"#)1*+%+M)HG\6W%!*O>RTU.MEU) >/;G:W*!0$(>] MD&I^LAKC'Q7H?N*S?V,0>? (. UPO,8.41: UM$$M6L#O\50#,I1@9MBK C> M +_DE':E-0'6SNB0F1%CL0!)W&K];U5&OB(9N9LLI/8>=]L1MID5O8_.'5:H M8!Q1+F)Q0M?46DO?RX%T]$">@E3#FG#113K/M("), G\!Y%NA+PY3)D7X+V+ M2F&4&B;-JH#Y7@7_[8_O1VL/<)H]H_O3_Z#$P+30N:'1M[7UK<]-8MO9W M5_D_Z/">Z;*K1+@$^@(,54YBP%,AR8F=[N'3E&)O)YJ6)8\D)^WY]>^Z[9LD MFP .D& ^D,26]G7MM=?U6:_>C=X?OFZW7KWK]P[@9X#_7HT&H\/^ZU>/^"=\ M^TB^?K5W?/ A&(X^'/;__F":I>6+X,GC>1F,XIDJ@B-U'9QFLR@-^8,P&*H\ MGCZ %^'5DT]][V4PB_*+.'T1X*./'[S^*3TOYB]?/3JI-%BJO\J'41)?P*-Y M?'%9O@P^NX]7>Z_[?UW&YW$);^\\>_5H[W6]P\]O_$TFL7)\L7' MVJ%GB_B_BKNU:X$-;FZ$+P-W+<P>Y.@O%3P;))DUW%Z$63S,L[2(NC@QS\ED_\LLI>P*[! M3SE]V W*+)@O\O%E5*B@N(QR&$PV#<;9;):E05%FXS^#>90'5U&R4,'9\']A M1H\?/PE4-+YLMRKM#^E]KWEH:SC.%N5^- L&Z7BG.J3];#:/TJ7[3H@#*A8P MKR!*)T&Q./^W&I.[OHS'ET$,C98ES H6\U+E"KJ+BN#5F>$3O5>/ MSEX''?AP%BUA\8-HIF"3)\$TSV9!";O6;N$8X9)/?HSQ/'C,]&$IQ E MC1/#7\LH3F5,<;H3O!J\/DL35< V00/Y=0S[-E%3?"8,QM$\+H$>_ZLF,!AJ M<%&8EW%_DR0@XL'.9RI*D5JB8IS'YTA$M,2S8 'SRND1'/G.JT>#C9_9VV>2 MH][>83_8[Q\>#D]Z^X.CMW]_\/@!_7W2.SC0?W_R+*[C27F)CS[^V\O@/,MA MI1Z.X>!%\P(&I'][0)?LJ]'IY]RB?#D??/K8KE1>QN,HT2RIS.8;9NMOB=VH M%QX;'QW4!SU'RDXO'IYG99G-H(6=Y_-/NK!O>2X5FO&FL'^,)'/T]P?/#7W( M1NO9["41\$6:4U!D23QY&6Q\PMQ0XQUSNPL!_YW>1_)=M^5W::P-Y/FE5+8E MJ,_DAP=1J7B ($@0<_PX:_QNQK]Q'GA_R7#%7C2LUR^??"@W3)(@(!8+%,YQ M:!.@3Y!54B1\ZN] +7[*7X)DW+O(E0)QMPQ8 M%O0I_+Z>[^V%<0=/ZO=,4' Z!R ^H];(@QPMYPH/6>\ZRB_82 M;2GC2S7^4R2X5.'MUKTG$MSV&'[S^1QEZ7\6T/HTU@S_!SUT]T62VIZI;SX? M/CNBW:@">HG0_Q$5\/W38)\-X,';*$Z+8)3CQI!P%72NX_(2/H%[5:ENT!D4 M>:22[>F[>V/=GK[O]?0=YY,XC?(E.MNRF=J>O^WYVYZ_KWC^0-Y\*"=,G[KM M,;NK8]T>L^_QF.UV?NMNS];V;&W/UF>?+0Q;^G[/3..2?L]-ZQUJ:OTK$HC3 MTX_C: 52YI%%Y]G5&D?K3TD^>_F;]K6*^<\X54/K=/VUP2,;S><)+,AYHH(D MNOZ1'+ 4I:WR<5S(,I_D\5C=$S?9770A=!0<#8;P/W'S[OVY;),( M(W0IDN=?_]+$1V3W4TY?W1+A;7XJSV#\57 MDS:^+W+:Z.TC[& ?OHK&Y;_>+)+D*)I95G"O[J%M=-"=8E^;W*X?XS0?+6;G M^E+$O"3.=J)DEV2)DKL5SHM[$@2R#>.],P1Z7TQLV_OD.]DDX'B_*Q!%TPL> MXWXVFZETS''\S:-D!GMX*W M<,L)W;0BW_W AVSZY^%Z@ 6N4;\3I^-D@=G"VO!?!#_O_$S&_I]W?L$'9V2R^0A.85U(8.P#G@8O]ZX[R JZ4\% M$X7G$6P"W2J%^L\"VRTOSF#U+X,Y;$4VX36+IK#8 ;9(;X^S15XHW:%] MGT?S-%BJ*"\H"V">9U?Q1$W0N1(&</Q M(L]QOXQ6[)'/"Z#5+J]>E-!*8GLP#5Q,Z*R,X6^8?*+?C(I"E45EWB&T4FEF MEN6(00&'81I/RR7NXMCL3.?YX[]UFZ;EH9)4UA8V+0K2+'TX7YPG\9AZHHZE MYTE<@.BW(#<;3"")_[.(86WIS\IH,[$1=.*K;H!MSU1^@>M.^"APY,8P\ MH M'2B Q,E(MTJ0'$ @67X1I?%_S>?GBR).$;,#9G >ITW=!O'4VRBB93F^2 \E M4%\1L9M0Q=1/I]?%A2MPIZ\OL^ :C@#,,P>>DN753? :G\.9R>OM3C)8P9*F M5<;E DXWT%FBHD(V)@)V^N\LCTO+ JJ]%0LX E>X69AK5-)J!IT]?Z"763*I M-765$;T+A(F_R:95'@!FX'B]IA4T71_GNL97+Q!P\.H:[3BWTKV6K+:B M^E94OV5G/MW<6TG]:Y#92 >JD,PV42B4$JP47IOC<99/(A " HK1KX!N>3$L MOZZ*83&(5B1*%21].#+OSG=!X8+=]/3YWS:TMAMGE'J$W_L ?_W* UR[+O=L MKO=O@,]^N=T16H;RB%#?7M\6J.1=@_:\A6'336+4=)# +U#?3K4*'T-;(&N/ M28*J<='PH5X::$:L5>-U4B8B_CB+)K IRE<:*6ZR$'& MGT=Y:0!L>$P[P=XRP&A^W]GK]N0J^M'XSS2[3M3D E8(]!P5STL&QYS'RAMZ MN[5Z[+F:YZJ 7XLF4T(TH='#$&E#XBCG2QB>BG-GH1@R$HT>8 MA[3I"=MW^_SQ\&+R) M03-\$9Q$%^HE-(*&H#$2=?#PH>9P!X/?]4"X>>- ^AFA_#[F5((.+>:DBS%9 MQ:#TG51U\,@*R&1=DK9B4X/$ZR]&HJ;T1O4FQ:;K<1^:?[YZ!&O1L"SG0+!_ M/CQ7TRR'T^[&R2N^=>Z\[>/,+-X?VX\Z2W.7[[;C $ALL8 MRKVWI_W^^SXTW3LZ"$;O^L&POW]V.A@-^L-@,!R>$?V=G<"C_7_V3_<'PWYP M_(8>Y!:&P;O>[_W@Z'@4[/7[1\%I_^U@..J?]@^"LZ.#_FFUS=[^"!MX\MON M;MAN]> #Z/T GN[@@X)PZS]OH'^/@4K/]M\%O9.3P\$^C>RP]\<0VSN&MT^# M?\!;PX/!/@TLQ.?_[ZQW.'@S,*/I'7UP1P.OPU,P#OBXWD2(BP(+>;;WCSX, M>W2,DQG E/JG[Z'Y][T/,F\8P1N<,CQ[? C_CTY[1T/XA#[J#8>#MT?XV\EA M_^ M# 7&]>[#"?:WWQO1T [[0]@3'$ ?5AVZ#?K0(@P"EI97]+1'^S4_W890TYN.3 MP1$.$GK:/SX[&O8/@R$,>_@&AG5\^D$6$+Y[?T+[ '/ACGLC[H:6$3Z"=>P= M]NTZ$J7@*N+(]#KZRXC]POB!2-^?C((WI\?OJ2]O\9#$3TZ/AR>PLF?#X*!_ M"".'<9WV_^]L<$K3'FKJKBRJG(YV2PA*>O3>% KSEGWGSHEC&*0J'.VV@=5O M!2>>V1(0C*;DKP80OY7E69;7YN_+J+!H\IDGIJ;1C$U%^.$*\;YCX<[YB2K* M/,ON)(W7C$<=_+C=LDV8K[Q67(QV+?<:7U8C?GJA2IAV#@*U/WH6UUUDRYU@ M9*7I)H1] THO"H?XUE*2MD'"GX/T72 N_ T Z[7NP*,)JR";HDRT6PQ57U>9 MK!X4I^,LGVD[];HETR9K+IZI!E6:--3S_W1=LZ[CC8JHS,! M!(Z?/RZ*!8S1G%:)6U ZV(&&\2C+R=]:J/$BA^'8]^"+25R4>7R^0$*G*V;-*\ V/H%;EFW:$4#5ER]U68DLUT/FC>J,X65LN:!ATVK"<@ OBST L9>3-<"]#M +NE>(SXA)IA[8"!PRJ<*'-.= :T*0) M)&FW:E1 [7C_@_I%KP0;7:!/A*MX8 B# MI-O"86'_,1$23E"7U/C8'4,.#[I.&BU)YIRL(TM:ZX\6&L&P$]M]R?S?5!?) M:3]"FJN]$&35J0->DG/T"*D9W_OTH/<0AK941Q#H2B?ME@UFPG[H22'\238G MU Q##!PP-.4K=2>HU3$I2KS&0KV.Z@K)"W> XCLP+ %X $R"(FDP_":/)O&8 MH3K.57F-US4=0??8US&LU[NJPLK>5)_RFN(%A#-W%<7)U[D_JP6&-E[6Z!/Z MW=R5^&0GP)3Z,Q >VZV#N)AG1:RC9$S9HC/*?/=4H^B5)4 ^)XFNO;>Z(5^/?B?VCJ%P)N:6<*&-*;HH%!F5 MV5&BKHA:BQC6)2*+[AB)ON.&;N$QO[B!?.'M]J"ZBA%55$&%35"[/A ]H]=6I;96"C'4.XQ0Q",XI M29&KY \CBN(Q5669,&NWC(=.D?X=[N1V2SB!?G-B7P7F@M<61O-AJ*6:=$/\ M?84H1#+8BOZOLT4R\6+Q@JLX2PRO@DFW6SV+#7*(1Y_$4A/<(4S!!#::JSIT M046F"OA7E(1\_>(HD!_!-KMR.#,6'>$H?!*XUH('A"78^([/U7\6<:Y8!)"[ MF\/M=-PDO@F$]2?(+<42EFC&RZ#M V:?4/J!/U-AV$XW9-U<71L M3?*N/?Z/=_VCX* _'* -OO]['SL[/GO[SGD(9_I[?SB"'N\-._FTKF_BR7NZ M]>3]2)Z\>WSG/:4[[\3H'>W66XJQH(01(U[L-)E6[%TRK4C(=<,DO MRH>2? MD-J7LPH(ZID >S7-,?DL8')N;M".IZ:;H -TK:!-^-F)T?YMEK5K3BLP!?1,9/%R6R)0\(Z=G6-&# M ;4*-Y*H$I:8>C0.#B^(G&ZX$6M>XX4^LJL'W6YI3F,-I0V+Z^MR3'J,U*L- M?OKA#J73@5IFUSQTU[Q+:V3:PIP]O=D16QL9[Y%,0Z0HX=CMG8+#HZW0'%I3 M$5\M_Q8683Z6P?N61K_-XOZ(_M](JMHEJ>J/"+-827X"[;F@5#$@\#@B*ZXE M+]F2:D%QP_E=TX"KV#NGU*^B[8>62B!G#"+7588$",?N&H=6V#NE=C&%.,2' M:C;'(E[H%7K(28XH2\!U/V?^+_>1T=6UY;'QGLKDXL%L-U3\%R5P_'9+6QZ- M B^29NH=HW,MFWCB2U9W_#AVA)I)0@B=9WR-_HPLT.FX>$NP5\$<+6WF=\=A M/&]3.JKN:(PO88V(F6L)<96@52TOO\:W0T,17YYV\[C#K(Z/W%F4SIAH]PM< M3IF(R98\X.HEPMUR@2_D L^("_0F?,S1J C[/T1QGXQL5/]4:)65K('KBZ(] M9;DTE1O-2#X3-4XBJ[9$DBT\B9&4TOC*-8 [Z/DBUAEN@JU7"27#D MBI:%?;HXD4+> T[)F;0R*/DLB8HBGL*%ZN=#:PYDL\V#:#K%]9,P_"J7=7*^ MVRV'>6@5PHO%)PE8UKW#A]G_T @H,(2K*%DHYCK,TLX5.F7T-Z)QI>HZ9!U0 MB (SPB-#,RX_,Y-$.5:A3M=Q'#2@*ET:"N@&3 \VC($"=:+"D7^<)6IBU'RS MP%5AXG\\G;XF:(7,W4ST%?4AUU,I=Y 2<":D0E*RT(BU/BK$#0N IVAZBK M$CM3[39 $50M$G4Q,>@AVYP@Z@0B;E[]A MEM#D(F%4'!O7P"*K7DX6@W1J2B>!X.N5[X^.R9:,L616= M''FR(577"I=:"0?VV&Y9VPC90K0M[Y=ZF$-%'A7EE(?N&SZ,&HU,6X0J-#K8 MB$P=AE6(F[3_UV5\'L-P]F[)&_H)V_Z=^RYVM[Z+K>_B7O#$GXDG'D1E!)=@ M'E]%8^@4_PQL- N+U=9B2?:F>M0YLC2RWZ#="ID+<2 RG)E;W 2_TC7GF%GH M0N2LR43;\VF6)]!AP,T\PF;!9"7S^=9G(J\R7HR63UG M3D" ;_VJFDE1"G.*D& PAFOH#25F (0+D*%0)O.<-SJ($'Y?DFVV -D&@Z"B M?$FB8S2Y8@0STY"XIU!TPF4U\$EB8ZQA&S4L@YU:D[YF+=*%MSG#6]>-+ MM/;N]&&HT%7@=9P9C<^E\FB6^>I.PZ@IV)6%86<#*Q96UQA+0ET8U%5"C8F4 M9&,N77:>9]'$69;0-5KKC5.YT()(L)DX$6@="T8W*QKD6OVPZSUP*:A&,D6H M[41"='0PX]S==1 ZH#LXQ.V6@9D* P6M9DLEMA83'!_A*X4)?77; :4 J0U! MJL@\4Z#)UC@GJB%XW=#8DV1QBDS8#,G3[I:N)X"X_.C.-84PH6<'@<[0^$SN M1U81Z>BI*;Y<$(V(=\9&$SLV.]*#&D=JW5^R3*9MG+4YET$Q!E6"/"YF[NAP M87NZ9<;MUHW-8.YP0-73-CZ$&*OZ,:;P)K,]WD[[B!944"L1.T4UO=@&Q+YV??][HZ1]36RTPD&N$X6WTL,Y/>=:_1-A+1=#*H7Q>$X.ZIK?+6$U!D$\QZ09N MG&.^0AK$!1UY(883&@\EW32:@CAE)JSY"F"Y4_C!PHV36V/2 GB\=;'2^#]Y MS67-Z#5,96 T2U*O5TYZ5:.^QQIO0: IK;'KS<'.$Y&(RJRV^2$SU90*9CCQ M%'B?B2Q<(A/G@G.M^)\%[ &[^9/L6AM%R1AU<8%Q,R6,J-I'E>[: M+9?PX#O.\"'9O!+1E$1%B=)XJ<1ZXAH5\6(?CVGM8E[,>;34D;[^F#0WDWIS M4R'-=FOH^<%D]^=(+Z7C2.?\G[KCP$7-J:ZSH\ZA&;&ZRN2V1L4OY,UH]6;H M5T?P$LLNIW,L$F.HF^C]1I!D$Z[@&.=6<@]?$69R&4W(7 MFCL>N<@/>JP71_<*H_O)J>:TR*PEP[MA6-)(NZ5G?JY2-8W+RDEE3FSLN*LB M,!T&9/S8X@;0(8G17TI['F;S15+@@9770 V0/36]#NNPC4]^6VWU]7,F)$" MD*P='_4:1Y0'.F42\D$72E9UHXE7N)Y#)!C&$/,GTP4\7N'!I:0S$@\417(B M[_AK!H-9MVBF)0=%O1"&A\9U"?%T4,-I17G"6^[VA=P-%(8_M)="4F^1P1DG ME0F!\HDVKMVEOC@7UHATU8DWY@8CYZ$V34R$)!I-6L3(H$V"JJ8 L^@O/AKL M6]/C:PBX]LY8R"_5G#]-[P&+HY,RB_Z$BSO/T8//-+OFOC86#S.S:EP;F@J( MF<22LXAM<52SGB$'V%KKS$Z[51\5WML2=3B6%&6[MXP%O^,$JSKS Z/T"Q%P?M3 MEH-@&Y#@T/X(##.?48)T=('U!CB9$T\*1A+;VR*)=:[Z5,,GD( ,],K.?X7Q MPV3*@[5.RB5SP"QUS;]-P=FZX5B)C51"0IV-V=I./I\9/M.VDQ.^F2C*S+_U M_(SGRHUHA JZ V,)-F$-U56DC8JZ'O79D/9V2S][2Y_K+3U5P%/&EQ%J1ZS1^1FX&(:(=A5-.HZML56$2;1J/'/.L MBVGQXY'SWS[:^^Q_8=W]/.-?/EG-QKA':E_Q0V K[JKI[2$*B:"%F:B%\ M0M)+-:+)-?/IO XMB55S&%GBTLR.Q'-C-+#6+SO.H,<^R2>_[3X+7>":#CYG M?>W^&[Z[75",*!-F!=OUC <=F>. MXWR\F"'YC54E<\O%3_.U$[8TX:4X6R07 M9%5:17XAWY[48T++K"C6.6PX);00""'C)C/&,\F'8U>GI TN&[N"D5]2RL0" MC;+C;)$6*N&]+K(9R/@BW-%6F0/[,6RJF#0?H.39G+.=J$%ODZ!C-.[;8&_, M;44,)%9D8G.TC>*+ :QI< 4J6[8H*J$ 3E!"4YHFT0+#71&8(0FTZ.6.=-Z6 MUF&E&)QOEN25IR <1XET-9H:4:"%'H/0,;>R=#QEQ@I.X%-9XD8'>8=+9_]X M4"2^ACMQ#X3./Y:O=U#&9R\5\:&J1UM.E&_^\TVZ" ,7RP$T-GO)^9/0"0J= MLIS!QET%V3Q.15D6HA(CB=AHA$+UJ,Q>8]Y?R4)C-6NT8MC4?(Q2Z AWI,+1 M?D!A7]D2SSU6G>[9;YSFI+%LKQ,T!R:LG:Y%AQ?2;F M/K)P#NC;\!T#:S#G&KR\H:Z7J<]W%1@ +ZYYF2SUQ52WTRUY.6XRVF;#F:$( MWAK8IP(HS;'DF@1M-T8LRK&@"^C#,]V6&8)@>QO?_[X*!_M-\_"/8^ M,*[]?O]TQ+#M_2\H6!!\M%Y!N_4U"A8$-ZE7T&[=F"!:LJ M$^CZ @VE"=HM6YL@7%><(/R4Z@3!IQI M9CSO>J>P$Z?]$_@!R[V"[1#2FU=*1!.;* &PF?#T/APMW.?!T?[QZ.PL3^.R&8/W!"Z'/X&TX>F3 M#SB@/]X-X&F8%#3Z9@ TQ/AX0+0P@L%)[Q /R&"_3V>,9\_]; 7OSZ>R7[7@ M/5+YC#7W_E_S.)>LCM7XM0J?4NM3_/R,AHBQTVNQTQP?SV$EN8[99^1J3!"7 MH!W6$#'V>_5VNV;9Q\9*JXW7CS>W7](%GO4V5EMESW,Q9,.K]D[^%*Y(^ M @Y]XC!@_!Y?@;L2Y45BO"PVX-4/+PG")OVEZUV!T$/WJ0Q$BQL'Q_ ^BE<@ M#9P!"V419'@"[PSV!H>#$6VR2PX3#!-5H&!._]:L?"D-I&EF)O$%C).!I!F7)VK(8 M&CU?5A.\L)[ .'(#&D0B'F#(+-K)1\LYZ?@4,J.MSY)D5 \8/%?6S#59,)X= MIZ7H<7I1I&PW'%.4-#&HN*#2)*%C7-)LD:V+Y)DD6[;^F_NC[!Q"O5D@L 3& M.I3 SKC5#B,G632!)X^?AD!XQX$P/@%HT"]T0QAHKH.OW5F>*R\>J*38%U25 MQQZPA&\)E6 ^-W#$1F283G>"@6])F62D?,H\=7#OVHG&9/)-)CHD"6^/"4.( MX(.4(\->2F/Z-I&"3B%,JE\1-CFF_=5HR("3@!8_;\MD:(6!D[>EL[G$XN= MX%0T;S:WR%;!/( Z)' E]*)9QEF!4R:\#+(!F GX45JT]CKV02Q"J28K)]^/ M Q098-*M_@ ?_!FC;001'2-"0ZF%HX652S6XA@^+#/%<0B>*:)+!FCF[;-Y: MM<7W1^C??,[\\ZW?_0?VN]\G&>FI$Q3K0W=('+\N#E$->Z0$-8M MO$QPE*5R+2&FE?-MR(Y%O'OA>KY81!J#T.9I,DILNW6*# YQ\UF)\)+53X=> M939BIB; S#96B5GC*3E)9D8\X*E&L8&&)SPF"56<4F:6K,>!%)'ALG,-GB9M M"'=A2+4H\.SQ;SUK'9\H8 =0BBKC58/M*)O]9F>MD)WVRC3(,9EE$R,5RD$A MOX8D9SML0D M6X>2F1#2+BT#.F(PU$"Q>$)X#5S^ ;0$K5QXW>AIKEX*=,M0T4=I&.L[S51% MPJUN O.GII7[D MSI6/C!T&=E?(WYBEC'KG5%F-4GU$M-:DCP>2OLXS51$I:O8>HPW'XI#:'8_' MD&Y R<"UUR757.-;E!I"=WF7+ %7\82@X:5G@8<)!D4>J20.QD8)CNNX)1I& MQM<'I9YA7.G@^E**,Z(<0>:*B>">7D18ITLCYB2,S"RX^3D&-5$@$H)K++M. ML!SKDAJ,W_#6)^#&W0.T_F$T3V)\W)(#Y@@\3 (8!P9[*KRR M<$6@G4 _PJ=1/T.=ZE@;H@!+%2YPBX2>58>F8;F].BHEG%6A_?10D#HAXW%K@AJ*>&$L8H]3?T]"F.Y#LA1S2D8FP M&G2A82[05F4K#89,W35LTV/R7;FY&):;.#DM$)=W2"K?2 MQ2)&; W4=RC6M[BT$QF,>CS,N%;S$H4VY*)Z03 GW8![^"&)^A;[[3'LT;*P ML88?VS$TXJ[;L2YCU$I2>&W5:H5-'8*1L&6L24JC((&[,L'FN4D8:2W<\ZON MB@&6T'H.DIM7"S64$L8VEU;+^%[]57?Y#:T*AJ=@ARSP9E83):G23F$-BJNG MKOTVQ<- ^@I;CW6Y>(.<8@&F*0I\H?T"'L[[-T *O26SY[=DI$]UV)Q4#:6X MN1IT^?@B#EF!VJ6AM$\@= M[$M;W#TV)0TTK+@N]TSHWZO.7<&U?ZXLOH;LOI2+RJJLT43&FD\4@9M3M*[; M0*=2!PNFB26IRD3&EHN[TI^59IR4SG>Q3": M0E(_ZJCD+ E^E <'&V'!N"E?Q(.#[X8%WRO?T\];W]/6]W0_U-K=G6"4L:@& M76D>?U.]I"F)++05UTS1A&F,%13P*G]1U:X([F?I9L9).(AKX;#7J0%X720& M ]:F&ZH4DRN%HTL(A2ZJX$1;.!J8.Y)*=EZ[Y>=AK#.Y\'*P]1I/^/@R*[A, MD1F'1O>?D6I@TB-1SB W5+48&5>=,&4M_(!! F.I(TKI=ZRBX5S>)+.M*J#D M:B;-X%;69]"QF;4\5+=FO=>GGUI;]S60FH%9-'6UNJDV'15B<48:-HE?)L^R M:1'8J*^=4 M,[L,V+J*R4R3X9/297?3.5D_K.GU60T96( A_9JIS?60O JA'_5. MB/-8$Y%<(/7S8IP[FOY=G(%&$KJQE(UQ $-E >=FB!2UH2@/%AVL]4^7 >$%RA0 M6U$*0RU!ZT/\9.*R"[^$QSO!5S@1VTK4&)>";5O!ZV/K7L$8K.+'2#0MCDD9 M$X]>*:S9*(C4=)1Q[J&V8!"BA@N48*\2+2*;4HDBV%;G1\MKH[> %/AYVE \ M:(AK#?21L]>; KPLOB.PF(5. )]ZU;6+C&#))64<+KQ+%27EI:8U4\S.+:G7 M@&'Z$LELR[(VQ;)V*RQ+GVVA%](-K,%37$,->E1(@5(<3H'4-*ZH5U]R1"EJ M_C/4)5>ONX&V5)GLM\D%W/GY&YD I>>;6 !_>1G\CL&>F[8%?I$)[;NQD%47 M\L<@F\UQ)0P[J[6&V$D1]L>&!B G()^+/(/3B^;@+'^!KNE2P4CV7K.W;>3> M=7G0T_XM:/[1GHY8P5MX+T-A'(45DRA*URFY&$Q,K+ 3(^M8#)=:*08N^L7^ M"3%@6>^:6^U40CC\<%1@HQ++;FTR'3^7K4'@(D0;5 S0TU'%T62W"CJ8-$0, M"QBB?DM!H1J.>Y\AQ^IE@\*J:\Q+8]*:ANZKU &RJ;6FZ?)>/++O/X"U@20_ MF\"?ZNG6&]7T?:.!KSL"[^-BK!*@0Y4M"H?>-S>-;8SM)BB!8VP%4+O=ZL') MS0G'CPUWKI(@=7543L4M./V"W\.<3&8&4AK#_];*2I&.R)3"9Q21:^N>L0#5 M;ADX.!>D")N_(,PTK%# @0@W@6PR$N W0]&]5P3#D9AO@4^Z(JH*.*YA8N?>O9"D'-!272NI MUM26!+^4!'G7U4RUI-!A>M=@V$S ,B7N2<;"9G71/&X>" M')@,*J:S*@(P# >K68#T<&G*PE'P)"(^=F@4*18(129/T3&<8T#^R:BP'A?$ M%73JH+,4N:[3[I:ROY2RQ8\&$FZ>$ED=1MU-DD MDAF74RTILCPX,!6$':P-=:7$,''FA@5R9'(UA9/1G97$C/*,<(O.M6M\Z3T, MB8J+.67CY50]2DP<7,]VK)2&T?$MK,TSHA@IK#&M_@(%I(#[/UF2-XW',YLK M\@R.,Y UL,V12H+>57SU\!_1=!KQ\5$1%F28>J=12IG&>:ZNLC&)(G :9W'I MG #I$/;?KK^QAE*/6XK_4HI_3A2_#SW>V@2NEZ.+;&(:C8L8MD]J&,]BNA1"KE"99VD\]KX@V[CS M'1=Z6^1>G34,KX@EP/@\EJ70L_."92INS)KPSIY#NV';(H[_:>UT#V42S8"57FK1EK;40-M;7 MX?BWS]QO[0C?9 D>T*E8<[Z9^3S0AP>.]?XQ#NSH[P^>/O!6Y5HA:#N^D0!G M&H)P4>Y'L^!P=$#'W310XP%?,@*WL5OJ8Y;X1;3 E_C8[W /2^BF)*$P# M%C8:E__2/]\LDN0(1+Z?Q9FOK!Z(HEXFR'C#O'?[PP6L-$&1D@A?! M2F?#C1I\'Z7 O?-_(6JT.5/?8CUNG037]"TF^.T)^](3]O5.UNO!07"4[;P( M:F,8' R'1[S1ND?DVY)F3 M2*5?GJ\(5?K&\OYO6WG_1Y+WO[HQ .^!S:C*FQQZ_Y_O!GN#4;O5NY/#O\,K MCSCJ[Z2,P2T X-SR^%?(>I_!=Y\\WC+>N\%XO\]S=(=9P'N"/6VWANB ?7@\ MG09>WMV=LIJL8 BC[ 7FD*P7X6]]Z[[6;+4QI=T:I.,=OVSNIJ/G),2JWF"- M)TL",6>!F=6^%]2%L6;DB$.+H\J+NTA+7\>9]+6VY$!AX=]AG!??I-:?6,^_ M21C[INWVB,:K8SW D:RX;ONHFBE%*&H[F*$O0E8\ )0>AP9I8;E"%Y M@QA1,LXNTMC-GA,8!8&UT!"E9L:4;(9Q+9@[+;A0XIP7%#HL:.&4S*B5]\2N MIR9A[ (]^O@1HI%32(&.#(@,/)QB2-)Y*<%=XBX?+VV 48E2HB*DV N@ _> M\#A=R@2WN:@2% ;A\#<#ED!!MH>(WWPVE[0[@I70:87D>.F&-L'2[9%6##8A M].+K.2A-TU4EH+^2$>6RW':K(Y\FB*CEC5;@O]S'=?8"SAH()>/)S J57"E, MS>2:)\F2\9;T7R'!G@ 534+>^3"8TX*&0.=8P97AH\8E13KQ1_@_(^W.;?$< M?@HI7]>K#70>9*S'IF8ED3F[Y@/*"\5\X&,% MBB,&5K E?YPR2[G23 A8(B(H4) H2D)+9U'XY#M+(Q'!\-4$.2+FE:HZ<@5# M@A6+A>7 ]4"MS.+T%=?1W*]498-Z=54D/':1'C R2#F'G(O,<>:\ MM^@B!XZ_BBE1E"%,/YO!'>QDN]/YAA.4%Y?Q?-VRZR-GXG/U\-TQ4JPDPL:. M$]H9GCSJ1 F@/>K4&69\!D5_SUM^QI2KW(!KHYXZ?$M#E8SU.PA.]G$ M+0\J2J>1.P>-Q0WG,JA*(N8K"N3_QEFT]T:.)"7)JZN.-UNDX0U(*+#5N1^[QR:O#(-(H3#.4K,RY#,IMQ M$Q&5<$<GL?H32"I2,*1X$">9. M*X+S+%T4UIP_A0-B[V<++PJ(H$BU9BM7[*LN21$7AU,TT5[M,*!M3 M;4<$5V1Q-T6P/2.LLG2K<5QKX("I8(YE#53D8& M63XH!3GE%$))>M)MNK87;26QEZBJGP >MG+RZP2%9D' \=CG)<$44@&;B6M> M05A!/KH&2-%D36NK3?6BA::XU/GD!R79&T#+/'FR]2??#7_R/:71S;)5S1,P M?2Z>D?%0ZPP-'%>GC+H%4^!W,0+ AEJ;8TR)I7(E5JW/1MC1CX,(<:&A&+3Z ME7O)=J;AE>8.E,$0#69%T5%K+'-OZQ^4T=W>W5Q#"JQ>?#6+/0,L) 3*)AX6 M:S) ==+F!)<9U0_R]$ZMA6BECX$+O1Y\(R)[NE9I^:"&BE&22HF7C!2$)4LF MI&HNQ6$TCJ/ T2')JBKQ3;2M&*&HKQF5)%%R#+(\0@BRV475H5*W6J M/ZXBU=J#[Y?!-18'CF0@ DT4C"J'E0582;9IMZAJG\B[:D:C*/Q=*0A2$SK_ MB[===O/. MFS=#=B)R2M54MJ(T=08L_BE1!QTY:VZOLG!6^6-3]Q6]()UOA/5PKQ@KFN0U M%RP<( (7;A*V%/.G'=;IL0*S29@2TCSP&5/HQ$*]QR;MH;YK,1< (+;XL M%C.>H1^BR##-'0T+B;$NW&=?FO?U\1Y6)]_=4H=[RWKF6U/VW2UU?_/LNTTDVE63X#:>D%?/Q[NM M/+MOPKJ_8@CK;4^E.HEUML:G+S74X8O@$)$/MJ;'CY@>OP?CX,9II7*5/MH[ M/OCP&G]Y-WI_^/K_ U!+ P04 " "P@'Q6+!CIF 4U #N+ $ "@ &5X M,3 M-2YH=&WM?6MS&DG2[G@F?6G M-QHHI-YINMGN1AKVUY^\U:UI$+)!MF8T'\8V--5955E9>7WR[1XX(_Q>!)-XV3Q^J91Z-DB_J_FE[IUP %KZ%LYR9%.2YWS@*_5,$O& M&^W=]@@_/AGT#KK-QLD'==;M#\YZ!X/NH>I_[)QUU?EQ;]!7OYQUC@8UV.:D@&?,AB"W[([T?\^+,IXLY,,X'6L<$M@T3K[C]]^DSI:'19'9S>&PX/8_5'V;P\B*:JEX[VJS\YR*:S*%WXOVDC M0<4E0BH?A38)5I@5\T&Z,L'<=EG*5$,GXIH_T]+W"D0CU_ M^ORIK :\'#8GAC4\37#)(YCC;($_O+Z,82HQ#%J6,"E8OTN=:WA=5*BWYU;Z M=-X^.7^G]N##:;2 C5#15,.& QV3/)NJ$K:0:(0_VRJ<)+XQG"%.#)^)QCR# M*'$34]Z\X*]E%*="4YSNJ[>]=^=IH@N8,PR07\>P;V,]P6?:L"31+"Z!.?^+ M[$$#S@O[8]S?)%'$2/CRJ8Y2Y)RH&.7Q$']!2SQ5HH2 M/=FJ,(8E,L=_F?!!Y_U15QUTCXY..X>'O>-?_O'HZ2/Z=_^TUQF M,YF@?##,RC*;RF?7\;B\Q/&>_@VH')R9UUSIO(Q'46(6!$:IE3-X:;\=')J? MU4HB\XYMRR!@XU]([NC7@50='(9$#;,N.)7B.A^(>/Y."C7#DX01*/__'H>4#? MXVN-=@[K_MM?_TG],!U@, MH& 6L*X1VA:@_SY[^EP=L**I?@'MM%"#'*]'VBNU=QV7E_ )7(E:M]1>K\@C MG;2^>@MW=[WY2[[U15RQ?L=9^EC6R*R;+-23%3X=XGG:@580:!'K=V-S4J,S4W?$W&YPU$_"L MYJ]6Y[8ZV)I%_Q6.&AS'':SZ(_0FPG$=T9E5:.;O?+%W+7:W*!77BZ,-8P\/ M!'^EU^3[(_O/(_4W=1?N0.$0J<:T]#&*,$_J/*4WR[!=!*BV.=D^JU'BTES[ M7Q"R\96FO3@=)?,Q:F6B6!7JQ_T?29GZ!_5[)1 MN'EO<&_::C+/<8D\@NEQ(0%^7I3P' 5H'1O'L,]C)"59;$(+Q)-R@0R$(5>U]_+IWUIU"Q($F?G[3:@PVPK\$JDT2Q_/YD,P MOX@.(DOH&L<%*'-S,MM@"9+X/_,8-H[^.0GG E_OQ5E;0T95S.0>C!,4ETA((3[JU_9WE<+LS;E\@IYG"TKY!9 M,'A?RE:];VU"A3_92]2ZEM]WE=%QEJAYP(E+KU:XUS@5;]Q-R+C4MW[UC9O@ MK_"^I[]]O5&U*\_W&C?9G<015K[_:Q;K6RB:7=9X1%*>TB5]LYZY8YUP8!2: ML49ECQ)6XI2IB$8CL+8CO*XH,E#)Z3&.M5<;NN)LZ@SI%X6?_2/)*C=X1W=F MD-U?/]_N4^*V+D\&J"NPU@LL,+6#RX.G4\ \.,\O=FL?ZRF< X,[ PX*]% MG1(>C6DD()BV+HYR/M;P5)Q[JP@K@L^A]0 K#$) SVA 8\XY">"T41B@+@MN M_^[Y]=7+_:J]/H LR*/AE3(_SA&W4RHR5XC2\2 M4?E&_8K)F/"U>OS8B/K#WJ]ALK'UJ_R(,[[)X8GI:+=Q^\AX(S \HED!M)B_ M!2ZZN,,%_"9 M_Z,GYE?XC;M#S/WQ]@FL<\V2#^%<_/YXJ"=@ KV&8XW;Z/N[?J2IUZ6#^X&U M8'2?*"26]WHWS+_3Z-XNU(V/O7ZST?FM@=$U5'GMSZ.=P*_/E/_A%_U#WL'@][)<;^-S__/>>>H M]Z%GJ>D8-%'S *<.S)T?P_\%9Y[@/G]!'G7Z_]\LQ_NWTJ'OX"Y ";_SX^11?>- 9 M$&E'W7X?!S_KPH+#6YN-+HP(1,#2\HJ>=9 BV'OX!>W5ZM6]U2JI@Y-?NV>X MI\@2(2\\.8$%H;'<*VA5\:T?8:8PV%GWH M4(M'JY+1WC$3"FPY.SH_[W2/5 M![+['X"LD[//LH#PW:=3V@>8"[^X,V"2:1GA(UC'SE'7K2/,C>IV&/Q2."Q8]IU>O/$J@[) :T]!Y4&#G#Y<;1H5@6VTY^I7^"?5LB$V=,AV M<2,!"]<9[7OTF!O12U3V!O5K<,A*L#[OVN*80I>P)CD8'^'4J#@HS(?>5P-C M>2S74=ER(['3Q$>?DF4"RS(#O;O BI]5I4AJN1*)26E7Z;!6&!SGJ, MTU&6S[*U%KK86-QY@L^2L]=F8\!P+YNS46.+,D6]X!3[9]IJSZ!$)J]X8MSUP7ZCCL MZ<4?XZ*8 X'V@%*(2L*V..R3+$["#8Y=&Y^.#?0OL*MH+1;7S;!JDH%'1SR)+MN<5(?1@XI"'Z,(Q=$-BTC!BF',86\VE2T.$KF!18BX@_@ MM7!J<7YC/1(Q0+N+-S1P21D%,WR?H3>(WTKAXKA$IJ%M0(+!>"WX!U$.HP$S MNI"WMSK-!BT/C1.(I[WK2TUS9EL6G^"H$@Z ^Q=)V%'8P!>=AD]:^^JWRSC1 MH&;D6+Q8OV7P\V:#TP#,W13R(<SJAH7S6[U/R*%,-T>MP\V>CG4\20L=5HRJI8)19!'[=KPS M2-S;,M&<-J--6FVSCOH*>8L$PX+NM;0 0"3H-@\!O3S M:!QS'&"HRVN\G.GX>4>>W)HK+M-ZWVV[LC?5IX*A> 'AP%U%<7(7#L<[O#%K MW9U?-)-M$OUL7V&B]CEHE\W&85S,LB(V<7!R>A=8<(WZH:>\N:./ZA@80FTU MH],XMN%V8D"*CP+_8XJ,DVG 43.=VVA[$ET'OVJ)SSI\B;N%*-&!Y:G^ ZXU M'*'FLBY$Y#_9JK82&OY2/:YGGVZ!H;#77<'MTRP=7<.-B M/3$P3CZ-DD?OGN]C)3//9:NU#>?O>N8FQAVOG!T#PG#^;K_&I-V>.*N@7:SR M(&]/^.P:9>/Y/HJD\W='^B)*V*X&Y3I%P_=<9)"QM3T@A124P"%,3_0T$!.D MYJY2D."6+Q.^ ZFR?C(/-&7<598N4?SJ3C2E>.4)J0+FQC^"QGK(_!4Q+:?M'+1(-,C)(V MW_LHH%#&P9;[VC\+*Y,3);(7).$\,2HNZQ:Y_L\\SC4KW$(E9<3L^XO)^C_/3@Y/NRQ,YK=K"=]^@D^,OBH>LF8NS^E#^G4WYJM<%FXQ=*'Z!L9"<\ZRQ= MD_]ICJY5NRN>H5S\8<37I(CGK)2#0FPKR7[TE54XZ0?.=J"7]99.^!OE*'7T MM\1@K/4[=##&FG J0,]ZE.IR(.%_S48"B@N;G&TEF^W-A8ZO%7;*M][L*<5, M.YT7; 6SENX$A3'E5R>D-AMF "?7]D!*@#[(-@:ZR%B=@U%06OK.$W0@HNR9 MBB=L81/FZFEKM3TS_\*L;;/A+/[E51H3M;,,YA0CHP'3S:/$L]K1H/?EFC&? M1&DS=TBM">9E0(,N6H4:6FNVM- M&Z? 3/5QG9ZA]FAY(U@(T#EI0^AGQ.YM!G'#ISE5'H["O$!_!ZQ5 AOR>#Y[ M8@0Y9@4_SB:3%FXL&9:4E4PV+XY2U'J*VKC=(W@;*>>4SY.3#9MD\'\O':6Z M$M[$H\K4V6B=4X8[^BB*>(SN6.(KFCV^AGG&&U L[\HNPSX-R1619[,<4SEQ MDREY K_2:3'/,9_>J!H\Q\JES%:)]?'579!!OB\R(9U*=E#AJ[."Y<]0AU^' MU(:^CKAPW@2!'R/CIXQ^ARL5?DQD+R2K#\Y$8-QX2Q,.RS*3#2BM]NA S8%Q M\2)=CZU>\5/81.=6;&:*/2HDB+8N;:_?L^5\QY^Q/Z#!X0:;$;Q'6_Y'1T&QT"BKV #Z)(W(H.Q$I8J4* M4FET'><-\&U[[[(*81G#3&#)LXW!T+C*4(*",G^-=/&56J^'M9&^QWHZ0UQ, M+%]ZS#54J#J#=CMCV2K:ES7=C7.S5BO+1,_"8A7T \S+.09ZC'/3&O1B6Z7! M/3 TJGB@K6?+T2?/K1#>.W2+D/3G&5]C8"53IA81M3D.;]B[P<0;?#IL^&]" MA8,^-3:FL<:PRHU!5+$K;"!18ADK]*X@QD2D2$#1A)M\,JOT4>24"I82$P8" M%2T3X]"Q!VB:Q+4/;HAO)3M^(-G1L0"PP!2YZJ-93,XZ0O@3)F=_1,\/IA$S ML/V6BD)H#82Q'B61L_(CJ5,:"(9/)4)1UWV,I$'YH%7P#J,SBBF7A4&/ R'PCGHE47[?95R), M06D5#C38(\E.$NT]C;Z//2]X-(J*2\L!+<7\X)(P*+$H*CS-WUNB.@G/5Q+< M,39?*7"!@:PQ=LKS-DM$FS%&P\N55LJ])>7\L%RDH1D#0#3Y< %4[?SI^%07 M %;7FV5KN?IZR7?G$[ZO.BAEQRA)V-KFL'IB[ 4_UN9,A+5[8CV&+@\D62R[ MW,.;82-H:.<%-!Y%^(?9-5-;US^7Y!S?3VU,-M;PW?URUXS11ARGM") M0G<593,8^\PMY<.]\ZWNG9=T[WPBKUNST2>WV\EDPG?,S=KKLK9:5K[&LFW:'SD/RTG=%0T7G$",=VA)]&ZJY 7Y62@$Z\6Z)WB MJH+UWFR\M[D'W]+*OT]L]2.QU6%41LW&:1Y?12.@%?^I7&(#:S'.CTKNL>5T M960,_X<$D92?8ARCLKOAXMVH#DO(8+4>=:) M/[DW@$>SK^T4.D5_N'B>V&V)BEQ\\QR][&IO1<(F 93M,=0,X5_QKRW/8(^S M^7(P[2ZB:^LE>@9NMZM3%Z\_#-L3 N.]^;DNH%P0[7%YX M&9H3S%+?9)W!WQ?D2R[@8L&$&(+*P9]=,7:/'4B"9WAGX;):G QQB2[!5-0L M@YT:78!+^K%SE!?^WGBKTPIC_<;*\MYAN= WM$S*$7NJ?3:/IEFH7M:038(T MXPU49O\J#F'?=TP7:ELM:^""3@$2%>P\RMH;YEDT]M:E[3O9S<[IW#"#R0QE MFYD0DAA?A\1Y1:$P#_M!#8^#@(HJSQ1M8] +U]')C'-_VT%VP_O0V+: (&VE M8=1LH66M; IUA+\H7$<--PQH8O,1X(\++VCDLD\]WPJI MRQZEL :&5!>6DW6R8^.LW;DL1J#'41FZFSML,GON/6F\J;LB/ N@7QMG# +! M5.,N$_@IRSW>3_>(N>_1HC*Z."74 '>@JY*>]U8"OPL6(EK>@[O*--N6%_^F MA+8-//DO'CSY6_7DO_BK>/*_$Q;?<<[FBSO(V;S#',V[;5/VIS&27V F: R $_0_"\C*KM[>-H9A1 MS,R&.M63N*S0QOJ6=5.L2MSS=\T$@L0WMK2#J.?.$] N%VAQ+=A#*&::?6M_ M&>GJV<^KG1IA8K%$V CDT@ORK'7(>A/B$EK04)-5[QC/$5DNBC>:I;*3+*4D MR2K=AIL0] A.1TF%P'[J"FB%-G)[B=%720UK2EI'>H$>")1")9H< M5J2BL(,Q&0X2TY2B/_AXL=/:@C.&[%IW1J?1[\#L>8[!+3X5!$3XK9JQ,4&4^7(86JF.3:5N@7F=KJ# M22X:OL5R[U]G5LE=6 #+M9U=S MV?E5EK!C3 GX=#:9D NU[1Q73 X==:I]"CL%-1M^C8"W2EX5&/P318U+-KAP M/O95^V65<)2X4H!O7'^C. <; SEJI/GV:#85/SFG@>_ MKM:"?,$$)D# ,'#9LDLX,MG4"BE"J;Q:EH*X:KK!KKJBX,57:K M,:>_%%.Z6OI1L<.,(*/,=BJNK(BTNRGQOA-XR V\US\\>*^WZKW^X:_BO7[ MX5A)]$NCIQ[I"]#NK%[:;)Q_M;:I;JELABY.LAY++@&DBVT&1Y?2$#0J!@8) MQ[AB_4)5HQU(+9^I5;RA6')-M2)]13Y'4)3F.>BGA78X45]0"[]4@1$+B70M"T; M$5,1IY#Z%VR!EUC!.E< #5-5OEP;GH>DL'9F8$D&"IX!=?",TL\_X&P,Q_&:?>[L78 M:2I=/@*X&/R>!R[^ M1BK_CT;E'^A\RK&I[A^S.)<QH?T>MS^EVXPH3_Z_Q"G,K)@?;" M3DNA.YNFP.X9S%+\TR7J[3B+Z:?=93$-HC_4)T&R0+XY #U\GI26<^X4<^X> M'N-=3^0GJU-[(&>=PU][?80X.T&XLO[YDK=2_@] M_@04$E3*Z3YBW8P:J9Q)$Q70)4E-V0^4N,,35*I1:P4EZQPN#];L^J236[^GSY4(;"DY M-<^VVBB49"K^Y(86QVC,S@Q*64#OPB@HE0WC)Y*6Y<+]-I!NW[BO>I[;2;J/ M;CZY9B.F$%$R-BDA>-^-N1P:GZ3\<_:3VDB9S?;R>K<1DKB7)7]##7]8"D)1 MVK FPI8_!$41IE)" @0>#D#%4R&IB[G)>FF;5(.V34!@QBEPQE3Z"U0,%VX" M898,+;S)MA'W66IXR2NFX3PS_,!E0<@N_AZG5%<*/Y^S7A%F [4-O>AXG2[Q:G>ZA"\^'.+S VKMK9;RE:#6 M=H'8F ]8LX&'P%M1/PLUQ)9K>XM/WLXLY:)XKY,,G#2YPXP,,I<67I!R;* M+(6,JE?DD4YBBI[R;1(O5]B1Y! (%R=>I4]#7'D!-HDF% ,T1NBZ'PN4RD6$ MZ.*FN#-AM#)!GJ06\90%0"VB6UZF"DMF"V=IEFPHR5_+DVBQA]F+=OM[@(HV MQM(3ZUZ7_%BOD)19 +,PGCZWB1V%GXZSK_QGC&SGG3>!;N( QQ5^C:'D?51) M,QF9!K?1!'@<5ATI"%4V,!$8.\!?P!]P?XHYJE-8$Y5_^1"5WVI4_N5#5/Y/ M?DRW"-[Y:O^YD9M;'!44"GL%2#^X0[@]]]DYN$8WVYGB].P[98!;7CA;G@;N M/NA_W0B!A]R.F;Q6P>\UM[)D0Y"Z50LYQ.VD@CHV=X7#JYZW7?4VF;*HI_EA M^\NHX#YHFG,$')!VI:K-5]3\[("J>FJ5M4U+06S%Q67DEYJ':76.++'@S4@K MG-L7H,.DQDO-17"=$_4Y^M@5DYTZ9^? MPO8L"I=N>--FH3=FQ6:U/ PMYHY@P9::1GEL(EG+V.^)"*"\Z[(18LSU0@(@%!GZFV8C1E5YID*C^"WE;^RELV%=0@7KYBCJ:! M'@OXN-^!B[+EN;8S&%-G):Y$B'?4/&VQ MZ'(THLV-^>8^69:+'5EB^>\M4]1R)QY.]2IAX$Q*'UW/@M69'I78/\8GG&3< MBZ>/@6C%&?'2=-!AGGEP4Z[K9M"8->C(2B"'JXYOP5T KAA*$M\CNR^-([*J MA+7)A?833?"-E/#H#[!7Z8@!T\3F%&4BM.42M@@G9[J=+TG@G<_0)>@5+4GCLN[Z< M@+(H5?/$ EFY*C"=1B-[1B1695 Y34C+4XE],JH54S.OO9$/J%CCB)/*(0J2 MH!-F=)D5#(AMB3 HCU-2V&S)&HIMBK=5^S8P8*D1%AQP].J35[72]A$=/$%( M]]\JG&Y?65P/ 8$7#)QO+F%D.OWNB\$[PQK&*EJ!" U,ZEXVNP[VA%ZL6BGL?V3*RU;V-LGA&D%XU_$\I[N((SWJ.LL) M*/,RFV-D,8Q3.D!D-TLOA@"7_<'D=0M7RF$;25Q0U;P% MLH" Q_/(Q%,Y_=SV%;7=5U:*1 FC>UHFBH8#QM)N-G[!LM$!B0,C,!E!+[#C MU[KWS:'!NM ODKGD)!D:8I&J^DS)HJT%ZP("@&- MUF(.G:>A"J1Q@K&H*:P%(RU30#PH(N#"1AYF9FH1E_5T%I4,)I N6JOK W9V M:EZ\W/_AY7;"TK<\-_;-VSTYSRKURX*'5&U)5=L_W._ =&.(2G'W.<,]:SD&:5TEC0%_2J_K'V=WM!#\!8$,,]Q'U\RD,# M%T!S@B5AL\?!?/N1%#\-9WD=*4VN!%$2%>*OF8=]83\*J-.IN'BH,?2$?"B5 M6]/9+#6K3:V?['*'):E5?!O)^$>:=& \HD9E&C;2A8@3;QM7"D&#^) /3A,C MKY^7H[AJFCG<2]/HL,D1R MMBU!0&&\U%%27AK^LMU#O#X:-8![;Y"YON'%_R#O5LB[%Q5Y9P2#.#7(.G?N M6XF7U7@R@"]BD^2&?#FJ.#B^YJ139O#7.BSJ7.^AOZ(RV6^2R_7CW6"5U+]W M>YSULRG/XC#.P)=?N>J8P(E-EB6A^CY#(X4ZWILR*A*0Y+TN+QU4O[NP6."B M5=&N^N.X! MEA-ZT_D"-1Q/%SOZ[EL.Q($O#G%,"$+\$@!LEW&QEG'@V]7(2Y [;TPQ\ZZ2 MBS\*OX^?:=C A#VDF-\NQ?S9T]WEF'^*BY$&$RS5V7S#]/('S^5-2PL;QDGG M@K&)74\+T!_3D>E5Z*MY?)IF.J?>2Z343?AW6.SCHV'K\%MW344F15EZ5E"* MNFM94=,>W&&&X/ 7A. UQR)6BFC7=WBNB;\:6?CM_-SW7_?:!?L]9_;+N5H, M56P/4E\=9V GF*_D_@D0Q>EJJ5IDUB5N-CZ=3X>,)F?L.A]GW>4&9'.Z(,;9 M=6J!>5(=44W5]666B%G2=DV5F*167P&DFBOS"XXQF!S7B39 MP& Q2>.ZHA5(+=)3N(,C>UI(!)*\I?=Z%CA% FWWGJ7.R$;!J7&(&\UQ*E7A MDLTC='#<@VP0ERB'UP&9Z/9E5\MH1<>K/NI:T'2?\='7@X)Q(C-3VTFXVCZ/J-^N<\ MCPM) JH],E8Z<_=M4SG&U@'8JIBI2O:L5])-*+W&D51*L@]7:3E3@YG?RGF, M5B8QPR0CJING4=@$">PBB^#FJ. @&CJ^D@UG;K,VTMI 9H2^O_H943(1MC[4 M?]@.LK8M!WH.-$5]1QFH43CF0">J[:6\,)KKW')Y(VB&/8(>W] MY"=@4N-K2B=WR0 %=HVQ I@0D%ERBQ3.,BDLH#M"&#.%\Z%,'KT=!AN$VTFR MQ>$W&V=H9EZ\ME!&3:$1=PJ6OWC0NN-6XQJ[/>9;&H^ +RK+U MON,>-_,\:#&#.3.Q9. .8UD*,[L@ ZH2J5XR2C@X[#;L0:N[G3,CG"W'2K>]=WS(!1B@+]<%DKF#:E'K\YYAJ[;:M#]'_]!"BWVJ(_J>'$/WNGI>=5:]_S[1N=/\-L1'(-X0,[%/LLMGH6E4'L3!V W2\ M*YYX;Y=Z*0+PW2WWPPA!T2=+]M_343:J$)>8''&@ EGB41NIS5NA)_8#FM4BZX2US M\=)4Y/(5U6A'B[N1,A@J&[=096R?!)Q K3YC+T3S#ER][9V%0_'$6*W:21W: MDUMM\#JZ7VR7[D_ /!8@$(^2-1O(5$# MYOX*47H/M^OV,OHK-XZ$<&__<%\=G^ROV#U?[GW5WMR"S%IQ_B6L]>B=Z@H> MG8A8?Y1-KN-[)TS7>U=>/7A7MNI=>76_O2M?]0;/1 MN8?$W]M51[QY;"1QU#FN 1[;W0S6.P^WN%(;E+7]_"#5MRK5?WZ0ZG?,Y%LT MJ//?==EL]#%9Y_')9**"BOG[XXD<9#MUG.Z@LV5_E,W+@VC:;/32T7ZU_[?D MW?J@&>M+EK[/26(* >4A8.!#Y\5]8JD[2XW?%79R'764-??- M88JI,&DJ)9DVR=BR,B9/5MK4HP&.]3+EPF]+&G8##6K,HM0#@PN:G%.?4VZ= M,8F3H+GK^7Y_7X4=7@GKCOHQ.I0#JN1$:JZB!+-D,(^.(+2X(-+/-9,*74R4 M&V47:>P7=0KJC^ O&91U.V.J\<1T/43\$$@X23L2'$OL<.'UT%AJCHJOGM@Z MS0O,5<*/@&I.*#1Q M;:'- /9!D"C!RQ-=!MR'RR*.8$KJ?";5KH2S9TIY*;+;\IK#^&^D%8--: >U M3YRY:_BJ4FQ5*1_TI6FSL2>?)@BF%U KR'_^XZ;*#&<-C)+Q9*:%3JXTED-S M$Y1DP7AKYE]MPN<"+AJW>>?;:D8+V@8^Q_ZW#!\G'73Y(_P_MRR9N?XY_!1R MONGVV[9_6_,PC\@ <>XIVUD8UHT*U4L#SM1L2/5R.\A$HW31C*N@\4'30E[: M N7+9]740KO#!F21RHV<2?"">,@D01QYFU!O;]5=*2GV6RO(E)"*'%.L]R/"]=<,*9$!VS0>4%XKEP$WMG2.& M W)-@+Q.2[DV0@A$(N+^M+@/C[_BYN1[2R-%&/#5&"4B5G/K9; EA@0LYD-. MQO6E8L9I&;0ST+FW3#66XVX# [L6H:]CF\,D*'E MBP64)\M#JHS<<*\B+D4I#W_"I1/-"RW5*"SZN0ZS[G*@?H#NDJ+<:$:$^-KK M FM=UMP7\"PL!ZX'FB,.HK.XCF9ATRI7^6#:).&QBPS!*"#E'#($ )?V\-YB M3@Y(_%5"B9*G8?K9%.Y@#U>"SC>H-WT%C=\"Z#JB9BOZ+:J6V6G/_Y]/5=:Y^$?Q#TLL?[,#) (92#EF@L M#?)*\(PR2=<@\3,CR1*3P?NJ!J8(/J?$5&7>:[77:34;\[2,$RE5\#%K+:JZ MA9"C9ZQ":Y!=N24;ZV$6/%[?*UI8 MP+BB^:" YR[W()S4C..@R*RNB&>%\-DC"Q. L_3!I"O:8M"6#1Z91'&"F]5FH89;.B^H]AW=7".:(-E),<-OCZE-HTS&Q\7^-9@F?9?E%E,HG!J&2 M,*!8*]5X0K+IT$/R\,M5'$&P7EA_$H5W>\2R*NQRYE!9_>5T"^-JUL@();B* MP$A%;%OZ!(,"=B[%+$X?PRGR,8D,DC4LBB8MEA5FLZ^R+$E4%%ZW3JM%R(2R M$3661,QAUJQ3Q*&U>C$KT@99"7C!GXHUEH<&!\ *;'^=UJGA^,8:Y8I*>$@O ME/HH''/Y.=99AQ8;W[.OVB++XNE4CQ'XB0$**I@JGB[$2)!U=R88/B3B=RJ\ M_AI-EK:LX]3X8KA+J44;HUZ!4LA9M1_P"8I3^ :'9UI@.Y65D-A6A0(+P_IU M*OOEX\1D:Z]X6J"FYM3K M]Y2:# MU#MP[+N%$,27Y8#%++;X',;;5+WJ82CN,C]^N+R_&:.;7<(2TWA*;BBC1]:< M 5-3[3?O@;^+.5EF,^>]BJGR6B1>U8]I[S+S.-P0%P:&Q:CD>5"0:@=>:3CC M%8N83^1\0/#ZL'&(<[OXPOA/*WK7)QH\>_J0:;#53(-G3^]WJL&]Y?/[.)$E M%6,)'+5Z?R\%3!A2*"$ 20EP.=\+VN4.::+,J %<8, ;R\Q8SP@Y4'E#Z,/E M0.,J=PG8\^(3IM[N)8/H8;.H,=GL"XG7C>(HM^Y%1Z]%K<1(P)5F5S4ZL=OB M^R<,@CG8-XBKRMH7P19456T#1X.K2-V:X?N%@A'0(&-"!+5/#2HW'"OU4ES9 M;%#?9[$!])2H*,)=*0@[&%[^!V]1!$(Q3_4"V 88@U6[<89+ RL)DWU"4100 M&RUQZFH@B-KM&9_F7M$RX&>^&ZG:B* NWE:W6^O\6Q)8E7MQ6FW8.#4VK45C M&,*:H(%,LG8-HAKO*)O7I%.(/==]E',ZG?#-F)R&L25MF*TO8CDOB+."PH^N1%.ZIZ M#[M!8'%P18%:#$+MK<,C>E"$=RF.,8YB9&?A@>+X@+K " CGX0G<0(#8K;W4 M,<:,$GT1(/5EJN6=5[F M9^L_ X:E9CXHF<9Q,0*6MWD4/GRJ.1RBR[<=$'>.0'48/"HR1%U!%TUB_70; M>?X9JAM=[]9)S(HYXR09?#M_*.O3DW\,Y_/;GT$40I2&29M<"Y2K9%H#$ MKY:30I[T@OXWR=WV,A(>RW5?0[CA"K80]3Y!\)%+2@@CFZYA3!+=+[R%&QBN M^NK;XW[= %'\*\:ORQS!,!;4OVSWH,@;3_*6J=1?A?F\\;N6B=WH[0P#H990 M(+:21'XW,__"W=W%6Z086=7C4-O#NS3U>UI2/$-E/[VP:T!NHC?*?(QL&!;" M?G7Q\8HW+C/_=JJ4ZVN4O7V\[SNXO'"K-V^3 F1_/++N0RP&?X77$;'-^N3; M,FL]/L67L6M=^":UELK1;#-_YPDVJW9\_>J!-6VU^K M(P2A>O!$;\$3_>Q+/=$W^XIOR2\H)-^?''XF:?EQ\.GHW?\'4$L#!!0 ( M +" ?%:!.N-+UDT !3M 0 + 97@S+3)?,2YH=&WM?5MSVT:V[CNK^!]P M4C534A6L^)9D$N>D2I:=&>V3V-FV)E/SM LDFR)B$.#@(IG[UY]U[0O0H"3' M%UGF/$PLD@"Z&]WK^JUO_?B/LU]_^6DZ^?$?SX^?P7\3_-^/9Z=GOSS_Z<>O M^;_P[=?R]8]/7S[[=_+Z[-^_//^_7RVKLOTA>7!_TR9G^=HTR0MSF;RJUEF9 M\@=I\MK4^?(KN! N_4VO:\W;]EY6Y.?E#\G39)W5YWEYKZTV M/R3P<_O!K&K;:DV???73CS^_?''FC_/>,EOGQ?:'J^Y.OVWR_S4\F*]^^FLY M:S9/?OP:;P@K\EMO+C<=-XTON?\D\1>ASL]7[W70/S[]Z?G;53[+V^GDT='# MHP<_?OWTI__GRGIO/ZY.4_ MSTZ.?YU.3E^<'-V=J;UG^?:I7].!62[-O,TOS'22-4FU3/ZK*[;)P^_2Y.'] MAP\.]R_N-L[E^-79ZLA<\??9.7[W,J MKY^?G)V^?#&=/#A*X*4>EV67%8F\6WQC1\EQ"6^4/E[SQRA VY5)&O^EXR:8 M5UU[DJV3TW)^E"89#.,B6V3)O*HW59VU>54F!RM3F[S,EO!*4KK+7XO%?[KJ MR8G[T5]K^N1P.EE6-?W&%"B^X7)XRB*OX8\*'ME62=/-Y\8LDJH$>=ZNJL8D ME_3_S0J3G!19T^B3:0O+PZ>3 MML[*)K,#H%M5\$V=;.IJ _^9=4U>F@9V?I.LM_(I#&A>K4TR,W C0]/0]6M6 M65' %\G*%(LD:_F6+;RI-%EDK:'';XIL#G^;G)YT"?_)2SAK_$]8:+KCZQ9_ M#H/BI4YQ!/;N"]/ 5H(?+)+9-JE-4Q6=3@(O?EIE]0+_>*9+"GO WUFS;/[F MO*ZZ9OB:NLO2E9N=1%F,-V\;%J3+<+%FT[P,;#4,,&U@=>$XZG-NH)5 M@=5?=R6\7IHS+ R\EXM\ :L!$S*\L62'OC(7>6,6M)Q="P?H 'Z>K4V)OU[6 MU9I>#FXX?DG>%H)#\^+5:SPINGE$+AS="?EP%T7=0Q)UKS=FGCM9U["PTT]E M9])^"N0<2@7:F1W(*Q T\*?\D[8_;LPY;% ^<_%3EJ L*<^G$[BPZ;*RQ8V5 M^0=??(ELN\7F=HP287%9_X#![W1U7G[5;/LWL _%7B.:S@NKDY2EXZ M\;AF99PTIL6YM*OI!'Z(E\/Q@Q];X1XNA)U;539PAFJ4N35.!(_3!H<,!W9P M47_QY-Z>K#]*7E0L3&$YX"=5>= V+,4BI=_P7EMX6RZLV8R4/T[-GF*NQA^ MPANI(7V/OXE9"WJ]W Z<7?A&3O<\:T1L] XI:[.8.$-1QP_/84,W(M=2'DH* M6K1 FX<.[R6H3Z=?87]GUK*:3HKLDA]R7,.LX2(9W^M&[0Q0(4L M%K58G# *6&TP;6%=^=%PRZI>Q,7MOT UF NX.V]!D/X-_/X_75[S('3AT7Z_ ME-UZF>47+()J@R(=#I;332RUO=7#7[45[EM#IJN\#%07:/7;W9Z MBVG6\ T.ZR(K#&M('C#X(SBF15;.93_+ $@!A2(:E16,JL-WJ9. 2]SA"U^O M>3LWFW8ZN43MZ4TMHP^+QE4['Z MX3'[V8L_JJXNP<-H&_6RMSO]:S2),KYJZ)'@?_'0T\O7?=> X-[HD$O5/Q5 M-E! CDTG<@I*=)_%EF&)*UN0SH8\$7YB]][2'6"G>%0T9#5^6H(1-C>+I&NA]L[9 F(P;I;JUF*QQ#NE/;E'7VOYRLX67*C M-6;9DE6&H>&9P7,O/W;#!QL;-H]3F$?)Z;(_!3R2RT E@;M>@TY"=93B6X!U M<^+/OS*#5W I(INT%2W',G]K; ABN!(HG4-[?;A85IKR:XVI/+(_Z<$1Y3>= M>"]O+U!NV52L0/F&!,I_TW%@4?*<]!B:!G';3((>[V*6X<\]9RY#VRQK,*'\ M*'GP]2/4F!ANU4T).PEWXJ:ZY,U&2AD#;8:CQ U,SC@?.VJ"!1I3SCG:6**< M88@S"KF]W8(%49MS\//8+EU:"X1T.?X"#CH\N -/F/QF?0KJ>!B9N,9@N>1] MXT&D#=H811@<& AJ.+-\JA:Q)R%/5G"4BX,^,CYC,WPQ(GGEOZ52Y M3B<8HX+C!)Y35F_'%V!D>FY0X E6>>F-:>21X;@:?3(E\P*;#83'&V,V_&%> M4G1E-0?HONGE+ZX%QP:YI)#"W8J-ZQ5YJ(SXS16PW=0[; MX2AYIPF3$*'Y+?LW#R!I_VGPW,/3WF2O-S@UFU^P%&)ZGV2_)X5'7S],+EW M3Y":/SX[_5T'TLN-?XNY\1D=)?O94]A$;Y('1]_ TC55D2]@+F?'3W]YGIP\ M_^67WXZ?/3M]\??_^]7]K^COU[\=G^C?.EF^'TRTR#8-C$7_]03VQJ)=X0K= M_TMLRZ3TN#!H.6:$OK:TVX5LLS)*N>*97>+=VRWKV#/&IK_#_< ;P7UB+ MR++,:I.]N<>!J1^2#2VUCROXEH=W^UXF\JW4Y/DK/M!D9P7(,J MF3])7F1KPUON184;Z:%_T==Z%7Z3W+MBE?T+\8:\+^.G^NL'][_[RY\XVK(< MGZ>Y-RHC/H#-]UTO*>&CL! ,3#\*U!,%,Y(+O.%H;3XMR J0H+F!4-X:,P$H1YSE9 8EZ6YV!VB".O:K5&.06W M$Q>%OSZ8TW44G0Y#J/V8\^6J2BXQT#2=Q(.M\F"UR<_S"UD8F9]&T_%&X )> M&17#WZW(-2D6^(+@TZ[JFF+K!>B6Z&!K>.[@F[\<)AJNEAGH*7IOA[/JVJ:% M'26^ +P0ZUW&WBTB(&#Q.!"XY-=#8T\J< $)N@?^557K_EAH)MQ?>EA@ Q,E M%]6F+V55KV>A4VX$%Q3& V?&\'[R 3*>OVE!-!PE@W>UR>KLO,XVJ^2$)++L MK.\^CJ^S5ZCOJ%"?@D+M \)ND49]^!C=L]OP9N_&)!$/)X@056\$G;W,;&0= M]=L0N0O'/)NC#"?X 4@B/> /DVQ679C413TD@L11CRNA<1("[$$3^A?QS3FJ M90+-9#>)97B&*7CY[GTOX8?=./Q2'#..FX:S2= M2')*7HYH5['CSF0U96L=_ HF"V$F4"8VKI MJ#!*C<6(1?6HF"+[K>>#!G+JVW0@HF+G@)?')DZM> F/, D;Q [2KFEX!KAK MII.R6\\XYH%[!-WH\.W0%0YWO+*;;FN-W^BAM[5;;DZ?!&JRMP[>[R3/*L1? MRKY.0UW?#_]M C-R: %X,'*58P.E*M[%IH:CFV_@8J,H% Q2+3U@I:^,PF($ M&('!LH/O[[M@&GU1E>;>"E:+)"B&5"]A.>&'#QYJ@4(0R5KF=8-ZH\3!-CBZ M \KXNPK#8_>=7VFH0Y0:!YF1F1N*N6'(S-4+!$OT!--!*CSPCBE^L*HNL3* M_R;%JHH0/L9CJX50_O-Z:X]:O8^!/7C4J\N( 67=CQQ,UIMV2I+-VR&R%X8Q M:)9*J XJ;P/@FX/U ,U2ZV,-@1],$.,^&-\74DP7BV$>:N%%],7G!BP8?/?M MBF;H7CZ+N7 !\3(&][<[APKCX&_XA_#-0<[F)VU+?NCWUWLF1K=SN7JX)O*< M%J:"\["W7%9%45U2G1%OBFVB,!'01S,0W1;YL?8PH;IY@GH<0CSC*:!(@KS4 MH&[E]5@EC&P$@EU&L@TQHUYJJ31X^\,=EZU?A (YR Z)W$5A[H*' Y=D/9 0 M8OPU7%7$EE^8-B,PK?T+CAN/PK+H%FD>2BWWR@>0BE8=5-PAPK @=P0=",_J;7P+.MRA M'A,&@V]1)5C'7Q_ '@L>"/97_'C&*P>'?/#XV&-% #.IPV@$///YVSFH(/#D MCAD-^^#[1X_)\59V!)].0W\\G<"OK9%RT$-A\E)8^:U9.DPLBW,P,_CC,EN[ M:LJ!E]VH'VL$X%AA-0$E4H/C"H8#.%@28#[\,-ORT8.C[Z^W+3_U,=R-,7RX MAQ/NX80? $[XZ,N$$W[ALN8NJWS2^5(,M;&%VV $L-I)F'A!_D DB2D;UK3X M#4;(EH )]60Q9O!0,XCT<]8N-]5'6C<'^,WUPW\ MLX+G\+]@SG*TN FRA;XV$MX4.:6G:1I-4\WIS]1SM9,5$3)0?5MFGV>HMID, M _[.JZ*YV1-HW?@9UH1)+?U6D:_%2$N3OOF'9AZX 557((I@W-KSK;%3L&R2 MQ_>IELZSS%[?^W\XL757G%-\.FJE.>/LD6^AFOG-5#R(N MM8T6N"=]Z7;S7=!CXCL;VU&]TFG"()IB=X MZ7Y'W]D=?7'(>AKLW@9W2IGEM1.%MFK;[2)K"*0,0S6M!)0=]8[G2I/(]Y/" M+@'XK)\ G$Z^V\O.NQ5O.YC9R*>3>@Y/HTF;L0#H#.W("-81DW#PG5GVS5PR M!_7V6 1M+1LP 16N$[F="P-Q:/1MJX+:,1]ZB?DETQE1L8&867Q:,EOE(!#+ M09H:EJ.'D*<*7+6 L3X:'MG:;+U+=2R'B ,]IE=;P(I\\2LHB,S%,W0_N5HC M;.6?5VL")AJL%JXM0DVC@?HE)P M.!4)#+"H3!M6W#N M;9-M&=!1@X&%&;^\86HLO$9ABVP3XM![+\$":&ZZ_$)]#X^YP"05F)XP0LX0 M@B(IA!L'G9]6:*S@MOQ3L9S>TT@*Z15;5*']'3L886]-AN;:0::!N6>X0!E%TD[MX&Q:-KZ%84T&6_AF M>Y;JJ QR"S6>N2JA<.]9L*71G.Q*9#(B4'KO$7QRXL]@\W*9M\S%DW&3!^)! MXH]U<]!&P,_!^T#7@7;)PLB_);EL-\GH1H#S'ZA[9!X0:HW*T79%CB2?VNNL-!9\>^NL=26(A> * M XKH>SONYCMH=-?0 >4##NLB,SV$M_"U>Y%:K! ME,&.HX,)8L#@/Z..'(0,>O<5./_?#Y6+C7)!Y=S<4V6XQ*J# Q:&B.IDL&(# MVN#>+&OX!X?\.J\UPQXO0%6^HY2;3J[U"I/,OO( P%E*-<-5"3+-">I""ED! M=4) >XP%VW5F;G5RO@:Y0ZDI-A9I7NJ&$ODQ#*,Q>*?D0'CLO1R=IYLW&U;( MF#H@YN3\ 'ZQMXV$1A'& $O9^_($P4[?1>7@'R-2C/61J#YGZ )"IQU\F M9.K+BU80DLBZ23LQQ%>I)!=;)95P-?R$3/-!@:>MR488"$*->M=3B49.@-U2 MP,CDE^_"+3,JQ7)*I$&.!"?S=56[KAJ6C,('.?-HT1D \P&;@R@2^EJ0Y@#' M;#.O72%!(<<,VP1H&P*]T%V^G$WYQ9W!BS$PWTWP>(JCN^%)#4!ZV@*-DA_" MYG80I$WSFJ+ES6'L 9GRD:^-;?Y47$GM_%%?VG[FK>U*YFHEOVXI52R7\_? M=(E=J:J\#O?!;BZ%/TN,,. 0&.%%"!/R-Z5$>,^C5&H" 6;&R D.,#3@M7P, MWJ%UHTLBMI=8;Z147B.][[T^_M9N^4^7AG_\MZ/O/UH>_B$<;.DAHH7982 . M.;^:ZY%Q6:/+:V'&EA7^OG2UVLX.HP"T1Q VG3!#F(0-8DT0;/C'ES+7XV.\ MFMLR\:DMIY,=W)9#1LJ=.9_W0$B9,B&J+3+-DHB&E^@T"2,F1#M,!RRN'-W1 M)5WE&^R3BJT;\!TO;#_&P3"HY+]&S7O_,& '20J!H7X:)008*[+'CI/\O&^O][PTJ++_ MT\7T8<%\A >B/UW)0GO8^R; ),>/KK(N*$%?KR7FGGGO%C+O/3N:3O[.Z0ED MS^N_HSNH$;\0O8\$>M3)VV])1-!,3 Z"JN0I-1W#<=YBYW,MGD1$-SG!"^1 MTFJ#ZF;A),,(5+2R(W2N9X@*WMG4^X:C1W$9'W[ OQH(K2L;Y-G.>*^,]*@] MOK)%WG3RU.N1M[OK4J_3#Z[:HN. G:H>[EX ?Q//Y>0!0"6DXQ2&.&$U: MGL@[9&VR4F/AG: _$F[G7)N"$N>U00R$LX^>59?)?X'Q#\(/!HU/K2\H^WVL M59(+ZC'7,)1NK1@,WIFP4TN\JN&K!*Z6)8MJSK Q'C)(SR6V%X^P(+FSZ&H_ M&25EP]LGX+3DW*O,CXOK^CQXE"8/'N.C'WQSL+ $8GYT?']6[L0L#Q[!67E1 MM;AEK-.+[QH5PWE%W+:H\AK-UO3/44BW*^T"BT8:(VP%BXD?.JIP<0XY2-[; M6T0*$P]29<(C[=0/MXY'=G,8/O.SC]D#C%,CAR9;+HVT@Q9L M%KIU,6,D8N-0JVVJY&/02R,) U5'S2Y'?)!L"Y)76"#]X'%V[V]CB2MU(658 M?EB2<'T*&04AM#0U.MU$LHT_AC%ZT0_+C^K9<_Q,%T^8YS4()KQD;CXTQ_JG M/R_O@/UXO,=^[+$?'P#[\^W%WY9XM%[G?H"E2G4W"F:,PE:KF^ MIY4F&IES7CJQO6M"Z;I\AC%'W@&]F4U5@KBCKF$+<\8+\FK!#52D1_B28*B. MU[GT.9RMCD9D?;443_Y8.XBG-R'MW1$OSN(E]&$MOF]M6/()MQOHPO]TL(G@ M*9E"!'P@NZUW=-<$Y;HN[$^HW>U5Y8_(YN=8[<*PQ[ M8K8<,NC ^WBNGLF+L'8Q_S R\)$J/9#4' M0K"$B]AH+!4">#H.@X$K&2 P$HX9$.%/QD_@C@M<0@!>4:O790TX?-+ )]WU MCKC8=05>G\^VX!,*7DD-FO(<,S;>J)A#H=HP"G("]:5ZE3N_<\;XQ [;5NW0 MBLH$<8>8TL-S#3OGD<4H)62#F_+-Y@03([ VNZ2@QI9&ST2,L=%K/\Z^P,V7 M9.3.RWS1@1\-^VG143DZ2PK/PZ#0'-G D6V$"]+?1^$>2J[<0COV0YHX^/[( MI'P10C4CP[(GGPTLA0OR]0Q\ #LBU$GKTLF9&-#.!1"RZQ'4IAPE(+BA+6'H MK3T.$ XWDB?/LTTVIP- \5P547]2H#'K%R9$D0W!HA.#Z!_%#J^_D>S+]WS2 MM+==6*"%?JI&6J83=W@TJ&N2\PKT5<7I-H,I.-@:*:-U0"MH3;$"I# MZQI2[SZNW"A'BZ"MLX5FXKQU)."&QG'.NQSU93G"Q.!F0*4#'Z?_U:>WF;X0 MR_";/QFQZ4KJ33 D ;8YC7S9"^O$*@")2%VM';,([(,+$PF3'":+RH@TYN)\ M+,,5NXA--F%EK^IK85)BE4FPX=?9&Q 7;1.EB3 AUV%K>>ZN2 VX0E8YCYJS M4(83O 89!:FG )+/-1E*IY2P-[BB"G/.2QNO4N.0]#UE>TA32W?26&CW*(G& MM0-KF#ID>/UWK;DP]JXTX#UEOO7E3FIVVNV'0?[_*#A>FH!^JJS.>\[AK8MI"2>+46 MJMYY&RTI3C(-P84$0;%=F+J=X:\47 Z*0.JU9#*$F1\9+=,J8DHAEQ IW\%G M4](UV747&3!:LJ;744$FXW&*\0$F]&OY=2$?>8?Z&"I)$[C MK5-IN[PR7DR;>OLHA2=6DG)_,+^.E,!?,+N47'.K9$?1:X@F*Y%OS34'&H#, M9$QP:W*;CY+GU]@CB;=%HN*', 56!<#/^\Z#HE@\H;W*UP0N1#E]E!Q[;,)O MMSMZ.S4.5UCUNLMD+=L)'EB3(E9(7G=N,3/X,861@R4D-6(Q[ZZ) 1]*&%^; M<#;9-8WN+\)TTJ]LZG5O %U<='56>)P,N,!(.]($)"*#_G9'R$K]O; M%5O/:\HLY!7M+3#YB"&/(R>Q9L(B$8/)80-+"CT*F,9:7#U<#CBCKA0;C94% M" =7H.:':VR4IA<#B+Y2F*KTG)I1-R,-C,U@)2IY:7QW]R48,_2M2.?P$F\3 M6 ;0WE*(**6)P[?4_Y*.##?QK UO(3U)8MYP)Z16HR949[OL!^4:7_Q1=74IT4@A&(]#D6E(H/;(F+:Z,!7UY7VDW#1X_%CA M&6<5<)S:-DIWS*-X:U6,/5V;+:J-AP**%S@L=@\$ZV9MR[MO[S/ZW'82?' _ MZ(_G8[E#Y.+IJ"VP8W0C;)96V^]T.+97L:L,P:I'8KG7O8))PEZ.E M]_%EAMYT^@[V3P1E[[N#.=>;@'8?VG?]2(6LZY]:-=TI&.!S46OO;(2>WG7; M-UYYD$H0.,&&54-%GHUAD(^"]-]K@'?6 _N^RH@&VB EV2O_":1I?(67IMY<1>8D0[)1]&.;V#"@H;T7)? M4&ZHO$/-I(,Q[-0E2];S4NNJ-8961UQ'< =+$EEY6H"FOV#]UMEW6'[M!JE] MLP>I[4%J'P"D]NT>I/:9"Q-G03P@"^*7O"%E_-H7X,\]U?L[F+%L/YRM@N9, M?0-":[9!V=;G8=@&7LCB/'J5JBK0BIM,VJ-@QB]U==<]-\D0K&QW"L>"OY)" MIK?3ND!+/=(]@D$C7%E7;%;9S- A9"-*(RE4OBO6L^4Q'T3:;0.L/@TU-[>B MB*;R A,Q>N0FT@V;9F1U:;4Q%DQHWF:^RT+@<#_Y)VK9*F1X([!C3(_Y+[5- MYF"><+O:*SQ;@7O0R(T$^4=/TE>%H:MAIWM[8XG9,VDT:!=&&RDK!P8:&?08 MI+=RC:4SFZ@41]/5+CS6+X=WOE@P@(HY>(B]N7)765]2!M4?!.'RW"#X)'CO M@0HD&)&'64+.+K^A4&SKXL[X(3^@5Q[(Z\TY0:*TII_;P @?B2VC9LC>E1QH M[P6/G$_Y78(QZZ1KW,5@ .[B@L"+7P+V O2\/)1IBJ0.5W;B6WRZS MO*"'2Q\' K&E+/!VE\WJA-SC)4ME/TBM:D [!Z^T*44$>EEUY+6$9*!A*H_ M?(/PCL..0!!"E;4K''.[ B^0@S,"7>#;=MHVQPZBG\D3T!YXO[#<.18%MCGG M>@@)1G!J24'@'6>&]-1TX@U2$)>\-0:K'_KJP_X&7MV/:I\@[2H:)HU>CFDC M$1I<2AV(458VJ+=T1R;_Z:JZ6TL"!>:YT)D:KKJJ+&+&3T%((($32ZED/:2. MDOJ"8QASA1N&JJ7MC/':.=[!@()N!*?-F1KXJ\X;J0J+<:4%'.L8*NB$PJK- M9EB2QG+TM.YQEGTXR='3G/.S.Y=, S/H7#_46XJTRJ88F(6_$J2P8) MV!>0>FDRS48.LW!K[[WK60)##3T;@KU:T;;DE#""Z>5*K/0+FH7.<6.'L4M7 M"F!_*/)CSGWC2^^LTI/B23P,D]F5\!-ZGQQ?LX^+7D>Y/B+E>LPO]E]"2OZK M#6?_\ZE8L%)$'M)YPQ@4H:P4M:HVWK\LOJ>*!,M1I: M5:W();)GQ;YS]]CMX 0_5^9U=PT!/D5<@0%MCVY*;4CP%UQF1%X+#P.4.-TM MC>6< \?)*@8.//L8 5$] T&#(T3)%93U:G,4D1=B;3CXG8R_3YY!%.\P?.DV M)NJ%0.-=F97YNNJ:<=S ='*V,O;6UJKV0J1H-Y%.,#7UE(&%*;!!-CQAX-7A M"C5L:8DT=A6) @OD#U&C;#QL"_D&UH,!T8E["[M:[:7-+9N*DS:/ M2=IPN?4O%.-PQOP5D8\P9TK\.8;2)W,C)4C*\7-%9@2=?L.I3?^1K-;)2_6% MEN6$>!"%&Z]XR\7;A'AY38?U9N")XFL'^,'!$;P3.^!C;&8.V[[/41^_.CL] M^>7Y=')Z^KD-_?-<<) -Y-)3@M+Z]"@B/K>9W$GI3<);2/.2W] K]F(Q-NA) M_OH2/;-H>985XUPK04)6:PPE!E$[/R.+Q'C$*AG)+[O4-_J#Y%PRAE(<;/+F M1UOX+BIWG#PY N*"*7)?_OU[SLCE7P0J%*I<<50+K+D?GF +K7#P;6KVICD MX-$AX>.L*0XFC717(LI;,=89]L;]S2A,7O%_,1[ND6>K!S $,3NX;HLH^KR4 MT,%^0_ZYJ3 U^/N;RXXZHC.,&D=VX"[IS-@D=*_(_\0=1UTW<0".T<(PBWW( M*\&4NW.ENS9O-\C#P$'1Z82_E5+'W9S;0O8K\;8< \)\VX!@PFU0;CC18N2< MFD# @4(L/7V%Y-Q8M2=ETQR^MB6!Z8[I- ;CD"/ST6_?=3[@U+Z?"26]^6@, M.SXG4&7U8$HVI<@^W 2R>@?GJ7 Y2H?$@@'<@UA(LQFEX'PGCZ.-/7+' MX(V ^*%/92+%E)& UAY7=!O\=LY\PH5@2)VP(>)>T2K?\$'YG$MFRZD,V.><9MP0MRT?7.Q" M%K3IR?IMUH54H,C_TR%,@ 9DR6^5@Q&L6&<;[J3!3;%D"E95S+N@(4\C^ _* MJFK3>-N06^&(&@1!ZJF^V+K0-S)N?/:?L8!QK- BY4IV"<@U 5;MYU6GXP'R)H5LLN7@3.;>0LF[ X?.2ZU%ZZ[A2LG>E_)B<(]\LH=/A:E MP:Y'C_#PQ4YXM4R0KG!G^XM+ MVE@./4ZLB7PG:C@8H#K[=X-;K==P4$$"XG&AF2 M%V'XT"*D)B #-K+(?1AV M@GI'$:WQJ>I0+(.$1P?FAGT$>^M:/>7\]Y-JA@-3Z77CB:2HAIQ%'/FO ME#+W2P((DGBUW7!VB-6^"E3\?$.=_;;:UBXY^.[^7RSO>Q^]200@&OX*F=[) M3)1&=R$'3R1$&F=X&6,MD5&TU;DTJJ&6@_!1(0%5)Z_NP/F_BZ+L&Q%EV("A M3P^AGU[#5Y'C001-EN\7(4R-5G54M<6FX3U>MP+R9!8:]JGTRI9F(Y1+8Y6V M P?%>B='TOTTH=+\:\\!\9V6Y8^)@R,<.@%^!N_D,J26+6J?/;IE4[';_5N& M: D!9;C=7X>TE#?8[D[\UV$IT\BFQ]Y!Q+V$.MB0!Y/YQO?580[6F[]Q3(%9 M@RD*WC?01S7:?HO>LJG8+?H=>^Y6@H6;U'W. -0XE6IDRQY(]T^ZK"<5R:/R M"5K-A);V;%LV6%I6=;6+^CP)*:2&RO*_:H17$/WX!?YN/!?[!_5PKV64.M MP:FB-5]00P.ZS-F>4BEJDWCN.ZL/^^XKP:<%'8KAC0:3<':5%*N4XBIX):4X M)HP#M%U=JJ&N//T8Q[!L>JZ"\[)*#AX>1HB),#[L,6$GJM?A*L%C *XI(?[M??VM:[MQVU;(7G$+G^^ OI[D0\7/ ML:6[L>'9LK"FFV$[ 8=O[Z](XM\S0=R_@OW]HCE4G2!)6BPIXI;54DO,&P9] M3I\/5W#.&3LWSJ=>Y>M]Z.0V:#?FM?UO*A D[_C7K!0>Z6/J.-^/1,=42HR. M#!*#>D5;C6NL>VX?#&;1<6H *\@'=&U]>TTBBP$P*+DT#/;UE]L^2![JE8&3 M/6;C>M97]X9$-]2.J_UB8??V>O]&3/+0#,?A'83'>/HI< M\UJM]"^C4925=H;F==[[:[=L*CWZU5Z-::9NF\L&]&M&V4!=H[VH6'E7\7DM MJ>\7?H)]%:W\)*@!9JAZX0RM>FR9&RWQZT)UCWH]">2?C,[CWL06)\O%B:YE M!S4)IR3>CA#*'=[/N[%OW^VQ;WOLVP? OOUMCWW[S(5)G\[U3-R0? ZOV;H2 MFF#^-2;5!^K!^2#2W3ZJ5<8\(2RZN8DKE"E@_J9N4++#"P+C*IB^;5Z7]2Q= MS_%AXV_N5R;W/)P[K'\^SZGTJ0A/A!YG$ &_9G[_VBZ<]0V<]VB-?^++X,Y@ MM3+WK3E@\<[927:6J/L@52]DZTI.C-\.1!H62CI[K->D,QE]Y& MZC6']*=U9S"4N,UR^%V MNJTQOM/JX,=43O.6ME#8[#0OYT5' +^ET8Z7O0:H2ZPZ@BMP)@&L;LF84&Q\ MVL0:W>;2Z5=:EZ9N8Q/'>1CY0$>&;J:= ()B:=!JZTU1;8T0BN$5RD_F3T@C M:[DW,O'84P^WI)=2M"8K,%OF<)C>[2R#5>]^;NA#R,X^KGTK3M0C/5%\+';R M.*9^.Z/K%R4S"HUQRZ1@J!&FX$_)1)M.J&#:'L[&.W"IS:=0H^=,^SIE97(, M/V@3._8T\06#^YRUDMU[)OF[[9)+7[V0-IMXHKR;*67I D9^GBG5'&;K*H9, M"'8-9R/\!:*EN)21(W3:OU24WLZ(L]8S((,!%33@XR6YI:-8^$F&'9K5,7=75B$']+<$2B";,1=V'Y([6)$_22L_ F!@#)?G?UN"Q6HT08R?S[.BM& MG@SW:D 8(VLBB-M-U30Y]J 4.YRL;&?1<,,H?P2N Y[.*!9,/P[#3.'2-#Z$ MFY/IO)\;Q[1KLJ:KS8YPT0Y&U"2;547>K&)OQ0/G1GP^^_FTG"%D;M*,@=\,%D4R/HT25C7>5U M8E2%Z0-/E4<)53@'N2BKC9?)3;,+;9R>K0\.RIC MM*Y*B>:]YL3]L]]XA=EX'AKO9%N!(?=9LX@)J\K1PS<[;>!>9353W5?^2(/" M2*YXS+SJ1C#HQ[E4F)D.+_%XYDU6%SE1=O>K2@DTI66D(\BL_0F_95/I%81[ M=8J-@R;HCOI@=8J)5Z;HB)CRCURGF S*%$,\T\>L4[P3F^LNGI.@MG=X1%#1 MG'OM6/M-,UV-J(5)$U#&JP2BRM#4/V%I7SU.)X%^O!X<" ^.!,ZTBU+6"$AP M.'[5"/B!)4<9'T;J:I-&;'.,9V5. K":L :!PW*;/[J%)T% 0; #GV_APY]YL*D5\[=H_4Y]BD-Y_.N MK@6)XSG[$74VVT:I9?I$,F@P67X$)I%QC7BZDADDD9FZ]LD9E>RDM1ZEUE>I MQJ 1M[L=1](W4@))SDE0UGB'%<7G.95>&3:3K)-/^LSV4!M8%LU-0@^."FWC M;BZ9&H6>$3,[5S-$[A,E2"/HG,45JBWS AYV3 MBP5OA/+3>JJU%YXRS*E'-.BIMS^!MVPJO2KSLS&R 7?FXEP$4@B:+QVRS",X MI(C=3E+@DMV+L)C[@7Q+2'B=!)' M[&%S^D:J=K6V6,8T'KB_$[OD+F[XOWD;/NK!^EM^1VC8-1\3&2XM/#D8U6T0 MM=78AANNV\<%(RJG$XO4P$:0F72IW-U5A(Z+W* 7AA;!S;<(,6L:9#8,?V/E MPKM^.G&]*%D'X>$2&G)\2*^Q9#Q5)U 4/]* &L"65.*WTK94:%?36 AA.@D7 M6(\Z0:&L73 Z#,'G&6I;E\T]0#AC$HN"XPC:&86S>3/CZU0*^?.\N4DKO17; M.#;ZW/<@I:+;3'K/1@35"+)X+Z?NP%1ZY80HAFQNVDDF1_CC[?!WDD/)%6(H M;ANK',(8.M+3X6-W2R)KNJ9(DH^7I&$ELN<3[CP0US1[3TM=CSY%4M]!X,/E MN0GA$1X<0!A&PU0KSFH?'NJ D@DN&!Y7\2[\([O*U[L!?[NDYOXHW[*I].NX M>D 3(;A $SG\9I<+.T+E?9W=A5W$;[Z]DOWNNIU3Z==)H5JP2"6G*>Q'LJL. MLD/>6?,53($!"G,8<;78^C81QAX0HX48AB6Q4XGYM.R02YO$)$<#V"P;E$X\ M20YFAPR')39FZ6_?$5X<*9^[DHF_)04K$9J\L04@%*CAMJ,S@]UV/=[P\$'S M0R&Q)O-M796Y6+XLMB^RHD,PAG(T+90[MLWAL:3D;M2;8(C+!/7("AJ^4V!+_A]]MPH9OD!8,6.Y[=WV9O MB'R6>]E?5+!4AJL5:DRR$'M,]12'A., MJ,3_G-[="\9;.I5^<1M*00OH=(+1\14ZP@J>N- +LJBT_KE@1[@N0GM@,75/G"U_V(+!%6LP,-7" M,*F5)WS!0A.+0TCTY\ZEU=H%-;4;DQ4QR2@N0OZ6_]4B,9N[H)4&H\0N/T-6D1(->]8"]GV MI7#N41Z"4C+PW&5LE%PPRUY15I >" (OK,]2J?] IPBK:AD4.)T$'^A-A;.U6BD9LA?. M=U(X,PY1V:->KFU?S'4K-M_C M'67O05EW@$R(!^7'*[_=9591N4;%(-N"X.V8A'N"(U4=AJ-,\0.)H?'?5KN, M[#U7<%OMCKN+,'61"*L$Q@KY$UN3HE4P$OOK0PE'J,Q[#TPIN&83"8K3/_9P MBV,9?X';;FKJEJ&M.=@'0R->\%+1![2.G)AJL3-,8M18#K!T=]^ MJL+[6XA#_'Z/0]SC$#\ #O'!_3T0\?,I@W5UT[]_;D/_/!<<&Y=0(R?*S;U& M'WM?/GU+#$MN*T-ACQ//FY=<#TC8K;3XLI6+BIR(ET]Z30$X;.H'0+Q6 @Z! M46;8+B,.X[V^(4;N42\O)H7!O)QAVI MXEQ[#C8( EP)\?>U1VB+ !?2!HP>>X4E:NP5FDYCFL2+F$'N?3/](L[T["^I@+7.4VA.ZY4KR1=.(>L'6;I](KK#Y368?G@!27 MG #YO/$UVG*\_Z;706IA5&GY6S-Z?+#+@'1AU:1MH/R]+E"B0"E7BXE_WIV$ MVP3/O"[-EK(H<+JK7@+8]1K5'S*U@&9(;(J!S^GP%-"G640MV$_FA:G?I-(U M%4.LM?'[._M*$BX+\B9$#MEQ 1$NLJ8_IA.X!1P@26G/,1Z4E3E/*>M-@1?: M#DGGYNV\ MZ!I"$U"O"J+0T7!5*48'&H$,&,!%D.Y;N!K4"Y9Z=KEDWX!$0P0H&ERU+7#O MWVDI]I4D,:]F&*0'$#\50?TLW MAWMCZ+7 )KCY6MI585P4\<5:>1=#V>01#9, HE7"D%)+6$];"81+A(_/9E03 M9;#%&GD)E1Q\O7 MJ\A;-I4!IP)69WK4(SOR>D28(7V-%CE> [N/F379DK2W2OD8E$(M1LV$1/MX M7:>PRL>GKD*&X06R B&F&/1(J>XG^2&^Z\)/(Z]%$Q]#O7.E7@?'DIYNB872 M &#ENYMT>#6U@DK87N"1EX4ZE ]\[&M2J (J<-\C1DT@^PTJ8:@LR M=RRLAH?'&X5"D!BI.)<8&@APTU-^QE5$]GB9"['7W*Z8]U2$=7+#MFM<V.RA$!@K>/P":]%_#O(F.!C'5W+!\(/RK+U8BQW6(;OSG@_N+]/>>]3 MWA\BY?U@G_+^?%*7-N7]43+>($#&NAN]UZ3RZ8MGSW]] MG;X"\_#EJ]?)\8MGR='LNW^Z@'>KJ! MU_U#):%?4700U/RI6%/2I^TH\O(^D@9_^!AUWFUXK7=CDE@[:J&*U,4YX[8@ MC5C"%#W3C>VLS-0&+^?Y15ZDR;S.L6,,_"M;P#\DR'(AU!%8HI:?LP^R"[FY MXKPV)ABHT;*#;-8!\V4D;<(SYPNE&93R,?<9,$***/>4U.:[&?90P^XPXB%J M@R=[:N:5T,EY3!IA9PNK;/$M Q![N$ M,HH[B4\GEL%I!J]]":\!O-8R.?"K8^#OOQ8+Q-Z+G(!!_[6F#P[=>Z+D9];D MKJO+^-MET"R[6?PKZIZG;P =#NW,-;*"B;]^M26HXT742^$T%<:]K*MNE"JA M]\Q8_S*79!5QC*^R>LW8AZ';*0X<%K+B5A ^+]>U67L2B=/+N(BWL(UI4U%" MPG*1(]!DC=DL<.X/9EV;#DE:M9,[_FQM..17;'ML8A:L['XG(VIBXY<45#*K MJXR!,X%6F$XT-;/*!(F"145>8^KQ6\*6K&K+.&)'A;E@ M<.W1$?<$#.)!.*EH2T*6Q!X!SNJYD*4XP+KN=88GZ"2^5H1NY@X"W MBR^%KH)"/7CNGGBD;H[= EZ0WV?1)@'A)J_E#H]8K,").>8^5LGO_8,<]M&& M538E.%%S/Y?6>Y@609I$WBFDIZ+;P 7[]%%C41] 3 &%4F M=G2$;.N)>5R_N*E')K(::0<*(H@;>@1J(49@M72ME\.HH*@6N!*.(G>CX#F, M/&HJ'PY@6-H\ DM,"L@&XX#Z4R0D0I".R@=[X^7!E*;#?8QQ(TEE@L6 MG_':+_ -69A'!T;.FM-C@V;0_-IM>']AYLP 1M!'V^J0\E.P[F#6UK3BM'MY M/38;*HBW)J;_7AMZ5SY J6=26P26W26:5(!K]80]_%@YA$\O5#]'G?G(TYG5 MTGO_9-8])>+PUV!3[;7FG9GDZ1*C.)Q4Y0/K:<,Z>1AQ5406J'=%1$\C!0/H M?.5O09P??'O_,%EDVT:Z>F6VHQ _>H71)$J-"T0P5H,PVN!$;K+@KM@+H:-*^CY'2I3;V0=IOQGH5&2.] MD%QW*PS8X<:!SOC$GO% :'8Q:K(%F35J26?M8)N-KQ*_6B@W>BX/(TK*_W+DB M[*THSNMYMVZH.QH6DC$S7^0EX0LBT1;;T8BNY+[ET?>"8,]:PD9=5O2F&-G/ M5[T?#F_)"TH^]/L9/^;8^%+#NCN717M'SBFI@XD$<-6Z]<8>C%WGHJ?P(K=' M!VT0F>9A72$-TYY(J]R>NKFP1HMD5%IST'F'>++BG*M;/J[FFW7UPI2BQBX8 M5CQ\*U=Z4VGBQ];=R*C$UQDTGH?ES#.?S\A)W&I8,KMWQ6ZQ*\:@^1=5>>^Y ME/X(N15Y9_NXY=V9Y!EJP_&TCM1!D? >D7A!,+,G#8+*)5=%%M06L:PEUX@Q MM@(NH!1FQ@EYKZWRG,'&+'Q(L+=9VR'<% ?YRDBQSDF(HSXMY[TD.N=#AZ6Y M*5=O3"=/M7P##;KSVIBU\!%LN2RL7\&&WH)KQ=2$J5J-D=LDV]^//T)1.?I3VBBG)9-5Z-:HK*@O4ER%R9Y MUN=JYJ+,O*2N)[F^<>IBC8ZN1?DP/JA%# M\;HHEXW% 80\!$4MG44I8NCU$*6$--U4+N8IKCA8,PMQ51S@R209;WDR' MDO%;,NE3_6!7Y+%>00[&H_:>VBV6AM^&TI"=_&URK ;KWE>[.Y.,"D:2*LCO M8 ]]Z_DK,<)S%'*.QY\D@XL9KPU2H#6*YHA5"*(P%)J5@'$X[?4 U/+P.)$_ MW$7'T;N+%^4ZQ_8<%\-0M+[H\N(0**B7V[1F' MD5WD+,PJ8IEP3+8VVD27,Y("F,W(/6YQ&HYBJ1\OZV-Z;:&P=6;EY\W DTUM M!3W'F@U[T*QO9"X*:B?4SJ*KN?A2FS?4YAS>,$-Y>JY_8Y,(48:#G<6:TPE6 M:(=-(IK1ER#=SVJX-B]BF&/X>\M(&N+>J4H!6I'/C=A9V>;]9V+"P5_NO2Z[ MS;J,^P*?]D/NR^1Y( :.Q^3*7M7=F4G&5%V_M[D'FXXT)AT#4J?)>8WYE)O& M/(/DA^+,HT[$]2HYY(?]/CJ[8/FK2IP%XVWF;9R"VD M7PC7S3X1<^WF%2P3]SE;7(#P0P!S1A3"#4EQ1VH8 M+(;B*!C[1L.Q:XTP,93*9%LC0MO-&0UF,E5A(@75F K)3;[>9'GMD'*2^!K4 M4.XJ8Y4"6:Y:0TM_3EAX:7FN)9#^ITOOCA2+6N=-(VK)EK&VV"Z.Z85&*NOB MZ[S7&;=99W [[]?4*YLC?'M]<64N=.2EB8]RVM**, M*I$5 W0!TT-^]H(Q97"3KA1P/TXD&S^D>L-E2!J9IU:V] M3:Z=TKC4'2/[TM%U?+17T0&8C'I6UQ*QEXIFO\6[=SM4@?)0OZ9)%NXFZR%] ML 11)4D'N8&4?5]QAT-/:PB,^E): Y"&X@)A5AU<$EV;V?:)AM .Q^K$JX8: M*0L,]L^OK30%KP.ZLI'U_3VVPE(%=N,E/@P,'*1,0Z[D2LP7HH:3=@"R$DAU M6R(]&_A(L"(.?V&?/YW0 *Y\] ?6;I]G>Y,/R6QT^KD-_?-<<# *_L[-5Z>3 MWZQDV/?SN1V4J ^4L%A9\[E3HN,]]0CUI?6M(PJF3TRDX> HQJ=O6)\F[=3Z9 M3JYH?:+LIK.N07:5T=XL'[6-[7[/O6OA[L]Y,PWU-W> ]< 8Q]N ?&[H&Q'P(8^V@/C/W,Q4FO:N?WBHJ7I8T]EA:^ MU"Z&GNAE$2V_;=QO0SX43U23RQRI8[,B'(LBN-L0_23L]RVV2)TJ4]8(RY68 MI=@<9RMI$,N/Q8R15'L1!LV9_3Z5\GK[:S9 8&3G[.P(=&29"QVE/@LAI5PZ MFDI3Q K,E*#QC6..X?2#XBE=!EI'YBVEZXTC01@%9TI7#0Q(O,WQJ30=':5M M=47XG;SM/I[!O3]@U^E6<5IRZH#0S1K3*$SV&@3EK(2&[8KJ(PBW/JE)44.;.8]NN1 M&;>&G_*$!WT:;0\84I_0^0^<"EKHW/$W3K4W&PDR'[;$O MUH8!>9KGXA=B$Y&V718Q2'DCIW)B0RQ,*C40HXVM:\KABYQ.V!6W,M(A+BG5 MVACSI@E9O'*[N;B@C=]WXK]NR^'0[R0CMBRMAEYR#9C+\' 82&N_W MV"V;R@!,ZB&7PU@WB7*"$UY8G''XBEG*N9W'?-TST%!KIB'L@:)C5T\G.\#; M^'0U^WQ;&T'@<6!U(@I9!+3CT[ LNJ/#5[4X. ]A^LS!$P6O;6RIU&5431XIZ M"'(G;A'!&E%X\5YMLE;;.$K M#1B'W&P],B*.)4D!UMJ8EL ITADP=*!MPT!I%%Y7;[?[:,DG/'>G@CDB)Q!; MLN+!FAD-.WA=V9?)ZSELF)-LC8;149H\>YG\X_FKYT__G9P\!]WU\[\9VE2! M7UC1]94ZT7)08@<0778^$D2%C>:+N+$"@B5;WW3,W4E!P*S03:9WO.9A7U 0 MX;^ZTB3_\S]I\O#^PP?[O?>1AMT?\*[LV:,GR4NBJ6M^2'Y!,;=/H;W'W,[M MVA=W9#M__?3ELW__A/_XQ]FOO_ST_P%02P,$% @ L(!\5@=#+#*1"0 MHXH H !E>#,Q+3$N:'1M[5QM4^K($OYNE?]AUJK=TBH07]9;MX2E"B&N MU.4(A3E;Z\-1SCR^,C!\$DGGIGIY^\G0GZ<:% M^Z77W-YJ7#BM#GP2_&NX7;?G-!LU_0EG:_GIQEF_\\=.D,3I*3D\ MF*3$Y1&3Y)+=DV$2T;BB#U3(%1,\V(&.T'7PH_WJ)*+BAL>GY&"GV3CO7[KE M$:H!C7@X/7UN#-56\O\Q/>5.\[=X)"?U1@T'!!T'/R\=-$4)7VNH.DG90UJE M(;^!0X+?C-/7U+]QUG0>QGS$T^VMX\/]PT;MK/G:J[&H@L?BE(GUM^%;2PTK MWW:&;O>\VVZYW?[E]E;_G+@7#FE?=)USXOSMM+^ZW;\\OMD^'7GD,.CVGU\/==ND<,5:EUM;W5ZO0'KM,AA7K$[1NJS973 MUMOO^."(Y%OPJC4\:UTZ5]7^WSWGFK3:+IXY.C@X,E')]\"'_V8RY<'T-<7N M5K:WKMDX(_V B0JLB\ 92#JFZ>D;7+#>>+G=UAGX?MOI]:X&K7;W\L\_=@YV MU.]!J],I?O^P%O?<3\?8].#7.ADEPF>BZB5A2"<2!"J^[2@RTW"'/S[!'2Z[ M1\/"T&DRV2P:,4&. M#RN 5T=') G(E9=D:9M&I!M[^_7R@L"_X?ILC3=>XR6_7.O]L"KK1IGJR!"W M/:.2^5H\\,QH2F[CY#YD_@VK:.\5VFW]!(:-DQ0 .4XICPF-IR2+4Y$Q(E.: ML@@N^NBJ%"Y+"0($G$4["7;K?2( :'EY**J98"VD7TEBE8F TL MX9@/$L&\(<9/.!$V\+CPL@B:Q3 &B /7#G(_YMZ8R S_S?O?,\'R05"+B,N0 M49_'-P#GZ1BTE!/FH92Y%"50 I5A\P$TC:;E)=G"T*)WG,9 *0!@.X_#8"S,D%8 ;)<^M /!P$4[)!-P>80OA M+ QGN*3ER"%!+LT/^.=S'+V"+;(0&@ 8)1,FU)Q2">51.29!F-S+ JD$N^$R M%11FHWA0"P^B5A:Q)A=)R5Q D84<"SGFF.IW0R#'';/"T0O7_$W(;UE2ESFH MY/$ZDH0D"#C\5$[;)50P!0_@[GP4,A7&, "F41A!HG)B+QF ^'I19E%[#!9P V&K.( 23HZ?)0 M*LD$# #4YHY+9#RS"(W%:C!,9,ZCN3+S$BRD"FB@\2).5')6AB48%[Z-%$@8C,']S_<-"F3&F&ID+92_F*RN(]G*F M\SU@*\28HQLV!42\XS[B%95)3)'<40E8APDF!#$J_ )+ .(X'?&0IU,,\AZ; M&S$6FVH\TS&IQ%)%\R%6;9&("L"95>.IYB?"5%"I?=<-B"#A#0#8Z8!0'S4GX'[B@? MR?7, LH7,#"ZE/U9H";(Q* C$">IDTRC)$N?$>,E1)'.6B,KRK\^D_@F(TS6 M89Y.03'3JP)BU;5 ,,?&;F6+.L:8RC<$=3K:C0O460(&O V7)XG4F4?1YP?8 M$D9TB>=E OV^%#FMCJK%B1*9PDE\Y <&E&!^\BV#Z O&W_V.- & &5"8I=:Y M]!Y@B[J-B'<8U7,#6K@]+=J8REG B>1'X1[S\\@4V)-:F9R[34G(;QE\J'N* M2YTJ/[U8=8MT%NE,,-6)(4CW$QEY]=B17R!E94Y1D#B5,6K.5A!EGO'U0II9 M%+J2S9K)1S.?IXF0LYA/'8!QHXBG*6-/<,-1 E$EGO#=ADV\X%IF2>&^%N?=CWH@#U. M+KQC MYG$&V)#':[/<]SVCMQA[Z6R-BKY4QDD]_E0\&_ "Q"E1,9V?IF*&B8^P&NI# M;\EFI.:[Z)3GJ: +0$PB "%5%"AA!606152 ZDJCG%8^^CR%C>\LTIAC*E/R MXJTX?_(Q$, 9*N#W3'$=0 [UI&(.,14= /'X+@GO&$9!,;W)G[H4.3UBT21, MI@S.WH\3S8GH H !X#P1)Q8!Y@L1:O_QK553[PDT[2L-Q+A7&DX.?GW5S 5L MW5,MU1YLQ39[1AEGK;GLV4STU1>Z?ZE6R3EGH7]* M!A FU&&L;QF+/1R#5*O%RG>Z?Q42:6EGU[]_3=(9=2V.G2U?$T&I.8,N,^9E M1KUXC5VEPDN4>?4R./>21_;^8H@6LD#UF&VJTM!S:Q=F+DS(J*IO/YQHLCEZR30V-H^VQ9GO,M H!3WJ# M <(_54CDO'O9NFQW6SU;2&3=5+*%1,Q2TN!"(BZ-IY1<)Y(%;UQ*Y&.,8'-Q M"P+;\B+O4UZD8NN+V+M;YIG*UA>Q]44^Z]ZV,&2,J6Q]$5M?Y#/L8PLYQIC* MUA>Q]44V<^=;D#+&5*8\YFSKB]CZ(NL!#R;)NE&F,N4Y:EM?Q-87L0AF$Q2/?Y367KB]CZ(I]Z@ULL,L94IB3>6[:^ MB*TO8I'&8%.9DA>W]47>XWTY^T[#"P2V]476'C;7]&)FO@'6N[Y(Z>4R6V'D M0S55EM"2Y.:PIO@@34LU1LYG],36&/EH39=KC*S89E-KC+Q7Q/=$J86G2X\< MU4E_HI*)IZ1'96HKD3Q7B<2,6B%/;XC:6;]SC?N[=N%^Z37_ 5!+ P04 M" "P@'Q67+WB'5 % E.0 "@ &5X,S(M,2YH=&WM6VUOVD@0_H[$?YA# M:D0DWG.I4G"1#)B+=100=JKFXV+68:_VVEF;)MROOUF_$/)2Y7('"6X<12%X M=V>?F6?GQ1Y9.3>_C+K%@G*NJ0/\!/FCF+HYTKI*/?[$T7HRK/0F@TLPS,N1 M]KED>SQL0[/AAV REP8PICAE7B ML"N\(-C50E5Y7NUVR.0N+A9-6K:G4>]U]*F!1'E*1+:/O'C-:O:_-3'VH M]U53GXR+AZ-@3MF]:_,/6O&DR&.$6;98\5U'!Z,3,NU+%9+)B3 M3"K0/"L6+FI&K5^#HX!:N&7SY+212554HUA0!Y.IJ0T@Y04R2HNA]6.?^=3X M"(G?&.JLIXXUHSKY-M(N0>V;+%@>Y^@F MS.-PP\(EA$L**NCI)GOQ$OD'$G' :5">W#EV#:D56EB>_ M@N,$TSJNDQ/G-(B&W#5\Y]X-&NF*MG=[RO;O!:;:&V&6U$8C8ZKV]?$?GTN- M4O1]J@X&Z?<7ZW##%N%23FU\Z,#<$PLJJI;G.,0/$%#Z7RFJ8Q5S]O(-?DCR M+>*D'AAZ?BFIBA5S\)\!-VJM4\9W:?9R\WAC"82QJ#2T*+O7*< M-5+E^H[T]8W_"WJ]8H*Z&*:#*/YL_*Q,,,8(:)Z6%\<;;[J+%IM(D;A4\]/) M[[%CNE'\Z(XF&2PR&)82." CQX<5*)5-N.$6_(Z"ERP M2+3,\CAKY<3^[OE41'L&,8K[:;GV]%&I1WFFFX&$>#CX!DA1NUCX0H2UA-99 M5)*='"[<]UA?)#O/O3#TW#;,'6)]AV;M%.4'GL,6L9E>I-)IX\-.;^_T;CVH M%PN; ENIZ]T=Q;G]('X_&4=R$@.)B=D!*5DB(O:: ^$BNNN,D3RZ]7QWS!R. MBY2G@F$]XA/G)]SLIF9[+7(.L0S*6D7Q6[4*0T:=11NFY(IV9N_=Z7+=JGRL)2Y7PD\KD$>U"J/S7_G ML$^XX?V;"8?:T8K-^=X2?6>N],2EITVIHRV>,,M<4/*].J=X$X%H_,B6B:EP MY\A.N-GTOA43DM.]IO>E;W%3E^3$?!S4HDGM+!?*6W$'JDK?D\I;<&[?D3,1)X-(+J)TVY8:;IX-Y4RY_:)8WY?*F MW*_SI"%ORATB*WE3+F_*'7YA^ J=NM>.*>^B$ME/^V[O5*4]O:T*?2]=O7>> MQ_:?,R1_,;R$Q"QDNG=.VE:C\-'M<$Y@!@A\V%)\Q&)&*L[7Z#/^1(F[[L\> M*YM_T>]K=6#B1U5O&T8D"//VWW/MOSTUZ-ZF.I6O.\K7'./W'N7KD?\ 4$L# M!!0 ( +" ?%:7]'>U<"UL0'8D.TV:V!? L=W&@&O[;+5W]Y':I20VJUUER96B^_4W#Y)+O1RG MB)(XIP*-O2]R9CCO&=+';[N_7;YN-H[?GI^/K4 M/3Y^](OL?\YX9'QT_Q0&!&C<+>'PJS 1O MC'RI!T/[.0$^?O/Z_,-0][1M-I[M=XZ?OGF].>AYZ1X3O3\_Q$#PL_.[T]N+ MF^[%]56S/;54 M1\;G_/;\K-FX^?WV[G? 3'2O$2G$6W0.A,/\4:-Y_N_3MR=7OYXW&R>G7<2H M\_+PV6/#8]-"]&=EK.[/W$V=IPH'/'@V_JR:["XI*GLJ1\W&19[LBZ$THLB5 M2#)IX+>^,"JI2FTU#%JJ@39 1)6*"J I8)Q<>XQ"T!P\N1@J]3L8,?_)BE*+;^96"(Q/Y8TKW=EBBJ4IBA+!6!DA2C M$EU4G& M, -1BW)O1Q7PS@N+U!QGRBH: M%>Z9JOP1E\!*_:U C!T+K0U EA0E\K.1&\&[- '7L@319\@&..R MF&@#* 3*K462U];A $PQ55F&/W&8*S61J01,83! ] [PK2R,L>/0O+J]\S@V M&PBJS&$!XJ+2_8W+ M]2-419_9"ER!)@ &[POE506(""]*K6HV:Q4>[UHLFH6?]P]_^KR6X;HJFXTY MU4M):W;;$QEF'S=Z!=7EY=^]"W+;%Q\;TE& M69UOI?1!4MK>_TGG&_3>4$AT,+,LIR"?H% /#DBT#KTQ1*-*WHXSMK5,Y:"5 MP59;,,A@?G,#[Q999)"B'=/&0#12C?%W"?]8F:&$';;;K3;_'P4SL77; M%V^+#.1O=<"!$Z'?;3.>!L.S"1A" L,M)(@W32L&*J,)%Z"*SV2UN* X-6/ MM+7\I>3OW"041PUYXLW;RRU?/0"+$T/^<.T0=5!KH^[&Z$9!E 3_O&AU#CJM M%XUJ)HG M/I(:J%R5\(2R*A361)JYA0Y=5I$$XS.5N:0; )!J$%1;P$NPI1L:7N5:CP),PQ6%15D9_2;*QQDK=< M^TUP+:B5,SW1,'JZ52;?SK)<@(9WCD3K'NF*8H:/!IK@7"BT[JE?;AP(O^Q7 M>)&I >N"B=09: +%T05%I=)"Y(G%%<*"RDDYWP'QK[ ^@W5& *!7R#*=\V6 MCC.NS^#'" ?]3!66Y'2N]L4)%NY$TMT+46_3C$P#^D^:9%!4$W^D2@YI@( M/ 0BEZJ>!=7*92WP[B"J0DPJY75F94"= @Y5:2@L[U4&,,3":TD#< [!:5:> M"J9!B.!S&=[Z[HDZUS6?718 M?E^5N_5+A H6M97K*@ Q*]58R:PNE<,D8$E0/$T"?AL\<)'IU>T==P=@&.D$ M-BER$&+J"AG[]HP@YRC-@U+FZ/G5'08PEL82O5'EA& "I9ZF&G]#D]+R[JTN M1R' #/HG,FR@G3(E#1@;_<'.@ 8?,-S&5A^Q\_SY#[NAG6,QXD7P2:\-5;[& M/)[*L49URK8QMHL]Y6)WIQQ'2N'H+:(7S@U4!# ,^^U 6[Z-;11 1LRZ 88P M$<#00\T&/G_I$K0CLBLR0V,3UJ6%O\JT ,9#51ZZ+*C4DQLLE,.D4VV'K5HP M+_X V,JB&@S%OR\N+A8;,LCA7^C(<&9:NI40SGP^9!T +-??^\\O==Z- %E'XV]Z>^$6K+'TE;N1 '<&'[RMLKH$/ MCL3UF'RK5SB!:PD[$G]@:Q8 )_;V7+?S\1GPI(-NH9GX^=@>@2M8 C^%>V\R M"6S2V0?4!#@C.@6PNB=O+L_%Z?GEY-)^0M=W-R>G_MK-X<9+ MBBR38P.P^-^.0%92.T1DVS^LPKY[Z\>8*)07F?D5L,5X9<&O>^:_B(:N&:)[ MACW>M_@/8@ _@18KR-(KE7RWUT,?&J 9$ZGC-NSG#-ZW3X55G>=SE-D3,5-Y M=CH2W=D8(#@IP85-C@1V"#'+717(2 ?Q1T_]5_A$['V$RO&'."#SY>,4S^]& MSY"CTN,F0.^5H)U3: 27W1,V43D,'[Y)5#G)B;B\.>N[\(&IM.6WTWJBPL"^6OV;7G M- 4ZU>1*E\KUU2O#O=DZUY3Y "5A; M;[8L\=75Z#;J,7>HZ,\8#8] $,A\: MU$''@ U4'\:ZI#*_Y9!GW: 0VF'2R8G[8F8FZA>W$80$B8:)Y'+M$>.X,;I] M$X6A&\Y4@9ZA $N#?J\?8_XL4<8@+A@8IE4VXX*F:U<(#><0#UI!K2WW@]N* MJ.,'PG04SH._4NXHK9>&TTY,.Z*8J@,Q_WT?HRUZ)R(O#.K>]QDQ(J:;B-LK M[J4K)Q =24(1=X%8GT*@[DJ31[L:YKJ2<.$&>40GF8&7F A9U%G@B E$A4+]SM1GVC%;4LQ=-1!CZ2+%\# M\/-$69!4J9&'@)V^'<>=DL27^"HC(9N3:T MLU.Y;2*^SX%5HB[=^)I+MC&=*>?OD=\7YY*J!7S-\#0;.*<7.Y9\3(7!\Z&* MQ!_%>*7.X!#K6^[*4(U#\4";O*WB)K2C$C%BD0]]B+$N+_I1PFZ,T M;SG4>8*:-D?[G,N!PA(<9X@AA 0ZR-)_0%LFXI%^>P3N0$ M=M.-QM:I]7H[Y\*&1!@'P;%#03B)M%"\#W)E M?-. Y^#<0-190@S4"H Q,68-W(BI04P!(:4^KZXT'S&Q5G1 MI()0D"^[",@#22D^D9*/2GH>I\#?\4HV&[_Q4CHIOZZ5-FGH5#&++BS\4H\+ M&<':W*DTEJ:<&N1SLIN\ I>T:DWJ,I=0RN@Y+H5#- ML)0C#A'_UJQ\+2YSB=P_9 +:0"O'9">@QR=T:^:/EEA6.MBW.S6%FG"H!XX< MY>M=X:2O/8M%;! 7'99X =/)G#NZK$;H KF\/P,9PMDHVX8S MX]XR!S]K[#C.C3)J"VE*D0/!T:S M+Z2L$&(>;$A&P& ]!DQ03ZD\) EZNKG13=,JD7"R+WZ6L9<2\M M*^VF(6=^9>G0B14MJD\%.7YVHW%3)&CX9@,Y/)&5<78]K_?R?%()$ 41I#;4 M_UZT_U+]+VZAG^^Z"=WY=6 2UP0)0/80U^0/'12V&+@2*!VB [I]CX8/D%C" M$XUA2;O>"[?*B'<=7GNLM_*\:7E^>+?1P;:Q:-M8M('&HL/'T%CT_ZXF+EYS M2KW9F$NZAP/"V/[S.^XX2.//!HJ3K'5>-*-SX)"+E/''S@D3SAOSENS%SZ&7 MEBY?'KI=N0:L^FZS@:,MI'L'"%GNR^@+L\N5\U,MSB4+EG>W&)^T=0CYS"Y9 M>@=ZLS'G]M3&-SA KI^'KQ-GD>7"F"NII5PU^/'SNX\=F9 2S<:40I,Q)F/@JXJW'>$" M8'(=<^&R%"FF?^:WP-#^YH-V&]U$2ITO0L8')(B=X+IU\&488PA>(GTMTQ3K MB50H;#8?*D00OVP#C# 8:C52J^;R& M,19 W:9PS)?!73HP$'=HAX3@PED_ 0SV;+(9>\',V!CT@:N::3HW:*XOW*T> MY>.C_+:>RV_#4*Z%#F;E)@!_2ABVIP\1!6Z"P/K&0T7"LW)HJXN7=\&_]\S] M27R-+2$@)E1(6!J@]J)EV+P0XXSS7_>!B(X?>=+:/\87R#]NB9V#W?IRW?NQ()9B MYW WND/%%OYH/LI8Y7+'U'#J:Y\:'92,.>'-FC MF 6UV_Y'RLM\A@1"5N\>X87R&B3>M V*G.U72#)9*@9V5KR MO;6(5LG@:)1@_R"QS(;J'S<_2MQ81DESF=/6D3*DXR/KH#W=N>L#4R_4?L2M MJK4-Q5#U9B_="]RQM48^B<$7-L$L9<<4+&G%)<<4%G%IU+:F)VG*[ S=B$\85("]*:U1H31+*=6C?G++6W+J)>#/7O$GU M!)GG6#PD9(J*L\6Y/&W(S9LSC(6%%[HJX$"V$M*YX@%RL@\I/VE)TB^]SG MR?L#E9VIF+M>K5657"ZL^8\"T<2.\^EB-P/L%YOG&-1/!'*7.F]=.=@5&"*H M:P"T6:KZK8(?UHOVCH2T\3+Q0S0<^W#-!NOH7($5Y'=^"01J72 M5,0=F E&EA%T0$ *TZ&S@"T\)NPY-2I(5^O!G*/IG 3:>V/H&&H\SY&\;Z)[ MH!+1J&S-V1P\F8>OR&?NM'\(@>,]OG.>DE^?:Q7:.*ER?] M*I>.+T378!+P4(X=>>OU\B"('\N;+%&L;=ZC]("U-S)E0(( MN?=MF!Q4REO6;M$*F@H+-!J$ LP92%)<244$HP*VF05G,8%Q]1I1KE,OQ4, M!+')$@?-1::U Q<<@U6ZE@S%Q_,,'_'N49]\BGOO3BM9X^)OW8JOUK;OMB.V M? FM<_@2 G 3H@6SV!S%?9EX D#=)HKZL+#N3)6Z=30*B98"]WYM6\ATUQ.$ MOBQ3L]%]\P!SCE$5\Q&();&:4S@]#L_JF&H1##H]PG>O.<9V9PN4P,P3E-D^ MR"M0,=%E4HU0E21(5,0-.%U10X6+_V#=;.7N1%TU-6E_WGFV^XA:X[_0[L4- M@-U%/=M'?^-D@.[)]@SK;^+F0,!#QZ(_\ M^+6-.PK8?M\W_-1^>;AJKC"Z!:TQ'F)^T>U-0H?NV?.7N^+YX>%>N]/N M? _&[IYJ^6%T-LUVMUY0F\UN6]*1Z/;I.S'A* )%LMH@P,8BB?WI)S-K08&+ M)-JD1%*X\^:T3(*%6K)RSU_^\G_O>[YSRZ-8A,&O&]6MRH;# S?T1-#Y=2-- MVN6#C?][M+[V2S>!Y^#9(/YUHYLD_7=OW][=W6W=;6^%4>=M]?#P\.T]/K,A M'WIW/_:Y6J52??N?SY]NW"[OL;((XH0%+C<_\D7P??+X^*UYM!7Y(O)(N^5*K5S;LP8IQ]S-#03_WNJ$ MMX^.KNIQ1@XGOU+\NL5BL^,>']IN_4[X GY1J^D'(]Z>..S>6_A6/YC& MY0YC??-PF\4M>E!]D1M5?5:.TW[?YST>)!-_A\_0;__>UK^.H^3!7ZKOAWX% MXT6AS^.Q;Z)OF*=N8)C$9;TM-^S14]4:D *Q LX\^*^#__=+(A*?'_WR M5OX7ONWQA#DX1IG_G8K;7S=.PB"!/2PW82D;CBO_]>M&PN^3MY)CO,7?O57# M_O)_RF7G7'#?>^?<\.2]<\%Z_)US[]V_=QJG],>W2NWXVY>;?]5./]3K5_ ? MG)Y3+C_UU]NGWW"IW^PE?M-+G&*S@ MX 2V)F)^(_#X_>]\\*T"_')W?W]G9W>:<0^M<>M OQ[2\+G/.M_:S(_Y-$/5 MK:%.0S>ED43L,O^*1R+TSN&S^-OYGU.,N8=G=_JM^DVQ1CDX?#3-&+5O-UT6 M\?A;[1M) CE(3)]-,\XISN5*C;4],J6?&_SPVU4:\6\[]BA]^&2:,;:_731N MOE7R,VM\NE%CM$)OX,3)P.>_;K3A:KUSJI5^XC1%#Z9ZP>^,H(_5?WN9>,9NW MYN[!QA%=A+F\:.(MV3@Z__.!-YY'S$7!JX92HNE= Y2Q'F^R^[/[/@]B?LP# MWA;)QI-G)KQ?-X"4:@*)$ 0)*'AI(.3O@,*!]\?O N$#0XY2.'T]0SV=&4^Q M*J=(?TV88'7F$ZQ[?Z5Q@H<2-\.ZYPE\!LZ&":\1G+"^2)A/+ #5%^\D[.$R M2 NZ1AD6BX3#Q;D5+I?'>5 ]7?0^N04L Q=,[8U$ ID8\82-JLR>&"YY(@OT4QO',3ZZVLU 3 MGG#0DR:_.[/)HW[UCC:J$<R?BUC3", M:4EHMS;;19W=\\@5,2Q@SO->$1XP>2,>OTU[L[]-"[8'3R2&O;W9$O$UF(C> ME[Z\@JLQ'P52=>+V!V*A3!*FCSJG?)^"(+@ MB;L_,L-9,\*K*'0Y]V*< &I;Z/9^JGKU!)-Q^V#V)J,]934_K5?]Q#RW9[NO M>B^56?L3$YL+%SAA<1?V\59XW#L>? %MI1&I#C^ZA;O^,[.>,9E> MA($+4[[F/DNXUPR!BT5XX1L!K )80#( 8CT#':N/VEFS&X5IIUL_Y?JING>+ MIP%JVPTZY@5(E!]=VTYU]B0]+&SKKIOV4EKK*6\+=UCHU>/+]D,S!)KQN"MZ MS(]_W2@#::,["=Z'?XE. )\-+>&HMK._5YN:R&%&$0@$%-%!JG7;:::Z6SN8 M^6;"CO$H BIA]_4XYDF,4BY!,G*:PB&$^D6H]PP70*>]].1<3=)(PF*)2[ M,U0<9CWUFQ[\A+O7P&I./R7>A 4 = _@[_"WN.57/@OD9+_%4?+MLPA$+^V-G_[^ M_O9&SH4TUA2OH\;0H=#L\2![!/86/ZKC9;OLXX/Q!U0MN/>5BTX7_EL'.X1U M8/=[P*OABF)L$O'-DU+Y7 &9/VSYP-*P2TL8^2$Z-Q. MX8J<,Q&-<:S,9DN&KLK5S+9%25.\.YK$T(XXH2O#([!^_!1/&R4&_#\4'E.: M[,S4Y[A M;/)K.IZTIMDK*^,60@K651JY7KV_L;0_OV"Q909"7O@4+KCNRYEQ\5N MXI9UBM'6?>QMJ*\Q/PR^%KV^SV4BE7I5?G#YNCB$#5-O@\]'?L^];8^;?KH M+$";BDA].,J6HT?*OAOY&0>KP/R(UIV]WLO]1'^>FX#^4&WIY'TVJGUEK[Q= M6;*]E9FUR5&V /,*]3=)+6"NF[2.\U=_A/-7GX'S/QY)?*E=SS:2=U"ELKY07WDPF?N^CQYM.5?' M$_"D+" Q?H$$]HS4RK]3S/8,>_TP0 VM?B_BC:-,R1]:]R]OQ[["GM[;\?-; M[-LUX=P?#LB^#AIX< ]>&3U,R-AX'80P?O$K3@&50A(LG"2HO,"Y%Y)@<27! M2]!#(0D621(\(P4LF;WU7)OT [49K^.NO+C@7'!?ZT_6R+P.(EHHR;OL!%6( M[A<7WLJ)!3A+?A%U[2@6&27V@H\'"#B8OXX/[,SC=_(ILX+M M?7>-I2_RO?C/W&X7?I 9DS*[+TCY^4C9WNV"E*%OF9 F[$%!2M.1$L'M=$/?:_3Z47AK5U"]*G)Z8!\*DGJ*B?^ M+O*J".FG=++E-/DGY#$7%+'(%/$<>1C>:Q4",_3*!!)&O%72BM40_YC M^_-*N$I!0ZM)0\_)APK[:>'LIQ?640I*6$1*>(X:Y\DF\7D8<=$)3B0BT6H0 MA&G/44^3;AC!U/,T,&[-A=T['=V&,771!.>-#XOB.RA@IU(@C MQGU[DX=0BN"K/SF+\*>K2E;8^"I/6I-V93:A+0.$Q>XE:E/^Y2,[_J(TK4AG MV@2$E\P9_< #'C%$&*M[/1&(.$&(K%L-I+U*9&SR@#Z%KH2^S)'2DW;BAV-]8?&=H_:_$AU4<_H(= M_@N$U,:W,GAM)#!V%UX7%R@(81$)X04XPDAOD-=& \,;\+KX0''\BW/\SQ'& MJI0KN^7JOOGKP%B35Y&XA0VZ\IF[0HX01/,7GF#1X(;YV.$0:VSSIN3XA;^H M(:E.:3I#4AWH7 W)@F@6BFAR0&JYTY^3[*A4R[6*EAW'(?9D:J^(08G%2DV1 MX'DW D_<"B]EOB4HQJ_V1<4%G<8\Q47U$$42.A_E7Y;SL;CY"R,N]"E-)2[T M@S!J#!'2U#J%%HH6(N '-0IS*M M+,EU>IU34\2"2!;%#IEC7]\G,H="*!3,(:]H;I?!]-%_;1>.Z,5P1 \KGGA* M4P>[\4#G'>PNB&9QB"8?[+9/?TZMU>3I%Q+F]9YVH4>NV&D_JABH;7@5YZX? MRZVY4 6F\FP78N%E#8_%]' _1BZ%7"G(Y4E)V84X>F%QM-AIV(406@!M=>YI MU^-/NY A*W;:F>Y0,S[N6KE6W/(%436G3K'6!SAG5;.:J9K5(B2R*.12_2%5 MLSKO>&D%PRZU[0P>.4EX-(3#LZJUH0]!$8W=B,=)Z"FO][B X3O,/Z/M6LS: M4T47\_:ZP3NJ/TF%J]LL=@7H5F7&7?9+M<.S%^'FEP:P2V/$]R' MD^6FF,=*.T<6^M)\9=N*+#R9K^#1O22AA%'\*N@D6V=!)A/*M@KB>.ER+?N4 MY^7PK^E";XR$FO-NWH7-;IC&+/#J@=>\@U4,;KHLXHW Q17=8JU!D'?%G/7Z M?CC@/,Z*[&,#Q@:C7"9='MWPZ%:X_"H*8>_YLD/2F?H+V(RL!0)1TC0[.!NO MRF.T_1/G\](>_>DC^XJ>YRI**:^YNF/^VOV9V[-:6(U+=3$6 SAR-,^^NC,U MS2,5SIOF]Z19JOXJ),;J7HPEEAA[4UOI0S^:E_$UOCR^N#W%[5F4V[.P: $3 MBW:F.?N"]%^4LA:SOF.T7;FUQ0]-,H6F>P4U+S91\;5*T&E=;O6.1A MEF$^A7MDG06A/(2@7Y#'RX7%GK-3@CYG;13+-)U1$IFX1;,1;(]T#[2$[KBC6'%RK1;D6I#K;,CU M97I5%(1;$.X*:HT3W=8%O1?T_M/TOGC.]&G5D8*2"W$_GOVA=W X*^>DRT34 M6Y5@RT)QP0\YRG!P()L7IALGBNZ-BT#>4T44#",']!S-6X^ MB]RNE1LF$\,N [X:!#0%HL <]=V [WPS[\P@98'!M@KC',(:ZZ,G4XBU;Z\D)2ZB:7&A5JJ K77F8A1:;+NBUHI. CC_$1 MM;6K3B.Y919\9#H^4M!(P4<,']G1?"2'Y7E"_^'1DC?T>2P1=6B9+\U(IH>L MK#T#9.43E=;#P_WMG>W]92651ZIHX^.!_CH*R?T(5?,7M:'$5HB8C(#=,@B0;?OMPL*\F@\F.R MS3[PL!.Q?E>X6@%2"WSWY:8@B2?6:Q4D\>K-I0E9"#K%#PYC/[*XST>N+%C=PL&0LI**3@(4_C(<>O@$*.%X!"EI>'%!12 M\)"'>,@(!H2GD$V'@68\0._E4K2&9!2.8'Y1 =XLMH*@7)+"?)S)_+ M;)IE&;)I*^9_I_#-V>VKH*P'M^5Q$IMF M&D-[.Z;EX[C-?U$R5]0T'9DKPIL/F2NPBH*X"^+^ >*V(#B&J'0ND"JSHU+S M[4G8ZX7!"F'?KCC]3C6'IT$MCI! <8NFO44KA=!9W*!E!2N=Z^V9HT%0W*/B M'KWX/5I 0R4-A+Q[7VY.1VY#C[,XC?B1B,.=6G7_'3RC!]-?Y5^!HTT8_Z;+ M(AY/?(7:!'KHA]\!\[N:\!ZJ3!ZSM_C;B[3'(Y:$8TAOBCT8GN.X4:V7GO(@ M[(G@L=<^OB_#[QTWL/X^MPM/V%!@'_R1(^O#GS]\8!>-T3J?X0UO?+IYXOB_ MB/MW$9;H8;5>5_2=-LB3:]Z.?]VX]^YK A^OU/8.-YPDE!^?AV$2A D'GET[ MW-DX^N7MT!!3C+M?F=.XM1F.>\[$D7!ZC\:R/W12N,X&S+2=A_YQS[S/WN[,!\X] 7WGM'?=D*$]#X M]/?5K=WL"7MR]NXAG:C_M:;W-C>_A=O8^1S]>P/R8LE65E,K^\J Q0:=) Q*ZVNG6R=;3JVRNW.X9*M9 M[CMR?GG]&69*0Z*Z X+RVV'EX!OWN"B73T,W[2ESZ9N+P;9*M5+]]@W_JM:V MJ]_^^?M#ZW_;K4.O(PYA/)"*01B06BE<1VGS(&J'8Z])F 7N-IR H;$*+WQG MOV_CJ%HI_TZ2-ALS(XR"1IYGUIN?6?1]?>TRX&^6;>K+N>'#=W%OZ"[6@R!E M_C7OAU$R_DY6JLU/Y^=_G+=ZU1^^D^TPZK'DUPUQG[QKA:'/69!$*1]W6>T) MX:8?[N_LO9]P;U&$77RI?W*NSZXNKYO.U9?KFR_UBZ;3O'1 T#5!F#G5;>?R MVJGN;GIOG,MSI_GQS,ED8";^ZB=-_+IZN+VS;$>\G(1Y'D;K:TF7@]H:N\QW M_N0LU.I_*__7\^??Q/9R94ZZ&S#7[7]=A@ M %/EP3CBS4UL]/)5U#I.T@@&2.3*<>$/+N4W?GMU,8B_AOW:S)>27\:D>6T< MG7)7.B(Q-6;L72R-G%IMZ-2R8<_ADWC\8O\Z=UGESYU/47MWAAK T*LW*--G MHC(PX>/ENE_+R17":-EFO)S[/'Q7SX95=(0!$^BW>D@U:!^>G1]W/O_C>MU9 MJ@9MYL=C=8/A62G]8&>R?M"\KE_<-$@1*'2$I:-2S*(0,8:]UM?:PN=.D)(0 M DLS]Q*:AURF-BI[!0G\V+\<.T5<_1UC7OB#C!X.L%4,!X M^MH[^<2.?]OW[]+]F=%7_KT8'+_\TCRI?UY?:UR<;*T>G6V>W3,W65_#?7#" MMA.9]3LL=N(^=S$5P7,$'%42.VZ713"#%?$_)*P%?-'EO@^?NR+H_+I1V:!_ M]YGGZ7]/O3(KE&$B%&[H^ZP?PX3T7S*4^4L23?^"6QXE",ZA]RL)^SHP^DOB M#05.=&RD-3XV,M62=@[_-7?EJC7"&6HYSM (@)WT%4>A/(X3B6QT$GH3&,55 MN_'O^G^ZS;V_?]PNLE2M#\*;_'FY"W!)\QSX^B"WS*//<6GFGBC M9SOUR=7F?G!#5VS4(IOLOJ&2MEPZ[8>4HNJ___QCT&M?WS;:,Q-:$R:P M<;2S7]ZI[>Y7=[:?2&CP/]&\^=+3QYOON=*=E+,+(R=$="/GKS02L2<(PAG$ MX2^MR'FK5B#L^TR_B#HL$/_0OV=T65_\ACYUJC"M11?YFXVMZZV;+3M;ZO'_ M.^OU_7# \XX4VJ-%7VZ> ,H9.<@*E[ M7L3C6/WG$_RB.EZX-+UZ6&U]%^'-+$+ $U\.O#,5R#OWZPX+/&?[^,E^[9U' M%E8;OS"/?71[?^[$?XH?=^,_OC 8NQ%X*=@_@OG.%8N^SVQ=V^/7]<_'SI?V MR17O-,4P7=)3]SUT[''=T)_'D9-<.[8/S!_9O% MS4A<__NWRQ\/[$XXN.S5&T>7/91%XVEP-%>D,G8E"MAV[#)._K[YSY?__;U] MNS>32!]91@IH=I)=E)\6W+@X8MR?L,B)T,WSB9LAH.[L2)^HGG,6GTF M3;X+FMVJX(9LP2F]Q_-\HEM*,5^4P]XFSR MI>E<55JW?WWP_CKX:P:7QG[?QM'_<[@_*8@\R< M^>*\^6?U;A:S'G[GQM'^MK.]7RGO[!U."N3AT[<]?_SW\=U*K[[X$[ M)=SG?3PP%?$JH>GNI^C/=1C0'Q"!QY=MHTT^C M.,400Q+"3Z6SI5K;;+W!" 2F-=5=6,T%'.&R+;B(,\S$J[L]?Z\N=2%5WK^V MPYG;=5R?Q?&LW>[+[V*O5>9_&!'#:R!7X]%U7P"<9*W^ML0-0KB_>UF<6IEM0+W^QB\N[BX6??S&5W,ZJ M*KF+/NMI7,1TGY;6E-]4NBW0&:FTA1=NS*S_2N-$M =; \?M MG.3F57([^P@YS#_"N_\'5]YH][8H!>.=Z3MLN#W MT_N/?]U79I>J,F$"<.7"2=Y 4\96$/&B$7$0)O#)WZE @0=RCO+,(RHOB,<+ MP&W,G#'_HJ*!3!P^3,F[.4K^(_33(&$1981'$PJB.H-ZK^W?'S0K;&84//3B M%Z?<.=# BI'N79=3@#'S5)RC7HLE MGRE[>7T-2!J_QYH7QX.O@PX]VX^XR\D=7:TY5$P8.YLP8!O^_S@%^SKNAIAE M[4A@+O@-2X8G?\?BT9M'/U:+>%.BU(S-VIOU-5QEBW/8Y;3U%ZP!?T#/PJ]P M&FH@0GRC6= L69PXAQ7'8X-X:V)(1MX)5?LH"XM@1$RMFU2D^$?PU8O[?WP. M>CLSNY/CW[]Q]"?"8#UX-T$!=TP=U)+1^^NXIDB\0+<]D21 ZMP'^HW" %U% M_L#AMSP:. V4W M5U9.R%Q$'K_9F@S_H7/*S4)QG8KLQ]\S]^O>W=5)]Z_]^NQDW_CW%_=L(:<] MY3TCF\2'&7*'N2[<,["+@5"1,M$@"<9^"AI@4![[1=R#"PIOB31/7E]SPQZL M;5!"X0GC@;S![>@XG2B\2[J.^GH+%L1I!P\&-\TO(]'IJI_./> Y?=BF,M/8TR>\ 7)6(U0^XYC9 M;"<^+ !F,L<9;VX]VU$YMZ7F%[I" ].H&CZX23$EZ_;O_1BC\= M;I_M\9DEO$I89Z(35[U\7.)K;G;H-LA)SARQ/9PZNC@QLKQ[8U'F=2,%NYS+ MB'1?N.D^3-.TF.,T%@&/)UC4'YJW/ML/;J]_^W$_[1- QL;,YS&,L=? DF9; M5;?JTSI3>K2<3%Z97KC)/@Q_HI?R@19Q(M=GZ+OK?^^K#S^X\CH3P% MZ^>!B3T&]_.\N0.%E6ZL]/;ZVF1C&'.7I17O/!:.03\9>I*2'[4WV9JQ-7'B$%MHC9 5'E!J%*8#H%&%)PA$ M X\73AJ18>#]3':5T9GX#HMCT!'P(WWZO-WFY#T,=!T1_E2@5S$ VD)6&(6^ M$X*TMT@N4^$H1<,0UDYEQ\H9OV%1B\&XYL&X:SW:WN8 M8/X&KU&V3$S465_KIRT?&+%%V6T1]:0/MP\O9^BPAVT;;CMJ(Y/AE$]V[%SGW4F5+F&_ZFG=YV+Z*L_5S$Q>5Y/EA++0O++>E-! M*L192!$HT)FR?F*BY+ O>W;'8MT0*=9C9(Q@?4T6T,AD%/D[1P4.VS[%$^$S M-XPBKH$SR+\;11A*#/$.W8HPC?V!OD+CWEM(@P63!J@&$"V$H$;(P\S.6-.D M13?$+TV "T6&&U)X#B2#/X@%4190$KI+;GFYQ5"Q0-V#!S&3H!4898/O*-AN M7F^3HI$MPU6G46R'ZR)0A&[Q@I@Y*'7'OCEX;/OO:SN5K6KEM%R%ZU.0X(*1 MX+@05=SEOJ_U8V=S3*9<+@@#K/#-PWE%^52&&QS^06.N=QRR\_^]#;SO/PZR M\71CSIY/D6NT,--N=H%H6:<#U(DB%JF6)\XM\U.N*>\V)%T2]66,DJI_QMAH MT8%#)29'X=,VIN' *&-$+R:"PH>_I0%WMBLE!VFHY$C6&9(L!O45R("#2JZ* M.TK;; M^%MS?\XIJP"F,4S^UHLVK+GOGPNW:*V]7\CF'C<%3WF;SCJC_C7 MC?+.AH-@YO"*O0T'6\'16-3-L'JXE<&:Z_F8ZP54XL._MYQS$(,@1?H@%-5Y M 5=";I0F2HB%@0]V.^:3:=%49DFY#X!EH 7"*_.=F6[=O#MG\_QCGM[M7=Q=<$?OQX/C3OVOE!+ MT-K!$^]+X^+/#MUCO]TKL_.SZ[/+D[.EFU-2\I:)C$. MC=L?9T"RW#L>P$T$=@-65!.F=>S#]1FOI1Z>B.;W[\W3\V;72& SI&./B7J( M&?6'-5H.\/) M??EWC,O!RP&1C-)4%N\?$\7/;S(F .(OO+'$I3=,ARAU>%)W_1W9%E"POY=; M''0=F$V?]E)M!!&EW 5#)M;A9^_JYT>W*6Y!V\2J':58'VIY[YRTW\?4),2" M^:5E5K9LA:V/K:M9/_YTMKYV>>Z<7%XT4;FQUNC,CT?^[*[1_^X<;NV9)>:E MTA!27%D^NK2IOG-'+6H!\^M$81IX.&X8O7.B3FNS5MDIU;8/2K7=W3=VYA \ M@LO^=:/V VL9FY7T//3.G&Z$.ME_L6^52I5: MZQR"M_"L/OZ&>Z,8[Y7]ZR MV>0.CJY7BI,\U5(F]BRI8V6:(O+*UOY,41U_@+7/ M]L!'!/;,-><77Z*F:7.$<()SI? ?6_&L+\)#/'*9^&)KB#76-HZN6)0X#["7(3"@B;WO@0ESWD!SZ*5C*Z@X,AC;VT#U% Y\>J6L[0D.X4R MOKUQI.LCEEWUWGG%7/;!$Q<94;/70=4[&T>1B+\[;49Q[&6G[&JU8-W3L.[6 MZZ#RW8VC-(AX'/J8A1@GK-VF4/4J^%%J^P4W?XS.:Z^#S/^=UD/?!QE$/3$PG9FV> M#!Q/Q*X?QFE$.:$%E:\\/R^"/^8QG<.-HZOZ==-I%$&=X@:L'N,O MXCLO3K+/$=]99I:/H_QWMK#-^!Z[/;LZN M_S@[58O__Y:=[+I+W%8T$7/"&ZCN"BO0#Y8=^9U9!54MS>._D8\%H'%\[>?CO2YZ?1:,G6TM+HL-T>+!Q=-JX.?ET>?/E M^LRY/OM0OSYM7'QPSB^OSQH?+IS?OEPW;DX;)\W&Y<6-T_Q8;SI7UV=_G%TT MG<;%S=69_&*E*'=%>&J12+,\2D(1DYTF3:::I3++0.!%GLS/,X2E(NHB M3V;5>;)505=Y%19;K0*:L@8[+CEG!J;_4L/TH]_"($$Z'83G1Z?="_GI=JJO MG(D^M<&$B1WQ/7_FS26^B?URK%\68TQ7'I+TOAC9[J MWKR.FM+:]L:1OB&4WXN)67!S8I6V):\##23A\.&=^(UN_H =N7@?.S&^F+JS M.Q]U9T78_^NH':WM;!Q=12)P13_?S[/-N1_%![RX@:L'.,O/.0O3K*%A_S)ZO?K*"6M[6T< M\?NN:&$?\?K%Z;AFR$[L=KF7^B^E@N_NO'+&^>!Q+CE/?;FUO;2&4'#B!SEQ M\^RSXL1[RYNY-P4CWM\X.K^\_@P_*__NW'SY_+E^_><+\=O=)>6W5D>N9Z&2 M^;SO@9,9;CDV3UXQAU9$B].5;".[5GV]YL69W11_')]EL_H M[2^CP 3F,R$RK)KK+6VSS8<[*=;>.Y=]"M*\PQ?=<(K8O'?^P!;N\/5K:[1H M?RD[]^5>MY%KMJFW\;W3'/3A_?6(M83[WKE@/2ZW^B+$#:SE^B7J7U$#T:*) MXZP]72O0Q)%>@JV055,[O;;6<'N[]36[O]V\-V%)VP./[Q]9V:K-M"<=C"2. MFET1KZ_5@R!EOG/-^V&48'DNG%I/JM&OLN&D4H;_D5O [62&\OA;QN(^_2D*G MG29IQ!U^:XKI,V<+4!V5E %#VG+.)\^$P0#]*/Q+"@BJ3=9OP"7DWA#"LM)( M?;B^-N%E#=CVL ?R (@>MG40IO GTCV, >?UT+:T!G"844\$H$)V!DZ Z,%2=\ MY*L6]P4L?>1S#H37&_>#?L0]8;W83*@?)KAZYNL?P%:JK[#B500IM[Y)NMP) M>(=1EAZ< OP[YK0S\@RH9- ->WT6D>2U]FS+:79#>-C:5$6;ZVO69Q&,'J&D MIG>) &=7@ M!>!_\3TLCM.>U$K6U^#^W'4%'#"=\A!%MH!VO"TL "92Q'T0 9P$IMW2 RY+ M<1Q,2,&KA/.A<1X@+OQ9$"9.)V4(;8?9 &$;J%B2N$7"$L$NN,4N&83$(N]6 M"E]1=@QV%9"I+_+=;H)L0>,: 94ZGFBW9;H8\!3F^T#T4=B#Q_%HJ.5\K^_K MYO0X;YC&Q(EO(5=8#5:ZA'>!(B?Y-Q%8 M*4]=]("\YJHAD;K%0!EP3=.$"-D7/4$I6>&[52>196W6/-9M\1,6].2NK?.H M$1;F-,2LO(9F ;5G6\'AWO[A[)8PX^F!U)13&:M,E;)K3_(5U%!@!@,+.P^^ M\,,8%*V1%?Z 59%1PO1*O?Y7'<3M$[X/%;[H=] M53S/PJ]U$T*AK>4E%DPO(*L7AO#*4:P\?Z7)@\5J!#NW=VYI,G'-.52_2?J8[\VO./%# MU]-.I2"X[CP+^G-C3CF:RIG;A +1 Y#%\)EN0VF6> M[B&]4 M1#*'SF=WM#J5L8D[PA+:-&M2668A+#7$/%<&5A1E%F';*;BCD;B%+TDSP3U4 MR5K4F W':J6Q"'BLW%,F$+GE7(3TG@AS-N1K\%S5+(;R W-]#W6VI_VER;#% M7XI;>:1WPOH\8;WA5.0[/OQ).I*N#$2392IG&#'[?!V)7&Y!W^LJGGY%V MYU;^MPP3_H&BLNVB?FRF]6/;1?W82M6/Z=*N6L8.GFF]5RQ*UM<:1:W8$#5+>=8Z9+%D_6TIU8L6TWDMTDWR69FAA MFBSB6KYRZ<]@3A_KZJ@G(5D;EN>JI)U5\$1I*"0)EJL(@O"64;'>E2I_@C\_ M,TK6H,*ZS2OO\QOZX4D82 ^8<03($PHMKGS9-C>"KA;I=J&JG:#EY\ M*R@A^%;$:"_%/(AU7]QZHRS->GB$@RD>,'\ ^EV,2FPV.AK0/>+B;PKC#L!@X'P0SEBL$J\WG]_)H1"!ZY" 0P2V+\2CT3_JFK^J6 S?3R0VL M"IEQPWF@=M0^"R 3=&OJR3-X1X?UR*<#!PV[[[1%%"?EL%T625S^#LLO.>>G M];+KE,[KART< [XK058YMD.B#<=R0E MM;$1^I9@$Z4?I]_WT7BV*UC'[*Z]!^A34Z2A=ZR-ZO#6:MST5>):6K1H;0KX MB,?]0L(LXEKHH!1_([:BF#9R?A.WD#GA%27%W!U@,R(:DVU,^ M7([LU^-]/QQ(1U(7W=1)6 9CV.TZ?J@O//X>OHN[ZVNYI$,&# #]N.23YPE5 MU(%LDJ+I^+.3Q@J_0#)(+4?0J17>H=<^DVEY7S#5O,W.%(4(L78 MN:4QY]]S8;P$[@[/!J=0!5C]H 5(XL-_==2Y3! O.>$M!;4*RBA%0L"-2*5H M1B@.4 IB/5SV2PIQT&G$(.(BU&1,%0'^$L5;&\\<0R2DWC 1M<(H@"- O $T M5$D(ZL.^//NLX$;DTQSQ%I@B:GJ1U"APHQ4DR:*8^A,V@?$0@YF.EV.'X+5 X2,CC_5!:)U%"%BO-$6=; MP9%HA=#H>J@.M$-?A,XF3C]$)H-(#Z!U=#"H E07"ZFF4=P''8C<4FJQQI:> MQ- ;_884IAA/Y(U=DFMSC,T[GGG))6!';K;P'.R";!R'T:N&OC([6Q6ZY0WX M T:79-A!W1&#<3:>C $1 0:(#8R2; ]<& M42W*>%Y;NBXFX9A=A<4(4$D@? MP!3Z<)S6;8'1= 3%7+Q;=*DCB0&E*K($[A\1.T%5% D.Q0<*1M9&82731$'_ MAH\\#%$25_=@%$R(QTB@E#W =30?\@?2+/J'$U9*FPF?(JU9A): ?X"VI*XM MP\Z:T'LA/!N'?:P_5VSSO%CW8W\C%ET6]:J7\'1'-MO[J=S9 1TI^W3#A MFB['PW[GU&JU_KV)F>SM5_KW&\[;%YK]ZXWZJ0EGD9^Y3GNYK]GPX3X0&=TI M(J,SC8SNO++(Z$K(D6?C8>+H:S<$:YI,A7?.1X6*@^K L<&A+L(^"Q!1N./D MZS -L3TT?9AID(WZFG1^H'?#9W>F')12@O ?%V!!>@S1-C^S""RC6JWDU"K5 M[9+UPP"X!QA4";!%@=XD^+DQ!C%/:7T-[&8U%9'(K#D>=%A'IV'QS', K[1L MSSO>(G.2^93R2.X?B;P8Z$3+S'BG1^2X>MA^"G-F,5?F'_-I3;>\PT'#%[#1 M[3"TG.DRS;$K%P-F>[+E? SOT-8GPYB6D,J,17P5=7)6L"B1@/-&TU O!,$N M2P99 %3N0+2!LP?)^EH^_Y"Y7^!47:Z])PF322"$"<;NN0$ M2^Y"DY0*FCXY(F2G>QD'TLU?8_1O='W5TN'AP>E2J7BQ%V&J<]JV-P; MP63\[\I6I8I&FWRNH,*%6\MEL+[V&PM2!C*W6B%V?$C\B2C$M#]"XXC3ABW!>V*"@A24C_UV'E7\X=BRU^'=X%,M7;RDXM21J4 M"=3H(<9K4(6?FH>O61O>XIS]$[&2/07C?#GI(N)M,W/.7DKRWLJMPA,>^=;) M)8K^$XN#$F<' CZ%>TF>NAUK1T"W]T@-UM2.C<1AEN1NM=Y04/G"K06I_(;W M$WFHU3U]JCD]@_K&HZT)5!R$C%T<(>2(UZPV&-_P^'W!:@5R+*_ M\Z3DD.5D8NA!5K]1!P9*[J[UM4VX$1YO"R1NC F)X$U!. NW%B0H! M5\MRED%!LPNW%GW&ZVM$D2AZE3!7>IRQQR1S0V:F58!M3>%DVH$6".*Z+"4P M9ND(3S )6:L9I4$Y"S" 81LC6H.M@F3',;>&;HI4"?+6)$8%J*02KE 8=< P M4QD]V1MU5.V.^">:0K)DSQ.4R 4WK3OI!F&R$DO2"/9*!@/Q_FB2+NGR+1GQ MM2([.P>U]UDL#@8@ZW@'*E870CT?2Y).J;2'.>6)V1 M'I7A &H6@N0OET5U#9P:R;12&E"2L/H;O,5;TT.G1DC\ST&$/<+FU"H9V M<5F!# ;+?<6-JT??X1N:/W-E.-\6Q2VPL._>R-HLNSF"WKR\:#>+NL$4BD\\ M2>PM<39Q%%6(-?REJL:B*#&,V!K(RD^\ >2-P.=H[0Q/P;Q(-8Z0CI6I#LC1 MZO4GT(E1WS'?%#Q\X=:">D<=I*[OU"J:H/-7=EC''$L+Y'K2JNL-IM C*\E( M@FZ%)FV;6NT?HNH\_$N;>O'6\W9;MO; V+0UDTC/A,G4&C.96 _)S&0\>A O ML5:T"L)$K3,RSYDQ&FJMC8^MHCQ%W* M4GA(2F>ELB=GU\UZX\*Y/OM4;S8N+VX^-JYNJ+\U?7)VZC2OZQDQ^JS+%HH@T8(8 M'IG&C:FSP!@$15-:W,6*">;X7.;TJ(0BRH<;KO:@=.(29>7E"S_($:US&TM* M\38YJ[*/EZN3BCS=#W04*$'I6>* MR.'WTOQ#(PYQR%04;C-^(S-T)7*+[I$V!.!C_2!6.!^J=,:D_XZ\6N8JFYQC M.1%#>@H&36!,#DB=@2(WP%G@*Y0=?AK_>%J6_ !DLE#"<^P3C16 MT?JFO.! V2=EPEXA.#@PIZ02($-3FWRK@QY4!PNN(FYZT 5 :ER>1)OS-[G% MQQQ7JU:/CC$KP5B*?#,/Z08C]!21Z-W7B;/CYJC-4G1E%;F#"[B61B -8$R= M=KP0(T#&I2!S]NT,;3L=FTA%<0\R:#(60A?C#EU"Z$10J;?RIF;5"2[KRQQ; MP64700G+0^3JHO.+1Q'4[;UU% MQ88SU_-SEJ4W\,-ZH^1\_E1R7#],O9)R_&8)][KPQE05P/4[UK^UJABMI'NY MGW2OT.\"HM0LD,7 .+DG@6R$0C62216Y+'8)+T5Q[BPI&1[DF !,JX7#]G4& MADIFIAU7^\K)PPB7&$^BI%.?5;@PPMR[! [+BT?8HO*2R!<,-+^CY&(*_ ED M6Z2)F!1J^0OS.ND&S=SYLHFI'(\2/(!F:36(]!/#&>4" )(PJ>MF?CM4OK4J M:I3IWW3RP+HCXY=>JO(0R0DB> M%FQ'H%RC:4+:7[8C(I:IZ&X($L_X#^R4<)B.\7^6')B]:QV-(CAJT!@H5UD+ M*0QFZ4H$L]S1R8U1^%VNJ5@&:=*E/!V4%PZ6]E(3WVR-L=N%X_&?260LJ71X MH4S=W2)3=Z:9NKM%IN[27L'GJ8?"6EK4A0*EDDC5PP@,%6"D"OMXN Y7F?M@ MIH!2QR-IJX>4R*E\B+=<%QYY6641L69,N]!ZC$*+6%_K\:0;>B!DFB'HASAD M%N5IR*C-)UD]&ELZC/$BJ"K8)"L0M@5VIM.H>5LBG%X#*AN!($3HYH!=5,(3 MG9IIG$D<2P K@2VQ, G6@+JDQ^Q6ULVJ!+SQ8E[+[K1/&L?H^(5-LW!KP2C. M.6]%%%JGI*/:MDP>"8(PI8BY5C=]KH.Y#&;^%Y"HK)B"7$AE;*I9_#-F=H>.Q#GV67 MPG7H1*Q7LB%.G@@! %<6$Y0#[BC'(%DH&1Y G/8E<*9=RC^I<%PB\DJNH%YM MS=S<:;KN:0#'A>%=N0MP8SE8ECY5?TM,@7P?(P4U, Z&@%(C4'?G&(Q&JP59 M3(K0F"%<6UVHB'X:D7#R791D&@!M*&<]7V7:R#IS=*](?N)A23[BV>8GFQU9 MH8*^M(/".-64NP$]AT8L2.G10R +4Y2?82K)DN$.(0=]-<_IVG^X5&U.& )8 M:0_\/Q(RHT::0]0SW@BL];5,P-*SB8@)YLA8^^0S)?@*!2* 5A CHZD;FN)A M5=B?LYZ-![##0U7RC(_P***;Q67I!,PT3E ;((E/[AERZ)NB]F>N82^DTK38 M+1EA@NE-&.3*4U5R6FE"L V8).V+GI Y.#(::^KAWZW&7HP_U\S^L^V]87MP MZO7FS,&)9N/&XC2Q4!.>^[;_7-^*.;NL6J3_+ M@M+R@D[KN=7$@EB>?UI+Q.ED'5EB>)U)H)9*N;3@3$P,>57LF$)+72=)V%[# M.E#)?,TTO UP1F9E$",G-,DF(FC[Y"$%W5].)4,V;8M 6G/#4%ZYV+R!ADJ8 M\"E>HT-P](A,2K\53*6Y*(<7?MCC+(C?.\6=685I%0QV$4_EU3)8E7-D&.P( M"\LA!L8YCL81 8TX&EJ+Z+=6T)F$+&E\7N25L]QUTI>M@055\8P%M::U6FZ# M'XRBK>F2.PN@$;MY:6=$<0-68EJOG%V^P/(7A(*6B(<&/,'L&,L@EXJE[/8M M+?"$N4D&7)_E-!ML>ZUICD+29^#V*N6TI/RW,N)CF>"R ^]B4O*K(-J"[15L M[]6P/2I?I;:@AO-A>PL*:%L<+F-?R+54,-A2VOA]%_1&DV=ZQS&U-,XL;\P1 M5NT)7=5]=&L\W5FT8B71\K*)W4!QV>DNU7(YD$X \R!X\J+4 8.*L(1*6DFI( 3!&5$5HF>C8B_/H:!G%5 MP49(^0=8B$]QVB:E< \%R)25 A3NRDAJ+'(X[%FWF5PUD@K9JIH+U;(E/Q'9 M&R!?X6+RK6VLFRUL@(FWZIW4V]-" MR8>)8PY'#9-#G M61&7*5:QW4K&!J-Z;YJRP MWYC9E5\Q\*M )XY9N?)FE2;$0?C;E/M"R(+#G7;4[JDU4MT"1>2!"G'VF$?6 M,H5'NFQ;4AUFF'@#NW?X;.]WP;AFS;@T6DJM@@B65'V20X7 KMA(.]B7I.P3 MW (U/XBHR496>?\;@UFIW*6;M"<2YESVI>K_P6>(24*=>3?E=V^PG(JD'J,T M^U ]VA8(\V%1HZJ)+LE^]4C%,"O3$J,#DY X'UB:Q>^!J5#?)E_!0F!C8#D7 MQ9;E:G)X'+I?,;9^6E\[%:S'L4C[#\H?.X%_1).(=?38PU0'A +9"139!GLBUP8:ZWW/+ MT< )"*Y$2S.IG-LY./%Y>?+C_\J7?E&6O. MYWVG5H@]3%&]L%=4+\RT>F&OJ%Y8J:LZC]YR)SH44(!%O'#FW8G6YF6=.X$6 MA@%7O@)MMY4LN(AS2\'OI2#WI?P%Q:++00WHN@2$:$/0ZKIX6=(AY;@)N?>P M[C"#0^8NPQY@B,DL.TXJOVS 642H6V2;_(83,&J?G<:/A<9VBRW\[2VN72D3 MTM,!F^PIPXY2^DT32XEMACGKJ#QE=;:ZI 56X?I"Z2HE&[*O-JFP0,ZHR[PL M^X'I2!U5GMJCHF;UW]6MG5V8B^^C6K,:9+9*5\;VF4SLH.H4#50+^E#T\6-E M1AC%QS*C*4N,1LI55%W+TTJ,"EG\;(H0PEH"&23/V;Y]27?^.8IJ(]6LW79O MRJ*@(1P3W?Y#N9"I)G4L] C*-?Z6KZXJ\5] MZJXB5S9N;CI#$U>C:V>D]!2FDZ/RM-/Y,8GYP?O *.TJX@R@ @%I+,":'!B* MPAU1+2$1447# UN](&6YM@8MN399-]KG-X2Z;>DP[]+PE$):Z_ M(WM89'7I6=FK51XZ IPC^V)/JH%5I;A%D=U+B]2K*.QCP3+88^MKUS)PAN>< M]2(I).TB5#T:JUH'(3.@OI8M%5QYE<<%.$=:BX.!A8S;"B&@K,36M504#N-B MB%;&=I7]U?*Y[&.&_+'+V2W" XK@UG0A)_9"<5,5>S&]H7%B%M+[:IS-RM'9 M<+C'4NY4C,N$GN@]F;R3D(^$5ND@'C^95,/Y$01^*'L-H#XD6[E+1$J;:+%3 M MLY2/CR/4VPCD>K ,:7PL=GV&:C^$$ST"?R?7B;A@U'\@"\7#@G2$<#B6-P'> M>G064T--@YCX(:QI%?9SOIB&B7JC5+_[M/47P=>$IF4 Z:',)%.UTXB*B? , M,&>B2_HE-B#*6D2,GGJN^#NCS&$B1H@2C?U-*)PF#CNA'8.IP9(THEO7X5=Z M,E]\F$X,ZJ_KW*1PO]$%=0:Z)%!3'W3>E:Y$7]:U4,KB^MJ511X#.YK>R-H3 MT5&Z+1HNLQ<'XT?D:LLD<\\"D.$N1KSN;*IP@O_S @5%AUL=- MGS*FSB.T$4K.!]0EG&.P-:C["FQ$(P%+\$UI?4WV_RG)/!1GT_0=E;:P3,MD M_IN28;)? K)HJ8$00IPBB+$4)>HAG#5]JH U4=J)(&6F4&AD%%"$T"G [_M" ME09Y-+C6T*QWC/T]Z5 7X:UL=E.C]B_;VS09 [VD/UV9Z_6:6 4E&3GSRC'* M<9KUM2>S&AFG@X5-XCFE7/:GIZ9ELQ?#5E"UH=9"T@L@_3V@(O+(7&!&$KDU0CY#G(G<$)(UJ?NB<(OUC4I5KT-+XZ-8$&D%[31P9;XI6$O* MO<8<5G+77)R[,=F',0R4=%43$:S MO^T)OZU9S N^RW1OV64:UHWA"-9.**'+U Z2/Y-31\^2,Y:UKJ^-9:HEBZM* M%^SW*[(WUN_)> R13WR=!D& MNGM2[L"(?Z61B!42SY)GG9V9/R-7:+W*U9IJKM5_D:A6*PE1KJ:,6 M;W=6-8Q;>N:69Y]<90Z(CM( M@P1UA2=E ?8EHUJ B-^&W[ENJDZJ:C?B7$DG%AA.O'EVY=2V=O8/MO8.I6)* M'^S5JEO5W<,W"N05/< U24N([<7&Q+#%1)1+4Q^WIN[2^IK9I*-6JBZE3LBP5MT\)P!Y# M1XT24)%/6?0[*T*DJWSA&,&SRH88!%+)= :\TQ:^O&YVU\R(=U@DXWR!L9*_ M;-UL*:J!BU&ME*H'!Z7:_JYR[UE?#UT]NG($L IWS'JU??-1_:EM&R+?,0JI MZS/14]'G,:\8(MM\RYT)+UM?\[+&-2X8"1(8FV@Y5W*]U#2P2O2=H#FO.?F.FBW<"2P+/D7XS7Z37G' ?D5P%8C41]DGDSE3TC0^,=LYD"["4S T?Y*Y?>@ M\A1D_H286F=3"@F!7%.X!C&X$]%7?+\+MK)FJ^;=6^B-C\)4KIWZKMV;5ESR M5269H2-_CVZ".-7M9)2' LOE7.P?'J*=G)LN]IC'N%88#72BC^P^AAP9Y% I M5X6E4CU*MB\W"4.?4I-BV5Y'-I,+A]P7ZN1Q>I,/DEP08WR/J+HEEO@@PW\@ MC7Z82QNV-TXIE495@)*BMWU8KE5V*D7T=@'7\BA;4!?SLM]-NLSO"=?B!B-4 M)7(UA(S(+W>9@>XP!BNX2S40\K.VCSIR@#?194&0J@'@/NH _-87PVJ>VNU ML?.6ZBC53WM4=HT%WZ7QB(/,^8O3I::P!%P1(7T1Y$/*"M3QYE$O)170[ Z\ M*"P#QX@Y(83IL"2Y++3#B@^P$1;<:ZG_T()U@E!F^:I>(V^Q?0?^09=9YE**N.\SZ1C1+1!DJD(L0>%3A1K%.=1 F"X6Z9$\M2J#0:*P#,=S FE3((/3'$&=_DFH\GI@ M:4V,,0RRO!4K7(-+,-5OU"]UG 4"BY*1EXR?H/';@!/P$X$F#'$EY S:>,^K M-U=9=7PS8A['9 WM[%&ZG5K8'6U3B^<,:>)"W';T[-2V,%]%N^V&EC#*VO3) MF_7(,$8N;K&^IN;.J26L\ULJ?4K;A7JU<&O!/L]TCY@?A_*@54,NR@I7_4]& M#2BE1<@>I6-3H440A+>,/K:*UX8Z@F(_2D2.D2GUPY<&F47.?4D3=7S1YE2Z M1.X=9P"T'$N9#U0)$RO(;.'6 M%[ZQUZIV4";DG&9ZQK-=X%4ZG.>IS- 7*(PZ+-!9>PH<$.LNM M,YLTAV'S) MUB"QP)3L.XVW[(/&&5%@'6$DC>07.!'=(K)DL/UT1U>#@Q]3TW99V:/-9-0Z M@&]L.1+ E>1 MYB&RH$<87JUJO5:,*YVU)FCO+;$W4M-U;!73^LCQ+PN>AD>3E\D>+E=!O!JD MN$K7:@K$LX,BBVZF670'119=<5E_7 9JRQC%2#MT4XVYD,MT8-A\_)VS*=Y@ MTH/,>:'R>?0AZK"*J:LU5;2FF_$0G+$,RMAR$H,IKG2>J@=(O*(\3#-)J]T^ M:#:[85;\2/[?K&2>_-,IV?2V" %1AE5Q!DC#])49LM?)ET@-GRG;78-'_W[5 MD.[W30';(+T'!N39]MO(#U M-;6,D>8[Y(X7 4AFG^">B??IMF&F3C@#$< 54VF!?B%.=0@M)+?20L8^L):9 MFQ!8)5Y \2P O1!K-# @%%C79X,&@@R<8]S8PYH=N('PY1M HYZ=U]&-B'69DPC"7ME'41L_EC1I=?[C9N+G$*AQ@H!WI M! 5+!2.+"C!%SS+FUO;%E+$ /)4/=V#\=QT13L#>R95R8YXI""9NZ'0)YS_KC_XW"I=D@"W)4ZK-40 N]&Y,'6+M-A-1;'>\I=/) Z5%&-HC M<9=Z% '#M LZ;2QW/SO%.F[G0Z_U$:MO5#V0XAH[!;_[[\\T; M75;92;BHB70G41%MI0B'P,JCQD7$X:;^QIE0M5Z0; M"DB+@87*(R)?#2\",[0;!S#GN'8,Q.-Q7T+U$JA7!C/1YG<\LB]2)I$HL1.; MM0!W#EU9E$.W:>CB6 N*XMR2"+#M*\]AWUE/8WZ& 4-KZ[AL@ D919F?0M,,NV=;!F3N2&E7Y)DM\C0&E2'"[T* P@Z3'E6 M^;"I:DVC?BC+))(PE296-T5!FE 2BH*T'7O0JHE"E&1\2YVZ9,P)^RXU*950 MG*+?4.Z@R9Q!"V@*$T4O-=#*&[FQ^/KT>TJW>V-VOD,V/OI&8_\[> MSDZY6C(]L8CUCT%<<7W. C H>PH2P[J7Z)F-$.PQ9Y'&N?F D.(]JK:6KZT< M'FZ7)B&[@#J+!CY><]445N5]#M7$4R&;++9 "454T(\$@N,!)U0&.NL92G-' MM4V"%HJD>P#?\)'] ^>(0NY& B-CZ?TI;#3EC<#.782CLWEV MXE0/*_MO:Y7*WLL60A>"<-Q:;J3V1&CQHIWC4QJ!*F-6)MZAV57@<,STB A# M: @-P>)*T@)0688QP7,J!M4"!7_8& /9HUBT9 763;8O+5#67F4/E#U\(7;' M2F1:DIH10F+AI$3L=F&;N=WF"Z?754!P,#W%_A*)\ Z0>#LU)"I( I5[)QP M/Q9*KV/4C8S+BD^+^9.G2RH"AMG)*)=*PR+SRYID'*O\3K"X*'%%(8I:^VFX M&X%&XP9L.9]AAB'IIGB9Y4^=2,3?;=46@;CBN*?1"ACEBV?W^NQ"\;;#_>H[ M4[$*'[UM H]5G]:*[.47+ZK3UT!;6G%IR 795WE.QJS*ZBM5-%4;0$9MI>$L MUX0O%2)I;ONLE5>:5*W>^AIVGL.23POF=2BN"M0-V@;H5X\J!0W5-BYV>8"M M_7*TG&M@AXN()5"*TJ5)$:.R ^U8M4&;B;2+F;!&D G8K=,#&."(I+2#?X$1!@!-= M]%1MN)9<]9O#:J5RZF@7(MT)VZ5B^L%F?5UM*5H0U<*M14("4!&!ZC$H3Q)M M:YB(2B^)C4O5\A+D-!+]O,_N8J>#BD*@PXIF*%T&@19(ID[1N_%GRBD2*<6? MP-BE[U>+HWX$IJ.<3L[QK5YP$D91"EMYI1]SZB_,R!8< NFP2-Z8:?+&89&\ ML5KL=\:A89F;)];7/A"#))/I2@'^%\'BA9"$&3B.%CI,(T(C)&)RA]6"!BP; M0?MT)UILIB3Q^AX#F\8JI6S0X8J1];7'@*:=G\&9?D,B4Q41-E2)%>!MO3E*[6P#<7,,LNE* M[&.15=Q?=<.$/ XG(281)0(QKY75HL997[._LUO_XH:O!NFMU#72& 'DV$-, MU"AKGA&V?(7DH7(G)**4#FDA4:4&!?TL0! F[5H"ZM'ITR4[,3_?E(.HRJ)J M281 RMH<^<3N2L[N/OK6#P]V#+%9/Z$GQCC 2>,T) __559V09*+OI9FE^ = MK/1'3/AAPH\M1#-RE$RFU''<+'?L)IB!ML>MD-"$-N:]Q<; B"=WCITZ/YZ8 MA@.0RL,6]?)-N<:\9*4!JC(#PS8HA@V.J=>;,P!0>;9,C*>/,L88V="J>&: M3#TKN;?/K=*!V;(T4]\4;V8T[SE/E!@23FX8H8Y*:#*-47() \9MJ5GP7X1' M5')S]/8[/0DD;7<9Q!A8LN5\U#E&B9Z%^IZP+H A)81KHQB@K&JTW=PR;"S' MCR<-I*! ,YF%N."6WVQR__N'BK*G-1XUX!!I4[NZ2RV%A.-DRL:ZY M\ZJE8U:3N0S60./=\C5\60?(%2-D!B1'<8#AZS"9P<'-2,8J7G(N*FKUN*XE M+RXZTSJA3,_I9%?)"[GD KH;I;Y_NIGZPY=/3F7,#20-LKB&2T#<< V7[AX: M&Y02(3-DG.SV9#:T:BX^ M$7YE?ZNZ#/ K+[^NR\S")X@\F0,J6^--//ZQT-$S-[5??G,*L[LPNZ>$NYS) MW.W0YJ(&O3Z%KI8\3_V_SSFQEW$>J9V:@B'D*M3@X $.I%55E7HWW3SL]'NE M'LB$H4QWL,K]U%0,YJ3=HM3.6H=1>JG?D3CCTTQGLK*1FQQ*\5:NI,3#+HZ4 MSJL"66 OI%1F@@UB@E"F#DXS%>4;H-(6T9;9ZID>06@R5+;H9:8!1BLVXYR^ M(7+FA"<++J>9QK 61:4IE!=B4(L%=>R@5BG@U[MA/*.E87ELGA* M2F&X$"I&[6H5/JC3=-/*J(9B6X8#Y!.#7 MXHR&5T1ZQS/ 4KM5)Y;*9#]"$'P,"F$S[GA::HUH3]-8%I%6_T6IFTJK-"#Y M*C/.D8#<5)*E7F9- X[,V=3!Y&JM\J\ISP:&W:YD]""W $&--/2LTL?S!W$; M^FDO:VBJ\EY'[M)0K02^T< W MJ/0>#*(0Q'DXW'(^&590QSA$,@=,UKA@FLEH_6D9)<\82WDY)E['(E#E0*-P M&OK:L4_N<)J7HE9#O5I=P*^E]JT4KGA8;58#J&Z(.J'.%9&;]G0-9^:9E'/! MB@*=[CW.3P=RQ%7=4UB^'0EJ,_!-IJ=.,B\(+Q\51A%W[=MMK7;(TSJRY))U M+]KVDG4W#LN7F)LF%0IU&6:HFZ"CG !S31\ >LB.@:IH,1.>8M,MFL MRK9GI+5B6@DBU#OFVEBH.2H_UHI"6XQ(40-!O1/3@#$\WNM+9!O.[22R&1") MT9,)$(BVQM@Y89#%BNF 3&9HS@"CJ2C[1!^]7'Z6+&2>E="9IG12&NT-M6H<.6Y&M&6DBV"J"(04Q\NXISG.:XU24^^B9+J%4 M&W996]9+%I6Q7?1F>I.K=:Q'GE)54ZT4934S+:NI5I:UKF8R%JA-I._WX13.T%F\[\@_P/N]8GJBN@ M/ !)H4:+S;KN12_M62J3\MGG]*4A;F\-S5HA]N*1H$+2C8U2DS*C5E94D;MC&QC\2WM0J-7V"0G$S,0\']J T=VD':,66V M/+1MVB@(0@OH(Q;W3D+D0;_M$<"142DV^SX5&"%DH<1-@ -^8Q*I+*@#O5$J M9Y 3XP2A&.D8RWW,CN3NA-SMX5L1_\RU&+T1>:Q0 MM2$(R0%#1JG/90&(YIT9[S.8&MH_\5T@EAPNSS Q^,=#3@-=M:[ANE4&<;PE M9]',>U[*CWM>*(5YV+^@1T>Q@+%3Q+%%J!XRD=L"NZOA6L',"&.,!&?%^'(: M<(&QOL2'Z2D?Z(0TIVE5BY47WXLX@^*X?BIZ,F\OK.4K3<9Y4"PY:>5Z4D6# M=-MJ+XAFQBI;@GP4A&0M,QHD"W9%7RB@KK2G.!W<<6Q/)8GF\D/'YH8JEI=MAQ+2PH9[IIQ1HV6A2]%DV(SF %@:K]%] M$&!.MH.4W>U11\DY9:4RDA/CC"%M4$]>01K'AG"^"-B.Y%A" %&5[1Y=:9*M M^+'$]/FABSP'YM'L2$H-+[<75/UW3MJ'0\"$.7A)2[U'>+]NL&^5RHYQ,"-L M[OI:E6U)#$RDPS"*?WG;*D!B-4)*/TH:U:H+H?T'?78=RZ3,'6\4SN83I0"B[8X M*92WY/+#^S50/5?U*TSA'NB $?KKF.]3VT59A!M_CW5^-+Z(._*2=R/R*.#], MEEOKLHACKUF[N\-6 0GUC+0LV4F\OG:MS!H0NI=IY!PKEW#)N33XA71XY\:1 ML44F\::$K-0L/HV,*T(H,#3B$>W9F'LHBLSLQ$P-0HA7HN9 0O77\H M";NB'P\UP4FPYX$.O,E4*)TDJ-QO%N(Z]FB1^.HQ00Q;]\QZ'5G1O1Z890+[ MCFI@86/OYPOABZNU#-2Z5%=+RPLD3UV &L[F4IOD(O]7^5GF$M,P7HL4O,G.7 **EZPN2X1%5,[5,J$!4*D$N 0&T;+ M%DJ^[E'H=*+P#AM+D6TJP"8744Y_*2AS&0Y[.2DS$_-:_JNJUMA)^RJ *+LC M4=LQTF,T%\64T-8 M0(J%T;WD7P@5A4HLK\W+PAX*6ABJ0CX*V??>:"SWCI^ MV,($&S<,PIYP[1 0Z@-=!LJOU7)^4,JT9QE8IT9!U '-^)P*HET&.E@JHC6( M8BIYD@! 21\PQ9XGEW\T3LO50S#? H\C+:-IJ9IVIT$_0B!WJ<#*)I[*GXW] MYZC%59"8AJV.EZI2%>I#=Y^H:"PIRCK31*AL6=0[7-GNJYT27LG86R&]\;?4 M&=E*;;-;V^E*LS10$=FY8W:];&#T*14JU:)"9;85*M5EK5!92A*??1#9"OHT MR5UU)=U5142GB.@LCO)21'0>MR CKCI)D[4(5[DL"X[C%&L#>"1KYWMA;,JB MK,[CLN>P<2S;Z:P( \Q($<&Z<6RZB!##L5)YC$JO$N8-ED&/\T2UG9?=[&V_ M-2:Q4K6#/U#J4YR4C4=&@8P4BO\RT-]271;;G3T4U50^0"13 KWF'=#Y\08! M)18VZ%*<[E*3(D7DXY0:)Z-]V!O!.C3120Q),M7Y.1B0VQJ?FG'\:Q:&$%+A9M(6?7'EAR!JPHQ6W,X3FI,KI"U5D&XEDJ2C^74?<,Y@XHS5?M MUC&/I-Q"X 29&P[_F[JRP 9/"PC ME@?+;FFA98LIOP3F_0]?ZF6XQ5^G[G0RXMJ4+<0PMU8;$USU)Z1,=ZDC"5L" M#[=G#3A:%BP:3#<7V4 UX2J? 4>-!$^PD-&JYD8];33%AB]MTH ME!C_N6'&A#[RA28@NY]EP$\2 MR"\H]Q'77M#M49U_NZ'O8= =#W:J0RD\$,_@@?@@0<_7U] 5X9PKG(8)%?"% M'Z+P0RRH'Z)P-(_-A@W'L0)[^EB,7B? M.V@!0;,D8>[WN"3AIV2D'/W0Z))+&27 -J2Q$?R537"JFFPJBI[(B[[TA&L;"2S;]NY2S/2X*T@ M[D6>ZQ(1MY8&$=J58(FJVK3X.] J4"@H/3%V-/.)W1*\YP@^"K!DM%M+, 9Z MB$FSZ86)N$5$G[]3F'M;Y(?*(Y6H<=3]&H<$9%79%P'W10JX4\'A)>K!&@T' M+=Z3L-<#4KI)0O=[8?465N_B^QOC2COPN]DVYY,L2&XSZ$?:KTHEN,BBISN#0SR M1GY4,D"A!J?>Y*!G>6"J\R>ULO'HEZJ='W65+XR#I:#$I;HVS8AYF7$@?4&7 MS1/GLX). ?EX&Z*7WP>S-NZ'^+BKNCXGU =(#,5>J.5D'*O&6830TH^$M G( M022E:XS258$K?N<(?HY-Q82;^LJNUN8'/:CC"'!?L#^13R4;(C]8<3N6@>"6 MZG9<\%OF,3D_7_4]L3JD*)!@I"+M) =EC?Y$([TZ6SCON M)ZV!E<\K@;*='H\ZV'@^X5FSN9 R]QD,D=T?);]: WT7=3^6QZYC M<8.6@2B7Z@89D)E'18'RYRH#7@L=U;81I(OZA-RZ=$-&2@.9PJ&!Y@OJ7@:"62KJ/N9$A(HM3Z!HC_,>LGH'@P"UROL^#[#- M 3Y2HH^J[U']44]3-T3#RDD+DB0<2O6'E)^XRR(>C[M&RN[0F$M/O77#N1G4 M?J"X+0M/@$MU6[ ^5Z)S*"-=F[P1!^6(3%T56NAI.(XVQP;WOFUM2QU)FN8F MY%90ZS(0P%)1JTFC,.Q7!7&=\ [1,+JB/]RZ1C-\X:>)[B/#%8!=0:'+<.A+ M1:&GP"DI9:^D:ZBQVP3U34+U 6BT9+5ALOTH,OD 1#WHTV1Z8OQ7.D'O$)3( MPF_$N!<"Y1$LC%(@6%\D>D2#[SC(6N"1[>IQ5YG)F<_4=N5X(070=,,CU&U: M7-T9$<'?<6):/!>>SZ4@R*6Z/3IRK.@0"ZSQHB18%320X4"P-%GH% $ MH=8U O:TN(233R,J,BH>59!8E,NRSEJF(BY>B"5X0$HET^Z@Y'0Y\Y.N M- QZZ+''4F!@4] M+P6)+!4]-Y)[+.CH[/__G[UW[7'CRK)$OR>0_R'0 M=V9@ \QL/>R2W35W %FVJ]13MCR6JHW&Q<5%D#PDHQ6,8,4CT_2OOWOMQWD$ M@RFI6\IDIF(PZ+*89,1Y[+//?JX%);LJ>P UB+LQ=]VU](5$W&; 5Q)B5"E3G.7 M[[?:58SSID]D(C\;(K<=3V?K7HCKO3I;:9?P A9*Y,,JD,R*>WNW?:51*N[U MK?>*G(J_YBU2823GK=!4L^G$_;N& D0GDZ^)[:ZL]PY#BHNAQ<*W/'*$5R,) MN'<@HDPIA3N)9A9!,Z\4$T5X&Z^X(I=LC498GX(;QJ<'?/@";4[ MS5.L=S;ZBS9[7E7 M?J5JV\P_A]!R_[XT<7_CAOD\;362=L[C:+HT%&CI6ST M@^N\65[\K:[?XKOL0+"O8(5MF*]^^:?#;OCOBW;1MZV=A^=57N[;@E?F1[]Z M+VSU^#N_RN*=G]%W0G@Y?EWJ8[=^2-[P:S1(7=429<),D0,O6WY\;#/,J-;<9RT%P[;8T(T*D"S\S,F$4+&+^Y1O^ MY]QKSWN8+1G-!\584K,X,X3='SGM]W+F]_7*F^/6@\W$E]PF1[ER66PY*J3' MF+0;Z43!<^"NK0.$U81Z8;01G@ZO%"D-/M^5>:4'==KTFX:M'Q;5TN&A'H;[ MH\WE+^1?DMV#W3FZ_S.4J]/U2&J<3[:[RLO>]AHHF36[K#'ZE+\YY$HY_%(, M3V7MM&*OTQ5+VKW?NJ:&"RQV3W);S+0.6&,[/M;)P9ZVK1=2X\8F$CG$Y?ZB MY7(VKH.@J["%'_P:%Z5<1VH1@):[X[N$Y/S\S):CJV=9+LNZ760]@OS_XIY,P/HAA39KK%'?E ML]5<106Z,R8K,]HF!3$B&TH*EAI'K_]#BEA";@Z529.4/8AA32KI%'?ELU5) M"BL.^@<'\+4K%*1=%4W-_5R3&#V(84TZYQ1WY;/5.5&]G,_, =H.[YD%(C1I M4N(&S1'^,^ZRF23N(0QK4D^GN"N?K7HZK%FB!T=&D71^H?- 2"*48E1:R7(T M"6^+9$I2",P45:YTU=V@_"1?)QEU"0RR;6?IG M[:#T,-Q]%1J2^$I3VLZYD7]R9TF^7#)=51OW?Y P+>JVN_#$G:!RKL##4Y!P M=6BTOTR^V'"G(ZA*T06#+\NK]6:_S%Z. M4)TF'5HV\VCMI?''KZBGMI:&S"W3R?PVX\+?OMT K]] M4(?UX_?3OESYJRZH8)"]S2^0#?E.U#GC9#;2 ML A0_%B3"YP!.BOP3N:MD,[OF ?% WY<6"F@M6E';T&F@!I#, )9&#D MV7=/ON,P)%DL Y.J 4*'L\O$D4.$B-"8D=9*'7:2B#E]F/?0-4$C!=O4[#F52Q#/"4Z58Q*D9PJ M+?OSYMX9@RE\9.8?HXM/QYO@/+2 M,S+S)ESE!!G,C<_E9:7 M,+PI7J%ZKI-Y7Y0,KI/3;Q>,\/8>.T_;KO@MD+ #T=).>SN P&# <3L_\W\? M1?O$O9(BWY" UDVY9&RX1C2&.497=7GE6^E-<.T: $C+\%*;'=QJYV?QM78) M3!TZQ3GJ1X!LLVCZPM^&I%.*2M9)UD=02;U?XOF_Y-NT*5J.:P\P.)LRW_.B MZ5)D9=Y7B\WE^=D;X/RH5PB7K]S//(A0H(ZD!=$WEC5H:5:1NZ:!4L:^V=6M M(!4QV\W(COH@ZN1+G=J9_5&@OO2F9$SG:E/,"X4!79'H=:T2MGL+R,7*WI\S M%0"ZR3!)W"KMPCK>83_8L->0*N$O)&45E>2;$? M.9=$@WBTB EY!Y[\DJZ>&MM.<'?O]U@G"3J%7;F/RHQ34J3'$*S4;I-F']PN M89"MR4)KI"1@J._(1[='Z(\N-*"R*CH#[H;GM^N9VP29WKA 4T:Q+-I\>94+ M):X$WZ^<.H8T900!.3Z".&=&*Z,1"A]Z0%1TJJ$Z03F[WV.=).@4=N4>J=6^ M4A[CRBK16XTA!SC5 7KJHG&Y!F?1;.SH:PC'C?K"=;,F92A-?5,=UBE%.M^1 MEW[_4/Y[)JCSI@%5DX#PLQPEF6@NP[HA%2W9LO?-1=^0C/.&@J9C-(-B\?[S MLP9T-+WSD,6AG,I2!#&F_P#/?ZJ/NM,#&B#,L55&6]3V-G @XG'VU M9(D.)I]AF5_E16EGHN=0OL+&\&<@2N*,LA8!3A4.)Z#/7N'L,N\%SFV[J9ON M CM%!YP3/,FNZ0__[?'3R\=@^BQQ M7Z&X,Y:C0]F1QM%*.+K637TM*J1.>0WH2Z9EK*;39^@UO;J@59@C](S;MF]X MH)R"4HH->I4AH@?A1,AF"PI=X5FL1#(C466EVK=)P>I+2>XRYQ9TH$YN&<]. MVV(%XIP&$'&92J1("46D>98'1C8$W0A*:!+] (LBA4>RDC3K X)4D-(4I'+U MO]E!&L&$MVI6OQU8]^3ZLCA6M$^V?+A$Z,+#4,OB+13V/)H[7MQC9TKAKXQH MTM#[V^JRT1KRNLVL>"9COI1-72Z1&9#\L#X^JDG)&=P74KHHX MQ7R9/1^1,2W:6?H)^AKHLC>W4W:*!,"UP@GC?J<[&C^/AS@5A-SJ1<0Z:452 MI84;/F]4PI8 $1*?C\Z(PHKM+B^:(0'8=+FES65%\GE(YQ%1]I+B/)2DW[50R+@-&98C=*KZS=M[0@.E;T55@S(4]Y MIE]]5V_A.R]%\P>4=H:O.=*.;3T3=V+1EV#XP+4GL.KABM$NB]%[(Z!#A'MC MO(4BWX&\I(%3[)?W_$S6=S;@]'H77]91,KA0X7177L8]50=WU5WQU=1=\7&[ M*[Z:NBNF0YA:4R,5V!*!5$YAW%I+MVX.>]*05%U>SJW%5Y*JQ6X3.T(!W !>+X?456N\FN^U4[#;SU4(+*>KZT=; MQ@2S!:'R^J8 97&(<_F5=8*_1'] M$#TF8D@]F)7TSM##K;UXT#%,U[H&R9$6#J$&%LAXU2[/S[[O&PP*P:B9[2_N M.WY;'JLJ,I4KURE=-0?:X^'R,M"BRI+-B]I6#02^=3.3">:MZLI##7=^%A[' M]N^A'!\&U,>WL79"XVH--'D5"BI+?(F/GU]^Z=/1'Y%!C89J]$NO*W(1%NA MBF20SJM#D"IJ5%N[2@@GXY]H0'] 6,ELX!;>+YU(^ TWAP:/1'@X(AQ!#2A# M=,28/-5Z3[7>=YCBGI@!TP)(TLJD]_*5Z_8SA$9((!;[?]9\HV@>^L?"%6AL M O*$4VU>D>XHC%5PH ?M0AN[&0YN.PSC)E5)-YWU\'*$H22CHI*8D%TV1RH] M[GT"?=(LDV:YKYK%(JZ%$"/M^?U44OTPAC65^9WBKDRJR7NA5>2I MCQ7I:5OK)&$/8EB3.CK%79G44=LU3,D>HBNC<$=MO]N1-D+P;F: #ARK\S$9 M(T-2')>9-6>@5"9USKSC-#5:/)1A3=KM%'?EL]5NNWY>%@MR "W.5"U<4[TK M]Q,G$.0/-^NOJ7/BCH;-^<,(]<7R+B[)$Z-9AO8)'X>4VZ[,$334) S];E5T MA_FRO=7_Y"TJ?E"*Q0G'C4M3A>=GH5VQS>8YP**T@"Q^5E+UGJ1 M(HL)$'< M%2"HXF:*R^PU$D/1=(_,*JVNYP['\ )./#%:E!77SO<:1]62MB3M=>]$XIY* MLG5&Y&])%)?G9^NRGM->.-J9>ELL0D&: &$!ZU?AKUC.2;9\^OQHP=KMUCP, MB@>>/+G\BB=Z'W?Z=@HA:CKR*#R/TAYCB7;&?;LNEFY,.BZSOXCDA%K&J%I> MA&-97U==WY HD3*#\5[NL[[B$"A$3WMJFB!HO188I)AT7._*R>RW;B]5%E6N M.D1'1M]BR)ZY!_206M:.:X8I>.)DZC0'% SN4!3L*W MZ[I>RDM#XYEU-=!#%Z3*T!\N+0PH\R?U1I_LPT>+NB'7!0HS:1N;95\"J+JNUCY*3P^_1KM"*[%:&> >;3[=/3WR_] 9HWJ"BTZ< MY,UVDK="V2X\LCI-VL?C:]PZ;[2O@6Z?+@J@>Y'"!2,E62HT?#&BC\%\P+"B MT9HP:!KK"(S"^0&TTX7*1EIP!50S-S\ M]VQ7P]#C.FSZXUHDDXM=4*0;*G11PZ]M,*$&>*3P-Z[TYEIN5JC3?7B76O*G M&IE:"%'%&)#AM#6LD0PZ\_+U9:1WP$-A%3?XSO+!V: MJ&'$B3KR*+)FXHGB['L MC2BP/;@EUE/WJ,&X ^]+YS0N:Y4LF4[A2^/KB.R4@BT9'/FK ,#0E::/@3CF_7#<, MGNX%*&5I+RX <]+O2FN]/]RH\S/;J>P]-FJF=^Z53%XR!*QZ!979UH:S J;R M8^W-T,MT4VTZ5ZD.-]J(R_.SEY5@ NA. 9Z]#YFL4F\>F2^CP]![RRP);F/\D618V'2LXAZJ8-8-*Y[^LV M;>[71XY<6$VS?O';BB.2J";C?M&\;&N>9.C_.S\KZVM3$/AXD>)Z\( ME(<0C=D!/;ALL9+K%C6?N559G1^X[W@Q2*5@D6?1J,&F_V%)< M*"TUTZUX@MTN7T_=+A^WV^7KJ=ME.H0^5/,&>3-M6]0D/?<'2-=X]N+5O[W\ M_N+QMQEZ-1VN:<30]ESWP2GDL'*.J&(J,*0(7G=-3V('KT7_32XS9>-- M'J3NG20%O!^A[^"2HWZW*PL 9(0I^&5"T+'"W]C#4O0/C"F$F[%@TH&>HX\' MW5)?^+'/V#$B41$RF%S)]+BK1X!2@E6J=JZ4$HBISQY1U:-_0[IOQ&$L:8O@ MO$@JA%SHLJBXA:;C'T43R:6W._-\ ;GZ#-$)^E*CC14=BK<54+4"4@!<2487 M,= 2>$D?LFZIKY&$W01.0N*R]*IPH*,E70KL2@PYT&[Z#B%<%H&V;YE=@X74 MYJC0*=+SQH'<:FD,G#Y$"YS-&FN6!-CRGG:K*03R"\]WY>J"!EJW\G.@U:23 M-SD\G/OEG2C68";=&W/B5_+/S\]^#;'4-URJ_(N4*D]=JG?2R2R<6I8CIOVX M@%SO(\F'TMAJ?$HSPKNZLN.2_K @.*:>NBZ35M M"*GAEB+GV>:G1FJ\@.A9E;YJ^4XRY[B01R;C469H,\B_Z[@Z2#?F,GL>=7Y9 M484=W.BQ'A S+Z_S?9L@PTT8E*=V>-]LT)4OB*L=,*,Z:1!J&1EL:*PR4AS_ M(0=.E/,'@ 7!,4;!%E6RVA$M,F%\T\=Q L2MD'/%%45!;[AJG:\%P8"3NCB7 MK8HZ *IR=LEP5E&B5+4U\.Z\S]?VTD7M!?7%3Z]>Q]5L\/;+O3W=&M*7-3X_ M/R.5P_:V'DSO+S4UW+IXB+W?N&^*-CWXPNE'Z/3KTK2+\ M<=^[YB.610-70IK:RZ"GD&3DZC*#T6VCR?ND0%7[7_0*F5 (CYT6I4F]QRI= MB&REW?VMHX$$!65?DY60A)^A&GK=&D]2-#M6KS=/3J,\?Y+]4GI%+YZ-XX63#*=?,C&>+#U2COIPL[@Z(4+O&@V 65'? MKA>'=-+'IZ:/84SAK'(F2@T)MIW8TS2B2QPET:M2 1D'"@X2E**RBL:;%1N6 MT1!EL9)1>,&+!0/*((Q4X4Q(,"HGAYJ.18AN"+R(:C$8'25'ZK2XY-573>XTN3J&G&^L8"I!N0!Z=\ZUWS!H=H8$(SZSV6(YT$!LD3T?^., 1K MS"]/J'2"+Q.@+J56$_4D?S@?>_9?+2*_40(% ^)P[ZB%F&0I%9]NR4)><%4X MCHY7&R;A]+*]SUJ=G_FRB:X^K-:HEL $\+2JKR3:&#=F&;1WJ.]MG7\:+(1Z138&61 -\+P];Q!W02@!WB4M MP+KNBMPW>FL%" <%:"T;+1]-J('()JC+*WI)9#60'6(5M\I*E:P-9)]7+PJM M1@UIS+Y1=\[*%4>6;( ;+G%K(;OR='Z([^@NI0;-&DEW%]>'QMY!TA?',1X) MGB"PLBAVDC:-V@-'EB3TZYG-0Z(C&_0^*\I9Z0&"N-9VWIGM_X!T^B=7#C\* M@00;XY%>MT*8,:T^H.'"61]3%(-Z!0-U+5"F[!:]Q[ -F?JVM&H/4]I&,Y&\CG0<:;ADI%M+>F4 1*U$O M@0VWCOS);+ISS9C >]\@.I$^T"I(WYP>)749C[@E90DEB-X5CE/RI:IE%*G, MM3Y7$KJVO+460W/?S#SX3K:3X^#3^I,H;[W,8*1(LJOE"4: R9K-T492(5"6 M$A0V=<0D"$%.1>SN.+X8Z.]P,@20G$^$T1M)K$:2+X@6-QJY[+6T#\IYQ^$#&RR* DJ_IB8/Y"(/2&.6&[*II07B"^8_#ZH^W M-K5R:)5CP[CX44,;N7(&2Q(ALT]7[0E%VB, 8%&35=!?A$PQY(P7+(=UXK MIYJY!S-U-YR$+=@!=GFSV&C5=T3ZV-1K$+&+>5/,7<-@4?0OLH#IL]0#*!)ALG%.1F]*Q5VOD;%0U#\J* Q M+T0>LE]0Z\6%#,^Y]T:*U7Y\\S[.MG3Y]=//[VV3-M\$F^UM2;8BZ=W?3_?V+Q^UL0/WW GQY= M/'GTZ-&,-;)%IV;)"Y]#?%\$D:9?1AU3?__?V71'8K4'*^CAU8 F3&6D)Q7JSG-M;@Z58VT0?I0 MJ7[4%J5A]?Q!8Q'*^G8P#JJ.+0BM'%@+T>J@68OC!@VBL@* M=&&H,?(GHM_2T_:'TZHM/_A$#;#X&FBBU6:_=6Z'"$?/9NF\KM]JYHVVB@ZQ MQ4<*:?%4#+320I5?-Z#+\D1+)?MZSZ$L()818+JNQC0 .N[86FJ5T4M M(#)T^\[;MT5JCAYI4>U MT0M!D7IH6UHM-HZ!Z$2D%EQQ'6=!>8X'NL&4*I#!F MHUM*.Y2:B_8(MSQ^20\.+1$W5XP>QW,8R>9-'N()PO(\FVKP/FX-WK.I!F\Z MA,?2&R])RMBQ18O5+^RY=?LI:'(B59#J_:)XI(H03=B$\[NVTUW+&L :QOE? MMISKSBI;\$6@!?.?4J!^NV^GF-FIQ,P@#<;=+?LO@*([042U)H:9N$RM$D/# MU%2?RY%/MTQ:J K#L-=FKSA^'GIMR9S4V(OD":+\N_"*&E02%HJBX MGDD(3.>A@_?8:8L-O$?[%_2"TG..1S2DVS15;]P6)>9 M.!_-HM]B1.H;VFP4 'Y)#\G751U2_(D:Q-)1!*'6JIXQ&05JKN2$(+.;18G MU8*,P[.,8UCJ2@>QP ')\J;N?;=CI%Q-:GRPJR7OJ\P;\U*NZ^9M^*/OE\8R M0"+4)VH7I(_9F4I><$G63H4HZLR_4M:GBRNE@M5S?&--UXB)GJKM\!? MD-;Y0WTCF6J5*BVJ0ID3A*UDTC+E:?&@=C.M?]=J=8ERN-\E/J&0_MIX[[M" M)?(+:-XDI.%+V[U"'QQM)I AQ;44[K2!6E1L W^NY=!X_2,8^3*B 3+0J'Y@ M-3J"UF?)R'WFP: 5! A( Q+#V$ IXM4'+\GMKKD0HK-+KW$6BG,E2T2, 9[ MPPALP@\:EHU60# (H9#IB30#4MULO0NZI#3,RY7@,29V#9P4 ?AAM\R MN$"!MH90_S!"_\Y'29GUVZXG+W:UON&YSW8Q? M9ZW5#X\3=?V7C99B380W+3_)EN< M;*\NL:>-V\,'F4D[KA@6H>#F_20#H7_W<"8>H"8V=8((SN(3_R[O[49W$/KA MO< X+[._DD*^LB[H$47+^;Z&*X?G3(12 .^!JY55>89U,]-+;19<"7%7^+7E M;5BGA QSU/0Q6$T>.P'3RT)QQX-V_[3J?!?^@&+\KN%O;A'9)3;HN7:0#HM MF@O"2#_T%$6(-4F@@#.UT&]TEDN&+T;:^F294N^ */8^C?4SVZI[=(JY7DC) M9-,+/+ZNM6P"E35U53>&PZS8S$C0NV4:ASJR_?>>1':Z&*>+\1V#9?=PX6-K.AXYI2.WNB^<]8Q4ZWX;W9JGMT= VQ M4$;(IS9OBC;J!;7^W]"(%J .!+U/O%D:6[V5+J#&'-*(KQT^/NI9&45@)F%# M)D<\"*5B(#T@2"P5ICRD7&0-G[Z)<'Q'8PM_IN]^QN(W:8I[LU7W2%/TE:_# MUKL^"G6I$PSVE8M-?7T0E?2E(;&;S%?^N)Y3X '>/1-G[AB)S0?,_H,JUP#!+@Q/#N:@?G493AI!/Y65NVNTPRW M,LF_5WIA+U$WL]L;;AAJ.BQ7-2H, B>,4+HSO.!W2DZ*#]]%>.;&>0IV+>W4 M6N080V^ OL PY<0:EQ@MZ;9?BP\1I?[>-0!F>F!: .XJ$8BR. 7H\\'"<"'> MB8=2TT3W"&B&YCY0;93S%P+!;%STH6N4E#&MWF,A#U*W,^V7B']HV=_*6;1P M73-"62[?Z1@0@E+5?HQV]XMR+]A@$D#8F M&.F%V3YO_+BTJ./=V_+;QE7",F#/S_4-^X/G,V= ]/QW/-S76W527IA7>;D7 M@*HBQ1+_9Y2)R9&-+&/5#G&END)<77(?.FNF:&/5H[&G, MP[7P5!069_*H_RA[$G((/U/IPT*:2="TNYBH;29 .*1.,F;/7KJ%YNIRSO30 M#4Q*O^T^Z+C,83ZOI5*NCPE3\+M'K61SALI(F0<3C3N MT2P7F\*A^3HJ\U:L-*;V"QUU&'MLW-5[1>&0NB<8DZ&,HZ@6TIW*$]PA LU& M(&L-X1+1FMJ#1:"]E><,MFSEM)[,=ZG*WV4@>P3-7+Z52C*&R;. F0=/Y$'! M,&\5_)]+I0TVUZIJ18L(;D#+/+NP]\RDUK?,'1V ELD-4(I6EI>95F$SM\6P MAF-07W>]J5DZYJ[$XA\8>>_T&=D@PMYSX*\.=M#17_*R],R5)VQXTNL,*E5L M-@<0="8GJ2#NA#C@UI362]$66N4(!(L>T9U409'49)'0%.U09N)FAQAD>ZCW M^F#&SR,D22FYXNZ/\S/MLPY4?NW0UC6'(%1;L H1N _@5DHWM!39F@&MV%M; MON+#EX1/9NBXY8 $X?+-HO4%RJ:62Y7QRGR*Y_''RR+>31OZ(R8!1D_P^I\7?Z6-\DERY MDQ&3V4,60VRSF#WB"S4%KR/P39CFX7]YS.2@I\8S*3A_MROBHTMHHGA;6W:' M[].E/XEEOT^Z9%(>[ZL\?*.49,$C4X4+[M&\YX/2==\M *$V:8?3>-^D'4[R M;#T@[2#.O?;'<*"E4O!:R_0,# =I@ERZE:N6.6/][T,W-O_-ZG5\N;MO76+D MHP%&E0PC#UWS"'^4MJ\P[$?=#5+GI*' MBJB(CJ(T!.-) 9[&^R8%>)+JXT$I0#-^#)MBH-P2,/XHH 4-V?D?%4G0*JI# M-I!*"PF-)/%Y&&E@=-(_I_&^2?^.N8&9"+JFJ'%,G&3$=PX?R4!!AYU$D[V&JA(!3FC G M\*,Y"V,32'[Z9]AHDRH[B?=-JNPD%<']5V4*7ZMV3#]G+.Z])+"@9%"AJ7 5 M(\I+J%VM(R0TA-Q"+?>4S'W'SCXOVQHT/Y(KM92"9C(C?*=NP^48=2_V\W7= M (0MIEN(\;@5L018'?N+^?Y"_Y,FU!8)5KUGI:2+9DMW"U=6*. M 'CC]QK6&( 6A4H'+8!! ;O2$!L0B#TRX$_#9O?8^NP ; M!M#IBXH\6/+OJ M/VKR+O!4?GZQW?95804.?)<*OM1E]L)PIAD&RY/+/1?XN(BVI6/#IQ0![F0"U MRC>B]P*U1WBW\);HU$FAM'? O=^M=,A@:>!QB7]=7U<)W+OIH;KI5G59U(9Z M&<\8]6?T3.45.#^3@P7,)>L3M M,K38;UC$E(.,:V3P[6.HG[@5\92E)TJ>!;YUX#M&.5_%8XM#M%S:%SH: M@\ MO0-09,GF>(!_WB51/,E4N0^ /_?J,1XV^#&NA._<+UJ::4HHX@>%.J&XA]0[ M#:YTRG#B$1:DT-^0/PTLWYL7Q[5>D(P'?NH_"]7&Y;"XC->U==Z(>[P2WAC) M1%AS$!.9U*2[Y(X#9E:!JL_,:"7;(1%!UY<4&ETOB= M(U+2OIN_LU)W=992B'F@ZA:EV'U;[L_/X <+?*!>LCE#G6O*M(>;LP#[S_+F MT2F[-^)Y'.>[CDK"1PAZ_(W,URC_6(9RG&1FYDF9/@RN?Y!J33.LPJ*DMHI7 MXZAAQW34.JD<-NHJIL()RS-"RC-IC MDH# ]@]P :Y:XYQ'O+@Q]6ALN"D0/LP$QIAV%3?XD7KO(_/%(.1 H^A&&E[P%X?H,"+1-V/G-R(P MJ>KJ(GSK_"SN&35\BG;0N#KS[GZ"5Q+5YT0S]#@2^4+^K5LK>H3DW,GMMJ;-5V%5 MU>=RR\,I6\P3]+]1P:1(4;?A8&6E9K8MH7<,[L3:_BQ4[RU:'*])01FE3R!2 MC3'\+!4K!22.H3FWE>'6&Y%0A/I/OES>+"T;%YU8GS*,":-O!+ A+Y&9?\IZ M'X/>1'+L68"UKWUXBR":C)](6[CZUZS$BTTM5$-I,RHB"'W1T27 IP/3X R< M',9HFO[-G!'(J]2@R<%_HV0FM*JTNYHQ%*)S 6_Q"SY+PO*<'%\QD5-->Q/M M MH\>ZYU+D$[@R[O8AEBWT?5,DB8?;B=*47F>ZF5M@;<]EAD8Y.WIL$0M9@[ M%V:ZY%MK\KI/MJ=6[.^_)*EJ.IY]H*[&\=QQZF@1LL-,T-P)(H=YV&%BYY40]TR= 10%R$VS,BMLN-)8X*@ M2906MF;EE&.1.]V%9D1_>"%"9QQ*9,H<9B*X/.4E/3;4A)#)[#5C5NJ$?NGR_ R-_CS%EPG#_!M&JGQ!:T5?E(1O*VGJ MQBT4=8[S*I:ZR1<1[2&O):M3-+,X)J7OJU5^53=F!\I('.TLLCIL\"*[RJTX M;!\6# S7 _'.:&<,:D&\(I(<>A6VB9/_%0F(3D\V3RF\FF2SL#<1N KF(%<( MV[A]ODS*^0 MJ WQE2IR[EHML0#Y*2=Z1+M>J14.$[N'SFSW;>>VEH&&K[V?N^:"%"I=8JWZ M[D*?NM R&39H^5L"&=7M)W+F4^"8>ZV[@8#3@J&56\VH_>XWGF^A%O\5EQB,:P)Z>GQG#,\=_@-;#AI.9T/Y1 M6W('Y1!8NK:I%-HU.BOJJ;[G0LTXZ7W5EU"D9!8(XBS[=>*7^J=?%4W/?O V M+Z]S,":3H=(#06A9M#GX["3LUM1-T6[)X\P;_+M$BAREIHL0&\2'N*#IMT<. M-E>[R"AL8YL0M1?LCK53=K5' 2>.P M+E 2&)@U)D).D.F*9=SGCQ26,YURX$.C;W "]/@&B MKU.<^I0#D>MM>R8D7W!(2A="*C.B%)@/QVKN(AEDXTC6HCI*T51<0CO@ED_6 ME/R")9=>M%9D,4=K:YGOL>F_H41GX22,%:4[?#%6W-3/7)%,.2EN'OLV&S+4 MZ0?_Z.G66A4DOGXGY!Q7CE5Q3IY2B\P$U^* J)2>I?Y8Z\*/)/@\&>NW:Q". M9VI-A$*60&1UYO^BCFVL%NU/Y+"2X+0QO>P*F?S(,00O?.(:JU^7,C&_!]NR MO,17,]U6D.I!"-,G-R]39X,VMD922_.)ON@_R!CC'HZ(V ?(D<"/HG2P\D@F M6\^2"]Q$B#L2 U9"W.8E*_4MHB?<@X TK8"(HE[-F$@DD1LSC_,UNO"Q(%* MJ.C-,[H'UJZ+S,_??"">N= Q89AUA5Z[_N%VR?Y'+X0G2]*';+WDW+W0VS)< M(_/<5TA:6 L/.BY+$ MIBB5?R7^ ,+9,/1W;@%I23AN:PR1K,N\:)0R;5?F"Q>_-5,T):TBEN+E Z1P MMG0-P#MN[JEJ;$VBKH482ES?530D;I1 #I-1?NWU>JHGR;\MJ_#]:W&?/)IJ M<3]J+>Z31U,M[G0(O6OV1HP#KM4Y8$L(]G,&*J>^")OP!6\NK 2._63!_1F3 M*[:DI;G/BUC@8T:HT8N6>#O63\XZ6WDG8+@4Z%@F-U44CV&^CZCM/BT(2DU1^B\\!K* JC7@9,RRLJ;; M,?;[8BN.]$@('9$+QVUZLD#F9('4(+QS&"'FJA!58,+2PK4"\N^#'M6^H__\ MP\6[DC+NL7:;[VE!!JMJ2:T0L;XD X;;\[*56S+W LN_1O(Q>? =']2V<,6' MG$&E.RSEIAX+-[3YRB&N6^:@NX"SUY),D%C/N'&^669OG=N)%\CP"H/C&43N MC9CE1@<4"Q7$OR$?'B=&"E?&)B*N?C*31L %+G",^ZT%14)IM ;D:!LU^!T# M,$3UXXE'+9%=?5!%KZ4M5QL<& ,?V19X2'8-AX@-U&GIH&DX ML/DV'4_6A14:4+XB9%S6U?H"+2:(&0LX!1M^G)=-7B@OXH[M MBA/I(?#)E41C&AG.I/;O/,:9=!0 0R=*V =!+%U^Q>F<6>AJ,M"' M^+ I&E0.FO?*@(9JB;H'Q>X!'/017-(P/'-!7#AE\3O<#=A=;%JL' =CR39C M@#DA_O.M4K-!M6K M%J@,S#D$DB MRU6*&3L"7([J&1N(30:3M1-_C52LN"M,F1TI.IBH*&+3ZR9$8L)5,.FP4[$I MV%4SPT*=R4W.3KI>B;2O!2=O32,DM_.O_R/?[O[\_8SSQ.W010NW%I*\'%G@ MX(OP#[+-PAG$3<$X-MX93BSJQ&I=-_4UH@M92_YUIPW1H2B,NSM=O2O5Y],: M&E@8'@LM8$/Y&Y>^MO6I3.-/U\HDDG2MQXL,'JL.L^"!EI(EF="H'I03Z=K@ M/"-+@"NE )A_X*06<3^%6#CF>D=^*=\'9=Y79!9%Z5F:_8KAJA4E-$*.J=[1 M R#^L%?ZJN6G@WI7Q4;!"T3T@RQ]$Y (Y2D6L/9P-^489L!![!Q]QS'DTU3[ M;MD*SPD 00(MI7Z,2WSUX:GG_-VF?]# M4W7'K\_!#^TJ;>6YC# )K-#S,_GG[&B.E[V0O7>9HH!RJ',=9R1;OW QFD?.E]4J^L?Y[9")<.G[3#T0C"3I,O=4[ >7"_ MB]7+R9,HBK%UKDN/;5@.?VYY4@9;VVYHM@9I(G$.;G:* ]L'X $+(]D09\3: M6G*/9ZND&3Z2* XH,I6UE2]8_54L(S-I&/-MM%ZSL4#2[0;)>O+HS^17H*8$ MG_(GC_\L<9480-$Z!9-8"5>0H [%]Q%&@1P 6L2AIU@1-X8[%OU=8R0,E1?G MA29U>*NU?W(RSL\4 /G5FQ=ZQCD#J!%M-\M:]',LBX6(_JICVH=B *&Y=*0S MVS:J*M+8]PBBLH96W@)Z)30#,O!^D%H[6N+.(F3N,E.A9.*3H$4.'A$+:I!(B?62@D= MF@;[AT"2H08H6Y4],,A\6['="RRDK35/;!&T5JZ'FN!W]C+[7JH-\8"O MGUQ<._?V_$RK1QT=AF7VO5LXSG@\?3R#%?ADQC^&&P ;BCND&H?LM SUZ3._ M+LM\[Q%-8VZ04'$(RHV6/]=X8!)(TFWN9>3(EV;+]%4T^U12>@L=4M M)>OP HU..%-=\+R024?U/]%O:^9_=5;[,@6XU M"UFSO)!F3WF=@3$\+''@VR/?RHG4ZHB.M9I?0 ;QM;Y2JT*7%8WN&6N4C-95 M.B&[>BT=4N!#OFB\?__/1+#^(:OJ^> M)3?SBK!#A8'S;*8P$^3)F-X-C=?U*BZ^ERN>(5]7OIZSJZ6")KQ+#$[Z!K@Z M&3$O04L%= ]#]C1^CV?^4D7!_*9N8<+Z$Z0XA"']QU"I=1FI7DY;HZ\A?$F0 M7JVP[HY*<>ZO$O[44P'.>V['.M(2OI*7ZS.4M"?R=+4#]5 '_^KH,R7PY-K\ MUTX[!9Y]<_GTV3<>T(?_^>U3=83X-M@4\Z+S2J&!0')OK$=K'("(^8HN+?@RGB<[L=46ROBEVL 610Q&\WKXJ MS/I$B\.5P!:::8A1D\QI?A(# &$I[=*NZ7#HQ)8(-L MB8=";H-W#S0",OB>ZD!IM39Q@U21,BP+!4((6_ @SO%#4DG5/K(-[7;Y,"-' MJTGWAG<:[!9#>I7#%6P6OO/8:0-8!V"TV/'*]2Z[X;Z3.U.0<_FX[>#T*%/P MT:#,PG'Y!"R4;=%O^9L2HQES:,[/0NQ'65>@EZ-F-/%Z \-%\*!PM! R-G*. M?#\:!7T@5;+B:=AQN*2MRD1KN MK!R/V$%MS-V^UHR-*K^9)IGR]E\^]KI^^IT/!3QQP#9Y'4\QRM^_DG M+EN)JGO>_P4C=4#_9$4PH?;G@P?\*5H4OOW3LV_#NG?+_\HP/[%VX* %!H=$ M:Z^ 4DS ,,";LN+F&'<*@8G ;FT%CG2,DLES9=2);/LG/%XGO1OE[B"\.A7WJNT],E46OIQ2TN? MW-?2TN/"-5D9DY41!JNA!+.T17NI& :659X5-D%5#I^2Z;MZV2NUB MN"A1OXWF=N.ZN@,FML_DTIM,D5/TEIA]0?&O683QGO0 M/Y.-G8[;*>[*/3IN<3&9/W 1..^86 JHO)7D<:8]JY:RK<9\"PJF*[R+[_C]4?DAOO\!5AMO3H.RC^S9-I_!*GORB'.2!)I$_ M%4T4TB_:VR25%X 45"33!"?PB,[R@=\I_3@%!N^5_,=91_6#CN44N>XOE '" MX?'5&?Q]A=A!EUDI8$Z3Y75J^SU97B>Y+=H"(0-D+/D )231=^XDAK^3,U!\ MM2H+8"*'!F3M?.;/L[GKKD%V^VO?MD7.0<2_OV4$NXCJ-9A7:U?O:L"Y U.( MR3VGDWMJ(C*=W)/1L0( EZOO.=Q/1P7 M2]HQ;H?G&YTR] -_E'UKA(>;]:-0/,<(S'"K[9[&_[$NZSF..[VMWFH"$)7$ M\@'=XCQ(UQA[-0E,TI[LH]4C;*!IZ<*P],'>L7N<.%/5/K:K<)U>9X7>WEY['C'^TX^^$QH%9RO"J9#8,S, =):!WIING[P22 M>5[4 ^AA9<4LBQ6]?U$(@H_US_" E#TG10)_SP=G-SU7 1:6M1/$!D%]\%UM MH\@/UG_FR:P 9""=Q,' 4'BIE]*"MLM;\@FBY.2BS &#*]29,/#7.?\G5ER& M-"P/"BX;6K/1V) MY5J#(=R33*O)4"%A"A/&T:WV'WWGN%6(MN-(SY'VZ^@.:A="OO!?2B;QRE@IAZF>[\4CK$/+(-NP%JK0 & OUBK4H? M<#7K-K[31!Y(^@1-*<(U0RBJ+ ]'D '#9Y5?HB\%O!\(*6= M1P_T#K5.'*VM(^>*+%'2E8>GUH(V^=?8\O8D "<0>0S8U1?OV B ;9WY^-N?%DM401C]MF;45P>[DI5%J M9]=-($9FZ+\#23>_ MB(T*] EO"Q$@Z;WUTPE52+1!?2&YGQ"VMW[?,!D9L<#])7_P=Z^^EF1VW3@I M%38D!OWN@8"%M3-Q6M G]9;;D+D1NBZ7Z8#-IL@7'&E0*>/HR#Q^.(X.'<>. M&;009>$!*8Z,!P>+B0#2E2_%[+(9A"&03040A\$JMA@H&#,".!3&>E74 K/H MP5;BWS4]\%DC+ F &E:.?Y+?5(CW=&D=< M&5!?2;W[',B*HYL=V()B=$0^;<,>_ @6\;C502=*K"#S"?@MQM,9\:"&D;&4 MQB,S&.6B592. -,WJD4_V+RAX9A]DSVGPZXA!SFNY(IL:G1YX_[B_O_&,AR# M$0@!F+@LH+A9 *^#!EKN9^GB&;]<7E[G^W9(GO ^RTIG;4[+!JTGQ?#R&[XB\\ M2Q=8>Q0D7] U<9,D3,ZD;HVQ*\8,9;P_A9\#10[PV2=W^!0,&U Q\1VGMV*T ML1;+5)\@26IJWC"YI5. ML1K8X/EF,"P0^B%Y?SL!\.3?2[U#X^_??I5%' ] M(E\2PY50(M>+P^,T5A!@;_%_5KW2N/^C)U/$-1XG-DZC1$./))Y\5GE6WU1% MN^'G]4M>$WL$#+O85L'"1I''R^S'@%L_9)V(;+B#DX/0)D//:O24;)$K1AUK M%'H2:TD3X_Y.B_M:2#=4=1D@HX9:%:LQ10,7PCQXETVA3[5*%.Y,(\]XE#1/ M/9TKW,,)D:;G-L@B,#WG?;6H%7.\Y4'=5U'U+FJFO^,M+H[T- M6FFFB9PHBL:28(W@D=20BB61:CE I6@F:Q$ 3#X(^N=(N2S-':S][0>$5]% MDLT)U*?!XWM7-P$"P!4;VQ(8 PH[N$M=LRA:5L'PV=../H;@JP1/5,DHE5ZE MR0L&]&0&8,Y8;HI&T?R$FQK_\/R_,]V3M*J6U+L])FR.O2$Y7UB(5:\9_- ! M/(LNL !AWS*57X.H1:'\-?-'JQ(HQ:,R!SI*O',2*$6X(*(P&9<"E66I M0XPF^=G$GCI/8J?KI?;_5^_=Y;6R32OY,B M8@)3,\AFL.@JQ,7*1#.JE1V@8['+PN=PS?P+4<5$ SVQU2U1VJ&[7V4DDF! M(KSU0[#09?K-?)I'4A0H&U_YSY^1*>_ M^>KRJT?_W<[$"!QU, OH'D'&3(P;;NP?@)-R(HICV([+:WA0!E_/9^LZX24P MEX>CTS ONL1T(3^SE,@:DT0P)G"I%H:.=P3VW]PIFLI"03/Y/=,RUZ0TI6XBJ]40HU9A* LFTY7>ZRY:0_'BP]2 M-HO("/ 8\8Q1#W-$DYWZAZ$YE[SMB^N-<&[,]YQSEH=WS*JA26VSJ+'&7R;_ M,J(3?9]FE ?8U68\B>+ZO/3L^SN$]Q>C_>-;3[]Q78BD_7R+%.KXC(=ID;<; M% \"PG\9[/L:WJ83AVZ*39Q,; +;R3=+Y:!]23^67!R$&R4OEH/=%//@VF5' M)>"]=Q\AXH8S4C, C9.WNV%=K+6Y>V8UJR*'S^"X4@Y$+JOAVE,A[0'SG+B2 M-@@F!-@ZX0D:N<-1TL4!8(=R8"CRQDG0ECU@4\$@JBN0YY_#-_4SO,Q^B%A< M1QZ/&P>54_B]+*YDN.GNC9:52=[(,4?5DGBB6N:(Z#=GV+X^BDTF!+G9I5=;7L^362;(! AS?[,H>)F3J(ON5T"YD'8JR&9AK MSU<>FSQD:!7+(@?((8_/=T3YUHF9W$RYX,?$%151,.7\S%CBU PE07%7\+B. MTT--VN76;H=#3GCLR:L@>G2"7[9-[LI)[=_%M:TIL#@S*$69R-%9\_',MPC. MLHW+2_ *<9#0.I^CQD%Q,*P-$?X<*@L/NRZ]AW"-(G*6AUN^_O_,=7OKA@:[ M1%U(W?P+AM2Y>RH@8R;JK1P4#T(3>N&2UJ)(3&\443)>WB&CZCG&4CML@+G.$?AHBAKMOE8%7OSAG4Q: M95IU7%[BG"[V"1$NO_O\K,SG9(" 3K;E O"^BFG(C>8TZA6,D[R5)S=/,KPQ M03CM3H_KCU-(<'EU0>4XJ:6%+HW&K>VBGZEAH-SM'#WXO3.7N(7)IUG@;C"Z MV<$J(1B#W<:BX-QK_7#&M59MJ)CFA+J4QB=C 5WL1=P!;;SNI;1P#9LT)$:$ M*OJR'+,8HME+)0,;.R&!Y0-<<)UMZ9C<,5]@47WG=+B?RGJ1=[$$#XH?V<2P M? [;77,72,9\],&7UH](K%AU,8R$;QWE66. \FY41,*<1;%[Q;61DRUS@@6/ M7TT%CQ^WX/&KJ>!Q.H3>;OW%J]#S,X]=<9,]JLJ3<]K;G5NZX3UJ%R8>PC'? MU".U>V2*3IU =(I+H21G93:##^IW+A>ZT'?=VJ.NS;%;.$B0Y79:LOE@4C,- MI-@S+%W^WH_,E:0>+Q@6E]GKHEIH]@;26A;MQEBF$N)2?3>-XO&W7WU#PXP* M/TA6&?9%D6DT;EL"I:/AH9JI8-DQ9>*")24 M"BVC\VCY87(%T-6U(=L FH<#F B?HP@$T=#SL_'G!E6C@>L*67-DZ2/:],2- M(!?JJFAJ+C$6Z"E:0$2$^ZC[-4G!'_:&\=_EO84_(.PJXK=]4\T&QV T6'L\ MM+QNZNMN@V@ XX+083:=!N[M CW.KEJ3$E^*=JC1!+<8*C>IZOMKOLWYU-$S M2A*$MO/0>1U>U.\DD:U)3:'R_4O^1TX*M8&#+$]Q?\QA#F^2)Y&ZNO%1)5[46S_$K7C9Y5>1DPI-M[Z*+A;E\>!]?[TGG#&K4 M\"MH\9;9OFFW*HF:DE:%CQ I= M.;DLG6@/$#@1]DYI!=H"SOKOS',5MN,1P3B$"W?L"J?3 M2*(124A=<=N6&OCQ"I4 81M/)Z1'I;1 M8S01D9_:9>)Q*E"4+%J\;[C(UL,)27%+6;>M]:WBS+)Q)DE*#:3AWA!DL+QM MZX446;$.(*,<5>SA*R\0A0-Q,TJ^4+DDX;'5;4+X!5W(/YE6 FFCY8V75+P M\=!J!<"P.-F6] AN64DN\V^*3O[:]C#QBV@F$E[V530Z:#G0NLA "9>/40IL M1C G'O\S]IX\>W@-X1X_=GG+6K,_H&7 9?$6Y_U 48VJJ0"4Y+W0.U0'T]$? MG\N/4L ]\^7F O UYK1A0\VP"MA=+(6QP2EWO(]ES.O]HNY@)[U6!RDD1]A> M\LEP+T5Q(]S(&,0B&0[$$A ^M4[#XHXVT76!'?,1-2KE5S+ MO&KC,LIPX$B9T+-I/_$W6X@9(X])S<=,TPH*\!J,=VYNZ/*W@H(B%HH9'W$+ M70K-ZJ<2#V.Z;4_LR*50A8Q@X:69/OS#59)PK.BK5>9"CC6FPNQ%#&YL7*YYEN.U]LY3@DP25%<$-1OT- M*(HMRXM^UR:0Z&'N]&*&V-K13G;8Q\W;=DRU]F+RRI[N5I9BS"8DMZ_Z1NUG3G M_Q$YFKZ-0Y1.F1?B/1(.)TM!_8L6/54XV- D'8B#@ ;$<.]^@15;%4[9W'%7ABPR MC6?F??9V00?.4 !7/0ZT@;@AW.#]',;S:UL-PZDVDUD%&#[2A[I\FC,H $5+ MKD"QJ>LE;=SX[J;1:<.J&D''%.Q4RUL=Y!F"M\-0;.\;WF[#JQJ7Q(Y<+74^7"QZU<^'JJ7'A0A_7C5S.\Y+XVQ>L8!T >0_AA2Z'B M9 (GBCQ"MG9U1:#A@C 3!]5#*T(=8&=NN_KVPZES3FY&J1,;A]A1P?B!M ZKNR/P;AN-6D%L M-C9H!463B[=WV5&4)DLSAON=6BBC\FI0\/;XZ 2L!L-!'R9 7!M'J\3A 7XT MYZ_218(ETZ#I!D#TCOZOM/,/CXTB".LX!%;C*/#53Z2WX0&P#1D<:3+&BM8L M;HW5^=R!=/8B XCG"$ O9^4TA$8#*;!,7)VTJ-=5(7!8T>Y;,4FR+KH2/EB8 MK--E9J%-Q6_D!IMG[./FU M)AII3_Y^^?I2/BF&F*X<1,!#XR5<^5^M M/WA+!EWA79)@,SU5/-A0Q1RM#_DRB"7!L.E06H7LCRHKO[OD2FF;N$\I[_JF M[:60AMQ.[**<(IZO[3%'>MGQ&V*NI7=;I-.JNKK@9QR[XZ:[[6[M'8,/!*(2 M;6S<->$U""Q=I "TM\(T,RLL[.WW< @$KOLPL<;U!'F#F,Q4LGD2]@OGR@/ MI* T2OX&X05KH"G:L,-+WF$)\BI=@D3X0WI[1U=$WA3XKWRO$/KQCUMK3%9@ M+89N\&VP^DA1QS3QFK'ZW3)Z[.!QE]E?ZVO']WAL2PM@JHZ.?H)E,?7X>N/> MNK+-OOCYY>LOI:.E!8J7ATH7 M""^X4SHLOS7_'@E&33'NTYO+0%5OR0@00U+0 #GDZ9;C4( AJPI3!*&A7*!8 M[2R/=VIIDBCN^_,N#U<3XVI8H$[8:%BRP=CPX+Z*J7I'._0TI6U%8R%H&L\B MNE%\.-3GN#7LR?C_4:$&@P(P#@N+N^>6$"VD+S?$U^LJ6_>T-(I/$T$5:)KM M,ONWA-/+)5NBY95"&7K(*5JT^E;1+7YF2YE=J&))6$!!/,Z6(;U1'EWNIX;< M4YV/8H!;'BCBP-/*4!5N*^CJVP#)8-=4E)]:-ZBT%'Q-]0^0C&4P,8X2R$,% M0DERQ%9(@NSQ%FX$$F,@E=!GI71OQNB&1&BQ*J2R*BK3M"R_P XK%YSY?OI$ M<=YU>%(Z-[6.?_2;Y%8F^6;#W;;BA%$FKV1$;RF M"Z-[D6^SOW7+R^P+G!G.U!T28G$^U3,S<:)M)?@QC";Z^,_&;?;BAU_?/'_Y M\_G9KS_\[?F;EZ]^?OW7E[^\SI[__'W&G_SP??;FU^<_OW[^@O\XX[]\__+7 M'UZ\>?5K]O+G[W_XY0?Z/S^_^,&HT9CO3/_Q97I.95B#4YI,BF_<(1+Z&#[\ MRZJJKV3&?T-(X+<- EP>HE[WM,W>5O7UQ088,]&VU1%J0,\8N]@0&==,HDE^ MR%+*KF,VGS!]>RB.8P0=W3,/11$*XVP%PJ "RT[<',[$4-$')+ K_9PB17,>J2([4&.0B5#%-HX@Y= M'+Y_@HY802(NVGZ'6 6$+]G#_Y(0WR2^=F:XIB_N5A9F1"TR]J90BBML\?$ MI2*@7&V,],$F4QL345 Q:[3()B_8IB';F\1+MR*DX8\/8R3/TV50A^W4NA/4Z70= @3 M;#[1G5RN&C>F(\W<:F?!MJ_LBL"_Z[W: FRFM[ 3P$ZAE14(15::3&#K1!$R M(^J3N$]& IK42Y,.W(=.JG#U#R7$LD>HJ_"\MT5C/#">O;HG8^[O[";%U0*_Y%S@\#>4 M4'S][,FSB\??_NF9[PJ+_^I%5?'=#4&65L?&,A@*X^T-NFIQ"!IA[>%8#\K% MZ3/FJ GC5:9TBU6(+0+N;ZFRT,C,P2%J9Q9BD4.#0 LGYJ0O0(?9S,@H94JE MW$*>BQ )BDMFPL0X&J\_!]2;F7'^"\<.M(1W9!W/SQ *B>F]U=PJ5MIUPY7N M@]"4'U!8:.E CA9^ENSIBX@%G;_YJU="+RR.,)-2+>$:T(]H/>;UDI-&="(Z MCNKU7F)B65 P8ZO1\>#+\8H@TX%V!FUX2A0CY%'@'FWG+@%(RS@@: #CZAJ@ M,",<'0B&94WE:1).2$UR//:H;)AH:%'.=6X"'(]:?!O9E!#/7A3-HM^"A&*! M \[[P[]O0G58Y5#&(UEJJ12KE;L3/9N=R,&+$,;!"KK?F,3O&2]B!4$LDDAFW+6ZO M#PT=J/)PK=P*#;6)C/B>C;WKHE8,FH +9PFAUK[,)6.1ET@:2H(<6Y[(P1<@ M4*/_AO#TTI+O4&?&Z>@H'U%H9T^0P2^CMOMK/QM:^RAC+KPM!%GDW3HS,Y9NFWNXHB.FG"V+*Q$ M3 H\I;^(WR"--0=Q1G4"([*U^/6L3X*UHZC21J)% _YG\&RA^2JQ;NJ&N4U0 M9\AO4+/&#<83V4#CU46WVR=\3TVGSV>7PH"+R)I7$ZX6FD;7M=.=NH=VZD_,VZ(+W>= M3M0)GJ@_#4[4DTOS&4CY3B?H!-A:E'H%Y43>F^/J)%\L63*II0"T&\G;HFX MM=89!9P60=F'&YSK)?+E]=9M_5OV=/'SU]-,M>;>$C:33ZFZ^^_=/7CQY)V2?^8L#<@.Q$ M!A^@0\H:@)B(S J&4!9RD'L&9I'F_H1L+GL\>_KUG[(6DT+UHE6]1[-GP/:\ MJQL4J) 9=,@@J@NI^*-D!OV:TRYE?\%.18 K?\V+54X#^60YOB.U&0?B]FRJ M;[SQZ)#;7K@K.1JEP#FJ/*"WW(-0,=J^MQ<.4JU.G:7%5I8_IG)2^*$^NLMG.'O MBYPU>?9OY(O6V0OZ5Y-G?Z6[2S+B/W'+'WW/77G$Z'\KR.GV;!Z_-/7<*;AD MN##Q]MVN;LW]C 0GDP0+^]BO_'=H)%=%&Z6_?_C%0@BO6*'0K59I=X/.2;_8 MTIAM?@7(S_T@)"!&J\2Q&QGND8'P<_5]F.,;P%.B$-B__4=XZ,&?/JQ2D]JJ MZ/GP^O_;B->E'GK MR[0.B&NE85!&ZML>))Z#V*3DT1-X;?#%)%^<;ID3O&6^&=PR7UUF'*)N\Y7K M]EQH5];<(G,Y7393H.$3;,8[BC2>344:'[=(X]EG5J1Q>YK59O:IU:3(PEW= M&-_Z&P/&P/G9RY?3Q7"2=_OC1X.[_>M+;:O3RAO$OM"%P(;QLS^WQD&,!%;' MO+?BJ# GL=1I>J0%B9*U/7VTZYO%!O";DQS<8HE5\;]^XKVD QB\(*E;NF=3 M>4@FFH?4]U3>Y#;]HZ\[SOF+N_WFQ?_Y+JH3:??;>5V:5_KZQ9L7ZGA>L@,L M=0GRL/%'H2)HU7%%0U'IP03R):H3:)A_ *]DCN:GY0"J CEV(WEH.+*@7;4, M3FRR.N/",JVCM < VG*^=EO,03E &D_QM'-354EO?ZL MN(9LZ5/7_<*^LB1WJ#'IDO9WH0\7OHCB)M09NDQICC:TB+"Q]3 "EC/<9SW_51I;IBOYKLN(6X[/ M?^\6#(N>/7T\ \CU$X.%9QZIIU_'5FX;AT]7!Q<.']%GL\=/'L^>/7TF;4SM MZ!?1K-1)\1G=?:AH##QK1][G"R0M_QN"MQ+:'7T3DMOH_M2QY$K0LZ&SLYPTS5UK&N3B(_;1I4-%MA@[N[P0"E+&&%_:EAE\ M>6+. N8J3N*1::\5X5Q'D58X MLC<>G9^]QN5,VX;X+9HQL(L3YL^]W%:OZO-EO1-WTL&J?)2-;;+O#^-OR"*"NNTN_?+5[-EC\W^D08Z[4/2U>2N= M)G4N;E1 ,TX1JP7#BB;,;Z#_G43T 4P2(KJD_>4<$[/)TQQ)0E^-BH14+V7+ M'EU*7K(C&"=C61SY)8>,CP18U+(>P9DS M?#H;V]HM*"HW@O>*3H\TGNY%?<>==)@OJ_3S,];[SZ/CP&[9.8;_\,.R+@;.:^S9_!Y<6E\@I40'BK3L%WL=/I(5R!3@: MCD\O59!QBPA(M M OG8-OV3[8@F0*R_=>_Y#O+D.!R(RJ3U'L D&8LKU2O<;'*@7%A06:*5,7%1 MX'^YXU@^6?>EBM(0,3MH%\9D$J%SZ9]H%,*3PJOSH"0?D8P0&?E%\:9HV/)G1 M^_FND7GZ"UBZPE+>E]#I#OM681)TV9K!!8L0O%$/!5Q+;@I'GWF$-IJ\X_R, M[PB:_:YO@.+(>RHS^.K)DX!02B<3F;Y?!8$\>U$O7;(:^, 6(EF'KQY]^]P> M@R]]].,]G==NO[](DU?2_/Q0/^ MT2PET7:G+ [3U?<1K[Z_0%;TTGL.%S%5]C%N26I560V2XT2(QWP<^G SP:QD MT1> 7G#L'D0S9HJ9,[0+Z<=,V5N7,9ZQ!' &;Y(1M5*XJ1#6XNCIR1D0#:O[ MD[I^W9Z15+R;%V6BY=!&WJX@*LGW#KVM])U?A-F:4UBAK\$HH5,S)-TC)>M0W"7%W_;'.J?;%YBP@@D=*ZS$J?'@])B3K@JNIW/M8 MC'D*=F?(P?Z"1OOX,3W/H(!SP21^^?I5$IM'4[,^8C\X,2NK^= 80B3T<2!BE;"%0XSQ&XF<(),JF>"\M1E%2+D*.)S8 M09*:%=(B-9;2_/QEYMF9>*-=]Z]&Y!FZU4:Z-D/7F2 M>(P E+@=M2Q%S &@S24]KET8]-,28@^B1!;Q6HK)O)^D0CZJ%&V M6]7*+(!Z4W!+%YV=0'J)D>4^[N_#$6%BAS:"-Z<;!\[IJMNT/EKACQAH&6^\ M@B\_U>KD*T1*=&G.S_S:9+>]-!SJL94A^8BB-.]8F><\!6'("ZLL=YT]6$)8,-73XM'<4A)%BQ;[T_PXETG6$$DXI-HSX9:R3N8 MJ0YI0KQBB7.L^,C^K??>B!F)LZ33[0YEP6Q]VB51$@QW5/[RVP M[#0N/H, NMC#VB4G'+8$ A\+8X"(*5B\E>T=(X;EF".+T?)2%Q6IF**3HH6! M7C#5=.U IBEJ6W4E3WYDJH=:/1A.HXKK_.RY52JW!D/)D3[;A(.%51;02*": MZ(?Z,W"6P /K0*@\HFQ=,BM5C"B)0@T,AT]L@EKK'4H>)P4X**8M+,N%63+RR^*0PU@H.^3O_;L&%\E2!C M7%E".'-,):9F'*K_N7)XUTF]7^K;@BN^10LW!3\F,N$9<7KN-!LF: MG67I.=4S.H>AWR%[,UKODM+"+-I:Z@C4%;P8L*9I% MHK.#6G0&OI4.9I=1D!9@3 M=*_ ^\J7:+EGYB!(4.Z^_'/P\7@(C.2H>:Z\C*2Q+SM/*BO&G#\#>E#0M@(- MZ8 :/*6<]*L]\CA%\YI M__K0GJ1*IK7WT<(HIJVTMOKN5^5.'6^5C06V6AY&Z?S:@7ABV4?%XUM:RRYM MI0\'DNZBM@U3U2_[%0FKZ&7M:&_RY+0^@$D>1.WR;.N:M5" 0(IADB=7^R*F M @8CN !E,4_>C]+.MAT'&C>(2<8:F,D!:J!:SHT.[3 MI+6C"K@ *D)F?N!:#,'*8$Y\,<<:DRB4\S)$&O[O[3V9-OOYH]?OQ,"K[C4M2"56TM>-BIST^B]-\> M?Y71J$KN:413A:6U"]2JX=L2GE[Q%0CT;>^:CIDE!_B[?+'A9Z2/&FWC]&5X MR>.2GTKA735L0>01?WWY]:-@D^NH[?%%FR0@5TDV?Z0EQ'Q\*30.E\O!1/0% M[?D9(Q'KNG.%'@WMBB$ZRWPAC:!QT^JO'B(D>VW+%LYL]GS!]^GC;Y\^%:\> M6MXM)^S.V].O+QD6_OSL%V-(P88(H.= N]Z[V3TDY?I]W_@PI&2?Y3C_:U[U M ' *@.'U&(SX-8*,$A[R"DBS@=P4(?L=(IC3"3P)KB0A@O_391;#K\X_I@+@ M)QD9TV.?K_M_?M58\/_K5W1^;U;UF##>CY&9=C"B2+I1PM8TN6F>.LIG*8N+)UU\S]PE$U&N/SJNH95VU7-QS"_A&M M:8\?7?QO3E09]@L,0/HZ^;S,QQ[1CRMJJBT&QZIM-8!L1?XRMW0C>'91UC7S M,D1#YA U.=0UZB";HGW+E>?J:0N!%M84 5GK7WWM/.S;CX,'O_8/]A5FBHH3 M1N6[5&]X"?Z[7A2YY?GQ"Q0G^,<+NE<.2KG2[R3GWXK52M@B72,Y!UC4,+&! MI:/#0,S3T8)=9C_&7',+WGH)BDNV0Y-@OJI8GNXXN*\T.3,.L >6L6TAN7IL M#%[)#5 M+W/H& T2/T%PXO'36?1#L'PQA&A9%JVK2.V]UF1J"_Q5IAW2%Q>2)SX_<]6: M+#BO%CVC)W=K7I$>W>&ZN7;S##H.@&^2T*NO ^&A,))67-O0ZU?DN?;8*&JR M])GK*[=V'=W7@#)>(;&T:VI0-]++KW1&@H?JNLOLK_4U"N=F,@$F.%(P[ M6S! 7(^$9T&[2RHY,)-RU91.)<%6"+:(9-07FX*^)=RNB *CE@99DRF8<]=I MD1"1>\1"_RU'Y'P/#J>7Y;AH:)TA:Z)$NR0*C"0+R")D@70O\FWVMVZ)/D>S M!*"8#0*-!#457U52X,1'0,B@7_YT\YT\D)O/8O MRY\$)/J%.63G9]\Q?--/-5T!-?M*7[SXCK[5N<6FJLMZS57A3A4J./#=[8, M&++L40E'7P>DSQ)85#U3\EYT6OMA7\'X^(CRA106QU6N6>^CKY$#![(DL:;(64L-OB4DR)'6XXTSSX5ZN(J6\(#;>M5=,RN,Z &Z>M?@NMAL!5!C[H1#FS'"V*;< M(&C1U1<-%Z.7M8D&?D]_:S=T;*^*IJZV E">+[A,-F=* M=QBHVTF"BQ[WYB M*A>$)_4HF<8Q-/5MI/W8" CQIL[E-$J20N5*T..#5HBHH96,1ZZ30TL"%@6F M=8404)D69LVD#]8IY8:^!PIR.R\X5!\*I;4FL.V+SA<6(.115#U(%V@$Y05. M'+IC52G/=(%:HV:@E8E/E@R8Z>FTEG&QEX*":U31-5R-R7<$*T/D)M=1&,I4 MH! X+%B;*#+0HM7B1;YE*BXSBP:F8$CAODE6/!JB[(^2G 8K9ULO72F%=/89 MQ,/__8OOGGSWI92606 **[V[1L3&O652)HGSH :/SHX+#^=0$0J;6M&.WG#C MJ;Q;$8E&WQ88LB^'7X?(-MF?7K>P)B6M MMF.3J> "Y+I9!FJ;-:Q+J:QG,#8XF4'4R)FCI^]*YXW_ M2+F8O"SWR$02=Q\;IQ630_= _W%WFS-Y/@CH2T^05.I+B@3VFK..$ZGRY;I_ M_FE92!]7 9A82ZM@+\H:F/[:[(=9_O_LO6ESVT:V,/Q=5?H/>#/.E'2+XG#1 M&F=<)'LM):NZ76TVP22(& 0:+9.77OV?I;C1(4*)D+J#<<^O.6!+0 M.-U]]I7RB"M?]%3RO=TKN?+$IZO7#&Q*AZ25=W?D5VSF3WU&$IWSS(^J$01! MW$_)FR6Q'Z=*8DZG3^6/O#\T'?RQLD=),\",@%_O428A9O"8%['NP<1_&)2$ M!3KI$Y&9E<2)W@,[K'&#&E"(7B32)5"UB+F]6.&CF](B>&L&A1DAJ6LB>>,0 M4IYC!+>.L!=[$CU3\B22A(K:BC%^U=?$J*'<9QAU"T)JJRA(1I/^KAK]PIGX MLC+VHXJO./BC4R)+1\][U0&,M*,64[A1QYGF D8D8IUGA M6D!5FB$EK"L5[BG>H-6U"@&BARI72!#G]%V?]O:J<'GM[ESI#BQZ IIR7]% M;.]MP7 +-KI<'<#]./Y69%( M;P\3*AKJLHX3Y2A:TBGX"$7X:+P8$D! M >3-P*,DOQ\#G\7YQB:4I=*.]?RFHJ!7MU_39[KPCHB-EK:$ MN$2ARBP(R59&Q<@TCRY6TRQXWEF4GZ1AI-YY2H69R(L;MN)'K10[K4Z[811U M#0AW(M;G9W1(X! A%]OE=J90.I'LLB@./%W)*+@M+DBKUWBE;MNE%2\WK;C] MW:45;S$Q5DKZ=5!H[\45UJX=4*AP=^?"&JZW&O?94[ND3=4IHYZ&F@67F5-5 M.?L$E! FN4^QW50'Z,ZO+KR3]FG#^SEX85\T^>4ZSPD1O#(&!"_(H67>I D1 MA##V:*!BG SFZ,R?*GIBD/EL:6JMG M,J,7#W%XRH>F\X$LO\]@^LQF!C*9YJB!:HM-#B_V0ZEU*M:@P!$E\-:.GX"Z^A5G[);ZAZ MR@28Z&3G&F^&,)Y@_?[FB/^C*ARFWA2&.&^D'L]:A235)#JFW"-#$Q4]5:HH M%[#,1DK5WJ8\"XG]+E4N80:)AK;P!].QZV/D"&WP= MA&@'L=-4VQJ*]%,X[&(L-9EB#N>W'^>I0.5^]EDP0V'U[;/X7Z-POALG8\E5 MJ@QD%@C<3^ Z1G:,J01%X 31U"^FERO3%KWHYB^F QAF%&*@ZB^9Q/ Q"C4! MO<0\YYT#Y^$M=; I=4E3PWCH.?PR&!;!!-?J4W0CC:V)[3*5DG,.P41(5+2,LD+!V#QT&!5W8W)C6H< TNV#K#1?# 7A+?M59L,'F7!:$Z=\4=?%UB9%6IF+5)FV)*F+"B.A6AQZ'$>0Q'-2'.>9RH07.<4%=0QTL'-9!!1DEC M3YR&-\VHEKF7WPQ/0,KF[+E^X?"T*LL*[H$7/\E[8>"CWIX(TE=31HB)E$F1 M9\^18ZP=.QA@7Q*=[4*L1%&8HOTR3[3(325JZ>"X2OO#?MY(Q12D_IR0PG#K MW:))CGIB10\K>O*-Q'XP6 !%Y>Y$4>2AHTX)(NC/,"W)3DJ+:P%_X]I"_>!\ M[L7I'0EJ"N$M$$U<,%,"U;L1J6FDAA0[R1.<[)Y:M%6M/U-H; X#X%._D:AA MH.8$Y WLB$/#Q-'#8&#QGI2@*"BY2"*B%$SMB#2F 2E&S4T3P5.C]&4G&"$) M N$5R1K>?]$O_9IZI\YT##%>YSL>:KM,I,T7.!D>M MEC>F5N%"=1 ?21%F(Y]*YNQ>LV0%QB6%M@3,A!OSF7&PNGDU-A4L*ID\>NR> M>*^LEJOE<[$BRR4X3)#V;(2JE."@>P*U\]]E-Y&!1H1H"R\+W#X+B^A;^[H] $TO (I?1D/JL\QR1BMJBA\%A53D)'M"! MHJLH1O(6K$7:9P9.Y\8][!\&!_'MH"C19C]#5$S5F1DH8X(IW J!6Q58?)YS MK\B-\!! R&MK7"=] T#?NXF3+V$LN/3=5,79>7(EBK'S/-:O&*\]X.(,K#L, MK"+OFF5@FH^1Y/^2J2KOK2JPT8Y\;HT\1UTC9.34O2P>QBK)#SH]"SC&?+OJ M@#VC^%+8?^ZI[1BMAI+Q2G:9612!PU/YYP^=Z62[.Q+Z*KXYFROWPPO$OVEP M*V&K6/$N,[*^VVU_1]O]T;L@]K&<+6NSZEZ*J/*2)\/>7J=UV.AT3QN=HZ-] MBVKT8HKT#H]_G,-M=,+W]';4BYT?YQQQ^;'VU/*<4UI]M_J5PZEW:%#:#R^. MCX\:K59KWEL/_]#ZM] ]/=GV+9S,<+ [O_'C$K#Y=X[YS&RN4CN9PPTN,& . MZL(\K'X($UF8<2QZY ];25U$NW$,.DT%-LWA-XL"LXTGT6Z=NI. I0Y/'GT$ MRR#4!<1.I:CYA?JKO(7_TN#?>V='1]78W@_$&MFY*A_I)*Z2E*2AN4@UY7XJSZ5PT;[K%)I4^BSZK,Y/CNKTU6=54O(38&SU^DNP/?JHCS^PHU6V/=3S#5$ M]^XT,]I>W:';.#JI9'??G19UU#@\=9HUD6GWZ-%GL!3J?2SC_V!ZWZU'JVP< M=A=D]ZO7*\\:[?:":L+*@7F$8KGR") +O,Q-/2R\(VXV8"T+J,ZQ(9H*?^G4 MG4ADJBD:=8#D_I.L[YJ<7]WS,L5XE7ZTU-9YH7:Z?CQ6'4 0##WNI @QZ_RN M#=9NVO7\:P_H+M(_HN/Z1RRW?T3GN^L?X3(,OFDO;[!WX?UIG3=2==@L-8/$ MB[Z* %O?I>DF]&$K5;ZA4ENY#IQZ+W^E M+%0XF&='73IF*NW2,W 9"H]S<*WF[P^#9W?'/H@"GO8F!=K3H.*EIPD%*5)/ MD>U6)B.18*%R/!A@U:*J#S1911NJP7"WN6@#KF_9!/]?UV=^[$$\J?<'F>LWU', 2->0%#OLQ!&5XNL9)"CO?%^D7"UBVR&X24<4=2L4V\Z] M?)*8KTT9]-4-+%-O3T_M_/A!#>O,>"=LK\0-GW6;QSBR* QY0IEN8L^U1_A$T=6B:$9169CD5=0ES7;_ M= I9W8B#FK6E7 #H'(GUP"]S(4;7L9/D[[)]@1\\,REFLY;N4:=K+-W#$[!T MR69*F!GX*MFN9#2;+"V>"GT/#.VRG5QI&CLM_I[BQ>Y1\W F.C=W6Q2,7-Z^ M#G9WSLOE2!-QFX %YEFC-%@'5'/.0:SH&B64%DD>9-S!?X_&;XMB6A\-R,)6 M-$GL@^2:'DQ( U8C58R%ZB+(W#C4I6"R&&;U)PY=HK%;U/\D3M)]GO8]H>'9 M).YPJI\9PYY2QR;[4QJ72XX4I7XN749M_E:?,+9>FB'LCZ]^-TVT3* %"\WG M^Y^*\G7V])DF[I:[K524/J?6W) 4<=K3EC*Q%BQ@KZP6IX%(=VME3T,'>Q*; M>&**)&4$[^YP\H9K@U,[=%/W$V+>]H(:)4CL9RK[NB)PT97,;1H+;_)4H75AB*?6>"+J9>GF,-9N M+Y3HPLGE[#JQAOUXKTU"Y\K8SO?5=W==>RQ?::E@8 ",(N,FD]3,@I6=");6 M[J726!F>J:=^159$8: ,\LCG?Z+=0!U8<>X]+$7CO;X&J1J^R'[IYN[.9QY% MIQ6T@O> FID&S&NTV7.@&P+IQQM>T4HC%:'@2>,]& M(0W2<;,XNYT4/7#A.Z!I.&%3Q]],_Z:@*\]6&T T/JM?SJ"? MKDO46FZB5M<)_?U'G:J.0P:Q-Y#T=HZ1Y.)72U/;@TF@/TUKLX=W" MG)3<&K+[W708YRBS:L5T=YDNQZ(-0M.T;36^FS%4SSVBL9 ZGX-04?E25>P: M4=9"9QRB,N_3=JYP*=9F;OS.5NFLPQ;\?)^V2MV)= MV$QI]1PCM[! E8576)9FKAI%\<:Q$EB6==B78W@Z2Y1E^V<>Z+H5BO"!AHLB MI; 4E:''4F>0"'@UYYFRJYJPZKC *C'J(>J<*KW'FJ92YF&G=68TN4YWRLG\ M3%7(/\2I;%:O5.-@80[DI45&8WEW[#%06M$86X:B2P5-D;5, /[;F],W9V_. ME\S*-4X^$9Y=I?.D8*OK5J\5N%JE\!1&Q?SWE9M2X8/36>J\%XQ1U!J,]\):+6/N^E4IC>>OG&.8\FM;H0E0 )K]*/\?O MPQ\#LK ;5;U&C%.^Z2W0D024(1J[IW*&:4PF/S^M)-WJL .F2BD?]@VP*(^D MVK2W'\$/Y5"$H*O!2ZB#V2&"(+J6.%"LH>:'J9(T"B4(W\>,80XEY&C(X;\R M\=72_TB?"V"]A#P-3ENKYUZ>QBX68@4/43U-$YT9Y;/=.&L=%CD.1]/JIVDZ MLV!Z[-.X@*=$$M2X_$Z3X*DT"O]6L/7_SRT;F[ZKY6>6= M''*>_]ZS#D._SV/T[H0;&S?]=OZ9[2_=&,&"TS-@3LU3Z;3:9P?L^P3P_YT# M$%7C[X0_4I O>AQL%]($93SV8@"=VGN?BU1GMG5#1:S]W*^JQ\?SZ9KS:;?H M7_M/1&NN@9=U%7-O=<]&SBMWI:-KG":]1( ?@C^_RT+X8B<(T[4SI/("9,RF MM>:"=OAT D^W7O>?PYU3RS]+G=G<72>8+I/=Q=;D"^?JNV@5.( ME592D54[D^[4J"Q.L+6EX2*.0LRUF-\I>[5--.J*QHY=+">+]M!ET2XWB_;0 M9=$Z(L3KZ;T@K3L)TC@B68G2ZK\H'%]7"RO3#?:.AUH__Z/G^.BF->%K=&O( MFZ>CWC^E"R(__U1/,J7CW7J]/,5IPZF=]FQWD,,PT8;ZEJSG3@NY;,OA:3G] MX/V6Q/1<<3XS1'3Q#\R96#[5"O_! -_5&F]E5U'5Q/\1D'?6 _K,[/1O@'W% MP!9]>!E&['2ERQQ0MI9ZQ7 SD>E^,51A'D72M[OPZH8Q!]B&)A@$/K[Q!R9L MD$.OU%QF3)D60B?!(Q@C*<)LY O*;DTF,6?)/D>89B9LUX9 MHDD'*QWP.K0 MJK:P;A%K-15D#"*V37IP*9E5&>=][+\CGGSQ\AV%A+F]EZ<[B5%\X5J7?*.3 M;,B-ST6>40'"M=QO,BCHX:.OR,$ 63)96H'1\&[)QS=5LT=S.J;-&5?/) M-[98MC[] 1-*L>O6'RCS"U2GS+(ZM"_?\*VNQ;*HWMR6F1PKMO26:%XL-B^UF\%N782VPF74!Y"36P_$ M(2>1AR*/_!%]@&V'@TDH,NQ=[?6#89!I(\(J2P)I*V#[M=7R:HK;WR4R9Q), MWFO)(!J5J,+*K>CD[UU^+)5,Y+UQ0)E=%(N- JN,,#*V=O<-?$:AL'[&L,Q,^J,(]./AK2K80C"X>3#LB)V3E+-8Y.R56+CNFW<= MI'G!G+5!6P*U9.@3X[8L^X8M#.S6('PLI JA"17G61KTI6Y?K$JM"Y'!EK], M8K0L))=@EZOYIMP'A9>@8;X#FXSBZ* ON=< #DG.9)H5+@T#3\-ZGY-^R/]0 M:X>M(_[Z$#]66")-&O('\8&*?"&'>&[?->(\N:*D#\8"QB>+OA@-[_*SMA!Z M\$(<%G0)S""\U68']ETT#BSB#)@&/TQ$7U8I=0R4%?&P&^VK5OPE>5<3GY6+ M>-\=\2XRW]D1D^9CS&K\B]AKHAK4$X,V>E&Y=C*=5\M(&(*Y)PU K:&DNFIC M,O@C$0VUPS>FB9F9'-//?73!)(R3R).QJAKSK,1P32'V=?J\%LAR6WQKB^7# MS;BVIB4*9^190F7.8'C:[(W$D?#X4MA_[JGMF*0^2O@K#98O&# AZ?RSQ\Z MTPE]=R0-5GQS-A_OAQ>(?]/@5L)6L>(/6[G=UG>TW1^]"V(?R]ERA39631%5 M?N1DV-OKM X;G>YIHW-TM%^ABBG2.SS^<0ZW*:9JE;>C7NS\..>(RX^UIY;G MO-7JN]6O'$Z]D^ 9_?"B>TK)]?/>>OB'UK^%P[/VMF]A;Y:%W?F1_1^7@,^_ M<]!G9GN5^LDBA_ZPE=15F"%G"W*<18'9OI,X.SMT MYX 8L:AZ,0O%,LAT ;%3*6IHP(O'\W<8_#L/>=$CK.)>:IK+78\JOK5R4(Y: MW9J QW=Q*GVZE,FLX.ZU$H30U_#?2XO M4RS,O%]N-4_]@LW2E=U%N)4'3T?G= [XY7GS7=.[RN$D@=/#DC&&B_G)Z;_J M>M6[]KJ[P\V9JEHO/6M7]-^G?4T]USWMZEYLN&/<:)!.-=6O:&]BU5GPI9@- MER;(8'\7"B7JXKHUM1%V-%2]ET\2,W@H&P;4 @TWK^ MZ>,'^E?[^3[@^@23FR*X43V7JB N;LD_ D2)X@P0%O!#RL@:C#XU*#*EC!]J M-U2,[$4C@I YY>6H?7\/T>LZ#GS9U_.']*QU:CO&GP?,'>0T502V%,3]E*:U M R96, ?$U(S(#K;GV>3SK-OL[.[ J894C,00W^A)[-P 2'W=BZ]E4AK3CI5# M=T]I]T"#@Y;M(9V[5"=Q$@F9; MDK7;A=!OMZ=ZDLV,'Z>N9!Q,6:@U>&NY(P:]N1,&:=JY4(D_".8H2*:F)5MY M8RS+-6N:K92W$L92S.#A#"!87/- 2@92$D#7S:NZ^-V=F<+X.37Q]S=,LZ8A MEGQH^^LDUC]26MSLXP2:KCYUO5= MW?QUJ+N@CJ"+*1P@J9ZI*'K%!./V:=$ =7KJG;#;C_+H@^["4_ 6TS0JQ2:' M;LI*R(SF(]!<2_TDZ&'%E>B![>,LE[IA*[DI[?:T=D7R&L:@K7\*\E.ZO>4, M4M3OL@16NF-Q#6] M#Z\"P#TYS"-5.C=E0$U7S8$YFB?>./"3V+ORXSR[$..__^WT\+3SW ,;)QN MGAO?5^YV;[5;1;\J%NTQ6Z M .6 _1]EU#;/\ABH-7D8*X]9!0!4 MX1OY9#?*45QVYMI0XG"9@!]&E@F_-;XTKYYEKS6:,_F^? /CX\*;;8U,\U397>RRG:O-NOPIV;X0P7/ M=YL74K?QFNW@=7M/_RXQMX,7SJ(L-?#BD K.9:8)RR)2TN?^IEX5_;S6A6=. M;='4)^7D]F=CE'CNUO6['"M M:IA\_PH7?N/P\-BH&Z?3*0//3(+\@@D"=8X(;Q)%UJY%K*N1[]/NV;M-K7FW MIC.OZTYO RLBW6O+8LO')T(*\,A,K>I*XMZ>K1V.%M 2R%\%4_-FO: MM9H77<3H%YL([7"Q9M>[5;A8R4./.J>:A\X+PFHLQ0ZE\81^,TR$8XWUN^&M M0DP(S^E&TD*;VER%(:?S7>Y'VQ9\.$VMVN5N%B3., M,8@J,U:LZ+E*M2^W6#:11=O_+(AO7KS^H%1/ZK\:RD3U//;243#(5)=EI2K$ M*C-?1=XOWGS@\CT,QQ]DL!>$8I"'(?W@NA;7$*6V'O\Q$4/2+ BL4^58>WH? M*7B# .TM3!TI B8-[U^?2C_2C*W)) ;SS&Y^W@\2SGDJYD=8M 5?64.G8O[O MN2-#JQU611K]4EQ(CX)AH0*.8U? L=P"CN/OK(#C<:CY)%S3JY@RKKNR<*V! MJ_NH01P81&!.Y>FP9FRZYICJ#-/99J' 4D762N.P5022S@ZG DEQ&2/4*ZI_ MS6,2LX.9753F4NCG*073R'AE?NWNP!/#N1V_&G.3_%C#36<[SC5*E27>&@M+ MMA3UE\IX>B_>!G_F 6A6MQP[O5##*S[)%,QL'\/=/<>)-LF)SE,J>Y^F[DZ# M:Q? C!0IDQO] _2.X!K(+.((QK-VJ]GV5#L+IL%1C)8CMJ;H2S(O55<<\U2I M EXMOKM3N?II\WBAQ=L6#-4].9K>9>05:>WBKEW;C%GX?C[.V3?4EX/ #S+V MJA\V3RMW]*Q]U.S> :"ER\L*C\._44N-YJR.XRB%\(/-" "M34\:^9EZ[ MXXWA$$8I0:HV9>]G=Z>W:I$8I]-&F"'D'0]-[D"6+'&)"#] \ZLZD47P#*\E!B^3S6 MS*^,)67DO#'Q63J+;IG?N^W&"+K/PUGQF=R>2RA[L90(#LU9) MGO5!1 Y5+5IU@0I8\LV:@6!TLF-Q2X*1+@U[ \)"J4$IQ%20JLJ5"\<#1R-[ MF?4+M%VYM9^2Q[IG&BW,#7NH,QL=H=+(]:BS?41A[]*@8D \( ] 0SC" >J) M>DHWLP:LKRU.&7L- 4+ "@1FH)_2A0'3(,*YD$%>#0^?K_59/2(P8>'55Q-J M0S7<$Q;OZ8H$HO"8]%PY8>)N&FC/FPSC[A2DX SO2J0E:92\B^I+Q^H M^ BBAQ#F4?EP-$ W(]@)HCP<"F(6;#RC*E+,Y%4;1Z#B/,0B;OR,4WU$=!.=FA359H'W/TKB.J:W;:L34ZH*%J*IWYJ:-W@-N!GV=^ D!*4(->:$<'$!G0:+ M"LM4DDTQG[;I?4")1WM%1)W:,4B=8LLSVA%*PL& &Z1:L6+3--7VBJ=T'*BF M1&5Y)%CY!4^"]&,UY71C,Z MQFZXXZ'VVICG=CIR-EC .S.Q6&94D:4F"]L&G7;LX867V>P" XP93V;KNO:* M&<7[;B#QG5]?\T#BE<^GGMR@FGY*;-4Q+T M7C%]YMQH#'/FI:YP=NOT4%\]'^:XT3JK'&YT]PC7^FS@J'%Z6CG@9I$-K'R4 MF(4/5 *#_+MWZ^TIY-CW+LG)4HT=*YL:"$=6JS&&>^UVXZ@:#5=S=0^<)#7G M%M]HE^ :[^Z@+G?6Z32.CLX>CD4KF>SD]-!%TNQL+'7)=O7TN+Q2CHY[,MTZ M#;8/M))1Z8FAQLS'13(,N;%3%:"CM//,RNUK'A7/F2D%:*?J,06"NFW29WLR MD@.==C*5;2.\@;B.$U+4\0O^2$3#J5P\ZHFH6@D%HJ=<+IPW4Z2JL M&?W1W M1W]5[4+VK50^W(Z&#KZ8#,UR1;H.&E/SJOPX-%4!:NX2:1>Y%8!VC'[KJ-39\EI_DOQ,RV2]7_BLOZ7F_5_ M\IUE_7^W'M$-B+7VPF+MJ'FVF%A[I%!;KDAK+U.D=98JT#C[8R4"K9"\55./ M:,TXSXI%=W>J5IWII'LS^V0+P\T/RP MO2&!\61-\^J3.;P:DY:8SV'65C\1-S@E %D6AD5-AB F8'&*8"T5XZ>!8'4S M<**X@S'(>ZW26;1Y]$T.P@Y)+.X4G7+DX MR'_U,"0F;&U;(PSF8^NZ$V"?%HHN#VRU? :7D8(U/?[)RR>@O<#M2V[U2=\) M^O_\0?Q?J]TUOA,X.V!T)Z+I_9EC8^=,4+-;Q #X1:A_[@>I'\9I3JC2 Q:E MXI%>$J1?7-/0NC(B'-\BO'0L<,ZGEX!QE7!+>.[ZW= -D:,X*[6#5AR)_+E! MA/C$;F7S#,T&#U+O$M#'N3MK2.&'4Q1^VK1&8H)^D7$TG2< P$+=3NOY)4#^ M%2G]C4&**X,4]$S[N4>1VJ'TWART>0(P+'L>13E-Z$)6XBB_AI1_-$7Y9TWO MH@AS475"D(IA(A4'H#$-./TACS+2_N#:U8\ZVZA DE=&#W LHJXLXGV<@=0' MEA[X&'Q9.I%NZ85LBAZ/I^D1=&TU?)W%[T6,G/L9ZF.)Q/E*LM_0 M$Z?PGVD^1M_-7S1-LJ\,-#6P2PR=R/> 6-Y,V+6GMS3L[I28VZ)-HU^/8FDQDVLM4^9)UBKL[CSQ&[U&G M: _?DTOB \X@PA0@' MS]+?"C5'_8T&^<#9ISC#"?X7-T>SC.",0H'S>B(:=972'&$0N4D\27#D5H-@ M$31 #2\0!QS#S:4T#"J10T&3MHHC*MPK3Z2!TEI9T#I&& 4OWAG,T@2WN\-F M$&K,EYA6@VGW2I!X\37@5H%1G[3OY>ETE'I*8H:J/@K>P0P[G:"77<\5DRGF M,@7I2%M%>M ;_=P'4L:03Z#QP+?QH'"]&!\<9WI6/KZ[4_&\-P(60S4FM@S3 MCCJLK8AYJID9463&(U MMEW0)$&"@&Q+-;$=!S72&#EDW85]"0P3EIZ$_"Y^_=3E42;56A_(_DJC6H0L5"5."JI#9E.3-(Z1O)YG=G7DTHZ?+"O3O^S*8 M*)>O79%&BG%/ J@!(Y:(B)'DFH#L_BF6IV*7P'YUD^US>^"'^" M8\+L:UHW*32F3$T2A6_ED?X\G07H3:D:UIYC(#*Q;];, M *@!D?$:)-6LZ4*TJNMQ7&!B\<( M1GJ;PB,IO836N'$P,"M'R]X7D1$\),PJI0_)-%3RU6SO"N9?$M\LSF2*85*J MJ-S=^9C$?TC?*!,BN@50@3,9"6E@HO)F&J-.$WZU/X?')??^4""0FAZD7[3$ M4MX7/+(>*!IC-"^,I=&S+J9<<\5SN5/R7K#>,D+/%X9\J)@]'D_ %#!G0!J_ M5M/BDM\,OTP''<2H9+E0PIJ(KO U[.Z@$H/>0JZG+R&44G,6)S[ RIG^P4WO M,H(]?V$[,:#!\; XN]#&%B"Y!L)/ E*?L(F:ZJ%&^2#2NXC'Y,(C/+M"\SG& M3#CO0S(4D=(<4T^UW/L,9-F_ 0RCMZAM 0#4[GJ#! 04]@!H<(N>LF>%O"^= MY_CK8<)^OS?Z!1AHB2%N M:&(DF(2XPU^$R=C M>.+@/UX_AO50WU$>$>P>(0H,,.\,-,/"O#P3T0DL]$@*A)@P0E@N@4& S=D+ M@_H!;LA9O[8&"AD*@FYI*#;H!9.U828H[@84O868@$PK>"SZ^%Y>YM+XPN\H^0O=A#<,D6WI'Z^B:BP[.&TGIP>5. M"8MJ)'VJ@_#N*8/H,,F3:TX[YM#SJ=M)Q0E0/ M+LH.'<[5+X/JQ+@'+SF#JM?T/E"*AY5OX'*G-LPPWL>1LSJVAJ9."YKZ_/H= MT-1%TWMU>77Q]L/5KY]>>Y]>_W+^Z=7E^U^\-Q\^O;[\Y;WW[U\_75Z]NKSX M?/GA_97W^5_GG[V/GU[_]OK]9^_R_=7'U_R'-7;!?SHXL ;2S'9WSDU&\)8A M]IR[N#M(=-AR0:*E!HD.6]]9D&A]G%GO;-6L4[?QWXS$.3,2!WNS@348!$YG MJZ5RT&E-*=SM%N82J\2.QFP.;:IR<9,)A8F\(9I7E,?C;GC-%0WZDG9W9F^I M@84-XSC3%Z9],!\YP]FY7#;OS!6ROI8G-UMIF)0XM_H$*'JYA\,:61]F8UT@=OZ7!Z4LNR=0 P M+@ CS3U5C;AX,- XN&9EF%0%X0H._G3EYWX^=,<^B^^=E9_[1Y5E:F^M:BC. MLKG#HNLM=:])/&@R)"]E)/K>+W'8O\&,A^3G-)^\H)R(0[SE?/)B*=BX9A3< M!%@GG=J!5-.3NAB)(($'&1@5(WX9BZ3_/1#?U6B15'$>AQF0PB1WB/ M!>OHN'8@U?2DM!WY/9#9ISB2BL-\BE,9]<(X'M?N1FJ**$?MVH%4TY/ZGDCJ M;8 Y&PC(^3C(G,!R LM1UQ*+ ^(4'84(R=Z[. GVO7,[.ZDIJIRT:@=2 M34_J>R*JRZ@GE*WUGT0&:5H(K'I=2DUQQ8DJ1U6S>_U?*:\9D-_R1(Y[B8CZ M3AU\M.1RQI:CL9F]_E>.<@;DPT F_U.[NZ@IBAR=U ZDFIX4-<=C2&:[YWT/ M%/991+>"(?EOG,J!H[$%P3ITIM;#:6RF"^7W0&+GXT!Y#'^)KY,@ M.B&O91C3",WO@=C^+?RXIV)@UT&4.TISE+;L_" 9F3CK;Q^1X#XF<3_W,^]C MG&2#. SB[X'2SI/@"P/R,0EDZ AM44([K1U(-3TI2W.\^MT[!XD68,/":N)2 M%9"NQF+JZS6IL7@PP&HT[HJO8CE<:^5@&O^?=CC7VGA:?<7=:D)9*X?;ZCJG MS,$[XR5;S])J#W9I)?I6'QO+"ZPS^8G'X81!)(O 5FJVN(:=NEX;#[G*0%?- MS%3,_"-X00U X=_7/#+ 5P4.NHZSA[4-^$-1T)D&V&7!],SJ'&//K/89-_:? MO]J5'^?9A1CO[KS-^DW3"&ON![BU,\X:P-;&'FW!@IUF+^&GJ&E^E"5RDLA( MYHF:6Y71&*,\8:?:6/:1BWO]&#^!#69W=P#HX\;LNJ'((W^$\'O8#II&58E) MD,';@QP[+HLDBZB7(/4JOCJ_? M;]ZZP'1EL%]W%,HEX9DMT+=.,_JGF&\_N M8W>G?&0"8*5S5<4E%><#/UQ&48S0)8'OX7&J,X,MG=#^+Z-T$B2B\"MB)V7K MP7^+*,>Y$)U6I]WTWB3QF,ZC>X"',GLF%GA1,6)%0X0 O0SB"Q%=@$[&G]G[ M?'[U^B?OY>7%V_V*R\-&CM2X-SX8Q-RC%A;Y+>B+,;;/O8S\9L-[!Y<&P-." M#>\37 ']"N^1'_@PR6+] &W[ETM8 PB#?G''+L;8J9'ZP96W,#;+ZXM+&5T1 MN;W+-!$R#+S?%%I<:+0 '&]ZK[BU'/8KULOX(I$XLVLDK6]?6#3QJT)/U1$; M_S0&3)*]8J<75"Z(G2-I"N! IBF#>Y4G0YG0NY]E>'!^'5SCH!I OC3(*A#- M&\$_Z0+?O:+#>O?RW!O S5>]#CRCZ:KO-\^X=<6556WEX;U8/$--"EF<43>] M=\ ![17-(">D;IN5XD0E:DQXV*)^B2GC84!H!!N'@P ,O,;VT2*:6=?P>)SM MD@34G,>,X2D-K^KE "OV%*=VCN,\S'"8C/Y"P+]^#?#7RV)5(&W#J3Y=_FO?$P/8"H!S MJ[M$JH$M:M0 G$N?9NK$"K',4VLR0?"1YX"G#%.@&*#OIR])G@'YQR$MWSUV!>=9^T4 M21"&N? XL#]B^DHZ D:$Y,]LUCH/:K6.1C1/KIG^8I :OJ19UB<1A,!DJ1DY M'A]\2!U\^[!A3H3;LFN&>:DQY?P&D928#O_-H,B[(*(6O?B)USYP]?&M$F3J M541%Y*UA,)!A#&=(C3.#7DZ=?]6H O5!ZF)-=XRS$X@:7!O-#7,R5=16%+1- M\[$IW:?@:7>R,6L]PY5,@^I0W-PR27WAF9O4UEKL[J0R'!S$-]CP'I[A%M T MR13.Y2_N5LT-Q=D-A -D'VE,Q\M*-'6=6WD?P<;O_7>"M)R<&T0S*.@I^9" M^68@@!YU9_T9EYIYO31"@,8$R- C\?TJ0)3WLP8<'&BF)3B0X+US8%RP1U:H MJS<21W=HG:B3#/.TT+>N!#I>WL1Q'RX?=;*I57=W<*A*$.>I9EKJGFFZ!X[U MBY$59L1.JS?3]/XEO<>HR#:P<..$1.Z+/XZ\ELC3'>C;,>JH4V;L:-;9=H\;E M-FIL?V>-&C>&Z7JC3V6@+VR)*W>Q:G<)AL^5]I("H!QX"GL5J^)@'AX6S=B3:Z:I#6C$F4JD2!$&5 M8G^_D,/.;$EA+&F!I"=0*X&;Q*'D46&%8X?$<:%&Z2_> M(8IIYM==[JI[W%%Y))4OJK@6DL>DR0COY3G"*\DP"'Q]F&:&!_T8H4<##F6. M2\-:FER'/C)'FEQ?G@DBR'&GCM.U#Z_=7G#P.=<;V[7&#V4.;V0O(0]H^ZAA M8QZM1?BA;74T.+W49_<%4158TV/ARYQDZ^[.C/.Y9)V7[ )>_E^ V; R[!%L M#- =1SC..Z=)%.S!.+.!F>]1M^G-FG-+SL$X]'X!57J6X/;>GU^].O]_(+W? M_O)VO_ ;'S+HZ+RXTP9(Y34. C:\9?HTR/&@O>V@^_MSV,^K8#@V7DYTH"L/ M.;Z$:7GD)E&3%=&Z!_&/= G\F.8NIV >T,! -0"1V!EH(:"R]0/1DYE4OJJ8 MQC*,)6@7:'/ FE$_06],/TBE2!$H? P4/O36W@/02(HD\ZY%>"W5YE+VGN.M M'2&-?BDU0F$_PL%<.$5TQ2VSL[KS# MB9 XJ8P<,6! @L8;7+-C=LH%=2Z3.*4GIG%][_+\R4G>79KTD',6#9<:G?';!A.!W;2,$*;Y\L:IM,@53Y+,8%8A!#TO/J78,FJAN*E":/J8]^?)"$A!D@C0WS=7=)XD M\0T(0=!B@P- UA#D)$B],2,+G,E 1JE4DM5(F9827<<-93?0%&$UT,X<.J_= M!3LA/A#9&%!JA$(,QZC!-6.D/C9,NW7"2[:[)4R_W\N83$<82N\77/7*I]G" M(W3,L1;&AT(C_0H&"\A)-UZ$(N \LCPCFZ>HNB&77A%&>2=2LNG@"R]5:,H[ M[X\I1J&P19L9%0Q<80X891FG$9#D +@277XPD-A2FZ-&3-=(HI%@T<;1+L[!H:W +^,IM)CSHR^ MWNX6JO598_I+.D%EWKG!^O_))T"\8,P%8] _\Y'LRVQ:9.[N !M/,,J4#&6: MH?X?9B-*# %65\Q\+JR(TP*J+F6.+ #)>1@;J])[&>8@'__,\1,$1ONYEA): M:6?7D"V;"JZMOXYFS&)?_SB*911\M9-FZ!-<-BSY EZ+) P0RU U1NQ4J3'Z MPYWBPR>/N8R+$"@X0\4)SQ?(CHPS[YHRZC=V=^==1@7@%74;Y&-AU MKHROM$2=MK@^'X!X%#H"A\5G??(BO/W\RN#\^9M/K_>5UXK,<'/]((Q?H14% MO_!>BNB+>N/5U<7G?1+6I2/[]8">F;4;4:C;.*&@T21W!?J??JF-\\*+MZA( M+O@2VFE7:9X4EZHLI3/K8YU[:79:]H-6!L)6TBEBD/(RQ/;*5C#-IMWIM:?4 M@: (^]OZ "=#&'[VU,LL@5:VW5!Q:*2@?=5R .DX?F;!MEV MP!C(6KR)"SL04X: 4_83-,,XWF@_2\45K>>_X[_;1_13^WF#((TGF0J\H*Z# MVGO@4R@(K+ A,7Z:HJ,5%8""TJ\HJPD,#F/]-:KVI-CV*V7 G6<9:/]__UNG MVWV.8OPR$Y@!]PM(55_27?0P^$26?1+#Q@1ZFW%T,@**K%7<,!A:-4&_KIJ3 MA5SR((L/BI\\FM,E?': R>P&-2L%$J5IX>>;WJ^3F/?#1U[FME,[>!,G/B?V MD:JSNV,VC5Y+V/3KL <273D\6. @BP?M0AWO 1UX"BP GJ-KSPK#QW8Y*IMV MF(BQL6EA*5 <>W$2V1<']X!*2AJ'N16D(ZA(AO';9=B,6B&,FZ5O_!*I*H2E M4SY(08B6'!,:+-:8^%$:*9"(OP*P:G5B).VQ&EO0@BP=527Z\-*_A'$/\-O8 MM*]L%\D[D7R1)IQV!9"B;]Q\![4E=EQH@=QI6<=39!?KM&+<1SDGYE\B&"!2 M@IP'PSV,K6P_'=1[&P_)8Y%Z>WX^1D=-7RH%I5(Y@&O41GA#F21].00J*&!X M;_Q/.NM2Y?'8+R]=PM=?&BR5QS\@O:;CTFN6FU[3^<[2:^I/6AM3M%1C.&H* M5Z%JH4.)U:V9GEXS23,G)LT6I" O>&_>!%5$C5%;4]4"P-^+Y']5(6;[OLL. M[W*"Z=Y[D?;%GS]Y[U[]8S$ )J"3UXM\0[A5D\^#X!1> M+^4!09T(]"=XNI3W@V,H0YF8LAYTB!S@!ZWCP+QBCME3I0 D8'P,8Y:D,O_ MP9J&$+U3[$,S/X.Z8WQGE'U,O3( MAL!3&$$1R,O8E1)TZD8RMM@'&2R;]^* M,8(I1Z8L3L^+'!DC#U_*Z. 7V!6H#I;76ON(UEKYXQ)?'D;>W)2.&])5%&\6 MY#W;3\SV&FO*-@$J5"J-/LEEC:I:DY5)_F*)='=W"MH%3+^+%8H9I.AO%1J?YE(VNPMO3PX(;!"6&4..LE*13]I>?FBB#1[PJ MT4&&W1T;2F)B@MB89+-4T_>B#*U9VK5-VIA.A?]3KJ\M!&Z-$GT<,=])S*I; M'G7*FT/)W.UL7J,S1J7)8\KJXYEC14@1/L-;LE91FBIB54EF, MIU*E+EKY(T1Z%F87!;0V_8GKH$AQ,4XKRNY6KC?-5I1DFW(OL1_1A&6HWC94 M)9^B?XWQH3[V3 !S-02"@J/7%#;$Q0C(634;B%AD() MV\55J<[K;[Z70WE-:2P UL'52%X+S7=8@ A.W,2H7,FK6E9,M&O-\MOM[BAH M*#&?7JU69SXD&;HS\[XT?C?T^EF/P0+_$ MR?S7!9.Q^&EJ)EJ(=! MIU7%7Q'[=-8@U=)@YG(P"8-()+>[.YIS$8I9*)=)=-H3:QXP@\$G(F"M0T'F M]D0)!)O$B1[ /L=4.52J^G(2QK?,U:>IT0_CO'_0$REEC^O]@IFC#/M+_EL1 M\@AD9>9WR8Y3)T).?)7'G[(4LR(G1@UJE#TJQ/LN/G_ \\,PW"0.>4=&-\0/ M&[VQT[8B3L ,>R19TDQD\B >' "!'F R_?DE?*4O0TS_'DI*UJ>C !40S_% M]H%AI/$@N\'DA0+,)J$*;U9!8^_1RB"U4DYPUQC.@@*:3;]@.$7G@T789,>[O,8'&5B>$0 MFU/M[JBIY*Z'SX/EVG.O)_PO0VK?@A&B./F)NT$LX$K.F9-][YCMH6%A*69I0@? M'(@%X'W'=Q> A_<">)X!UR4_T%W/->SR/M)TJ=#82W/?ER0& "$L)+JAGQE" M!50Z$F'H]:1Y'0T>0<_,VP0*%TY?5=\!R+#HXRY(50 M'4RCB(_6!J2% O5=%ZA?;J"^^YT%ZI>"J4ZM6(9:,1:W5 ,7H$-*>+TD!FD( MR@)[8[#[7*Q[6)!YR_5[BJ]RP09K^L4>\$4T 2+)M;MDL*"]HK^* IT*W/'C MJO&?B?SWC:M*?;P)EA$S^2A&X33&(G,LV;X%L(:P(6H42#OKK\RT>$KXMG2T M4N&8M$)NDW]3!5_8]0CBOR]%-FI0L?XP4C66"?PX!C,UQ#+J.?5-\)!9-; 4 M@930 ] ;E8!4R?^F]WDD;S7RL=(R":5(,2(\MXEQ+?6$K42])1NP;^C5W9U/ MQ(F Z: WQ5FQ&R;_S^CP0C2@V?HQ@,M6,#_O@5I&J)EK$PZ(B]OX2H;5U)3 WJ,V4?Q M)8IO0O20-Z;HC/S$,X2FU:N,[>B $80S-B(3,QS$6)R.VI:\IF+./J= DF3% MRH,,WJ5(RD]/! G<@*$2P-I<6>]=?-M\FO6"+O:W8ZP.4#4#UQ/1ER2?9&!, M363&"62# ),V4 T'D3T$R0"D#;KVR,.T8];5D2N8$B1@#VS.V0_=4#X$M;-" M>XU#8)5BG@&1 87XM'<1P#>] PH0XT3W/\'*/ [:E@K6Z<42ZGQ74YZ62CD. MUCM@=6A54UA[V\:!_3BZ#GS=MTYX?A*,@X@:*6I%'/E>3U+CP[Q'6;I8F.)A M&U9*FZUX8T]^U5E]62*0T7K701Q:_CK5_S"(]&!6:F6?RG3?(?HV(-!VP^K0 MJJ:P^EO"/XD?,G@V4T1K%>VI!GRS/U1YT>AQ]A,)QC":N/!X2A&VC'Q5&#&0 M_0;\.J6^UGU\_EKXV+.[P0VP,4*2)]1A#1-\988Y>W^ \9OVF7,W&!!0?0%T M7IA2Y\:3.!$)^L1DI!/O1H%JKX>99\B#;X)4>B&6[^DQ84'AH-$F.+6PA>]K MI;NA1P51L_&$E&1S()@+>VW^1'.&<%X1C?C0X^EP4:6JJ^19E7&K5L(WK4\4 M2SHRW@;RV&Y8'5K5%-;^]DD'ZJ".W@QQ'Q=7^C?PN= 3*C^)>LJ^OO"X(IQF M+,5]#$Z_R3GG^G/"*>(T?ZD@2J-R6Y=FA$ MCV[&:0W84$[[F<^ATXC'"F*=$W;8)B=[@D6$(L?M*S%*/V%G;4SB]HM*\U(H M #O 9[?/X2W')[: _K8;5H=6-85UL,WB!_F?ECW$W%)@I3I'48F61=Q(C2H_ M$LV75BS[BJ-J]@T?#*Y%B%)-?L5.,31TM)C>VK"> MM]?FX.B(4ZD1/NPC2F?]1^K)9C5%JF3U[4W] MJ#W8/P
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�(H;G9]PG_7[,093=JN@2HZB,TA>J6*YT,B;HHEP*6KV578=77P\.R. M%>Z'85;K/"%:IR>B,-056E8)S[XWG1"9Z3?<(SH]<<^(:F]^FK+GD!6L]#7$ MLQMHHP*P$IP&>XH)4>K06Q<:[ MF +#<*#?@[9N9!S9,PXV>_ O'Z25DR#9N*@,&,,["TA'59'%@FZ0>!W[ M+@>:?K5+_,A@)U.AF=L!+DP">]N< M;T5X5=NZOQ4:\11/'V:*=U!/B01>R M2D2F8'8D81!9P:_7)&O!<=)L<=J5'00% #C)H@I.K8F=*AHEA\$=1*9F@\?W M>>-)6EE"XS>*Z0%KH.DMBX,Q--K#0SL@?X8@PN0+H:K1V@E)-)'I[S8/JP39 M! LTP=M1S+Z 9W5ZXB1_44 %B F1;Y(%>.$J3' QL;^&AB+DQZLD+XM #AG4 MO?1B6<&+L-)1 )6"BW26M:@;;L(B?SE55W. /X"*X4O)H2 1!#O#\E2,.(4( MI%2 @/N0N3),"7@7Q\C TV;-0/%DSNF94=@'82;*!IL*_T\QLYH-^AQ-\5J':%R@<&23 MG>NYX_)E9P1]9<8,V> !FC-;]\2LP;$/HK!+5@I$#W\*A M#QT;DTQHB>_@%3($6MS&5AK$L2U\$B:6()X$]B%DT[N6DF[I6.@A5FWLF8Z3 M5N*\W42^C9 1Y'N00F5+4<'.&T#@G .C>BPKY[6G)^X? ._+*4>Q0'('[:Q3 MADN T=WQCAJ":UD@?(.[GLOXKB?LNYY,?-=SS)HBON1YMUL?7_+$ESQ[JW." MZL%ZMPENUO*:IK*GIFGQ0^UIM6?\>GE!/^S'['M"-%BF_ZGB?W-6Z4P;%ECT M;",6F&E<[W3<]4YJM.N=;MK3/_5'/=E-=U[R$C2Y-"VZ .R0<-=PW\!;<:WO MFBN@I^6>%*U?X 7B_*; K10G#BOV@<^YUZT;YDS]-X7DTL[[.ESA0B!_T%$! M!UQ#"0&B?D-2E*#!78$FD_L:4A5.$:IY="_A]%[@T#_GQ!4G-<<$^@L*S;U- M)DD-,BLA=[X3EY(?%7G1 P[')D%-J"%AL4::D!@PI,#SZ,=K-\%7/*&IZ[I\03BIU[Z M*M57/HW-.SG][69=X-HFW?9]O1;[38S_%'H_7[(PCTB M97JWA;DWSDX4.5NK$,.L'ILZ=@\O\.#\REDTJ7HB!:\$$H@$3$UJF"GLFG6) M=39GC"4<(S%!(8!(Z>DY5)Y.!(]!R;N88)O3Z!T(LQ&;)J@EOFZ"V1C\2'OZ M)=CI%B[8*O&Y/U4=;:TD/=Z6K J#" :?3)9 4 ME1A6_$A%&#\IFDA$8,PDWFZJ2_I]-M;IB0]!>M;5)?/D_;/P! T$W< H-C7'@J88V*2A&;._ MF .,GW;>R-4S+L('_F@!+L$7<5 M#7O$6*D+!!V1PK+!^_!T#(3?%X#'%B4BBCX;D.0=#P0.P2EA9+0N!2ENOC M M3S%I*C:/SZAH1'KGP@CBF#+"S"OY:P@_>L;%']D2DA-0FJPAP!,D<3]6^^)" MJT#J$3SIE,D J2;<:8DC45$)KR ""2^AA)/OXR:[$. 5"D.(Y)@P#[J"1XUU M)*0D01H;.L7K?E&M: QUAT3?G%BAGQ0!M@>+Z/,4EM)4:-,T=9&FRD-O"=&# MX4!&\% 4RXTEC0EYJT3OO*"[!%X0K7[R$Y3S%TA3=R4?_AU2]4EO1*BKUPUH MFOH,^?N8>#5"FD[U%9'*SKO&BJK"R";>=I' RI*N%Z+3WIKQ!WZ*Q;_=O%8/ M4Y"O '8FV+D">$B6F\S/WI5PP(J)OX7W@6T(5P;0/*)':K8,.N^NTK6OB2TJY^IZ8F M.OM\AWJB2E<@>1D_]M2/5)*!IL!&(/X2T:(*5/G.5GZ3YDYVQU1D!5IT=Q#Q MOQ5MI*LCJOE5.'8*5X] \!$_E AT2;8,#:QU,!L4(CS3YU:K+,)H",>%QQC MVZ!Y_!T($&#=?R$TH1DX5ND6J:3$(]+R!RAG\HP]@*DZMJ/C0F%3 Z;J5A\, ML>&@2%1.T]IW$R[!\8.^EDJG)]CD-4AEA6[X"=DMR(++8]*8W- [M.TVU$&* M&BFBU#41H"PZP&R<3U C/T4EP4<;M:U MN"S@"&O[W:Q_"* G4_^2.'KZ7_;;BCH DE/AJ0.80VG\>^]55[^F14 MNOW60+V]ZI]]OA)-1?*D?RFJS?'AB2\R)/AA@X$.,\)\S=;X:6].=S%WD8QX M\X4]N4WL*!<>'4%\P[XH.>#.A/9:!J^9/Y& +#'>&HR$QWF/./ TQPC V"!] M#,L/L+7=!M0F* "3-DQPWW=Z@EUE @X$+Y%M@U_/PV7W^W-0([6""N7S$*F% M76!M3"6"ATA.3V:H)"$,59LF5ZP6"K2,*#EP+A)DI5A:$.F?R\^37> M!@([-C,F;Y#>%V4ZD&*:-BS333*Q#'(A/F&OY[T@ ZXVX2(SG8>+3)YMPHTG MLNO$?.(Y)U$FJNBS14E5_5*+D>B0761#'T31,$1(BG&)S \Y--/BG5_/7!ZC=%) &PU20A(#83T\RJ80 ICQY,_]88)_B?YL*:<^(J9I$_DPD MV?3.F,X.0#@QJ9\[9(ZZ7219!TC!O0/\-W2'.6;5I5_:XV,L>:H][:K?AY?: M6*N7PVF>'M_RQ?Y%I&[Y7J)]RY=O3V^T;\/'@C%!E@BW?,#FA^ZS'NM#?\HM MN;6:LV:PF/;?Z'GZV/".-:!\0%7V:,H@1?@$74* !D5!A?.> 4U=A/W)&I=! M9I/;&H?<>7G?<2&4UGDG&(+DZLSS3?R=$9H02_/TQ$&=YFB(\&V;7B(2$@;[ MD: 8T^1@T.&B%]M,&>[)0Z$Z. Y@BWF:OM,\0$(NII_J MYC/45%WKG1/8-4(XYWKWG-?*8V+FN,4/]4<'MYC]">C<[.N&1>NGW'$HF7IS M=UFV-A 17%"2;+29XF6+/>;%E[L0ZD-"=;GTU6ZJ/ M4SE'TK[?O/\034BGO>#I@ RXW721ZNCG9)VDY94'#8_@MPLEDV(OTT'G6TJR M4Y%U=OO.4OXP8PX 3U"Q!*A G\DX *A!V$>+U,'1-&91!8O*H!V32-6Z;XEX MY9H^P 8PTD:*H1/$4;PI 7.&X^'$P]W#N0UBF\,WY$*X6 M9TGDU0QE$$GJ'*:?,K#+1'&@#9$P (!#<%#G^5./9=_ARP>\+1<0P^,EVS'J;'X\M=MZ>=8OY;3V_5 MFX]O=>6./CDE%2>GA)VAD2D6 MSSXWO]0?6N>MZX=[H7+=J#>K'NK:-??'YF7 "@@%8I\:W#M%&R'38AX#,11G MKS#2CM/3$;5G0("#(C;L>HL&A973;.RD*;RTS.#-:_QD<>GC 2#]JH:=$1O> MS,O2'O"C3:AHEANTS@TKY+92;0\5N2T/VW8#^V9M"::42F=2[6FZ^D5[R&KU MYFW_3+ 4"S:FZIW'&6?X&X,U0?+S[OK3.//)BI)9[WKE X&QM_Y[IKQ:GS1[ M(.N6C"1E(&)&9C^8>&:U&\S7V!C#$SA/GPFVIM#18%EGG[-<5O&Y?P&?G&$=]<>@B,PN\>EA7L, J>&V/-8=H3P>%6P-5LIGFU9LS0\]FKY6NBGC\_(OY4A^_3"Y3SOBR M8@Y5$9\>WC@L$9OE+]>5Q[MKH7XCS&[Y<=SU;KPOJWWZ(OC86]_J^G9P_I*7 M1B/>=,^[5P$)@8'927:@T]TZ,V4'YX1@2'AF7S?3^%SAX_^>8=G(Z3Y[F?:H MW%=T7\@KY9]F"\V&?):$E3;<@]V>%BPFLF<5J%4N#""4K)Q;8>^>K?%29QLU(A#5AYSVRI^(F$L4\=/RG%:R; MHLE#L4434\W?::[$PC82I_6>#);'9H4NA^1!Z;8I:K(9V9/Q\9'CF25S0?'4 M!W%\SYOWE#2Y:=/,-W+7H66T3'L@5FO33+G5GO:SN:\WLO1#&FP3APMFSW^% M#J:,GJ';F@RQ*-WX)!B]SH=T,IM(9XJ)="[W,8QB@#RDIP1DFX1V"G@?Z2S= M5D@D7Y/MYU):VF =Z7^.O: AM>.-7D-J;C+;_,QT24YNJ.'\I==^J_@PA,N^ M\XQSUY?Q7/5AD7?V.9LI+KKK>_O61HH08L:*&2N="HVQ+B_?$U\%VQ/9('OB MIVX\5[4&H/"9@5;$M]*+_)B9=J;Z-@U1UKY-AFQR+$7+![A=Q*&GH8]I=!PH6Y@2'3-B1T(4Q2\8LN25+AF>@Y//OE26##9? M=/ :LMI*R[%7+&ZO5$;?I.+UZ^W#O7SD48;9+4\'R)*97-H0]MO90#ISO(VA MTT[00@XB%,E$!%FW.RJ*KE0,8Q6'$HN8O'9LG^0SR=U+PW1D#928%V->7,&+ MX1DFJ7SAO?+B/*S<!;;Z*/M:8U2GKP96L#V9YW/]9_)ZJ M=3PUP6P00)\2%0,J3&>+TC9[;SI(3\77F_O4P\/9Y\9#O7']T/HME&H5X?K[8[4!N"P)H7;=6E9V M' H.Q4$W*9B\]TC.BPJI,^L0L8=TG[I6]>>?^VFZ^F;PZX/(&;[&Q.G)$)9) M5#;B"TV0)@,$,16:"SCPDCJTA@R+DH/'#\N2C^22XS@VN&BQWH>_/DRN:T/R^5.E&N' MXQ*NHR"LO,<_:C4?LL;5C]=\MA!APHJKO&*1'5=Y;1C^BD\&RSLN2X]&$GF8&U+63>O3TL.+"U@B6\"R@SD>Y3;& M!!@3X,XS?6_6N=VZ-71O@7%_]1-7$V@,4WI5S';;^?:]*/45#1D3[S?O29B@ M/?U:3Z7O7O]\*:'.D6<1[POFQ-DN.E>XAE-%;%6))+G$N9&+41F.C*^/!)5A M.3PK!AY!&GWA5P0\QZ1[.?$62]U%Y9+U=X5UA$P:9-:O>FC62; MV,PX/R<].ONZ*E<'T/24MJ^M=[N*A&YL V^];: @HZ=1_UX:]Y+5VTDONK7> M81ZNLY$L%N/9SH2@DPT5NGQ'_9E)L;=U%)[,\8M:;N50YFUOQ[LA".%,+A5Y MW(N8SV(^6V72')S/4CNHWOY;+!SGV]"7VK:0,6?#_.R.)F;E)?O<*QQYX.8 M(#5\UTPWAB.QCP13[UICT4 Q1,:Q2.)W I$10N1G ;>'4;%:W ':UW%@:<2\ M&_/N$82.=LB[V3T@/QP3#LXVMV,#L=$H7=>FR=_U]O1;OC>Z:>2+_?$VW;V/ M(0\C3#RV*IH(;F"A@;>&Q%6BG]6$?R ][TTT+&*GI+/ M%YY)6ZEQXT!6V@/38Q]\_7'__4\]:;4ZV^ !292. NR MY;'[=2Q2,S+NUX?E@C4LGM^QN9)+O@^0X(\Q!\<<'"$.#K'G02[S#CDXV*@J MK1-&F847]EA)A0X78G3L"6& MBPRX\\+T,+'\"&!A()1?N/@SKNE_>H)>AT@S\0!C9"#A?V8Q@+U!/^^#S!8- M1!R^^H*^O]J9E^N?+O2O]UF!OW,5?WH?V@KU=UO_8R%O.O7OQ'B*T5T1:^2:LOH\W_^W_FY<*,@5?XD-,0>5JA-[*D@ M3<*#%-+_"C]$U8;QA/-S;F3(RFC]> 7=$><;=($;H6FNQLA,):$,=%XEN[ + ML^ZGI0\#M96K"^=%N^]U9Y]OSKU;QS?M7P'2-C\))4/L*-*_0@TS#MW8F@Y; MF,I[G_H__AC\R=5I7)_]Y__P5@?MNH'$Y_,.PM2.!Q^24V/[C!?&-]DA7P]1 MNB0Q](_NG13,ED[(0R>A<,3Q:\==Z_3_=#XWR_7'5KET?WI2K94O=@$D'4W# M9->SKM5;U\W3DU9=:'VY%LKU6K-^5ZV46M<5X:9:*]7*U=*=T&SA#P!;N/F7 M:(,]@-?7L48V[A0L$%7%4I"Y&K/^VF/=K/%T>YK6E$KNQ_V7]*#XCJ#J\\+_ M_G]%;+W].P=8?]F>5K]]'3X9:/BSUSW[7,#NWM->?Y#V-/GX\#SXKLIHD'\' MA^X_X:M\>]I(]?+?KUZ?\NK3.E#I2VD@1C7?^MX@1IS;$'SZQN.AU\KB:^UG M[T$O2E$%I8L10(^%L'*>8,;#TUW3^JH/>YH28<**/$AH#!$:@;-Z3Q"A,:9Y MS$-'PD-11J>.+9J8:OY">?OW^M3VM7EMZQ_XN9@N[K<()-;_4 MA:$-<]OY%M*)L8T4V$Z^M3 W!KR,+N"E=R3HYGRNO)[W%5E&^&V8$=/*:\=0 MD[ET\>SSN;.LD%87J;.(:3MRM!V8<=0LM\J?@C7*CM,F=X&R<6S@K$E7:[/; MMFN6 5:&GNU0-.MJ;5=3YSO?'HV[*VDPS<7ULK.;SS:23IHGU,4%=BL.)BZP MVT >!O/JCDL\THO3+R-5*A=#AL4,>4"&##$?NO"7X8#E9I/"YC.$'+/%4\+J ML5N2 RDYR3Y7TD_1B3"L4TNV(W@P'3894#]@EQU;)JZ1BX($C6"-W'*>?@_F M35S!&G/G7\2=(>)TI/9@ZT2DAC73GA;EW^F*7+EM/?>C6<.Z^YJ#JB;I ]02 M7U<7&Q0\=N6RQ]K3;\."-E5>BLUN.MQ]WT'MK5-$4!#.Y\H'TNVI>E6[@E/CM8]:HT=V]:^VS:^];AW.0; MDMG#N'TDQ=S'?M^1O$B'/$OQ(J09[IX3KT138=TG]*Y@B:\B!4[L? [0!3Y- MX'!<4#VJM^8S.5=JF_06>^ZRW,-7A;MR3LNKAS,-=\ZZ7U_*<(U[6$!KW(K(:\D,76Q<.7H"03J:*@ UP>J)K M8]&03=B46>"%*X^U<-WM4O QVQXP*,^(&S 2-@^)DQ>LFX0=@!$M6F)E@U= M@WU?;@\5N2T/VW8#FQJ!(!?M>>.D9%M]W5"LR4Q[H!O=0)AXRKJM6<:$]P:J M/#^KM^6KVTI)<6 ?G)ESFG>VQ/#-/B&(EM"E"\ GPU8P^] JWR&$?5H&RA'0 M.B5H)];T0ZJU&\<1.4][/!$X(>R*+$0,_"=LYEA/($1 J"]8R)S*]DI[ODJB MVA=)_04#I\-6!8\7S0O2,TK4F!(@:GJ1&@A75\^R"J<%,EC8!\S@T03]%L0SWFJ&9(O#UZ/5'CSA.AON'#OA!/>\,&B;4C*SU>%. M:-9:#QWOIX*ZR#!XVNBZ_[A2#9FS(#\[J'I[&SD?*07_E=.*Z2*JT]H#9J]7 M$GDE#+:TNBHVBX@1JB&+6%.(6$HF"92@ =BLV-J2%?RI ;B6IM!!UA@AC3PD MB88Q ;=1'("90YX231/AG\"45=VT @+DVE4T$=M;/!W-0$/H&((?']K8.@8D M87@*!N;CV2:B&+ >>X]_^4)HXCU3NIAR-8L$Z>O='^ZX/G]O6,8&<.1L F21N0&E&]&Z+9Q:4 MNN'Q3F?$R_D80F,$>Z-T&PS%E/#A?Q4[F_B$[G7X3,QL6:L],*VA- M%*_"OZ(%F@*J:>EFY'6?EH9W:R8ZDPMF1 $O@B.EO4Q2 -;;2 M"P_^-V[IIG@DT>?7F!F/EAD?FY49G(RPMS6XK_QB$\@M@9U>CC)YT?Z1?;ZY M/%M^/%M6A;AH$AMT+G.F+JAX[M3&9I-?D#&3_F?A8,MBVVMD,B\M< XFQ@U& M/5 -NI,!O9!&=EV;D$^D+W/K)D![SF#M#.?@HXG)98_D$F)A8"Z1*Z;W12YK MJZQU*OQG#GTI?:U+,0$DL/J+00,>TVR"-5K1UQ2(AB_@^HT$+TA3>M!FT\;4 M_C;^?=-\D7J[T6/SM,#NJ.L[GH4 MM*.[[JR82.8O WAY.,?(AR+?-UT5AKCGX0G03"(7J&XWW?.WF)T_.$N4.$>T ME1JW1&6E/7TLYZ-D_F48&[<>< M6>@.S5HYJW8L'"\J1-=I%1LLP1S,9;V8@VNL>_V)O^MMRX6\;4'UQ"LJBK/M MJ?[RJ]ZIWZ=3'AXZ5!9[>C]9[.'G,1Q]>FF(*'=N->-<>]6$]SI=Z(NF,#3T MD0*M6$6A:ZMJD+\'(\TUN;UF-V^CAZEE9%[_/+:0'7T@F=%P##J.R=='+FX_D_GNR+J]JPI*1O?MI]Q[PHK9I11"\7'8OC0B@'2PS0F[3" M_O0$,B/QSMN:J@P4V K9-HC1=2$\:C+H9'R64'5;MBVBJ;_J'5,H218\E4ZF M"@E!=[\$GW\P[*A(D/FRV*-8%Q/R:<&B%(9-5]5^AX31]J];N/D$1J$\,#3 /Q ME9@$4'QE"D@C)HC8Q4[1+,VF"N2]BG9Z0NT']LQ !'.)$(5"LU3)3D)+V:Z" MCP13:4+HV-SFD6U\$"0=EAA,IBWUE\\9VU%LVR^$*C&K;&SL&)8(,U&Z-%=6 M%\9@5F%J CMN)!H*/EX!ZJ2X682W"VB*UT%K:(RY!VF8+ *LW'.V?"@6 M=-%5$;/51L=?-A-0]D76'L]\CS,/MWSLK]N 7:YYUW2UW@-+'V($ZCI+(N$SLD=5G,)Z!4 UM:^&&9&@22;D#01*,)G0D)E^&?L!6B0 T*>K&)4>"\6A\!3#,>RD#HG%2'X]$47::VLV<- M3FV+R P+K.1M$\&P>"/0.7VG@(T?G^UJ>J(J[M=.3TB(R;(,!5LM$ +2\19V M(:V#C*>;%A^0@ZD8K)"(F4*.N=($XX;\QHP[^ *-6O&P#'H=*G01<$X^ ^CT MA%E +)O$MO#BIM3N/.Z"R..Q58[6+ EK>?(;0S04FV$@DI K@P' X@/3[\!7 MXN9"#C@ !?[Z,BS26-$:U"XW W]SD9]2:&>2ET# MS))>7SF8;68]$MEV4) <#X(Z(71N(N4*VU1=Q6*1.1L_3L)S4'B7;+LE>,N0:&K8)IQ!HZ%1+.^7&""-^Q7\QP8Q MK68>Q9__QG87O)F#V/SI]KXV\O<]^>')B1)6W:ID7NL\61487+#V0'@9F@B4 M=%."''B9A6OC7YA;P=M"B_A(SCX7%O?0<^**">'#BD!M;GU">&Q6CH\0)JWZ MGV3^UJ@]J'\A(= 8N3H*WP MH]021%M6+#=V34 #TLG4Y3DL_*C=A@, MOT5<_U[$%>B="KQ7#USK6MT;C5] M1 VJ5''.H.HJ*L28-+C_1'!5XQ6*RHQ4U%G.BT*#8,05'8ZZQ M##S&4XGGZL6GLGE^X7R(RI\:!HBFE!!'"$V%NYH]+-]N_NL^5N[FO7<50:?,'$0,:K"M=+X6BHLU[* M6C/>K6/"DUBYFTHO=,:BZ=(#]A[8[0ZY(!%]4W7Z9?(;#(?2@"Q8%%;7&*I9 MK&FC('MB3?O.3R6>Z\SU.\SMJZU.6"ZFXV482)3ZS,_H&8C*M;%B]1<[&PE_ MVP J3UWP1G+MY L!,26*12[7MK(M46T;%#!.;1XP3B<+'+H\6=A-G' R1/5N MR3#@'APVB0XAX=/2!^?G);YW7 ?_^M.3,S4Y-3;R0<%"IE.$#QVZH(]AJN/T M>;+ PDZVC/+""%TG%DC=+PR! M@PT#A2:Y^@0_+C![PKLQ/LPU,45]1:_$3OS\G_]W?B[<*$B5/PD-L8?^Q8.] MV%")]$DH9/X5H#0-QA/.S[DVD)71^K7K,YE9>9+\M1'HZ6HH4]H&:KZN9(.V M3ZR7[C+ NIF+\)MS[];Q3?M7 *'Z22@98D>1_A6 #>G&UG38PE3!^]3_\2<%LZ80\ M=!)*_[N0JX;X6GS0\CMH!1M^XV$\^6:Y_M@JE^Y/3ZJU\D44%Q&ME%K7%>&F6BO5RM72G=!LX0_NKVNM9M26=ZB6 MU@\TVM00#6O2P@:E2;6JN;K#M=<0VF"4]O3/_9]JH]1Y^9[O;9'5-)^[E;V\ MR"]('&8?0CD,C'].O[J3CMA%DKV;2OT[UQ>[TI[>*8_6G_S$G(ZS9Y\?KN\( MV39*#ZWJ;EMC'WY_#IGQ=A1QBOTFML$476#^C!>8'UQK6\6.XR)F;<&A>/AT M_*?244??%>U!W.(LULJ5VTZ>P?<4S49R"?L295U+)I.Y0@9_;46'@PUW8$=M MQ6=$NO?D0@K6X#>P+:+1X$7[Q5#F?3L8KFAD&PWK@\V&'AQ7H@JYQC-%X3-3 M7MCX@CI!OM7-+"$=0KXC^77&YAWH4QL:Z0(D MO/W$F+?&;M]@@;L]"GX_2]=$>C9$]%3"O:2)>6CO/+1I*XFCX2':GR.B!Q&I MR;XSJDE%]B!B81NETWI/!LMCLT*7X^]K$]&3V04?;0G+NQVOT6NHBF(@R=(- M4_@@\Q]9=3RD*1C8 R)F>F M^J$S!'H.0L-HKH\I7$^]?_,D/SAGP M.W+#GE[]TJ[+W[]);XQB<1#>I5?HZZQZ&?@6SWZ864<(=^?98L#5^7;TMS[. M<>0I.O4FBIY-K0V%HE-ZT?ZC37^5OH=%T5[1O@16NE!8#"L=UA'M21,L:E6Q M<5P_L*U:F-JR.< D@20ZTX?_%0?#?RO"G25?"!],A !P%@E%Z>.;C\7IRW6T MF8E+&WOMVLIU)4+YX#J.D<1#29,KF!*X7&B6;O+*[:C2@MZPZ\FYK<_@P&W0 MPM*R@3L92I[:NOTN(D+^L3C9E3@I'=S 6"!.'LSOI<=B[>=CA'LE*SUX>)#F*B:XAY=:-5FUGC^]/^"4/;DLQJO#(O>O+ M[J_QY1>K^R.WH>#;U:D<3AQF0A2':W?V.CI;)N;X\#@^?7!S9Y[C^X/++P]B M,X_&3^^6XW?C3J7\[M3LUH;1/'#M-I)1DT21B70MZ)1W]&)Z#_/[)_%1JL?AF -8Q^C(EG#Z\62"[KWV06K1=*6BX7$&X1$-@1C M;EI\^/-00O?7V6XV%A);F5\1,;,.(R2"6M<&U!MX6]>FVU.E>/6S4'XJ]RZ[ M;ZU1.U2U>%B5OU&IH/Q/YW-0->Z^P-6/HM@LAE9?;^J=<*#5]X;->2].."QG MTM^\4%15P&>CP&& ):>,:,\'TR8M'2Q=N+\02L8S_O.'U.7EY4>6/,!ZS9"_ ML/XR'Z'?BVZ)*H")S>*>>.^IFI8N/5?Q*Y!VA M(A-%GTSF4@6"?P(_%3WQFZ;=,159$8U)4X3"/#+P#/Q)@RZI@;6[#]5&>[FQ M7ZO)@7WO(LM5^;))PT#%,E>IWO56$@B DCQ/YLY3!>>GH@. $CSC-;5TM7;C M4SS\6+0BJ]\'#YTOQ,*W@"GIR!8\2_*$CU:,\U M)JN_=JY54DNNL6YY#C+?G#CRF2@)@5T+T"95],O$^B?J";I)"2.==)9R4/\2 MH*9 SELNJA]]$(9@XPD %TB?(?A](]!S^,6*P;M8 6*J240L: M)'PP 9-<$ M#02*L2N.=(,C^2*5+8O]K@^'NJG@$2'J,'&:W&'-BO>$&%P&&N*1H;\>O.B# M^9&V!1P.54S@V.E(< C?*QTZ8''A_4.GC;( O7L"#\?LW"]L.$[8MZ"C-Q*TY(V^Y90_6ZW*1R[ZYMM"U^HH! M'=NPI4ZGX9>_L>A]KW07[;G&9!7/]>VB5^*B=ZQO*GBWE+LJ,J'KN*AY!2^7 MN70R(&H'.KR/?&V,H-E2+)7_#I*,]EQCLGK_^#S/(SME/TZ0C[UQ:I!?]\>?ZK.3Z>A]!^_EMRJ[<9MY MK==&.80BD^+B%$<'PY0[UKN>S90[13:_[/?WE\>FJYG6(B"B' M /^:1OD&D]F;%Y19PQ#?>0OS/=2?K]VM/!MW*P^[6WDQ[E8>=RN/NY4?;M:U MN%OY+KJ5D^)QJ#Y#AGG]8BO6I*9;:'6O\M0L>,$Z8[2GK5_5;T\-ZRF?SAP] M"HS3B/Q2.)]K09YI3U.WKW^ND\WTKU'Q[//U]\=JZS<[OT^[$ OTWP Y1B1-25#800LKSGDFX 1A*/PTV+'@,8!' M-^N$Y?QW) -=(Y*.0DR4G-=PW [F=:63[;9I6.?G+?"QZMVJANTU1;9%U8^: M2Y95[\XU(_KV,WV9Z]R.L]\4[_4)?CO-ITJP9;GK7.,B9='<%X"@826"E\$P M:(,G^D;PE5PBF4S"_Q:Z;K-EYBR;;"@:P@B5P7R6H3RV!9]=1%C[!RO'?<#6A1E6?DN'%(Y,]]9.*^'C MQ&'+3/1[S6%TO=N-"1YR(*M/R9(4 +0'8'\YBZ!,,&;&SZ$U[< M#F$>,X7+1'H5S./:.(ZE37 @?HH&?K?! M<$3)=,Y6QW.WX)69$UZ]$6>? 22-"D*"B0G7TY"Q8R@F(G$7:ZROX8T35]#K M\D&2#UVV)91F0%0["/MU'TEJ*HS.OL:R?ZX"OSP7#*<4<2&TH&IM,$#XM$ R M&[J$D&P*'WJ&;IH?:6H2KVSC.*?P.V-]Y67,I?>RBLP5X#Y\0!5.O= MV4-I#[6C/;L5EE71Q(J&C5 W'J Z ME5HGF">0A*T,TKT!6V1(OIK ^_S?!;TK2X%]#$G0#.B37D^!<8>E$Q8X_G > M&Z_$N:MQ\^-W_E[J7/>+,X+<\JZ-16170F._>87K-&#VK\''B="7$+AQK!NR MB;35QA/>H^5AHSE],!._ [M*XUNUS+!*K2*$:S8&,5.9=%^"CQ]=T5K&UQ;+>V-I[Z-#9:[R.1RJ\.Z@DQ,?W+DJ;2 R<#" M,F!(/ %/[)9$?*D?!6*;@K+RG;R""OF("HHKQ^+[5NI__?ZG6"KFHB8HKHY9 M4)R>S$F*R^.1%,[QWQ1>\^FK_-5+M1<521%T[-MY:\DEZ9>!DF+V1+V-\?B2 M2II,UU1W,2A:R!@0UK7N UN7;GEX6O9/_O[K5?.IB&8/C];.,6AH#QI& AM3 MQF"I_U8*;.>YBN?P+A$A.NO&K=J6,TA0#/:/J%065@GEG9B>V?1%[G"AZ2A9 MSQ")Y*D(^%M] PV$/XJ*B00_+=P:NCUD76;@W!CN>=DIQ'':S8P5>BV*R1XH MF7BUK(2'GCCQ=EV@=:"$67[,M]$,K_CD3H/BQ8@]U):';;MA&RBP#'2M"W1W M"0X[WD]J(_7'RUTKNTB5>H0IF\DB:=HLM\J?EB]B6<7HO/2\F\I.YNN=I MCRB%W$PJ$%-BC#KY\ MU[;P6R^$*OT5C0#' GZB<6PG@.*4?D&Y M2QXH63%SMSP;^,N:3DE.=B#RU5 MW=YHQ,P!F>VAEJ=1D["(ZJ7R]-50Q1H;"5)MJR^>^%I,[S MBX,GB\.G+'0BL#P,"TLE9HHI!I2 *(;H;3?A%/KQTS40UJT&E2N*-D*F-7_, M&5=^\"UQ;94'-D!+KY+''Q F1NU&IW%GK#0]:1+MX3 Y3(9)!Y6K9LXT!XID MJ@XA\#D*7FH.6*=!9DHJ?8*#H4N%T-MV8B\4E70(*CE'4+GE.23^SA6G)_CW ME=L%OW-,,*%$_CQ7*I406%HQ]Q>@=**G@]9RCJHOCF:$''J5L! BXFF..(N; MRZ#92JHM::\W0I52I2BAY_S!A-!<]=5AA9 F)P11DK"7B4]4GMG42'3+I1"ZW.!?7"6F4A#$R/!HS08(< ;GOB\[J44-[ M.*U.0Y&:O=]&.;?LM&QMN_/RK.%@)Y;-)PINV"8@,\4U:CR'1XQTN)?7EF9 M+(L8W8L61) G%7PRWFAH2$>GC[]=E3+EY.C+;/J#Y7$QUHF>;;#W,DP5(EVR M.('J>XA:KQ]#\^X(EF*.&4KK4I*+4@^B+*JCKVQ:T.3)8RTZ\8HYX["POM'/ MX1-"%VAR+_M4_3.U+@>7"\Q_%& 0ANX!A"O8EJ$RY!8G<'!4AIEPM'<# C+O M#F@[3)/5ER_=ARQZZ2W61G^!Z1!+O*,PKX%93(2I119>;$ <)F1( R8!LF]] MQDDEL]S=3>8SR;=?KM6_?NT\U_LUXRFU;Z,;LTV6^ZC)_'DF&>(-*.><5#&7 M2!?6X)RKM8SN)4(NR.@._;32C]]'I6'^MZX>Q.C>QXGE"IE$.I??S.J^6F9U M5]Y@=;8;?:WCC88/C8&M:=#&MVK!%MX1G=V<=;>%D9WY1"V@W-X=]GG MXC>EF[^=BL=F.X1A=:]O.[Q#D1>7C<9EHW-33T>D;+3.RD;O14/J"QD:(_27 MC;(N6L$UH\M*1BM;EXRFD\E,,DVC'OBG3%@EH\-OMXWL[\HW(^U6'9+[>[9& MEME)$PQYAG-"T/!V*K0(=&>EI! =R9Q#=@C[*;/+4M)4LI@H%A??1&Y62IK> ML)0TU$,=WBH3]<^OGMU/':*4=)>GM44IZ9[JR&(/8SW@C65%].O5]>Y(%)8> M!X]J_7[T^BLSYU]O5M>[A>#:NJ[WT#6]M)SW]&3=>MXHTV[TN6^K,L[K'55G MS3'O=HYDZ\?]\(_Q/=DL!5U('TEU%I<#D2[C7$D(FQ1GA73ZWVH/O3\_Y%(E MF3J^XJSU3WU/99S+&A%L4IP5TN')&?-1R4^+I0I0K(%?'!)3+K3$-!.<" M:&>/GM&[702Y%QL@=656(749-(!"N\65R]>U7*MM\ MDA?<0'M7/K_JK5"]?*O;,'#NFW\(-]*7V<4I[FYW+J'4A2PV&">ZJ%3AWUV^^#G)[Z M5IEV5U&'N'2#5H;G-UGQH2DFN1BNDU/,^Q/E&[1WR\7MW<)N[W89MW>+V[O% M[=T.-^O:8=N[4;BBRXO\ K0B]J&BR8#L+YS3KT;MV';;)(TT;$K]*]!6: +P MS@&N2OE!YSOKY0W5^BLO?MA5N@TT=!BM?%_6Y7.WYBRGBT.7X\].3V=';[NG"0RD4M- MGPBI8E!F^JJ&1A!=+QG/Y(\+L]2OWY*EGDL56 PUERJ&E)HY+63S7Y]>[>J5 M?)19ZKGS5,'YJ;C++/5T^C*1"ZWATKA'6IW>EU4=+$F_DD?*DM]5Z<5 M9ZF_,[<@OU66^D)1N-UUTG6G7Y:_9KY/)#?1%29#W&@B#3=/4U\@N68N?>+L M] C0;/2Y;JOL])4=([9.Q=N(:1=%OZXN,U/MNUY._II+<3VJ['3"_G%V^D)# M9[O3S[8*K[=%(_L2?/B'SJI;\] /E)R>VCJK+I2SJR>OIL^OO5Q&N]Q)5MTF M'+>SK+HX.?VX5[!-/K/7 F96JW5F.O>LRN5N(-$ M\W0V3C2/\ KVF&A>VC31G#<5"3WV;K19!VWV]D99(Y MT > VVV?9)[;.LE\%S1!FH]'(*\\3 )9TE(\=;'X5F2NI7@$Q5[T!3=/4KM! M'<,6CW\:-X_ M! ,][8"*SO1[QM1J@NR#;$S>]-F?WT4JLD1F:"5H?I'DSG>]#*,*ZEA5 MS;0,&UY,EVLI6'BX*R?1.B?L:+O1,^9!Y=/>LERH^JMW2R!J>V0Q?LUT1_:E MQ%?*%%1;1@K\K2>JU]!&>^)_B.W$G25SA=:X_UV_1;WBKT=B 8@M?%_C@[_S='+;,7F<4-%38C.D\N!R823Y!04!6-AKTQ;2L6 MWE,T4G3;5*$UMH4TF0+1<"K%I-B4\.-E<9# )*O %6'H^S3H8'8*D-X\\>#J&.H%\=-,?J:5[M91= M9.>9'AFQ90+F>AN[*/2 N2;U1OYQXA5S6[!^\U-_H")33"52F<4]2GS!_;NHS3% N)[.7B^RDW M8<]CCY"BT,*_YF;RUWNYB6V@SDAUB#03*Y>^.$)X M[DB#ZSE H"%E3":GS,VF@ H)Q MT9@X36F#N;HB>)VTML(N!*^3VN:7O5LJZ7+UAS8NO=H_JX6C3FWSBL-H)GNO M)(;-4MM".?V'JT&C^C(ULX_]HTQM6_/4(P=%'LKAU3M/HV^/Z:9NI7>2VK8) MR^T,BIS9$QNE?$=#J;PC;7AH!/*WL)/C%MP]C>J=6U/M#8+QI(]8$VZ8Y+T MZS+RL.*AD$%N^BWW9SSYBAI!/8N/4B4>4;;W]K#BH1Q>3:HG7X;7N>O[W+Y4 MXOYAQ6.5>'03YVE.,%MZ7QZ8YG2U69Y@/MSVQ;E6\OYW_^>5^7* [L7Y77^GWG(@>J!OV^TY= 9,$&L!,A<$NYU0V$/TGF(@HPEAX3'=B\JV$,* MO<[1QQHRYH5\?GO8ME0R \43[*?+=MLTK//S%M@U]6X56],C1;9%U2_DJV0+ M2$(;E_/->LJX'18,XR=GRZYLIA;R-L@VA+9_&4BM3AICH&T M*>#52WVXW877@9-R=TYZC^YK[JA M/J'G;_TU*A*]$8ZM:A&]B]GF=-VIAU&,N#CSWZE&7)JPM2:$6$A'U?NNWO>4 M7[>5:C\8."RQ*7+8!IN])7:88-KX7[#M5"I*4']H6B0!Z8/RD8"!!T0U>]"/1-<.F-D\M,!-[6+$6EJEC534(0'=M4- 0=->?AJ M; MPE'+(5!#2?HRN1M^[S1&<_V0%P?M!FPB@DQ@H-?!I][@6,-$J*9&6B9%C+3\ MPA-MV ;H#<+W<&P0E71R%ZT]W0DP\6)/P1/]*F&%4@;XEB^VNKG/XQ'KA M4H&;ASXA@EYL@-4U0+L391B@"?CY>93:-?DV-6B@ 8O80Z&)B&;V*:/WJZF, MU?>4,'AA%^D[E_KFR^>Z:^YGJO@\[1$$^)0Q2:0"!, _3C(U/3D1SAP,//Q' M;(5R^<)FMP,+@3\&2TR4P><@24O$3*,;9@Y5!4B&X6[".2!- M=C[ !-%1-)YZA+E.Q[/ SRK8/! -P7*UG4E+].E,.((%(HS()\\)]",S$Z$\ M1S$PMW[()#\2Q8CIR5)&",8E?@AF--/OP S$"3R-UPF?.OIMY@W, \&6Z1B[ M+0B(&/\,A4 )J+^0D8K?0J\K"%^9R/6#L-^BZ19C#/(J=Y_WA6Y[7!&0#7J^ MY>.>;R'W?,,F>MSS+>[Y%O=\.]BL:W'/M[CGVW$M+?A$5D8[TK0KDJ63GTEG MGC,!88MT"/K+L-%^ MRM-MQVQ/E=_77ZR'YTYE(FUQX7(PN(F2>7J";4GG>I-Y?6F_90LEN]2KX\Z; MM[#8N8GW!H"\[MIN&A<>@]SQ>9W%JV)[>JEHA7[AYY7T4W3H0%:P*R/BMV 6 M@ Y0Y2_7E<<[S/WU&RR=W5QT%[B&';K^QJ]GL89X34BMZX";PM7V.7UI![/M>M 7H9$# M$PP^%VSV&F[-:?TKL.-S%DJ6N.<+SR/>:WY=P1(SL!,?;_L>MOW:::[WKC8> M2S/X^+]GZ5D?/:Q#V+4/<.T+M)&;@_]T#.'_/@L-K-!)$%_X\#\?(WM6D9KL M>R(LFBA&5X1M1'H=Q$AKYE:/??J(#2Y#G8!1R#[A%G-D#]2-I.[4MMD KVN? MK';H"<7[%._3WL3S=MERY*[W+]O&HYM0?*Y'J^S^%3K8S.D9NJW)$$70#;RW MO*B70N]S&,M.!,_I\]& @>J ZX>Q?6^," I "Q_)]TDD,RI]_4EY[00VNLM_JZ;>+7M<;XJY.ZAGA: MR%.A_".I_'D0+^=JWMWDS94I0?X@N1LBGRG%6#&;=5.&2"K*FAOJ9XG+I2WM M8RXY")?D83<4S3F M9U\!6S6.(<>Q]GB?(K1/D;#8CC^D?O!M/$ RS]I4N%4JPKYMUNQ1V*R+V@J/ MLD.[VBC>_9"#N@IL89N^X63>D<*!).^NKWM;7>&G!0& M:M);O2,*;!1R+4S'7S(6AA[?3=$.*0LY[X@FDC=NQP/]%^AEAJ4+:#!4]0F" MUW$D(EK$;")C1 *TA@[USH;Y:6YKO%65NZL)FJFA@!**O4":A5(;DL-R9\YC MWP%)5#5_J^UD(JASDW"EBX8,.K[BGC64OX]8:Q#2P(-FZE8U2.2$0O.&BB?I M;5X)'_".E;OI<;NO;7L')]_JH],3Q=; M]%:;P8%?@2PI>Z2#IQG1U<3]2D.OO, M\9[M^"< M7!AK/";,]*X+/P3V11CSK6?Y[\Y*)W;'0,[)DW;/2;S.5<,9DH7BY&Z5K@ MV0"^1H_C13DM=UUU*+FKF-6-#."#+N7TQ%&1%T)=8]""J5QB2SE,.%DR$!0O M,D2;V<=U;TA'V9R(+.A$#,86L3OBFJ<_Q?V1O_9U)9QO^95.X M_$_VNMYU=MK!M/OUH_$G>?N[<]=_IZR=.4]EG9]R;V'MX#U\$]?FLXGDY6+4 MZ6"F)0Q&8<+3(?"7PS/K,)BP$7]=[8V_\@R]F?T4+?WZ,N@/7T:IZM>^$B83 M)CQ'RG*.K:;#*5N%R<%;*0;2MNXPL3X'7>^?CU'DR&]B2(4I\7"@4 M$H5"<5,^CK2G_+ZN!.G"WQWA_Z#I M.^=&G]=+(S9!][D=(79L]M7X"R&D @1" BULO_ZMT@)B-1@)2U@3,V?<+*(J M*S,KUR"+Y MQ5LP!ACMSA%0V0-RU+%)7_9:%$9K$;Z50+; HEB2N4F2*$M!WPM]B^XSONIP MPC=+"\^ATH4.#6M$"2BCS[?80?\^EKA2@"!-BJ%*^U Y[7[.T,%] / M1#5AUZ>F !J(B./0@2),>81BOR]Q9VHU5GFB\S'7=XYQ/6": !4Y 8:1DM^(:/) MK7G.?E[3HF(5M GM*>J_\W!-(V6TFKC2(?+O43Q(FR/49GY$U$1^(USY[]]O MB;??OTN!UI;>0%SRQ,Z?^BS# *A=((7][+PC[ 6K9R_@WNP%;_:"-WOAZU9=\&8O>+,7G+4U]Y[(?ZQ66W]_IQE8&$E# M6X^5%_#N^&N_3KN-.1A[HW$J676KU2!J#5D%AP9BQ/8/Q/CDP]M+26G$7SF_ M$HU\!FSF[$8%/X%:CBS/_JY'7TC*""X*OB_IV5O= Z+T_5]';=B^Z_T3+O#V M,E@6Y+=1@,X$SYEP42S5LL4"1L9KV0;4M=]UAL7GFIEL-[G'D%LZYG$EQ[-*Y:["WQD1&+TO9$:1&I+=PWUQZ4JQ9[NUREQSFQ5: 3,T4Z M,13JQ'ZJ04YOW(C':>?>@[V>"% QH+:I+.0KEI>@EZ1&CK&?+(_)>F; S>SE MK'DB#K S'7I0WV:D@*=EOY.6_5_7GH*K%GN"]G $[)>KB.JJQ=Z4TM V8[; M7'LN;IYQ$PS^8VEEY'IL@;:VIYU!T#[K(+L=BZ+I$.1MTL)*=-/):G![;;9Z ML$%EF>S5\66T(X27H55QE_Z@1\ST*(R2L0[HL;SJ^0M=O8KQ$@RUKX7$MIS, M>Q$+?48:[Y+&T0#QZ L>Q&VP!/3:!6BRGC*QA9Y7D,.MFMJX/JP6NLJ[P-9F@R[ZS$J^H,/Q-5/4I/74T;'R&"YBC(/+_$_A_'# M.LI359ZJB(0X::\FEJ:D!EJT)^GA>2D<-J2H3/5=70 M3H^3GJ?9U%2H96U+6QVI5?*MBOCWZ0^C_![]CJ6U]Y^@XH^_X6=_P.;1:^X2 M)$\Q?>2060D88)Z>:22VU+R6:I7P 3ZPWQ:)+*8=7'D)%X=K(5\ERK9S9)ZS M]JDCL, B>@I NM(4HD!@TS128>6#]DXK\L82V1TXU]N]O#DRUFM9XHM@69:+ M]_F\Q>4'S""X&_72#]QI"5]GP#'L@+38";CBVK$^GCZPTXJ]J@L8/$='26=) MV=&(U4GAJG>I4$]2V8Z?H$\/5QGZ[5*-8MUF;=0TY@A5\-EW)(KN:1Q/XWR) MQGGR>,_C/8_W'.6 6EK!87NE2TH0NX"]W$F]O=&6J>>VJJR?]CK">RA]!4<8#_@? M_3[">D?X"Z:9'V_0\+30%:T,UPCUMM?MM]+KWB/2E[O>7#I;R$Z&_F0S=+KK MO5:[=CO?9^[Y2AYXX#D0M,T#_P)5Y]XF'$_?N=SO\KC=XW:/VV\R^'!I]GN7 M7'ZK1>R$]A'<\D.W?!>?513J0C!&4#H<<+:F6$4^QK M8<$V,^"B%A/;CL)EJ?K3.D\LB4H\^D.!QU#HB,UNJ6R[TGSQM)*E]HLS!7HK M/&%E:/?"%I8==3L8"_,@UX^_-XGOTL)B87C"OA863^-Y&L^]&F]G5M95FSC\ MJU:8G3ALO4]0)).L^A?A"UIA3FEY.1X.W=?RLJ$;KTNP'W]#S^&075TOGB[[ MQKIL[5-:.4#OQ"Z9'7.G+X%%M1B7*'_'XBX9%REK!S7/G&>+'6N>"3U&(C?K M>;JOCLEQRMPK*G1H4:$-:W0D&3T&]!C08T!74LYC0(\!'72X'@.Z*;_N=9<[ ME8$VHA-GU9!>T%V^$Y*81.-RM#EO%4IAK[O\K.[RO1/0+DA@!XGHH\_G\_K+ MO[-&<)B@;256P@[J+]\MW8G68K4DM51"^,WUEUNE:S8[S$-'E(VG9>]\>E'JZ5^&D?=YCO6(?T?#X,IZOX%/B]#G/K.\RM M=H9QPO\8PJ^04?=ZS+^%'G*;6&][WF=ISVOTF.\H6*KVGN-SDY?:>^!6>\SM M\,(#SZ$C2!KN4W9>WZVG\;YUWZW'[1ZW?Q]N=TD6W!E=YGZO(^#K-<75NLR3 MAY/N_7(P)X4CQG.">&06K"6=Y1\%01W86XX37F^Y MI\UL]"3)Z_26)X_UEK]- W'Q+=\#L?XG>LL]+].ZKO+S[+#C(QEQW(:1C,[0 M6NZK77*<&O<*"1U:2.C.EC:/ 3T&=!D9/0;T&-!C0%=2SF- +Y]^+)^NN5[: M$LTY42^O[CRVW8B&^"R,AI@.WLBK9]=Y=2WR44ER4_J]V0HO]I3V>]GT2ZAM M6S8] KWQ:/1F$?,\'>3EESZ37[))=1[/I6?WY](UY1I0PHGNI)>@IV>4]1]5 MNM?385^80WX@2>RS<'/JH;W._ T62V>["QBV/M0V.G;YL M4KJ_@ZI@)WSYJ-H'U$JEL"N5,D6B@-2'H(D+UM/PRC!6PB!CTPI'J>:)I#Z! M8;M=( *>!E@'R#, >/7E3>\,HWCF_@Z]3G."A&P9[65!^[ $Q1MCX%.?74=> MEW)%K0_N[Y#VI/@%!N#CH6(#VH%V*59<\X D"_"2T#@!HY 2E8Q34]E"/39, M4<\4O:A>*D]5NB]P\'GZ]]!AHP^,! 9PSQC\<6RFVWE/NI5[?V=ZG&D)\ HS MGF*P(31"C5]#QBBZ[."K.PR.S2"'_N^'8YJNB":XSP5HKU:C/KBV& -RSDJF MUZOH!+0?S*L[;"_I:8\JIFI$E.B<&A]Q"=C@^KHU"-#>V?_%D1+_,W&PP$WC MSDT9 !3=UW@?J4!#6J!"T]A^'\L_;; \IEHBAMQT!8X39FH-I"0I(XU\O[=5 MR.<<-@!-CS$\5EE$=8)V8M1NG;#Z9@*2)05)IQI3-60%U."B8QP\P!\;=W_T M+%!/.]?57HY*89QKE44Q'[7%!M%?9*&60@_U$\\16SRR#447B47:RTZA%N^7 M\Y5)O;/:&<-*8XZ"OP*9"RJ%:CR33-1SR?N[8@JK9LA*\BE&5I,)K$2V\LE" M[;%:*\9?L6*IEBT6JH]8@\S52?0W1E:K];SV\K;7K7.P:@9B"&I%-U#_WP_? M#_7?\'.T\>^S*:Y[,324(FHL02H8?_W!9BPC]W]C4=\_QL$\(<,7GLXS$6+Y M'U9GN2]*9E_7,'$E2@0\6?3R__OAMQTCC8;"":^6OQ:;;JO'6N<:=_ZVH-6C M$>G4_U%-I/]^=M'K2:HFTXJZ65OFI M@AP_+0JB_CO/\NQ(&1G1#Y$/YJ12B!$;Z^DQ:UXSA2]%J 4H<:'SVTD1D _+ M--"*VAL+NC@<$7H^/(#EZ<-F\/,H2],E/&WH=&VXDU;>D6'\=&V8C<0S*:;G#W>)*\HP;ILV))[#!U.DG]"&1RFY MJ0TC5#/3?)F'AW'ZJRAIJ3;$?<^!(]EF=ZE#U_2HZ#'(,(I!VFQ@&UD5;;5: M1O5RHWJU!?\_CKU1]!7B_[CB?[=.XKF1Z3XFX78E8,B7V+"5RAO5+#-)\ ML!ZA?%G&'8K&/L/9_QS&3S:VSY,:#5HB(U5"YPD&,Y5EY@/__QHN0.C M=Y7[46**Q8H8*)0/]TM#FSHW; M2DD1P?[*PI-BZ4&\6W\?E)O5T ]KK >=XEM$BER92)H2_C21-N^C0#;Q)KS6 MEB_$D]]TPZ'C@+[2;JS^'[>%I3QM[#!M; DJ MJ@7:&%\IFC.\F;PPZD=\D:3F]Y+ M[]WNSKO=[8AJ6C)4X9@>^P#Y 0B#,*C-9K[7=1$3^LH!MG0L@L.')/CQU[9! M"([G:4\;N$0;[(0G[-4&V\;=LE%>IHE>*S3K]ZS2!CO6D:<+W&=.N2F"76&E MX5-7!'HY"HOZ"X D8R+JZ/:BV-]&EUH")[A/E2 &2T'^RNJ<97TT/$K,:M5L MQ-\*KNNA5VR]Q=$CW3.]IH]\A +GA'*MC[#@S]'(H3SE/]>+L>RECZ6I #K MY0++7&T8_YA!]!C[ES.($V+]@><]P$?_N/3R]RZOF[V\=AJ5ON3R^E3R +P6 M>CD"STM+_"8NKZNE!WS/Q.[E=3!!8%N"Z:S+ZU/I@?);JH G)[778/0F;J^K M)0#PY]!N:9U;;Z^S?B=SD+]COK!%( [A'NI F(4Z"MSP"DZ\/O\8*,C2F6P1AV MRC* 9^!:*![^4P#:FQ0OLS0[1LIJ3*D=6JM/&EN!L@\?#U0MSB$3YG]25]Q0@T3H7E0K071$A=<2Q(\"<1#IB&_*4VM.\BY](H1IL4Y"8&G@FR30N681S;W4!@1*M:X8[!W:F+5BB.0\S" M8W"7Z(LKK#(5*<_#4KPFEJ+"BX 6>CQ\??.HU4/E)6"&SE105^$*;/%)8Z$1 MD/N"QG1FT$5IS16R@$V1S%(J-^X"'K)(1,9C49BKC )5P@[\H3G0G1R-.6$! M -S7E*7!_JN\(/#H-P&CWMI239 ISOQ^7)#D@B"W +POC?V;$/LD#=PXR(?- MO>F?P3S,]02*++?P81ZLC)?J#C@E)#TD$%(/"Z@&UT?RD1US%5H<[8:_%.[P M*;BR8,([N,//P8-M2= 7X#B5?KP&;VCBM@XPD1 3H);"J!WD3AUE&K'DL49G MVRBLP?ZE!%%_"7WN<.+U4[R7JHD^21Z^S?/<,=[;T>=GH^^?S0_'\CC7I;C* M9?B!](X*U"IY-]*5EIU0$7+O[]1; _O-2F!;&_-1C.3#G;_.I#Q#OI[CE,&FW/[7U; MOF@D6S#TZ#N,?F,@14'N@R;52. -RZBK&>"&OX!8_+^]?0>):S D[FB&;/1F MO4 ]G62EKN,9$O]RAHP$'@.!(R,"-;[\X9=(JHDGHL@!F@2@NL;P.ZP. M^_^H.B0&UOK]W0&P]4=5!K=?AO]%$8,=+\2,2T!RG$ CWM[/84EME>8!*0, M=L-#^/PO[(6,7_VL8;.Q>9 M-$3H,7)$:$XR/1#MF)6+N/G>,[9I4" KY62+XM#TEO,,BI33#0HU'5M#W%CL M9E?A>U.J5I7B8G7#([L^E,9BM\O2I@B,G*H$*9:F0- ,*Z7/6?RQFO5'3*9-DN78E"IS@0>HQ&B/N[TX)!V$XL"#Y8 MIE@4]%%_Y",[[8/ S_W=Y79:R!_8NGHC!'Y8FV[64XTO&^_Q97K5S#.K[/^* MUGH1C,&3F]4;K+Q1,W)_!_0[$?[ZVOQ&A)2TI!XV%@54OP)?W2@ZT"9SSEBYCY'5.$;@D2?<=Y(=KDWN5/4Y-1(47L\,[YA0'W=]'+.XC\F- M$2HQS .29U:7QZHXH+8H^F?!>(=:5S;N.X;/J=\3E:@>]SB\3DLF" KNMW=X;%X56JRW( MQ">65#Y8/&_*V,O&W"@[9T]N\)N9XKX=1O=M\-_GFX/AXU'7[R4(G[YG=?CE MQ4BAOF>_]B KSY!^WC@_*XKH;?!PX4(K0))%=HW1>>K_:,8[NB*PG\@/]OO^ M5*IU]2_\S[_(F%H9>?LMN]\[!#+K"'=4)!T55L>OWHAO?.P,F4U[8UZY+>VO M>V-2RXM%!J=1KI<4E>IU;4U6&[%>[0_UOM M =,7JU%$]4KTFM$>6K!M,9'#-#HSL'V4+A>%2G!\?ZC$L!;AKT@H_"4I*"H& M=05BL!)'\9;74GIEDW^3%-V_OX,DAQ<>QVFU]JMN%\0P+*^ M8*>]5FZCTJF M>X!'O2S<0BN1EONHPT:K>%7[/+20)H,Z579;1O328?2#&^76]W?4X?Z155A! M_T'TQ8G"2BS\B=7]H;+[OGGVXHJ=39?3=I.)UN!S?Z:_2AJ'X1^*AW(GUUH?D!U)3#LNM,+<;IQ23&K*@-XBYE/&1ZQZ9Q1 M=Y1LBM,C[GA4VP96C*/U#6STH=S?':WC^33@D*[@&VH!NZ'@5YVE^$DYWD_> MALKM,+^]79!:TI6P=L'"R !S9&$101LNHV:])]P"@HA+C?JC.W M2Y$H-(92YS#'O.^M'S)R#-= 2..6FE7S \?DU7>)#HY?_W MP[\=_3X283]S@_8>!:E>M"N$9:A*7'LLGV)TM[+/ISG'6LUO/4/^U_G;U/MR MMV*/F!O63FJMQ.>%G-6(EQMWFX V^'E;1=Z)&W>J>E1N7#CT?LX[(=46W]JI MJ_2KJRZM6[(E#+VM[4G7A%@%C"B61XY+''X!.?X*Q6$J6O8I,QRV&J4A.4Q+00G?#H ^IFISJ\BB*JJ9P\R=C2[#"SS.<5=U-54-P*)RU M2I\?$&:+RA'B4=(??GFCTNL!4LUM.,+]=4A0G+6*A$=-S&]#R@.>E']+*7<6 MNSZYC?=<,R963W2'(O]829&T5@UW\:GIJ_-;NCA+)=/H9/GG:Z]B2P!#OZ(6 M_KU4>4]EI.(P&]RUGH6U]?QH5%A>TFWTC]VWJE=_?PCO\4(-\#7RY>DKN_35 MSJ!8R^3B8__!-ET6*2S?Y*&8J):("YP'3\^==YY?K@/KU43)T(/AYX.UU)X. M]'3@):NU7:HO=[*^CK#N2UI<(;F3$L0N8*WPP[XTN6=S!>:U31]+L-;TJU(_ M807>/<9]V68+VIA#UAXC)Y85<_GY".#OT0\<-AJ!)7&N^Z>B]@1[9H4Z!.R1[9YOW%298:OI'# M67+P>>]/VY7[%*:]C;2?/^XO5ZMFYY!X]M^$7G5O1>2-*5>W:8G+/4QG<+MK MLGO;Y/);+6)U73%K:T2P6^:*I]W:.;_E'&#YECZK-=2%8(R@=#C@;+6QMLEV MT$.LK;I+VF=M#4&R^A[L\',!?%AU![2_=HMQ;#M'ET7<=X[NI"F']OF@H2OY MH'[7VDJ>UKM ZT6_J&[11G6XI O]&!&9^HO]"U*/BKX7]2(WQ?(,#=JA.!33 MNTW]>14F^"+%NIFB#%S!#?54Z[=4K8DV,##L/VV4:(.=LCP4 D4%$BO*?2#6 M^A3_@;BM.II-#&2TO61]5"\PH<$P&G$\ )V;@545WH0=N1>3EZ8X6E%G_T+5R.C@D4AU M/FFJHRYOT.FJZ6)A-W&?$6(M";,690!Y]QD,' M[!@=J-UUEY%+[]"-4:%7F!":^HH)H@;F_=W!(9CZVLZ:A7G2J,0#L\F_&.E^B?>9Z.OPO<_F<&=:3E=&JO^$ M$!PU?_P?SV-TYG"_J#?Q+ZU==*-:2U?N[6A&K99)8O%BH%G/9!%E+)K!4MD 6XEDRAU5K\(5\LE"K MNLY\WG\JVY[-J;[?YE5X;&Y'!4P!KP#T=<.[:K)R/Z[F3(!X8#J'+V&R?4Y] M1'L9]2W?2N6A5&=PQX21J<^=N5\Q)MU=[:?Y^) M$,O;OA&R&H>N:L3WB.F3.ZN@IQK!%3 61#0-Z%$?Y(D&8,%KG97Z (UM@T:? M.H =^0VB\5EH(VOFIFII=P1%-N8,P?UA ;#W]]U%(GE M@22MYW,)/-A]Q".*(#-0FD6VHQGF!4$&T'!S\TGL5WS>F%_3?Q_/\K7^\MY<>;&KW\1'YVJ9;^Z3 MOM]>^NA$9CKLY3N5X:77MOK?4/B9V$X,VWY9F1][;/X3O*K)=+J23)/J!"CX MBGZK;X/..6 4U$II(3_XMZZQO?E0&XMT,K3Q'KSHL%LAQEN TN>':%%4:,3\ MUQ&Q7W\WXJFN/2IO@H.;3NN6L/L_;%)R\D&X:K$WQC7'8>&=?!">LG73:=V2 M%5.O)K3MJ,.CM22?Y-J3<24*E>[>A+?AQ:PN'4Y 9Y<3QBBPIJT6?G#*TO 9 M/VD]=(V1_V(__[_+45L\!+H3NS7PT],*237#B4HH)0G _V5JU/Q(M41;$N6G MIY(H, HM%T7]K+<*]?17]<*\[FM<&+>7U+Q9BE?BLU*:6959Z&N3+@A!AK\6 M$_,3U#T3NF2#F#_40T[!7_'Y?%&_SX+ZC !^L#[#C8"!GEZQ4:\D+=,K^$JO MX!?JE9X4;H32@\*5H/K6*Y?:DS^7%SV!$K MO7F81([VL5U&OKTWQS=T?>E> M#E?7FJMIMZMM-W>*PYW&X0H[(ON(90 W!VY&FT1H$CA9F&Q= RA=K+_%0(2A(@Z$28W]8LJFM9+M%%3N'MH GVLMA MD24BU3 UQ?W6; %I^ZX@R#QJS5&3GOH_4.(3:>7YB/O-48AS ?]4KQK(&2H* M@02@9F>PB4*)4+"T[0M='83 #(B >OLY(.O &XAD M :,PH[#A21K#"Z#+TNAS P _A_J9*"PEB++"[X)M!-8HBJ:RB:2&L:"[ 4'# M#?"% SX];%-#EW>QF^49=LHR"L5I<1OC6<8E1QJ!FYS(^9,Q-AU;K&]^TP\: MJ Y0 W"4)&FK&_=YN5U)<\N6?SZE XW%>Y64L_%8K>SKIRJI1KY2C94J;"Q9 M;11B%1]3K=296"/)E6JL^GJUTGA/U;A&*AOO)]_?*GVJ.5^^5DFAGDXMWILA M'Y5N^*AFH=^)#\E#M[D*\+=+FD.V?M (^/K"3Y!8&CW:6^2PX (/'0:MQD8* M!QF#0J]1'-8'%"?W:4H$]W>T((X%47T'^ZGWQ\57)3%Z7]R_*O332)A"'NS" MC6TSHL:\8Q6[9L_VT]/W3#]#?5MNT?7Q44I9@3 3 M.:R=#:YYU'075(H(*XV%*UEHC<2&SID!<0-O;]5"C!33"I8/6BY*%R&G:3H5 MB*,M0^$1-432_0UE"G00.J@H=16ZS;WFT9$E$34LRXL2-&YDA.XV45B5:'4) M=!4NQW;!_H A^3++516JEZP']^#?*>JW,0Y^W0%,=F[WYAY(O9D@,A+@MWLY M3R#?C[^$!FIW /'N67W=,#YWNU$MRTQ[R];J<9 33\6Y:\WR M]W\R[/1L,\%;;3E-[X5>M,:3_J6[L:_.2JQ^<$=U/'-ETYNQ+< &(^ MM'YI.^ZB&\D:3(O&\RIM]<])8*\9_?Q!C/HH5CS17G;I<:8>Y"I1SO]II 8' MQK(_$P4^(S"[+PA\^E5D1=C58E@6^V+#%N-S='; 8YQ[H<'E&GZPMLC. NL! MH2=2XSXR;1!(+(7]W/"_.('6PF@(WU:/H$G_[H6*V1)T2R"<_+[GX!6 5O8+ MK:U8=+&VR= "DQ21G ]"Q.DD01E7^[#^VO-YBJ32[^M!ARS@1LW(A61 M6*"]++R50W@@Q/1F@=59'4,"6J'Y-;.U3+: I9/%=(4L9;)QC*PDR>J637*+ M@$ ;Y/$ZZQW06>]?^QK!:*2]+YX6+A&A ;%8-F-]M[;A>Y@GCF*QW0JM]+LP MFZ5R4Z;C8A9S/4"*!X_B@K.Z)7@4#^3-$RS'G-:-P75Y!H_'-=_0AO&4K2M. MZY:LF!L&>5LY;AMYR,_WY_35,MZJ3,EJLC9MBG?K566H"DEF\7RP^XD(UXWCS:%IFX#1H>8002\'4O'PGZQM$+QY;#9=6MOUJA7%Y:& M!\#F": G@&=@:E@J@'[BI@1POQT3OK(=DXZUE[/7]Q$UG_0 'K+5CKD<].U: M!LLKI"HCC"[D+L=J21>HQAM0AX?MD73,"K0+&\ N',\8GDA]:Y$Z;&%8(E)V M 8ZPJJP!KWD=*LBFVLOT_E1(O,RC"9[KHF.6-H0((D4X#QU=Z/JSORD(ZC0 M(9^%J-".)[K'KDYEUR^^G;,Y*_J'HS=Z.Q\HS[;\=M8[XHMR'XA&]U1Y&%A4 MTH.T7PDZW/>W/=>DTL6#67:*ZO0 BT^#;3")LQ4NT,V"%7O"[ FS4X1YCZ7D M"?/EAI0UQL3?N-@8(]J/$O ML),\\?7$U\/Y=@K.]S$4E20T=^K1495(&,8$]$N8]U "?,-."3C@BH(2/, M5)0>'7 .@5SCQ)\55C0"^QDA*JV9&_NY^0*F?@?_(VZ Y6I87^LO0?: VY(5 MM;*.DN$52$DR7-X_*C"8(%/<&GV%Y1%D._2>*?@7 B7[UW+@E:^7GBOOP'J/ M?P_2#&"H,C%F:V'%OX4IDR=?BA4L7J_6BOED!8M5DN1KHM@L8/"]>#%?(@LM MG?6JF(X_\PU@9KYQ,]\7=NV=M<[K(PLXG[I>!ZN;^B1OJ8/50-O0]N1!;G@R MY($GG+L[#W+#XQH//VN]1:YD.3O#6@Y9:"T[PT3VY/J+Y=KG (]X)==^ M)C.+E/NC0?5:'O$-Q.X.ML=ND=<24!$;4$6-VQZHM+(<9W>()SU;'KK\O%QRVQZ#YO! MTT,VZ:&( V(+*SW4FBU?,\677N&5\?209;$%Z_20'7#BSM!#9\-,Q-O+^2#M MZ\U)(I6_M(?Z:UIWM=9WH/(9^/O?_SP]82D6<,QOK$3UH!15P40!/ U0R^@? MK$%Q"GH>]O1DJ$.&G9Y>SJQWG!J?"*L"MK0CM8I\M?%L9[ M>6W-R;MUU5O@&JDG,^D,HOW!:HLQ7 $I4AV6_H,5H.QKA"T(B(3^H/E;OXRO MH;?6'&EPXW^_(*GW41UUOC]U !1L^/"Q>FHZG>'&#"*O.K1-/+=FB?'FT\V+ M0JO5%F3B$TN:OK\UK,JN#PH/ZYMAK5P#T81Q%P"+801HB^PJ7)?E.(3>@5'P M^IBZ5S>7R MR4(-(ZO59*V*D87$^OU>@CA>I^O(HM$!&O,>[+&^/\/]:H MM]'0.IBU](/@I"BPN=B4<6OOG->H[!3&2JZC$TM_J?06(,>97H-P,6-YO MRO9ZF<_;G0>^XLF00V3(S3 :GDWC<8UGL'C*UIFG=4L&RPV#KZQ'W?A."?@5 M@-QFL^TE67C%7P1Z'N4#GX@Y.1# Q=*ZKP\"R;\OSMFN4!"OX<$0WA0-4U4IX;#8! M H_A8-#U ]$]4?%$Y8"H6'>M^Q^#?I_K1>7LFMM0>SGLIF?59;3Z]MIS?!6/ M(^;E6&0=F"P#C.752E",8J84*ED=4PMUR-0C-NNS=!^C1/B:"-E8A#^*B8"C M9,!@LF!\@<'@HSB6[TE($B#+3P$GC-4 A03$*4L#Z?FKJ&8P6]P7W5-"-A(6 M=#X;IC4#+CBK6ZH9\(H+Q;!N/ M:[ZAN>(I6U>F[NQ+U=S-U&''* ZE.[654C+6 3V6Y^%%A E=; $HT2L8 M=930>06C-U@PZHF58^CI.K'R62A6>,"&@BVGU6&G3K$@2HI(]RD)$-2L M;I#N+.JA;UR(34(7%3&%I*V/441D*,A]8(6EX%@]Y@+EY8BI4A'"PJE2CB>Z MQZY.9=?/W:^&QC\-OMB*^>5!&VQ81]RPH398H6/I_[QT S+0[F;#5$T(B$F EKH\?!#C/E>'L,G"(SE^-=731NC/_6JT&J_%#^O0#:$^-H]B$\#U$ZI4@KN&K^VX,!$;')B]S&\O M#_WK2:PGL3:9Z5'KP.[OYVSD!P#,6 M90,\I^FVG";78JXX_KP]2?D>DN+XK)@3^JV=/\G%37V5A]I'-Z=UN'=_]IR0 MU]Y8SHTEZSZ,:/>LVB#O'FCW3R[32+3CIC-LN]O,23/;?6 M^'H-%4YAL=C>9E'09>1Y*/O#DZKO+E74=HY%@Y):DZN#< MGF/=+"M:)T 7B")@*F *> 54$*0\O!=K EQ3%=)OU>4B!A(IL9E(9DOVXE$X MN\C4()>V/%$CF@;$KS:O"!@/GR4APCG:\'0H>=U;2G>PQ>1T2;.U]62GZ@X/ MN+[JSA,J3Z@^)51V-,9"D0KBKA>I_<9$X$1C8G4*1E-G8CV IJK/GS'LB8@2 M]P6CHU(S[*(YPU_0.*33U# X]K7+6A+ \%KO+-*HKFF].[=9]BPQ_XH^VD D MZO71>L+L"?-5A-D:(^J *(=O49+W&U?$Z5<=O#Y]5RZU0@J>BWS@8XW7\ M>GZB-V/9"ZFXE'(N$Q7')S:=T/.[9T(LPTXO']1J>_NI]J3U[%IBS^S:Z'LY M_S(5B&5QW^S:[?FT@375#H[-U?^?"]MU-YZD_A;D?4%4]_<;\COT&CB6!RA^ M,Z)85&IR?U<"HBH[:+)SL0.7IGY:N@%JN+^]_.-CPG[^W_\3\?M]?RJEHOH7 M_N=?3 1C$4AH1/>J(QTPJ[R@W(=6:9^2,%Z0H5F*ZHX ;PKB&6.]];'?$M2? M6CC;>,+]'05M6FH$;7+X"^KC9BS'P>>80X&4M/I%EL>ZBHR:KS4,/>D9(R5D M%!M=2*@!"4.&SZ,:.I0%F>(PN"/]1[1IXO^[J0VB/MSDHZP<1IU@)G*MJ=5F ML[JO0J_;;#NS"4T'I,*;%/F!R:R,#FWU&+3@%=F%-=D_NLA.6LY7VGZK&NK' M^SOMN!'AX\((OKG P'P,:'2VPOI$,0%Z:.JGM'?AH<#]*%WX7#WH"\01.E05 M*U$4&(66-95CGOC^98/>;5,H< ^0Q&"N"LO?__[GZ0E+L8!C?F,EJ@?^P(=- M% #/_3<6P?]@#8I3T/.PIR?#C$3CV4\.[.BX ,8GPJK6/PTO8?,WC@ 0X#Y4 M^;A[N:Q+U;=]=5D8[[5TU@;3;G/ QL_]^)MZ,I/.(-H?K+88PQ60(C0"Z3]8 M 4J91MB"@$CH#YF_]RAN@BHX5,'0(F##Q^KIZ;3&6[, M(/**44WLMV:)\>;3S8M"J]469.(3QV&Q_-=9[:5C^:UO=W,(7'PU7JS7XF3^ M_BY;B#^[<1/7P%JQ?M6%8BU9O;^K%;%:)HG@4JK%7#9!UI()+)4MD(5XELQA MU1I\ 4&K5-VVO?V'HE^J!07ZIRQMV +Z/T_.,0%XO_B(+;0#T_"?MHQ;+/>*_^SL<7JC8IGT(;>'V,D24 OYE MAP$D=/QR2;*:7'.@]1KBRVT15^V@R-_?'7 TJ*@C)$[@Q-_)*Q2K$-O0@+0 M($6.!X=8VHRPA4QE3# X7GM?TIP(:*3NN U1D[1LRDD%1;N*W;H$5)RYO>[" M)%"L-!JA9B/?7;D+Q#O+-I=*[3N#Q^L55P[5]!]DI"SQ$(' M:'%[OH^K=K!/W^!7T#?XY_2-#M&4\*='-$[QX<87ZQOK(NW!B/^3^L9WKK[1 MB?@F1J/C<"(:RN%7UC<64BUTL/K TS=.W,$V\\8_L-(3T!\0V;$:J$2\ZUNA MM?E4+FZOOHUB(L4N*8H(=Q1%U<@Y*[7;1C6L^C2R)P+UO;RJ\-I+,9(1D_E! M.5.D5S*@+>-Q6YD]0I97'">Z-;U5UHS=$Z6MI[UO**:Y.POS[6;/B1K\! M:4X+BARG1ICJ\$&MR_*R@%&ZKJ:,']0T=;?+T@!#H3 U%%V$VWC$LI)( >X9 MJ_7-GVNGW6^ 9RZ.-< O]]\;48J0F!K3(K&Q^#KSN1/C/ M\5@4YE AR5"%[*K@U$$57-(?;3;WUIB6\"__I2QA>R\4B6"AD\YQT4EVTK/\IC9+@?TWM?^RF[I"01'$ MTN@$CU[7N'_GNKZ_@SIBM10\J$67G@]OFOS6+GI^XZ[GM7:99TQ?3\WT8$8 $J_[ MIK*>>\4./_X9VY"+W>K9F58]"W]"5#->CSO; )R:WE4W@1Q*+:&+E!A4=>H* M&!812 0]2D3I1DSJ"Z+\I": M:MHM9.SS8^C/M\IEY+F\<5;0D$BZ^-7/[5S MK:#*!G1+6':G6-P'^_'-X=T77[B#?27INE A_6?(]:9G>0,[%-6L8/>45+[XC&=%>7[.)E+ MT8+O8%3<^/WSG!O]MZ^HPOSACRN/SDTI[%)P!\\^,>[$P=R7'*;ZUZ.@'7W; M\&$?TP\9$D:GK83Z3*!UM9-04ZFL12)LC0U^D3*Q/O->I?N 43AHML$T&ZSEJ2J[^2TC3O M[OZ.AGO&NG#3T.S2Y ()FPI.H]5U[F12=F8N8WHY*_S\#)G9R.KGX!-O8K;2 M9M%"+-A>]F>M8:[_RD1):G7L&Q-\((GU$4;W=\445JV72CFUO(;,87&RFL%2 MN6(3RQ92Q4J>K&6+!:R2S*DE.;4B5BPE*_#%0AK;JH?8I.19-86G4_LFQQ]Y MD--[6J/VSZ&)[QUUY'_/R+B/;A(QVJWXU-XP *>P&+%WU%$E\%9ZB\QZLSGC M8A9S_>2 ;XEW[N1SN:49 2WH"&G[V76&7'M WWM4@)-/YL:FTGCFB\7#G/ T5WM66.*5;/\^M-\GHO/:-Q FNHDT/I6.3\)ZXK":"?%YZ&[?4=TM_,K[BVO2G$_%KXG+9ZT?'$%DFMD MY2 8HKD"W%2U0T;:RPD(-N)4+=&MA]Q4;D52M9&G0"F)FP#D!RKE<+7@SRL^H7V,I<-C")B/CYSUSFJF[F_4TOI4>4> MHV\=@WL%1ZNF*&D%OK93-(5J56^]:NJEBX]\Y8:<*1$G54VIU4]8+5G)8V0A M@26R"$&J4,,J9"WYS>NESHQM.R32Z@6]'7,4ZSYDM"^46_4R M\A[7G,\U7D;>4[:>P7+>[KPL_;?)TC98I/ M%?OSTG#5L;K-H1\QYU'<#_(P[N63!.C?C"*BIVQW09Z[M1]_?<^1X %X#1>G MASU9=PP]KR_KAZL SI-UO06)?&?FY6A=2.0)6V5]7Q+(:EDGPKRFIQ= MR;'?/-I(0WCYZ!O-1V^IO\2IZL^>[@'/H_GFA_ M#]$^V8LY5;1U$T=5Q7P#R3Z[,";87@Y&4CF8B$;]B\], M]_[J>H%/SVSS>S/;K)[9%O9FMKFCZ.L8[NMJ[$&>0O,?Y<71$B_?!XBZ'SP- M7BS\I!R6 KG.,N(F[5/K0P=JI.T)30[9U^NE8T$>*.C: ^AV<\5<+M[!=B$: MT5[RXR+7[_5+RT7HI$*T/%FK5[*U;+*JUZ3ELF0LF]->J1<2RL5P'U]_O+V4LD;D$X)$U:80KTF.U*M7*6&7K;9 M"8=WH(7NHW$WJRO?:&U(** R5Z; 6X*5-AP:3W,:43EBKE<:1FI">UE]Z5: M"D^S9:7'V=IS9T=^.[*=W[;A4D((]5X6RV'QG>MEL8X&5#XKBG9/4_0=B:NX M.Y6T5HF13ZA$A&E6FPD'-&&-*21)N1:O32@7=1_;H_*"7O#Z1H/7EB@T79!L MUF.A@[CWSHP+GZR[PI_577T1@ /:JT&'?7XEG"&7P#UVW-Y!Y[:;W9!)0QZ:@X4#/LWX635B>389N6)VV #[N5YA^C4P"=T:INMK72I;-*E68[B MXME$HL0&7&0)6DWZFJ#.G$!K@VO6T\/ F.%M3!_S#$7/4#PL879[NH0-6LX1 MZBQTJCJKFT0S.:?A1TD5)['-%@S=QK#M9:X:5.JQ4(./N2C,MWT25["Z$*U_ M:TO.CL:*K W9!"*09,]D=(J*=(W)^/,"+7I(L.VV&P].S'25W?CO"3H6/UBX MMSJ$E;/M,CMPE^9^JY6-R3S<*<.PG&,L7_UG5:6Z$(P1T#Q;]^I**W;QI1!N M*P&UV\ ,7T$=^K_6C3X#T"T,V/>6F.[AN<\$&1U6&K6]5^MK_2I I1(]Q-@ M"CAAK,ZLYQDTQA@:EF)5Z,HS2@3KH94'*OXV8AN??F9[F<[[Y50:@YS]I'[546W3^%HJUY/T=[L?4B>[X'VRK@,P?:B_K ML81_RM7Q7AI>L)5D-4E6XAD-I"S92.:*)33J$4N^E9*%=2W8[_]^=78*PFS# M_S-.%('SK0]5GY)[M!(TL@_L[XS'M9>55J4 XI/N6[IW$RQA2'IGIY@PV5XJ M2B89;A!C"IR&:GA^\="CH$D;E87,;3 MD:A;"_T\#"^GL%AJ[U#0XD0(Q4(1.4+B+F8QUP-^>37:+CBK6X+[\@:%>N+D M/'%R,^BD9^9X7/,-+1=/V;KBM&[)=OD6S6-F?)(JQ5$B"R229YI4#TBK2N(* MF4@NQSC;7F;)1I9L^L:M?-\]E2+7 CPUZ*A3:OYQ?WV!,^(M=EWAK37*/KLB(J2PT'6:"'3QU$-GVLJXEX M7@W]=ZRA/TVBKF@HA&Z@FMZ3'D]Z/I(>6T:\A@C7R\[!QCJCR"@/Z2VRD!;0 MW*HJ'41:M%=!W!=':'9:B<6BWPAU7=QQ8B7%5]1;!P^D#2)ZBNP[*3*U"O"P M1%WQWLP%SEJ@^'0JX7EH]AYA)@+$)RJ,940>#'HL HZE[W M7/7+0K"1S%!<,L8XVL6WDJAF^GAZZ#OI(<,#.2@AU[RZ[>A/P+S#03& MCJL[$'6]M.R_N4G3S5T3J2G@H'V41.42,L7RI@:@/;;[YM]181T7IBM<\X=WRGLPX1V;,3T+#,)_8^5.?91@ ?PW> M1WYVWA$YW!?Q_?C[Y(:!3N=;EZ?YPG2_AZ)HF4)T#8KB$97YL5A?L] ^>+.8VYZ@>H+Z%8)JA[F#!_!;%=./DP-' MT<':;&T%A[^V@G)^^;TG53(9DG9X'.,4U- M^"H+3L @Z=H",E'6/KO'@T2U M5)^Z$!+UJ"Q?T>X)/N)1&ZJ?G0&3ZHFJ)ZI?(:JV!'H>?3[_K0KJV7C&R?;R M+494\45CV8H$+X4_M7\Z^@:ZZ=6PC%7K/0UX(%(H$4XR(Y9G)1EA<4]/@"[& MUR&X,Q[27HX6R5HZ_#J>1X:7GHSZWW#@.;)BRA4&K?'JKC$ZTXQ1._"* P?Q MBO'VD@^7WE]SE5DUT_OQ-YTL)"MD3L6?)1/Y;"%;K:'9]8WDUR(6'SK)4S"+ M4_LPB\]Z8'N9: CS92+]6IC> I#U)A/$4I )^(G,S_JI_&@-2'4,J/AT/CFJ M1#S<8@\VZLM 9>-[<8N+8H-.]U_!2.FY%6/* _1S"HM%]^(6TUPV%1A'_./D MP,4LYJ'_>6K<0_\[;W<>[W, (/O_C83CR@U=L" M6MTO?M<%*?+;4&3@2F;PA.O;"I/ ;H!DG39G'O9B169[F% 8P67XW M'TF)IGRDM,?LF)"!;CD7"&3ESY02W$JWIP=S[$Q%]U5EWY<*VA4-C*C/ UGP MA.K;"I4]AD4PXGZAVF]-X*;81$D4ND"2X.94JL<%#902_L:4I8%T.%9!%Z2I MOUK$I[2]$!&N@5XR4U);HJ03T=-SWTG/&9[1:9)U12LA$G(_A)PG/9[T?"0] M-L49HK=J#D37P842)0->WA M4D0$.W4X&"\4WX+3_JP9#-L[!\%)WOF*+)YV^D[:R0@0'A".:][E ??/3?7$ MQ1.7ZXPOBMPJ4G/TX&"%BQSY>KB<""3Y%S_S&:"0&\RO>],8OKTRVPBG.5BC.['POV;&E#,_O<[WD'(PBK*P!:(4) M(U"CYCIY8Y#Z759&-9 LK[!\KS@&HIJ9D4@&@7TB0.9B-P&Z0!0! [](2A*0 MU[56"[ZM-HT$201?VU71-CAL7S"BQA-O3[RMM:2N(MVV M%%OZ4*7GS3@BAGLR$W^T%K0N"ESY>_![[27H7Y]7NYU*7;RF5+? MJU.^H V."F)/.R.C?.UEM)YD2\O8F,H-?ORMUF/59+F>+-2P9 /^]^B J+$+ M]GZ8ZQR_^B)_?Y='4_\P//R(058//&)R'V (M8?B%T@P)&4T4N%75> TK*3 M3U,2P,B>" !R726D=S$*&XOL%'X0@SX$K;Z!S5BYC_UD_\7R@@0?2HI#%0H8 MNC:]/M9GI?L[EF?8*)0&9%[7L434/O1U8]AI\L_'X-?KO4%P#/SK%5 M:>-JD3F9>58_6^T+1L3S@J84@8UE)I "WFF5F/($L18N'FX01YH M5Y*Z6K1Y"5X.ZO-825+47Q*Z\-\8U8-;[J$M4B-U??#E36:/;KB4*L&R\!F M22@BO !*\!0$1L5&DN 9J6])[3'+M&E$>E\ #ZEC7]!?X79[]:#:8@R*75*$ MV^ZI%"+GK-1NKZ "T>\8Y[(^EKPZ*<+TF"UM@YZJ/>C0)_0G+.?\)):JQ%^: M5>CFRJR,V"YKH@VZ1*6/[OC3J+'WJ@\\^0)/>&CU5UC?>OOXSO5?;N_=U8G6 M0K:0,AD)VF*12>^/!A]Q_*!9?W^GT@3[B::&(?Z: FZAB1;B1K_O3QV]K_Z- M__GW$:-D)$&&;$%1TBC[OT?Y2UV-1M(2^@:DJ/I:F\VJ7*5 HZ:D?6K%84[B M*S[?&S6'TR!'1U9\5=J@P8=,=8@$FWQ$2L7NUW//^C1^_ T^^T.'F6<,1 PQ MR*.JAE3U:E8_)_!)[&,]U* X!:S5D+-54#\:' TZ"?IE1*U8A3Q D$]JHDUZ M.$T1^782,,%'G\^'_N\0'SW?WR4I>+4C3E)O4%(A.D'?RMK>>8]FYP[8((40/ 9*CQ6L'%]Y+U$4,RKY[' M1^Q[ HUMUGZK=W>V?+%>]#W[? <]<$TQ:DS[TW27ZB15UV%!W,@TJQ)S][?'56T<8Z2(*V;VH\5Q0J*HB3UAZC7 MT^I-27]7PF]6'O2=&K)0Q\=OR\A@.$CZ5[*0W"#PAXS_&?)>2Q0V=GNQ&(2> M0P?5^OV=F?>-#1M\_ZPZ2\:K&&)O=C0"# L/C5L8+*V.T442,F,Y#J5AH.N% M/#, MOD[;!YPPO*0Q'$1/DU.4;2:G4RB[ZK93.T6;3/SG+-MB8LYN3&O"EF) M?5V^!5:_?[\EWG[_+@5:/U;1 ;/W_B0!^HF=/_59A@'0QX=$ M][/SCLCA>(#XL3[R!:!$Z&A#,T2]JQED]4"UM?)05V?9@4I-Z0R@SX&4G493 M2EQ@U"K5+#U_%!PSA:MPO+UL^@IOOH)0Y-,]QX>BMN*>V@;A%O_GZ0E+L8!C M?F,EJ@?^P <@QJ#A%R.!/UAQK.;C?V,Y2I*QIR6@>DC6#T?[\@J0VJF[^&GJ<= MR.?B:?LVIQ\4I(S*ECLGY[,U'67PI"9Z'8%9_$5_].41]W>34ZM -L@*A?$/ MEDVH?[1]$6AUS&7 HT)%2:..^CWPLDPU&5E)+X?57ZU*(V[[8H"E?B8KR\C!>I&,&&7@:=2C9'C_QBR3_X12MR<%*?AB>=.B]QO42Y M6!UQ33['SILI:EI:2D2IHS0*G%!@IT%B%/7/8B-_H)CHD*%<,AVKDN1XSG=_ M*:-DM*P#,JA7Z7,K!8)YKA!E?/-$T"J*Z4IOGCH,MW< MX&'.1J _YI/\8-DG*@_RX/7]_3TNO0Q+:88>IQ>C4.J=:^4&5#%83G5#C7AG M^M[$4TRY."ZQ;,_W\"8.N%]$+L=&DAP(E:?=>+>1B 04(L+P1(20 X2R;"Z: MN5QK.)9?DAUF'$C$1HWQ'!>C3;Q>K09*>"S^0([9^BSX2^GCH]@LW,S.RO'A M6S=2G(9JN4YD$!CP$S(16A*#)3X"HZZ_T,@T\CU1DH)U82*/JZ_AFAB<^PEZ MY)OU*M7W)K-XK:2)_D.@E2L+L0=&&(,WLC,:MD)#[KU(CD=ELC9["R[R4VX^ M#M1C8:I27B2D!$?SOM=()#>*A[LXMXAE!-&7QH'OH2.,AR56(OC?N@E>XM*N)/M%*A9+=P;"4IUGGP8O8GXRZPNO<26D0F=IJ*=6DH. MT/-<*R\6>FF&R<='+ZE\L1H>L2U\'.25SG0I,$PSD^H."'F2*?V2&V>H1_@7E[?8U2_\$9/>EPJ6Q&F+]D'.CD;)WRIP7(X).L#?/#^ MV@D6Y]F'%,62_4(GV^_F?G'D+.;/].O)5K&:8%\DJA=>)N,"'1KRHS')^.G! M9%3N+MALO\/#VUP9,U0M\H931&[4ZKT-13!L!LNS=&2 SQ*5='^>G\V:#V_9 MY:1"TO,%&0G-\LGXC!^\%">MW&R<'2_(AT@MN\#?Q4%.FJ8G8J09E(A*L#4/ MYJ+E4"R3B1%\I%Z,34_3V8;<2J?&Y1J(]U\> M,@DIV?*7ZFR%%A\8,EJK,(MT(L93,2H6$27Z[6'Z"\>'S?"TE!Y.F]3 +P42 MJ?R;G\T4FF.JDTB^MYJAB=(KI_(OKV0L&G_-ENJ+^AO'AR-OK466[+&Q(<]V MT^E78O3V/O+E(^QK<\@49XL^*RT*12Y0:X9RI84BM*:YV M>X\NQ6+CK3::36;OI3D1CRXZ9:@Q!XEAGZ0Z+6D6J(T(X)$;O@N+4NY:&:<;HGQ MI$Q+\_);-SE+O>9ZQ59V4DV\B@^59: 9_Q6D9\'YH#;K%:OQ132Z8.M*M2DE M9Y7<5%:&;[+P5I>K\U^!6C65CDZ[V5Z_P?,/"P!:"Y!]KS5BC%^6$\ M^I[KO(B#9J9'O_M?DFSR%Y7FV"%9'/HJ_9?YZ^N2Z)?].;;S,JGRK_5IN5B7 MZ&:YMB29%ZD!^L1P29"A_K N]A92)=BI=W_)C;XTE91%*5CJAH.I>K8C]F9# M.KK(5AL!LE)](X=$/!3M=H;)4B89F63(9)D% 4F(!!J9<#WEB^?*(Y$BB7ZB MG\A0H? X46&8>CHM)^0,+A;JM%())J;-E]ID'&Q6^HIO@(\? KY4/I]+O/*5 M/ET/EX:C?%B^#",I15%LCJN+RBPM==[Y6?#E)14IOPGI4F=4+B2[YGJXL0V.2?1\UIF&J$*V UXY43!>9PI)ZX/&< M4'X;%\*Q!*F,RA-I]AH2$S&B7RW%!V+F]278JN7']=&LR_DKBWRGD!X54>+,,FLV./S+KR8(:\V_)(!_Z@M% M?PFCE)S+](1L.! ?E-)]9OKPL$Q(K?X+V9O54A,0;DT)R,J19+^&QQK)L2+% M!^_I^J\&$5QVJ:0@_BKZ0])K/2TOHC4B^S8;S(?!XBC0"Q=B9%C^E?\U# G" M;$Q4.X50)Y@)D,U(^$T("#ZY1=0:O4RB1)!TJU(/N[CZ"@[*,][ M3'F.XT(K7!0:'6Y,*H'F*.#+A_!2]M9C$\9*/KS?H<8B[,-X2TMEX*!ZHNOU0O->T1HV1<" MO@@Q'DU?9L1T7.B5V&RR@ OXS%\9QM/S23H<]F>FZ52@$N6*[_QDH0P?RL-) M/S1KIBJ00"?=:#Z/T,E(:/20:A7'7GQCXFWZEI^3?PW6\R;Z_4,0@NGA] M;5*@-)H @F#R?"0\E).U6B+!+KE*IA$7HV^S:(D7IW@=A"/C>$G**2P _LF\ M7R]'^N3;,!CGTJ W7,B]RKQ8IDJ_RN,6R_A:]50X_#Y:]/JY3I;)YZ"F"K.= MO- =]%-S'P/F07RZ+!/#JE+Y1=&5V)1HTH-X>E#MUVMC1N1[HU;NU9_J]1^8 M>:Z*#R.]6K-%IMF7Y#"9PB=R3>2D?&11IZ.Q8#":?R&RY;[P7@R]+X+%ZIM< MZJ:6/1_1$;C"@,^,A6)P,:D%>Z7*I, ,B6A+P3M4/L\H/"#\[\D<1RT?R/!$ MGI&9Y)(O3)K@??F0C7!5$9?*5&I1I'J!6J+V+D5SKQ0QE:=X>LFU7N?LE$S6 M0Z-NE*%*U6)U6EYF)C33;!'5B!#O5!K-0;W69!_Z9;;";._$J]];AF)E^HU MNM'O^B1"&0SFK#(3Q5Q^V/>'A&F@]]H*OC=E.1)7!##'_51%>$N]2?Y&.C++%-ZF L=W!7$\?4APT[>WNC]"S<7Y"^Y+'LVJ. !KI0 $ &9O*@N#N[L&A<'=WJPKN M$-R=X!+;\YC?G7JN>9I[^ M -Y*BDN( Q 0$ #?GS^ IWF * 5&1D%^24J"@H*&AKJJ]("*]1$9!17N%_GQ!]5O "P1$Q!=(B"]?(B$]]WH\]P.0L%YBD[.* M(+^3UT&AL,%A\X[*0J7\7-Z&JS!V3,6N:^N#]@KO/3X!(34-+1T] P?G)RYN M'E[1+V+BH*\2DHI*RBJJ:NH:>OH&AD;&)J9V]@Z.3LXNKKY^_@&!0<'0Z)C8 MN/B$Q*3D[)SWK[^\8G)WU/3,[-S*ZMK MZQN;6]L[NR>G9^<7EU?7-[=_Z84 0$3X?]H_U0OK6:\72$B(2"A_Z87PPNFO M"["07I*S(F.+R*/HV+RC8/-&Q?DAD;)KG",JVL[]@J/BF.%^N0OU?ZF MV?\[Q7S^6YK]FV+_KM<%E$?C+F"=#3X?$2 MI$H"%1'#40;(B^'\#XC=7.GXSA+=^-%K^*54YE1T_EH5ZP81:7WOR'@QPV$' M2%3,KO:=P%$(5;!^I,;.5%Z>DFU6KLTO[G/YC.ZL\NGOE<=+T>;[A[3Q9_06 MYA.6=CX2"UL_+XHO+=OT"GN'V4?RG_M#!A%G%X&#URI3;8>N%-SLZC!9\'.BJL]J MLQ8P_*6$,-_U=7K!7-D.82EO5U!],"D;?@^5[%54CYRIIH8J^OMMF%D7F>FD MI86]%,%Z@(GR(95S8I&R_&EHA KE:1'3O?B[-CV-9';*#OQWXF_>'+>!=T8X M-R"UOP M0:G6%*3QN_:<5@Y'=JQW"&:ZTJF-\:GOL?1BX"&-1R>*567/VVUH>@1.'M!4 M#C59H,X9*3"U*=ARW]0Z])@:!-0:%6PK:G99V<[#M?!73-Q[HJ5G?M%F7AY( M3^CH%67_S#UYV16?X>!4M,.NX?(J3TFR HW-&J#SB^>B#$-P]W2'>''&(P9_ M-GA*>&V7X6_S8UQ*5&] RC-!CET77+K!Z!T^[O3F:[%1MX)'_.H!!SBALCHN M)UV'XD)QDBMO+\&+HK]H38%^AAHA-W@)8Q/5K33I(.W6-OW## MEGXNOM6N #UX'I14>C RPAJG%,E;D;4>,?CT4ST1ZRID56JVW,4$ZT4E*N:*_*#LN*0!,R[FYKUB'BZ.KVP>WM M7A)I?34S69LB$L'3OC+F4"U;EF0J56%K:Y"U39>1],[I3[.#]+(<6]@\\1](PI)$MQN_8[%5&1\3/(\MKQ<5MTLU>:>,( MV]^AAP!-+#=;J41>1.:N'>FG(W\TA84X<6Z%.M#654:/&U3Z:]"2MP;7(UF# MFH4,]^?1201PXXK-F'19M4WU+_N#1#!1W"-[KE1X@UOI4G"R]@RJ>3L M6L,YI;0>+$6V20_($_E97BMF)W^=?0HN*GTO7,\;*LPN3 /)0NVU>!!ZU6@% M)UHD)+H#HFU%J[(F(@+DO3\CWQXQ%F3KN?V 3F)V9$R-\>#U3CV"&:IZL73UL-^JN 04&%-T+XH MF.!$KVMBSVU2L=.6Y6R(IQ'.M.DS$A J(XZ(^U@3*")F]WYN_7T+P1158U4Z M346_I@CQM?FQIRK9<)F6V8A>(7@G?LY^VJ[/DEJX J%'-C$]0T-K6$3/$;KN M((N])+T"^;PY/"4%'E!E_48HDHA*&6D34(8W#6/BN%-IF)@_J&6F]%FD46$C MUB\W!^00)WL^JVLYIA;I[)=1*^:@/W7E&'FS2<;!;=^V_O'65?DK/X0J:G9A M*&=!5,=^CU"S"FH]-+&Q%WJ5M[^.9R0MIK_+6[:16E'6$L/4:0W;BATL]^VV MKK_K?%5FMUJH6SE^^+TR>=V4_TN0\'>;5%U_- &?P>7L\E+.,_[IFJM+61V! M7%T3K-PWKXVNO*CPN.IA% M$_@Q='HGO_]6HV7"GEHS*M42;3)TZJ!#%N&.W=U:D7775Y3 M.X!P?-7-BT]QDG(JIZ^^IB[V?JL.U;EGO)KZA.J(/"$*_-C7%#MCL, MVM/XO$+4A6=B8\7!9:%[&LG,3@CX]5;I];L1#<^A//C%]_)&,3NFU5GITF0_ M7L[.!H5W*5D4/DK$>&B3T$J75=$W>59Z!@4#;DQ=/^N"NE=$D-:B73&]VA,J M(]53JE1>76>39T-,W\U)O:ZI]$@'V_Z*HA%&%&#MW:RJNBL9*%R$[0OVBG_2 M-8CDOH7*,%GB,^L#DWKS+.V?QYM[V+Y> H2?_#,*7Q MPFOBK<);Y>4W.[6$EADL<[,80YU'-G2R#:6+@:,(&N=*]36EP-0%3]+H)P!X MT@%##$;..(#[T^FJ;JB9O$^F(RDHQ MYB U^<"X6%F_%=;FJ&>&]Y[+-3R$ Y6 R?);#,DO"TC=O5GJY#U?T2)S"7&R MKI:FS.'4580]X(L #OTV2%;RB"Z/,)SOA>-'B@GFZ4Y>R&PHJL7Y&5)8G?6] M3?@#[Y1X6H'$$P"MNBO2P$*P7:59C*R#ZH>.%V;B(^>\TL#1ZXA7>>S;GAO8'.2)C MB]RP9>N58"2;JM9&\[Z:>I+^9)Y2@$%862UK'3U?1$ "EZ"C2 M")*G\I*\,B'L0U*[=I>GNY@%1DR%YKQ);\5^&@4P9H(1GTNF VKO:N\Z'9A3 M4U[Y L)VG/0A'3+ [O7^" 6%9P]B- M*>NKKE90R ^&9AAT/B*Q<\S^M\\##"5P92(HM#!F!)M/_QR_%Q'J%,SH@%Y_ M7G^^G1,M!?8%HI$9=R_OC=<6EMXLF)SFI8 U,F._ MBK(.GX)PDTQ6]DZ<7LA"H+-556=Q'3JV!BH9D\,68@4R+B3D2;08/^907?L MZU4YO;P@O8"+81?.:/8?'[>&2 3,/?:"!9I,7JW*/7Y71G0BX;4O/LB5L%F% MB+NL(O=O]GT87NG;HGS^'0Z( MS(^8I[=*2IQ#OIIHX&"8719:Z,PZZ--B'9J_)IEMZ\DW^YE=,M=_1<;:"5I9 M_.+LUNE8I(?;E-!)9(S]_=?K-^R/G'4<>UFKC69'C!YIC-\8YP,QTQ/WP/8* M#D2XPPH>R+>K YW'%DIGZ^O'L=S.]HNI] MUJA)K_[<=_QP@^X9%QR075R]'#:<_DHQ(G]:A6^_8U#+"@KN:(S&1"%&F&C^ M=";>DM!.:)D>A6B'^$L?\D?/!.DL555>C,7XR+J^=W>.\V&XW(NQP717;C!3 MHW)A7XV[K?_!I;= ?=O5[],2/BA85(V'"]_F-"S79D3(WR%6\1(V]=CXJNRC1FE*@.BAW@0I[KKN]FI_$[O' M>,\XZJ;8[PL\LA[QA\U4^JT0W&DII6Z\H%SZ*:!4< MPRJ@ CE[#P[HJ:ES@KGII*/Q1 [11S+1/%0_>M\[(J-BC,,Y_3>V@LJLMFK> MMMOO?(C[X@WEX^9>@P-.@:[/8^^? &_KNWMT5HF\,&L#%;I1(O2$:[NM<<3M M^F3JV\JDI"G"Z>M625;SP^KHUPCGNJ+S$ M4-6HYG,*[OT21U[X?T)PM_[B >\>3LZS*]RB-3,>!8FV&7BCO:ZOK3(+=]?* MOSX_+/-_BGG\GR+_'0:EY&"AVR-6R:4Z@3IQK5K"7ZUNCV2^;QWQHGUJ\B#V?!VUKCO-G'A91C7 M*IYO(5MNC$!N8-4:^A/ XXT0[RYE%'68?MCOL0!1^E[*/6VNJ?R(51)9T42! MN $&(Z9WMF$7N*$_!_:C5V:N=H%QQR/AC X'-1,(9AX1%^:>JD\ ^R> Y&Y) MO+R-HZ&%VK,U1?V7)HFK=7L[+UWE5M(73R=G.^@ELFLVX"YV@G?ZD+XLN6AF M,3'X!(B/>,3-I>]WP\F>W6Z !YVGX9#5+%'TS5'?I#XBWDZ3>9TH4%,_Y\(9 M8YOFGCY-8XNYMH==B:G1/5039C!NY[(+#CF0GE!GLZOH7;G%VW.LK9OD'^Y? M3O"%3LZPG@ UG^LU@+)&;[IL?O&03])ZH]A%1"!LL;PVT6Z-<]0/*J9EM MZ0#6O6R M?.<\K? P'^#H/=<)>2TUK 8!Q=L^I^"NXQ:ZF4Y2IE?TAB1",CN%.)A#BE$& M3O2ZA+Z7(DVS6T<,1P[AOQ3%R6HP"<7,@K8F%?T\;?PE8A&<;TJ0=D%2@XEB MX7,:TGAH^>T;GRI_'EF=PAI7%W)QM1\"TD8C\.W+@G>FCD$>_*.R.UH$'J6[ M&C%X3@KY,W M+>?=_!#@L?KL >>QC'2E-R)7.6Z2[>=W-]]DC9O- 95)CFD,(Q<.[OUPFQM[ MV CH.LT)3>U"#6]5,$"M>YHL4%1] ).Z)K>.?7*[F%>K4J=TWN7R/3K#$P#[ MW. V_+=K_5Q-Z(]L*/W_IBZHL_?(,.$N0,I,=<:,VM]&,$ &S\R/L>QELK.M M/+H88OGV!(@8N*:P.HP?\!1-/H68]20/EPYQ*V8USRZ"1'DS5!^@.J@=3 M7= TY 1XF233.0E UU9EO-$HV&VX&D#>M[_93V2E1O"XOKANF/73E7G"7]1C M[1V[2X^N;#.$^23 M@>WV$7A[A$"ZV@8C/X< Q7JOVV5_5^U =Z>"/?.:L]7QXV.LD?ZMAY@'#+OA MT!S8.C>'@[V\F*[P_[8JJLZ[%71^A#E_DQ#]>!P1C;,Q?WQ^!6>9>OQ@.I=E M?)"QK[)UK2O$2GKPB%M*+_F7I^Q.WVXFY$6 *\[C#:=7XP>VT2IV>VV=1Q#"G MF8ZX=67NE>?X:UW?%O@O<,'Q#)U??:!TF2_^@[PZ^RM8!3]>W\JK"_0QRSX! MR##.<4DD_A6%;69RGT?)_3NH*'$Y6<_,#CE8KY '2U62B0@3+)&?O(0'VJ_9 M"0U1NI=_P61>7CG2HBW9>]^P> ;1ZH=$+&JOB&R_E%XEL?5Z:SJN]>VK;".. M1Q3?JWZX>!SU2Z?Z)KWOV5!;RMXV>?7$\U=L9H8']:+&95)>;W9K^"839=L K?D&3)H-#]U(+PW_Q!6XB53<$\"%^]%T.6B) M$+:C/:'=VY%=JJD&F?/JZ:HJOZM(578]#%WC=&[,04YVU"W!_=[_];LM*K^O M5MZ?"**4U625$MI;V:]&5C #(U"/H7#OO+:Q!IEXJ0D,J/IFUB.$I!_^QE $-^09'& M#A[VTF)?!5W/:L]/T@OS2 2J'RA4R2?:1,YQU8O*V?XC,Q9]:K^V>QI5JHK. M&G%Q'>5/R(*M^,5<#1)C:Q7O"A%64"X$+T+$<+=SHRNX7M&5A5&V-RS5$TD4 M[)P.8/M\R[60$4#;NY:;T_C)N@V7'GW$'"HVF;J:V&,%X9P$OQ7%LO-A[^/> MK*S6#JRY=:P53&WP@U$$D[F$VC4*M+[:* O-$6>V2G M%,@&=ME&'UI#3&'Q#1M/WZ]3[Z\\YJ54@4\&ZZ)(\7/X.A&Q0ZR>26-7M+]AZTB MU0>X]>J<+%"0QLS-.WNQ[RY)QF(V8M'J\ 'S#*9Q#JN/2EV;O""DRZX+_7OK M_C>IS\"];I_O*'=A]4]^Z%9A/$Y_]F66D"9ILD#[Q;YJ. W2Y\ GP&?!]B:9 MU56SQF!F9BH3ZJA:]O+UY.T]W.&62_W\9??6;9M=S1DZ+()$1[.&INK9#> MC@=,>7<[\J60')WD'F!H1I$4N1YM@L6VN6[*'9G7HC)\#BSO^ASH[L9VINY^ M/ &\21D\LG''>L:TPM.)C_FN%63?HDP]]L;<(%E*WU5.D["J(WXYMLQVW'FD M21]6O%*4K_WU!&A)\%8H+AA[:-_DO@5F3O$3E&X?>Q2M2)50CN^.-?6>'((H M3V">50JR2LJ'ZC\GF<\'JNLKTU;BW(KV]CW$7*_\FDRLX)DU=?-O,G-B1[#= MX->JH8HKR5(NT<:0Z"_D<;%_?.45DI.IN[?&SE79_RSCL 39G\:\K1T%4&L? MO1D$YL-Y_P(;IO^"FZ@"UZQPO+Z;M*,[DEG6(='>H2^VMA>SVCJ*2FZP$#BO MV(?=>B;W7W7JK.\^.S_>H_+ZF313YPC'.$"2_+9H51\_X51EM3,"1:XD269%4"^92R%TU">935:OF1 :.O=4Y!% MFIK@X,+B5X K.3" _ICR LZ%4)Q/5IS/%W4A8V3QP #^@DHWM^D"'U0D8M_1 MZ:'JG65,?J6)EV-6N=237CE\I#EWK2N:<44>A4G] O+;L?)B-DG_*?VR;6$Y M"=4B"]F?FC>8)+$M=A47D+U6/L*Y#A!ZL\,DA&%'._""]P]_986AP.H%- M4_/KN#0EGJ%E[K08H>9<7>-7Z'*7!I\OG/P!FV][Y$F1 MC&)TH#4QEWVU%1]R+V;#H=3/(#DHK7G[F0=;;>KK#._'_F=/$S#YO?&LL,+4 M&2S$C?907VA[O^>0Z\HSH%F\:;:M;3:1T_ Y'@C[_/AFO[I"#Y=8$\DD2)U"NR/[4O/J#P.BKD,25_Z92/G]=T919)GLDG*IE"2M\> %$'0[^R^ MR[IR0=IV8RM90NWT6RCX9M(^"Q2EPO"WGK:0K"K32%5O&,URGZ_ MZS&R]!B[?8^ T7/$S[=ZAYYQF%,?W)*(-)TAQ\U#3":OM,.G\03PS)8H2UK8 M]<0[62S+C;_"BX& ?]Z$BAGTWH:;A=15UU5Z)'PZ_;7(RH#[Z)"ELPJQDJ+< MURA;^."%&AMW'X&[_8APDEZV"K&H&C+66 *C.T5613(?LH:G>L:EZNQ3W.A& M+TNC\ SMT=KU;N=YM2PK2D"$3:^=U#S0-6N;%1R!%G&@$_)=(?B*UF5X17<% M)3(((3;\SSD\96^N":&(1+0]$EC.!F;UKSSH?4"%??MFK\">O.N \Y\9/G%" M)XGYC@9";7#-@M8[?,I"[56AYQ2,$%:Y2I-MY:Y(15Y)4ASTXVK7*\W687LL M@A%CM=3G!QHW(M7Y"^BY;,#CZZ;?B&:]8[2S^F0&ZA.VDFLPC\!OX<]I3_V0 M""2LD>(H4/"]%DU\0]<]/=,X;CP3KT@GE(?AT2_"\,%[S! 'KYZ=:W#3<$=O_95W@\CZO&5K0$WA]OU6OWL*'3)NM9_:K0_* 7);\W2;6VIKA]HFLC+J;O":3^T MTS>1P,_%Q]VD;.3F93I-=WG255]_X^W^W?Z@KVQ^+\2D%* 4OC=RHRN3-7+] M)K^I!6[BFCNG/#?R]C7*2Z(L%)@ L*M+7VFQ0*1JK:(E G97)BL9+ZC17:"5 MGUZ]XF*__7(08[,3<(;,H[AW#G-M9A!0=Z##,3FY*=T[2T+&%C*\$&RO&_(2 M]Z YL)Y?B34 XV_5E?17OJKT4NTR$4Q;+KYOA#1'^!VG3F797T(YF0?=$!14WYVPJ'QR M)7;$JJ%JM$HA6R#Q8H<6@I(E,("-I%:K&(80)[7DR\^?8VHX'G??^%1L9S=_ MB58!"0,D "\D_B L-9I!:+\=^\=J) 1]?^^:6](R+47K1Y*N?5S81&MBD6N2 M0,HTF:VN5V/%T(Z\P_'8*K;W!-B%:3P^;BFV)%^>JL2O&BX<>HU(!KKP,04O MS-5F/&(3$>VAA'/4J[H-<(199UY$Y>V''RF@IO:(8E> 4_!3VRGE@/O\OVY/KL3AB57RI7?3>2]'4)/M3@ZG5= M8?XZO$ >N*MCW$+^FU_(9G-G6IHPH_6=^UC=.8,SY[AT@8GGI^KX,U%O1H?> MR:9;TXQHF\7LJ\MBWA'_LI1O%G8="4QN>8C!.39W>WK;:Q-+]8U2C2%$=; # M ^."8%_*HG7"1GJWL>7;!;?=H"1U_!)Z%44?U#;DZ$8A'!&K51)L,KR9SO)! M-=&B7VG86L,H.:H$J@1VY 5VHE]^YX]Q&K-D\F?=)%2R6)LM,S%GMU0&["(O MXA22R);#4_=^M^#O=J])94A'55P.-;,_=#\!]J;P@R!V6)QYPZ=0.MB[#]E0 M.L#?R0M@2-"!15Y=DD\7=H*N&X(6"LQT?,^UN>L\]_[@E.5*R1YWIQ6[6M0H MDSKY$^G!L$5728Q<7CUI+&40-4E#-M9ZQ/EAX_= M8F*0S1@[LU5INGEMBJ;C4"YX):)F?G5>34PA!P$3 5&.+2_T]&=28'4)HX#: MZ62$3)@3"&(N1(7[E:\K:5+^JROAA8SH;\'WUV_F%0/OG%2"I "Z3)DZI^4D MZLV@3-A(#REWU;%_4&6EVK)"E)<#*AFCZ-V@@ "*Z]RQNWS'GP-R\NZ1BJRU MR=",:WQE1Z-_I2?$'ZDI;F M[GO;Q<7!,TW)^700#]4D;EZ6L=,2Q6^*GQ.KRY2G0_=TS3,9DON>E,ZR,L?Y M8=EMQER:[!);WSS/"Q!C]OE>'=I!HP,5S7+W738D7H^#1XA'ZR4HO_=W%%+D M9%<1'"V1_I[0'&,Z2D"8L8@"'=?M:<1M/ '0JT5)#J82#T[[6\SU'K+:'H3B M7/U=XB@':$*I2MNA=*5]_U#90P/HIR*(V2U]FAQ.6'$KPJH9^'BJ.,TT?3[$ M7=*( 4P'KV'85"^ZJBL'U_C=6(?/@[PZIY[)87&T9.^VQO,748L5;Z\\D(.! M8[2,N!;E+Y0)@8BIGYVZ)CKC<:KZBZTK=X2*>;QAA<#(:ZU#= _5_KHO^G7: M+(SLOD^ Z1WEB\6/.ZZYD1$7TF<]CSL'U\H$?Y*G'*'ZQANB_>G9#4^ -\Z8 MFB<_P'M)0\WQ'YDMV:00'L86W,YA7@8#0;>#1H=]ZK"'9 9EA;S]]6I9V=\$ M&L@E9CH%IF\76%7C!(61;:W%@0#$7R1FO\%M0IC[:O-+UWG)-FU -@#F*.+] M;DO6<3:PA*;IN+L<+_.'4;^C9L;WCM 'X>+<(L4B7NA5&MRC2H4]SM.XFT7? M[FI4),M93:,WZ,I)+S4<5'0/C"Y1?0)82.7[RIWY=Y(UZJ?PQ9"4R$H>=TUE MAO!W@N>QTH8F(W34QM=_C<>>O)N2KKEKZ7-5VXX[>2=?0(+]"-.15['Z YV[ M-?Z>*$WX"4]DJ40U#XV^2\)\V+!TOTN%KBTV\M%"VGM$/@VMU>AQNYYN,--=@ 7&N",<[83?PC=A$6 LZ' $=;_ M?@'7X#IZ>];93#Y-AN"[1<%"*.:6%J+6\EH-\$^S<,07LNO;Z2!51P*WTBFB M9SH!H0ET^:.]["S5=9ESQ)D90SJ0_*='\D@0#TNPK,1D]@9NOT,IO^O5!WM; MI,+@Z@OM%R).R (Z4N/(:\3^[9WYDCL#$>>0Y/;#O(<@2$^3Q*D%\0D@>MP: M4OUI1:57),-IR$#UCW&2N;7^>LR1A/".F*F<:LX]?;V@89ZQ+!)5IN?W9^9Q M!CWTQ"M_ OA!=]R(/GN=7)26 -MBF"+4GZ=BZ.,_6#Z[=X8D?857L=>5[&DF M9OH%V->A9$E&YEL,GV>U3.I](YF=-!Q"0ID3O!E'$6JP_ATJT/<+GETE+2[T MVK@FV3 K;W%6S I?D;<@!4M@IF(]-#5=S-G(3P7YQ#/F,N&+GV8)'Q\@\XT+ M3?-9YR/51-9Q2_YE0UK*,%,J1>ZN!)7>#\QF&UW(7%AHP?P3XE">;:] G,U7LC\9XZU5 M]!RI9*SVAYX OK4VY1TU?$[<'71TW$>_K8,'>=:X=4:?IV[Q!,%"42)2U.C33*LS=:1Y M-^\?4EG<3K#D]X8 96ZZEY6)MOUO:T*5-%=$[L3SA6 M'!]<79D71[21'_((%&(F[D<8LF-#64D#<>(N>B+MTU_4?7K\6+$5S"7N]=8+ M!IPO:7.G^WIB&!=QSTP#T33&G=&2L#=B$>#(O*/Q[I$RUM/6[( MRJ0RKRW;+=B *77W.S1$/R400"MRUX$=I#23[A)%6AC8-U-F"08Z:&T$:V3^ M5L;)7$'F_)0.C'/2ZPER,E'S\_B]AJ)7$;"7SK.QK.\Z"E?R3"#:8.VM77L= M!GD_N*I>RLGBXN]A^(LABH=T;MSO_LB3P2!\Q.,B"WNIF?/$JC(Q/)K)V$63 MWJ&S4B@OUCUY#^(R;EZV,UAKJLG(0+ ^%R)F"&^1/GGKK:3/LFJCY)!&U,V[ M'+0YN2P^B:>:B!\^J]C8(['; 5AJ]81#T8#Q^Y77Y$"U,7&3HU#H?- MRX^"VET,/9!%=&M]>)@\1YW>]PY87HR8KA<<#R? U*2]5J2"T[^^=[^U&.;_ MK:U$>?3JPFWYQ4-KVQ6O1+T:LZ7!>P5>9CGI-G/,SZ ]+8G\:[NN1[)I\J;J ML:.F>77/7JQ MF,9)> AR1"EC/*UCBL?;^BJK2Z)K+\2>#; @Z[%,*;^L W-<#J3/Q*;&X'25 MBEPG7OO79MDN*>&T50OQCEQ+C+-5*0M5L.[IT$;->]*W&H/+4I MU'$7FZ!:-WHH>TL#1P3_%$!Y7T=6C$Y*N-$I!P;-LJ":^P338N+A$ &P^&2Z[*%MOQQ9/)C I0MG+OO@O0QNZ[?ED]\ M=[M+748$)=(LD, GG)PF@W%J'%QP"Z=TY5SD,BIVRQ[.*= T<3)$]]\J_KG= M,:FPHZ%\6%W8I:.#%K^J^ -%F"_:#0&"6[:^Q%@5 I+"J_M-\B-LVE]^L6]? MP&SVGNC/O!":R9*F<_REW.LK)-N>45>ZTAW=XF(5.)&TR?K]= Q[IQNWU)7E MSB-I?D+ ><+H/9]>O@17ZN4)DE$WFT=SB7041+(A0'$2*]+LQ[7OR1LAS"]S MEHE[-(5KFY;9 +>,R^:7+O[PSE:\N2SY8@*1)T#Z&)!L!!K=NH74R+!U)NQC1RA#*5/,]M0Q@&' V2PH)K M,F$$&,1J"6M[=#C"/-LG**#961GO$H]A_Q:.B1 M83&MP2&1WWW\Y\-+5S$7EJ[WM)TJ.[,6W4+89J:OSL0Z[ *?AXY]>I4^=;K: MK\-45484ONOZX&'J04-$<.1C^@[_^YS,2H^ O]G2SB-1>+]J;:MC(K.\TQ;M M#G0%#BU NR-HEWD"+%J8+>Y;R<2FNDQ(+CD:9" ;CU]/=*.RS/0AZ0W7Q;J)2T$]!63M$Z3MQ#1(&BOYY5!CH5!07&L=[ M.;LW%G'6Y5)6$'DUYE&>^%G[*M>A2T,^-#U9S#AANY4R0WU$H>6ER?9<=]'* M?&\UAJ Z.<\Y'Q5)&PDJ[(?SYUGXN'T=B@RPE:C^UFABJ>(>5-KAMC$SFQWR M%1,)L\G5YD SMA)?UU0\#?6,I6HIM46K!:1_#$LE*CR8'WE$6+B>&Q_H%GQ5 M>Q+F]YFO4!B<2_)U&%5PUTOR3.+"[2[D2W7T2BC=1QR;J*,]K:CC8P)/PNML M^N!3@+M1YL,RYU8#=4N2[2F&S$J67([A&S:W,W#?A)]F :DE*#_!BS(Y@MT2 MR[$U+;0?Z*5<,?JAW*B\V849@4C1T6YO[B?079""CT*JN2L[P?^85(Q3:+T+T@4ZPDH-/2C%Q"SG#W2\CB@RQO/@ M5)O_?0ZEXSS\3LB/DQ,Q%_P$.(K&/(>_@F_>MYN"\_,:IVAUWSQE%B7.K M-*]L2+44V\<2Z\&,P]K!UBSUI]PMX*;Q[>YP(( MV"+!4WX", HAJ LPT"Y_=C3*&!/#+1+Y*]N'G$7L>_E*$FVDJ#8OY$QQ/@$N M9;I/[[D+&7F-5(0Z!OK]["1Y8KSY3>FRJ^F +=>J:!8:CY9] -FARB= Q32B5OEQ2V='UL+2Q[:Z M%/3#8M;[OE*S1I$8@?!=*!V<^]??>Q<]ZD*N:ZC"F# 9[_)GBPOTQ*]MX2J: M'FC%%V/7N[]FG"OV$?P2@Q-.]FZG>;1*(>-&GV?FCD/:TS^.2[?G?+94AD!L M4?EM,=RV@N_Y"D96/&3X+'C':#X-RT>_1'K+WH8XUV(.!07HQ[,'BK\N&/6- M B?7AKF+E;VH=-2/;32>XO-GLJL^499\I5A5+1*?K"\LF*LZ44LH M'F%AP C/G_&'L@UV+W(#'':TF8!L'_5U2]^(TKYB] M -)N<2ZR[7N(S' '=] $ACG"5"U_/#=B_?"]$\GWW W^\+SO&]]^/N%0-$X M9GE'+OMNU]3U(2MBTT[K3HMV;4_1;/6N,I2Q39\LZ FPIRI#<#=$*&J75-:* M,ERSQ#:V8>OA%SK+8?*^'S<.O18IIP%RF< M92YG*'W_!MJB88VP5FUJHL5Q0O($\.$<\"[F,\53$&-HZ>H-2N7"[_I^+^S- MS$G$Y+E@.*]2JU[!]Q69V,.5K+OD&F\7[&'IW"G%6=95V65'1(S\62C=1C.. MA%O>@2I:2O5T0=XW+0>WJ'9%-FAN[3J]FTE;V871P(M9N#<3HP.P_J8'5U7] M)"/,7L!R2[;^]P8VN!^;&5,$"G-J4DC,N\G'Y M$=*!J[RM/\@Z+;XOF=NZ(+^]?[^3>JN:/'.]U=TP#,=(RR^B3;%C_OTE[&.] MD,P/5>4W@;F8_C&S+,$6TB%:P8(+NN9O0/VJL-T-,NTQ=U83SEK_SEJN,_)P MB,**8YSBI'AS2W49=X>6LI-=&G595,X:9A#O1FTPK,R^3'U\:MF<1TF!8%(G M)6IALW3I>J+3T0O3?F!Z0(8ORF[SMC1N.->%&."5LRT MYCM?=4TW5,<57'86#*=1]L2G^OQR5?&*,%2_=RKE3?46'+PK!#QFE]X+5 M['"Z13T&Y[9/*[R;L,:7OZ"I#RE)8F'>;(C=E,@UP;^+B5'%SQ-X.ZXZ"H4; M%^I/,[YUX$(5.EE1,LL\EBYJ/''P6:/@.@-OYPB-X-HZANBYD:Z[/B/8!O'* M/]D<@A+L?,M.%@J7>!0(%3J*>L0=4G4Z$1_L*IN'>)\.O1GWF'P"7.SYP652 MFK#&2'R@=&7(N$X2XU8.S9) =-1OE;W.)+%.5);U?_87^ENM,;#:,A+$Z0"T1"YZ^,MJW@".-_=OBHZP5PE]B0+/A]B M^GT!PGV#M8*AK T1ADR=\UIF@)-5#W"GFHOKS 7?UC9ZXL MY/7V)ON^6NHFKA9"9D4Y#_?+8Z+??@)@RI[R7T)K"W>F"0WFP0O,J!MJSS=G MR/,(I27HDGFSD\Z1O;I_]1>#%0M!'9P+JQ(MZ2\6P@9NYTQ.^U^S#2Y=5[2Q MQDGP3]VR/*_D85Q7L&NN@=PSV&RP_T-B?FH%98T[>5F:EKR V9M\D7S6"JTQ M*+._&Q5!>SOG,$UEDW&H_9_UI7CMDNTPD\_LGN>E860!R7^.KT):1CP2 M,YNT*:37B, \"G9'/6O*[AXK]/?L,"D*<9DTVXV#=1)D%SJ/GE.8Y>.EA?C) MH1'EH-=A*(!/M>0:1<6+\-I)_KB[\NX,YT,'NVV;Z^L,9>ZVK+,VAFB-68A7 M5.@! 1=)!#U$\L1<.GJ!NY8V]@D@4,P'!H?,%QY8Z+@4Q-7D&K-)%*Z+XL") M',09O%Y=L 1$@8U;WDTUJ3)2@(,0J=3W<8P0)ZBFHC?R\%9K[\'$^0=%1ITO M6!#][<(IQ"3XU\U-9 SFGR-RH&'\CR-'Y?N"TZ*<0_ M >02!_@SHL-_O?FE,IRR:JSQFY$3[!"_P#RZ8N=]*%0(,QTO^_Q*:67X"%;C MQ?P8$$O?+EW4W\,JIM9RQS*??T=Z5&GYL'185WPQ3V G)CE5CZ$^0S]69((% M4A#.GRH(9!QZ @25,I5'3M!;9?((9>8OQG6Z3:)MS'=F+ H+D2O(B[G0?OP/ M6WD0M+Q:!&/E_SI0":2MI^[[^R.H,#Z<9^Z,ISPVC^7A*\SPCHXB 4E MN:#F:)4LXPQN4,J"MTW924@PCO*0-;_MJE)5,$"1O3_R*CMU>ZQW MK"'.@8HM/1-JX2J^ CGZ<611;<%[US87ZTW13&J0&O;,C39),S0Q>\,OVA1S MHE;BJ,-FJ3X3J,N@4F;ALD>P_4RNUU.8.+1/$W=#[QUT>LL#TMX5"%.&2T*W M9*[C"L3,W#@G0SMB?WT3_CC@R M$DS<1:G5SE/*SZGCTO5"5A=;\7BSU:V1#%CYIF$N/06B)"I_=!ZRYN)BUX)( MV5EO;,8--)*NIR8OG%A!"TX$;C^&@F? 8?$U ^.<%[?)6\4Z[TOS&K$A:L_< M-$MT)4 J>"V FHDJ%%?X4-KC9CK;BQ9Q].4) ML"3S>SXP;1K(Z;NM_XSND\;_>+ &HNWMSNU0IJDIXS>K$3F2'KZ8<&]J0(WK M2+/ORN)C;Y=S;8D3Y3@B=)1[.2)RH]O 0 =GEDU:3.2RSH;2H_Y#(C?<0F_B MGU4Y.>:Y\K'7LREB3RM$J=KC$Y.V9%UYRF&_'^+#Q,RC@_W& %7/>T/W"S%9 M%Q-.__6IVE^%8>5QV;W3(^8C5'*8#T!%/8T[$M=\Y-?U76 M-QXO5>WQOS0,2LSWOQ9NAA1235X3U#2=8@5XU>?C77=*-X<.6?Z:3K8B TG^FNBY;@*XX/O>JG";DS!R\%C?TI[5YVE,E-[DCL@%=C3TWY/73<@D MV+.$7=N@Q#O%]6Z1Q@V![X4FR66KS&I5YC@S-Y)7A?4I'V*)8\ _31N"KUEL M["[O,OBU_;!O"JPUP]FG<3=/AY@ZCI)5XYX 3?MJC]75G%P>KHG 70<->+ Y MHWT]AQ!Z%]4G6QL[-Y9W$*\3X(%FU5LI.W['8_%Q*C'M6H[FZ8OMH_O&FBD;^<"EVUCZJ M"YH45?S3K+SO<-"U>OX[ZLW"O5\O\$=VE\>;3I>6P"5!!RN?3WO;E$&V9LOV M)/0<$+RYKH_?S!)T[K^Y)O=@ <47^U)&QYXSLQ^=_VQ'V/HC^0Y(_GABA' 3 M+'XF+M0XUMIS#"> YY+@?=%W>%V*^N$*=T60;G1]U*&^+$A0E.2XMICL> >2 MZ++3;X8RV@4;6/%,LRIR7IU]3F3(Q9/D&_!(A-+-PLHPWJDUC'*&>$B.1GS" M&\84)VF[I&B@20GY6ELL8-:]C,UI]<:YW'Y>ZFORW,?0)=VT":-"Q9WY/CT M%\!M\X,8^XJ?RF13+;FG$9^OP7EOF2]4M3 /=6G/K':THI2JTCZ14$K6E@<> M?JZCO>NIOY>&P)ESZW-G1V@=_W[OS=^DW%TU+TV[P\FQN#Z6)8GL;J#W,>>D MK)B^P,@>]:8JE)@06'RRZ6/OX; 5S&IB_RT()+S<*3129EN]*RXIN;TM\TQX ME5\#,X\C@JLQ7^^R2^?/4W?68MUX@NFMK(6)IX4TTDFG84V#D+\%V#E0?:R)TBVSV3M\_"3< M()Y&17/M@^,6[HSHB5"W$Q;CSVM''DJ=./O:6!^!<+/4$^U.#"OMGQ:T\N6U MU?(?G.2)4'JW!?6Z=%/7#^C@36E:VZO;V=!MQK^!:\NU=AY!-3!,>GK=V[U* MZ("TM> ,AH=*59_.3?XO/J8@[382:&\_6O654?7EI&50O/NMR!V)N! M%Z-R#<;2U<4D^+'GOQV/O.MB(&;C;D/9D9_6*7PA@H2-NHXUUT@"7%6IU3%E M//I"F)>)?WKTS@9QPDE[A+-'7I&NR-)OW"WMS%TV>NH3(5>@?=DGE3T&@_$2J=ID,#K:UPPS9K&>[S)]H>)EU5I-5L&CB5*&A]44OF=T'T\MF MEZ':;22(GTMO%2C+O.'X+>?*KO FYAY4[8+4;9.Y2O(J^I: M=AMZ9T*N?>7 9@;D*&S]H/Z0O8M+N,UXU8 %F0RT?^Q3#_[>8H2MQPY'&#E8BLY'G#=]WT/BT/3 6KEX\S[4 .B/(Z\6_9^=T+76?MO$.'W\!#";!:4$ M);RC"(> O H?E3>4S^-<"D+O4=O6)\^=*PJ8.!O"00T1SY9A^I!$^!E"L(4C M)X*"]!T*_#FYPY%!9-I@ 9\I.'4@$2J8M5(U2S)6Q*3]O6R MBD9TT?P/1,GK=(7V4WLBZJ2QR;4^[]JBG>U-DS.BKTB]$BW$CUW7QLM?'GES M'"5CL"O^IB81_$T'Y7]X_SRH2"EZMZO??BXCG%-J3U3/,-+$U4NV4IWF%^A. M>G*:70PW&QK>(?F_V'O+J#B;=4VX$P@2G""-DS228,%=@T. $)Q&@KLT[AH@ M$#S!+;@VWMVX!'>'X![?<^>Y\S[_GFQZQ9\^/^45W/JJ?DJON^ MKGJJJELE"3>%L0Y!\65XFJ@#A/78^L/EI^>%J>-JOW@,+]J:G\/J(BS/ M!656[RB #D_NWW;!/"@ 2P"6K86M@X)$D_7.7]8>5-Z@M=S=(YB:Z@1./ MAV4\J<1WK5S"+*KW_06H^.:UATR<:6']-N0C\$GU74O2\T7"RW>S[1_<"R1X M-EEC5X,I(^ZY5NLBD]QSYF'072R"XIWAJ ^>8:<6XRIZID=QO=^5)2T__#N% ME$7&G^N/;B6394QEH.ZA\P,^H0&@T_L]\SCPNZ5S\K3;PQCO..T[+GP Q,MO MG7'A!-ZBU1G1918Q-"[]YJTKT=MX5/@,^\5A,*N;"O;O==3_=!7_?]K E!/8 MVU,NOM>'H]]NGJRB[/GXZ6P:W3V8L:97GJ2K"KO=4V/X+&1%'U/;+7+(N+F^ M5NRFT&_=.ZH NCFQYN))3*)YF,QP7Y:M;YX0/'..'W'+)+P3]<$RR#7?6[G\ ML4$M^TS"C&Y12F-[NZM$"N1X7X8;Z'F1D'BY^G8\!A:_<%DX,ZZD>]6@]ND6 M 8! P@Q)"0-@?0Y-[!\RVD"2H5C@V0>MT#^4[6D&JMNSF-5Q6.*A] !AE<:DNP3E!\ #DHQ#X"6 M^[CM['[])#R74L>3GLQ''$^.NUDM!KDZ+4",;-$;5M!7X.XV2K*$9 M=Y>J#P V<(F2DT:UL$OA#UA-G7W\H3QC>M@7S?NX?75^TW0NA?<8&*)$FC^C M7OKHS[]9C60TP /I5F1E7;]N*7)+L0X9=&M*6<+R_$#=8\L,$NG@:WT -'D\ M8N" 4RFD3CV^CVO2SA:5+]K+[^;MY92NI '#6 RV@M\C^%LH'J4E(_Z[?[45 M_7]:"HWR )DT V,V)GMY-VA+,7MH]6QU5XF"6E#0LDW6J(.W M8)6^I!KZ=#-B5TH1JWHM_ $ ([2LP#IE3#W"\,7:T9#&W7)5V#>B]C%%G#X M@I,'>E#VEJL5;U(\T_.]>+& M_?W]1\,8T67[U.5M'OW@QW^V3>O/AO3]B,K?Z.LU M=HZ\0GYGI&_DV^C[.'_((4+>X3UQ@K(G.9<3DP3E^DEV[^LRZ:_+<=6(!%PL M1>4U0LSW1FEM7)FH/^?9L,T::Q-^&5BFN;U\?(Y17^9P$@JM(7(I6]](TE\7 MNWP !'GLA01R4O &A[720$9^"PSM=-@6!7TH B#Y 5H(OU>(](8Z[CH(DQ]B M!8?W.+I(SB^M$5&]HC*X4W ^5=:I_/:MGL-V^5^=Y?C;F8[(PAS-'>Z\A>MY M$\6N[#=GJ#"]K&27B2?K'E-MC'TN%DY)0?W>$A\I2D4H@VOJ!_@OE**[7*TX ML38W);WQWL>^_OTNMC/VY7;ICZC).M"7V$4529[QJY]A%RE1Z.;$$DF<]5[I MF]R/V.RJ.90.F=*H"K+^$BGSVU3YY5IIOR\'F$E"_UWMR.H$$]')7#K/86HAEO6N*^:&__O&(,8N8;RU9 MI"U-[[9XP;#WQ90OB_088E7O6^:ET?MA4$<.7V(XYT%?QB&5W*^LV@UUE;D0 MNC_V@H7^5R<^&;9);=*++2>GRFE&*/OY*)?.N39(%]L8$^7EL_OIHLJ^O6G# MR=RT&C>'OOSXX9>E I7 @L54G5>>0)_6)\CT>%BQOG0?IDJG43)G#(Z:,[*/ M5$6I%\7R37829[?J=5?"?9[3&D4L_#M*)$4:QR1P71H9:Y6C]N M:%#OM159?9]M6_UB.H6**%%MQG]XYZT,$,G0KM62Q[_OI1VJ&+ST;4TV]8>K M*E7K/@"&W%&5+J0M-PNR:E-3TZ:Q_O@0\NY_[Z4A9K\> -T:Z@^ TI$'P&8. M]/E0Q0,@NA3Z -#-?@",R&H3?IRS_B_/AOZCF0T] $#/HNX\=7PWE=6#_BZI M)F$^_,B#)?[JE25FTX\U-5)[ 'A0W3VM9A0>NAK>0[+OHQD_E<.ZY]6M.JQHIW%]Z-Z/>A\56,_Y]DB&]V^ _:_C_OVOXGOS# MN#$*=]V_JT/4OY7)Q!AALAM.)'(V=XCV#,EM?\^^=^&N]EC M-2,T[C9]3Y\/E]R(7&%:-A^(/P!^J >I(L@>T9,C]E\>E/Z3:5V('%..->]$ M=-V//0+M, XB/-NU(+6&[#[E,:/YSB.7UB!)5;WLG.>.YW&8 M?:]/?8U\QWQO71\ 94I)V+_5"(OO(AX "H]86+QOI/JU>+KX *!X .R,] ?\ M'Y>YP?7W"'SCM,?H4U92EA91U2E\<,P!<'CP ](H^:J#T%S%J M_'M?B%0T;S7?"SP I@I_BSDRA$W\^?&H7;MKNP= Y /@;//_Y?ZUW*J-!T!, M0-=]8ZG(Z>OBW#\_6L7"6>*6HJ0D ,WM&5R4"KFUS*9!C\B"^?YM+++_?8#2 MC8G9"Z#Z?RK]ST5%_K_<_WVY?,5_=HS,P0GU.A-3@YV3(6G-IX.P?Y\I1=_C M6JO^]?!ONT?K]/Z+T>3[?UG_D/5WE&!*_D^.SF3>0O.(,HDJ;1(C,*WI:$)* M;BGQ^S]WVRK_!WKF_XLR-[C^@1T3[('EIIUS< 0$RBHN/'RVY<;^/!<*>[2> M_=\699[_P3#4H._Z=D^*[.;C!B&1O\."SVA^C37=/@#4[M5\"BP6?7R+'N5X M\\?_E.6V*H-BW-\E'%ZCYVOYZI_34ZH3,IE_E>%X:.1D+K>AI-._9MRJ] ^ MB\GW[6Z%^C;BW'\E+/MOZ3B%C=L(?HT[ST?:SUNL76DGLF8QVKRSL''5H4;1 M&6'YWZ&-BH\"A2KY[9WO V"/Q$J[TCGC\G;$=^^"]4G,&.R-%E MQEF_+XMBQG9S;]GPOZR#S'Y!^*Y] M$;O2C]QL*,"ACOA+M>/5K!YIVO8 5B7-6Z]I.?P8;;W V6$&97?^9E,PN?%,V)[)Z M2@F#"H.;;-O4M_]8JS?^2Z(KQ_1Y;F@+$EU\&&#]U,97IOZ(+I^B*=N&<7#$ M72[VJ3[>292.85W8JI? DKPW1L=U7GDFIB/5J2K5<3_/V^M#H>)*J.7QB6>V MR^9??G6IBNH1783%RBQPGPL(IP'W7\59*@<*T*.\I7CIXFV97O+ M\8P5H.R:9ZH=U)C>E:*ED239-4%TH6V=VR2:3M2G7-UN?2W#E_FJHZ4]JL>T MLX[;AV==4R"J"!>TKZ0,KX+4@ !L -2DKX_,EL<*.RN,\>6_FGU C[\A4NH/ MD(<^"JRN$\X/S^8%#H;.]--XJEDSZ@P\@L5\8?WU/&6*I#OOU%F5 ;2/+K^0KI! A:CJANX5HLTO MB(H\U=MQ;S*AG3_D2W5(A?]9<7L V(BWGBTCV2@J!B[Q 'A]VK(S6;:]?UYS MI:21U1"E<\3=:%.D?:4Q%> 4.9W\>D58HM5OK@5X+"TT#=G2H)^";3J_Q>TR MX@A 1XDJ[IT-811Z5]A5M#6FW_C9]7S(+;4: M@R%!OVB#J\=+:/P,2ZRL8S)OJIPZO"RYE"8BTO7I>W.T53A$YSQ#4-LUC/Z^ M!Y&^15)J$F=2S@@Q75=BI)="/B7AC*/0MC-P2"]T=GX65X+08"_Y()$[/YOE MOY ]YLRHH*\4=MVISSVC\]T[US% ;,G/(U"/\QI>57SIVTY4J;]-3+2J! XZ M4?F]0(ZB=&;5B4-MMFUYMU^XPLSX 5%.VMC1 !%[4NV>;?@M'@"_B^&VE]4K M#L>&^:IO>4MW>UQ^<@S YN7=D]>3MR(JS-=U*]OUB+L<9RY]-O/S*.);)QK- M-T2LE-237=[2J=;DH-\P ^<2'<& A>,E6,[;J/GVYM>WW725:2QJGJ&=7?*2 M!.HT0?_*J1ML\>_6!3="MXXER2%;0Z39 0ZM_O0B<;8:-%YO"CM6F,4_5$^^ M"AOZ8,+#O6=5&^8?CCK?I3+(*/.Z>I_+<,Z'_W"\2HG H\3Z$"3@3Y8:=#.K M*&SM:0KE":N6L""$H;5&CNN)],Z]\^!1&BN#?=I*?YH\Z0D\@!FXYF_UO-*> M_6K_&14HD"+"0_FS:FS9 /==5 F'3&50S&W&67S+:]Q5UQM0QBAL/=N[MUJQ M2 FXB6>)^ZNG(&NN%[>(P)8'H/HB_ T?.3EI>E>[AV)NH8[%I&L N-[AI^9/ MUAG5/<&82-B0GMN3O"/,J<-%\7/YI-5T3ZV]_B3&J#I73*=5ZA7$*=:+&WR! M,PYTA8G3*7=TA+EC6J,B9$>95D%:NB M4D^)S*KPKM"G3B&U3C'%Y?"]NND+ M&Y6 %KRHR3J,*-)+C\%M,G":'&]^G'( H5$U:^\^M8''Q:L*JA;M\*B"60HW MNK@"7:[V\Z/9)R][>G37ZWP([L1;..;F%J4MBN]2WH]3\M3"N9=_?0=@E2HA M/1<@'2EZ6W:6?XMWDW=YI!CV7GQO&Q,A-?!$BN2[LUZJMX?G.+$>]^%>JA5M M9TY!R;%4?J]C;38U+U#/7N8^+K30BT]^7O%\FUFBE;SX-[@=-!0CC.N>-"1B M#^F:+)N^9-66S43,3#P J@QJI/OU=](_L,^[K;U8A"HQLZQ<2%-1;NZ565P; MLY-\O*9BYQOGGOL6I&/4+/+>4=9N%?H*B[+W0+T9$0S.C?G6+:L%!,7Q]FZ, M%9SMJ9T>(.ML.6Y^ UL642G*&B:P&BN0-:V@BKS92[?@? \Y8JUZ)W:HO^U MQP)M'E^%)%W8[G3R>]ZH6$;Y[NA?(ETH6+TE;*ELWM..G)W'6.ID2% #O;"_,^>%ALN%K:&FD1."K:Y@5]8H?2&-P814W<4C M-,>94UGRD\P_TA$-JB(W^/54QU:6]HS6'@;9-T>1[R*98)@ES0#&KPGG)!6< WC['3_&UX@_!,P1A*3H8U M!Q#9A-SGD-QFD"WU="-]O,*M32Q#.44IZH.*,]'=IA'D@J,>.9S\T^F0W#KG M(IJE=F2NUU2"DE4^7?6%X33TWB(,KA:X\5)IM%3R\/[4RLH74NJ^15)S/+(D MX!='XBY0T;G?X@0E?\.2JTW7KWZJ^CQR_S5TQKQ<<:K+3KNM_A!C('LS?O(ZML,U5VJDI!/_HV@;*@,0 M;VRR>BBHSXW4%SMT.>*W_PJ')/;XLZIX] R?I)P)6M,,_19M8#).NUIM[*[5 MJ][7U %\36,F( 4@BRB:/4=S>@!BMG.!0H&;61)&0U39/0*ZLNOSCZWI%.LJ M*+"[?6UR.,>OE^*4[#62.)T7AHL?;LA^/)/P*W/7!-)DP4ZT$IF[G6)#R25CK 8'2&0> MK)1KQW$Y9=ZT_6ID=K:/(43J_?>/]F* R/2X&,>EG=JWS@DARH@;NKP^$%C) MZO\"@*V:D4-%>?O!&8.N4-L',UR&:PS[HV7@?1PSZ?$# M((#>Z'G?"L&%'F["!RM@9Q$+_HR :)>5P%*9D+WJQB&4C(IJ"R0^]M;YZ_>J MFD8_A?4B 3]T$!]@";)0/'TK'#:E53&.M;\.K];4?OOVR;KJ:YJ=+N2CZPFR MYN I!*E0>@IEXWH;5M0TC8JMC(_L', @LO%$FTNLWEK$:1KTZ*"V[X7J*5Q+<6,EN;=2)_\=8:XH]@%E MV-6(W$/U]>@^H\1T5.<]><)'?@]+\RE .:C/N_DU;9.U34OK!J?8JB^VCO:\ M3D=A9MB$^/M.'C+55*0 =BF9-6.-9\O0Y]>>-U_)]E"N\1PIVC_.]_<7/Z^E MO_A4H9+.X<)T-?WK%&$".#< M@7O)W1,-V%QO]^838MKN\LH9[C>$E>+%SC9XSXM6ET^Z2E.ZS]#T!N6_U\8O MK,S5,K&E06N>C 4&AH\[C#PV=$J)W,T!W%D=I2)5H[N4'[_Z?7 YU4B0DD'I M^67>4(>'X[QVL=1(K1;HDX^>(E\+*K599%R*S5+@4XM>.^6(O'SF&]:09VWQ M AY'X9'>=>H)0:>,&3B: R;,EW6($ZTE2O4VT@J: =7!X\C.;D$QO4Y"FAF M_6,01OXC"./J#=I8L[ 0B@.SS0 7+0..W,(BHQKOQNR<4Q)W]]\R!W5]+]AG M2X7X>4XIN=N=%[_9N[ Y,3*>#U\%D93*#;5$6!&&<5V+3#O5B;A5W-RY M7?O JOF8#PB@X^.((T0(R_W8FF5,-W,6ASR,ZC.%S&IZ8Y56.X&A:X]<6,>;"\Q4 [O([Q%Q.>>" 'I2NVKZ)% MA=O3BP]C)M[2ZBB_K8!00RI3C#7JE^4M5(GG0X1%$80'.BZAXX]8E.&2.:T] M0YN\ZBU+@)63A #@W &.P\G%]%&W;PD.D).KK5X1J:N0':HN1=5/1:;=J%LW M 1S+>KPI;IDMN'IU^FR$:KTJ5_?36G!LL1D\[9"NL(P5MGFF87QV0_L^Y[>W MC9X>-TX%Z]ESZJ'9]!%> D1)*%G7L=[QRV'M/WEHO^P<^]='Y=(N1@KR&);# M.@M)2T;0LU]2(%[R=K<(9P1]$FESCP=J+ZIK[F?6U,3I_J#EEG-0+?CD=C:T MK %MP*2FNH M1F\&EY0N/Z31,NY#+X,#)%<5[/P..M? _'SC>"R&32";"X '$G7?J 4_5!NH3CC?*=Z0 MK^.HF[U+<\WN1:-I%"%BUG;A70O VWS_^>X'4"MB'^5Y-.^ICGFPBBV.T!VC&%%ZT.A@\ ]9@ /+0AZJ>> M80K*=O87BG5M.N43U3UVI[-!-<%"+='/HUO,D''11)1U@K\>O9+?0U5K;*R, M)$OAPL&4:0^-BYSHND4SK&-&:ANU(-6=KSZ9[8,X[1YPL@(OC)]T,SEXGVBZ M-&.M^I]*>=ZM*G6G26@2@_K9J06/8%&->.=R6[?^FK"\<6O(F:V;Z,5#C\JUS-3]+;-OU<<.EML)["%8"F")A?MTTW%/\^16I-$3 M#6IS-D2#GN^.&NU2U^L8CD(>52I4*+*LVW.7PIQ_GGQ[;:EI>\Q/^,UGU_:6 M[7K,,O("QZFYX%9BV,;)"OIN=$GO+ETB-$O2A#;QJ(>"%;B13^BB3W;I0 R7 MY>*4JI%T:XVXW]H$1R6([!E6G8D@^9H_ "Q7K@R))^,G=[[X3B2"[6T;-B)Y MMU3+?*@6%O0;=[8/99E[I=X26;WK87QKG]DI',+YW;RI>6J.IK7L>J+-6 & M<:4L) F8"XJ!\ZZ=MG2"A:=+NKV>?C7+F97W(&&RV:>.S@&_;S+?YENEBK2L M>NSLFI&L\KHIY ASHYL7T (QH*+_XWSN5WG4'UWF:3YQQ;^L7'RMQDK5W5P) MF9X@XXWCBE+?6>X97IJ)?WM7'D^R'F"Q_KWWN T]G!LR3L0G? 4M^BE+=^5" M^\\^8R-%CPEZ?IKA;9K,#>MN'"^7(M0*M!9N.0D;%68_O$14IUHRC,P'L^Z& M_BI7";!'D<+16:D\/4#B^KH5/K5#7=F4O!M%3W;;ZM?HU@55_;:\-_3K!R)$ M/8PHS-U4:_17J(KG_D]66WZCU, M769E.X>[,>/+NLZ>,_KQ_;W,@,E-<&:X M3+_L!WNI!:6;6F!)2L:79&N/R0PFUZ,'@*&2W1OW]S@UW24 @)%P8_';C@72 MIFK36GC _AT+["VL&_Y%O!W94[2WW&C(7M+RTK7MF\ZCTIG3>@"8?@5K0=5[ M)9ED7)9[Z*G3'; ]SHK6<[+[?_9.<4I'GKH<4-W39=%+]9W3_CW61D)('0->*[Q3;[0"!U=^6_@"Z_V05]^^$,YZ2LYWE MDYKTUV*;QO:UM]N2GWI)9*C# P2F&%>^QROAFLL_RX7-U=M^"5Z&%WM]743- M^%G.[%S<)\2C6%%9%_M:\IL,C=%SGTL9L8B&L8C"< -%>VFNRMP!@A%U(8;B M+F\K3G8%BG8% L7N@QH#+44T>C@6)#D_K QJ1RW&)_]E9MH4H<382_?>]J;+ M\]#-N(7RDJMJ67-4040E8D(7.]?I>7FW2 -G&@]P/JSSIZ4Z/CGM7A6YV5,U MD4FH1H8L%JPL^%96T 4^.Z9JHCM<#.#IZD0K5MFNZ].9;]!.C !-Q'>\.L;[ M#F)82V>788[IOD IGG8Q6A?P8 QJF#J39[=.WIJC^W%^X(;\^@;9EU*I"L. M_J(76%)Q(YQ"<9U1U^^4;V94_DH$6U"H?E42G4C1L?*\KH\_OA@[U?8HIJ\ M)/SXFX74=&JJ[=!0)]K6H)7PJ/K]Z.C MN6J&_;K 3KWY@?5O6(IK'#MPT8J0%X2*[)2G#=;>^Q-IX+ MA*PC\_PL+B5:RQ>TM9M$$M1(15\&H=3XB*#(X[!E)MB\J0 %_SEXQ,G.AL68 M-5%-39LM;K;:[-=:QL]JP9>%^I8)Q"^4"F0=K D-[2478AL8UT1I\5#J[JBC> .D+DF[!5HT.FS[4?."!=JM8_A\+IO*4C;GR9EPK^BTVR]2R=/O$0AQGW47)=E^@ M90<'AB=+QQ^7J>$F@KWOY=:\'<#')57+X,*7[N'VM-<]R&%#WIQ;;^/;@VQZ MGTO<4G-,5;D@ Q@$F&O%8SQ-3ZL)PI8AJ%$7G: M[2;)UP1B( E9NU4*C>W7W\"C*^FO*>^?T+1J$;M=!7J/79Z?E3#JXVQ/NBI; M/I_DT"VYP!=\WQ\3]SVPS88&+TK1(D&8H#;]?D56G>RK9P5>,E=]_+Q:-,"^ M",V@4PH2IE.^3R3U.[],TX+8Q67*@< *;B(>B?*$3WC.Z*BH3CJ4^< L>?*W MIUOIY+XFZ LYT7-%_D?FKCFQR[)O6SU;+T*;4Y64VL5!B$U"HD1-CEV(M/EI/DK;=?9X4 2*G MZHU?51_;8UFMKJD/$PAE@W/;*BH^^[3I0YSRO@'&\_P;;7[2FM+YM"Q9I<@$ M7C4^#B^7^VG]I7-?7[U^I:R=URO\J_5 Z7*\8S_6:,LRK8*Z7Y.E\]^K*>YTU'%!2UQ%++4,W>,I1DX"YN_3=OBGVK0_*UM, M.I+Q5(\9NX:V<5\= P%MML3!:P'3IWGY(5R2%6ZQFB#-_ P6-S^6!H8?ES? MNP\(__3)/ZQ4VW7.15I>.-/"RO0M?8W,7C>R3!=@(W]#,[DK;,\&6D+Z\W@B M^7CM764W1A8 W5"4.I8MW-BYN*XIS=4KV;N?4K2^*E5I7::KS[&Z&*O%V'LU M,#([UTQRN7[,^=G:Z&Q)U\<;IY%.635*+=$B2,\:O@S%MF%F_3.C?)T]LB_, MD3) DMRLL.[H?[JWC%$)']H59LDSN.7AD!)65 M9GRHJ:X/PZBU'?6TL/<16_\R1U44O[6G+28Y+V,Y+\OL973>4T;$2(@W.R_Y M5):V18RAMO,H9IN7_#=L=X[P; MIWP])AG4<#&E#H]5H$I:OUIN(>D4Q\Y>R'!<822L:$CO79G9!JO-'5TMH^HX M=/GQGV@14>+7P?P_RD*G@Q-HXZ5\;OBL3[<"%1L/P<4&A2'<&LJ*+\C@Y*M" MC"@G;=>1N:Z%S-/P8Q;HS"1ZK/JB'8E>#P(Y?NVV#?2TU)R?:9+XHZ[NSX#E M+,V&CJ9X+S_'<%XR*6^.CZL8>M=AW5#/54;)BN;XCI&\RMI(=.1LC. 8@O+6 MK6"1+U"G*4Y$I6='D]]L]J[9?(N=4ID0(^E!&^("=QN>"7U/[!JC"ZKB7H:M M,N6ZK&:1DU_D;?L0U3;4U]>&F8\W[O) ?L2LSE<*?2;24SV6 0D]4RMLRA[> M8K:S*;.1'*C>8D+E=1:$3!;1?^$,9];A7_-R.S['<#*$KYO,H E$SI6A M^CUIW;=4-?+N,+:B\)4%<];S'+IC_^;RGM=TIM)C$!#!W;J8@0VF(.?,B1*D M1I*!!+T%)@7OR9KCR0KAVG=-V^NE2-*.-.^FX0&9@6[7[_M\-M 5V:4/#$=*P @'CXA MCJWDS)R=?+4I9P'-=<0Q4T8OWF*)AP2OF9$%?%Q7)#/U\G92C-]:MSV PMW55X6OKVWY$2BKRH,#1(#]IA=F*N6G8F_U)#!G* M7L8\UQKD3!>0!1"5'"2?9:'CQ"LXSF;(^ !3R=Z(9 MWGA1N-.&B6W,QC(Q0Q4= T:Z=:,4/T/ ,PD.U3S&4WN4:+D5\1AQ5M\1OHO( MO\ [XZ>KC6^.N+]01&^[S";PD=UAHUT'SE0=>/%!'(N&7,G+BV2=K7A1^=JU MNK?&UPQ3#):3]GRK!+L01A;N$(^39NXS Z\\_=B7RQJ M5?R"?%0U>H@DM7VCS,:W6"',UYVC(^Z-AH^2R!P :_(?-Z4;[&T?3T7V\A=YTWT24#7:& MIV2@/+36#F%M[Y_=FP?.7P4H2!6TUO&U:7P^F7<+A%A[6S'>X^\03F1'RB>" MRN.[=6A*96B_QG6-/86RA")^QF[A,8"KH^N,!BS4M"J5^G_1&$^H#9>9U7BF M9%3F1.6F4!3L+G$K\3'PME(42HJ# RJ@D)(M>%4'YD6Y-,T/]C>V/PYQAL<1 MB/-DIU=6M:/ GAF,]/QA#;H%K%ILM=OZ1#I$ ,DJ3V7+DPB70P++^61B%!$XDEH:93IRF^] /CS,/O M,U=I+TT$D4[SE4HMX&-]R DQH5D*^WYK_N&/Y+F]=IA+XWY$,S)=0Q6N:8MA M2RD/4/T.% C& <0,39:(_9B?W4%GKI>V,P=-LVE-)V_@!7TW(7=0#ZXGSP;YT*X/+ M#"Y?=%K M;F&#T/.:5?;(YDCRN.)F-!FJ[G1@,)S=U;"2MB6KB-\]5:\)E$* MGD )S X=./M '!#)_&?XF>!P-D9]^?"O,6.]*";F;\HP^WV7=PQLR'IL'LKHHA-5*6]1![&LA,!96]@H%M7;N MR+A-.\NC;[G3=-8O@_$KN,J%#9(AFOW$V%[QS$>O.7>8X&#-89GK746[BRM; M#31LH."FISEPJ*X=IFTK4?2S=PY^FT/$(]A%G\O== WZI4:N CFO+"XP0%DI MX-&]_J?@2X)!),D$*E8AM/.+?):*?*ZK"O OA6$:(,(QFEUZBJ(8?ZCM(EGM M9U,&5G2PO/E2[)M2$$GL1*FVQK 6%88V]TIF%SLY+#7DR[)GV M4-6U?I22&71'S27_@T&-7@;*6EFP$-V_P+3&RQ!\J@BXR%)BPP7I;;5B66]<P41VK^+@F74N61G7882"ZORPNY"$Q*A7SP MO@K'[\WBTN\GI%%IH+!RI@Q&) ,WUU^/$Z>2U M#0J0Q%G0-G?%3S]\">LB:7H*=C=H;*#I.MQ MI*ADCW2;,G.K9(7*Q]_U+II]]/5+GSX%)!>+!)^!(VPQDEBRK-SL/JZ+^*RB MH7"[?[(94JGGXZ(H"X))P*HK:V+;P3/R3#TTDHAZWD]/D#\]:5A;VZ!XQD7J M,L<4\54$;_H!8+(U11HT3G0RWQ*[R^S?32%4"1DP7]CF]G"29U[OMP?!)\RL MC<]:+E9J>0YM1G- ;'/9FI)F$+R&^'D?42DQ45>DFD/1.RO/CR,SAUNO0*1= M)@ZQE;7T#$52J,T@Z!LIXI'@@*ZR&1RXK",3[FSKJU?R&RB+M>*8D47N6U.- M*G:$TY)0SA>Z8%K_:JW55,0";2*EQR?#K)K#O$C,[-SX!XW6\.@97I:<;STM$-'];PC[#CT6G'/%[*V$30QQ2;E MC9 =S>-+1^43XP#NJALR2Z,/)^2(9)]/'9!PI%2_:4$70@(]X@DJS;#?^_L\ MD2+5+$<<\&7JES+A?H5^TH"3';4^Q=G([E\A':2"=<:D@7K2!"]8-/IY07XR M(N]/9F 3@:]-J M)D%U+^3?:ZM8'OYD9F\$E@T>@NH:U,4@4F1*?@Y[5444? M'>A*)5F>:ZNEY827'(K&5.A]+O+O6E?F[6 &IGU5598T_?.2%1*.U@,@JOT! M4&ITE?QZTG?U2&0G\=XT#%"?[WUU7WQ;=/?A;XLF?W<,!;> "1T0,[R::Z9G MX:#3*Z=[I7RW'OZS!.GZY-<%Q9V5W(^F&GEYC*^AA-.O(M("G*DQCPXDRS+M M4[[6L67"Y(M#(A?UPBR6EHI*;'O2,_TV-GF[&BU_S8EP(.ECO1E]BY2.8YM7UXRO6">< MF6]5>L.\S&SG--^ ($&^(]$XXW=NWA[S$_%C 8R7$J-BC+N#C'.>^LC)F M,P$PXZ_Z>4LWC#%+>5,J7Q^A$L$+"!ZM_3!>2*XT9 ]63@>9O: M S9%8AA\(1;.SH,DXC&M>^G>A0P?#8P:C\<&>SL6 MGEV(74'^SD[WK@I4:=:$VI=AV79$EUU4&E-L,::G/52O M<*.4@4PKBKS'(+7:AATBW*!,:E/_++(CNV*B>BJ2#Q0_8SXC=,@+0@V$!:F/ M<:)Q]N75$K^8>V^(&_S]U9ZHHQ^>JO.^&)?'3_K@GVAK3JZJ@$JZ%I] >D+# M[*3BW/* ?[6/4=5Q3LPZ92.9]QOO/.@9R:VEW.\&\_!S#^T2MOXNE4"\G@MP M>@A458.C?*3:69=7FWFZ&7;#86OC;$"V9#"'MKFTY77QR=3\_'8BFZC&WTK"8GK]/2PMG%.,>4UN6^OI[' MG5&4(3_OXMW11G>VH_Z2V_Z>%KD+UKH867-6JMC7=AU.[&%M9V8)JFR,7RZ] M[6\HNKDQHKYMXQ,J:M CF5BKJ!S3I0Y@%+ JAMA7KB$2<]4"5J-4!GC07#% MN75'=%$63Q7HLJV-W..Q>AC*L97$AX '6XH-DR!$X]A>%OJ;NGF0\"V3?=%: MDS>[*@[42"%GFYA4K>XQM&BU0JRXJCYK/3GY;(S/8^0?OLI9V<8\:G6=VX^# M#E:O]@' M 6=DAX%[**4HR;W?V>T;_.M!<#XLLQ:A >_)O7DI7*:U5U>BF_1_4/N*? MUJ,$1WHHEXV=09JC,_/[Q!^K6$$V%A([,*5,OA8N6SY\\TF9-#T>$G65:.D" MKB[I+,ML!=P>Y'#FWU(5:C7AL@#TZMA9[O(-('6J&5U=&A_+ZIA-[-6J)RQ" M DJZ+&^4^CQ)DCDQF5E9DC#Q7_T%&EKR;V17J60N\RG/@!9"?95-7L%QI<)? MT@P2%Y-]H&@\4K5GH21 DHT $?[6R=,T.5VY:T^TETEV)<^R26BGU\N9 \/) MPWFVU&@/H>/QR;V)-OT7ZN-&?+G@'>EZ*XDZ_](/)IGX3[>%IJ".-LO%L0F1KP*'4M3E85XG MZX5Z^11NMD+;T/R@LM6ZXWU*AU#.XP[[;U+$;^M_,Y;S\5J35VPIQ5+\[-YY M\;$\QLRX$6X2> ?14OWR %C8B.J,WJYSF&&>U9_Y:FJ39<2^2S_F DE>SSF\ MSX4L;SH] "JT9Q4LRPMBWQ D_62E<<@'K(JP"IYG-HAXP:,$U2]$9ICM3;4H MM]_&P*T'G]I01Z+-SD3*/**^F#0BIC;REQXX:4VW!S?.E;73 <5!BB]'0>ZG M&)O\K"DNN0)<35C_9N[H/6I80S9'WN M1&RUO7(YK]>,EXZ&[Z72F/=*<$M&Y]K(%7KKNY^F<[1>:[Q9\6:+.(][EB2S M<*6881_&WQJQYG\_./8 \%8K(Y)0W61KLR&8?3MFS&*?CS9GADKP_06\/BAB M:H+S<@]_[P"J/CU(9)KTCF>D*E!>.-_ 4K2F$?XEI@:=5JW[;.U&@Y[.'XJF MFQF)=C_F".&,D>JI>TD- R6L+4R^[$KZ!Q>A-B6L.R9-D82F5?7V/ @U81\ M='W2I?A]CCKN41#LQQ5K6:G+NAKPR[_PP(L3_NS"Y5)QRV'BG+<9_6N^E=P. MY0.[\#)USU4=Y!0:-BA+-_KB/^QSE^DOR$WT^V$T/%&4(KF#I4+ M627"#HM_^)%N2(0)'<,6 'L<;>2OY?9U_M3K\Y])B7]X_8)JL^.>2(&2)W$3QZG]+. M_Y[8Q67(%^6FP_1S*+'5DX/T.U2H85GP?HIVY&_S)3=B]=C#8+XK3 '550I7 MHZLQFU.L=[WGO2N\+V,,ZNH, ]X3RLHPM('@_,I]V(_NIZ] 2_!$%!&_QT2= M9(1?:-Y5C'ET.8*2:>)@@JL'[C4DB99F@ ^5XA!V:;EI? @23(GBE@I@# I6 MYC3D9G]#PH#+PTJ,[#TE=YW]/1;^=^*6DU)BJ M08$3!-/*C9>OEM:R@]H^'WC%-@M\605[MY''6PS]H3^[C>6)B=M?6"CO$-^I MD!FSHC8(\6L)\"4E?SG'%!FO(-5)YV_<@)"JZ8HE54-Y?SH[)"0MEY072B.S M(*'AM?NQA:A+!_NL8YL2V%Q;GW0;"Y]RJ6BC;2P9^?'5UN%')27?H ;YY.(7 MI[Z^8C(+SM&\^T'1PVKHXQM*T"\^*HT_5\0;4]8B[7.U7F%'X+%^$T"S=UTM M%8(H2Q99G+31#"_.]!"886^QQZGLBZW4LBWM#+TZ[Z&-8%Z%F5N#::*' M8; M.:IQ,CGK0D*XF+4%:DD[)P=RJL/&P27^<>?=P%C13@#R$Z4_8JQ=_A?F#(W8 M"6._F=P?M3SOE!$)QB AWMDI+J./XTT_F8DXM6CKT@PBY#\Y]O"= Y);)V]Y M/)U7@#!&KL]M-G:DN56ITAQ,X7+E74!4ZG-JB$:#>&)IM4"7CC36)KYO5:.6 MV&UW=CR/.@9(1W\ZI9!9,%4E*3= MH9@0-9-74(-F!J464B(MN$+%\,86O&:L^DJTU:5 87K-S)'2P4+_)X]-CI;V MNY<(IY'T7G7QJ 7VLA]K^&3T"__FTGS&=!%-DPN=HS)F03:?%[P^AI#,:=A1 M*6D7>Z_,HC&7)8]JEM)7);V*IV)]RMZ;<[%D>]OY)EDXQ9.RF2Y;* CV7<$X M?H4W9\ZA1(D7*9R2(3US^>8F\:Q8%>Z?U5@3YA23ZH!$MPZBVDVV9/T]UGF?099BPQIEJF:7E09C"-B"= M,C-%*)#AYZ%2;W39M$C'_T&Y /+ZF.S;1WMWR,UY."I:E+<5^&L/2+\]SI+^ M(B#=5B;9['[9 <%Z50NY8SI#5NDH*6K7@=+L?MG"6'.B])A)5%%2'* M'>Y6A3[,KRZH]#9*R&A!V. 7CN/4UH #OW?C>39RI446CQVL>TI%8L1@.D;T M.+&8960D1.<"2L'8=IV>:BW>AEGO-&;&B,ZV7FXH1N[ !TWCA?[:C;A[ 89/ M*,1QCVS7_5&3?CS1J!.V>TK M'M]I;>^25QCN1J,;U4G##P RZ]G9F.C%- DO1F]'(WX%C*M]^!$>YTCB#&4" U3X51L6OZW9UG7N%$$#SN##M*N)\1_TB,I]7Y>>/AGA M@ICLG%8D-6#?11W^8X-\[7)]FO2'.C=#O]D^PAP#X!(>>?\^6I="_E') P!? M2R%?3]8%:H>LLHTK_T+6'_CF!5(SK_(LB5 P7^8[=EBB%@4,M@[;%7:&MG-T MI-J%MK%XLS.\/E,0-G\_HC_3(!9 K/6]P&C83,B[&$DLHM2+T!$E-72#+TTM M__F(+(B--GCA.;XB6Y=E'R71(WWKT\WB3;;B9N3\TEZBE##8KK8U;)A 8SMF M8.P2J#(V$--(/-DY3$[RZ+BP(1=5D0UJ"B+@X./1Z[W;FB58NLQM*S5#;W-' M>NHDUU3(0?P]N)LZ6%57P0Y_KJ=:IDG]I\XV[IPXLM)C MR"LF4(C[<(/@GCV:H MCNV9L@YYVQ!DNB8NJ&$AII W"#L7W-42RD/7"Z*=76_[ICCK6/A23 MAE4C1\!(!7XBA$FP^?$5P.[9B-_6&,D&U&+3A]R&1S5X.?,IL 1_082MK3N< M(C'<#X6/0NB-'*YV'A8H_Q]O+,(4,KL7>7%?&_7;//O/\O_I_O]WTN1,7/'F MY$[C2NWZ/WR(SJ8,S7U7R>1A$HL.Y A"*-<$1BN11[L7:Q =ZHH.ZXB3CXA@ MD8>1*(V3QE;!%)1+:*H1 8M[Q!H.P)5W-\1^FO'6Y #4S"(-:Y/"$J@M9&-6 MG 4W?PAH]_V,_%PX#N><.^'\;86OZ?1=@LL# -2MF]+HLDI24GBVTUF7WF(Q M@!FCA9&TQE%J.-]@8(^]&K?Z8^.P9$?75?5["5BL^KY3/IM#3G!)+B.%S!XL M5.=Z7OPA#D&1-"8:9>JZRG3 2K$J FZ#A 4P>-4)PT:1-3G6@L*?4'KL MG=XR9@1VHAS.=)@9?IM3@C W]]D+_NBN1Z#.GKQ!=D#Q+IS48XI?MS%.D(M_ M;1NK1&^=.9_.*L\R++#DYSC(CSEJGU@R&";@9OBYC9PM1YI/\@/QMV]=M?0G M1<-;I":P:OBAQ62,V-OK[MAG:KX%2"@_AIT=H9HI:?%;W60O:T[DCE)Y>KG+ M3Z%R(4Z[+0# )_O_E4ML<.?GNDQ,A.;J&VI %E3F/3_#4WW4"./SK0HXO]J] M?$N:S1]'7;H^)U3GH<&X4FR5=.!,$$\A9YXSUJO%_,.AR6*^WF6!X\+G CC( M0,)L-]"XK4![BU=8S<8@SAEV&?7[O?3)LR$=HV@.,(-%YP5#EZL:TQGP;5Y] M&/4-U.38>([MY!.E4"WASQT[J$*^V+FW\/7,.M.HS&"MYV 275,"LBL([\&7ZI(06,JV/0GO,L=&3JOK#O$)&R[;O.R5GLV0] M1F$\SK&R=*%XT>OATCACX=Y6)Z?@AK7@MR?V=)4=WL<1 MCO/'Q^21&,9?8.EIGDAJ9, *AB^^1N4^4$M\M?5\WD]7$]>O&S__K"E>!=OD'Y[W(WB[YE#M(?C#T8 ,0E19\UW?D>=C5[*5S-Q-?*=BN5[NRZ-]<8A= M\M92///IXY,>*=_&=$IC ME1*"&)U(3EA24@@(1LW/ZQ-^,+GWE&LZ=MB(]LFD=G>25;QUXX\BRQ5V*JCE M]3EA%14'--:VD:#KZF]U4OKOLM![!;I#-(NG*QR67.JWB[8'1#Q"W@<=A,70 MVE1?F$3X"O*F=7B&VM-+O2,86?[CX+1GST)>A7 F\JP<3K$\3N\?.H1<7ST06,A-S*2HC1)K!'>LV$**':X%Q!!0I@=<[R63 MN'L[!_3#T04YA;U?PAY" V?>[+\Z*][0AI;<*CZJJZL7"D%-;S&PH2X^NM3[ M;OD#%4 6/U@60W-//CZWK"BO'J8I"67&UV3 MXE<'T!L(SFV:P@C#/3(A@EZ E$-J*-_SH"%9ORF"?F&=,+V!D#E@T'M H0QU MO<$@-F!$'JWM""Y9GS,">C!%DV O8WFX>5_&LP.&BV8/4&92T*$T3"_C5%$ +X%O#W2\^RF2S"EM?/UP23=D=],0][,! MEA.6Y*UN'X*C=3_>)]GS7TQ]=^@^5JOX:O%Z9UW/;TOV-M^)]+R_:IJD$)Q M-3D,:FN.32$+9_ M^_9S^,6C-6>DY0KFU;6KQ^+8S^8Q=/K6C/*Q:_$K2'*W20S_$8=?NPC!Z?44 M'-B ?Y4=)MF5\5Q,!"F7I+&W2!$6F;"R>$,4'&I@,&:R%V"^S-;]%Y(,?/!G M0>%-U+RY%O.-"9I/[<*$;97!S*A0EL@U6#T8*6'!%OU>JZ?]O%[:P%I_^+Q\ MA!2D[$I+^(M@D(KHO'S65&R^0=Z1J!'.8^97]>]N3IZ!6W9KLZ@Y%C1Z"<%> M)BJM*<&T\EIX_)4'PTL^8'*L=*)2@XN"P%1,3**XW"0V.!/$?B VCCZ6$N" MJ-U*!7R,0Z#B!)Z0YJ/&QZC#E#&W_#.X[ 6+"#V@M6Y+8ZZ;\3FGQ)'ME4>^ MR4FZ%87?SID,XER51$T!H@0%?%(?ILS-('Q_[K/(](I:GKI_M1R0E<6]*H11 M'V ($N_X;&EXSC938-(]B+7=*TWG!#,^/,7* 6:F4R[?FF=4JMV;:8PG7_[5 MY]$/)EA; ^5O91OUI$ =LU2K@M9[+?<\DJ:J-@X3B/9]PM]Z>Q']A3>[S3I" M3'W?47@_!3L(Q:'H QF ?FYC=G.(MYK#?>%(2G@7]W!AJ6R@55.V]CFYP1[& MEPP-"R-OO"%YBA3/C9BVN2YTBJP##7A_[?1D?0EAW/]#TZ&\-J;+#UFK6HX% M2Z'VG3E!P#))JY1$+=R:+?[ K'K;/*;;UIC,V;+NQ!X&?N1\EC(;=9U74)*!N7>/3PCW2O$.7&AZ3D7>N M3P)VT6M3-LOMX*1[T_R<]IA_AD\MJ8W6&C1BHY;9E"8PHAQBCL[=H13+&YB G+4\Y:\-3%62BY2[VD#UVMCBDX_R70\[ZLF./>;J9W*,+'W"5="?.CB[2Y>&S-7'/S.^8ST=8>P M'=X[1^J./Y@>"%7SP#1FE-]PK?;E;L+IN=E31=@4>P.R?ZA""PRIAB7!%2IT M;FR;6&,Z3^NUWN:^5IL@9%T,*"2H\!LGK4*?\E..63PM$K0*?)IOFHU6[4SF M+2,1Z8$<\F^T@KS8V0N',9J *1JAHQNK+9]/.@C?_49_TM+P]!HJA#]]2W M#[:.7JNVDRBB>;"_)B#RW'W4!OK;?I!%^G2>.]3FGDH4F9UG1>2@V@(: ?GE MUFRY1VS?F$O+B[W8K%XO!H7^(J-,5\ZX,\MAQ802=&O6_GH(5_H,(EUY(#JY M3H/YJ5[A4[G8<4+>C?6&8T@S!.OIZJI2A.9,B6')/Y@&E5,$+B(.5*ZMS$Y63-O8UV[EM:\NO/&90Z]<74YOW89K MP,K7&O>PQ MD!LDQV>7\:;"Z)/(0U'E55W9A.7-2VTCY+>Q-,'H0:+MN]ELP[1 O\J@19J= M7V#B:;$["MI4R[?8T1'Z:\ <04M"Y:9$K7(<] 19Y2F8KN$H:M:=43>Z=_[V MIP?57$J*$U6T72AUWPL 3>7&+=+7%\$"3X;G+HF4!.%(\^NT:LB%MBT!Q+-[ M.?$EZ*O!%A",B^R'=D<_,"=.F@%O\LNC\0X%YZ\?PM-'U\<'1GI%)I;1W+&^ M6WJZF0%[E?!&SP*GECGU>?_]T:$0WO-K0@-=6'S/)4<64<8+GF(8(2RA)^+. MR_;&?,;RD,8 8\FTHAY#C+FIRVFR3&YN3[(SQ"TL])41YBI]2=B!Q5KQ6Y5@ MDQ5DWU?(R\E-^#?,E$)@B_D5JMI7FQ*%^@V2+S9K*8Z""QZT*"7K !_E3W+W M!02X59"OXK06D"PMX4U:.Q43487"Z\=B9^#I2J=T-4(\6QHK9.0N_ZE6\A]4 M($=;"=_3ZRQ0T1P)D_WC2[^6C(__L9(B\CM POQW,^I$%4?+-;MR%Z+ , 'V MUTS!__>< \= 9 M_@/C'TR_32']']/_ %!+ P04 " "P@'Q6R')RU9$- !L#@ #@ ')E M<&]R=%\P,#$N:G!GG91Y--0/]\<_8S",9>R,&%F;#%FS#_(-X9LMDCVA?.UD MWZ:(4I8HDF60+824L27[5G9BBK(,LC/VH3'STW-^O]_S_/&>\[KWG3?U*G078#/4,] 0" 3#KC860EQT;.B(DAI55FDI!)*1%3^LKR2.EI;6UM"5L](5]-054L; M_7L(B(F)"<8"$V1C$T2?%SV/_H]%;078&8"+ !$,$@%HV$%@=A"U$Q " ! = MZ&\"_E<@&C M'3V$@1'*=-J 8P-H0& P#2V8CHZ6]K0:>5H':-GI.(3E+M%S MFCE!1/RXY.^GY#.(ZE2W<9N/$,44;OE',T)Y>/G@_.(2YY#G)14O*BFKJ*K] M<5E73_^*@>$U"\OK5C>L;9Q=7&_?/XA^G/GN> MEOXBXV7FJX+"HN*2UZ5E[][7X&KKZAL:VSLZN[I[>C]]'AW[,CZ!__IMX9 9Q\N,4D;_/P*63DE_=QBBJ8$[DON4_ N414YP3W_Z-]C>R?P\L M^K\B^W^POW-- LQ@T.GQP.R %G#@WK7-^T2Q!5KT8?7=)[YZJ>KUA.8KW6&1 M'NY-Y?.YY#"WEOU1QX4:4 L58 IN;]G=]Z,"]X8H7*1F*9*Y/M2G*!D]_:.5 M8CF;/C'F8*_KY05/#?Q9 "QJF+JFHV\6?!EXQP7 M\_$Y([SB@+>HQ,M(GX""JO39E'U!7<>JYV^V+BC^JM]\4Y+*.+SHDOA6-Q)$ MW.UV)+YPZ_?6J88!]-M2/S_B!LZI7N>G4LQZ M^@X>CAU8U%B$)>WN7SZH0E9VE18P2N"($;EG@+,?@ MVS'+BLS[4&29@D>F_?OGN>;OXMO:K'(ND>/S=%G-P1R='WI8<35$E+QH&V%](+;JV=] MMY8M-EO1L"]6V>X8Z,VF\:H+)O%>H@J#.UQR"94WLB,WOU4.M3J<>=(>=G&\ M<=5TNF#053X/RKL(ACQ;T194/)2UO; 67Q ?:1^=/%'ZC11C^,4'.]AC5MM0 MKSL]TG76G]X/J_FJR82P7OV=]+W&7ZSZ)%V#VZM#U?T]T=VM@FP;,&8@8'2@ M! ^":AX?#T,:+7AY:VMCE)5EV]$NOBV#:3+2A8D+1H]>[\V&HX]KD\)85*PT"U12Y8)P0X*!CY1__G)OV\.?DH8 \M5C /6Y694* M]!0_H0+VKA0CAW('R^TA"EK1\7A-9L<&V$UFQ/3.%V#PZX[';%7%VYE'S]JU M=E269_9_\5(>H%8^TP]E4T26B02N>GRL]TY+OM*K*6\:\&J#AA=^J)LNI)2+#FH?&7IHNECRKSL>T[&O)/@VK5V3I>S^/"]=NI /\0 MP9;Q#4X"AKD-DG=&N"/ 0KXA6K&A0O$1CJ]#*C9F+'XI_?)MXT<>9 NX((S# MK"X1_:2;H*MB23SFO"'=U=SW\]VM7FFV%O/COM/EG4_:+83H/? MD]DY*/'M':2Y(2!XS?US+)5>Z0FP4/]T13$IZ]W M%1Y^PA))-ZO%4_6DAMU/Y$WP4^47?OQ[+-\>5@M0 A>TN*6=<:3[X8M(,TE] M%.B$T)3;PUU'U MV9%LUI0E"O_97=[4%4P$=15![2#P7*Y9VJ1$IK=Q+"&$JD))E206J/K7L*3C@B$84W=.G.R9K M'=,,0Y[T>5S,8JB47HC^$_SN,M)O+<8X>C <+S=E:^0[ZXT2<.U%U'-/1CB= MSMAH69N0^3GN,5M%3CS$["_,'/./TF @*\%/R0K;GAPWOO=(E>_H#;^]\MD%.'> MX)D+Q&\E-("_S%KAR(*X+&-B!;&I+A7/ZTE*E\_V= C=Z+KK2*NUH%6&P9=1 M@67+%0>5AG 36@_.R[Z$\5;-EWR4&A"!HKR]N/7X(N.MZ%#AT93'75#!YIM" MG=,->\LHE"'1NZ["&CV=5=2';EQ:.F.AI!;["4Y&"3 S6SD6D4WQ-9'RT^U# MZR@?[VA%%E9C2.F0#= V&IACTJ&6G%,R)/UFNQ:A\/3-I47[L*W\ M<"-0QB/MFK;"B-NKQ[3KWNZC50J(%YE62E#4([>:G)FQ:8K M3+5[Y7PC;WS?!)AO"AD"Q $1\E]A VE'R?T\[PNG0-T;)2I#[GMHDWFO]8,! MQ,NB'@\4,Z/KB_ZI35X@*M"*PH5M./UY%O5=#$6B\.%L4F6_QH9Y%V^#;I#6 MZ'WL78T=$\5G0Z(&4@GV/Y*,.#])?*R;.Q T<]!$2*1/*\UR5!I1X_ MX89'!Z[>QIH/12I)X$Z$T"B6@._,#.#L0$&2YF8Y,@9E+_$-JF]O.?01 '^X@\?+HCF6=B]NE)W.;@J@;1+F,*,4\;50/Z8D?* MFBMJ"D^?,LF@ D$HYMP3^D892"YL=3(B;#"^:&K21X9/A,Z GI5!9;_UXN($ M%:!O,D 1K*6$';?@UBW:N%4'"+$0RS;BT&T[@X.+RZ=RNN>?I8%$^&DG,_V# M*XQH0MOK^%EQS+G^!M'*P\62=8\TV=?XZQ[A6'28IF@?_PQ*X^[;!+ D[HD( M-6+@5LRZCU,S=OIV?9K]GZJM(+]![;P[#]PS72:5R@-+[$JMO0KEL@\%DX<3 MA+H_GIM;ZLR1N4R<7 GKZ..T5>#+<;X -QA46;XD\4$+3M8<(SN4JZOB6A*# M*MHO!,/T!'M640.542PA2><-.\0?K'SK+,+H(,&9VT&-&D:$\ $#]M3S##?2 M&A^8W<^-H@*)8; V01%=RLCXCRN)[5.=5WY]574F/URRK'&,#C91TVS Q3\ MYYO'QL]A#2SD(N[U7QE"[$^1-8A%,P\"PK.,5O+2#;R9\SJR036LLV&FD,P( MY_BQ'NAZH51Z2IIFO13+[0CT-KHJ5D/O\,5([\%.ZW!U@NOS!3:_F:*PPR0R M$RS!2]@EPW;&=NGS\TJ+F/$;81C)7662*L'U:5D6O=W)MBI .>,&'B/+S9^H M=S46=6%SZ#X_$N& BYOF[2: 4CT^1TF+GNMD>J4';N.$^=4)#>/S(]1)D<%S M3!_*^]9ZQ5-#'MQ2L9@+'0Q&M*39;F_=$]V._L./=LWKM7:1Y5=7^[ -[Y,P MH0H@U*:9&3=D&N:=#V:P(Y8?N%GSJJ/2%NIQ2+'**(KDQ,I)6V^CZ6# MCIX!'Y[0T-.;Z*"&DMMF...5DM]R#\WL#FKM">#S(M2)W/B8R9WPOM[B]$7+ MH,LE[G2?5L/V]_)@].EPZ<54^'!A=;7^M;;K NP.!7,P+M+Y/8]PK_"KU74? M8VDTWMG06_NU>MX+1>].-^;"(^3>;FML1'K(?,71"RG$?D\]]G9T]#O&@[3: M6CATA6]@VUW7VV^UY-L JS)-]D3"<-32U9H/GDG";P%8Z4VZ8-9:A."HRPN3 MFFB^C#A&**V5*2%1)[F]0=:]MGG,1T'2 M[GB78T27^[LGEYDN\-\DAOKM?P!02P,$% @ L(!\5G3]*X4>$@ $+< M !$ !S8W1C+3(P,C(Q,C,Q+GAS9.T]:W.;RI*?=ZOV/[#>JMVS54=Q;)_D M)#[)O840LMDK"2V@.+E?;F$826P0* /8UOWUVS,\! P,2+8WW$7Y<(XUT]/T M8Q[=/3TSG_[\M'&%!X0#Q_<^GUV\>7LF(,_R;<=;?3Y;Z -1EQ3E3/CSG_[E MGP7X]^E?!P-A["#7OA9&OC50O*7_AS S-^A:N$$>PF;HXS^$+Z8;D1)_[+@( M"Y*_V;HH1% 1?^E:>/?FXH,I# 8M\'Y!GNWCA:9D>-=AN VNS\\?'Q_?>/Z# M^>CC[\$;R]^T0ZB'9A@%&;:W3V^3?^V:3YW RAI_?#_=!K\_:<[7%?(^1"/3 M>PSN3%-1[^X]7;WR\.K]\^_;B_.MTHE.XLQCP^LEUO.]5X!$%H>E8!W@ZS!GG@=^=Q90'4 MJ01]'X,Z*:B-2G !LMZL_(=SJ #XR\L4, H&*]/<9L!+,[BG2 ,<#H)H2X%_ M7*7@4%H)6L!)FH:[+0JJL=*J0@,[Q*4&!;E!]3FI)FW>#MY>#"XOTI:Z9$A9 M(]WRH] R-Z0_4_P7EU< B5RT05XX]O%FA)9FY (+/R+3=98.LL^$T,0K%)(. M&FQ-"S5@2WNYZ7D^# 88D4D)*=MN'>CM4/!/GTBWN,:^BPP@7"!_P#"LQDTJ MSR4?II(SP;$_G\5_$BR D^*QT=+Q'/JQ9+Q=" ,RNB+"&/Q)FWPZ+P/G4$0! MLE7O3_3O+48!M*/43Z @:9B U#2R3->*W,/:[$FI;)(4I%(Z2FY#TR6C25\C M% :Q_(I%?#E>@O#(I(8R07J![SHVE-A"@DB(,9W$.SXR"OQ3V.'LO>FEM M>BL4*)Z^ACZY]ET;S#+Y1^2$.U87/&"^RGXV)%)UH;T!U^XOQ-+!OP"UP\BC.#'C3R3 M-7'22_GISLH#L]0RO5"TH-8+P9N<0U^S')1V8"X(7]8?RK+6E9N9,E8D<68( MHB2IBYFAS&Z$N3I1)$76^ZF#M4^<%$2\A:T?.*E965'.E_9'1MJWJF8,#%F; M"B-YKNJ*T4\)*]X#L.+C9,G<_^3*\^)M69[*[(L\,U3M6R^E.,<^V&7A3O1L MLM1OR1HT0V$LT[I*OH0ORA*>:^IUA8RB/OK7)[I/9V$%0_^1(;Y ME,HW7\ 7ZQ4[34CJ5!8,\6M/A:DAEYBJX$6'F1E1*N.+]+>R2#5Y(AK01^>B M9O353LA[?6VSL#6A97M3AG)PDC1I8FJ+[2>]N4),K.5+/F;+UK&:YO(8E_7 M*@U8,;&UAEXZ@@[K^M3:*IH'#3!\83-N&W136=2D6]J/1]"I)RHUS/IM,R3Q M!A"Q:&_@8T%(HI8/J*B)1BB^+ABG+@E74%6(HZDR4W1#$PWEB]QO;>C1?8!^ M1*27$_RI87 SH@7-0N;'3)N(4-82/A MEQ1Q3_=J>#(WS'NWE7(20+YJ&!^R434QVGXJ)HLTY950+N0+O,*[3()0_19M M3< I+V@^"%_LC ?*B4SU6Q%5@:B\%CCU?!4P[FMUN*K?TL^%J8IS3+F8+VO& M<\W'L/HMX6+@*B_DRAJ^G!DWMA38ZK>HXZA67L2%$KYH&:0K@7%C4R7\ MDB 2,DS]E#DY+F)'+E*756ZKZ'D1D3EP;#F4=@U,SR"171+<>0X&OO88;UB7 M;N718B(+ZKC&,X9?LP7H=R3/-5E28'BI,P%&&1E;R4=[JFA>#*YZR!W6A*]* MQJMN#."=!FA-FEZ-LIKA^!IB?/&*-+Z35IAI,PNKUDR*3#U?"XRGGI_RQ@U8XL'RM<1N^N= M&U-U>Q^]'DA[J9-K"WP/^%*7([1$&"/;,)_$(*B= UNTX*N+W0G/J4M2IW-U M1J8[^#&2Q[*F@=H,\:L@ZGKO)\#<[E2=X5 /P-<*-QG[-+,Q R&Z MN)]5,VZ:&_ 5Q TE#$4P&"10U)UBW+)[8[T>-)7"+HV;!AB^9IC(0)W\3Z,G M'0QZZ%O?[X@TR/G>*"0WK9#[> Q_'F%K;08(EIF-[U&XF@%U% Z^)MD(0FZ, MZ88J_46X$S4-;'-=4!>&;H 12&(^ABK,%YIT*^HR6<&FZBR![O?(*^E*W9*O MB18, ">LBS9P(/FZX\8=8FVHRT$Y!8H2CS8>-$F+JM3WM&(^+IECT/G=7LK:O)@"&./S+C?J#N6U[?^J_!% MG"SB0#I8D8MI7-QS]<<9(M7+84T=7TE,:"/-(SFM?J7Q!E(R5RN,5I1&=9DD MD-0,J@9HKE+>,?&+PM 9*;IX+F8J*#5-V"*NF./=('^%S>W:L42,S+JEK54;OAJY@8\LW8MX<,I,N)'5 M&TV85.Q?]2-4%:@"DRE35A"$K\RTB]FZ51+G'V[=__[]_Z*=9EXE* M>B$VK7 .ZW B+D=BX>N<&X:1U)FA@7LAC!>3 ML3*9Q/D<)' 9IW%F]1-%'"H3Y12=:4RTK8O7'-B*K]2*"$Z;Y-N385MV)*/M M-K[#U733.]O(M<)X$R=.Q5$VPT_N*?16<<)NG3?Y/&Q\E?-#/8OY?"*3T2M. M!$G4;X7Q1+T3E-E8U:9)1E82XS-4@6P(BC3W)\TA[O6(WBN0ZL- >$.RA$'6 M) &+),\=V ^.1S$=AQ)XU7G,&H7J1KZOCZ8:)( M)3&?%MN]1\H[@E'KQK9IQ%71>_:NAX(?VWB(H]<#9J^*IC,:-1ILVXRO0V[. M3*MS'OW68NEVE)J,YB8HOH[8>%'Y3I7_W[,B^0_92]+04J /?5R3MR4^GP4. M>6KE+"E;8[2$,BNT!NG;#W\#UMX\;=P4A*#F//1!-5J61O+A% 7,F0P6YB$2 M0$)S#L% .4^)3Q& DTJ:SW.?$/,4V'M*#R%B+X;#B$C; M'4%$S6- 5=\/ZL#)'[0SM?UH]OQ/\MI0FX]6MCE';ABD)<\BH?"VT>&$_+C* M(QK$10?34GYCJ1T=Z7-+0$."X-CO PMDR@B>KP^*YB"%-+_P5$=.4TOZ.SAJ M0- @$-X=,BCR3=(?Q_7,_3-:A_6#6 FD*QS[V2-Z ?OQVBZ0O+\5VZZ2(?V- M>O#DG1)E VO"0_H);NV_8WI>$J(-@029 0F.*Q9 M$8&^P7ZT_7P6HW, A,>ZN,((L3RQQ5T@=N1@9(4^#HK$LL5=(%;?F#A$ED9" M$)/0+I)<5]D%PJ?(=E91P-!<4=X%^B6V2AE+9-VIKNT!ZDM4K%DEF2CM$ MZK"2U&&G2"6O(44N&,6E.:VBO OD3E 8(EPS#]=5=H%PHW-',8P7FH-]Y9#7Y(IN*AHWJHR=,N8CK-KZ'0A/O7J(/)1E N[&/\V1G_:B^_FB.+ SN_>NQ M-'8\^([CK>*C^^DN_FRO'R[$ 3WK_Y8O.B24((A@58HPN7:-$D7. *8'!8D% MFI[?+8RD@YK]HTG@4-:?R7.>N8"B>@GS]@EARPE (V4F*FLZJR*6VEC:]=QD M]3];!9H?>?9B&],SBI#ADYQX'"#:C?2MZV032#O0SBKI!M8_%4_\(% ]^'-.BL!9H6&V8#AMPFHL]PI7HB@8X;Q\J9X&@JVX ^3 MZX725YW3<%0S8(>YM,A)031"\?^!?&>U!N(78#'FS;$V@,=S^;KV&3D<:6/S MT73I99Y&X6GN)%# !>DJ8^EM!OL(KN'7LM@6N+-]=8Y]"R$[(-,E,4C(1SDV M6WOPKJHWI7K_ &$R%MGRSBIMYGN6&:RS0S'I/*)X53$K9]+6\<,%Z0H?QSPP0-_18/E]$52=D\NA1SR;A/-L?)V3 M$/?@5I,X#FO<.=X;EJ F[@]MWA'^:R\;KQGE.7/\T';/X!B@2 +%2Z37^5ZX M=G">AJ<\$PWN9DB2:HHA"ZJ:KNZ+5&ZB%N*,+D_ M*LN"K:OM*CMIZJ!GTV!*_KK0U,<;P5@H9QHV@Q]IXMK0^D4,/_"QZ76+Y/XB MT 7]E$B(7U'0X6X/DH0EQ$>2^!G?OICCZPX13I$M$GMJ!0LEV7:$\O2B')@Y MR'IZL3DE$@$OF\2+ MD-U2'@5-=(6B]A/ *^DG&;KISLTN^#?$/6T M7DI>S,XX_+,_W\9@??0L+%M5T]6I)Y4MV?++73KKHJC-.<<+I'G(.BJ4(CQZWCTR^J2!CW]990DG &'60*E MCR5"CNLFH,5]-/7>=>+G#C)AO0;BK@IQ"-.]77=:L:ZR"V=#I+7IX$WYS"Q3 MV@52G^L/)KT,V6G@H)CQ_7KH?W8HXL4X*[G2U,$FNR%CZ"WTG,:+R[+-%Y\7 ML(V/@K_O"4;R (7>A_.KMX]?I, ;X#-ZZ_^W2V7DW4 MU537SY0PLOV-[4$??#KSX=D__N<__T-!?W[]K\E$N7:!M_FHS* ST?TM_$59 MV _@HW(#?!#8$0Q^4;[87HR_@=>N!P)E"A\.'H@ ^B%Y\$?EW:N+GVUE,N'H M]POP-S!8F_JQWWT4'<*/Y^>/CX^O?/C-?H3!U_"5 Q_X.EQ%=A2'Q]Y>/[U. M_R3DOWJN__4C_M^]'0(%Z]HPWYQD[QY[1KRZE?8Z3 MT/T8$O;FT+$C8G;F8Y3&%OC3)&LVP5]-+BXG;RY>/86;LTSY1(,!]( )M@K^ M&UGO^-25 ^/(L1^PP<[QC^=3B 8DXI20[0.P_706.I&#>K^\O+A,^OY;H5'T M?$ #,W3QN#I3SCL^]\KVL(Y6>P"BD/7\VL8#\+&T ^!'>Q"YCNVU8JJ6LA\. M\90!#ZCWT-@:!SS-T3ABJHQ.U3]GT[WM[T"H^ZL]4L4>>AOD;K2_8C=Z;L,J M1S<#\&Z'^VL//K92:H6H'[X23\XG$W?GN%HU@/U(=]*L?HP["R9V9&DH?T($;B72#Q01*8]TK+OO1.Y M+G;1<\SFXZ^A^:#QFX\S+N+A8CD?DVS*WN,ZKUT;"(:(\7PLT6CZC/=\W-2U M'2?V\VJK32]]X@ ^_NK:CH$)>+7'W\R(P?:?PZ[CK5N__6,H/PIL)[J.O:WK>601BT$/3B%E MO\U=^][UW$[A_K3^Q\FMM4<%W?KK/0[%!]035JGM9248N, L>$A2#PEXL6!: M\^+ODO1;^V#4RW/ZEIX\Q$*+?IRN0\K'20N<;>E-[!,?T+\?BN* 3!+RN-RD M6?L;$)PJ[4G=]YE);CL;Z53]QS5:CKA#8&O17=^RL/+&K:5IV>$PN]:MLX>< M]#1N$9!R8H]XPSGZ7* 3Q% ,VB3]8.9YBU"1<$%-T[K@B^4"2XBCO$00?], M6P[&27VE:8&C2\3&L1"0L.2'T',WV#\J*;V2=I"RF3'J0:? G(>K@F&I_#:K ML":UOUL[O"<%P'$XV=GVX1R;\1QX49A]0PQ+C)I^\4>"-:9Q@"%OUK=GWP./ M//&/M%VIV;D07G%HQ:@(_8574-]L#P]'-9JBD?B,/"^I$V^6@9.\+%MNP*B! MH\ .?M/9Q?9P\L0,1V M"%0J/@.]$6H@'KEELM-QY^DF@&'8;)ER.SY;O!5JBWK99-)^LGO#Y[7JVO)9 MX9U0*S3+*),E$@87T'?X0$N^I2# M6JE#IJ%'VSYO-A^=2@XLPS0:C^@RF:J8CC$Q-\9V'0(B+L5UT\GDP#5,8W$) MWZ.U:G(&4VOZQPJ@]3=>X2[MYR:]XX8U[>0 +#!Y]!MAO; MQJ]SD(H&:-R&XU:#3+8K>?=BE67;X-9 +3HCU374494ADQ'S!=]M9A^+CL]P M[\4;CD\!,IDLQR5/8JZAN80XJVN:L;8#B4!RIV0C12LR#<8&R,%C2@Y2B2!S MRWS6..9KR&D='WX-@WP"J"&UU=Q<(N1+3W.Q))9IRN2$XO+:4OFRAL%_:N04 M.+'9$LGM@"6NUPLIT_!1-QL7 MBVQ[2]O=Z/[4/KBX0OR%=S 1]@C1"N9 M^"$FB\\9V+J.2P%@/+2B$0"W^?@5(9/Y(,VS4 I62:BT8C>KG$;RNVY%(9BO%2*@4&L0A%%PFT\'Y\.I#*;B]"90C']6,D M[ N$O@);&(#<<5C:$Y(+J=WU[>!91ZHC"5B,C2 9LKH?@0"$%.@[Z$-%1\L1 M--JTLU4S0B6*OF0G'PD&B^PR:ACJ"$1'7 $FINMN^"W+:\2X[QP?G)TU4/_. M"J:@$8B.PB/:CZ4*^:8I8HMGI5)J)MKKUG)=>4%T>+-+9,BC&.F NT+PA)J1 M:B00[6_YC=LH+0-TC9N\;7O_6"$/^HX_#YKVK;B^DN_][_8!AK\HY7V(8<6L M7%Y6$.I]"Z%03TK2E2C_B%E8!O";BW1Q];P.P4;WCR L/1Z36CW2IH__CP*M M'$5+VY2\2+VGDI MO6AY.S\IAG.>KB\U@G M&[>#ROI,=34L3/&SC0 _W?"U)X<@'@SO&\I]&U:KK7L1_>)+=VMV$G MAU?]# .N+]MR3@<='P&^DE2 M W$K1K:\/S[5&\Q \K?N5X\RHV8*.*CY[/JSA'9M)>9W8=WL<#3JLI1!QF?/ M#]^3/6O4(KDA^7%-H] G@IJ+U]^3A=M#FMX#9YDE]D%225QATG':2\9\"Z>$ M\BT<:T88WIM+WZIBG93$1\UI5XDS-FVT)+G#+9TO^$VW#22EK7P6FE5@J2"@4TR'VLQSXA,-3VT>NP#* #P(:4*NMA&.,MX/3& M:GR<07:U>-/ Y*66U,M33%08FNV4)!-HR;.>\JD]@N@%6EZHV'QBUS+ M)0A]N700: MH^<[%'->6&A0W_NJ^M"$7FNK9+H@]XAFSIT^TY29OIK.C=7:'%2GI!ZO@==* MS)EKZK S@WHT4@.7E9B#%*:IYO0ST>@,J7=N$!/0&*Y$/@K2&4.$.LA#X[\2(NN!SS@#Y(B :!Q7@F4>!XW!9Q$0T5BMQ,H2 M+!J#VP0?T;BLQ,H$)8VC2CI1A82N:1)4HR8&P1I1IAH_E]\(%WFS!(M4+48F8F1 _I/3*L8-! MH8JS!YO8 \:V+HBJOA]C@5[.BL!INS#EL%ZP2F1=33]KL_5<4XSKABB+/BW6 M2/29MC2UJ8XL9RP49$!LMO19PN :GS4KX9@)W,:U<[&'S5?5(10#N!JJF]Z#V^-N:I%55* MHUQC](-\V@V$&QZCE-J+WBML8Y1:467:M2N'%$9XK*S JO%$%(JK%.0B\U#C M9'7KK :V_:@LYP31%- ;29&(C9\TL:FE7Q0J845L]3R1BR ZR)+2B8ZM/!:J MEJYQJ$(FIUZX@>UET83^[0&B:;3X+H:-YA0/2M7JE. ML&U(8G-%HK>5S!0UG2TH-M7EN&DQZ6UU=R<7DYH2WF(#4<,[7E/FS> ,NM[/ M'?-M+\WBKD#PS77J3F$XGL55TUAT/.%3=.54L4:QAZ^!+HW\YB&!6S*WW8K;>E3S4%/35RI: MVDR14'>Z];FZXS>"<6HE8=BGDGAN8GQL$Y$[7[.WA8PX"B/;Q_6_%ES&@;.W M0Y"[9IIJM6H2.F>UE65,_ZG MK;%(6X^RIU!4A'$@'CHI6:8FK-]2$]:) ,:2[)"H4TO_0G9\QQ4(OPLVN<=' M4F?O,;Z(&.);WY-P%**0DGQ'E;=:9IR7][-J:I,K9$(\HG\G&#:O@]6/RA=U MODYVC) ;7=\F7X^BDF2+GF^>5M(KV6:]H.F)>+%WNP#L2+_'ZSYIEGI76604 M3#735^K-C:G=),9 WZ0;^R,/3[ID['N=WU56'6W%'/.VYZ/864D&#HFN?P/@ M+K />]=1\>L75+-20ZO^KV$JTS5R,K=H>7F%9/SGS+A;9 !. M7?S^][_]?'GQTR\K0>,[.S?J.O:VKN<]' __4_U-]EL.F5-5005$4V-AF2C& M*-?K^;4^GR<[]1BJ)J4ZQ]_GNGJES_41<1*]^HC+([^K04X\=4BBX!3>7R0W M]MA>=O&/[F]AD"S:4NAHP>+9K'3KTX'5>KF<:]CFZER9JJO/RO7O% M#+E0BB:$9.CF^$YYT'"&<09H9[0;W?E[$+,+PO$[#;V\K[[85EC<,BOAQ6(5 MJN#-4Y1!)NA&/]NS\:4@Y!"I':U0M-I2-(K@LD/YXKX&>64*"ZI'^@6;^EL& MF0.-EUXT .ABOW:Z&7[[N%AM?.^DJ1X8-!VF12,0'9%;&80EC'SS*E^=M(#^ M(8";F%SKV#R5*"2BK[GL,GN8&I#)7%9@([&2="((4,#WN<(L@TST?99=S,:E MB>%]W1>P=QV/=5I@I97H:RE;>[4&.8=7L$E>[MO<(@,C3(YK*= G4MO#T#D/ MH>C+)UN;@5\;,JWH7M9'K)=IJ2LD:I$EUYNU8M=(#.&;W3>34%"JQKZ' 3E@ MC^Q=,,5H:B]ZS<1IEW*NA2K]\(ZQ'NSK/CZ]$!\_6)4*5VM5SP0JWZ=\B MEU MS=F/T/)!Q64 MR ,D1R$\6S#/2TF#IFSE9=>] *MV^QMIYTQ+B*( .5$ M]^Q7T0NL#G.K)-GPJLPOZ$YVAUT[$[VDZF"HT_0FD^M+>=9]A!-SAYHS 5:5 M0/0ZK9MS8\@_^JKXY%EX0G^BEW@=)N+)VI-I+I+%:>>5#Q\UGXV'NX&MVRQM MHQF9+'I\,R?E\0J)L'4C#*%"]_MRH ,>/ @ 5 &UL[7WK M<]NXDN_W6[7_ Z^W:FNVZCB.$R>3S#ESMVB)=G17EG3TB&<^N6@1DGA"$1Z M]&/_^@5(/4B1>) B"=#QJ5M[)Q8 =O>O@6XT&HU__-?SVC,> <(N]'\_.7_W M_L0 _APZKK_\_60V.34GG5[OQ,"![3NV!WWP^XD/3_[K__W;_S'(__[Q?T]/ MC2L7>,YO1A?.3WO^ O[=&-AK\)MQ#7R [ "BOQO?;2^D?X%7K@>0T8'K!P\$ M@/P0?_@WX].[\R^V<7HJ,>YWX#L0S<:]W;BK('C OYV=/3T]O?/AH_T$T0_\ M;@[7<@-. CL(\6ZT]\_O-_^+N__#<_T?O]'_MW_O7KU[/HUVW33,OG M>^1MO_'Q;$O.;F3RJQ/L.B0;?SJ+?TPV=3E#)XC&[F\XXJ0/YW80:8B0(H/9 M@O[K=-OLE/[I]/S#ZO?5R1R&P=Q>4VS/ MZ(]G'4ATEU :=5LAL/C]!,^#.1G]PX?S#_'8_YYJ%+P\$!W&+E7!$^.LY'0U8FZZ_0#5Z*D"HQ3 VTVWAUY<&G0D+- M=*J&KGC1%RK?0;.*9.(N?7=!--@/S#GYU0^($1M!SYV[0"P;FHAJ*>_TBT B*AKF<:5O/]$8)DC@+EU'=!U\=R#.$0R4I'K7PVU?6!+ M:&^Z555RPL!&\Q7ALTM8]F T667GDUSO2BT8^93IK%W?Q0%U/AZ!+*VR_2NR M)>$]!G^%5!IT919;$D;[!BQP)9:X)HO,^^34OO>.I#H]1,4V6XX^1O-:[;<< M95*=Z[/EU9NUV5Q972HP\;+D<3K4Z6]EZ,FKVTSME]66D5&J=(/D*,O MKVT3/H&L].3':,8_D*.[V"B54MX%@>UZ>&"C^).2I+*Z562!YRO@A!X8+O+, M@>G[(:7@ 8&Y&X6"QF2%P1N2A*:Y@K$;\#.*XE)JL+HB&(6)EQZA:OW:.4*% MM8?5LV)_KJ@HA1WKFJ$CCZI>VFLK/24E!JO55RTJ]8+#5(U!GC]:6/82@U1- M-SWZ@SZ1U7#1!0N $'"([VIB7$)UY,>JW#%7:N6].9\!]^ZP2KMD1<6 MM/10=>PYBHI:KG?5TIX$3NSQ%(Y"XIX2%YIHZQKZ4;O" M !PS>BV<#A^HHV3.B4C)CJ4:GL>=TH-GHADOT1G8G@9,3_XCUX\L M'N$Z_EMQIH[]1)5[XZ*SAM^K:C3(]M9>+A%81A(9+C9[X,(BEQNG6>H+'<(? M-6C5?&TC$729=_UK )?(?EBY]=Q2YOZX M\9N)K17W"LJ-5[D="A_(2%2DMK=-P:"Y:&@=AQYBYV4*-SDO_C(.OQ4W1I5\ MIVKNHX],R::?ANN(\&G0@D9;*F/[R ]4OPX%(8HF2?2YQ*29^0Y QW)[U/!5 M1I*+SD9^K^KM&B]&7,*P%1BN:EY$<>/"W!0(KA49 LW#>W#JN$0I:&KSB;'Y4%(BNU%0N2FN]9/J^UYQ2B,.M1/EP\# MLRAIVSZ-ZB18V*$7E%;*;?3/9+FCSE"?_#-%-W@. #&@SI9R.J!L#CKQ M+6GCS0V"<^.47C<(J84@_[EI61V M S1"9_[6-D7T1WFBC5]2X_UG?4P(,M13#%SP&-@/9,"%D1RJ"=)E,M93O'R2 MYV4SMN'Z1G+T_[ ?(/Z[L?G(ALM#ND=J]))MK2O5DW)8U3O%C_-H=^0'3/BG>:9,$'2_H?6\H6"*Z% MHMR(#7(Y2,J6$')B0$0TZ?>3\_=[6LA.'CB_GP0HS&&Y88!BW=X=4&'SV971 ML/QNE<*7ZV&*X$JCP("*QW,.*2=:!%@'"E36488"% MRX?W;0;F[CR'_*JPV?J1QRY^QX(7,;O14+NTS3N\IA2V_R M&)#PYP84TZS=ZF8Z3B0RVQO9KM/S._:#&]B>"!!NMQHF5>7HB!E@0J4,JS&- M6OG L6SDN_X2BT#*;W^7MV)KA@Z'DFE+4.9GC@GBT4&DA?.(_@AW=ZM#MC/3M@E1#R MHXGSUTP=KM1IZ^<"IZUD)&,S5%TGQX=UNU*T_DJ3'78IM>0?U]; &IO]&@^R MI8IVI8C\M:D1N+91;U2%'_- M4/QM.)Z>3JWQC=&U1L-);UHCE=F*7TGBSM\?$M<;?+<&T^'XS_I($I7]2A%X M?DC@:#P<6>/IGX8YZ!K6/V>]T0TA^&_&P)K61S*W(%B*W@^'] ZGWZPQUC?EB*M(M#TL96WYP2L8W, M\;36R&1J3RS)O%,(%9 &R%)$92T/$99GCSK=(GETBW/XP6GL: MF-321H#>9CLUI[[O5 _,TF5)FC]D#-)D=CDA$RZ2 M,S5-=5)8J')9BNR,F1*X)<8OV_'J3'$L4-,LQ4W&B FYB4>KD1=6_;,4W3FF M;>/--$"A7!VT%+T9>\=Q;AK@0*)(6HK\C&',]W4:T0Y6%;44P1D3F71]&B"3 M6UDM16G&0AYX0@T0FUMX+45DQD+&CM&>-G4'SY>'IVHFC=XMH]WVY:F MO_ED(R<3NF"<5!\YMJ* 5+K. 8\'S&)"E+9KZF)LL[']F< M!**:I*M34GC[M4CGE'15FJ9I!OL8X "Y<^)A2V6QYS97E2Q=ZX)PF,W+XIMI MA-19H73-L53>ZP &8%=4#8W=Y2K 4S)]+@DI/Z3EJV+/+1B2E-R[->L/<>(I'V.+TM@&UZOHSG3\^/$AEM MIPYPS$> ["6(?NS: ;BR711E+4IKH$JR7I_R*IP@IAC*G31+' ME,VQQ*Q-E>(A<_*TY>&737]C-T"=!WY5O)20XBMS0C7I?+.ZL[YE#*\8IU7D M7X,9X;QKC<96IT=P&PX, A\%;?,M12<#S%KU$I%_F;ZJW5XFC=*!>]$(VL3E MY:%D>JURTM(^K,YDX_)%'&R7ZJQ!"%X2*UB<.>VV'VQ6R4=% 5"ISFJBXD70 MD,0Q*Q&=0M]U ZES8+I6L#6-/M_8\Q4Q/BCE41XE-AO,)5090C0V$P8 26/$Z* J?%4>)1XCS*5/&4Y1 MH(4>'_36#P@^QN=5(JPXG>XNVH:7B!D69A?58H91D,"+_&N/%?G'W9A&-QD[ M O)[XN?6^?QI\B6"JPU)FSD+M@1O&S3LE>?*"^:3UI!O7:$XM?2-Y47>I('&?A:*-=FD\;04L5PSY#$=_+*29=1# M8!H&1H [1[QTG*+#W'W6S"EAACI+<\="4+\8BH4#=TWO4LPP6(1>WWW,Q5DD MPKQAVH-S:>XDMN*-UE,H]1)VZIPJ&.MT7,Y^=>R4UQE[BOEE Y0=<+( M?$T[Q4'F'E/R_#!Q.V]W,%C_!4(YT6?N-F6)572D*_/2=HJ5; &*G#/YT;W#MT/;MT/;MT/;MT/;MT/;MT/;MT/;MT/;4F"_'=KJ>7#1\*$M M(Z23>WP2GU1>A8@(CSBN4@C1T9"OU M)1CK#&]&PP&-XY)_=*TK:SPF#$[-/PQS,DE%=ILHS":G?MSJM+GZIB9W-'[F MV5_2-V$ZA)B7!43T?BB6"$M+=5:4$\LD31".%G;4)@I= +K#U%DYX6@??=Y- M2C,,5A"YQ%)P \ZL]LIBS+) 0"DVM'.YLH2*(H_L'FKBQ@)1BW#1-SY<'30Z M1X(K@4_3B.\51,!=^AV:9H)>1(&FO-:*8KS":0*E*-=NM2-< !RXJ:HM0<@O(L,#%29LP(H7&E+K[].FC6 M,I.5RV0."LI!$*UVF89J;%&^/!DRU]?BE!6[SG:E!#2:6@]"Y9_ 1N3OYR*S MD6FJREZPE#XC_QQRF0@H=I[W#YC2CU#I2>QT&)U:9C-+.; MRMT.7_)26.EK?>J 2V?+5#&DFEHM0;E/D263ZJXJF4]NBL&2##'74W5[(S+V M<)$H?2S8(^4W;YG-XS*=1>>3LK2]Q ,01+L&T+?W?YF2_\+V/"I(+9IRA0=2 MM.?BX@*/8TD_ZZ@*7ITM:(TJ4(\U9=QI,)<( .%EA8-6=Y_4&+VR]9B >AC%& 7]*3E+\: :.G<]>+,73.X @ZUY]0)".F=\51C]BRL8/"[ M+VH4H'Q65%5,LW1%V>)\F(B)!;<<\MNW#U .'\QC:OWR%'V9,#->TU0U%-UI1$&A?CR)?6+;-F1 M0L-ID_TM"S"S DD)*6J?$"['$S\N5&0,#8J3E('Q\!G-HD+3R&]*DBB*Q>>U M51,=*B%R-F;ZGID MP1WF3#%:UB97^37F27B/7<>UT6 M?L4! E:+U^RC;?-1#O@2K^BS<983A4.M\4U2%S[W7*NI/B;8TX7=7OA.K!C MJ0=#4AKMB!,4TML/PT7"N(DV83)]U>R8Q0C PISHMV&N%SN=-]35XZMIQN$( MN8_$$1MY]IR?5+'ID-]>T5:\P*PZK#S%XD*_]9-RU\,X!$XW1/0!A^B*P&1E M(X 'X"GZB6>Z%#E&W#L3!<'$-H6/ZS@2@1\+-!'H.&\(RH[4* MW=(,,IT>'0X)$N;$7$=AEI2)*7QHES=(JV NRA?3WU&=@!%Q>QOE8A*ZPP ' MMD]U=0I'(9JO; R(1J^A'[7CYF1DWQ)*Y&1,IL/.?QNWYGAL#J838SB;3J;F MH$M?3)H.C=%LW/EF3BQ:4/!F.-BT5IRID:BZ&I6#I#,;@17UJ[>IB#1'1R*8 M57PDY25\>70*PE?%1M$F/%46;G:M7FD9ZA^0VMY5BB,SNUJB6!"4XG=3%I@J MA=&AYRTA$8V\N ,R13$+1G-%(28I64,9!O2++%4!C-;QHZK :S0-8^,0W9!O MK*9/<+J"(29^T?2)D/,R]-GW3VEONLA MA0>38.9Z5G&FQ^;+9-LZ=I>KU$:!!C)H"GC?%PL6%BB"(6K&?B-KL81)'( MW8]X\RL^YX3RR@S7<@4HS[-VX;U<5@8AE>)P,0%SJLPT[U#A8.'R([SXI2&NI<( X3(43\LZ#^K*]U8DDGWOHDHS[QSJX&GY_U*3)[--6I MTLYL/2+2+LI:(9^W@ 8+@&,^ F0O02H U8@N\@AXT]"C!%>U+\^Z'$T)OA?S M=%^8IS&@8$7ICGZ ['D0VMX4H'5>*#FZQ]P\):](195*4+N@=H4SM4<8=HFG M/?]N>V$SJVKZDZ](29L1E438O%W:>!T=#?3\^%:'H#AD#1][TT!I(;%T3]DK M%N6W@+FLUN1Q5D?$3ZBK50N/I:/;EL*IH$2U(R4^HM;5(D*72ORI5Z4:WB1\$6MTL,:]4L54( MD:7;7[1=K@4S?#-_Z9%[W2']S*=>J5Y6+R)F:+2U\:8$HVIB^I($O*GH48)C M*J[:T-01EH/-?I'P?T5FK 0QKU2A50B1J=QJ8U_5B"(=9VY&AP^^^::J167% MU$BUD:PC.![ N!CBX;8S"O'1&T=7MHMD#JH:H>%-8X^5'5.#]8V''1.,+JS& MS1'R2G6Y:0$R%;JUT;#=E$['"/58H@O3]$K57*$LF1I?-D;&2^0J(\!ME64< MH# *@D?7'JP3I,S'>]OLF(Z M:6/181RNX[]QK[5^X5YK_6:.K=-+C,YQ"GOUE=],W5(BNEYZT$Z?.Z),L;,JCFEP<1.C( $. M^=<>&/*/NS%=@!@7-1MH2O&W0\-W%7'G! M?-)DK(1>XM3R$I^\R)N\;R>0^@T1V3I<\^2>:M)TC32&KD(V=5JL#3?VLU"L MR28U*/2QQFX,_107EY!V* UI9$F_?A;G=3CSAT-=]GB[\ M9DL4HD;>FUDKU2G8 Z#7H+]#CPSCD0WVF,A]8S :4S@.#3^= @IEP71%7[-" MQI96K4+&-+PIY*$LF%YZZPY)> *H*QM(^,V6*%R-O+,43-]K:D5FV-C%/ZX0 MH$DA $<-&^ .12T1/D:DP1+%=MWVTR:_49-+X>"-U64,[N?U9Q;Q<=S '][ +S2(.Z4SNOAHN<[[J/KA+;'/D!C-'V5 M#WVSV=4B])ZA[=8-5M'C@-3RK-R'*;3\@"[GK.J3>0R*!FG^>(^/ 0\TNTW6&SNU];*>Y<-EB2_K5B4<=VD\[C#E?6F79W'YNN2UN-M!F, M,!>5TA5FN0(GLTI&WOMF=Q_;J=SY?#"E7;5Z6^L'#[X @/>3#._6-=./7VG9 MO*(]0I!P"00+_1$CWGW\VDH,CV:9"??7:D_)! [:H5WKK&P7K6V?E_/"[W/W MJ>F'AHY'5)(I9FCUHE',AHL%T2K$@RC5Y.Y3^\Q2/@], *JV2-OI36:RG*_+ M[G#WZ4OKI"_#$1.++^KR3O("88*GM-E=7F781\RV?LD;>PKIJPG#Q139/K;G M% GAVR,2?14]OBU$ !;FI*&8CS;8:1GIJ0U?3=]W&2'WT0[ R+/GD6A$#[OD MMU?U3'2!:05EV6!.0W6&4>:Q>,[EKOQNK]I RDA,HX0R[G/G6609S1690BE9 M0QD&]+. 50"CM9VK"KQ&SS&VS\IS]W3I1JK>3^9K.N22RQ+G1<7;Y;G=1+9#G$ERF5M>989]0Z3(YTHUNSMO.B!11/1LBID';>H"#H27-?0C1T,$ M0:;IW8>F(]\E8&!0S32S7Y4Y0/1MQ>$BD,"CV-)/X=8%;PZ.]$UJD"C;G4?! % YA(! M?BB(-LYM>_=!D6]2=F)!*8:8L[ :UP6#^;LE?#QS@!O/0/(?^XE'_D& 6=I> M?.+#L(ND5:;1J[2&>8PR'?MFT!&D0)(F2M-4.1*## KK-3M52U1+TU!8ZHVN M]#? <9T+&IWE;[D.FKU*0YG/*@LS?1\L9;Y)O.?,=V3W$?5\348PP./)3(0JM]O=9UT?UZD.80D!,*.[[Y6A':MD MSW? ,W"FL(=Q"!".72FQSRC7^S6[DD7DEP7^JZZPBZR];'\U7F A4(KAJ:^[ MUPRD.KMDM<.NJ>^UO>5

    ZSHHN*IC$6C@ 3]%/W.((,OW;A681GIB^B-(S&QQ3 M'[V.)IZ.S"XM@XW/!M._T* J4!?@.7*C76>J]@H',W'GEJ$GRQ#3>5%7^@?. M 7#P%9$#U3[;GQ-.#BOCL*&4Z]\N-(OPQ )4V5,]'8]XS,/%YO+]$(W=Y2H8 MA%1*A'TP)S8A< 'NV)X'G,L7RYZOTFTYGL^Q0[=+#2IBEWGJI96&I-XDW?V( M-[]BSIMTI89[!9H@QR(+_6JSD0N@OZ73])V8T&$8X,#V'>(JTM?PV$"+>K8+ M4SEN6/"5S8WC%]])J11Q .FM WN9Y_PFJMLP.K4$#5E&M#M"3CH)!PSP+O9Q M>K4$,6E.*C^88!5ZWGQVOP:/P5^ABZ)SM.AT90R"$/E7,-Y1D94\$?)@3*[C M!FT)E%4QRD2ZZI+>3%H',*@%;,EQ7P7>A7AE0EXV=L2 ?.MO;XG=DI\76*<= MF.U;!)& !Z;HRP:#)$4_\T%!X2=ZM%C\&2Z8 "B+XO"%(H<.\]$/\G MS5V)MK:<6)KT$.V"MR!;3&C5W4C,/U2-SLCW/% W>2([[*A2C$*_,/ :%+ZKD'2'R(Q''+<869<8XZL0^#K: _;\>&6Y1A#S MUM[J/]82!:E; $S%JCAN%5%W+V;@GL< <&X!C1@ QR16ATR.,: 2)_.%V*$ MD9U(:'OTG##/FZ=D-$Q%2W1,F628RJQ\B0Q@?'\M+AB IS"PO>3O'8B# 0S^!,$8S.'2I[<" M$M<4.8:XD<^W2RD;% E3'95%46MC/IZA5Q!M_D3;<6)TS=+QIJ BV3 U55D@ MN+0'O4LNE;Y$5OFGVJ5O-;'/5"EE 6C3B\8%3C['UC/]3XZ?)]>_7> 7X8F) MJ+K8<5G5C55V%*+YBOY$UL3HSS6L$8POM4M+ZN&>I4\**]#E\EE4*UX#M@*$ MU-U6/3+N\3URFK8[RBO;1='I&<=5K>N++=22VJ3 U+/6ALMC?DW?H1:4%O2; M0OJG1.J4N5PBL"2FM^<'R/6Q.X\D4E]0O31)+=14=6)BJK*Z6\:53%V>0(Z( M\E>ZO%1!8PN572.Y,;4_<4+PC[,#D1(F?VQ_R_DI-2AX#H#O['?S*00F>;U9WU+6-X971[$_/Z>FQ=F]/><$#_,K:^6X.99?RR M&?4_3]3DT.6SFM&EG-0Y84]%68'Y=*7*O4ESL^E5Z12W/>^D;"DM6;@.\P$E M9))_;VQ+)U%KX/Q^$J P1QQ' "MXM&.$H!/.@R':!#C9;R[EMU16I%!*XE! M/1,8!1#0E/X-<9A9J6[/25[SYE]=XHHU(WTVB[5GNC6$@995 BO 2=-"N1LB MA0\4))O=-?_HD%C](9_>9M:I8MF@E".1X%/-[O*FM&:2SQ+,7)\45AJ.+!U- M/]WZ_;=NL.J$.(!K@*SGN1=&.V., ?E_SM1^9B-48K [18][E'3-RG+( OZ] MWING$=E@^L$*!.[<]O)W4N?'[J2,7U)?4;6S @N $'.S34'ND5WSH^N0;?$. MYDRXB:X-(X@#1)A!\38=^ 2V ,OLT1JD09&)W>M=W;Q>ODRIG@X7^V%(V\NH M6GS^YP5[SC;0KL_.M_'I=.CUM MC7?R68Z86WE&4W4/#K0'>2@2HA8AA0QM M5'!1Q7(:9UZY#U-H^0$M%<#9Y!8>I/GP Q\##E9R\E =E5 !HZX1C)J@;O2M M@^V>P^0^"%OML>T 3)OT(WTL(9!HO0Z[L+#LH2G7]:[&5E([&Y4G,8NE%;3$7E^M< M+I']L'+G)@(VYN:3?C@\!4T>@FZ./"?&;6_ZK3MU#'-LF9.W MK-*WK-*WK%)FX#IZ<)%*9#\A>>=1G.9MR2\5GRW47K_Q M2% )H6ZH;"H"- Q6@D?G$RT:WR46D5\>K2PI?OYY/N<93^79 MRS?VOR#:TG])=ND_'/@4%<->/]C^"Y:Y"OJ1MW6_,?__<&QT9I/I\,8:&Y=D MN_[?W>%ME,G<&=Z,S,&?__'O7SZ<__KWR=L=T;?=_-MN7KAE24U9S-[&Y[5K MR_Z=S:/BC?O 7A^NFKS](J=Y\QMWCE"A#,5Z[-BK0D#7'?MQ*+TE4.:(5*S3 MS:9*"L1Y*27.2W77.$O)\[+.5 Z!1#M2$NTHRM H*]%.G3D:[=];OMV+5;JS MW')Q%7H+U_.BZDJ$\.AT?/M;W[7O72]Z:(F[P[S@[3 [P\%T;':FQM6L?]7K M]V^LP=0P)Q-K.C',07?_>[]G7O;ZO6G/2AX8[\54L2BV9^'T'#]*S[]U';#G M8LOQ@#XA&KB/()_U3X>L[\["*6^$U=[T3^.VU[7H3>%.?SB9C1/L&;O1:V1T MC_DD?'B(?1S;Z]AX=>7!IYZ_@&B]>6TQRD&;PN%#]/ZBO^P#&PNP_\S#?C(; MC?H61=SL&QUS\LVXZ@]OC=[@:CB^B6],CZV^.;6ZQG1H#$?6F/QQ<&WT+7/2 MC!;LA1/Q2NN!$86@#-$(ZYC(HY14?N5))>+.F%KCFTA)J&(,9V12$.8M?>2Q M>1^7S/V(W\1:,"/CH2+2^,*/0$UGXWC6QX))K@.S0=<:*Q%$BBW!(O#UD+\# M,I/37%&>>,-HQI2#YB0G1] /TYX^=D0KQ$>*W:KZB^P%\!-](7[JO[EC9A MOSI4CGD%OFJLU 06"ZAI?$$LP0K_WAVCN097["I'#LHPWDRLL@">6<[M?&9% MEQD*#Z3FWAP?%W@<2PT%0EL KY9!U/I5H-$H:^0HFDL$(F*XD:R\IJJN?96= M55""G+M; M?9'%=M?AIT$US;%V'E&?AE%!FN0NP'/D1N7?V;@*.KYB?&4X9R[->LS;[14M MV6F[;?^*4>4PS'1QE$5/0K(5(U3V".=K7N0CU>X5@Y?#*/,H4(\9*'Q*,+?Y M*X:0S2\+R4^JS_;& -"T(J>9&3NH'-#]9\S[X:D[WE.+'/<^18?6UC?K?YP M%!WG67^,K$'C)Q37P"?0T(I)IK,FH^,@!EJ*T4Q9WR2CU]; &IO]B$^S>],; M]"93>@+QW6J6U? >@[]"BMTC56JITXC/V:NZL\N)]<]9!-1W\G\U.I@XX# S M%W--!Z.',I.7I$<4\L]MK4W07@1'UKHQ>7\+H=<<0N?)_BT(_A8$9VWTWH+@ M;T'PRH/@T8M_V[>2=R%A?C4T;I^FTY"KBXH+V=)NW3TT)>13?%O([- &:RC@ M5J/06 ZEHN*;G"YJ;)Q(VD)L]"V*6B4\.MNHBB#4M2QJFEYA>=2\YHJ,E7BV M<*$16R1U*]^V+ JML!:\T-O.T(]L,M\N\;NUPCK)<*Y1Q/^ 3-$"R&BNR#9) MR1K*,*"?=:H"&*VM4E7@:6J7")5KZ$>;"9%-RC15E5/$GQR'=53SB&;.(V4+ MW&VT 13Z!:EF=WEJHYG\LP0SYX"ZXV2J'3V,0^!T0^3ZRQ% +G2BBJYX )ZB MG[C^@$Q_5>5LBP;;Y9EA(:G.R8Z(C(D?(7<.".W1WSC8L;JT!2XN_?K%@/*U MZ[OMA:#\3$MW;PMRTKQHMV]*&-61C88H M+C:V>8BBS%OKF6PT70RB563W(][\BL\YB)89KBT8E^:-A;JR!"S*ZG#10K#R??5:)W2S"59H4%H43FU>;O]/_&UL[;U[<^NXE2_Z_ZTZWP&W^K,3&]K+?"W@!\67@L+__F_7SL8DB]+DSU]]^/UW7R&<+-,P2M9__NIA?CZ:7TXF7Z$L#Y(PB-,$__FK)/WJ M?_^O__%_(?K__O/_/C]'UQ&.PQ_15;H\GR2K]$_H+MC@']%'G& 2Y"GY$_H4 MQ 7[2WH=Q9B@RW2SC7&.Z0_BPS^B?_O]A_\(T/FY1;F?S-?/N%-2\V7L_@[02[%_GE=@Y^]/YA^_/?_CP^]U/<&G?8?D!QC0U'=NPB+-@W@O\$U- MY[#O\'XUOM-S7]/4S^/]:KJA>1+8N0QYEI\M6N3'SYBF1;6= R1Y-GJ-LNI;W- _?V6I\VW7 M$*8](I4U 5GV5$DI\>TRI0/:-C^/1>4+]15)-]90ROI++15^B1_K[XA*IU T M!K7$",[2@BSQH#9O6C6DADN4FYAJL4D<3LX?YE_]+R&*=K+H[TSZO_[SV]T7 MO%",(MJDR3Q/E[_>XLTC)AJC%7(NJ:2%V:2/) 2&,CID79H(.<0%T=^%J'^. MC,(P8E/5(+X/HG"27 ;;B([ 1K[TZ+CDCA7\)H^,"F X98.RRZ^=#F)*=(F$ M2C4X;)OA/(@2'(X#DM!U<&:DF4[8);_,@)O$4DN"89017I=*E3"JI.$PZ)ZD M6TSRMWL*.!\E(1M\MVS OGA;T,\:)D]6FBZY-<"4)M$LU,"PSAYKEX(W:;(^ MOXF>*0D7]._18XS1*,MP#F5R=1LLGV@?(6]-LXS^S*CADG@6T)N$,XB#(5H_ MQB[!:@T4)-3153HG]G09R1ODHO_:$8O^XY<91:CR89W?7)!%"8?1HO6#=P*H MT'2;FBWJHBR/EG0J=(N#K"!8-/4)/4E/0]]&2;0I-DI_H?C=58,K856-WOH1 M1,.K$$G]7,CX[=>WP:NYN=N_.VMN%:RZN9L_PFAN!2+9K;\Z:.X!\X3I:A4M ML=T,02/KML@QL6./5MKQ9IX)7:IS"65X7)(ER.H_N7?P>5)(+ MHAW!5$; XKQ3LS#L5L2MAQIZ_+0R.'2>X"_G"3+=(,7P>NHR)]2$N5OAGU% MG;!++VD&W'20:DGO%+2"UV69$$94&M7B4+8'KU."HW5RF19)3MZ,8ZU:U"5] M3&";Y%')@:&. 5R7.*5HESE0W,\5937;KK(ACT;6)7N,<)OT40J"X8\)79= ME2Q4!LENE 7D#AK$=@I^![(NZI(^.2.$IX3;:T!,!01(6J MRPM&""$$Q;501#_C@-"_?S#Z%(6<8TZH879XT1:"Q TE,A4_F"!BDG F.$+L]OE.)@R-2/43/#J550I0/%"XG[=?$H"4?A)DJB M+"<4WS,>OVYQDF&C9[+4=4FZ0>8TZ6>E"(:(0]!V*5GJ\E"@MC8JU>&X/Q8X M-UV-"&%1+ZS_F.9-:EFG8Z4);FN\5 F"89<)G7P4&%/MM"100T?PJ_'O:?Z$ M"!AAA3@-G!_J&'M8'Y;;>_\VQNR'/3/Q1"7 M.ZT#NHH(7E)A=0R"6L29 ]* JQU0YW?O!#" DK:M*ZE3AP[,-Y1$>#FCD[&K MFSS4-[-&T%EC&X'63:Z4@M'P)FA2'+2013,^#[E"5/[41+C%8;0N,B,'9!EG MS:^#5[=\5P!&HVM02;&P0NRH[7SXO??B,8O"*"!O\R"F4VI^']9TYUTO[_2^ M>Q_LUEUWG;!W^M@BE%P'E4+IJKJ]#&.?YIY$SW3*M-'*N[F88859W-)1" MWEG2ATPZ9V"RS+OLI$^[_KA( Q).5Q;+$)VDLQF*&6H]3U&+>6="/[8N%[@P MXX*SMMKWPU;87 MYK:] -BV%U9M>W'JMKU,DZR(\\"TC2W+.&M?';RZA;L",-I8@TH^XJC$X*PL M2^895P$=&9>3?R6\YIR_)>"=#294NCY_\@M)>8Z)Q>F51M#A=2(#T,9M(864 M]W;OA2;?]6&RZ,2'6QE>_GZ=/G\;XDCX OH?.Q= _T$QKX-XG.3JVSI*"1>$ M,$!C3%#\[)T">DQRVU,I),1.NV2;),\XRQF_+O7]7B'DK,]K =;]79+PWM!& M6'+85B6'+D_MZ<6WZ.*OM[&;,H[;6H;7:>J= *26EE"I&YJMO(_7SH?O]5*( M/7=8VB).]W45X%J[N8W?O5/! $K:N:7_.N;5$TUO7[RDBZ>TR((D'"7AXH6Z MF+?Y4T#PA-9\PN*A&!"])QBF[\Q+[&-6[4&&*'NGU+Z(NWRCU/@.<1U4*R%. MPA./-^/--D[?,,YVZ]JLWH"DUO XO3DFS]$2WY/T.0JQ:=?XH.*<\?,(1M=T M/: L&.P]W I+7A5XAEJE'G6V-AF41@B K0L&-4EPQEX1R\!"7M2JW9DG": M5L%K)7QN"GCGF@F5%"[*9! 3@G+@SD__IUL65VC<95/(N7V;0 .S_1Y!1P@, M-W3(-.\."$DX#D/@F20A?F7/N4RRK* .38#M\2-VJD[3X0TPII4=ST(/#.$& M@)5RYPGRE;HH3Y'0_EV&A/X9* =6C:8-8+0I60=T;T(9,C%],5VLGZC5OLAE%=/@41 MV6CVQ6P47$4RV@&O0AK-TMXI9 W1(K"MTO/+*Y&44>UN%+^[8HT25D62UH\@ M.*%"I$XT?3PWTK.9R:X$]4>XFJ2=;T7J(4L[C;*H=Q[8X=/M$XI+64>/>CW" M9#;+2;2D\R$^7W](HCR;S1^,ZZ8>';<36@OX[2FM0<$[QX:@E*>UE4YYCX=K MH:^I7O8-6,(-(1H @ED3"S:AAA')31CW+:V:I\8QHSACG";JC#R#-%V'?5N: MT@T'[U'S3J;A6'6AI%S;1>*QGMDQ70*&Q3*?5F=_FLMB:C%78(KU.!/E,Z7JR!3(SG()QWPLUI9Q>B2F@M.>%"96T.UP1 )T'1G<"8*B@0J7S#Z>^>51D>;K!Q'!E4!)Q=^](#6YW M[:C]N_?V-8"2+AV54J>_-U@> %SA9QRG_'&2RS33/)EDH^"L]:V UUPP2L-@ MA@U$W?%-0PEQ+;]3R3KAZ4>NNQ M+2=!I!TFLDCUST_J_W?*:E6!9EF*J426H^"NQS1-L!WN:)-TC X8@-1.F7AY_R5THXU@ *56$Y;_(^"@AH_ MT__5<]=(*^TZJ[ !GL$+4.Z/L\$ETJJ41%P=U2ZACBOE,5RWKD42&,UZ5 M(%0"F;U1ESZ>^#I&<T;,K H( /3,Z$AZ\FQS_"Z?/,Q3>HC8X,;T\B[=OU&V-VQ0"D,@C0V M"+6C15-I]ZJL)QZ-DJ0(XAG>IL1$G[:8:]:H0';)TI0!Q1$%,"TUA"P2PIX8 M\=>"O;I%XK=>4DB2KGFA@=JE1D<,%#O4V+0$J<7]U.IN>)2?>81&E( MI]FDCT.2I&OV:*!V>=,1 \48-38M5X0XXO+^23).0BN*U')^"-*!J:9'*020 M'&UD?=08LR03_HAQ'67+(!98KNG?5,]T&&1=$T0+MTL221 4473HM&01"A5G MN(I7POR, V)'EX:D'[)(4-54J<4 $J6+K8\F3-X+22X+0EJH]2..7M39H6P/ MV/I\5B,'@B@]X.3H0B[>(HJG$6C,'RFZCF)\5RCB.=0BKKBA U=QHOL[""YH M0$GYK<3K4$P."4$O+5^=$B0Y>]!$:TY7S"T#U"#;+&C+ &*"$IBM9_KZ, M%T9<4L]$@ICGKOX+?M/:)Q)M M O(VCY8]0X4LZ)8:.J!M;G2E )%# TW#CE(:S2>7/D>21? Z"2E1HU6TY(?. M/2S1RKLE2P_L-F8^KU_TGQO2YKO09/F M^WU(LWA)@9#FAP&F_N"?-#_8DN8'T*3Y82_2T(;WZFLNZ7].R2)]405G:R6] M4$:&JB3,3@P>721L?61A"FP^PU1\TH1/K*:$OYJ9+/539IVX%\)H0"M9TY&% M1QTUP#[^U!/B2L^KKQ&3\MY.4HGY\3)MD&H74Z9< D>2-K!>YR*D?5+B/LWR M(/[_HJUQ(:X6]D(/)6 E25J2\*BB@M='&*&#J)*/A75)5W:@H;Q*UOG=W15@ M!:S=%>#&CR!(H$(D7P$6NR="R'4S,XX2'&@\0OMG9XVL %6W<>,W&$TL Y): MF/=K*N.C(]^D+$;J*4WT 0*RB*N6UH&K6KO[.X@6UX"2\A"E/-:,R7G:C7_- M<9*IW7?C-VQ=./9!7/X!HW2X::9BN?G? M8,4&60($%;2PI*P]M2"J)!V3X)Y@1D),&X)? L1)B,ETM5*.]B9A5Z3H!UR1 M0R\)@B2]\.2W7/#YLJ&!A KB.GYI,\FR I-!Y%&H>**0%KR&2)(\1#KI0/:2 M2BCZY-8<+PLZ/KY]^/YQ$>6Q:G$IBS@;DS3@ZA&I\SL(;FA =;G ?V,/7/WY=/E%06',A02WF MVO6K0';=?U,&! 4,P.3G(X4HJF1]7$C8#5GK_DG VMLD8-TS"5A#G 2L;2\*,(H MQZ$ ]7<<862_ U<7KD87#(#J1$)Z%6Y3*L%7>I+EUO MI8L C,\XCO^2I"_)' =9FN!0[*6H3HK,\FXC9GI@MX-F-,(@Z&2#4!,ZPY3. M?V5:J%(K=\*\,.E3&A=)'A!^EYRH/)-&SBUS-##;C.D( 6**&IF&(;4P$M)^ M+FB+[!'U)(LY/&4*&+.XX^O:1M"=6]M*64"<,0+4W>$ND7*?.$:"*.>.J44 T4.%RY!!AJ!*U@L7YIL@CB^*+$IPIA^(.E)N MN:"$V.9"2P00%U2X-%S@HJB2]<*%\0:3-1W>/I+T)7\J\[-J;=-(N^6&$7*; M(TI10%PQX=-PIE)!0J=*J>N'/*^[A.(BRZ+>4H6H8]IHP78X(\E!(HP.G,26 M&"_9?LM=FJ-%BAXRC/(GC'@X:TC_WL@$+\KQ]=+(1(&1$4AD[#S M5T>T@*6W1R1)$$3JA:=_AZ360)6*8]9,*8=)=NA7<<4@6_ 5 MC_KD0;#)$F274URMO;CFBHAI^LQFU$QNKY_BM80FF MQXVAY':>!?I>E)>,X8YX,KY,L;R< B $R*@T!MEP0K9BDE_:_ M"))?2;'-EV_W)%UBS**LLMI;]>V_66J[Y#4,W!6!&F6< M-48LGYMY+&B<97-+E[_.GP):@=,BS]@(2H'I=\&-2HZ/%RP,Z!PR�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end